10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

þ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the fiscal year ended December 31, 2017

o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ______ to ______ 

Commission File Number 001-31792

CNO Financial Group, Inc.

Delaware	75-3108137
State of Incorporation	IRS Employer Identification No.
11825 N. Pennsylvania Street
Carmel, Indiana  46032	(317) 817-6100
Address of principal executive offices	Telephone

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of Each Exchange on which Registered
Common Stock, par value $0.01 per share	New York Stock Exchange
Rights to purchase Series C Junior Participating Preferred Stock	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ X ] No [ ]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes [ ] No [ X ]

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days: Yes [ X ] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ X ] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer [ X ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [ ] Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes [ ] No [ X ]

At June 30, 2017, the last business day of the Registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's common equity held by nonaffiliates was approximately $3.5 billion.

Shares of common stock outstanding as of February 8, 2018:  166,876,131

DOCUMENTS INCORPORATED BY REFERENCE: Portions of the Registrant's definitive proxy statement for the 2018 annual meeting of shareholders are incorporated by reference into Part III of this report.

TABLE OF CONTENTS

PART I		Page
Item 1.	Business of CNO	3
Item 1A.	Risk Factors	22
Item 1B.	Unresolved Staff Comments	41
Item 2.	Properties	41
Item 3.	Legal Proceedings	41
Item 4.	Mine Safety Disclosures	41
	Executive Officers of the Registrant	42
PART II
Item 5.	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	43
Item 6.	Selected Consolidated Financial Data	46
Item 7.	Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations	47
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	114
Item 8.	Consolidated Financial Statements and Supplementary Data	114
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	197
Item 9A.	Controls and Procedures	197
Item 9B.	Other Information	197
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	198
Item 11.	Executive Compensation	198
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	198
Item 13.	Certain Relationships and Related Transactions, and Director Independence	198
Item 14.	Principal Accountant Fees and Services	198
PART IV
Item 15.	Exhibits and Financial Statement Schedules	199
Item 16.	Form 10-K Summary	199

2

PART I

ITEM 1. BUSINESS OF CNO.

CNO Financial Group, Inc., a Delaware corporation ("CNO"), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products. The terms "CNO Financial Group, Inc.", "CNO", the "Company", "we", "us", and "our" as used in this report refer to CNO and its subsidiaries. Such terms, when used to describe insurance business and products, refer to the insurance business and products of CNO's insurance subsidiaries.

We focus on serving middle-income pre-retiree and retired Americans, which we believe are attractive, underserved, high growth markets. We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing. As of December 31, 2017, we had shareholders' equity of $4.8 billion and assets of $33.1 billion. For the year ended December 31, 2017, we had revenues of $4.3 billion and net income of $175.6 million. See our consolidated financial statements and accompanying footnotes for additional financial information about the Company and its segments.

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting the long-term care block recaptured from Beechwood Re Ltd. ("BRe") effective September 30, 2016, as an additional business segment.

The Company’s insurance segments are described below:

• Bankers Life,which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices.  The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life").  Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plans ("PDP") products in exchange for a fee.

• Washington National, which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite.  These products are marketed through Performance Matters Associates, Inc. ("PMA", a wholly owned subsidiary) and through independent marketing organizations and insurance agencies including worksite marketing.  The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.

• Colonial Penn, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing.  The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").

• Long-term care in run-off consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC").

3

OUR STRATEGIC DIRECTION

Our mission remains unchanged: to enrich lives by providing insurance solutions that help protect the health and retirement needs of middle-income Americans, while building enduring value for all our stakeholders. Our corporate strategy is rooted in CNO’s unique customer focus. Our focus on the unique financial security needs of our middle-income customers is essential to our growth strategy. Our diverse ability to connect with customers through captive agents, independent channels or direct marketing is a key strength of CNO. We believe that our product portfolio mix is well-aligned to the retirement healthcare, supplemental health and income accumulation needs of working-age customers as well as those in and near retirement. Unlike most insurers, we provide solutions for both health risks and wealth opportunities. As Americans live longer into their retirement years, our customers need holistic retirement income planning, which includes both our insurance and annuity solutions, and the investments offered by our broker-dealer and growing force of registered investment advisors. Specifically, we are focused on the following priorities:

Growth

• Maximize our product portfolio to ensure it meets our customers’ needs for integrated products and advice covering a broad range of their financial needs

• Position marketing and our distribution channels to respond effectively to evolving customer preferences

• Expand and enhance elements of our broker-dealer and registered investment advisor program

• Increase the speed-to-market for new products that are a good fit for our customers

• Make strategic, measured changes to our business practices to improve our competitive advantage

• Continue to invest in technology partnerships that will support our field force and relationships with our customers

Increase profitability and return on equity

• Maintain our strong capital position and favorable financial metrics

• Work to increase our return on equity

• Maintain pricing discipline

Effectively manage risk and deploy capital

• Maintain an active enterprise risk management process

• Utilize excess cash flow to maximize returns

• Maintain a competitive dividend payout ratio

• Reduce relative legacy long-term care exposure

Continue to invest in talent

• Attract, retain and develop the best talent to help us drive sustainable growth, and provide them with development opportunities

• Recruit, develop and retain our agent force

OTHER INFORMATION

Our executive offices are located at 11825 N. Pennsylvania Street, Carmel, Indiana 46032, and our telephone number is (317) 817-6100. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act are available free of charge on our website at www.CNOinc.com as soon as reasonably practicable after they are electronically filed with, or furnished to, the Securities and Exchange Commission (the "SEC"). These filings are also available on the SEC's website at www.sec.gov. In addition, the public may read and copy any document we file at the SEC's Public Reference Room located at 100 F Street, NE, Room 1580, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Copies of these filings are also available, without charge, from CNO Investor Relations, 11825 N. Pennsylvania Street, Carmel, IN 46032.

Our website also includes the charters of our Audit and Enterprise Risk Committee, Executive Committee, Governance and Nominating Committee, Human Resources and Compensation Committee and Investment Committee, as well as our Corporate Governance Operating Principles and our Code of Business Conduct and Ethics that applies to all officers, directors and employees. Copies of these documents are available free of charge on our website at www.CNOinc.com or from CNO Investor Relations at the address shown above. Within the time period specified by the SEC and the New York Stock Exchange, we will post on our website any amendment to our Code of Business Conduct and Ethics and any waiver applicable to our principal executive officer, principal financial officer or principal accounting officer.

4

In June 2017, we filed with the New York Stock Exchange the Annual CEO Certification regarding the Company's compliance with their Corporate Governance listing standards as required by Section 303A.12(a) of the New York Stock Exchange Listed Company Manual. In addition, we have filed as exhibits to this 2017 Form 10-K the applicable certifications of the Company's Chief Executive Officer and Chief Financial Officer required under Section 302 of the Sarbanes-Oxley Act of 2002 regarding the Company's public disclosures.

CNO became the successor to Conseco, Inc., an Indiana corporation (our "Predecessor"), in connection with a bankruptcy reorganization which became effective on September 10, 2003 (the "Effective Date"). Our Predecessor was organized in 1979 and commenced operations in 1982.

Data in Item 1 are provided as of or for the year ended December 31, 2017 (as the context implies), unless otherwise indicated.

MARKETING AND DISTRIBUTION

Insurance

Our insurance subsidiaries develop, market and administer health insurance, annuity, individual life insurance and other insurance products. We sell these products through three primary distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing. We had premium collections of $3.7 billion, $3.6 billion and $3.4 billion in 2017, 2016 and 2015, respectively.

Our insurance subsidiaries collectively hold licenses to market our insurance products in all fifty states, the District of Columbia, and certain protectorates of the United States. Sales to residents of the following states accounted for at least five percent of our 2017 collected premiums: Florida (10 percent), Pennsylvania (6 percent), Texas (6 percent) and California (5 percent).

We believe that most purchases of life insurance, accident and health insurance and annuity products occur only after individuals are contacted and solicited by an insurance agent. Accordingly, the success of our distribution system is largely dependent on our ability to attract and retain experienced and highly motivated agents. A description of our primary distribution channels is as follows:

Career Agents. The products of the Bankers Life segment are sold through a career agency force of over 3,900 producing agents working from over 275 Bankers Life branch offices and satellites. These agents establish one-on-one contact with potential policyholders and promote strong personal relationships with existing policyholders. The career agents sell primarily Medicare supplement and long-term care insurance policies, life insurance and annuities. In 2017, this distribution channel accounted for $2.7 billion, or 73 percent, of our total collected premiums. These agents sell Bankers Life policies, as well as Medicare Advantage plans primarily through distribution arrangements with Humana, Inc. and United HealthCare, and typically visit the prospective policyholder's home to conduct personalized "kitchen-table" sales presentations. After the sale of an insurance policy, the agent serves as a contact person for policyholder questions, claims assistance and additional insurance needs.

Independent Producers. The products of the Washington National segment are primarily sold through our wholly-owned marketing organization, PMA. In addition, Washington National's products are sold through a diverse network of independent agents, insurance brokers and marketing organizations. The general agency and insurance brokerage distribution system is comprised of independent licensed agents doing business in all fifty states, the District of Columbia, and certain protectorates of the United States. In 2017, this distribution channel accounted for $673.4 million, or 18 percent, of our total collected premiums.

Marketing organizations typically recruit agents by advertising our products and commission structure through direct mail advertising or through seminars for agents and brokers. These organizations bear most of the costs incurred in marketing our products. We compensate the marketing organizations by paying them a percentage of the commissions earned on new sales generated by agents recruited by such organizations. Certain of these marketing organizations are specialty organizations that have a marketing expertise or a distribution system related to a particular product or market, such as worksite and individual health products.

Direct Marketing. This distribution channel is engaged primarily in the sale of graded benefit life insurance policies through Colonial Penn. In 2017, this channel accounted for $291.6 million, or 8 percent, of our total collected premiums.

5

Products

The following table summarizes premium collections by major category and segment for the years ended December 31, 2017, 2016 and 2015 (dollars in millions):

Total premium collections

	2017		2016		2015
Health:
Bankers Life	$	1,213.4	$	1,235.3	$	1,242.3
Washington National	642.5		628.4		619.6
Colonial Penn	2.0		2.4		3.0
Long-term care in run-off	16.9		4.7		—
Total health	1,874.8		1,870.8		1,864.9
Annuities:
Bankers Life	1,030.6		970.0		803.0
Washington National	.9		1.5		2.4
Total annuities	1,031.5		971.5		805.4
Life:
Bankers Life	462.4		461.1		446.0
Washington National	30.0		29.4		27.7
Colonial Penn	289.6		277.8		259.9
Total life	782.0		768.3		733.6
Total premium collections	$	3,688.3	$	3,610.6	$	3,403.9

6

Our collected premiums by product and segment were as follows:

Health

Health premium collections (dollars in millions)

	2017		2016		2015
Medicare supplement:
Bankers Life	$	739.4	$	739.3	$	739.4
Washington National	51.6		61.0		72.6
Colonial Penn	1.9		2.3		2.7
Total	792.9		802.6		814.7
Long-term care:
Bankers Life	445.3		468.6		476.6
Long-term care in run-off	16.9		4.7		—
Total	462.2		473.3		476.6
Supplemental health:
Bankers Life	22.6		21.2		19.2
Washington National	589.1		565.5		544.8
Total	611.7		586.7		564.0
Other:
Bankers Life	6.1		6.2		7.1
Washington National	1.8		1.9		2.2
Colonial Penn	.1		.1		.3
Total	8.0		8.2		9.6
Total health premium collections	$	1,874.8	$	1,870.8	$	1,864.9

The following describes our major health products:

Medicare Supplement. Medicare supplement collected premiums were $792.9 million during 2017, or 21 percent, of our total collected premiums. Medicare is a federal health insurance program for disabled persons and seniors (age 65 and older). Part A of the program provides protection against the costs of hospitalization and related hospital and skilled nursing facility care, subject to an initial deductible, related coinsurance amounts and specified maximum benefit levels. The deductible and coinsurance amounts are subject to change each year by the federal government. Part B of Medicare covers doctor's bills and a number of other medical costs not covered by Part A, subject to deductible and coinsurance amounts for charges approved by Medicare. The deductible amount is subject to change each year by the federal government.

Medicare supplement policies provide coverage for many of the hospital and medical expenses which the Medicare program does not cover, such as deductibles, coinsurance costs (in which the insured and Medicare share the costs of medical expenses) and specified losses which exceed the federal program's maximum benefits. Our Medicare supplement plans automatically adjust coverage to reflect changes in Medicare benefits. In marketing these products, we currently concentrate on individuals who have recently become eligible for Medicare by reaching the age of 65. Approximately 61 percent of new sales of Medicare supplement policies in 2017 were to individuals who had recently reached the age of 65.

Bankers Life sells Medicare supplement insurance. Washington National discontinued new sales of Medicare supplement policies in 2012 to focus on the sale of supplemental health products.

Long-Term Care. Long-term care collected premiums were $462.2 million during 2017, or 13 percent of our total collected premiums. Long-term care products provide coverage, within prescribed limits, for nursing homes, home healthcare, or a combination of both. We sell long-term care plans primarily to retirees and, to a lesser degree, to older self-employed individuals in the middle-income market.

7

Current nursing home care policies cover incurred charges up to a daily fixed-dollar limit with an elimination period (which, similar to a deductible, requires the insured to pay for a certain number of days of nursing home care before the insurance coverage begins), subject to a maximum benefit. Home healthcare policies cover incurred charges after a deductible or elimination period and are subject to a weekly or monthly maximum dollar amount, and an overall benefit maximum. Comprehensive policies cover both nursing home care and home healthcare. We monitor the loss experience on our long-term care products and, when appropriate, apply for actuarially justified rate increases in the jurisdictions in which we sell such products. Regulatory approval is required before we can increase our premiums on these products.

A small portion of our long-term care business is included in the Long-term care in run-off segment. This business was sold through independent producers and was largely underwritten by certain of our subsidiaries prior to their acquisitions by our Predecessor in 1996 and 1997. The performance of these blocks of business did not meet the expectations we had when the blocks were acquired. As a result, we ceased selling new long-term care policies through independent distribution in 2003. In December 2013, we ceded this long-term care business to an unaffiliated reinsurer. In September 2016, we recaptured this business as further described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Consolidated Financial Condition - Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off".

Our legacy long-term care insurance block is not expected to generate significant future profits and could produce volatile earnings if experience deteriorates. We continue to sell long-term care insurance through the Bankers Life career agent distribution channel. However, the business currently being sold is underwritten using stricter underwriting and pricing standards and generally has shorter benefit periods than the older long-term care business in Bankers Life.

Supplemental Health Products. Supplemental health collected premiums were $611.7 million during 2017, or 17 percent of our total collected premiums. These policies generally provide fixed or limited benefits. Cancer insurance and heart/stroke products are guaranteed renewable individual accident and health insurance policies. Payments under cancer insurance policies are generally made directly to, or at the direction of, the policyholder following diagnosis of, or treatment for, a covered type of cancer. Heart/stroke policies provide for payments directly to the policyholder for treatment of a covered heart disease, heart attack or stroke. Accident products combine insurance for accidental death with limited benefit disability income insurance. Hospital indemnity products provide a fixed dollar amount per day of confinement in a hospital. The benefits provided under the supplemental health policies do not necessarily reflect the actual cost incurred by the insured as a result of the illness, or accident, and benefits are not reduced by any other medical insurance payments made to or on behalf of the insured.

Approximately 73 percent of the total number of our supplemental health policies inforce was sold with return of premium or cash value riders. The return of premium rider generally provides that, after a policy has been inforce for a specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or in some cases, a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy. For some policies, the return of premium rider does not have any claim offset. The cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned.

Premiums collected on supplemental health products in the Bankers Life segment primarily relate to a new critical illness product that was introduced in 2012. This critical illness insurance product pays a lump sum cash benefit directly to the insured when the insured is diagnosed with a specified critical illness. The product is designed to provide additional financial protection associated with treatment and recovery as well as cover non-medical expenses such as: (i) loss of income; (ii) at home recovery or treatment; (iii) experimental and/or alternative medicine; (iv) co-pays, deductibles and out-of-network expenses; and (v) child care and transportation costs.

Other Health Products. Collected premiums on other health products were $8.0 million during 2017. This category includes various other health products such as disability income products which are sold in small amounts and other products such as major medical health insurance which are no longer actively marketed.

8

Annuities

Annuity premium collections (dollars in millions)

	2017		2016		2015
Fixed index annuity:
Bankers Life	$	964.7	$	868.1	$	706.6
Washington National	.6		1.2		1.9
Total fixed index annuity premium collections	965.3		869.3		708.5
Other fixed interest annuity:
Bankers Life	65.9		101.9		96.4
Washington National	.3		.3		.5
Total fixed interest annuity premium collections	66.2		102.2		96.9
Total annuity premium collections	$	1,031.5	$	971.5	$	805.4

During 2017, we collected annuity premiums of $1,031.5 million, or 28 percent, of our total premiums collected. Annuity products include fixed index annuity, traditional fixed rate annuity and single premium immediate annuity products sold through Bankers Life. Washington National no longer actively sells annuity products. Annuities offer a tax-deferred means of accumulating savings for retirement needs, and provide a tax-efficient source of income in the payout period. Our major source of income from fixed rate annuities is the spread between the investment income earned on the underlying general account assets and the interest credited to contractholders' accounts. For fixed index annuities, our major source of income is the spread between the investment income earned on the underlying general account assets and the cost of the index options purchased to provide index-based credits to the contractholders' accounts.

The change in mix of premium collections between Bankers Life's fixed index products and fixed interest annuity products has fluctuated due to volatility in the financial markets in recent periods. In addition, premium collections from Bankers Life's fixed rate annuity products have been negatively impacted by low market interest rates in recent periods.

The following describes the major annuity products:

Fixed Index Annuities. These products accounted for $965.3 million, or 26 percent, of our total premium collections during 2017. The account value (or "accumulation value") of these annuities is credited in an amount that is based on changes in a particular index during a specified period of time. Within each contract issued, each fixed index annuity specifies:

• The index to be used.

• The time period during which the change in the index is measured. At the end of the time period, the change in the index is applied to the account value. The time period of the contract ranges from 1 to 4 years.

• The method used to measure the change in the index.

• The measured change in the index is multiplied by a "participation rate" (percentage of change in the index) before the credit is applied. Some policies guarantee the initial participation rate for the life of the contract, and some vary the rate for each period.

• The measured change in the index may also be limited by a "cap" before the credit is applied. Some policies guarantee the initial cap for the life of the contract, and some vary the cap for each period.

• The measured change in the index may also be limited to the excess in the measured change over a "margin" before the credit is applied. Some policies guarantee the initial margin for the life of the contract, and some vary the margin for each period.

These products have guaranteed minimum cash surrender values, regardless of actual index performance and the resulting indexed-based interest credits applied. In 2016, we began offering a guaranteed lifetime income annuity, which allows policyholders to opt to receive a guaranteed income stream for life, without having to annuitize their policy.

9

We have generally been successful at hedging increases to policyholder benefits resulting from increases in the indices to which the product's return is linked.

Other Fixed Interest Annuities. These products include fixed rate single-premium deferred annuities ("SPDAs"), flexible premium deferred annuities ("FPDAs") and single-premium immediate annuities ("SPIAs"). These products accounted for $66.2 million, or 2 percent, of our total premium collections during 2017, of which SPDAs and FPDAs comprised $57.5 million. Our fixed rate SPDAs and FPDAs typically have an interest rate (the "crediting rate") that is guaranteed by the Company for the first policy year, after which we have the discretionary ability to change the crediting rate to any rate not below a guaranteed minimum rate. The guaranteed rates on annuities written recently are 1.0 percent, and the guaranteed rates on all policies inforce range from 1.0 percent to 5.5 percent. The initial crediting rate is largely a function of:

•the interest rate we can earn on invested assets acquired with the new annuity fund deposits;

•the costs related to marketing and maintaining the annuity products; and

•the rates offered on similar products by our competitors.

For subsequent adjustments to crediting rates, we take into account current and prospective yields on investments, annuity surrender assumptions, competitive industry pricing and the crediting rate history for particular groups of annuity policies with similar characteristics.

In 2017, a significant portion of our new annuity sales were "bonus interest" products. The initial credited rate on these products generally specifies a bonus crediting rate of up to .5 percent for the first policy year only. After the first year, the bonus interest portion of the initial crediting rate is automatically discontinued, and the renewal crediting rate is established. As of December 31, 2017, the average crediting rate, excluding bonuses, on our outstanding traditional annuities was 3 percent.

Withdrawals from fixed interest annuities we are currently selling are generally subject to a surrender charge of 8 percent to 10 percent in the first year, declining to zero over a 5 to 12 year period, depending on issue age and product. Surrender charges are set at levels intended to protect the Company from loss on early terminations and to reduce the likelihood that policyholders will terminate their policies during periods of increasing interest rates. This practice is intended to lengthen the duration of policy liabilities and to enable us to maintain profitability on such policies.

Penalty-free withdrawals from fixed interest annuities of up to 10 percent of either premiums or account value are available in most fixed interest annuities after the first year of the annuity's term.

Some fixed interest annuity products apply a market value adjustment during the surrender charge period. This adjustment is determined by a formula specified in the annuity contract, and may increase or decrease the cash surrender value depending on changes in the amount and direction of market interest rates or credited interest rates at the time of withdrawal. The resulting cash surrender values will be at least equal to the guaranteed minimum values.

SPIAs accounted for $8.7 million of our total premiums collected in 2017. SPIAs are designed to provide a series of periodic payments for a fixed period of time or for life, according to the policyholder's choice at the time of issuance. Once the payments begin, the amount, frequency and length of time over which they are payable are fixed. SPIAs often are purchased by persons at or near retirement age who desire a steady stream of payments over a future period of years. The single premium is often the payout from a fixed rate contract. The implicit interest rate on SPIAs is based on market conditions when the policy is issued. The implicit interest rate on our outstanding SPIAs averaged 6.7 percent at December 31, 2017.

10

Life Insurance

Life insurance premium collections (dollars in millions)

	2017		2016		2015
Interest-sensitive life products:
Bankers Life	$	162.5	$	175.0	$	169.1
Washington National	19.1		18.0		15.6
Colonial Penn	.2		.3		.2
Total interest-sensitive life premium collections	181.8		193.3		184.9
Traditional life:
Bankers Life	299.9		286.1		276.9
Washington National	10.9		11.4		12.1
Colonial Penn	289.4		277.5		259.7
Total traditional life premium collections	600.2		575.0		548.7
Total life insurance premium collections	$	782.0	$	768.3	$	733.6

Life products include traditional and interest-sensitive life insurance products. These products are currently sold through the Bankers Life, Washington National and Colonial Penn segments. During 2017, we collected life insurance premiums of $782.0 million, or 21 percent, of our total collected premiums.

Interest-Sensitive Life Products. These products include universal life and other interest-sensitive life products that provide life insurance with adjustable rates of return related to current interest rates. They accounted for $181.8 million, or 5 percent, of our total collected premiums in 2017. These products are marketed by independent producers and career agents (including independent producers and career agents specializing in worksite sales). The principal differences between universal life products and other interest-sensitive life products are policy provisions affecting the amount and timing of premium payments. Universal life policyholders may vary the frequency and size of their premium payments, and policy benefits may also fluctuate according to such payments. Premium payments under other interest-sensitive policies may not be varied by the policyholders. Universal life products include fixed index universal life products. The account value of these policies is credited with interest at a guaranteed rate, plus additional interest credits based on changes in a particular index during a specified time period.

Traditional Life. These products accounted for $600.2 million, or 16 percent, of our total collected premiums in 2017. Traditional life policies, including whole life, graded benefit life, term life and single premium whole life products, are marketed through independent producers, career agents and direct response marketing. Under whole life policies, the policyholder generally pays a level premium over an agreed period or the policyholder's lifetime. The annual premium in a whole life policy is generally higher than the premium for comparable term insurance coverage in the early years of the policy's life, but is generally lower than the premium for comparable term insurance coverage in the later years of the policy's life. These policies combine insurance protection with a savings component that gradually increases in amount over the life of the policy. The policyholder may borrow against the savings component generally at a rate of interest lower than that available from other lending sources. The policyholder may also choose to surrender the policy and receive the accumulated cash value rather than continuing the insurance protection. Term life products offer pure insurance protection for life with a guaranteed level premium for a specified period of time - typically 5, 10, 15 or 20 years. In some instances, these products offer an option to return the premium at the end of the guaranteed period.

Traditional life products also include graded benefit life insurance products. Graded benefit life insurance products are offered on an individual basis primarily to persons age 50 to 85, principally in face amounts of $400 to $25,000, without medical examination or evidence of insurability. Premiums are paid as frequently as monthly. Benefits paid are less than the face amount of the policy during the first two years, except in cases of accidental death. Our Colonial Penn segment markets graded benefit life policies under its own brand name using direct response marketing techniques. New policyholder leads are generated primarily from television, print advertisements, direct response mailings and the internet.

Traditional life products also include single premium whole life insurance. This product requires one initial lump sum payment in return for providing life insurance protection for the insured's entire lifetime. Single premium whole life products accounted for $45.4 million of our total collected premiums in 2017.

11

INVESTMENTS

40|86 Advisors, Inc. ("40|86 Advisors", a registered investment advisor and wholly owned subsidiary of CNO) manages the investment portfolios of our insurance subsidiaries. 40|86 Advisors had approximately $27.2 billion of assets (at fair value) under management at December 31, 2017, of which $27.0 billion were our assets (including investments held by variable interest entities ("VIEs") that are included on our consolidated balance sheet) and $.2 billion were assets managed for third parties. Our general account investment strategies are to:

• provide largely stable investment income from a diversified high quality fixed income portfolio;

• maximize and maintain a stable spread between our investment income and the yields we pay on insurance products;

• sustain adequate liquidity levels to meet operating cash requirements, including a margin for potential adverse developments;

• continually monitor and manage the relationship between our investment portfolio and the financial characteristics of our insurance liabilities such as durations and cash flows; and

• maximize total return through active strategic asset allocation and investment management.

Investment activities are an important and integral part of our business because investment income is a significant component of our revenues. The profitability of many of our insurance products is significantly affected by spreads between interest yields on investments and rates credited on insurance liabilities. Also, certain insurance products are priced based on long term assumptions including investment returns. Although substantially all credited rates on SPDAs, FPDAs and interest sensitive life products may be changed annually (subject to minimum guaranteed rates), changes in crediting rates may not be sufficient to maintain targeted investment spreads in all economic and market environments. In addition, competition, minimum guaranteed rates and other factors, including the impact of surrenders and withdrawals, may limit our ability to adjust or to maintain crediting rates at levels necessary to avoid narrowing of spreads under certain market conditions. As of December 31, 2017, the average yield, computed on the cost basis of our fixed maturity portfolio, was 5.3 percent, and the average interest rate credited or accruing to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or fixed index products) was 4.6 percent.

We manage the equity-based risk component of our fixed index annuity products by:

• purchasing options on equity indices with similar payoff characteristics; and

• adjusting the participation rate to reflect the change in the cost of such options (such cost varies based on market conditions).

The prices of the options we purchase to manage the equity-based risk component of our fixed index annuities vary based on market conditions. All other factors held constant, the prices of the options generally increase with increases in the volatility of the applicable indices, which may either reduce the profitability of the fixed index products or cause us to lower participation rates. Accordingly, volatility of the indices is one factor in the uncertainty regarding the profitability of our fixed index products.

Our invested assets are predominately fixed rate in nature and their value fluctuates with changes in market rates, among other factors (such as changes in the overall compensation for risk required by the market as well as issuer specific changes in credit quality). We seek to manage the interest rate risk inherent in our business by managing the durations and cash flows of our fixed maturity investments along with those of the related insurance liabilities. For example, one management measure we use is asset and liability duration. Duration measures expected change in fair value for a given change in interest rates. If interest rates increase by 1 percent, the fair value of a fixed maturity security with a duration of 5 years is typically expected to decrease in value by approximately 5 percent. When the estimated durations of assets and liabilities are similar, absent other factors, a change in the value of assets related to changes in interest rates should be largely offset by a change in the value of liabilities. We calculate asset and liability durations using our estimates of future asset and liability cash flows. At December 31, 2017, the estimated duration of our fixed income securities (as modified to reflect estimated prepayments and call premiums) and the estimated duration of our insurance liabilities were approximately 8.6 years and 8.4 years, respectively.

12

COMPETITION

The markets in which we operate are competitive. Compared to CNO, many companies in the financial services industry are larger, have greater capital, technological and marketing resources, have greater access to capital and other sources of liquidity at a lower cost, offer broader and more diversified product lines, have greater brand recognition, have larger staffs and higher ratings. Banks, securities brokerage firms and other financial intermediaries also market insurance products or offer competing products, such as mutual fund products, traditional bank investments and other investment and retirement funding alternatives. We also compete with many of these companies and others in providing services for fees. In most areas, competition is based on a number of factors including pricing, service provided to distributors and policyholders and ratings. CNO's subsidiaries must also compete to attract and retain the allegiance of agents, insurance brokers and marketing companies.

In the individual health insurance business, companies compete primarily on the bases of marketing, service and price. Pursuant to federal regulations, the Medicare supplement products offered by all companies have standardized policy features. This increases the comparability of such policies and intensifies competition based on other factors. See "Insurance Underwriting" and "Governmental Regulation" for additional information. In addition to competing with the products of other insurance companies, commercial banks, mutual funds and broker dealers, our insurance products compete with health maintenance organizations, preferred provider organizations and other health care-related institutions which provide medical benefits based on contractual agreements.

Our principal competitors vary by product line. Our main competitors for agent-sold long-term care insurance products include Northwestern Mutual, Mutual of Omaha and New York Life. Our main competitors for agent-sold Medicare supplement insurance products include Blue Cross and Blue Shield Plans, United HealthCare and Mutual of Omaha. Our main competitors for life insurance sold through direct marketing channels include Gerber Life, Mutual of Omaha, New York Life, Massachusetts Mutual Life Insurance Company and subsidiaries of Torchmark Corporation. Our main competitors for supplemental health products sold through our Washington National segment include AFLAC, subsidiaries of Allstate, Colonial Life and Accident Company and subsidiaries of Torchmark Corporation.

In some of our product lines, such as life insurance and fixed annuities, we have a relatively small market share. Even in some of the lines in which we are one of the top writers, our market share is relatively small. For example, while, based on an Individual Long-Term Care Insurance Survey, our Bankers Life segment ranked fifth in annualized new premiums of individual long-term care insurance in the first half of 2017 with a market share of approximately 6 percent, the top four writers of individual long-term care insurance had annualized new premiums with a combined market share of approximately 65 percent during the period. In addition, while, based on a 2016 Medicare Supplement Loss Ratios report, we ranked sixth in direct premiums earned for Medicare supplement insurance in 2016 with a market share of 2.8 percent, the top writer of Medicare supplement insurance had direct premiums with a market share of 35 percent during the period.

Most of our major competitors have higher financial strength ratings than we do. Recent industry consolidation, including business combinations among insurance and other financial services companies, has resulted in larger competitors with even greater financial resources. Furthermore, changes in federal law have narrowed the historical separation between banks and insurance companies, enabling traditional banking institutions to enter the insurance and annuity markets and further increase competition. This increased competition may harm our ability to maintain or improve our profitability.

In addition, because the actual cost of products is unknown when they are sold, we are subject to competitors who may sell a product at a price that does not cover its actual cost. Accordingly, if we do not also lower our prices for similar products, we may lose market share to these competitors. If we lower our prices to maintain market share, our profitability will decline.

The Colonial Penn segment has faced increased competition from other insurance companies who also distribute products through direct marketing. In addition, the demand and cost of television advertising appropriate for Colonial Penn's campaigns fluctuates from period to period and will impact the average cost to generate a TV lead.

We must attract and retain sales representatives to sell our insurance and annuity products. Strong competition exists among insurance and financial services companies for sales representatives. We compete for sales representatives primarily on the basis of our financial position, financial strength ratings, support services, compensation, products and product features. Our competitiveness for such agents also depends upon the relationships we develop with these agents.

An important competitive factor for life insurance companies is the ratings they receive from nationally recognized rating organizations. Agents, insurance brokers and marketing companies who market our products and prospective purchasers

13

of our products use the ratings of our insurance subsidiaries as one factor in determining which insurer's products to market or purchase. Ratings have the most impact on our sales in the worksite market and sales of our annuity, interest-sensitive life insurance and long-term care products. Financial strength ratings provided by Fitch Ratings ("Fitch"), S&P Global Ratings ("S&P"), A.M. Best Company ("A.M. Best") and Moody's Investor Services, Inc. ("Moody's") are the rating agency's opinions of the ability of our insurance subsidiaries to pay policyholder claims and obligations when due. They are not directed toward the protection of investors, and such ratings are not recommendations to buy, sell or hold securities. The most recent ratings actions are described below.

On August 15, 2017, Fitch affirmed its "BBB+" financial strength ratings of our primary insurance subsidiaries. The outlook for these ratings is stable. A "BBB" rating, in Fitch's opinion, indicates that there is currently a low expectation of ceased or interrupted payments. The capacity to meet policyholder and contract obligations on a timely basis is considered adequate, but adverse changes in circumstances and economic conditions are more likely to impact this capacity. Fitch ratings for the industry range from "AAA Exceptionally Strong" to "C Distressed" and some companies are not rated. Pluses and minuses show the relative standing within a category. Fitch has nineteen possible ratings. There are seven ratings above the "BBB+" rating of our primary insurance subsidiaries and eleven ratings that are below that rating.

On June 23, 2017, S&P affirmed the financial strength ratings of "BBB+" of our primary insurance subsidiaries and revised the outlook for these ratings to stable from negative. S&P financial strength ratings range from "AAA" to "R" and some companies are not rated.  An insurer rated "BBB" or higher is regarded as having financial security characteristics that outweigh any vulnerabilities, and is highly likely to have the ability to meet financial commitments. An insurer rated "BBB", in S&P's opinion, has good financial security characteristics, but is more likely to be affected by adverse business conditions than are higher-rated insurers.  Pluses and minuses show the relative standing within a category.  S&P has twenty-one possible ratings.  There are seven ratings above the "BBB+" rating of our primary insurance subsidiaries and thirteen ratings that are below that rating.

On February 8, 2017, A.M. Best affirmed the financial strength ratings of "A-" of our primary insurance subsidiaries and the outlook for these ratings is stable. The "A-" rating is assigned to companies that have an excellent ability, in A.M. Best's opinion, to meet their ongoing obligations to policyholders.  A.M. Best ratings for the industry currently range from "A++ (Superior)" to "F (In Liquidation)" and some companies are not rated.  An "A++" rating indicates a superior ability to meet ongoing obligations to policyholders.  A.M. Best has sixteen possible ratings.  There are three ratings above the "A-" rating of our primary insurance subsidiaries and twelve ratings that are below that rating.

On May 9, 2016, Moody's affirmed the financial strength ratings of "Baa1" of our primary insurance subsidiaries and the outlook for these ratings is stable. Moody’s financial strength ratings range from "Aaa" to "C".  These ratings may be supplemented with numbers "1", "2", or "3" to show relative standing within a category.  In Moody's view, an insurer rated "Baa" offers adequate financial security, however, certain protective elements may be lacking or may be characteristically unreliable over any great length of time. Moody's has twenty-one possible ratings.  There are seven ratings above the "Baa1" rating of our primary insurance subsidiaries and thirteen ratings that are below that rating.

Rating agencies have increased the frequency and scope of their credit reviews and requested additional information from the companies that they rate, including us.  They may also adjust upward the capital and other requirements employed in the rating agency models for maintenance of certain ratings levels.  We cannot predict what actions rating agencies may take, or what actions we may take in response.  Accordingly, downgrades and outlook revisions related to us or the life insurance industry may occur in the future at any time and without notice by any rating agency.  These could increase policy surrenders and withdrawals, adversely affect relationships with our distribution channels, reduce new sales, reduce our ability to borrow and increase our future borrowing costs.

INSURANCE UNDERWRITING

Under regulations developed by the National Association of Insurance Commissioners (the "NAIC") (an association of state regulators and their staffs) and adopted by the states, we are prohibited from underwriting our Medicare supplement policies for certain first-time purchasers. If a person applies for insurance within six months after becoming eligible by reason of age, or disability in certain limited circumstances, the application may not be rejected due to medical conditions. Some states prohibit underwriting of all Medicare supplement policies. For other prospective Medicare supplement policyholders, such as senior citizens who are transferring to our products, the underwriting procedures are relatively limited, except for policies providing prescription drug coverage.

14

Before issuing long-term care products, we generally apply detailed underwriting procedures to assess and quantify the insurance risks. We require medical examinations of applicants (including blood and urine tests, where permitted) for certain health insurance products and for life insurance products which exceed prescribed policy amounts. These requirements vary according to the applicant's age and may vary by type of policy or product. We also rely on medical records and the potential policyholder's written application. In recent years, there have been significant regulatory changes with respect to underwriting certain types of health insurance. An increasing number of states prohibit underwriting and/or charging higher premiums for substandard risks. We monitor changes in state regulation that affect our products, and consider these regulatory developments in determining the products we market and where we market them.

Our supplemental health policies are individually underwritten using a simplified issue application. Based on an applicant's responses on the application, the underwriter either: (i) approves the policy as applied for; (ii) approves the policy with reduced benefits; or (iii) rejects the application.

Our life insurance products include policies that are underwritten individually and low face-amount life insurance products that utilize standardized underwriting procedures. After initial processing, insurance underwriters obtain the information needed to make an underwriting decision (such as medical examinations, doctors' statements and special medical tests). After collecting and reviewing the information, the underwriter either: (i) approves the policy as applied for; (ii) approves the policy with an extra premium charge because of unfavorable factors; or (iii) rejects the application.

We underwrite group insurance policies based on the characteristics of the group and its past claim experience. Graded benefit life insurance policies are issued without medical examination or evidence of insurability. There is minimal underwriting on annuities.

LIABILITIES FOR INSURANCE PRODUCTS

At December 31, 2017, the total balance of our liabilities for insurance products was $23.5 billion. These liabilities are generally payable over an extended period of time. The profitability of our insurance products depends on pricing and other factors. Differences between our expectations when we sold these products and our actual experience could result in future losses.

Liabilities for insurance products are calculated using management's best judgments, based on our past experience and standard actuarial tables, of mortality, morbidity, lapse rates, investment experience and expense levels with due consideration of provision for adverse development where prescribed by accounting principles generally accepted in the United States of America ("GAAP"). For all of our insurance products, we establish an active life reserve, a liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims. In addition, for our health insurance business, we establish a reserve for the present value of amounts not yet due on incurred claims. Many factors can affect these reserves and liabilities, such as economic and social conditions, inflation, hospital and pharmaceutical costs, changes in doctrines of legal liability and extra-contractual damage awards. Therefore, our reserves and liabilities are necessarily based on extensive estimates, assumptions and historical experience. Establishing reserves is an uncertain process, and it is possible that actual claims will materially exceed our reserves and have a material adverse effect on our results of operations and financial condition. Our financial results depend significantly upon the extent to which our actual claims experience is consistent with the assumptions we used in determining our reserves and pricing our products. If our assumptions are incorrect with respect to future claims, future policyholder premiums and policy charges or the investment income on assets supporting liabilities, or our reserves are insufficient to cover our actual losses and expenses, we would be required to increase our liabilities, which would negatively affect our operating results.

REINSURANCE

Consistent with the general practice of the life insurance industry, our subsidiaries enter into indemnity reinsurance agreements with other insurance companies in order to reinsure portions of the coverage provided by our insurance products. Indemnity reinsurance agreements are intended to limit a life insurer's maximum loss on a large or unusually hazardous risk or to diversify its risk. Indemnity reinsurance does not discharge the original insurer's primary liability to the insured. Our reinsured business is ceded to numerous reinsurers. Based on our periodic review of their financial statements, insurance industry reports and reports filed with state insurance departments, we believe the assuming companies are able to honor all contractual commitments.

As of December 31, 2017, the policy risk retention limit of our insurance subsidiaries was generally $.8 million or less. Reinsurance ceded by CNO represented 13 percent of gross combined life insurance inforce and reinsurance assumed

15

represented .5 percent of net combined life insurance inforce. Our principal reinsurers at December 31, 2017 were as follows (dollars in millions):

Name of Reinsurer	Reinsurance receivables		Ceded life insurance inforce		A.M. Best rating
Jackson National Life Insurance Company ("Jackson") (a)	$	1,408.2	$	696.3	A+
Wilton Reassurance Company ("Wilton Re")	305.5		1,215.5		A+
RGA Reinsurance Company (b)	228.0		101.3		A+
Munich American Reassurance Company	3.6		494.8		A+
Swiss Re Life and Health America Inc.	2.9		628.1		A+
SCOR Global Life USA Reinsurance Company	1.4		86.0		A+
All others (c)	225.6		230.6
	$	2,175.2	$	3,452.6

________________

(a) In addition to the life insurance business, Jackson has assumed certain annuity business from our insurance subsidiaries through a coinsurance agreement. Such business had total insurance policy liabilities of $1.1 billion at December 31, 2017.

(b) RGA Reinsurance Company has assumed a portion of the long-term care business of Bankers Life on a coinsurance basis.

(c) No other single reinsurer represents more than 3 percent of the reinsurance receivables balance or has assumed greater than 2 percent of the total ceded life insurance business inforce.

EMPLOYEES

At December 31, 2017, we had approximately 3,300 full time employees, including 1,280 employees supporting our Bankers Life segment, 220 employees supporting our Colonial Penn segment and 1,800 employees supporting our shared services and our Washington National, long-term care in run-off and corporate segments. None of our employees are covered by a collective bargaining agreement. We believe that we have good relations with our employees.

GOVERNMENTAL REGULATION

Insurance Regulation and Oversight

Our insurance businesses are subject to extensive regulation and supervision by the insurance regulatory agencies of the jurisdictions in which they operate. This regulation and supervision is primarily for the benefit and protection of customers, and not for the benefit of investors or creditors. State laws generally establish supervisory agencies that have broad regulatory authority, including the power to:

• grant and revoke business licenses;

• regulate and supervise sales practices and market conduct;

• establish guaranty associations;

• license agents;

• approve policy forms;

• approve premium rates and premium rate increases for some lines of business such as long-term care and Medicare supplement;

• establish reserve requirements;

• prescribe the form and content of required financial statements and reports;

• determine the reasonableness and adequacy of statutory capital and surplus;

16

• perform financial, market conduct and other examinations;

• define acceptable accounting principles; and

• regulate the types and amounts of permitted investments.

In addition, the NAIC develops model laws and regulations, many of which have been adopted by state legislators and/or insurance regulators, relating to:

• reserve requirements;

• risk-based capital ("RBC") standards;

• codification of insurance accounting principles;

• investment restrictions;

• restrictions on an insurance company's ability to pay dividends;

• credit for reinsurance; and

• product illustrations.

The Company's insurance subsidiaries are required to file detailed annual reports, in accordance with prescribed statutory accounting rules, with regulatory authorities in each of the jurisdictions in which they do business. As part of their routine oversight process, state insurance departments conduct periodic detailed examinations, generally once every three to five years, of the books, records and accounts of insurers domiciled in their states. These examinations are generally coordinated under the direction of the lead state and typically include all insurers operating in a holding company system pursuant to guidelines promulgated by the NAIC.

The NAIC has developed a principle-based reserving approach for life insurance products which will replace the current formulaic approach to determining policy reserves with an approach that more closely reflects the risks of the products. The principle-based approach became effective on January 1, 2017, and there is a three-year transition period where the approach is optional until it is required to be used for all life insurance products issued on or after January 1, 2020. The new approach will impact the financial statements of our insurance subsidiaries prepared under statutory accounting principles prescribed or permitted by regulatory authorities. The Company is implementing the new approach to its reserves on new life insurance products as they are introduced through the transition period.

State regulatory authorities and industry groups have developed several initiatives regarding market conduct, including the form and content of disclosures to consumers, advertising, sales practices and complaint handling. Various state insurance departments periodically examine the market conduct activities of domestic and non-domestic insurance companies doing business in their states, including our insurance subsidiaries. The purpose of these market conduct examinations is to determine if operations are consistent with the laws and regulations of the state conducting the examination. In addition, market conduct has become one of the criteria used by rating agencies to establish the ratings of an insurance company. For example, A.M. Best's ratings analysis now includes a review of the insurer's compliance program.

Most states mandate minimum benefit standards and benefit ratios for accident and health insurance policies. We are generally required to maintain, with respect to our individual long-term care policies, minimum anticipated benefit ratios over the entire period of coverage of not less than 60 percent. With respect to our Medicare supplement policies, we are generally required to attain and maintain an actual benefit ratio, after three years, of not less than 65 percent. We provide to the insurance departments of all states in which we conduct business annual calculations that demonstrate compliance with required minimum benefit ratios for both long-term care and Medicare supplement insurance. These calculations are prepared utilizing statutory lapse and interest rate assumptions. In the event that we fail to maintain minimum mandated benefit ratios, our insurance subsidiaries could be required to provide retrospective refunds and/or prospective rate reductions. We believe that our insurance subsidiaries currently comply with all applicable mandated minimum benefit ratios.

Our insurance subsidiaries are required, under guaranty fund laws of most states, to pay assessments up to prescribed limits to fund policyholder losses or liabilities of insolvent insurance companies. Typically, assessments are levied on member

17

insurers on a basis which is related to the member insurer's proportionate share of the business written by all member insurers. Assessments can be partially recovered through a reduction in future premium taxes in some states.

The NAIC has adopted the Risk Management and Own Risk and Solvency Assessment Model Act ("ORSA"), which has been enacted by each of our insurance subsidiaries’ domiciliary states. ORSA requires that insurers maintain a risk management framework and conduct an internal own risk and solvency assessment of the insurer’s material risks in normal and stressed environments. The assessment must be documented in an annual summary report, a copy of which must be submitted to insurance regulators as required or upon request.

The NAIC has adopted the Corporate Governance Annual Disclosure Model Act ("CGAD"), which has been enacted by our lead state insurance regulator. CGAD requires an annual filing by an insurer or insurance group that provides a detailed narrative and sample documentation on corporate governance structure and policies and practices.

The NAIC has adopted a model law governing cybersecurity consumer protections in 2017 with enactment by states thereafter. In addition, effective March 1, 2017, the New York Department of Financial Services (the "NYDFS") has a new cybersecurity regulation which includes transitional phase-in periods up to two years. An annual Certification of Compliance involving our cybersecurity program is required to be filed with the NYDFS.

Insurance Holding Company Regulations

All U.S. jurisdictions in which our insurers conduct business, except the Virgin Islands, have enacted laws or regulations regarding the activities of insurance holding company systems, including acquisitions, the terms of surplus debentures, the terms of transactions between or involving insurance companies and their affiliates and other related matters. Various reporting and approval requirements apply to transactions between or involving insurance companies and their affiliates within an insurance holding company system, depending on the size and nature of the transactions. Generally, all transactions between an insurance company and an affiliate must be fair and reasonable. Currently, the Company and its insurance subsidiaries are registered as a holding company system pursuant to such laws and regulations in the domiciliary states of the insurance subsidiaries.

All U.S. jurisdictions in which our insurers conduct business, except the Virgin Islands, have also enacted legislation or regulations that affect the acquisition (or sale) of control of insurance companies. The nature and extent of such legislation and regulations vary from state to state. Generally, these regulations require an acquirer of control to file detailed information and the plan of acquisition, and to obtain administrative approval prior to the acquisition of control. "Control" is generally defined as the direct or indirect power to direct or cause the direction of the management and policies of a person and is rebuttably presumed to exist if a person or group of affiliated persons directly or indirectly owns or controls 10 percent or more of the voting securities of another person.

Insurance regulators may prohibit the payment of dividends or other payments by our insurance subsidiaries to parent companies if they determine that such payment could be adverse to our policyholders or contract holders. Otherwise, the ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from financial statements prepared in accordance with GAAP. These regulations generally permit dividends to be paid by the insurance company if such dividends are not in excess of unassigned surplus and, for any 12-month period, are in amounts less than the greater of, or in some states, the lesser of:

• statutory net gain from operations or statutory net income for the prior year; or

• 10 percent of statutory capital and surplus at the end of the preceding year.

If an insurance company has negative earned surplus, any dividend payments require the prior approval of the director or commissioner of the applicable state insurance department.

In accordance with an order from the Florida Office of Insurance Regulation, Washington National may not distribute funds to any affiliate or shareholder, except pursuant to agreements with affiliates that have been approved, without prior notice to the Florida Office of Insurance Regulation. In addition, the RBC and other capital requirements described below can also limit, in certain circumstances, the ability of our insurance subsidiaries to pay dividends.

18

Insurance regulations require an annual enterprise risk report that identifies the material risks within the insurance holding company system that could pose enterprise risk to the insurer and which must be submitted to insurance regulators as required.

Long-Term Care Regulations

The NAIC has adopted model long-term care policy language providing nonforfeiture benefits and has proposed a rate stabilization standard for long-term care policies. Various bills are introduced from time to time in the U.S. Congress which propose the implementation of certain minimum consumer protection standards in all long-term care policies, including guaranteed renewability, protection against inflation and limitations on waiting periods for pre-existing conditions. Federal legislation permits premiums paid for qualified long-term care insurance to be tax-deductible medical expenses and for benefits received on such policies to be excluded from taxable income.

Our insurance subsidiaries that have long-term care business have made insurance regulatory filings seeking actuarially justified rate increases on our long-term care policies. Most of our long-term care business is guaranteed renewable, and, if necessary rate increases are not approved, we may be required to write off all or a portion of the deferred acquisition costs and the present value of future profits (collectively referred to as "insurance acquisition costs") and establish a premium deficiency reserve. If we are unable to raise our premium rates because we fail to obtain approval for actuarially justified rate increases in one or more states, our financial condition and results of operations could be adversely affected.

Capital Requirements

Using statutory statements filed with state regulators annually, the NAIC calculates certain financial ratios to assist state regulators in monitoring the financial condition of insurance companies. A "usual range" of results for each ratio is used as a benchmark. An insurance company may fall out of the usual range for one or more ratios because of specific transactions that are in themselves immaterial or eliminated at the consolidated level. Generally, an insurance company will become subject to regulatory scrutiny if it falls outside the usual ranges of four or more of the ratios, and regulators may then act, if the company has insufficient capital, to constrain the company's underwriting capacity. In the past, variances in certain ratios of our insurance subsidiaries have resulted in inquiries from insurance departments, to which we have responded. These inquiries have not led to any restrictions affecting our operations.

The NAIC's RBC requirements provide a tool for insurance regulators to determine the levels of statutory capital and surplus an insurer must maintain in relation to its insurance and investment risks and the need for possible regulatory attention. The basis of the system is a formula that applies prescribed factors to various risk elements in an insurer’s business to report a minimum capital requirement proportional to the amount of risk assumed by the insurer. The life and health insurer RBC formula is designed to measure annually: (i) the risk of loss from asset defaults and asset value fluctuations; (ii) the risk of loss from adverse mortality and morbidity experience; (iii) the risk of loss from mismatching of assets and liability cash flow due to changing interest rates; and (iv) business risks.

In addition, the RBC requirements currently provide for a trend test if a company's total adjusted capital is between 100 percent and 150 percent of its RBC at the end of the year. The trend test calculates the greater of the decrease in the margin of total adjusted capital over RBC:

• between the current year and the prior year; and

• for the average of the last 3 years.

It assumes that such decrease could occur again in the coming year. Any company whose trended total adjusted capital is less than 95 percent of its RBC would trigger a requirement to submit a comprehensive plan to the regulatory authority proposing corrective actions aimed at improving its capital position. The 2017 statutory annual statements of each of our insurance subsidiaries reflect total adjusted capital in excess of the levels subjecting the subsidiaries to any regulatory action.

Although we are under no obligation to do so, we may elect to contribute additional capital or retain greater amounts of capital to strengthen the surplus of certain insurance subsidiaries. Any election to contribute or retain additional capital could impact the amounts our insurance subsidiaries pay as dividends to the holding company. The ability of our insurance subsidiaries to pay dividends is also impacted by various criteria established by rating agencies to maintain or receive higher ratings and by the capital levels that we target for our insurance subsidiaries.

19

The NAIC is working to develop a group capital measure to be utilized as an analytical tool to supplement the existing holding company analysis as opposed to a capital standard. The measure is expected to be based on the aggregation of existing regulatory capital calculations for all entities within the insurance holding company system.

Regulation of Investments

Our insurance subsidiaries are subject to state laws and regulations that require diversification of their investment portfolios and limit the amount of investments in certain investment categories, such as below-investment grade bonds, equity real estate and common stocks. Failure to comply with these laws and regulations would cause investments exceeding regulatory limitations to be treated as non-admitted assets for purposes of measuring statutory surplus, and, in some instances, would require divestiture of such non-qualifying investments. The investments made by our insurance subsidiaries complied in all material respects with such investment regulations as of December 31, 2017.

Other Federal and State Laws and Regulations

Federal and state law and regulation require financial institutions to protect the security and confidentiality of personal information, including health-related and customer information, and to notify customers and other individuals about their policies and practices relating to their collection and disclosure of health-related and customer information and their practices relating to protecting the security and confidentiality of that information. State laws regulate use and disclosure of social security numbers and federal and state laws require notice to affected individuals, law enforcement, regulators and others if there is a breach of the security of certain personal information, including social security numbers. Federal and state laws and regulations regulate the ability of financial institutions to make telemarketing calls and to send unsolicited e-mail or fax messages to consumers and customers. Federal and state lawmakers and regulatory bodies may be expected to consider additional or more detailed regulation regarding these subjects and the privacy and security of personal information. The United States Department of Health and Human Services has issued regulations under the Health Insurance Portability and Accountability Act relating to standardized electronic transaction formats, code sets and the privacy of member health information. These regulations, and any corresponding state legislation, affect our administration of health insurance.

The USA PATRIOT Act of 2001 seeks to promote cooperation among financial institutions, regulators and law enforcement entities in identifying parties that may be involved in terrorism, money laundering or other illegal activities. To the extent required by applicable laws and regulations, CNO and its insurance subsidiaries have adopted anti-money laundering ("AML") programs that include policies, procedures and controls to detect and prevent money laundering, have designated compliance officers to oversee the programs, provide for on-going employee training and ensure periodic independent testing of the programs. CNO's and the insurance subsidiaries' AML programs, to the extent required, also establish and enforce customer identification programs and provide for the monitoring and the reporting to the Department of the Treasury of certain suspicious transactions.

In April 2016, the U.S. Department of Labor ("DOL") issued a final regulation that expands the range of activities considered to be fiduciary investment advice under the Employee Retirement Income Security Act of 1974 and the Internal Revenue Code (the "Code"). The DOL also issued a new "best interest contract" prohibited transaction exemption regarding how such advice can be provided to retirement investors. These regulations focus in large part on conflicts of interest related to investment recommendations made by financial advisors, registered investment advisors, insurance agents and other investment professionals to retirement investors, how financial advisors are able to discuss IRA rollovers, as well as how financial advisors and affiliates can transact with retirement investors. These regulations primarily impact our Bankers Life segment. Most provisions of these regulations became effective in June 2017. However, certain of the regulations including the "best interest contract" exemption were scheduled to become effective on January 1, 2018. In November 2017, the DOL delayed the applicability date of these provisions to July 1, 2019. We continue to monitor the status of the remaining provisions.

In addition, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act") generally provides for enhanced federal supervision of financial institutions, including insurance companies in certain circumstances, and financial activities that represent a systemic risk to financial stability or the U.S. economy. Under the Dodd-Frank Act, a Federal Insurance Office has been established within the U.S. Treasury Department to monitor all aspects of the insurance industry and its authority will likely extend to most lines of insurance that are written by the Company, although the Federal Insurance Office is not empowered with any general regulatory authority over insurers. The director of the Federal Insurance Office serves in an advisory capacity to the newly established Financial Stability Oversight Council and will have the ability to recommend that an insurance company or an insurance holding company be subject to heightened prudential standards by the Federal Reserve, if it is determined that financial distress at the company could pose a threat to financial stability in the U.S. The Dodd-Frank Act also provides for the preemption of state laws when inconsistent with certain international agreements, and would streamline the state-level regulation of reinsurance and surplus lines insurance. Under certain circumstances, the

20

FDIC can assume the role of a state insurance regulator and initiate liquidation proceedings under state law. In April 2017, the Trump Administration issued a Presidential Memorandum that calls for a comprehensive review of the Dodd-Frank Act. Such review may result in the Dodd-Frank Act being modified, repealed or replaced.

The asset management activities of 40|86 Advisors and our other investment advisory subsidiary are subject to various federal and state securities laws and regulations. The SEC and the Commodity Futures Trading Commission are the principal regulators of our asset management operations.

Broker-Dealer and Securities Regulation

We have a broker-dealer subsidiary that is registered under the Securities Exchange Act of 1934 and is subject to federal and state regulation, including, but not limited to, the Financial Industry Regulatory Authority ("FINRA"). Agents and employees registered or associated with our broker-dealer subsidiary are subject to the Securities Exchange Act of 1934 and to examination requirements and regulation by the SEC, FINRA and state securities commissioners. The SEC and other governmental agencies, as well as state securities commissions in the U.S., have the power to conduct administrative proceedings that can result in censure, fines, the issuance of cease-and-desist orders or suspension and termination or limitation of the activities of the regulated entity or its employees.

FEDERAL INCOME TAXATION

On December 22, 2017, President Trump signed into law the "Tax Cuts and Jobs Act" (the "Tax Reform Act") which enacted a broad range of changes to the Code including individual and corporate reforms and numerous changes to U.S. international tax provisions. The Tax Reform Act reduces the corporate tax rate to 21 percent and makes significant changes to the taxation of life insurance companies. Among other things, the Tax Reform Act modifies the computation of life insurance reserves, increases the capitalization rate and extends the amortization period for policy acquisition costs, imposes limitations on the deductibility of performance-based compensation to "covered employees" and interest expense, and allows for the expensing of certain capital expenditures. For net operating losses ("NOLs") arising after December 31, 2017, the Tax Reform Act limits the ability to utilize NOL carryforwards to 80% of taxable income. In addition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is prohibited. We do not expect the Tax Reform Act to have a material impact to our projection of cash taxes prior to 2024 due to the impact the Tax Reform Act will have on the timing of certain deductions and the impacts of our existing non-life NOLs. Beginning in 2018, we expect our effective tax rate to be in the 21 to 23 percent range. Our net deferred tax assets and liabilities have been revalued at the newly enacted U.S. corporate rate, and the impact has been recognized in our tax expense in 2017, the year of enactment. We continue to examine the impact this tax legislation may have on our business.

Our annuity and life insurance products generally provide policyholders with an income tax advantage, as compared to other savings investments such as certificates of deposit and bonds, because taxes on the increase in value of the products are deferred until received by policyholders. With other savings investments, the increase in value is generally taxed as earned. Annuity benefits and life insurance benefits, which accrue prior to the death of the policyholder, are generally not taxable until paid. Life insurance death benefits are generally exempt from income tax. Also, benefits received on immediate annuities (other than structured settlements) are recognized as taxable income ratably, as opposed to the methods used for some other investments which tend to accelerate taxable income into earlier years. The tax advantage for annuities and life insurance is provided in the Code and is generally followed in all states and other United States taxing jurisdictions.

Congress has considered, from time to time, possible changes to the U.S. tax laws, including elimination of the tax deferral on the accretion of value of certain annuities and life insurance products. It is possible that further tax legislation will be enacted which would contain provisions with possible adverse effects on our annuity and life insurance products.

Our insurance company subsidiaries are taxed under the life insurance company provisions of the Code. Provisions in the Code require a portion of the expenses incurred in selling insurance products to be deducted over a period of years, as opposed to immediate deduction in the year incurred. This provision increases the tax for statutory accounting purposes, which reduces statutory earnings and surplus and, accordingly, decreases the amount of cash dividends that may be paid by the life insurance subsidiaries.

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and NOLs. In evaluating our deferred tax assets, we consider whether it is more likely than not that the deferred tax assets will be realized. The ultimate realization of our deferred tax assets depends upon generating future taxable income during the periods in which our temporary differences become deductible and before our NOLs expire. In addition, the use of our NOLs is dependent, in part, on whether the Internal

21

Revenue Service ("IRS") ultimately agrees with the tax positions we have taken in previously filed tax returns and that we plan to take in future tax returns. Accordingly, with respect to our deferred tax assets, we assess the need for a valuation allowance on an ongoing basis.

As of December 31, 2017, 2016 and 2015, we have established a valuation allowance equal to the portion of the net deferred tax assets whose realization is uncertain. The determination of the amount of valuation allowance established is made by assessing the effects of limitations or issues on the value of our net deferred tax assets expected to be fully recognized in the future.

ITEM 1A.  RISK FACTORS.

CNO and its businesses are subject to a number of risks including general business and financial risk. Any or all of such risks could have a material adverse effect on the business, financial condition or results of operations of CNO. In addition, please refer to the "Cautionary Statement Regarding Forward-Looking Statements" included in "Item 7 - Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations".

Potential continuation of a low interest rate environment for an extended period of time may negatively impact our results of operations, financial position and cash flows.

In recent periods, interest rates have been at or near historically low levels. Some of our products, principally traditional whole life, universal life, fixed rate and fixed index annuity contracts, expose us to the risk that low or declining interest rates will reduce our spread (the difference between the amounts that we are required to pay under the contracts and the investment income we are able to earn on the investments supporting our obligations under the contracts). Our spread is a key component of our net income. Investment income is also an important component of the profitability of our health products, especially long-term care and supplemental health policies. In addition, interest rates impact the liability for the benefits we provide under our agent deferred compensation plan (as it is our policy to immediately recognize changes in assumptions used to determine this liability).

If interest rates were to decrease further or remain at low levels for an extended period of time, we may have to invest new cash flows or reinvest proceeds from investments that have matured or have been prepaid or sold at yields that have the effect of reducing our net investment income as well as the spread between interest earned on investments and interest credited to some of our products below present or planned levels. To the extent prepayment rates on fixed maturity investments or mortgage loans in our investment portfolio exceed our assumptions, this could increase the impact of this risk. We can lower crediting rates on certain products to offset the decrease in investment yield. However, our ability to lower these rates may be limited by: (i) contractually guaranteed minimum rates; or (ii) competition. In addition, a decrease in crediting rates may not match the timing or magnitude of changes in investment yields. Currently, the vast majority of our products with contractually guaranteed minimum rates have crediting rates set at the minimum rate. As a result, further decreases in investment yields would decrease the spread we earn and such spread could potentially become a loss.

The following table summarizes the distribution of annuity and universal life account values, net of amounts ceded, by guaranteed interest crediting rates as of December 31, 2017 (dollars in millions):

Guaranteed	Fixed interest and fixed			Universal
rate	index annuities			life			Total
> 5.0% to 6.0%	$	.4		$	13.4		$	13.8
> 4.0% to 5.0%	32.2			281.9			314.1
> 3.0% to 4.0%	924.3			47.3			971.6
> 2.0% to 3.0%	2,120.9			206.5			2,327.4
> 1.0% to 2.0%	801.8			21.6			823.4
1.0% and under	4,668.8			352.6			5,021.4
	$	8,548.4		$	923.3		$	9,471.7
Weighted average	1.79		%	2.78		%	1.88		%

In addition, during periods of declining or low interest rates, life and annuity products may be relatively more attractive to consumers, resulting in increased premium payments on products with flexible premium features, repayment of policy loans and increased persistency (a higher percentage of insurance policies remaining in force from year-to-year).

22

Our expectation of future investment income is an important consideration in determining the amortization of insurance acquisition costs and analyzing the recovery of these assets as well as determining the adequacy of our liabilities for insurance products. Expectations of lower future investment earnings may cause us to accelerate amortization, write down the balance of insurance acquisition costs or establish additional liabilities for insurance products, thereby reducing net income in the future periods.

In the fourth quarter of 2017, we completed a comprehensive review of interest rate assumptions on all of our products. The new money rate is the rate of return we receive on cash flows invested at a current date. If new money rates are lower than the overall weighted average return we earn from our investment portfolio, and the lower rates persist, our overall earned rates will decrease. Specifically, our current projections assume new money rates ranging from 4.65 percent to 5.42 percent for one year (previously ranged from 4.90 percent to 5.67 percent) and then grade over 5 years from these levels to an ultimate new money rate ranging from 5.73 percent to 6.50 percent (unchanged from the prior year), depending on the specific product. While subject to many uncertainties, we believe our assumptions for future new money rates are reasonable.

The remaining profit margins for the life contingent payout annuities in the Colonial Penn and Washington National segments and for the long-term care block in run-off are extremely low. Accordingly, future unfavorable changes to our assumptions are more likely to reduce earnings in the period such changes occur.

The following hypothetical scenarios illustrate the sensitivity of changes in interest rates to our products:

• The first hypothetical scenario assumes immediate and permanent reductions to current interest rate spreads on interest-sensitive products. We estimate that a pre-tax charge of approximately $42 million would occur if assumed spreads related to our interest-sensitive life and annuity products immediately and permanently decreased by 10 basis points.

• A second scenario assumes that new money rates remain at their current level indefinitely. We estimate that this scenario would: (i) result in a pre-tax charge of approximately $2 million related to an increase in deficiency reserves related to life contingent payout annuities; and (ii) reduce the margins in the long-term care block in run-off by approximately $8 million but not result in a charge because margins would continue to be positive (based on our 2017 comprehensive actuarial review).

• The third hypothetical scenario assumes current new money rates increase such that our current portfolio yield remains level.  We estimate that this scenario would: (i) result in a pre-tax charge of approximately $1 million related to an increase in deficiency reserves related to life contingent payout annuities; and (ii) reduce the margins in the long-term care block in run-off by approximately $4 million but not result in a charge because margins would continue to be positive (based on our 2017 comprehensive actuarial review).

While we expect the long-term care business in our Bankers Life segment to generate future net profits, the margins are relatively small and are vulnerable to a variety of factors including lower interest rates, higher morbidity and higher persistency. In addition, our projections of estimated future profits (losses) indicates that profits will be recognized in earlier periods, followed by losses in later periods, which has required us to establish a future loss reserve for this business. Our 2017 comprehensive actuarial review of this long-term care business indicated margins slightly decreased by $5 million in 2017 to approximately $315 million, or approximately 7 percent of related insurance liabilities net of insurance intangibles. Given the concentration of exposure to interest rates in this block of business, we modeled the following additional hypothetical scenarios to illustrate the sensitivity of additional changes in interest rates on long-term care products in the Bankers Life segment:

• One scenario assumes that the new money rates available to invest cash flows from our long-term care block in the Bankers Life segment remain at their current level of 5.42 percent indefinitely. This scenario would reduce margins by approximately $105 million but would not result in a charge because margins would continue to be positive (based on our 2017 comprehensive actuarial review).

• An additional scenario assumes that current new money rates available to invest cash flows from our long-term care block in the Bankers Life segment immediately decrease to approximately 3.50 percent and remain at that level indefinitely. This scenario would reduce margins in this block by approximately $410 million and would result in a pre-tax charge of approximately $95 million (based on our 2017 comprehensive actuarial review).

23

Although the hypothetical revisions described in the scenarios summarized above are not currently required or anticipated, we believe similar changes could occur based on past variances in experience and our expectations of the ranges of future experience that could reasonably occur. We have assumed that revisions to assumptions resulting in such adjustments would occur equally among policy types, ages and durations within each product classification. Any actual adjustment would be dependent on the specific policies affected and, therefore, may differ from such estimates. In addition, the impact of actual adjustments would reflect the net effect of all changes in assumptions during the period.

Sustained periods of low or declining interest rates may adversely affect our results of operations, financial position and cash flows.

A long-term care reinsurance transaction could adversely impact our financial position, results of operations and/or cash flows.

We have previously disclosed that our strategic priorities include a reduction of our relative long-term care exposure. To achieve this goal, it is likely that we will need to transfer the risks of a portion of this business through one or more reinsurance transactions. The comprehensive, nursing home and home health care long-term care business written before 2003 has negative margins. In order to meaningfully reduce the risk associated with our long-term care block, a substantial ceding commission would be paid by the Company to transfer long-term care risk through reinsurance. Such a reduction of our long-term care exposure would result in the recognition of a loss. Due to our current tax position, it is likely that a portion of the tax benefit recognized on the loss would not be realized and we may be required to increase our valuation allowance for deferred tax assets. Although we believe reducing our exposure to the risk of long-term care business would benefit the Company in the long term, such reduction could initially adversely impact certain aspects of our financial position, results of operations and/or cash flow.

There are risks to our business associated with broad economic conditions.

From 2008 to 2010, the U.S. economy experienced unusually severe credit and liquidity contraction and underwent a recession. Following several years of rapid credit expansion, a contraction in mortgage lending coupled with substantial declines in home prices and rising mortgage defaults resulted in significant write-downs of asset values by financial institutions, including government-sponsored entities and major commercial and investment banks. These write-downs, initially of mortgage-backed securities but spreading to many sectors of the related credit markets, and to related credit default swaps and other derivative securities, caused many financial institutions to seek additional capital, to merge with larger and stronger institutions, to be subsidized by the U.S. government or, in some cases, to fail. These factors, combined with declining business and consumer confidence and increased unemployment, precipitated an economic slowdown.

General factors such as the availability of credit, consumer spending, business investment, capital market conditions and inflation affect our business. For example, in an economic downturn, higher unemployment, lower family income, lower corporate earnings, lower business investment and lower consumer spending may depress the demand for life insurance, annuities and other insurance products. In addition, this type of economic environment may result in higher lapses or surrenders of policies.

Our business is exposed to the performance of the debt and equity markets. Adverse market conditions can affect the liquidity and value of our investments. The manner in which debt and equity market performance and changes in interest rates have affected, and will continue to affect, our business, financial condition, growth and profitability include, but are not limited to, the following:

• The value of our investment portfolio has been materially affected in the past by changes in market conditions which resulted in substantial changes in realized and/or unrealized losses. Future adverse capital market conditions could result in additional realized and/or unrealized losses.

• Changes in interest rates also affect our investment portfolio. In periods of increasing interest rates, life insurance policy loans, surrenders and withdrawals could increase as policyholders seek higher returns. This could require us to sell invested assets at a time when their prices may be depressed by the increase in interest rates, which could cause us to realize investment losses. Conversely, during periods of declining interest rates, we could experience increased premium payments on products with flexible premium features, repayment of policy loans and increased percentages of policies remaining inforce. We could obtain lower returns on investments made with these cash flows. In addition, prepayment rates on investments may increase so that we might have to reinvest those proceeds in lower-yielding investments. As a consequence of these factors, we could experience a decrease in the spread between the returns on

24

our investment portfolio and amounts to be credited to policyholders and contractholders, which could adversely affect our profitability.

• The attractiveness of certain of our insurance products may decrease because they are linked to the equity markets and assessments of our financial strength, resulting in lower profits. Increasing consumer concerns about the returns and features of our insurance products or our financial strength may cause existing customers to surrender policies or withdraw assets, and diminish our ability to sell policies and attract assets from new and existing customers, which would result in lower sales and fee revenues.

Claims experience on our long-term care products could negatively impact our operations if actual experience diverges from historical patterns and our expectations.

In setting premium rates, we consider historical claims information and other factors, but we cannot predict future claims with certainty. This is particularly applicable to our long-term care insurance products, for which historical claims experience may not be indicative of future experience. Long-term care products tend to have fewer claims than other health products such as Medicare supplement products, but when claims are incurred, they tend to be much higher in dollar amount and longer in duration. Also, long-term care claims are incurred much later in the life of the policy than most other supplemental health products. As a result of these traits, it is difficult to appropriately price this product. For our long-term care insurance, actual persistency in later policy durations that is higher than our persistency assumptions could have a negative impact on profitability. If these policies remain inforce longer than we assumed, then we could be required to make greater benefit payments than anticipated when the products were priced. Mortality is a critical factor influencing the length of time a claimant receives long-term care benefits. Mortality continues to improve for the general population. Improvements in actual mortality compared to our pricing assumptions have adversely affected the profitability of long-term care products and if such trends continue, further losses may be realized.

Our Bankers Life segment has offered long-term care insurance since 1985. In recent years, the claims experience and persistency on some of Bankers Life long-term care blocks has generally been higher than our pricing expectations which has resulted in higher benefit ratios and adversely affected our profitability. While we have received regulatory approvals for numerous premium rate increases in recent years pertaining to these blocks, there can be no assurance that future requests will be approved. Even with the rate increases that have been approved, this block experienced benefit ratios of 132.3 percent in 2017, 135.0 percent in 2016 and 139.2 percent in 2015.

The results of operations of our insurance business will decline if our premium rates are not adequate or if we are unable to increase rates.

We set the premium rates on our health insurance policies based on facts and circumstances known at the time we issue the policies and on assumptions about numerous variables, including the actuarial probability of a policyholder incurring a claim, the probable size of the claim, maintenance costs to administer the policies and the interest rate earned on our investment of premiums. In setting premium rates, we consider historical claims information, industry statistics, the rates of our competitors and other factors, but we cannot predict with certainty the future actual claims on our products. If our actual claims experience proves to be less favorable than we assumed and we are unable to raise our premium rates to the extent necessary to offset the unfavorable claims experience, our financial results will be adversely affected.

We review the adequacy of our premium rates regularly and file proposed rate increases on our health insurance products when we believe existing premium rates are too low. It is possible that we will not be able to obtain approval for premium rate increases from currently pending or future requests. If we are unable to raise our premium rates because we fail to obtain approval in one or more states, our financial results will be adversely affected. Moreover, in some instances, our ability to exit unprofitable lines of business is limited by the guaranteed renewal feature of most of our insurance policies. Due to this feature, we cannot exit such lines of business without regulatory approval, and accordingly, we may be required to continue to service those products at a loss for an extended period of time.

If we are successful in obtaining regulatory approval to raise premium rates, the increased premium rates may reduce the volume of our new sales and cause existing policyholders to allow their policies to lapse. This could result in a significantly higher ratio of claim costs to premiums if healthier policyholders allow their policies to lapse, while policies of less healthy policyholders continue inforce. This would reduce our premium income and profitability in future periods.

Our Medicare supplement health policies allow us to increase premium rates when warranted by our actual claims experience. These rate increases must be approved by the applicable state insurance departments, and we are required to submit

25

actuarial claims data to support the need for such rate increases. The re-rate application and approval process on Medicare supplement health products is a normal recurring part of our business operations and reasonable rate increases are typically approved by the state departments as long as they are supported by actual claims experience and are not unusually large in either dollar amount or percentage increase. For policy types on which rate increases are a normal recurring event, our estimates of insurance liabilities assume we will be able to raise rates if experience on the blocks warrants such increases in the future.

As a result of higher persistency and resultant higher claims in our long-term care block in the Bankers Life segment than assumed in the original pricing, our premium rates were too low. Accordingly, we have been seeking approval from regulatory authorities for rate increases on portions of this business. Many of the rate increases have been approved by regulators and implemented, but it has become increasingly difficult to receive regulatory approval for the premium rate increases we have sought. If we are unable to obtain pending or future rate increases, the profitability of these policies and the performance of this block of business will be adversely affected. Most of our long-term care business is guaranteed renewable, and, if necessary rate increases are not approved, we would be required to recognize a loss and establish a premium deficiency reserve.

In some cases, we offer long-term care policyholders the opportunity to reduce their coverage amounts or accept non-forfeiture benefits as alternatives to increasing their premium rates. The financial impact of these alternatives could also result in policyholder anti-selection, meaning that policyholders who are less likely to incur claims may reduce their benefits, while policyholders who are more likely to incur claims may maintain full coverage and accept their rate increase.

Our reserves for future insurance policy benefits and claims may prove to be inadequate, requiring us to increase liabilities which results in reduced net income and shareholders' equity.

Liabilities for insurance products are calculated using management's best judgments, based on our past experience and standard actuarial tables of mortality, morbidity, lapse rates, investment experience and expense levels. For our health insurance business, we establish an active life reserve; a liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims; and a reserve for the present value of amounts on incurred claims not yet due. We establish reserves based on assumptions and estimates of factors either established at the Effective Date for business inforce or considered when we set premium rates for business written after that date.

Many factors can affect these reserves and liabilities, such as economic and social conditions, inflation, hospital and pharmaceutical costs, changes in life expectancy, regulatory actions, changes in doctrines of legal liability and extra-contractual damage awards. Therefore, the reserves and liabilities we establish are necessarily based on estimates, assumptions, industry data and prior years' statistics. It is possible that actual claims will materially exceed our reserves and have a material adverse effect on our results of operations and financial condition. We have incurred significant losses beyond our estimates as a result of actual claim costs and persistency of our long-term care business included in our Bankers Life segment. The insurance policy benefits incurred for our long-term care products in our Bankers Life segment were $599.3 million, $636.1 million and $669.0 million in 2017, 2016 and 2015, respectively. The benefit ratios for our long-term care products in our Bankers Life segment were 132.3 percent, 135.0 percent and 139.2 percent in 2017, 2016 and 2015, respectively. Our financial performance depends significantly upon the extent to which our actual claims experience and future expenses are consistent with the assumptions we used in setting our reserves. If our future claims are higher than our assumptions, and our reserves prove to be insufficient to cover our actual losses and expenses, we would be required to increase our liabilities, and our financial results could be adversely affected.

We may be required to accelerate the amortization of deferred acquisition costs or the present value of future profits or establish premium deficiency reserves.

Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. The present value of future profits represents the value assigned to the right to receive future cash flows from contracts existing at the Effective Date. The balances of these accounts are amortized over the expected lives of the underlying insurance contracts. On an ongoing basis, we test these accounts recorded on our balance sheet to determine if these amounts are recoverable under current assumptions. In addition, we regularly review the estimates and assumptions underlying these accounts for those products for which we amortize deferred acquisition costs or the present value of future profits in proportion to gross profits or gross margins. If facts and circumstances change, these tests and reviews could lead to reduction in the balance of those accounts, and the establishment of a premium deficiency reserve. Such results could have an adverse effect on the results of our operations and our financial condition. See "Item 7 Management's Discussion and Analysis of

26

Consolidated Finance Condition and Results of Operations, Critical Accounting Policies, Present Value of Future Profits and Deferred Acquisition Costs."

Our operating results may suffer if policyholder surrender levels differ significantly from our assumptions.

Surrenders of our annuities and life insurance products can result in losses and decreased revenues if surrender levels differ significantly from assumed levels. At December 31, 2017, approximately 23 percent of our total insurance liabilities, or approximately $5.4 billion, could be surrendered by the policyholder without penalty. The surrender charges that are imposed on our fixed rate annuities typically decline during a penalty period, which ranges from five to twelve years after the date the policy is issued. Surrender charges are eliminated after the penalty period. Surrenders and redemptions could require us to dispose of assets earlier than we had planned, possibly at a loss. Moreover, surrenders and redemptions require faster amortization of either the acquisition costs or the commissions associated with the original sale of a product, thus reducing our net income. We believe policyholders are generally more likely to surrender their policies if they believe the issuer is having financial difficulties, or if they are able to reinvest the policy's value at a higher rate of return in an alternative insurance or investment product.

Changing interest rates may adversely affect our results of operations.

Our profitability is affected by fluctuating interest rates. While we monitor the interest rate environment and employ asset/liability and hedging strategies to mitigate such impact, our financial results could be adversely affected by changes in interest rates. Our spread-based insurance and annuity business is subject to several inherent risks arising from movements in interest rates. First, interest rate changes can cause compression of our net spread between interest earned on investments and interest credited to customer deposits. Our ability to adjust for such a compression is limited by the guaranteed minimum rates that we must credit to policyholders on certain products, as well as the terms on most of our other products that limit reductions in the crediting rates to pre-established intervals. As of December 31, 2017, the vast majority of our products with contractual guaranteed minimum rates had crediting rates set at the minimum. In addition, approximately 21 percent of our insurance liabilities were subject to interest rates that may be reset annually; 50 percent had a fixed explicit interest rate for the duration of the contract; 26 percent had credited rates that approximate the income we earn; and the remainder had no explicit interest rates. Second, if interest rate changes produce an unanticipated increase in surrenders of our spread-based products, we may be forced to sell invested assets at a loss in order to fund such surrenders. Third, the profits from many non-spread-based insurance products, such as long-term care policies, can be adversely affected when interest rates decline because we may be unable to reinvest the cash from premiums received at the interest rates anticipated when we sold the policies. Finally, changes in interest rates can have significant effects on the fair value and performance of our investments in general such as the timing of cash flows on many structured securities due to changes in the prepayment rate of the loans underlying such securities.

We employ asset/liability strategies that are designed to mitigate the effects of interest rate changes on our profitability but do not currently extensively employ derivative instruments for this purpose. We may not be successful in implementing these strategies and sustaining adequate investment spreads.

We simulate our cash flows expected from existing business under various interest rate scenarios. With such estimates, we actively manage the relationship between the duration of our assets and the expected duration of our liabilities. When the estimated durations of assets and liabilities are similar, the effect of changes in market interest rates shall have largely offsetting effects on the value of the related assets and liabilities. At December 31, 2017, the estimated durations of our fixed income securities (as modified to reflect estimated prepayments and call premiums) and insurance liabilities were approximately 8.6 years and 8.4 years, respectively. We estimate that our fixed maturity securities and short-term investments, net of corresponding changes in insurance acquisition costs, would decline in fair value by approximately $445 million if interest rates were to increase by 10 percent from rates as of December 31, 2017. Our simulations incorporate numerous assumptions, require significant estimates and assume an immediate change in interest rates without any management reaction to such change. Consequently, potential changes in the values of our financial instruments indicated by the simulations will likely be different from the actual changes experienced under given interest rate scenarios, and the differences may be material. Because we actively manage our investments and liabilities, our net exposure to interest rates can vary over time.

General market conditions affect investments and investment income.

The performance of our investment portfolio depends in part upon the level of and changes in interest rates, risk spreads, real estate values, market volatility, the performance of the economy in general, the performance of the specific obligors included in our portfolio and other factors that are beyond our control. Changes in these factors can affect our net investment income in any period, and such changes can be substantial.

27

Financial market conditions can also affect our realized and unrealized investment gains (losses). During periods of rising interest rates, the fair values of our investments will typically decline. Conversely, during periods of falling interest rates, the fair values of our investments will typically rise.

We use derivatives in an effort to hedge higher potential returns to our fixed index annuity policyholders based on the increase in the value of a particular index. For derivative positions we hold that are in-the-money, we are exposed to credit risk in the event of default of our counterparty.

In addition, our investment borrowings from the Federal Home Loan Bank ("FHLB") are secured by collateral, the fair value of which can be significantly impacted by general market conditions. If the fair value of pledged collateral falls below specific levels, we would be required to pledge additional eligible collateral or repay all or a portion of the investment borrowings.

We face risk with respect to our reinsurance agreements.

We transfer exposure to certain risks to others through reinsurance arrangements. Under these arrangements, other insurers assume a portion of our losses and expenses associated with reported and unreported claims in exchange for a portion of policy premiums. The availability, amount and cost of reinsurance depend on general market conditions and may vary significantly. As of December 31, 2017, our reinsurance receivables and ceded life insurance inforce totaled $2.2 billion and $3.5 billion, respectively. Our six largest reinsurers accounted for 93 percent of our ceded life insurance inforce. We face credit risk with respect to reinsurance. When we obtain reinsurance, we are still liable for those transferred risks even if the reinsurer defaults on its obligations. The failure, insolvency, inability or unwillingness of one or more of the Company's reinsurers to perform in accordance with the terms of its reinsurance agreement could negatively impact our earnings or financial position.

In December 2013, two of our insurance subsidiaries with long-term care business (Washington National and BCLIC) entered into 100% coinsurance agreements ceding $495 million of long-term care reserves to BRe, a reinsurer domiciled in the Cayman Islands. BRe was formed in 2012 and was focused on specialized insurance including long-term care. BRe is a reinsurer that is not licensed or accredited by the states of domicile (Indiana and New York, respectively) of the insurance subsidiaries ceding the long-term care business and BRe is not rated by A.M. Best. As a result of its non-accredited status, BRe was required to provide collateral which met the regulatory requirements of the states of domicile in order for our insurance subsidiaries to obtain full credit in their statutory financial statements for the reinsurance receivables due from BRe. Such collateral was held in market value trusts subject to 7% over collateralization, investment guidelines and periodic true-up provisions. In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business as further described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Consolidated Financial Condition - Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off".

Our investment portfolio is subject to several risks that may diminish the value of our invested assets and negatively impact our profitability, our financial condition and our liquidity.

The value of our investment portfolio is subject to numerous factors, which may be difficult to predict, and are often beyond our control. These factors include, but are not limited to, the following:

• changes in interest rates and credit spreads, which can reduce the value of our investments as further discussed in the risk factor entitled "Changing interest rates may adversely affect our results of operations";

• changes in patterns of relative liquidity in the capital markets for various asset classes;

• changes in the perceived or actual ability of issuers to make timely repayments, which can reduce the value of our investments. This risk is significantly greater with respect to below-investment grade securities, which comprised 13 percent of the cost basis of our available for sale fixed maturity investments as of December 31, 2017; and

• changes in the estimated timing of receipt of cash flows. For example, our structured securities, which comprised 25 percent of our available for sale fixed maturity investments at December 31, 2017, are subject to variable prepayment on the assets underlying such securities, such as mortgage loans. When asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage

28

obligations (collectively referred to as "structured securities") prepay faster than expected, investment income may be adversely affected due to the acceleration of the amortization of purchase premiums or the inability to reinvest at comparable yields in lower interest rate environments.

We have recorded writedowns of fixed maturity investments, equity securities and other invested assets as a result of conditions which caused us to conclude a decline in the fair value of the investment was other than temporary as follows: $22.8 million in 2017; $32.3 million in 2016 ($35.9 million, prior to the $3.6 million of impairment losses recognized through accumulated other comprehensive income); and $39.9 million in 2015 ($42.9 million, prior to the $3.0 million of impairment losses recognized through accumulated other comprehensive income). Our investment portfolio is subject to the risks of further declines in realizable value. However, we attempt to mitigate this risk through the diversification and active management of our portfolio.

In the event of substantial product surrenders or policy claims, we may be required to sell assets at a loss, thereby eroding the performance of our portfolio.

Because a substantial portion of our operating results are derived from returns on our investment portfolio, significant losses in the portfolio may have a direct and materially adverse impact on our results of operations. In addition, losses on our investment portfolio could reduce the investment returns that we are able to credit to our customers of certain products, thereby impacting our sales and eroding our financial performance. Investment losses may also reduce the capital of our insurance subsidiaries, which may cause us to make additional capital contributions to those subsidiaries or may limit the ability of the insurance subsidiaries to make dividend payments to CNO.

Deteriorating financial performance of securities collateralized by mortgage loans and commercial mortgage loans may lead to writedowns, which could have a material adverse effect on our results of operations and financial condition.

Changes in mortgage delinquency or recovery rates, declining real estate prices, challenges to the validity of foreclosures and the quality of service provided by service providers on securities in our portfolios could impact the value of our investments and such changes, if material, could lead us to determine that writedowns are appropriate.

The determination of the amount of realized investment losses recorded as impairments of our investments is highly subjective and could have a material adverse effect on our operating results and financial condition.

The determination of realized investment losses recorded as impairments is based upon our ongoing evaluation and assessment of known risks. We consider a wide range of factors about the investment and use our best judgment in evaluating the cause of a decline in estimated fair value and in assessing prospects for recovery. Inherent in our evaluation are assumptions and estimates about the operations of the issuer and its future earnings potential. Such evaluations and assessments are revised as conditions change and new information becomes available. We update our evaluations regularly and reflect losses from impairments in operating results as such evaluations are revised. Our assessment of whether unrealized losses are other-than-temporary impairments requires significant judgment and future events may occur, or additional information may become available, which may necessitate changes in our ongoing assessments which may impact the level of future impairments of securities in our portfolio. Historical trends may not be indicative of future other-than-temporary impairments.

The determination of fair value of our fixed maturity securities results in unrealized investment gains and losses and is, in some cases, highly subjective and could materially impact our operating results and financial condition.

In determining fair value, we generally utilize market transaction data for the same or similar instruments. The degree of management judgment involved in determining fair values is inversely related to the availability of market observable information. Since significant observable market inputs are not available for certain securities, it may be difficult to value them. The fair value of financial assets and financial liabilities may differ from the amount actually received to sell an asset or the amount paid to transfer a liability in an orderly transaction between market participants at the measurement date. Moreover, the use of different valuation assumptions may have a material effect on the fair values of the financial assets and financial liabilities. As of December 31, 2017 and 2016, our total unrealized net investment gains before adjustments for insurance intangibles and deferred income taxes were $2.2 billion and $1.3 billion, respectively.

29

Concentration of our investment portfolio in any particular sector of the economy or type of asset may have an adverse effect on our financial position or results of operations.

The concentration of our investment portfolio in any particular industry, group of related industries, asset classes (such as residential mortgage-backed securities and other asset-backed securities), or geographic area could have an adverse effect on our results of operations and financial position. While we seek to mitigate this risk by having a broadly diversified portfolio, events or developments that have a negative impact on any particular industry, group of related industries or geographic area may have an adverse effect on the investment portfolio.

Our business is subject to extensive regulation, which limits our operating flexibility and could result in our insurance subsidiaries being placed under regulatory control or otherwise negatively impact our financial results.

Our insurance business is subject to extensive regulation and supervision in the jurisdictions in which we operate. See "Business of CNO - Governmental Regulation." Our insurance subsidiaries are subject to state insurance laws that establish supervisory agencies. The regulations issued by state insurance agencies can be complex and subject to differing interpretations. If a state insurance regulatory agency determines that one of our insurance company subsidiaries is not in compliance with applicable regulations, the subsidiary is subject to various potential administrative remedies including, without limitation, monetary penalties, restrictions on the subsidiary's ability to do business in that state and a return of a portion of policyholder premiums. In addition, regulatory action or investigations could cause us to suffer significant reputational harm, which could have an adverse effect on our business, financial condition and results of operations.

Our insurance subsidiaries are required to comply with statutory accounting principles ("SAP"). SAP (including principles that impact the calculation of RBC and our insurance liabilities) are subject to continued review by the NAIC in an effort to address emerging issues and improve financial reporting. Various proposals are currently being considered by the NAIC, some of which, if enacted, would negatively impact our insurance subsidiaries.

Our insurance subsidiaries are also subject to RBC requirements. These requirements were designed to evaluate the adequacy of statutory capital and surplus in relation to investment and insurance risks associated with asset quality, mortality and morbidity, asset and liability matching and other business factors. The requirements are used by states as an early warning tool to discover companies that may be weakly-capitalized for the purpose of initiating regulatory action. Generally, if an insurer's RBC ratio falls below specified levels, the insurer is subject to different degrees of regulatory action depending upon the magnitude of the deficiency. The 2017 statutory annual statements of each of our insurance subsidiaries reflect RBC ratios in excess of the levels subjecting the insurance subsidiaries to any regulatory action.

In addition to the RBC requirements, certain states have established minimum capital requirements for insurance companies licensed to do business in their state. These regulators have the discretionary authority, in connection with the continual licensing of the Company's insurance subsidiaries, to limit or prohibit writing new business within its jurisdiction when, in the state's judgment, the insurance subsidiary is not maintaining adequate statutory surplus or capital or that the insurance subsidiary's further transaction of business would be hazardous to policyholders. The state insurance department rules provide several standards for the regulators to use in identifying companies which may be deemed to be in hazardous financial condition. One of the standards defines hazardous conditions as existing if an insurer's operating loss in the last twelve months or any shorter period of time, (including, but not limited to: (A) net capital gain or loss; (B) change in nonadmitted assets; and (C) cash dividends paid to shareholders), is greater than fifty percent of the insurer's remaining surplus. All of our insurance subsidiaries currently exceed these standards, if applicable.

Our broker-dealer and investment advisor subsidiaries are subject to regulation and supervision by the SEC, FINRA and certain state regulatory bodies. The SEC, FINRA and other governmental agencies, as well as state securities commissions, may examine or investigate the activities of broker-dealers and investment advisors. These examinations or investigations often focus on the activities of the registered representatives and registered investment advisors doing business through such entities and the entities' supervision of those persons. It is possible that any examination or investigation could lead to enforcement action by the regulator and/or may result in payments of fines and penalties, payments to customers, or both, as well as changes in systems or procedures of such entities, any of which could have a material adverse effect on the Company's financial condition or results of operations.

Furthermore, the SEC is reviewing the standard of conduct applicable to brokers, dealers and investment advisors when those entities provide personalized investment advice about securities to retail customers. FINRA has also issued a report addressing how its member firms might identify and address conflicts of interest including conflicts related to the introduction of new products and services and the compensation of the member firms' associated persons. These regulatory initiatives could

30

have an impact on Company operations and the manner in which broker-dealers and investment advisors distribute the Company's products.

Volatility in the securities markets, and other economic factors, may adversely affect our business, particularly our sales of certain life insurance products and annuities.

Fluctuations in the securities markets and other economic factors may adversely affect sales and/or policy surrenders of our annuities and life insurance policies. For example, volatility in the equity markets may deter potential purchasers from investing in fixed index annuities and may cause current policyholders to surrender their policies for the cash value or to reduce their investments. In addition, significant or unusual volatility in the general level of interest rates could negatively impact sales and/or lapse rates on certain types of insurance products.

Litigation and regulatory investigations are inherent in our business, may harm our financial condition and reputation, and may negatively impact our financial results.

Insurance companies historically have been subject to substantial litigation. In addition to the traditional policy claims associated with their businesses, insurance companies like ours face class action suits and derivative suits from policyholders and/or shareholders. We also face significant risks related to regulatory investigations and proceedings. The litigation and regulatory matters we are, have been, or may become, subject to include matters related to the classification of our career agents as independent contractors, sales, marketing and underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, administration, additional premium charges for premiums paid on a periodic basis, calculation of cost of insurance charges, changes to certain non-guaranteed policy features, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies and recommending unsuitable products to customers. Certain of our insurance policies allow or require us to make changes based on experience to certain non-guaranteed elements ("NGEs") such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. We intend to make changes to certain NGEs in the future. In some instances in the past, such action has resulted in litigation and similar litigation may arise in the future. Our exposure (including the potential adverse financial consequences of delays or decisions not to pursue changes to certain NGEs), if any, arising from any such action cannot presently be determined. Our pending legal and regulatory proceedings include matters that are specific to us, as well as matters faced by other insurance companies. State insurance departments have focused and continue to focus on sales, marketing and claims payment practices and product issues in their market conduct examinations. Negotiated settlements of class action and other lawsuits have had a material adverse effect on the business, financial condition and results of operations of CNO and our insurance subsidiaries.

We are, in the ordinary course of our business, a plaintiff or defendant in actions arising out of our insurance business, including class actions and reinsurance disputes, and, from time to time, we are also involved in various governmental and administrative proceedings and investigations and inquiries such as information requests, subpoenas and books and record examinations, from state, federal and other authorities. Recently, we and other insurance companies have been the subject of regulatory examinations regarding compliance with state unclaimed property laws. Such examinations have included inquiries related to the use of data available on the U.S. Social Security Administration's Death Master File to identify instances where benefits under life insurance policies, annuities and retained asset accounts are payable. It is possible that such examination or other regulatory inquiries may result in payments to beneficiaries, escheatment of funds deemed abandoned under state laws and changes to procedures for the identification and escheatment of abandoned property. See the note to the consolidated financial statements entitled "Litigation and Other Legal Proceedings." The ultimate outcome of these lawsuits, regulatory proceedings and investigations cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations or cash flows. We could also suffer significant reputational harm as a result of such litigation, regulatory proceedings or investigations, including harm flowing from actual or threatened revocation of licenses to do business, regulator actions to assert supervision or control over our business, and other sanctions which could have a material adverse effect on our business, financial condition, results of operations or cash flows.

Managing operational risks may not be effective in mitigating risk and loss to us.

We are subject to operational risks including, among other things, fraud, errors, failure to document transactions properly or to obtain proper internal authorization, failure to comply with regulatory requirements or obligations under our agreements, information technology failures including cyber security attacks and failure of our service providers (such as investment custodians and information technology and policyholder service providers) to comply with our services agreements. The associates and agents who conduct our business, including executive officers and other members of management, sales

31

managers, investment professionals, product managers, sales agents and other associates, do so in part by making decisions and choices that involve exposing us to risk. These include decisions involving numerous business activities such as setting underwriting guidelines, product design and pricing, investment purchases and sales, reserve setting, claim processing, policy administration and servicing, financial and tax reporting and other activities, many of which are very complex.

We seek to monitor and control our exposure to risks arising out of these activities through a risk control framework encompassing a variety of reporting systems, internal controls, management review processes and other mechanisms. However, these processes and procedures may not effectively control all known risks or effectively identify unforeseen risks. Management of operational risks can fail for a number of reasons including design failure, systems failure, cyber security attacks, human error or unlawful activities. If our controls are not effective or properly implemented, we could suffer financial or other loss, disruption of our business, regulatory sanctions or damage to our reputation. Losses resulting from these failures may have a material adverse effect on our financial position or results of operations.

The occurrence of natural or man-made disasters or a pandemic could adversely affect our financial condition and results of operations.

We are exposed to various risks arising out of natural disasters, including earthquakes, hurricanes, floods and tornadoes, and man-made disasters, including acts of terrorism and military actions and pandemics. For example, a natural or man-made disaster or a pandemic could lead to unexpected changes in persistency rates as policyholders and contractholders who are affected by the disaster may be unable to meet their contractual obligations, such as payment of premiums on our insurance policies and deposits into our investment products. In addition, such a disaster or pandemic could also significantly increase our mortality and morbidity experience above the assumptions we used in pricing our products. The continued threat of terrorism and ongoing military actions may cause significant volatility in global financial markets, and a natural or man-made disaster or a pandemic could trigger an economic downturn in the areas directly or indirectly affected by the disaster or pandemic. These consequences could, among other things, result in a decline in business and increased claims from those areas. Disasters or a pandemic also could disrupt public and private infrastructure, including communications and financial services, which could disrupt our normal business operations.

A natural or man-made disaster or a pandemic could also disrupt the operations of our counterparties or result in increased prices for the products and services they provide to us. For example, a natural or man-made disaster or a pandemic could lead to increased reinsurance prices and potentially cause us to retain more risk than we otherwise would retain if we were able to obtain reinsurance at lower prices. In addition, a disaster or a pandemic could adversely affect the value of the assets in our investment portfolio if it affects companies' ability to pay principal or interest on their securities.

Interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality or privacy of sensitive data residing on such systems, could harm our business.

We depend heavily on our telecommunication, information technology and other operational systems and on the integrity and timeliness of data we use to run our businesses and service our customers. These systems may fail to operate properly or become disabled as a result of events or circumstances which may be wholly or partly beyond our control. Further, we face the risk of operational and technology failures by others, including financial intermediaries, vendors and parties that provide services to us. If these parties do not perform as anticipated, we may experience operational difficulties, increased costs and other adverse effects on our business. Despite our implementation of a variety of security measures, our information technology and other systems could be subject to cyber attacks (including the risk of undetected attacks) and unauthorized access, such as physical or electronic break-ins, unauthorized tampering or other security breaches, resulting in a failure to maintain the security, confidentiality or privacy of sensitive data, including personal financial and health information relating to customers. There can be no assurance that any such breach will not occur or, if any does occur, that it can be sufficiently remediated. 

Interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality or privacy of sensitive data residing on such systems, whether due to actions by us or others, could delay or disrupt our ability to do business and service our customers, harm our reputation, subject us to litigation, regulatory sanctions and other claims, require us to incur significant expenses, lead to a loss of customers and revenues and otherwise adversely affect our business. Depending on the nature of the information compromised, in the event of a data breach or other unauthorized access to our customer data, we may also have obligations to notify customers about the incident and we may need to provide some form of remedy, such as a subscription to a credit monitoring service, for the individuals affected by the incident. A growing number of legislative and regulatory bodies have adopted consumer notification requirements in the event of unauthorized access to or acquisition of certain types of personal data. Such breach notification laws continue to evolve and

32

may be inconsistent from one jurisdiction to another. Complying with these obligations could cause us to incur substantial costs (including fines) and could increase negative publicity surrounding any incident that compromises customer data. While we maintain insurance coverage that, subject to policy terms and conditions and a self-insured retention, is designed to address certain aspects of cyber risks, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise in the continually evolving area of cyber risk.

Third parties to whom we outsource certain of our functions are also subject to the risks outlined above, and failures in their systems could adversely affect our business.

Our business could be interrupted or compromised if we experience difficulties arising from outsourcing relationships.

We outsource certain information technology and policy administration operations to third-party service providers. If we fail to maintain an effective outsourcing strategy or if third-party providers do not perform as contracted, we may experience operational difficulties, increased costs and a loss of business that could have a material adverse effect on our results of operations. In the event that one or more of our third-party service providers becomes unable to continue to provide services, we may suffer financial loss and other negative consequences.

We have substantial indebtedness which may restrict our ability to take advantage of business, strategic or financing opportunities.

As of December 31, 2017, we had an aggregate principal amount of indebtedness of $925.0 million. CNO's indebtedness will require approximately $45 million in cash to service in 2018 (based on the principal amounts outstanding and applicable interest rates as of December 31, 2017). Our substantial indebtedness and the obligations under our debt agreements may restrict our ability to take advantage of business, strategic or financing opportunities.

In conjunction with the refinancing of its existing debt in 2015, the Company entered into a $150.0 million four-year unsecured revolving credit agreement on May 19, 2015, and made an initial drawing of $100.0 million, resulting in $50.0 million available for additional borrowings. On October 13, 2017, the Company entered into an amendment and restatement agreement (the "Amendment Agreement") with respect to its revolving credit agreement (as amended by the Amendment Agreement, the "Revolving Credit Agreement"). The Amendment Agreement, among other things, increased the total commitments available under the revolving credit facility from $150.0 million to $250.0 million, increased the aggregate amount of additional incremental loans the Company may incur from $50.0 million to $100.0 million and extended the maturity date of the revolving credit facility from May 19, 2019 to the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the 2020 Notes, which is November 30, 2019. The amount drawn under the Revolving Credit Agreement continues to be $100.0 million. On May 19, 2015, the Company also issued $325.0 million aggregate principal amount of 4.500% Senior Notes due 2020 (the "2020 Notes") and $500.0 million aggregate principal amount of 5.250% Senior Notes due 2025 (together with the 2020 Notes, the "Notes"). The Revolving Credit Agreement contains various restrictive covenants and required financial ratios that we are required to meet or maintain and that will limit our operating flexibility. If we default under any of these covenants, the lenders could declare the outstanding principal amount of the loan, accrued and unpaid interest and all other amounts owing or payable thereunder to be immediately due and payable, which would have material adverse consequences to us. In such event, the holders of the Notes could elect to take similar action with respect to those debts. If that were to occur, we would not have sufficient liquidity to repay our indebtedness.

If we fail to pay interest or principal on our other indebtedness, including the Notes, we will be in default under the indenture governing such indebtedness, which could also lead to a default under agreements governing our existing and future indebtedness, including under the Revolving Credit Agreement. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we likely would not have sufficient funds to repay our indebtedness. Absent sufficient liquidity to repay our indebtedness, our management or our independent registered public accounting firm may conclude that there is substantial doubt regarding our ability to continue as a going concern.

The Revolving Credit Agreement and the Indenture for the Notes contain various restrictive covenants and required financial ratios that limit our operating flexibility. The violation of one or more loan covenant requirements will entitle our lenders to declare all outstanding amounts under the Revolving Credit Agreement and the Notes to be due and payable.

Pursuant to the Revolving Credit Agreement, CNO agreed to a number of covenants and other provisions that restrict the Company's ability to borrow money and pursue some operating activities without the prior consent of the lenders. We also

33

agreed to meet or maintain various financial ratios and balances. Our ability to meet these financial tests may be affected by events beyond our control. There are several conditions or circumstances that could lead to an event of default under the Revolving Credit Agreement, as described below.

The Revolving Credit Agreement contains certain financial, affirmative and negative covenants. The negative covenants in the Revolving Credit Agreement include restrictions that relate to, among other things and subject to customary baskets, exceptions and limitations for facilities of this type:

• subsidiary debt;

• liens;

• restrictive agreements;

• restricted payments during the continuance of an event of default;

• disposition of assets and sale and leaseback transactions;

• transactions with affiliates;

• change in business;

• fundamental changes;

• modification of certain agreements; and

• changes to fiscal year.

The Revolving Credit Agreement requires the Company to maintain (each as calculated in accordance with the Revolving Credit Agreement): (i) a debt to total capitalization ratio of not more than 35.0 percent (30.0 percent prior to the Amendment Agreement) (such ratio was 20.3 percent at December 31, 2017); (ii) an aggregate ratio of total adjusted capital to company action level risk-based capital for the Company's insurance subsidiaries of not less than 250 percent (such ratio was estimated to be 446 percent at December 31, 2017); and (iii) a minimum consolidated net worth of not less than the sum of (x) $2,674 million plus (y) 50.0% of the net equity proceeds received by the Company from the issuance and sale of equity interests in the Company (the Company's consolidated net worth was $3,635.4 million at December 31, 2017 compared to the minimum requirement of $2,684.9 million). Certain formulas used to calculate risk-based capital have embedded tax rate assumptions that will not change to be consistent with the Tax Reform Act until actions are taken by the NAIC. Although no action was taken by the NAIC for the 2017 calculation of the RBC ratio, it is possible that changes will be made for future periods. We estimate that the full impact of changing these embedded tax rate assumptions to be consistent with the Tax Reform Act is an increase to required capital of approximately $80 million (equivalent to a 65 percentage point decrease to the RBC ratio).

The Revolving Credit Agreement provides for customary events of default (subject in certain cases to customary grace and cure periods), which include, without limitation, the following:

• non-payment;

• breach of representations, warranties or covenants;

• cross-default and cross-acceleration;

• bankruptcy and insolvency events;

• judgment defaults;

• actual or asserted invalidity of documentation with respect to the Revolving Credit Agreement;

• change of control; and

• customary ERISA defaults.

If an event of default under the Revolving Credit Agreement occurs and is continuing, the Agent may accelerate the amounts and terminate all commitments outstanding under the Revolving Credit Agreement.

These covenants place significant restrictions on the manner in which we may operate our business and our ability to meet these financial covenants may be affected by events beyond our control. If we default under any of these covenants, the lenders could declare the outstanding principal amount of the loan, accrued and unpaid interest and all other amounts owing and payable thereunder to be immediately due and payable, which would have material adverse consequences to us. If the lenders under the Revolving Credit Agreement elect to accelerate the amounts due, the holders of the Notes could elect to take similar action with respect to those debts. If that were to occur, we would not have sufficient liquidity to repay our indebtedness.

The Indenture contains covenants that restrict the Company’s ability, with certain exceptions, to:

• incur certain subsidiary indebtedness without also guaranteeing the Notes;

34

• create liens;

• enter into sale and leaseback transactions;

• issue, sell, transfer or otherwise dispose of any shares of capital stock of any Insurance Subsidiary (as defined in the Indenture); and

• consolidate or merge with or into other companies or transfer all or substantially all of the Company’s assets.

The Indenture provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, breach of covenants in the Indenture, failure to pay at maturity or acceleration of other indebtedness, a failure to pay certain judgments and certain events of bankruptcy and insolvency. Generally, if an event of default occurs, Wilmington Trust, National Association or holders of at least 25% in principal amount of the then outstanding Notes may declare the principal of and accrued but unpaid interest, including any additional interest, on all of the Notes to be due and payable.

Our current credit ratings may adversely affect our ability to access capital and the cost of such capital, which could have a material adverse effect on our financial condition and results of operations.

Our issuer credit and senior unsecured debt rating from each of the major rating agencies is below investment grade. If we were to require additional capital, either to refinance our existing indebtedness or for any other reason, our current senior unsecured debt ratings, as well as conditions in the credit markets generally, could restrict our access to such capital and adversely affect its cost. Disruptions, volatility and uncertainty in the financial markets, and our below investment grade rating could limit our ability to access external capital markets at times and on terms which allow us to meet our capital and liquidity needs. See "Management's Discussion and Analysis of Financial Condition and Results of Operations-Liquidity of the Holding Companies" for more information.

CNO is a holding company and its liquidity and ability to meet its obligations may be constrained by the ability of CNO's insurance subsidiaries to distribute cash to it.

CNO and CDOC, Inc. ("CDOC") are holding companies with no business operations of their own. CNO and CDOC depend on their operating subsidiaries for cash to make principal and interest payments on debt and to pay administrative expenses and income taxes. CNO and CDOC receive cash from our insurance subsidiaries, consisting of dividends and distributions, principal and interest payments on surplus debentures and tax-sharing payments, as well as cash from their non-insurance subsidiaries consisting of dividends, distributions, loans and advances. Deterioration in the financial condition, earnings or cash flow of these significant subsidiaries for any reason could hinder the ability of such subsidiaries to pay cash dividends or other disbursements to CNO and/or CDOC, which would limit our ability to meet our debt service requirements and satisfy other financial obligations. In addition, CNO may elect to contribute additional capital to certain insurance subsidiaries to strengthen their surplus for covenant compliance or regulatory purposes (including, for example, maintaining adequate RBC level) or to provide the capital necessary for growth, in which case it is less likely that its insurance subsidiaries would pay dividends to the holding company. Accordingly, this could limit CNO's ability to meet debt service requirements and satisfy other holding company financial obligations. See "Management's Discussion and Analysis of Financial Condition and Results of Operations-Liquidity of the Holding Companies" for more information.

CNO receives dividends and other payments from CDOC and from certain non-insurance subsidiaries. CDOC receives dividends and surplus debenture interest payments from our insurance subsidiaries and payments from certain of our non-insurance subsidiaries. Payments from our non-insurance subsidiaries to CNO or CDOC, and payments from CDOC to CNO, do not require approval by any regulatory authority or other third party. However, the payment of dividends or surplus debenture interest by our insurance subsidiaries to CDOC is subject to state insurance department regulations and may be prohibited by insurance regulators if they determine that such dividends or other payments could be adverse to our policyholders or contract holders. Insurance regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in some states, the lesser of):

• statutory net gain from operations or statutory net income for the prior year, or

• 10 percent of statutory capital and surplus as of the end of the preceding year.

However, as each of the immediate insurance subsidiaries of CDOC has negative earned surplus, any dividend payments from the insurance subsidiaries to CNO require the prior approval of the director or commissioner of the applicable state insurance department. In 2017, our insurance subsidiaries paid dividends of $357.7 million to CDOC. CNO expects to receive regulatory approval for future dividends from our insurance subsidiaries, but there can be no assurance that such payments will

35

be approved or that the financial condition of our insurance subsidiaries will not deteriorate, making future approvals less likely.

CDOC holds surplus debentures from Conseco Life Insurance Company of Texas ("CLTX") with an aggregate principal amount of $749.6 million.  Interest payments on those surplus debentures do not require additional approval provided the RBC ratio of CLTX exceeds 100 percent (but do require prior written notice to the Texas state insurance department).  The estimated RBC ratio of CLTX was 383 percent at December 31, 2017.  CDOC also holds a surplus debenture from Colonial Penn with a principal balance of $160.0 million. Interest payments on that surplus debenture require prior approval by the Pennsylvania state insurance department. Dividends and other payments from our non-insurance subsidiaries, including 40|86 Advisors and CNO Services, LLC ("CNO Services"), to CNO or CDOC do not require approval by any regulatory authority or other third party.  However, insurance regulators may prohibit payments by our insurance subsidiaries to parent companies if they determine that such payments could be adverse to our policyholders or contractholders.

In addition, although we are under no obligation to do so, we may elect to contribute additional capital to strengthen the surplus of certain insurance subsidiaries for covenant compliance or regulatory purposes or to provide the capital necessary for growth. Any election regarding the contribution of additional capital to our insurance subsidiaries could affect the ability of our top tier insurance subsidiaries to pay dividends. The ability of our insurance subsidiaries to pay dividends is also impacted by various criteria established by rating agencies to maintain or receive higher financial strength ratings and by the capital levels that we target for our insurance subsidiaries, as well as the RBC compliance requirements under the Revolving Credit Agreement. CNO made no capital contributions to its insurance subsidiaries in 2017.

In addition, Washington National may not distribute funds to any affiliate or shareholder, except pursuant to agreements with affiliates that have been approved, without prior notice to the Florida Office of Insurance Regulation, in accordance with an order from the Florida Office of Insurance Regulation.

We previously identified a material weakness in our internal control over financial reporting which has been remediated, and our business may be adversely affected if we fail to maintain effective controls over financial reporting.

We have previously identified material weaknesses in internal controls which were subsequently remediated. We have emphasized the importance of performing and reviewing calculations consistent with the design of our internal control structure in an effort to ensure controls operate effectively.

We face the risk that, notwithstanding our efforts to date to identify and remedy the material weakness in our internal control over financial reporting, we may discover other material weaknesses in the future and the cost of remediating the material weakness could be high and could have a material adverse effect on our financial condition and results of operations.

Our ability to use our existing NOLs may be limited by certain transactions, and an impairment of existing NOLs could result in a significant writedown in the value of our deferred tax assets, which could cause us to breach the debt to total capitalization covenant of the Revolving Credit Agreement.

As of December 31, 2017, we had approximately $2.3 billion of federal tax NOLs resulting in deferred tax assets of approximately $.5 billion, expiring in years 2023 through 2035. Section 382 of the Code imposes limitations on a corporation's ability to use its NOLs when it undergoes a 50 percent "ownership change" over a three year period. Although we underwent an ownership change in 2003 as the result of our reorganization, the timing and manner in which we will be able to utilize our NOLs is not currently limited by Section 382.

We regularly monitor ownership changes (as calculated for purposes of Section 382) based on available information and, as of December 31, 2017, our analysis indicated that we were below the 50 percent ownership change threshold that would limit our ability to utilize our NOLs. A future transaction or transactions and the timing of such transaction or transactions could trigger an ownership change under Section 382. Such transactions may include, but are not limited to, additional repurchases or issuances of common stock, acquisitions or sales of shares of CNO's stock by certain holders of its shares, including persons who have held, currently hold or may accumulate in the future 5 percent or more of CNO's outstanding common stock for their own account. In January 2009, CNO's Board of Directors adopted a Section 382 Rights Agreement designed to protect shareholder value by preserving the value of our NOLs. The Section 382 Rights Agreement has been amended and extended by the CNO Board of Directors on three occasions. The Amended Section 382 Rights Agreement provides a strong economic disincentive for any one shareholder knowingly, and without the approval of the Board of Directors, to become an owner of more than 4.99% of the Company's outstanding common stock (or any other interest in CNO

36

that would be treated as "stock" under applicable Section 382 regulations) and for any owner of more than 4.99% of CNO's outstanding common stock as of the date of the Amended Section 382 Rights Agreement to increase their ownership stake by more than 1 percent of the shares of CNO's common stock then outstanding, and thus limits the uncertainty with regard to the potential for future ownership changes. However, despite the strong economic disincentives of the Amended Section 382 Rights Agreement, shareholders may elect to increase their ownership, including beyond the limits set by the Amended Section 382 Rights Agreement, and thus adversely affect CNO's ownership shift calculations. To further protect against the possibility of triggering an ownership change under Section 382, CNO's shareholders approved in 2010 an amendment to CNO's certificate of incorporation (the "Original Section 382 Charter Amendment") designed to prevent certain transfers of common stock which could otherwise adversely affect our ability to use our NOLs. CNO's shareholders approved amendments and extensions of the Original Section 382 Charter Amendment in 2013 and in 2016 (the "2016 Section 382 Charter Amendment"). The 2016 Section 382 Charter Amendment became effective July 31, 2016 and is scheduled to expire on July 31, 2019.

See the note to the consolidated financial statements entitled "Income Taxes" for further information regarding the Amended Section 382 Rights Agreement, the 2016 Section 382 Charter Amendment and CNO's NOLs.

If an ownership change were to occur for purposes of Section 382, we would be required to calculate an annual limitation on the use of our NOLs to offset future taxable income. The annual restriction would be calculated based upon the value of CNO's equity at the time of such ownership change, multiplied by a federal long-term tax exempt rate (1.96 percent at December 31, 2017), and the annual restriction could eliminate our ability to use a substantial portion of our NOLs to offset future taxable income. Additionally, the writedown of our deferred tax assets that would occur in the event of an ownership change for purposes of Section 382 could cause us to breach the debt to total capitalization covenant in the Revolving Credit Agreement.

The value of our deferred tax assets may be reduced to the extent our future profits are less than we have projected or the current corporate income tax rate is reduced, and such reductions in value may have a material adverse effect on our results of operations and our financial condition.

As of December 31, 2017, we had net deferred tax assets of $376.2 million. Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and NOLs. We evaluate the realizability of our deferred tax assets and assess the need for a valuation allowance on an ongoing basis. In evaluating our deferred tax assets, we consider whether it is more likely than not that the deferred tax assets will be realized. The ultimate realization of our deferred tax assets depends upon generating sufficient future taxable income during the periods in which our temporary differences become deductible and before our capital loss carry-forwards and NOLs expire. Our assessment of the realizability of our deferred tax assets requires significant judgment. Failure to achieve our projections may result in an increase in the valuation allowance in a future period. Any future increase in the valuation allowance would result in additional income tax expense which could have a material adverse effect upon our earnings in the future, and reduce shareholders' equity.

The value of our net deferred tax assets as of December 31, 2017 reflects the current Federal corporate income tax rate of 21 percent. A reduction in the corporate income tax rate would cause a writedown of our net deferred tax assets, which may have a material adverse effect on our results of operations and financial condition.

From time to time we may become subject to tax audits, tax litigation or similar proceedings, and as a result we may owe additional taxes, interest and penalties, or our NOLs may be reduced, in amounts that may be material.

In determining our provisions for income taxes and our accounting for tax-related matters in general, we are required to exercise judgment. We regularly make estimates where the ultimate tax determination is uncertain. The final determination of any tax audit, appeal of the decision of a taxing authority, tax litigation or similar proceedings may be materially different from that reflected in our financial statements. The assessment of additional taxes, interest and penalties could be materially adverse to our current and future results of operations and financial condition. See the note to the consolidated financial statements entitled "Income Taxes" for further information.

Our results of operations may be negatively impacted if our initiatives to restructure our insurance operations or our efforts to become more efficient are unsuccessful.

We have implemented or are in the process of implementing several initiatives to improve operating results, including: (i) focusing sales efforts on higher margin products; (ii) reducing operating expenses by eliminating or reducing marketing costs of certain products; (iii) streamlining administrative procedures and reducing personnel; (iv) using third party service

37

providers to improve service and reduce expenses; and (v) increasing retention rates on our more profitable blocks of inforce business. Many of our initiatives address issues resulting from the substantial number of acquisitions of our Predecessor. Between 1982 and 1997, our Predecessor completed 19 transactions involving the acquisitions of 44 separate insurance companies. These prior acquisitions have contributed to the complexity and cost of our current administrative operating environment and make it challenging, in some instances, to operate our business within the expense levels assumed in the pricing of our products. If we are unsuccessful in our efforts to become more efficient, our future earnings will be adversely affected.

In the event one or more of our third party service providers to whom we outsource certain of our functions becomes unable to continue to provide services or experiences a failure in their systems, our business could be adversely impacted.

Conversions to new systems can result in valuation differences between the prior system and the new system. We have recognized such differences in the past. Our planned conversions could result in future valuation adjustments, and these adjustments may have a material adverse effect on future earnings.

A decline in the current financial strength rating of our insurance subsidiaries could cause us to experience decreased sales, increased agent attrition and increased policyholder lapses and redemptions.

An important competitive factor for our insurance subsidiaries is the ratings they receive from nationally recognized rating organizations. Agents, insurance brokers and marketing companies who market our products and prospective purchasers of our products use the financial strength ratings of our insurance subsidiaries as an important factor in determining whether to market or purchase. Ratings have the most impact on our annuity, interest-sensitive life insurance and long-term care products.

The current financial strength ratings of our primary insurance subsidiaries from Fitch, S&P, A.M. Best and Moody's are "BBB+", "BBB+", "A-" and "Baa1", respectively.  Fitch has nineteen possible ratings. There are seven ratings above our "BBB+" rating and eleven ratings that are below our rating. S&P has twenty-one possible ratings. There are seven ratings above our "BBB+" rating and thirteen ratings that are below our rating. A.M. Best has sixteen possible ratings. There are three ratings above our "A-" rating and twelve ratings that are below our rating. Moody's has twenty-one possible ratings. There are seven ratings above our "Baa1" rating and thirteen ratings that are below our rating.

If our ratings are downgraded, we may experience declining sales of certain of our insurance products, defections of our independent and career sales force, and increased policies being redeemed or allowed to lapse. These events would adversely affect our financial results, which could then lead to ratings downgrades.

Competition from companies that have greater market share, higher ratings, greater financial resources and stronger brand recognition, may impair our ability to retain existing customers and sales representatives, attract new customers and sales representatives and maintain or improve our financial results.

The supplemental health insurance, annuity and individual life insurance markets are highly competitive. Competitors include other life and accident and health insurers, commercial banks, thrifts, mutual funds and broker-dealers.

Our principal competitors vary by product line. Our main competitors for agent-sold long-term care insurance products include Northwestern Mutual, Mutual of Omaha and New York Life. Our main competitors for agent-sold Medicare supplement insurance products include Blue Cross and Blue Shield Plans, United HealthCare and Mutual of Omaha. Our main competitors for life insurance sold through direct marketing channels include Gerber Life, Mutual of Omaha, New York Life, Massachusetts Mutual Life Insurance Company and subsidiaries of Torchmark Corporation. Our main competitors for supplemental health products sold through our Washington National segment include AFLAC, subsidiaries of Allstate, Colonial Life and Accident Company and subsidiaries of Torchmark Corporation.

In some of our product lines, such as life insurance and fixed annuities, we have a relatively small market share. Even in some of the lines in which we are one of the top writers, our market share is relatively small. For example, while, based on an Individual Long-Term Care Insurance Survey, our Bankers Life segment ranked fifth in annualized new premiums of individual long-term care insurance in the first half of 2017 with a market share of approximately 6 percent, the top four writers of individual long-term care insurance had annualized new premiums with a combined market share of approximately 65 percent during the period. In addition, while, based on a 2016 Medicare Supplement Loss Ratios report, we ranked sixth in direct premiums earned for Medicare supplement insurance in 2016 with a market share of 2.8 percent, the top writer of Medicare supplement insurance had direct premiums with a market share of 35 percent during the period.

38

Most of our major competitors have higher financial strength ratings than we do. Many of our competitors are larger companies that have greater capital, technological and marketing resources and have access to capital at a lower cost. Recent industry consolidation, including business combinations among insurance and other financial services companies, has resulted in larger competitors with even greater financial resources. Furthermore, changes in federal law have narrowed the historical separation between banks and insurance companies, enabling traditional banking institutions to enter the insurance and annuity markets and further increase competition. This increased competition may harm our ability to maintain or improve our profitability.

In addition, because the actual cost of products is unknown when they are sold, we are subject to competitors who may sell a product at a price that does not cover its actual cost. Accordingly, if we do not also lower our prices for similar products, we may lose market share to these competitors. If we lower our prices to maintain market share, our profitability would decline.

The Colonial Penn segment has faced increased competition from other insurance companies who also distribute products through direct marketing. In addition, the demand and cost of television advertising appropriate for Colonial Penn's campaigns fluctuates from period to period and this will impact the average cost to generate a TV lead.

We must attract and retain sales representatives to sell our insurance and annuity products. Strong competition exists among insurance and financial services companies for sales representatives. We compete for sales representatives primarily on the basis of our financial position, financial strength ratings, support services, compensation, products and product features. Our competitiveness for such agents also depends upon the relationships we develop with these agents. Our Predecessor's bankruptcy continues to be an adverse factor in developing relationships with certain agents. If we are unable to attract and retain sufficient numbers of sales representatives to sell our products, our ability to compete and our revenues and profitability would suffer.

If we are unable to attract and retain agents and marketing organizations, sales of our products may be reduced.

Our products are marketed and distributed primarily through a dedicated field force of career agents and sales managers (in our Bankers Life segment) and through PMA and independent marketing organizations (in our Washington National segment). We must attract and retain agents, sales managers and independent marketing organizations to sell our products through those distribution channels. We compete with other insurance companies, financial services companies and other entities for agents and sales managers and for business through marketing organizations. If we are unable to attract and retain these agents, sales managers and marketing organizations, our ability to grow our business and generate revenues from new sales would suffer. In recent periods, our Bankers Life segment has faced challenges in retaining new agents, which has impacted sales of its products.

Federal and state legislation could adversely affect the financial performance of our insurance operations.

During recent years, the health insurance industry has experienced substantial changes, including those caused by healthcare legislation. Recent federal and state legislation and pending legislative proposals concerning healthcare reform contain features that could severely limit, or eliminate, our ability to vary pricing terms or apply medical underwriting standards to individuals, thereby potentially increasing our benefit ratios and adversely impacting our financial results. In particular, Medicare reform could affect our ability to price or sell our products or profitably maintain our blocks inforce. For example, the Medicare Advantage program provides incentives for health plans to offer managed care plans to seniors. The growth of managed care plans under this program could decrease sales of the traditional Medicare supplement products we sell. Some current proposals contain government provided long-term care insurance which could affect the sales of our long-term care products.

Proposals currently pending in Congress and some state legislatures may also affect our financial results. These proposals include the implementation of minimum consumer protection standards in all long-term care policies, including: guaranteed premium rates; protection against inflation; limitations on waiting periods for pre-existing conditions; setting standards for sales practices for long-term care insurance; and guaranteed consumer access to information about insurers, including information regarding lapse and replacement rates for policies and the percentage of claims denied. Enactment of any proposal that would limit the amount we can charge for our products, such as guaranteed premium rates, or that would increase the benefits we must pay, such as limitations on waiting periods, or that would otherwise increase the costs of our business, could adversely affect our financial results.

39

In April 2016, the DOL issued a final regulation that expands the range of activities considered to be fiduciary investment advice under the Employee Retirement Income Security Act of 1974 and the Code. The DOL also issued a new "best interest contract" prohibited transaction exemption regarding how such advice can be provided to retirement investors. These regulations focus in large part on conflicts of interest related to investment recommendations made by financial advisors, registered investment advisors, insurance agents and other investment professionals to retirement investors, how financial advisors are able to discuss IRA rollovers, as well as how financial advisors and affiliates can transact with retirement investors. These regulations primarily impact our Bankers Life segment. Most provisions of these regulations became effective in June 2017. However, certain of the regulations including the "best interest contract" exemption were scheduled to become effective on January 1, 2018. In November 2017, the DOL delayed the applicability date of these provisions to July 1, 2019. We continue to monitor the status of the remaining provisions.

The NAIC has developed a principle-based reserving approach for life insurance products which will replace the current formulaic approach to determining policy reserves with an approach that more closely reflects the risks of the products. The principle-based approach became effective on January 1, 2017, and there is a three-year transition period where the approach is optional until it is required to be used for all life insurance products issued on or after January 1, 2020. The new approach will impact the financial statements of our insurance subsidiaries prepared under statutory accounting principles prescribed or permitted by regulatory authorities. The Company is implementing the new approach to its reserves on new life insurance products as they are introduced through the transition period.

On July 21, 2010, the Dodd-Frank Act was enacted and signed into law. The Dodd-Frank Act made extensive changes to the laws regulating financial services firms and requires various federal agencies to adopt a broad range of new rules and regulations. Among other provisions, the Dodd-Frank Act provides for a new framework of regulation of over-the-counter derivatives markets. This requires us to clear certain types of transactions currently traded in the over-the-counter derivative markets and may limit our ability to customize derivative transactions for our needs. In addition, we will likely experience additional collateral requirements and costs associated with derivative transactions.

The Dodd-Frank Act also establishes a Financial Stability Oversight Council, which is authorized to subject nonbank financial companies deemed systemically significant to stricter prudential standards and other requirements and to subject such a company to a special orderly liquidation process outside the federal bankruptcy code, administered by the Federal Deposit Insurance Corporation (although insurance company subsidiaries would remain subject to liquidation and rehabilitation proceedings under state law). In addition, the Dodd-Frank Act establishes a Federal Insurance Office within the Department of the Treasury. While not having a general supervisory or regulatory authority over the business of insurance, the director of this office will perform various functions with respect to insurance, including serving as a non-voting member of the Financial Stability Oversight Council and making recommendations to the Council regarding insurers to be designated for more stringent regulation. The director is also required to conduct a study on how to modernize and improve the system of insurance regulation in the United States, including by increased national uniformity through either a federal charter or effective action by the states.

Federal agencies have been given significant discretion in drafting the rules and regulations that will implement the Dodd-Frank Act. Consequently, many of the details and much of the impact of the Dodd-Frank Act may not be known for some time. In addition, this legislation mandated multiple studies and reports for Congress, which could result in additional legislative or regulatory action. In April 2017, the Trump Administration issued a Presidential Memorandum that calls for a comprehensive review of the Dodd-Frank Act. Such review may result in the Dodd-Frank Act being modified, repealed or replaced.

We cannot predict the requirements of the regulations ultimately adopted under the Dodd-Frank Act, the effect such regulations will have on financial markets generally, or on our businesses specifically, the additional costs associated with compliance with such regulations, or any changes to our operations that may be necessary to comply with the Dodd-Frank Act, any of which could have a material adverse effect on our business, results of operations, cash flows or financial condition.

Reinsurance may not be available, affordable or adequate to protect us against losses.

As part of our overall risk and capital management strategy, we have historically purchased reinsurance from external reinsurers as well as provided internal reinsurance support for certain risks underwritten by our business segments. The availability and cost of reinsurance protection are impacted by our operating and financial performance as well as conditions beyond our control. For example, volatility in the equity markets and the related impacts on asset values required to fund liabilities may reduce the availability of certain types of reinsurance and make it more costly when it is available, as reinsurers are less willing to take on credit risk in a volatile market. Accordingly, we may be forced to incur additional expenses for

40

reinsurance or may not be able to obtain sufficient new reinsurance on acceptable terms, which could adversely affect our ability to write future business or obtain statutory capital credit for new reinsurance.

Our insurance subsidiaries may be required to pay assessments to fund other companies' policyholder losses or liabilities and this may negatively impact our financial results.

The solvency or guaranty laws of most states in which an insurance company does business may require that company to pay assessments up to certain prescribed limits to fund policyholder losses or liabilities of other insurance companies that become insolvent. Insolvencies of insurance companies increase the possibility that these assessments may be required. These assessments may be deferred or forgiven under most guaranty laws if they would threaten an insurer's financial strength and, in certain instances, may be offset against future premium taxes. We cannot estimate the likelihood and amount of future assessments. Although past assessments have not been material, if there were a number of large insolvencies, future assessments could be material and could have a material adverse effect on our operating results and financial position.

ITEM 1B.UNRESOLVED STAFF COMMENTS.

None.

ITEM 2.PROPERTIES.

Our headquarters and the administrative operations of our Washington National segment and certain administrative operations of our subsidiaries are located on a Company-owned corporate campus in Carmel, Indiana, immediately north of Indianapolis. We currently occupy five buildings on the campus with approximately 430,000 square feet of space.

Our Bankers Life segment is primarily administered from downtown Chicago, Illinois. In 2012, Bankers Life relocated from one downtown location to another. The new location has approximately 135,000 square feet leased under an agreement which expires in 2023. Bankers Life has subleased its prior location of 222,000 square feet through the remaining term of the lease which expires in 2018. We also lease 276 sales offices in various states totaling approximately 885,000 square feet. These leases generally are short-term in length, with remaining lease terms expiring between 2018 and 2024.

Our Colonial Penn segment is administered from a Company-owned office building in Philadelphia, Pennsylvania, with approximately 127,000 square feet. We occupy approximately 45 percent of this space, with unused space leased to tenants.

Management believes that this office space is adequate for our needs.

ITEM 3.LEGAL PROCEEDINGS.

Information required for Item 3 is incorporated by reference to the discussion under the heading "Legal Proceedings" in the note to the consolidated financial statements entitled "Litigation and Other Legal Proceedings" included in Item 8 of this Form 10-K.

ITEM 4.MINE SAFETY DISCLOSURES.

Not applicable.

41

Executive Officers of the Registrant

Officer	With CNO	Positions with CNO, Principal
Name and Age (a)	Since	Occupation and Business Experience (b)
Bruce Baude, 53	2012	Since July 2012, executive vice president, chief operations and technology officer. From 2008 to 2012, Mr. Baude was chief operating officer at Univita Health.
Gary C. Bhojwani, 50	2016	Since January 2018, chief executive officer. From April 2016 to December 2017, president of CNO.  From April 2015 until joining CNO, chief executive officer of GCB, LLC, an insurance and financial services consulting company that he founded.  Mr. Bhojwani served as a member of the board of management at Allianz SE, Chairman of Allianz of America, Allianz Life Insurance Company, and Fireman’s Fund Insurance Company from 2012 to January 1, 2015. From 2007 to 2012, he served as president of Allianz Life Insurance Company of North America.
Yvonne K. Franzese, 59	2017	Since November 2017, executive vice president and chief human resources officer of CNO. From 2016 until joining CNO, chief human capital officer of TCF Bank. From 2007 to 2016, Ms. Franzese held various human resource positions at Allianz, including the chief human resources role for Allianz of North America.
Erik M. Helding, 45	2004	Since April 2016, executive vice president and chief financial officer.  From August 2012 to April 2016, senior vice president, treasury and investor relations.  Prior to August 2012, Mr. Helding was vice president, financial planning and analysis and he has held various finance positions since joining CNO in 2004.
Eric R. Johnson, 57	1997	Since September 2003, executive vice president and chief investment officer of CNO and president and chief executive officer of 40|86 Advisors, CNO's wholly-owned registered investment advisor. Since January 2018, executive in charge of corporate development activities. Mr. Johnson has held various investment management positions since joining CNO in 1997.
John R. Kline, 60	1990	Since July 2002, senior vice president and chief accounting officer. Mr. Kline has served in various accounting and finance capacities with CNO since 1990.
Christopher J. Nickele, 61	2005	Since August 2014, executive vice president and chief actuary. From October 2005 until August 2014, executive vice president, product management and from May 2010 until March 2014, president, Other CNO Business.
Matthew J. Zimpfer, 50	1998	Since June 2008, executive vice president and general counsel. Mr. Zimpfer has held various legal positions since joining CNO in 1998.

___________________________

(a) The executive officers serve as such at the discretion of the Board of Directors and are elected annually.

(b) Business experience is given for at least the last five years.

42

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

MARKET INFORMATION AND DIVIDENDS

The following table sets forth the dividends declared and paid per share and the ranges of high and low sales prices per share for our common stock on the New York Stock Exchange for the quarterly periods beginning January 1, 2016.

Period	Market price				Dividends
	High		Low		declared and paid
2016:
First Quarter	$	18.71	$	14.66	$	0.07
Second Quarter	20.55		16.00		0.08
Third Quarter	18.70		14.30		0.08
Fourth Quarter	19.89		14.65		0.08
2017:
First Quarter	$	21.70	$	18.54	$	0.08
Second Quarter	22.60		19.38		0.09
Third Quarter	23.94		20.69		0.09
Fourth Quarter	25.83		23.15		0.09

As of February 12, 2018, there were approximately 24,000 holders of the outstanding shares of common stock, including individual participants in securities position listings.

We commenced the payment of a dividend on our common stock in the second quarter of 2012. The dividend on our common stock is declared each quarter by our Board of Directors. In determining dividends, our Board of Directors takes into consideration our financial condition, including current and expected earnings and projected cash flows.

PERFORMANCE GRAPH

The performance graph below compares CNO's cumulative total shareholder return on its common stock for the period from December 31, 2012 through December 31, 2017 with the cumulative total return of the Standard & Poor's 500 Composite Stock Price Index (the "S&P 500 Index"), the Standard & Poor's Life and Health Insurance Index (the "S&P Life and Health Insurance Index") and the Standard & Poor's MidCap 400 Index (the "S&P MidCap 400 Index"). The comparison for each of the periods assumes that $100 was invested on December 31, 2012 in each of CNO common stock, the stocks included in the S&P 500 Index, the stocks included in the S&P Life and Health Insurance Index and the stocks included in the S&P MidCap 400 Index and that all dividends were reinvested. The stock performance shown in this graph represents past performance and should not be considered an indication of future performance of CNO's common stock.

43

*$100 invested on 12/31/12 in stock or index, including reinvestment of dividends.

	12/12		12/13		12/14		12/15		12/16		12/17
CNO Financial Group, Inc.	$	100.00	$	191.14	$	188.63	$	212.24	$	216.62	$	283.81
S&P 500 Index	100.00		132.39		150.51		152.59		170.84		208.14
S&P Life & Health Insurance Index	100.00		163.48		166.66		156.14		194.96		226.98
S&P MidCap 400 Index	100.00		133.50		146.54		143.35		173.08		201.20

44

ISSUER PURCHASES OF EQUITY SECURITIES

Period (in 2017)	Total number of shares (or units)	Average price paid per share (or unit)		Total number of shares (or units) purchased as part of publicly announced plans or programs	Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs(a)
					(dollars in millions)
October 1 through October 31	33,200	$	24.10	33,200	$	411.8
November 1 through November 30	663,003	24.01		662,263	395.9
December 1 through December 31	411,576	25.00		411,576	385.6
Total	1,107,779	24.38		1,107,039	385.6

_________________

(a) In May 2011, the Company announced a securities repurchase program of up to $100.0 million. In February 2012, June 2012, December 2012, December 2013, November 2014, November 2015 and May 2017, the Company's Board of Directors approved, in aggregate, an additional $1,900.0 million to repurchase the Company's outstanding securities.

EQUITY COMPENSATION PLAN INFORMATION

The following table summarizes information, as of December 31, 2017, relating to our common stock that may be issued under the CNO Financial Group, Inc. Amended and Restated Long-Term Incentive Plan.

	Number of securities to be issued upon exercise of outstanding options and rights	Weighted-average exercise price of outstanding options and rights		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column)
Equity compensation plans approved by security holders	5,120,818	$	15.95	7,488,231
Equity compensation plans not approved by security holders	—	—		—
Total	5,120,818	$	15.95	7,488,231

45

ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA.

	Years ended December 31,
	2017		2016			2015			2014		2013
	(Amounts in millions, except per share data)
STATEMENT OF OPERATIONS DATA
Insurance policy income	$	2,647.3	$	2,601.1		$	2,556.0		$	2,629.7	$	2,744.7
Net investment income	1,551.3		1,325.2			1,233.6			1,427.4		1,664.0
Net realized investment gains (losses)	50.3		8.3			(36.6		)	36.7		33.4
Total revenues	4,297.2		3,985.1			3,811.9			4,144.7		4,476.1
Interest expense	123.7		116.4			94.9			92.8		105.3
Total benefits and expenses	3,816.7		3,631.9			3,444.2			3,969.6		4,171.3
Income before income taxes	480.5		353.2			367.7			175.1		304.8
Income tax expense (benefit)	304.9		(5.0		)	97.0			123.7		(173.2		)
Net income	175.6		358.2			270.7			51.4		478.0
PER SHARE DATA
Net income, basic	$	1.03	$	2.03		$	1.40		$	.24	$	2.16
Net income, diluted	1.02		2.01			1.39			.24		2.06
Dividends declared per common share	.35		.31			.27			.24		.11
Book value per common share outstanding	29.05		25.82			22.49			23.06		22.49
Weighted average shares outstanding for basic earnings	170.0		176.6			193.1			212.9		221.6
Weighted average shares outstanding for diluted earnings	172.1		178.3			195.2			217.7		232.7
Shares outstanding at period-end	166.9		173.8			184.0			203.3		220.3
BALANCE SHEET DATA - AT PERIOD END
Total investments	$	27,854.1	$	26,237.6		$	24,487.1		$	24,908.3	$	27,151.7
Total assets	33,110.3		31,975.2			31,125.1			31,155.9		34,750.2
Corporate notes payable	914.6		912.9			911.1			780.3		838.0
Total liabilities	28,262.8		27,488.3			26,986.6			26,467.7		29,795.0
Shareholders' equity	4,847.5		4,486.9			4,138.5			4,688.2		4,955.2
STATUTORY DATA - AT PERIOD END (a)
Statutory capital and surplus	$	1,904.4	$	1,956.8		$	1,739.2		$	1,654.4	$	1,711.9
Asset valuation reserve ("AVR")	246.8		253.3			196.9			203.1		233.9
Total statutory capital and surplus and AVR	2,151.2		2,210.1			1,936.1			1,857.5		1,945.8

____________________

(a) We have derived the statutory data from statements filed by our insurance subsidiaries with regulatory authorities which are prepared in accordance with statutory accounting principles, which vary in certain respects from GAAP.

46

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF CONSOLIDATED FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

In this section, we review the consolidated financial condition of CNO and its consolidated results of operations for the years ended December 31, 2017, 2016 and 2015 and, where appropriate, factors that may affect future financial performance. Please read this discussion in conjunction with the consolidated financial statements and notes included in this Form 10-K.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our statements, trend analyses and other information contained in this report and elsewhere (such as in filings by CNO with the SEC, press releases, presentations by CNO or its management or oral statements) relative to markets for CNO's products and trends in CNO's operations or financial results, as well as other statements, contain forward-looking statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995.  Forward-looking statements typically are identified by the use of terms such as "anticipate," "believe," "plan," "estimate," "expect," "project," "intend," "may," "will," "would," "contemplate," "possible," "attempt," "seek," "should," "could," "goal," "target," "on track," "comfortable with," "optimistic," "guidance," "outlook" and similar words, although some forward-looking statements are expressed differently.  You should consider statements that contain these words carefully because they describe our expectations, plans, strategies and goals and our beliefs concerning future business conditions, our results of operations, financial position, and our business outlook or they state other "forward-looking" information based on currently available information.  The "Risk Factors" in Item 1A provide examples of risks, uncertainties and events that could cause our actual results to differ materially from the expectations expressed in our forward-looking statements.  Assumptions and other important factors that could cause our actual results to differ materially from those anticipated in our forward-looking statements include, among other things:

• changes in or sustained low interest rates causing reductions in investment income, the margins of our fixed annuity and life insurance businesses, and sales of, and demand for, our products;

• expectations of lower future investment earnings may cause us to accelerate amortization, write down the balance of insurance acquisition costs or establish additional liabilities for insurance products;

• general economic, market and political conditions and uncertainties, including the performance and fluctuations of the financial markets which may affect the value of our investments as well as our ability to raise capital or refinance existing indebtedness and the cost of doing so;

• the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject;

• our ability to make anticipated changes to certain non-guaranteed elements of our life insurance products;

• our ability to obtain adequate and timely rate increases on our health products, including our long-term care business;

• the receipt of any required regulatory approvals for dividend and surplus debenture interest payments from our insurance subsidiaries;

• mortality, morbidity, the increased cost and usage of health care services, persistency, the adequacy of our previous reserve estimates and other factors which may affect the profitability of our insurance products;

• changes in our assumptions related to deferred acquisition costs or the present value of future profits;

• the recoverability of our deferred tax assets and the effect of potential ownership changes and tax rate changes on their value;

• changes to our estimates of the impact of comprehensive federal tax legislation related to the Tax Reform Act;

• our assumption that the positions we take on our tax return filings will not be successfully challenged by the IRS;

• changes in accounting principles and the interpretation thereof;

• our ability to continue to satisfy the financial ratio and balance requirements and other covenants of our debt agreements;

47

• our ability to achieve anticipated expense reductions and levels of operational efficiencies including improvements in claims adjudication and continued automation and rationalization of operating systems;

• performance and valuation of our investments, including the impact of realized losses (including other-than-temporary impairment charges);

• our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition;

• our ability to generate sufficient liquidity to meet our debt service obligations and other cash needs;

• changes in capital deployment opportunities;

• our ability to maintain effective controls over financial reporting;

• our ability to continue to recruit and retain productive agents and distribution partners;

• customer response to new products, distribution channels and marketing initiatives;

• our ability to achieve additional upgrades of the financial strength ratings of CNO and our insurance company subsidiaries as well as the impact of our ratings on our business, our ability to access capital, and the cost of capital;

• regulatory changes or actions, including: those relating to regulation of the financial affairs of our insurance companies, such as the calculation of risk-based capital and minimum capital requirements, and payment of dividends and surplus debenture interest to us; regulation of the sale, underwriting and pricing of products; and health care regulation affecting health insurance products;

• changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products or affect the value of our deferred tax assets;

• availability and effectiveness of reinsurance arrangements, as well as the impact of any defaults or failure of reinsurers to perform;

• the amount we may need to pay to a reinsurer and the earnings charge we may incur in connection with a long-term care reinsurance transaction;

• the performance of third party service providers and potential difficulties arising from outsourcing arrangements;

• the growth rate of sales, collected premiums, annuity deposits and assets;

• interruption in telecommunication, information technology or other operational systems or failure to maintain the security, confidentiality or privacy of sensitive data on such systems;

• events of terrorism, cyber attacks, natural disasters or other catastrophic events, including losses from a disease pandemic;

• ineffectiveness of risk management policies and procedures in identifying, monitoring and managing risks; and

• the risk factors or uncertainties listed from time to time in our filings with the SEC.

Other factors and assumptions not identified above are also relevant to the forward-looking statements, and if they prove incorrect, could also cause actual results to differ materially from those projected.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by the foregoing cautionary statement.  Our forward-looking statements speak only as of the date made.  We assume no obligation to update or to publicly announce the results of any revisions to any of the forward-looking statements to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements.

48

The reporting of RBC measures is not intended for the purpose of ranking any insurance company or for use in connection with any marketing, advertising or promotional activities.

OVERVIEW

We are a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products.  We focus on serving the senior and middle-income markets, which we believe are attractive, underserved, high growth markets.  We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

We measure segment performance by excluding the loss on reinsurance transaction, net realized investment gains (losses), fair value changes in embedded derivative liabilities (net of related amortization), fair value changes and amendment related to the agent deferred compensation plan, loss on extinguishment of debt, income taxes and other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to VIEs ("pre-tax operating earnings") because we believe that this performance measure is a better indicator of the ongoing business and trends in our business.  Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of net realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business.

The loss on reinsurance transaction, net realized investment gains (losses), fair value changes in embedded derivative liabilities (net of related amortization), fair value changes and amendment related to the agent deferred compensation plan, loss on extinguishment of debt and other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to VIEs depend on market conditions or represent unusual items that do not necessarily relate to the underlying business of our segments.  Net realized investment gains (losses) and fair value changes in embedded derivative liabilities (net of related amortization) may affect future earnings levels since our underlying business is long-term in nature and changes in our investment portfolio may impact our ability to earn the assumed interest rates needed to maintain the profitability of our business. In the fourth quarter of 2016, we began reporting the long-term care block recaptured from BRe as further described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Consolidated Financial Condition - Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off" as an additional business segment.

The Company’s insurance segments are described below:

• Bankers Life,which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices.  The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company.  Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and PDP products in exchange for a fee.

• Washington National, which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite.  These products are marketed through PMA and through independent marketing organizations and insurance agencies including worksite marketing.  The products being marketed are underwritten by Washington National. This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.

• Colonial Penn, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing.  The Colonial Penn segment includes primarily the business of Colonial Penn.

• Long-term care in run-off consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and BCLIC.

49

The following summarizes our earnings for the three years ending December 31, 2017 (dollars in millions, except per share data):

	2017			2016			2015
Adjusted EBIT (a non-GAAP financial measure) (a):
Bankers Life	$	418.9		$	397.9		$	369.6
Washington National	98.3			102.9			111.5
Colonial Penn	22.6			1.7			5.6
Long-term care in run-off	1.7			(3.9		)	—
Adjusted EBIT from business segments	541.5			498.6			486.7
Corporate Operations, excluding corporate interest expense	(40.3		)	(42.5		)	(18.9		)
Adjusted EBIT	501.2			456.1			467.8
Corporate interest expense	(46.5		)	(45.8		)	(45.0		)
Operating earnings before taxes	454.7			410.3			422.8
Tax expense on operating income	153.8			147.8			148.1
Net operating income	300.9			262.5			274.7
Net realized investment gains (losses) (net of related amortization)	49.3			7.6			(36.1		)
Fair value changes in embedded derivative liabilities (net of related amortization)	(2.5		)	9.6			11.9
Fair value changes and amendment related to agent deferred compensation plan	(12.2		)	3.1			15.1
Loss on reinsurance transaction (b)	—			(75.4		)	—
Loss on extinguishment of debt	—			—			(32.8		)
Other	(8.8		)	(2.0		)	(13.2		)
Non-operating income (loss) before taxes	25.8			(57.1		)	(55.1		)
Income tax expense (benefit):
On non-operating income (loss)	9.0			(20.0		)	(18.6		)
Valuation allowance for deferred tax assets and other tax items	142.1			(132.8		)	(32.5		)
Net non-operating income (loss)	(125.3		)	95.7			(4.0		)
Net income	$	175.6		$	358.2		$	270.7
Per diluted share:
Net operating income	$	1.75		$	1.47		$	1.41
Net realized investment gains (losses) (net of related amortization and taxes)	.19			.03			(.12		)
Fair value changes in embedded derivative liabilities (net of related amortization and taxes)	(.01		)	.04			.04
Fair value changes and amendment related to agent deferred compensation plan (net of taxes)	(.05		)	.01			.05
Loss on reinsurance transaction (net of taxes)	—			(.27		)	—
Loss on extinguishment of debt (net of taxes)	—			—			(.11		)
Valuation allowance for deferred tax assets and other tax items	(.83		)	.74			.17
Other	(.03		)	(.01		)	(.05		)
Net income	$	1.02		$	2.01		$	1.39

50

____________

(a) Management believes that an analysis of net operating income provides a clearer comparison of the operating results of the Company from period to period because it excludes:  (i) loss on reinsurance transaction, including impact of taxes; (ii) net realized investment gains or losses, net of related amortization and taxes; (iii) fair value changes due to fluctuations in the interest rates used to discount embedded derivative liabilities related to our fixed index annuities, net of related amortization and taxes; (iv) fair value changes and amendment related to the agent deferred compensation plan, net of taxes; (v) loss on extinguishment of debt, net of taxes; (vi) changes in the valuation allowance for deferred tax assets and other tax items; and (vii) other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to variable interest entities. Net realized investment gains or losses include: (i) gains or losses on the sales of investments; (ii) other-than-temporary impairments recognized through net income; and (iii) changes in fair value of certain fixed maturity investments with embedded derivatives.  Adjusted EBIT is presented as net operating income excluding corporate interest expense and income tax expense. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.

In addition, management uses these non-GAAP financial measures in its budgeting process, financial analysis of segment performance and in assessing the allocation of resources. We believe these non-GAAP financial measures enhance an investor’s understanding of our financial performance and allows them to make more informed judgments about the Company as a whole. These measures also highlight operating trends that might not otherwise be apparent. However, Adjusted EBIT and net operating income are not measurements of financial performance under GAAP and should not be considered as alternatives to cash flow from operating activities, as measures of liquidity, or as alternatives to net income as measures of our operating performance or any other measures of performance derived in accordance with GAAP. In addition, Adjusted EBIT and net operating income should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Adjusted EBIT and net operating income have limitations as analytical tools, and you should not consider such measures either in isolation or as substitutes for analyzing our results as reported under GAAP. Our definitions and calculation of Adjusted EBIT and net operating income are not necessarily comparable to other similarly titled measures used by other companies due to different methods of calculation.

(b) In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business as further described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Consolidated Financial Condition - Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off".

Our mission remains unchanged: to enrich lives by providing insurance solutions that help protect the health and retirement needs of middle-income Americans, while building enduring value for all our stakeholders. Our corporate strategy is rooted in CNO’s unique customer focus. Our focus on the unique financial security needs of our middle-income customers is essential to our growth strategy. Our diverse ability to connect with customers through captive agents, independent channels or direct marketing is a key strength of CNO. We believe that our product portfolio mix is well-aligned to the retirement healthcare, supplemental health and income accumulation needs of working-age customers as well as those in and near retirement. Unlike most insurers, we provide solutions for both health risks and wealth opportunities. As Americans live longer into their retirement years, our customers need holistic retirement income planning, which includes both our insurance and annuity solutions, and the investments offered by our broker-dealer and growing force of registered investment advisors. Specifically, we are focused on the following priorities:

Growth

• Maximize our product portfolio to ensure it meets our customers’ needs for integrated products and advice covering a broad range of their financial needs

• Position marketing and our distribution channels to respond effectively to evolving customer preferences

• Expand and enhance elements of our broker-dealer and registered investment advisor program

• Increase the speed-to-market for new products that are a good fit for our customers

• Make strategic, measured changes to our business practices to improve our competitive advantage

• Continue to invest in technology partnerships that will support our field force and relationships with our customers

Increase profitability and return on equity

• Maintain our strong capital position and favorable financial metrics

• Work to increase our return on equity

• Maintain pricing discipline

51

Effectively manage risk and deploy capital

• Maintain an active enterprise risk management process

• Utilize excess cash flow to maximize returns

• Maintain a competitive dividend payout ratio

• Reduce relative legacy long-term care exposure

Continue to invest in talent

• Attract, retain and develop the best talent to help us drive sustainable growth, and provide them with development opportunities

• Recruit, develop and retain our agent force

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management has made estimates in the past that we believed to be appropriate but were subsequently revised to reflect actual experience. If our future experience differs materially from these estimates and assumptions, our results of operations and financial condition could be materially affected.

We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. We continually evaluate the information used to make these estimates as our business and the economic environment change. The use of estimates is pervasive throughout our financial statements. The accounting policies and estimates we consider most critical are summarized below. Additional information on our accounting policies is included in the note to our consolidated financial statements entitled "Summary of Significant Accounting Policies".

Investments

At December 31, 2017, the carrying value of our investment portfolio was $27.9 billion.

Interest income on fixed maturity securities is recognized when earned using a constant effective yield method giving effect to amortization of premiums and accretion of discounts. Prepayment fees are recognized when earned. Dividends on equity securities are recognized when declared.

Our evaluation of investments for impairment requires significant judgments, including: (i) the identification of potentially impaired securities; (ii) the determination of their estimated fair value; and (iii) the assessment of whether any decline in estimated fair value is other than temporary.

We regularly evaluate all of our investments with unrealized losses for possible impairment.  Our assessment of whether unrealized losses are "other than temporary" requires significant judgment.  Factors considered include:  (i) the extent to which fair value is less than the cost basis; (ii) the length of time that the fair value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for specific events, developments or circumstances likely to affect the value of the investment; (v) the investment's rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) whether we intend to sell the investment or it is more likely than not that circumstances will require us to sell the investment before recovery occurs; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values; (ix) projections of, and unfavorable changes in, cash flows on structured securities including mortgage-backed and asset-backed securities; (x) our best estimate of the value of any collateral; and (xi) other objective and subjective factors.

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio.  Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

Impairment losses on equity securities are recognized in net income.  The manner in which impairment losses on fixed maturity securities, available for sale, are recognized in the financial statements is dependent on the facts and circumstances related to the specific security.  If we intend to sell a security or it is more likely than not that we would be required to sell a

52

security before the recovery of its amortized cost, the security is other-than-temporarily impaired and the full amount of the impairment is recognized as a loss through earnings.  If we do not expect to recover the amortized cost basis, we do not plan to sell the security, and if it is not more likely than not that we would be required to sell a security before the recovery of its amortized cost, less any current period credit loss, the recognition of the other-than-temporary impairment is bifurcated.  We recognize the credit loss portion in net income and the noncredit loss portion in accumulated other comprehensive income.

We estimate the amount of the credit loss component of a fixed maturity security impairment as the difference between amortized cost and the present value of the expected cash flows of the security.  The present value is determined using the best estimate of future cash flows discounted at the effective interest rate implicit to the security at the date of purchase or the current yield to accrete an asset-backed or floating-rate security.  The methodology and assumptions for establishing the best estimate of future cash flows vary depending on the type of security.

For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including overcollateralization, excess spread, subordination and guarantees.  For corporate bonds, cash flow estimates are derived from scenario-based outcomes of expected corporate restructurings or the disposition of assets using bond-specific facts and circumstances. The previous amortized cost basis less the impairment recognized in net income becomes the security's new cost basis.  We accrete the new cost basis to the estimated future cash flows over the expected remaining life of the security, except when the security is in default or considered nonperforming.

The remaining noncredit impairment, which is recorded in accumulated other comprehensive income, is the difference between the security's estimated fair value and our best estimate of future cash flows discounted at the effective interest rate prior to impairment.  The remaining noncredit impairment typically represents changes in the market interest rates, current market liquidity and risk premiums.  As of December 31, 2017, other-than-temporary impairments included in accumulated other comprehensive income totaled $1.0 million (before taxes and related amortization).

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price.  We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives.  We carry our Company-owned life insurance policy ("COLI"), which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs.

The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information.  Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value.  Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value.

Valuation Hierarchy

There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable.

• Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities.  Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.

• Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data.  Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies.  These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include:  certain publicly registered and privately placed corporate fixed

53

maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.

• Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions.  Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information.  Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities.  Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.

At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value.  This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions.  Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs.

Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities.  Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade corporate debt securities and in many cases severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer.  Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are generally more sensitive to adverse economic conditions.  The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

Our fixed maturity investments are generally purchased in the context of long-term strategies, including funding insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities.  In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities. During 2017, we sold $427.6 million of fixed maturity investments which resulted in gross investment losses (before income taxes) of $24.2 million.

We actively manage the relationship between the duration and cash flows of our invested assets and the estimated duration and cash flows of benefit payments arising from contract liabilities. These efforts may cause us to sell investments before their maturity date and could result in the realization of net realized investment gains (losses). When the estimated durations of assets and liabilities are similar, the effect of changes in market interest rates shall have largely offsetting effects on the value of the related assets and liabilities. In certain circumstances, a mismatch of the durations or related cash flows of invested assets and insurance liabilities could have a significant impact on our results of operations and financial position.

For more information on our investment portfolio and our critical accounting policies related to investments, see the note to our consolidated financial statements entitled "Investments".

54

Present Value of Future Profits and Deferred Acquisition Costs

In conjunction with the implementation of fresh start accounting, we eliminated the historical balances of our Predecessor's deferred acquisition costs and the present value of future profits and replaced them with the present value of future profits as calculated on the Effective Date.

The value assigned to the right to receive future cash flows from contracts existing at the Effective Date is referred to as the present value of future profits. The balance of this account is amortized, evaluated for recovery, and adjusted for the impact of unrealized gains (losses) in the same manner as the deferred acquisition costs described below. We expect to amortize the balance of the present value of future profits as of December 31, 2017 as follows: 11 percent in 2018, 10 percent in 2019, 9 percent in 2020, 7 percent in 2021 and 7 percent in 2022.

Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For interest-sensitive life or annuity products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we generally amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate.

Insurance acquisition costs are amortized to expense over the lives of the underlying policies in relation to future anticipated premiums or gross profits. The insurance acquisition costs for policies other than interest-sensitive life and annuity products are amortized with interest (using the projected investment earnings rate) over the estimated premium-paying period of the policies, in a manner which recognizes amortization expense in proportion to each year's premium income. The insurance acquisition costs for interest-sensitive life and annuity products are amortized with interest (using the interest rate credited to the underlying policy) in proportion to estimated gross profits. The interest, mortality, morbidity and persistency assumptions used to amortize insurance acquisition costs are consistent with those assumptions used to estimate liabilities for insurance products. For interest-sensitive life and annuity products, these assumptions are reviewed on a regular basis. When actual profits or our current best estimates of future profits are different from previous estimates, we adjust cumulative amortization of insurance acquisition costs to maintain amortization expense as a constant percentage of gross profits over the entire life of the policies.

When we realize a gain or loss on investments backing our interest-sensitive life or annuity products, we adjust the amortization of insurance acquisition costs to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We increased (decreased) amortization expense for such changes by $1.0 million, $.7 million and $(.5) million during the years ended December 31, 2017, 2016 and 2015, respectively. We also adjust insurance acquisition costs for the change in amortization that would have been recorded if fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. Such adjustments are commonly referred to as "shadow adjustments" and may include adjustments to: (i) deferred acquisition costs; (ii) the present value of future profits; (iii) loss recognition reserves; and (iv) income taxes. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity. The total pre-tax impact of such adjustments on accumulated other comprehensive income was a decrease of $682.4 million at December 31, 2017 (including $514.5 million for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from our sales of such assets were invested at then current yields.) The total pre-tax impact of such adjustments on accumulated other comprehensive income at December 31, 2016 was a decrease of $343.2 million (including $204.0 million for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from our sales of such assets were invested at then current yields.)

At December 31, 2017, the balance of insurance acquisition costs was $1.8 billion prior to shadow adjustments. The recoverability of this amount is dependent on the future profitability of the related business. Each year, we evaluate the recoverability of the unamortized balance of insurance acquisition costs. These evaluations are performed to determine whether estimates of the present value of future cash flows, in combination with the related liability for insurance products, will support the unamortized balance. These future cash flows are based on our best estimate of future premium income, less benefits and expenses. The present value of these cash flows, plus the related balance of liabilities for insurance products, is then compared with the unamortized balance of insurance acquisition costs. In the event of a deficiency, such amount would be charged to amortization expense. If the deficiency exceeds the balance of insurance acquisition costs, a premium deficiency reserve is established for the excess. The determination of future cash flows involves significant judgment. Revisions to the assumptions which determine such cash flows could have a significant adverse effect on our results of operations and financial position. While we expect the long-term care business in the Bankers Life segment to generate future profits, the margins are relatively thin and are vulnerable to changes in assumptions.

55

The table presented below summarizes our estimates of cumulative adjustments to insurance acquisition costs or premium deficiency reserves (when the deficiency exceeds the balance of insurance acquisition costs) resulting from hypothetical revisions to certain assumptions. Although such hypothetical revisions are not currently required or anticipated, we believe they could occur based on past variances in experience and our expectations of the ranges of future experience that could reasonably occur. We have assumed that revisions to assumptions resulting in the adjustments summarized below would occur equally among policy types, ages and durations within each product classification. Any actual adjustment would be dependent on the specific policies affected and, therefore, may differ from the estimates summarized below. In addition, the impact of actual adjustments would reflect the net effect of all changes in assumptions during the period.

Change in assumptions	Estimated adjustment to income before income taxes based on revisions to certain assumptions
	(dollars in millions)
Interest-sensitive life products:
5% increase to assumed mortality	$	(29	)
5% decrease to assumed mortality	29
15% increase to assumed expenses	(11		)
15% decrease to assumed expenses	11
10 basis point decrease to assumed spread	(9		)
10 basis point increase to assumed spread	9
20% increase to assumed lapses	(10		)
20% decrease to assumed lapses	11
Fixed index and fixed interest annuity products:
20% increase to assumed surrenders	(74		)
20% decrease to assumed surrenders	91
15% increase to assumed expenses	(7		)
15% decrease to assumed expenses	7
10 basis point decrease to assumed spread	(33		)
10 basis point increase to assumed spread	33
Other than interest-sensitive life and annuity products (a):
5% increase to assumed morbidity	(11		)
No increase in new money rate assumption after one year	(2		)

__________________

(a) We have excluded the effect of reasonably likely changes in lapse, surrender and expense assumptions for policies other than interest-sensitive life and annuity products.

56

The following summarizes the persistency of our major blocks of insurance business summarized by segment and line of business:

	Years ended December 31,
	2017		2016		2015
Bankers Life:
Medicare supplement (1)	85.0	%	85.9	%	86.3	%
Long-term care (1)	90.3	%	90.0	%	90.4	%
Fixed index annuities (2)	91.2	%	91.5	%	91.2	%
Other annuities (2)	85.2	%	85.8	%	85.1	%
Life (1)	87.5	%	87.1	%	87.3	%
Washington National:
Medicare supplement (1)	85.3	%	85.8	%	83.7	%
Supplemental health (1)	89.2	%	89.2	%	89.0	%
Life (1)	90.6	%	91.2	%	91.8	%
Colonial Penn:
Life (1)	83.4	%	83.0	%	82.6	%

_____________________

(1) Based on number of inforce policies.

(2) Based on the percentage of the inforce block persisting.

Liabilities for Insurance Products - reserves for the future payment of long-term care policy claims

We calculate and maintain reserves for the future payment of claims to our policyholders based on actuarial assumptions.  For all our insurance products, we establish an active life reserve, a liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims.  In addition, for our health insurance business, we establish a reserve for the present value of amounts not yet due on claims.  Many factors can affect these reserves and liabilities, such as economic and social conditions, inflation, hospital and pharmaceutical costs, changes in doctrines of legal liability and extra-contractual damage awards.  Therefore, our reserves and liabilities are necessarily based on numerous estimates and assumptions as well as historical experience.  Establishing reserves is an uncertain process, and it is possible that actual claims will materially exceed our reserves and have a material adverse effect on our results of operations and financial condition.  For example, our long-term care policy claims may be paid over a long period of time and, therefore, loss estimates have a higher degree of uncertainty.  

The following summarizes the components of the reserves related to our long-term care business in our Bankers Life and Long-term Care in Run-off segments.

	2017		2016
	(Dollars in millions)
Amounts classified as future policy benefits:
Active life reserves	$	3,846.0	$	3,816.4
Reserves for the present value of amounts not yet due on claims	1,366.9		1,338.4
Future loss reserves	190.0		191.3
Premium deficiency reserves assuming net unrealized gains had been realized	266.1		—
Amounts classified as liability for policy and contract claims:
Liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims	200.1		187.5
Total	5,869.1		5,533.6
Reinsurance receivables	221.5		194.3
Long-term care reserves, net of reinsurance receivables	$	5,647.6	$	5,339.3

57

The significant assumptions used to calculate the active life reserves include morbidity, persistency and investment yields. These assumptions are determined at the issuance date and do not change over the life of the policy.

The significant assumptions used to calculate the reserves for the present value of amounts not yet due on claims include future benefit payments, interest rates and claim continuance patterns. Interest rates are used to determine the present value of the future benefit payments and are based on the investment yield of assets supporting the reserves. Claim continuance assumptions are estimates of the expected period of time that claim payments will continue before termination due to recovery, death or attainment of policy maximum benefits. These estimates are based on historical claim experience for similar policy and coverage types. Our estimates of benefit payments, interest rates and claim continuance are reviewed regularly and updated to consider current portfolio investment yields and recent claims experience.

With respect to the long-term care block in our Bankers Life segment, the aggregate liability is not deficient, but our projections of estimated future profits (losses) indicate that profits will be recognized in earlier periods, followed by losses in later periods. In this situation, we are required to recognize future loss reserves. Such reserves are calculated based on our current estimate of the amount necessary to offset the losses in future periods and are established during the period the block is profitable. We estimate the future losses based on our current best estimates of morbidity, persistency, premium rates, maintenance expense and investment yields, which estimates are generally updated annually. During 2017, we decreased the future loss reserves related to our long-term care blocks of business by $1.3 million based on these calculations.

The significant assumptions used to calculate the liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims are based on historical claim payment patterns and include assumptions related to the number of claims and the size and timing of claim payments. These assumptions are updated quarterly to reflect the most current information regarding claim payment patterns. In order to determine the accuracy of our prior estimates, we calculate the total redundancy (deficiency) of our prior claim reserve estimates. The 2016 claim reserve redundancy for long-term care claim reserves in our Bankers Life segment, as measured at December 31, 2017, was $6.4 million.

Estimates of unpaid losses related to long-term care business have a higher degree of uncertainty than estimates for our other products due to the range of ultimate duration of these claims and the resulting variability in their cost (in addition to the variations in the lag time in reporting claims).  As an example, an increase in the loss ratio of 5 percentage points for claims incurred in 2017 related to our long-term care business in our Bankers Life segment would have resulted in an immediate decrease in our earnings of approximately $23 million.Our financial results depend significantly upon the extent to which our actual claims experience is consistent with the assumptions we used in determining our reserves and pricing our products.  If our assumptions with respect to future claims are incorrect, and our reserves are insufficient to cover our actual losses and expenses, we would be required to increase our liabilities, which would negatively affect our operating results.

Accounting for certain marketing agreements

Bankers Life has entered into various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute prescription drug and Medicare Advantage plans. These agreements allow Bankers Life to offer these products to current and potential future policyholders without investment in management and infrastructure. We receive fee income related to the plans sold through our distribution channels.

We account for these distribution agreements as follows:

• We recognize fee income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract.

• We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract.

58

The following summarizes the fee revenue, net of distribution expenses, earned through these marketing agreements (dollars in millions):

	2017		2016		2015
Fee revenue:
Medicare Advantage contracts	$	24.6	$	23.2	$	23.1
PDP contracts	3.3		3.1		3.2
Total revenue	27.9		26.3		26.3
Distribution expenses	10.9		9.3		9.4
Fee revenue, net of distribution expenses	$	17.0	$	17.0	$	16.9

Income Taxes

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and NOLs. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire.

Based on our assessment, it appears more likely than not that $376.2 million of our total deferred tax assets of $465.3 million will be realized through future taxable earnings. Accordingly, we have established a deferred tax valuation allowance of $89.1 million at December 31, 2017 ($77.4 million of which relates to our net federal operating loss carryforwards and $11.7 million relates to state deferred tax assets). We will continue to assess the need for a valuation allowance in the future. If future results are less than projected, an increase to the valuation allowance may be required to reduce the deferred tax asset, which could have a material impact on our results of operations in the period in which it is recorded.

We use a deferred tax valuation model to assess the need for a valuation allowance. Our model is adjusted to reflect changes in our projections of future taxable income including changes resulting from the Tax Reform Act, investment strategies, the impact of the sale or reinsurance of business and the recapture of business previously ceded. Our estimates of future taxable income are based on evidence we consider to be objective and verifiable.

At December 31, 2017, our projection of future taxable income for purposes of determining the valuation allowance is based on our adjusted average annual taxable income which is assumed to increase by 3 percent for the next five years, and level taxable income is assumed thereafter. In the projections used for our analysis, our adjusted average taxable income of approximately $345 million consisted of $85 million of non-life taxable income and $260 million of life taxable income.

Based on our assessment, we recognized a decrease to the allowance for deferred tax assets of $151.1 million in 2017. We have evaluated the recovery of our deferred tax assets and assessed the effect of limitations and/or interpretations on their value and have concluded that it is more likely than not that the value recognized will be fully realized in the future.

59

Changes in our valuation allowance are summarized as follows (dollars in millions):

Balance, December 31, 2014	$	246.0
Decrease in 2015	(32.5		)	(a)
Balance, December 31, 2015	213.5
Increase in 2016	26.7			(b)
Balance, December 31, 2016	240.2
Decrease in 2017	(166.8		)	(c)
Cumulative effect of accounting change	15.7			(d)
Balance, December 31, 2017	$	89.1

___________________

(a) The 2015 reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income.

(b) The 2016 increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the IRS.

(c) The 2017 decrease to the deferred tax valuation allowance includes: (i) $138.1 million related to a reduction in the federal corporate income tax rate and other changes from the Tax Reform Act; (ii) $13.4 million of reductions to the deferred tax valuation allowance primarily related to the recognition of capital gains; and (iii) $15.3 million of reductions in the deferred tax valuation allowance reflecting higher current year taxable income than previously reflected in our deferred tax valuation model.

(d) Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences. Under the new guidance, any excess tax benefits are recognized as an income tax benefit in the income statement. The new guidance is applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings for all tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable. The Company had NOL carryforwards of $15.7 million related to deductions for stock options and restricted stock on the date of adoption. However, a corresponding valuation allowance of $15.7 million was recognized as a result of adopting this guidance. Therefore, there was no impact to our consolidated financial statements related to the initial adoption of this provision of the new guidance.

Recovery of our deferred tax asset is dependent on achieving the level of future taxable income projected in our deferred tax valuation model and failure to do so could result in an increase in the valuation allowance in a future period.  Any future increase in the valuation allowance may result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future.

The Code limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of:  (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities).  There is no similar limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities). This limitation is the primary reason a valuation allowance for NOL is required.

Section 382 of the Code imposes limitations on a corporation's ability to use its NOLs when the company undergoes an ownership change.  Future transactions and the timing of such transactions could cause an ownership change for Section 382 income tax purposes.  Such transactions may include, but are not limited to, additional repurchases under our securities repurchase program, issuances of common stock and acquisitions or sales of shares of CNO stock by certain holders of our shares, including persons who have held, currently hold or may accumulate in the future five percent or more of our outstanding common stock for their own account.  Many of these transactions are beyond our control.  If an additional ownership change were to occur for purposes of Section 382, we would be required to calculate an annual restriction on the use of our NOLs to offset future taxable income.  The annual restriction would be calculated based upon the value of CNO's equity at the time of such ownership change, multiplied by a federal long-term tax exempt rate (1.96 percent at December 31, 2017), and the annual restriction could limit our ability to use a substantial portion of our NOLs to offset future taxable income.  We regularly monitor ownership change (as calculated for purposes of Section 382) and, as of December 31, 2017, we were below the 50 percent ownership change level that would trigger further impairment of our ability to utilize our NOLs.

60

As of December 31, 2017, we had $2.3 billion of federal NOLs, (all of which are non-life NOLs). The following table summarizes the expiration dates of our loss carryforwards (dollars in millions):

	Net operating loss
Year of expiration	carryforwards
2023	$	1,744.8
2025	85.2
2026	149.9
2027	10.8
2028	80.3
2029	213.2
2030	.3
2031	.2
2032	44.4
2033	.6
2034	.9
2035	.8
Total federal NOLs	$	2,331.4

We also had deferred tax assets related to NOLs for state income taxes of $9.3 million and $12.3 million at December 31, 2017 and 2016, respectively.  The related state NOLs are available to offset future state taxable income in certain states through 2029.

There were no unrecognized tax benefits in 2017. A reconciliation of the beginning and ending amount of unrecognized tax benefits for the year ended December 31, 2016 is as follows (dollars in millions):

	2016
Balance at beginning of year	$	234.2
Increase based on tax positions taken in prior years	3.4
Decrease in unrecognized tax benefits related to settlements with taxing authorities	(237.6		)
Balance at end of year	$	—

In the fourth quarter of 2016, we reached a settlement with the IRS related to two uncertain tax positions: (i) $280.7 million of life NOLs and $130.0 million of non-life NOLs related to the classification of the loss on our investment in Conseco Senior Health Insurance Company when it was transferred to an independent trust in 2008; and (ii) $66.7 million of non-life NOLs related to a bad debt deduction with respect to a stock purchase loan made by our Predecessor to a member of its board of directors. The settlement resulted in a reduction to tax expense of approximately $118.7 million in the fourth quarter of 2016 (the period in which these matters were settled and the fully executed documentation was received). The $118.7 million benefit includes: (i) a $98.2 million tax benefit related to additional life NOLs; (ii) a $17.1 million tax benefit related to additional non-life NOLs (net of an increase to the deferred tax valuation allowance of $51.7 million); and (iii) a $3.4 million reduction in interest recognized in prior periods on alternative minimum tax that will no longer be required to be paid.

All of the life NOLs were utilized by December 31, 2016. Accordingly, we began making federal tax payments equal to the prescribed federal tax rate applied to 65 percent of our life insurance company taxable income due to the limitations on the extent to which we can use non-life NOLs to offset life insurance company taxable income. Under current law, we will continue to pay tax on 65 percent of our life insurance company taxable income until all non-life NOLs are utilized or expire.

The IRS is conducting an examination of 2013 and 2014. In connection with this exam, we have agreed to extend the statute of limitations for 2013 through September 30, 2018. The Company’s various state income tax returns are generally open

61

for tax years beginning in 2014, based on individual state statutes of limitation. Generally, for tax years which generate NOLs, capital losses or tax credit carryforwards, the statute remains open until the expiration of the statute of limitations for the tax year in which such carryforwards are utilized. The outcome of tax audit cannot be predicted with certainty. If the Company’s tax audit is not resolved in a manner consistent with management’s expectations, the Company may be required to adjust its provision for income taxes.

Liabilities for Insurance Products

At December 31, 2017, the total balance of our liabilities for insurance products was $23.5 billion. These liabilities are generally payable over an extended period of time and the profitability of the related products is dependent on the pricing of the products and other factors. Differences between our expectations when we sold these products and our actual experience could result in future losses.

We calculate and maintain reserves for the future payment of claims to our policyholders based on actuarial assumptions. For our insurance products, we establish an active life reserve, a liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims. In addition, for our health insurance business, we establish a reserve for the present value of amounts not yet due on claims. Many factors can affect these reserves and liabilities, such as economic and social conditions, inflation, hospital and pharmaceutical costs, changes in doctrines of legal liability and extra-contractual damage awards. We establish liabilities for annuity and interest-sensitive life products equal to the accumulated policy account values, which include an accumulation of deposit payments plus credited interest, less withdrawals and the amounts assessed against the policyholder through the end of the period. In addition, policyholder account values for certain interest-sensitive life products are impacted by our assumptions related to changes of certain NGEs that we are allowed to make under the terms of the policy, such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. Therefore, our reserves and liabilities are necessarily based on numerous estimates and assumptions as well as historical experience. Establishing reserves is an uncertain process, and it is possible that actual claims will materially exceed our reserves and have a material adverse effect on our results of operations and financial condition. Our financial results depend significantly upon the extent to which our actual claims experience is consistent with the assumptions we used in determining our reserves and pricing our products. If our assumptions with respect to future claims are incorrect, and our reserves are insufficient to cover our actual losses and expenses, we would be required to increase our liabilities, which would negatively affect our operating results. Liabilities for insurance products are calculated using management's best judgments, based on our past experience and standard actuarial tables, of mortality, morbidity, lapse rates, investment experience and expense levels.

Accounting for Long-term Care Premium Rate Increases

Many of our long-term care policies have been subject to premium rate increases. In some cases, these premium rate increases were materially consistent with the assumptions we used to value the particular block of business at the Effective Date. With respect to certain premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these policyholder options:

• Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.

• Benefit reductions - If there is a premium rate increase on one of our long-term care policies, a policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.

• Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.

Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the

62

Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit.

Liabilities for Loss Contingencies Related to Lawsuits

The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.

In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.

63

RESULTS OF OPERATIONS

The following tables and narratives summarize the operating results of our segments (dollars in millions):

	2017			2016			2015
Pre-tax operating earnings (a non-GAAP measure) (a):
Bankers Life	$	418.9		$	397.9		$	369.6
Washington National	98.3			102.9			111.5
Colonial Penn	22.6			1.7			5.6
Long-term care in run-off	1.7			(3.9		)	—
Corporate operations	(86.8		)	(88.3		)	(63.9		)
	454.7			410.3			422.8
Loss on reinsurance transaction:
Corporate operations	—			(75.4		)	—
	—			(75.4		)	—
Net realized investment gains (losses), net of related amortization:
Bankers Life	33.6			(3.6		)	(16.7		)
Washington National	11.7			19.4			(9.6		)
Colonial Penn	—			(.2		)	1.2
Long-term care in run-off	7.0			(5.3		)	—
Corporate operations	(3.0		)	(2.7		)	(11.0		)
	49.3			7.6			(36.1		)
Fair value changes in embedded derivative liabilities, net of related amortization:
Bankers Life	(2.7		)	9.4			11.7
Washington National	.2			.2			.2
	(2.5		)	9.6			11.9
Equity in earnings of certain non-strategic investments and earnings attributable to VIEs:
Corporate operations	(8.8		)	(2.0		)	(6.7		)
Net revenue pursuant to transition and support services agreements, net of taxes:
Corporate operations	—			—			2.5
Fair value changes and amendment related to agent deferred compensation plan:
Corporate operations	(12.2		)	3.1			15.1
Transition expenses:
Corporate operations	—			—			(9.0		)
Loss on extinguishment of debt:
Corporate operations	—			—			(32.8		)
Income (loss) before income taxes:
Bankers Life	449.8			403.7			364.6
Washington National	110.2			122.5			102.1
Colonial Penn	22.6			1.5			6.8
Long-term care in run-off	8.7			(9.2		)	—
Corporate operations	(110.8		)	(165.3		)	(105.8		)
Income before income taxes	$	480.5		$	353.2		$	367.7

64

____________________

(a) These non-GAAP measures as presented in the above table and in the following segment financial data and discussions of segment results exclude the loss on reinsurance transaction and transition expenses, net realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization, fair value changes and amendment related to the agent deferred compensation plan, equity in earnings of certain non-strategic investments and earnings attributable to VIEs, transition expenses, loss on extinguishment of debt and before income taxes.  These are considered non-GAAP financial measures.  A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of "pre-tax operating earnings" differ from "income (loss) before income taxes" as presented in our consolidated statement of operations prepared in accordance with GAAP due to the exclusion of the loss on reinsurance transaction, realized investment gains (losses), fair value changes in embedded derivative liabilities, net of related amortization, fair value changes and amendment related to the agent deferred compensation plan, equity in earnings of certain non-strategic investments and earnings attributable to VIEs, transition expenses and loss on extinguishment of debt.  We measure segment performance excluding these items because we believe that this performance measure is a better indicator of the ongoing businesses and trends in our business. Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business. Realized investment gains (losses), fair value changes in embedded derivative liabilities, fair value changes related to the agent deferred compensation plan and equity in earnings of certain non-strategic investments and earnings attributable to VIEs depend on market conditions and do not necessarily relate to decisions regarding the underlying business of our segments.  However, "pre-tax operating earnings" does not replace "income (loss) before income taxes" as a measure of overall profitability.

We may experience realized investment gains (losses), which will affect future earnings levels since our underlying business is long-term in nature and we need to earn the assumed interest rates on the investments backing our liabilities for insurance products to maintain the profitability of our business.  In addition, management uses this non-GAAP financial measure in its budgeting process, financial analysis of segment performance and in assessing the allocation of resources. We believe these non-GAAP financial measures enhance an investor's understanding of our financial performance and allows them to make more informed judgments about the Company as a whole.  These measures also highlight operating trends that might not otherwise be apparent.  The table above reconciles the non-GAAP measure to the corresponding GAAP measure.

General: CNO is the top tier holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products. We distribute these products through our Bankers Life segment, which utilizes a career agency force, through our Washington National segment, which utilizes independent producers and through our Colonial Penn segment, which utilizes direct response marketing. In the fourth quarter of 2016, we began reporting as an additional business segment, the long-term care block recaptured from BRe as further described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Consolidated Financial Condition - Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off".

65

Bankers Life (dollars in millions)

	2017			2016			2015
Premium collections:
Annuities	$	1,030.6		$	970.0		$	803.0
Medicare supplement and other supplemental health	1,213.4			1,235.3			1,242.3
Life	462.4			461.1			446.0
Total collections	$	2,706.4		$	2,666.4		$	2,491.3
Average liabilities for insurance products:
Fixed index annuities	$	5,139.6		$	4,527.8		$	4,075.5
Fixed interest annuities	2,899.5			3,188.2			3,487.8
SPIAs and supplemental contracts:
Mortality based	160.5			174.9			189.5
Deposit based	149.0			153.7			153.8
Health:
Long-term care	4,987.4			4,998.0			4,916.2
Medicare supplement	334.9			336.8			331.0
Other health	55.9			50.3			47.7
Life:
Interest sensitive	778.2			714.6			643.0
Non-interest sensitive	1,089.9			1,018.0			941.5
Total average liabilities for insurance products, net of reinsurance ceded	$	15,594.9		$	15,162.3		$	14,786.0
Revenues:
Insurance policy income	$	1,666.6		$	1,659.1		$	1,648.7
Net investment income:
General account invested assets	953.8			909.5			918.7
Fixed index products	153.5			27.3			(34.0		)
Fee revenue and other income	44.1			34.4			27.7
Total revenues	2,818.0			2,630.3			2,561.1
Expenses:
Insurance policy benefits	1,448.5			1,417.4			1,442.5
Amounts added to policyholder account balances:
Cost of interest credited to policyholders	105.0			110.8			118.5
Cost of options to fund index credits, net of forfeitures	63.7			66.1			60.3
Market value changes credited to policyholders	154.6			26.3			(32.9		)
Amortization related to operations	163.6			176.5			187.1
Interest expense on investment borrowings	19.8			13.2			8.8
Other operating costs and expenses	443.9			422.1			407.2
Total benefits and expenses	2,399.1			2,232.4			2,191.5
Income before net realized investment gains (losses), net of related amortization, and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes	418.9			397.9			369.6
Net realized investment gains (losses)	34.6			(3.2		)	(17.2		)
Amortization related to net realized investment gains (losses)	(1.0		)	(.4		)	.5
Net realized investment gains (losses), net of related amortization	33.6			(3.6		)	(16.7		)
Insurance policy benefits - fair value changes in embedded derivative liabilities	(3.4		)	10.7			14.9
Amortization related to fair value changes in embedded derivative liabilities	.7			(1.3		)	(3.2		)
Fair value changes in embedded derivative liabilities, net of related amortization	(2.7		)	9.4			11.7
Income before income taxes	$	449.8		$	403.7		$	364.6

66

	2017			2016			2015
Health benefit ratios:
All health lines:
Insurance policy benefits	$	1,149.9		$	1,192.3		$	1,205.1
Benefit ratio (a)	93.4		%	95.8		%	96.3		%
Medicare supplement:
Insurance policy benefits	$	550.6		$	556.2		$	536.1
Benefit ratio (a)	70.8		%	71.9		%	69.6		%
Long-term care:
Insurance policy benefits	$	599.3		$	636.1		$	669.0
Benefit ratio (a)	132.3		%	135.0		%	139.2		%
Interest-adjusted benefit ratio (b)	71.2		%	76.7		%	82.8		%

______________

(a) We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.

(b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Bankers Life's long-term care products by dividing such product's insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of "interest-adjusted benefit ratios" differ from "benefit ratios" due to the deduction of imputed interest income on the accumulated assets backing the insurance liabilities from the product's insurance policy benefits used to determine the ratio. Interest income is an important factor in measuring the performance of health products that are expected to be inforce for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time. The net cash flows from long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by the imputed interest income earned on the accumulated assets. The interest-adjusted benefit ratio reflects the effects of such interest income offset (which is equal to the tabular interest on the related insurance liabilities). Since interest income is an important factor in measuring the performance of this product, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance. We utilize the interest-adjusted benefit ratio in measuring segment performance because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business. However, the "interest-adjusted benefit ratio" does not replace the "benefit ratio" as a measure of current period benefits to current period insurance policy income. Accordingly, management reviews both "benefit ratios" and "interest-adjusted benefit ratios" when analyzing the financial results attributable to these products. The imputed investment income earned on the accumulated assets backing Bankers Life's long-term care reserves was $276.8 million, $274.7 million and $271.2 million in 2017, 2016 and 2015, respectively.

Total premium collections were $2,706.4 million in 2017, up 1.5 percent from 2016, and $2,666.4 million in 2016, up 7.0 percent from 2015. See "Premium Collections" for further analysis of Bankers Life's premium collections.

Average liabilities for insurance products, net of reinsurance ceded were $15.6 billion in 2017, up 2.9 percent from 2016 and $15.2 billion in 2016, up 2.5 percent from 2015. Such average insurance liabilities for certain long-term care products were increased by $107 million, $184 million and $196 million in 2017, 2016 and 2015, respectively, to reflect the premium deficiencies that would exist if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields. Such increase is reflected as a reduction of accumulated other comprehensive income. Excluding the impact of the aforementioned item, the increase in average liabilities for insurance products was primarily due to new sales and the amounts added to policyholder account balances on interest-sensitive products.

Insurance policy income is comprised of premiums earned on policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies.

67

Net investment income on general account invested assets (which excludes income on policyholder portfolios) increased 4.9 percent, to $953.8 million, in 2017 and decreased 1.0 percent, to $909.5 million, in 2016. In 2017, net investment income reflects $17 million of higher investment income from alternative investments compared to 2016. Such increases reflect higher returns from credit, private equity, and equity related strategies and a larger average alternative investment portfolio in 2017. Prepayment income (including call premiums) was $31.5 million, $13.3 million and $26.5 million in 2017, 2016 and 2015, respectively.

Net investment income related to fixed index products represents the change in the estimated fair value of options which are purchased in an effort to offset or hedge certain potential benefits accruing to the policyholders of our fixed index products. Our fixed index products are designed so that investment income spread is expected to be more than adequate to cover the cost of the options and other costs related to these policies.  Net investment income (loss) related to fixed index products was $153.5 million, $27.3 million and $(34.0) million in 2017, 2016 and 2015, respectively. Such amounts were substantially offset by the corresponding charge (credit) to amounts added to policyholder account balances - market value changes credited to policyholders.Such income and related charges fluctuate based on the value of options embedded in the segment's fixed index annuity policyholder account balances subject to this benefit and to the performance of the index to which the returns on such products are linked.

Fee revenue and other income was $44.1 million, $34.4 million and $27.7 million in 2017, 2016 and 2015, respectively. The increase in 2017 and 2016 is attributable to fee income earned by our broker-dealer and registered investment advisor subsidiaries. We recognized fee income of $27.9 million, $26.3 million and $26.3 million in 2017, 2016 and 2015, respectively, pursuant to distribution and marketing agreements to sell Medicare Advantage and PDP products of other insurance companies.

Insurance policy benefits fluctuated as a result of the factors summarized below for benefit ratios.  Benefit ratios are calculated by dividing the related insurance product’s insurance policy benefits by insurance policy income.

In the fourth quarter of 2017, we completed our comprehensive review of actuarial assumptions. Such review resulted in a decrease in reserves of $9.0 million and a decrease in amortization of $1.8 million including the net impact of changes to mortality assumptions related to interest-sensitive life products. In the fourth quarter of 2016, our comprehensive review resulted in a decrease in reserves of $42.6 million and a decrease in amortization of $3.2 million including the net impact from changes to spread and persistency assumptions related to fixed index annuities. In the fourth quarter of 2015, our comprehensive review resulted in a decrease in reserves of $21.9 million and a decrease in amortization of $3.9 million primarily reflecting the net impact from changes in assumptions related to mortality and the spread earned on fixed index annuities.

The Medicare supplement business consists of both individual and group policies.  Government regulations generally require us to attain and maintain a ratio of total benefits incurred to total premiums earned (excluding changes in policy benefit reserves), after three years from the original issuance of the policy and over the lifetime of the policy, of not less than 65 percent on individual products and not less than 75 percent on group products, as determined in accordance with statutory accounting principles.  Since the insurance product liabilities we establish for Medicare supplement business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Our benefit ratios were 70.8 percent, 71.9 percent and 69.6 percent in 2017, 2016 and 2015, respectively. Our insurance policy benefits reflected favorable (unfavorable) reserve developments of prior period claim reserves of approximately $6.0 million, $(1.9) million and $(1.1) million in 2017, 2016 and 2015, respectively.  Excluding the effects of prior period claim reserve redundancies and deficiencies, our benefit ratios would have been 71.5 percent, 71.7 percent and 69.4 percent in 2017, 2016 and 2015, respectively. We currently expect the benefit ratio on this Medicare supplement business to be in the range of 71 percent to 74 percent during 2018.

The net cash flows from our long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) which will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio typically increases, but the increase in reserves is partially offset by investment income earned on the accumulated assets.  The benefit ratio on our long-term care business in the Bankers Life segment was 132.3 percent, 135.0 percent and 139.2 percent in 2017, 2016 and 2015, respectively.  The interest-adjusted benefit ratio on this business was 71.2 percent, 76.7 percent and 82.8 percent in 2017, 2016 and 2015, respectively.  The interest-adjusted benefit ratio in 2017 was favorably impacted by $11.3 million of one-time reserve releases which was comprised of: (i) $6.5 million related to lower persistency (including the results of procedures performed to identify policies that had terminated prior to June 30, 2017 due to death); (ii) $1.7 million related to an out-of-period adjustment that reduced reserves; and (iii) $3.1 million related to the impact of policyholder decisions to surrender or reduce coverage following rate

68

increases. The interest-adjusted benefit ratio in 2016 and 2015 was favorably impacted by reserve releases of $22 million and $6.3 million, respectively, related to policyholder decisions to surrender or reduce coverage following rate increases. The interest-adjusted benefit ratio in 2017, 2016 and 2015, excluding such favorable reserve releases, was 73.7 percent, 81.4 percent and 84.1 percent, respectively. The interest-adjusted benefit ratio in 2017 also reflected no increase to the future loss reserve, given the outcome of the year-end 2016 actuarial review, compared to increases of $33.0 million and $38.2 million in 2016 and 2015, respectively.

We currently expect the interest-adjusted benefit ratio on this long-term care business to be in the range of 75 percent to 80 percent during 2018. Since the insurance product liabilities we establish for the long-term care business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate.  Our insurance policy benefits reflected reserve redundancies from prior years of $6.4 million, $11.1 million and $16.2 million in 2017, 2016 and 2015, respectively. When policies lapse, active life reserves for such lapsed policies are released, resulting in decreased insurance policy benefits (although such decrease is somewhat offset by additional amortization expense).

Amounts added to policyholder account balances - cost of interest credited to policyholders were $105.0 million, $110.8 million and $118.5 million in 2017, 2016 and 2015, respectively. The weighted average crediting rates for these products was 2.8 percent in 2017, 2016 and 2015. The average liabilities of the fixed interest annuity block were $2.9 billion, $3.2 billion and $3.5 billion in 2017, 2016 and 2015, respectively. The decrease in the liabilities related to these annuities reflects the lower sales of these products in the current low interest rate environment and consumer preference for fixed index products.

Amounts added to policyholder account balances for fixed index products represent a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the S&P 500 Index, over a specified period. Such amounts include our cost to fund the annual index credits, net of policies that are canceled prior to their anniversary date (classified as cost of options to fund index credits, net of forfeitures). Market value changes in the underlying indices during a specified period of time are classified as market value changes credited to policyholders. Such market value changes are generally offset by the net investment income related to fixed index products discussed above.

Amortization related to operations includes amortization of deferred acquisition costs and the present value of future profits. Deferred acquisition costs and the present value of future profits are collectively referred to as "insurance acquisition costs". Insurance acquisition costs are generally amortized either:  (i) in relation to the estimated gross profits for interest-sensitive life and annuity products; or (ii) in relation to actual and expected premium revenue for other products.  In addition, for interest-sensitive life and annuity products, we are required to adjust the total amortization recorded to date through the statement of operations if actual experience or other evidence suggests that earlier estimates of future gross profits should be revised. Accordingly, amortization for interest-sensitive life and annuity products is dependent on the profits realized during the period and on our expectation of future profits.  For other products, we amortize insurance acquisition costs in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits.  The lower amortization in 2017 and 2016 generally reflects the favorable persistency experienced as compared to the prior year. Amortization was also impacted in each year by our comprehensive review of actuarial assumptions discussed above under insurance policy benefits.

Interest expense on investment borrowings represents interest expense on collateralized borrowings as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Investment Borrowings". The increase in interest expense in 2017 and 2016 is primarily due to higher interest rates on the variable rate investment borrowings.

69

Other operating costs and expenses in our Bankers Life segment were $443.9 million in 2017, up 5.2 percent from 2016, and were $422.1 million in 2016, up 3.7 percent from 2015. Such expenses in 2017 include $3.5 million for estimated future state guaranty association assessments, net of premium tax offsets, related to the liquidation of Penn Treaty Network America Insurance Company ("Penn Treaty"). Other operating costs and expenses include the following (dollars in millions):

	2017		2016		2015
Commission expense and agent manager benefits	$	70.8	$	71.6	$	64.4
Other operating expenses	373.1		350.5		342.8
Total	$	443.9	$	422.1	$	407.2

Net realized investment gains (losses) fluctuate each period. During 2017, we recognized net realized investment gains of $34.6 million, which were comprised of: (i) $25.9 million of net gains from the sales of investments; and (ii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $8.7 million. During 2016, we recognized net realized investment losses of $3.2 million, which were comprised of: (i) $17.0 million of net gains from the sales of investments; (ii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $.2 million; and (iii) $20.4 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($22.9 million, prior to the $2.5 million of impairment losses recognized in accumulated other comprehensive income (loss)). During 2015, we recognized net realized investment losses of $17.2 million, which were comprised of: (i) $1.2 million of net gains from the sales of investments; (ii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $6.7 million; and (iii) $11.7 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($14.0 million, prior to the $2.3 million of impairment losses recognized in accumulated other comprehensive income (loss)).

Amortization related to net realized investment gains (losses) is the increase or decrease in the amortization of insurance acquisition costs which results from realized investment gains or losses. When we sell securities which back our interest-sensitive life and annuity products at a gain (loss) and reinvest the proceeds at a different yield, we increase (reduce) the amortization of insurance acquisition costs in order to reflect the change in estimated gross profits due to the gains (losses) realized and the resulting effect on estimated future yields. Sales of fixed maturity investments resulted in an increase (decrease) in the amortization of insurance acquisition costs of $1.0 million, $.4 million and $(.5) million in 2017, 2016 and 2015, respectively.

Insurance policy benefits - fair value changes in embedded derivative liabilities represents fair value changes due to fluctuations in the interest rates used to discount embedded derivative liabilities related to our fixed index annuities.

Amortization related to fair value changes in embedded derivative liabilities is the increase or decrease in the amortization of insurance acquisition costs which results from changes in interest rates used to discount embedded derivative liabilities related to our fixed index annuities.

70

Washington National (dollars in millions)

	2017			2016			2015
Premium collections:
Supplemental health and other health	$	589.1		$	567.4		$	547.0
Medicare supplement	51.6			61.0			72.6
Life	30.0			29.4			27.7
Annuity	.9			1.5			2.4
Total collections	$	671.6		$	659.3		$	649.7
Average liabilities for insurance products:
Fixed index annuities	$	314.2		$	350.2		$	386.0
Fixed interest annuities	97.9			107.0			119.1
SPIAs and supplemental contracts:
Mortality based	232.1			248.6			258.4
Deposit based	269.5			267.2			260.5
Separate Accounts	4.7			4.7			5.2
Health:
Supplemental health	2,732.0			2,604.4			2,494.0
Medicare supplement	24.8			28.3			30.9
Other health	13.5			14.1			15.0
Life:
Interest sensitive life	149.2			150.3			151.9
Non-interest sensitive life	175.0			179.8			185.9
Total average liabilities for insurance products, net of reinsurance ceded	$	4,012.9		$	3,954.6		$	3,906.9
Revenues:
Insurance policy income	$	671.4		$	655.8		$	643.8
Net investment income (loss):
General account invested assets	257.5			256.2			256.0
Fixed index products	9.0			1.9			(2.2		)
Trading account income related to policyholder accounts	3.7			1.2			(.2		)
Fee revenue and other income	1.0			1.3			1.3
Total revenues	942.6			916.4			898.7
Expenses:
Insurance policy benefits	550.7			538.2			528.4
Amounts added to policyholder account balances:
Cost of interest credited to policyholders	12.9			13.8			14.6
Cost of options to fund index credits, net of forfeitures	4.4			5.8			6.3
Market value changes credited to policyholders	13.1			3.9			(2.7		)
Amortization related to operations	58.8			59.1			55.2
Interest expense on investment borrowings	6.3			3.7			2.0
Other operating costs and expenses	198.1			189.0			183.4
Total benefits and expenses	844.3			813.5			787.2
Income before net realized investment gains (losses) and fair value changes in embedded derivative liabilities, net of related amortization, and income taxes	98.3			102.9			111.5
Net realized investment gains (losses)	11.7			19.7			(9.6		)
Amortization related to net realized investment gains (losses)	—			(.3		)	—
Net realized investment gains (losses), net of related amortization	11.7			19.4			(9.6		)
Insurance policy benefits - fair value changes in embedded derivative liabilities	.5			.6			.8
Amortization related to fair value changes in embedded derivative liabilities	(.3		)	(.4		)	(.6		)
Fair value changes in embedded derivative liabilities, net of related amortization	.2			.2			.2
Income before income taxes	$	110.2		$	122.5		$	102.1

71

	2017			2016			2015
Health benefit ratios:
Supplemental health:
Insurance policy benefits	$	489.8		$	469.3		$	455.3
Benefit ratio (a)	83.2		%	83.0		%	84.0		%
Interest-adjusted benefit ratio (b)	59.1		%	59.0		%	59.6		%
Medicare supplement:
Insurance policy benefits	$	37.0		$	42.7		$	47.9
Benefit ratio (a)	68.1		%	68.4		%	65.0		%

_________________

(a) We calculate benefit ratios by dividing the related product’s insurance policy benefits by insurance policy income.

(b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Washington National's supplemental health products by dividing such product’s insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income.  These are considered non-GAAP financial measures.  A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of "interest-adjusted benefit ratios" differ from "benefit ratios" due to the deduction of imputed interest income on the accumulated assets backing the insurance liabilities from the product’s insurance policy benefits used to determine the ratio.  Interest income is an important factor in measuring the performance of health products that are expected to be inforce for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time.  The net cash flows from supplemental health products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases).  Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by the imputed interest income earned on the accumulated assets.  The interest-adjusted benefit ratio reflects the effects of such interest income offset (which is equal to the tabular interest on the related insurance liabilities). Since interest income is an important factor in measuring the performance of these products, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance.  We utilize the interest-adjusted benefit ratio in measuring segment performance because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business.  However, the "interest-adjusted benefit ratio" does not replace the "benefit ratio" as a measure of current period benefits to current period insurance policy income. Accordingly, management reviews both "benefit ratios" and "interest-adjusted benefit ratios" when analyzing the financial results attributable to these products.  The imputed investment income earned on the accumulated assets backing the supplemental health reserves was $141.7 million, $135.6 million and $132.6 million in 2017, 2016 and 2015, respectively.

Total premium collections were $671.6 million in 2017, up 1.9 percent from 2016, and $659.3 million in 2016, up 1.5 percent from 2015, driven by sales and persistency of the segment's supplemental health block; partially offset by lower Medicare supplement collected premiums due to the run-off of this block of business. This segment no longer markets Medicare supplement products and no longer actively pursues sales of annuity products. See "Premium Collections" for further analysis of fluctuations in premiums collected by product.

Average liabilities for insurance products, net of reinsurance ceded were $4,012.9 million in 2017, up 1.5 percent from 2016, and $3,954.6 million in 2016, up 1.2 percent from 2015, reflecting an increase in the supplemental health block; partially offset by the run-off of the annuity blocks.

Insurance policy income is comprised of premiums earned on traditional insurance policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies. Such income increased in recent periods as supplemental health premiums have increased consistent with sales; partially offset by the decrease in Medicare supplement premiums.

72

Net investment income on general account invested assets (which excludes income on policyholder portfolios and reinsurer accounts) was $257.5 million in 2017, $256.2 million in 2016 and $256.0 million in 2015. Prepayment income (including call premiums) was $5.9 million, $5.1 million and $3.8 million in 2017, 2016 and 2015, respectively.

Net investment income related to fixed index products represents the change in the estimated fair value of options which are purchased in an effort to offset or hedge certain potential benefits accruing to the policyholders of our fixed index products. Our fixed index products are designed so that investment income spread is expected to be more than adequate to cover the cost of the options and other costs related to these policies. Net investment income (loss) related to fixed index products was $9.0 million, $1.9 million and $(2.2) million in 2017, 2016 and 2015, respectively. Such amounts were substantially offset by the corresponding charge to amounts added to policyholder account balances - market value changes credited to policyholders.  Such income and related charges fluctuate based on the value of options embedded in the segment's fixed index annuity policyholder account balances subject to this benefit and to the performance of the index to which the returns on such products are linked.

Trading account income related to policyholder accounts represents the income on investments backing the market strategies of certain annuity products which provide for different rates of cash value growth based on the experience of a particular market strategy. The income on our trading account securities is designed to substantially offset certain amounts included in insurance policy benefits related to the aforementioned annuity products.

Insurance policy benefits fluctuated as a result of the factors summarized below. Benefit ratios are calculated by dividing the related insurance product's insurance policy benefits by insurance policy income.

In the fourth quarter of 2017, we completed our comprehensive annual review of actuarial assumptions. Such review resulted in a $1 million increase in amortization of deferred acquisition costs related to interest-sensitive life products. In the fourth quarter of 2016, our comprehensive review had no material impact on this segment. In the fourth quarter of 2015, our comprehensive review resulted in a $1 million decrease in reserves.

Washington National's supplemental health products (including specified disease, accident and hospital indemnity products) generally provide fixed or limited benefits. For example, payments under cancer insurance policies are generally made directly to, or at the direction of, the policyholder following diagnosis of, or treatment for, a covered type of cancer. Approximately three-fourths of our supplemental health policies inforce (based on policy count) were sold with return of premium or cash value riders. The return of premium rider generally provides that after a policy has been inforce for a specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy. The cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned. Accordingly, the net cash flows from these products generally result in the accumulation of amounts in the early years of a policy (reflected in our earnings as reserve increases) which will be paid out as benefits in later policy years (reflected in our earnings as reserve decreases which offset the recording of benefit payments). As the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by investment income earned on the accumulated assets. The benefit ratio will fluctuate depending on the claim experience during the year.

Insurance margins (insurance policy income less insurance policy benefits) on supplemental health products were $98.7 million, $96.2 million and $86.4 million in 2017, 2016 and 2015, respectively. The benefit ratio on these products was 83.2 percent, 83.0 percent and 84.0 percent in 2017, 2016 and 2015, respectively. The interest-adjusted benefit ratio on this supplemental health business was 59.1 percent, 59.0 percent and 59.6 percent in 2017, 2016 and 2015, respectively. We currently expect the interest-adjusted benefit ratio on this supplemental health business to be in the range of 58 percent to 61 percent during 2018.

Washington National's Medicare supplement business primarily consists of individual policies. The insurance product liabilities we establish for our Medicare supplement business are subject to significant estimates and the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate.  Governmental regulations generally require us to attain and maintain a ratio of total benefits incurred to total premiums earned (excluding changes in policy benefit reserves), after three years from the original issuance of the policy and over the lifetime of the policy, of not less than 65 percent on these products, as determined in accordance with statutory accounting principles. Insurance margins (insurance policy income less insurance policy benefits) on these products were $17.4 million, $19.8 million and $25.7 million in 2017, 2016 and 2015, respectively. Such decrease reflects the run-off of this block of business.

73

Amounts added to policyholder account balances - cost of interest credited to policyholders were $12.9 million, $13.8 million and $14.6 million in 2017, 2016 and 2015, respectively.

Amounts added to policyholder account balances for fixed index products represent a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the S&P 500 Index, over a specified period. Such amounts include our cost to fund the annual index credits, net of policies that are canceled prior to their anniversary date (classified as cost of options to fund index credits, net of forfeitures). Market value changes in the underlying indices during a specified period of time are classified as market value changes credited to policyholders. Such market value changes are generally offset by the net investment income related to fixed index products discussed above.

Amortization related to operations includes amortization of insurance acquisition costs. Insurance acquisition costs are generally amortized in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits. Such amounts were generally consistent with the related premium revenue. A revision to our current assumptions could result in increases or decreases to amortization expense in future periods.

Interest expense on investment borrowings represents $6.3 million, $3.7 million and $2.0 million of interest expense on collateralized borrowings in 2017, 2016 and 2015, respectively, as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Investment Borrowings". The increase in interest expense in 2017 and 2016 is due to higher interest rates on the variable rate investment borrowings.

Other operating costs and expenses were $198.1 million, $189.0 million and $183.4 million in 2017, 2016 and 2015, respectively. Such expenses in 2017 include $1.3 million for estimated future state guaranty association assessments, net of premium tax offsets, related to the liquidation of Penn Treaty. Other operating costs and expenses also include commission expense of $69.8 million, $70.2 million and $68.3 million in 2017, 2016 and 2015, respectively. The increase in commission expense is consistent with the growth in the supplemental health block.

Net realized investment gains (losses) fluctuate each period. During 2017, we recognized net realized investment gains of $11.7 million, which were comprised of: (i) $7.4 million of net gains from the sales of investments; (ii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $2.5 million; (iii) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $2.8 million; and (iv) $1.0 million of writedowns of investments for other than temporary declines in fair value which were recorded in earnings. During 2016, we recognized net realized investment gains of $19.7 million, which were comprised of: (i) $24.7 million of net gains from the sales of investments; (ii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $.5 million; (iii) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $.8 million; and (iv) $5.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($6.4 million, prior to the $1.1 million of impairment losses recognized in accumulated other comprehensive income (loss)). During 2015, we recognized $2.8 million of net gains from the sales of investments; the decrease in fair value of embedded derivatives related to a modified coinsurance agreement of $7.0 million; the decrease in fair value of certain fixed maturity investments with embedded derivatives of $2.1 million; and $3.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($3.7 million, prior to the $.4 million of impairment losses recognized in accumulated other comprehensive income (loss)).

Amortization related to net realized investment gains (losses) is the increase or decrease in the amortization of insurance acquisition costs which results from realized investment gains or losses. When we sell securities which back our interest-sensitive life and annuity products at a gain (loss) and reinvest the proceeds at a different yield (or when we have the intent to sell the impaired investments before an anticipated recovery in value occurs), we increase (reduce) the amortization of insurance acquisition costs in order to reflect the change in estimated gross profits due to the gains (losses) realized and the resulting effect on estimated future yields. Sales of fixed maturity investments resulted in an increase in the amortization of insurance acquisition costs of nil, $.3 million and nil in 2017, 2016 and 2015, respectively.

Insurance policy benefits - fair value changes in embedded derivative liabilities represents fair value changes due to fluctuations in the interest rates used to discount embedded derivative liabilities related to our fixed index annuities.

Amortization related to fair value changes in embedded derivative liabilities is the increase or decrease in the amortization of insurance acquisition costs which results from changes in interest rates used to discount embedded derivative liabilities related to our fixed index annuities.

74

Colonial Penn (dollars in millions)

	2017		2016			2015
Premium collections:
Life	$	289.6	$	277.8		$	259.9
Medicare supplement and other health	2.0		2.4			3.0
Total collections	$	291.6	$	280.2		$	262.9
Average liabilities for insurance products:
SPIAs - mortality based	$	73.0	$	74.1		$	73.1
Health:
Medicare supplement	5.7		6.5			7.7
Other health	4.1		4.2			4.4
Life:
Interest sensitive	15.5		16.2			16.5
Non-interest sensitive	717.5		689.4			670.1
Total average liabilities for insurance products, net of reinsurance ceded	$	815.8	$	790.4		$	771.8
Revenues:
Insurance policy income	$	291.8	$	281.4		$	263.5
Net investment income on general account invested assets	44.4		44.2			43.0
Fee revenue and other income	1.3		1.1			1.0
Total revenues	337.5		326.7			307.5
Expenses:
Insurance policy benefits	199.0		201.2			188.3
Amounts added to annuity and interest-sensitive life product account balances	.6		.7			.7
Amortization related to operations	16.3		15.3			14.4
Interest expense on investment borrowings	.9		.6			.1
Other operating costs and expenses	98.1		107.2			98.4
Total benefits and expenses	314.9		325.0			301.9
Income before net realized investment gains (losses) and income taxes	22.6		1.7			5.6
Net realized investment gains (losses)	—		(.2		)	1.2
Income before income taxes	$	22.6	$	1.5		$	6.8

This segment's results are significantly impacted by the accounting standard related to deferred acquisition costs. We are not able to defer most of Colonial Penn's direct response advertising costs although such costs generate predictable sales and future inforce profits. We plan to continue to invest in this segment's business, including the development of new products and markets. The amount of our investment in new business during a particular period will have a significant impact on this segment's results. We expect this segment to report earnings (before net realized investment gains (losses) and income taxes) in 2018 in the range of $10 million to $20 million, but because of the seasonality of advertising spend, we expect a loss in the range of $1 million to $3 million in the first quarter of 2018.

Total premium collections increased 4.1 percent, to $291.6 million, in 2017 and 6.6 percent, to $280.2 million, in 2016. The increase was driven by recent sales activity and steady persistency. See "Premium Collections" for further analysis of Colonial Penn's premium collections.

Average liabilities for insurance products, net of reinsurance ceded have increased as a result of growth in the core graded benefit and simplified issue life insurance block in this segment.

75

Insurance policy income is comprised of premiums earned on policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies. The increase in such income reflects the growth in the block of graded benefit and simplified issue life insurance business.

Net investment income on general account invested assets increased slightly in 2017 and 2016 primarily due to the increase in invested assets as a result of growth in this segment.

Insurance policy benefits in 2017 reflect: (i) growth in this segment; (ii) the favorable changes to liabilities for insurance products including a $2.5 million out-of-period adjustment and a $.5 million refinement to the calculation; and (iii) favorable mortality as compared to 2016. Insurance policy benefits in 2016 reflected a $2.5 million increase in reserves related to the impact of loss recognition on a closed block of payout annuities resulting from changes in long-term interest rates and mortality assumptions.

Amortization related to operations includes amortization of insurance acquisition costs. Insurance acquisition costs in the Colonial Penn segment are amortized in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits. Such amounts were generally consistent with the related premium revenue and gross profits for such periods and the assumptions we made when we established the present value of future profits. A revision to our current assumptions could result in increases or decreases to amortization expense in future periods.

Other operating costs and expenses in our Colonial Penn segment fluctuate primarily due to changes in the marketing expenses incurred to generate new business. Marketing expenses were lower in 2017 as compared to 2016. The demand and cost of television advertising appropriate for Colonial Penn's campaigns has fluctuated widely in certain periods. In 2017, higher advertising costs resulted in our decision to lower our planned spending. We are disciplined with our marketing expenditures and will increase or decrease our advertising spend depending on prices.

Net realized investment gains (losses) fluctuate each period. During 2017, we recognized net realized investment gains of nil, which were comprised of: (i) $.7 million of net gains from the sales of investments; (ii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $.3 million; and (iii) $1.0 million of writedowns of investments for other than temporary declines in fair value which were recorded in earnings. During 2016, we recognized net realized investment losses of $.2 million, which were comprised of: (i) $.7 million of net gains from the sales of investments; (ii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $.1 million; and (iii) $.8 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2015, we recognized $2.2 million of net gains from the sales of investments (primarily fixed maturities); the decrease in fair value of certain fixed maturity investments with embedded derivatives of $.4 million; and $.6 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($.9 million, prior to the $.3 million of impairment losses recognized in accumulated other comprehensive income (loss)).

Management believes that an analysis of Adjusted EBIT for Colonial Penn, separated between in-force and new business, provides increased clarity for this segment as the vast majority of the costs to generate new business in this segment are not deferrable and Adjusted EBIT will fluctuate based on management's decisions on how much marketing costs to incur in each period. Adjusted EBIT from new business includes pre-tax revenues and expenses associated with new sales of our insurance products during the first year after the sale is completed. Adjusted EBIT from in-force business includes all pre-tax revenues and expenses associated with sales of insurance products that were completed more than one year before the end of the reporting period. The allocation of certain revenues and expenses between new and in-force business is based on estimates, which we believe are reasonable.

76

Recognizing the accounting standard that requires us to expense certain direct response advertising costs (rather than deferring such costs as deferred acquisition costs), the amount of our investment in new business in the Colonial Penn segment during a particular period will have a significant impact on the segment results. The following summarizes our earnings, separated between in-force and new business for Colonial Penn (dollars in millions):

	2017			2016			2015
Adjusted EBIT from In-force Business
Revenues:
Insurance policy income	$	241.8		$	226.5		$	212.0
Net investment income and other	45.7			45.3			44.0
Total revenues	287.5			271.8			256.0
Benefits and expenses:
Insurance policy benefits	169.2			168.5			159.4
Amortization	15.6			14.5			13.7
Other expenses	33.9			34.4			29.3
Total benefits and expenses	218.7			217.4			202.4
Adjusted EBIT from In-force Business	$	68.8		$	54.4		$	53.6
Adjusted EBIT from New Business
Revenues:
Insurance policy income	$	50.0		$	54.9		$	51.5
Net investment income and other	—			—			—
Total revenues	50.0			54.9			51.5
Benefits and expenses:
Insurance policy benefits	30.4			33.4			29.6
Amortization	.7			.8			.7
Other expenses	65.1			73.4			69.2
Total benefits and expenses	96.2			107.6			99.5
Adjusted EBIT from New Business	$	(46.2	)	$	(52.7	)	$	(48.0	)
Adjusted EBIT from In-force and New Business
Revenues:
Insurance policy income	$	291.8		$	281.4		$	263.5
Net investment income and other	45.7			45.3			44.0
Total revenues	337.5			326.7			307.5
Benefits and expenses:
Insurance policy benefits	199.6			201.9			189.0
Amortization	16.3			15.3			14.4
Other expenses	99.0			107.8			98.5
Total benefits and expenses	314.9			325.0			301.9
Adjusted EBIT from In-force and New Business	$	22.6		$	1.7		$	5.6

The AdjustedEBIT from in-force business in the Colonial Penn segment in 2017 reflects higher renewal premium income due to higher sales in recent periods. The Adjusted EBIT from new business in the Colonial Penn segment in 2017 primarily reflects lower marketing costs. The vast majority of the costs to generate new business in this segment are not deferrable and Adjusted EBIT will fluctuate based on management's decisions on how much marketing costs to incur in each period.

77

Long-term care in run-off (dollars in millions)

In September 2016, we terminated certain reinsurance agreements and recaptured the ceded business as further described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Consolidated Financial Condition - Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off". The long-term care in run-off segment is comprised of the long-term care business that was recaptured.

	2017		2016
Premium collections:
Long-term care (all renewal)	$	16.9	$	4.7
Average liabilities for insurance products:
Average liabilities for long-term care products, net of reinsurance ceded	$	572.4	$	138.4
Revenues:
Insurance policy income	$	17.5	$	4.8
Net investment income on general account invested assets	34.6		9.4
Total revenues	52.1		14.2
Expenses:
Insurance policy benefits	47.3		17.6
Other operating costs and expenses	3.1		.5
Total benefits and expenses	50.4		18.1
Income (loss) before net realized investment gains (losses) and income taxes	1.7		(3.9		)
Net realized investment gains (losses)	7.0		(5.3		)
Income (loss) before income taxes	$	8.7	$	(9.2	)

	2017			2016
Health benefit ratios:
Long-term care:
Insurance policy benefits	$	47.3		$	17.6
Benefit ratio (a)	270.5		%	365.8		%
Interest-adjusted benefit ratio (b)	104.1		%	213.5		%

_______________

(a) We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.

(b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for long-term care products in this segment by dividing such product's insurance policy benefits less the imputed interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of "interest-adjusted benefit ratios" differ from "benefit ratios" due to the deduction of imputed interest income on the accumulated assets backing the insurance liabilities from the product's insurance policy benefits used to determine the ratio. Interest income is an important factor in measuring the performance of health products that are expected to be inforce for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time. The net cash flows from long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by the imputed interest income earned on the accumulated assets. The interest-adjusted benefit ratio reflects the effects of such interest income

78

offset (which is equal to the tabular interest on the related insurance liabilities). Since interest income is an important factor in measuring the performance of these products, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance. We utilize the interest-adjusted benefit ratio in measuring segment performance because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business. However, the "interest-adjusted benefit ratio" does not replace the "benefit ratio" as a measure of current period benefits to current period insurance policy income. Accordingly, management reviews both "benefit ratios" and "interest-adjusted benefit ratios" when analyzing the financial results attributable to these products. The imputed investment income earned on the accumulated assets backing the long-term care reserves was $29.1 million and $7.3 million in 2017 and 2016, respectively.

Average liabilities for long-term care products were increased by $23 million in 2017 to reflect the premium deficiencies that would exist if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields. Such increase is reflected as a reduction of accumulated other comprehensive income.

Insurance policy benefits in 2017 were $47.3 million and the interest-adjusted benefit ratio for this long-term care block was 104.1 percent in 2017. Our 2017 comprehensive actuarial review of this block reflected relatively low margins. Accordingly, this segment's results can be volatile from period to period. Insurance policy benefits in 2016 included the unfavorable impact of $2.6 million related to the impact of loss recognition on this closed block of long-term care business from changes in long-term interest rates and mortality assumptions. This block of business is particularly sensitive to changes in assumptions.

Net realized investment losses fluctuated each period. During 2017, we recognized net realized investment gains of $7.0 million, which were comprised of: (i) $25.3 million of net gains from the sales of investments; and (ii) $18.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2016, we recognized net realized investment losses of $5.3 million, which were comprised of: (i) $4.6 million of net losses from the sales of investments; and (ii) $.7 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

79

Corporate Operations (dollars in millions)

	2017			2016			2015
Corporate operations:
Interest expense on corporate debt	$	(46.5	)	$	(45.8	)	$	(45.0	)
Net investment income (loss):
General investment portfolio	5.6			4.8			6.9
Other special-purpose portfolios:
COLI	17.4			(.3		)	(6.4		)
Investments held in a rabbi trust	3.4			1.1			(.1		)
Other trading account activities	9.1			11.0			10.9
Fee revenue and other income	8.5			10.0			8.6
Interest expense on investment borrowings	—			—			(.2		)
Other operating costs and expenses	(84.3		)	(69.1		)	(38.6		)
Loss before net realized investment losses, equity in earnings of certain non-strategic investments and earnings attributable to non-controlling interests, fair value changes and amendment related to agent deferred compensation plan, loss on reinsurance transaction, transition expenses, loss on extinguishment of debt and income taxes	(86.8		)	(88.3		)	(63.9		)
Net realized investment losses	(3.0		)	(2.7		)	(11.0		)
Equity in earnings of certain non-strategic investments and earnings attributable to VIEs	(8.8		)	(2.0		)	(6.7		)
Fair value changes and amendment related to agent deferred compensation plan	(12.2		)	3.1			15.1
Loss on reinsurance transaction and transition expenses	—			(75.4		)	—
Net revenue pursuant to transition and support services agreements	—			—			2.5
Transition expenses	—			—			(9.0		)
Loss on extinguishment of debt	—			—			(32.8		)
Loss before income taxes	$	(110.8	)	$	(165.3	)	$	(105.8	)

Interest expense on corporate debt has been primarily impacted by: (i) the debt refinancing transactions completed in May 2015; and (ii) the timing and amount of debt repayments in 2015, along with the mix of interest rates on the related outstanding borrowings. Such transactions are further discussed in the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations". Our average corporate debt outstanding was $925.0 million, $925.0 million and $888.6 million in 2017, 2016 and 2015, respectively. The average interest rate on our debt was 4.8 percent, 4.7 percent and 4.7 percent in 2017, 2016 and 2015, respectively. Interest expense in periods subsequent to the debt refinancing transactions also reflects lower amortization of discount and issuance costs primarily due to the extended maturity profile of the debt incurred in our refinancing transactions.

Net investment income on general investment portfolio fluctuates based on the amount and type of invested assets in the corporate operations segment.

Net investment income on other special-purpose portfolios includes the income (loss) from:  (i) investments related to deferred compensation plans held in a rabbi trust (which is offset by amounts included in other operating costs and expenses as the investment results are allocated to participants' account balances); (ii) trading account activities; (iii) income (loss) from COLI equal to the difference between the return on these investments (representing the change in value of the underlying investments) and our overall portfolio yield; and (iv) other alternative strategies.  COLI is utilized as an investment vehicle to fund Bankers Life's agent deferred compensation plan.  For segment reporting, the Bankers Life segment is allocated a return on these investments equivalent to the yield on the Company’s overall portfolio, with any difference in the actual COLI return allocated to the Corporate operations segment. We recognized death benefits, net of cash surrender value, of $4.0 million and $1.1 million related to the COLI in 2017 and 2015, respectively.

Fee revenue and other income includes the fees our wholly-owned investment advisor earns for managing portfolios of commercial bank loans for investment trusts. These trusts are consolidated as VIEs in our consolidated financial statements,

80

but the fees are reflected as revenues and the fee expense is reflected in the earnings attributable to VIEs. This fee revenue fluctuates consistent with the size of the loan portfolios.

Other operating costs and expenses include general corporate expenses, net of amounts charged to subsidiaries for services provided by the corporate operations. These amounts fluctuate as a result of expenses such as consulting and legal costs which often vary from period to period. The increase in such expenses in 2017, compared to 2016, is due to higher legal expenses primarily from matters related to the recapture of the long-term care business in September 2016. The increase in such expenses in 2016, compared to 2015, reflects: (i) higher legal costs (including a $5.5 million increase to legal reserves related to legacy business of our predecessor); (ii) higher expenses related to various corporate initiatives and strategies (including costs to comply with new DOL requirements); and (iii) higher compensation and benefit accruals including accelerated stock compensation expense related to retirement eligible employees, severance costs and performance-based compensation expense.

Net realized investment losses often fluctuate each period. During 2017, net realized investment losses in this segment were $3.0 million and were comprised of: (i) $3.8 million of net gains from the sales of investments (including $1.2 million of net gains recognized by the VIEs and $2.6 million of net gains on other investment sales); (ii) $4.3 million of losses on the dissolution of VIEs; and (iii) $2.5 million of writedowns of investments held by VIEs due to other-than-temporary declines in value. During 2016, net realized investment losses in this segment were $2.7 million and were comprised of: (i) $5.8 million of net gains from the sales of investments (including $11.9 million of net losses recognized by the VIEs and $17.7 million of net gains on other investment sales); (ii) $7.3 million of losses on the dissolution of a VIE; and (iii) $1.2 million of writedowns of investments held by VIEs due to other-than-temporary declines in value. During 2015, net realized investment losses in this segment included: (i) $2.0 million of net gains from the sales of investments (including $1.3 million of losses recognized by the VIEs and $3.3 million of net gains on other sales of investments); (ii) an $11.3 million gain on the dissolution of a VIE; (iii) a $7.9 million writedown of a legacy investment in a private company that was liquidated; and (iv) $16.4 million of writedowns of investments held by VIEs due to other-than-temporary declines in value. We no longer have any investment exposure to legacy private company investments.

Equity in earnings of certain non-strategic investments and earnings attributable to VIEs include the earnings attributable to VIEs that we are required to consolidate and certain private companies that were acquired in the commutation of an investment made by our Predecessor, net of affiliated amounts. Such earnings are not indicative of, and are unrelated to, the Company's underlying fundamentals.

Fair value changes and amendment related to agent deferred compensation plan relate to: (i) changes in the underlying actuarial assumptions used to value liabilities for our agent deferred compensation plan; and (ii) an amendment made to the plan in the third quarter of 2016. The agent deferred compensation plan was amended to: (i) freeze participation in the plan; (ii) freeze benefits accrued under the plan; and (iii) add a limited cashout feature. During the third quarter of 2016, we made lump sum settlement distributions to plan participants with account balances that were below a certain threshold consistent with the provision of the amended plan. We recognized a pre-tax gain of $6.3 million related to the settlement distributions in the third quarter of 2016.

Loss on reinsurance transaction of $75.4 million in 2016 resulted from the termination of the reinsurance agreements with BRe and recapture of the ceded business as further described in "Consolidated Financial Condition - Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off".

Net revenue pursuant to transition and support services agreements represents the difference between the fees we received from Wilton Re and the overhead costs incurred to provide such services under the agreements subsequent to the sale of a subsidiary in 2014.

Transition expenses include one-time expenses associated with our comprehensive agreement with Cognizant for our application development, maintenance and testing functions as well as select information technology infrastructure operations.

Loss on extinguishment of debt in 2015 of $32.8 million consisted of: (i) $15.0 million related to the write-off of unamortized discount and issuance costs due to the repayment of our previous senior secured credit agreement and the 6.375% Senior Secured Notes due October 2020 (the "6.375% Notes"); and (ii) a make-whole redemption premium of $17.8 million due to the repayment of the 6.375% Notes. These transactions are further discussed in the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations".

81

PREMIUM COLLECTIONS

In accordance with GAAP, insurance policy income in our consolidated statement of operations consists of premiums earned for traditional insurance policies that have life contingencies or morbidity features.  For annuity and interest-sensitive life contracts, premiums collected are not reported as revenues, but as deposits to insurance liabilities.  We recognize revenues for these products over time in the form of investment income and surrender or other charges.

Our insurance segments sell products through three primary distribution channels - career agents (our Bankers Life segment), direct marketing (our Colonial Penn segment) and independent producers (our Washington National segment).  Our career agency force in the Bankers Life segment sells primarily Medicare supplement and long-term care insurance policies, life insurance and annuities.  These agents visit the customer's home, which permits one-on-one contact with potential policyholders and promotes strong personal relationships with existing policyholders.  Our direct marketing distribution channel in the Colonial Penn segment is engaged primarily in the sale of graded benefit life and simplified issue life insurance policies which are sold directly to the policyholder.  Our Washington National segment sells primarily supplemental health and life insurance.  These products are marketed through PMA, a wholly-owned subsidiary that specializes in marketing and distributing health products, and through independent marketing organizations and insurance agencies, including worksite marketing.

Agents, insurance brokers and marketing companies who market our products and prospective purchasers of our products use the financial strength ratings of our insurance subsidiaries as an important factor in determining whether to market or purchase.  Ratings have the most impact on our sales of supplemental health and life products to consumers at the worksite.  The current financial strength ratings of our primary insurance subsidiaries from Fitch, S&P, A.M. Best and Moody's are "BBB+", "BBB+", "A-" and "Baa1", respectively.  For a description of these ratings and additional information on our ratings, see "Consolidated Financial Condition - Financial Strength Ratings of our Insurance Subsidiaries."

We set premium rates on our health insurance policies based on facts and circumstances known at the time we issue the policies using assumptions about numerous variables, including the actuarial probability of a policyholder incurring a claim, the probable size of the claim, and the interest rate earned on our investment of premiums.  We also consider historical claims information, industry statistics, the rates of our competitors and other factors.  If our actual claims experience is less favorable than we anticipated and we are unable to raise our premium rates, our financial results may be adversely affected.  We generally cannot raise our health insurance premiums in any state until we obtain the approval of the state insurance regulator.  We review the adequacy of our premium rates regularly and file for rate increases on our products when we believe such rates are too low.  It is likely that we will not be able to obtain approval for all requested premium rate increases.  If such requests are denied in one or more states, our net income may decrease.  If such requests are approved, increased premium rates may reduce the volume of our new sales and may cause existing policyholders to lapse their policies.  If the healthier policyholders allow their policies to lapse, this would reduce our premium income and profitability in the future.

82

Total premium collections were $3.7 billion in 2017, up 2.2 percent from 2016, and $3.6 billion in 2016, up 6.1 percent from 2015. First year collected premiums were $1,374.1 million in 2017, up 2.2 percent from 2016, and $1,344.8 million in 2016, up 12 percent from 2015. Total premiums collected are summarized as follows (dollars in millions):

	2017		2016		2015
First year:
Bankers Life	$	1,245.6	$	1,211.8	$	1,065.7
Washington National	78.4		78.2		80.2
Colonial Penn	50.1		54.8		51.5
Total first year	1,374.1		1,344.8		1,197.4
Renewal:
Bankers Life	1,460.8		1,454.6		1,425.6
Washington National	595.0		581.1		569.5
Colonial Penn	241.5		225.4		211.4
Long-term care in run-off	16.9		4.7		—
Total renewal	2,314.2		2,265.8		2,206.5
Total premiums collected	$	3,688.3	$	3,610.6	$	3,403.9

83

Total premium collections by segment were as follows:

Bankers Life (dollars in millions)

	2017		2016		2015
Premiums collected by product:
Annuities:
Fixed index (first-year)	$	964.7	$	868.1	$	706.6
Other fixed interest (first-year)	59.8		95.7		89.6
Other fixed interest (renewal)	6.1		6.2		6.8
Subtotal - other fixed interest annuities	65.9		101.9		96.4
Total annuities	1,030.6		970.0		803.0
Health:
Medicare supplement (first-year)	69.3		75.6		80.3
Medicare supplement (renewal)	670.1		663.7		659.1
Subtotal - Medicare supplement	739.4		739.3		739.4
Long-term care (first-year)	16.0		17.4		16.7
Long-term care (renewal)	429.3		451.2		459.9
Subtotal - long-term care	445.3		468.6		476.6
Supplemental health (first-year)	5.0		5.5		6.1
Supplemental health (renewal)	17.6		15.7		13.1
Subtotal – supplemental health	22.6		21.2		19.2
Other health (first-year)	.8		.1		.1
Other health (renewal)	5.3		6.1		7.0
Subtotal - other health	6.1		6.2		7.1
Total health	1,213.4		1,235.3		1,242.3
Life insurance:
Traditional (first-year)	82.6		78.8		83.0
Traditional (renewal)	217.3		207.3		193.9
Subtotal - traditional	299.9		286.1		276.9
Interest-sensitive (first-year)	47.4		70.6		83.3
Interest-sensitive (renewal)	115.1		104.4		85.8
Subtotal - interest-sensitive	162.5		175.0		169.1
Total life insurance	462.4		461.1		446.0
Collections on insurance products:
Total first-year premium collections on insurance products	1,245.6		1,211.8		1,065.7
Total renewal premium collections on insurance products	1,460.8		1,454.6		1,425.6
Total collections on insurance products	$	2,706.4	$	2,666.4	$	2,491.3

Annuities in this segment include fixed index and other fixed interest annuities sold to the senior market. Annuity collections in this segment increased 6.2 percent, to $1,030.6 million in 2017 and 21 percent, to $970.0 million, in 2016. The increase in premium collections from our fixed index products in 2017 and 2016 is due primarily to sales of annuity contracts with living benefits following the introduction of that product in the third quarter of 2016. Premium collections from our fixed index products were also favorably impacted in 2017 and 2016 by the general stock market performance which made these products attractive to certain customers. Premium collections from our other fixed interest products decreased in 2017 due to lower sales of these products in the current low interest rate environment and consumer preference for fixed index products.

84

Health products include Medicare supplement, long-term care and other insurance products. Our profits on health policies depend on the overall level of sales, the length of time the business remains inforce, investment yields, claims experience and expense management.

Collected premiums on Medicare supplement policies in the Bankers Life segment were $739.4 million, $739.3 million and $739.4 million in 2017, 2016 and 2015, respectively.

Premiums collected on Bankers Life's long-term care policies decreased 5.0 percent, to $445.3 million in 2017 and 1.7 percent, to $468.6 million in 2016, reflecting the run-off of this business and a continuing shift in the mix of new business to shorter duration long-term care sales, which have lower premiums per policy.

Life products in this segment include traditional and interest-sensitive life products. Life premiums collected in this segment increased .3 percent, to $462.4 million, in 2017 and 3.4 percent, to $461.1 million, in 2016. Collected premiums in 2017 and 2016 reflect strong persistency; partially offset by lower first-year premiums.

Washington National (dollars in millions)

	2017		2016		2015
Premiums collected by product:
Health:
Medicare supplement (renewal)	$	51.6	$	61.0	$	72.6
Supplemental health (first-year)	73.2		72.2		74.9
Supplemental health (renewal)	515.9		493.3		469.9
Subtotal – supplemental health	589.1		565.5		544.8
Other health (first-year)	.3		.2		.2
Other health (renewal)	1.5		1.7		2.0
Subtotal – other health	1.8		1.9		2.2
Total health	642.5		628.4		619.6
Life insurance:
Traditional (first-year)	.7		.9		.7
Traditional (renewal)	10.2		10.5		11.4
Subtotal - traditional	10.9		11.4		12.1
Interest-sensitive (first-year)	4.2		4.7		4.3
Interest-sensitive (renewal)	14.9		13.3		11.3
Subtotal - interest-sensitive	19.1		18.0		15.6
Total life insurance	30.0		29.4		27.7
Annuities:
Fixed index (first-year)	—		.2		.1
Fixed index (renewal)	.6		1.0		1.8
Subtotal - fixed index annuities	.6		1.2		1.9
Other fixed interest (renewal)	.3		.3		.5
Total annuities	.9		1.5		2.4
Collections on insurance products:
Total first-year premium collections on insurance products	78.4		78.2		80.2
Total renewal premium collections on insurance products	595.0		581.1		569.5
Total collections on insurance products	$	673.4	$	659.3	$	649.7

Health products in the Washington National segment include Medicare supplement, supplemental health and other insurance products. Our profits on health policies depend on the overall level of sales, the length of time the business remains inforce, investment yields, claim experience and expense management.

85

Collected premiums on Medicare supplement policies in the Washington National segment decreased 15 percent, to $51.6 million, in 2017 and 16 percent, to $61.0 million, in 2016 due to the run-off of this block of business. We discontinued new sales of Medicare supplement policies in this segment in 2012.

Premiums collected on supplemental health products (including specified disease, accident and hospital indemnity insurance products) increased 4.2 percent, to $589.1 million, in 2017 and 3.8 percent, to $565.5 million, in 2016. Such increases are due to new sales in recent periods and persistency.

Overall, excluding premiums from the Washington National Medicare supplement and annuity blocks which are in run-off, collected premiums were up 4.0 percent, to $620.9 million in 2017 as compared to 2016, driven by sales in recent periods and persistency.

Life premiums collected in the Washington National segment increased 2.0 percent, to $30.0 million, in 2017 and 6.1 percent, to $29.4 million, in 2016.

Annuities in this segment include fixed index and other fixed interest annuities. We are no longer actively pursuing sales of annuity products in this segment.

Colonial Penn (dollars in millions)

	2017		2016		2015
Premiums collected by product:
Life insurance:
Traditional (first-year)	$	50.1	$	54.8	$	51.5
Traditional (renewal)	239.3		222.7		208.2
Subtotal - traditional	289.4		277.5		259.7
Interest-sensitive (all renewal)	.2		.3		.2
Total life insurance	289.6		277.8		259.9
Health (all renewal):
Medicare supplement	1.9		2.3		2.7
Other health	.1		.1		.3
Total health	2.0		2.4		3.0
Collections on insurance products:
Total first-year premium collections on insurance products	50.1		54.8		51.5
Total renewal premium collections on insurance products	241.5		225.4		211.4
Total collections on insurance products	$	291.6	$	280.2	$	262.9

Life products in this segment are sold primarily to the senior market. Life premiums collected in this segment increased 4.2 percent, to $289.6 million, in 2017 and 6.9 percent, to $277.8 million, in 2016. Premiums collected reflect both recent sales activity and steady persistency.

Health products include Medicare supplement and other insurance products. Our profits on health policies depend on the overall level of sales, the length of time the business remains inforce, investment yields, claims experience and expense management. Premiums collected on these products have decreased as we do not currently market these products through this segment.

86

Long-term care in run-off (dollars in millions)

	2017		2016
Premiums collected by product:
Health:
Long-term care (renewal)	$	16.9	$	4.7

The Long-term care in run-off segment only includes the long-term care premiums collected from the business recaptured from BRe in September 2016 as further described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Consolidated Financial Condition - Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off".

INVESTMENTS

Our investment strategy is to: (i) provide largely stable investment income from a diversified high quality fixed income portfolio; (ii) mitigate the effect of changing interest rates through active asset/liability management; (iii) provide liquidity to meet our cash obligations to policyholders and others; and (iv) maximize total return through active strategic asset allocation and investment management. Consistent with this strategy, investments in fixed maturity securities and mortgage loans made up 88 percent of our $27.9 billion investment portfolio at December 31, 2017. The remainder of the invested assets was trading securities, investments held by variable interest entities, various types of alternative investments, equity securities, policy loans and other invested assets.

The following table summarizes the composition of our investment portfolio as of December 31, 2017 (dollars in millions):

	Carrying value		Percent of total investments
Fixed maturities, available for sale	$	22,910.9	82	%
Equity securities	511.7		2
Mortgage loans	1,650.6		6
Policy loans	116.0		—
Trading securities	284.6		1
Investments held by variable interest entities	1,526.9		6
Company-owned life insurance	182.3		1
Other invested assets	671.1		2
Total investments	$	27,854.1	100	%

Insurance statutes regulate the types of investments that our insurance subsidiaries are permitted to make and limit the amount of funds that may be used for any one type of investment. In addition, we have internal management compliance limits on various exposures and activities which are typically more restrictive than insurance statutes. In light of these statutes and regulations and our business and investment strategy, we generally seek to invest in United States government and government-agency securities and corporate securities rated investment grade by established nationally recognized rating organizations or in securities of comparable investment quality, if not rated.

87

The following table summarizes the carrying values and gross unrealized losses of our fixed maturity securities, available for sale, by category as of December 31, 2017 (dollars in millions):

	Carrying value		Percent of fixed maturities		Gross unrealized losses		Percent of gross unrealized losses
Asset-backed securities	$	3,254.4	14.2	%	$	4.1	9.8	%
States and political subdivisions	2,056.3		9.0		.4		1.0
Insurance	1,831.8		8.0		.4		1.0
Utilities	1,694.2		7.4		.1		.2
Energy	1,488.4		6.5		6.4		15.0
Commercial mortgage-backed securities	1,377.5		6.0		10.3		24.0
Healthcare/pharmaceuticals	1,320.5		5.8		.8		1.8
Banks	1,268.5		5.5		.4		1.0
Food/beverage	1,024.3		4.5		.1		.3
Collateralized mortgage obligations	742.1		3.3		.3		.7
Cable/media	649.2		2.8		5.8		13.6
Capital goods	596.0		2.6		.1		.3
Chemicals	573.7		2.5		1.7		3.9
Transportation	573.1		2.5		.7		1.6
Real estate/REITs	530.2		2.3		.1		.3
Telecom	486.6		2.1		.4		1.0
Technology	426.4		1.9		1.5		3.6
Brokerage	352.3		1.5		1.3		3.0
Building materials	296.8		1.3		1.0		2.5
Autos	296.5		1.3		.3		.6
Aerospace/defense	283.1		1.2		—		—
Collateralized debt obligations	259.4		1.1		—		—
Retail	226.3		1.0		.7		1.6
Business services	191.9		.8		1.8		4.3
Other	1,111.4		4.9		3.8		8.9
Total fixed maturities, available for sale	$	22,910.9	100.0	%	$	42.5	100.0	%

88

The following table summarizes the gross unrealized losses of our fixed maturity securities, available for sale, by category and ratings category as of December 31, 2017 (dollars in millions):

	Investment grade				Below-investment grade
	AAA/AA/A		BBB		BB		B+ and below		Total gross unrealized losses
Commercial mortgage-backed securities	$	8.8	$	.3	$	1.2	$	—	$	10.3
Energy	—		3.1		—		3.3		6.4
Cable/media	.1		5.4		.3		—		5.8
Asset-backed securities	2.5		.7		.3		.6		4.1
Entertainment/hotels	—		.5		1.9		.1		2.5
Business services	—		—		1.8		—		1.8
Chemicals	—		—		1.7		—		1.7
Technology	—		1.5		—		—		1.5
Brokerage	—		.7		—		.6		1.3
Building materials	—		.4		.6		—		1.0
Healthcare/pharmaceuticals	—		.1		—		.7		.8
Transportation	—		.2		.5				.7
Retail	—		.3		—		.4		.7
Insurance	—		.4		—		—		.4
States and political subdivisions	.1		.3		—		—		.4
Telecom	—		.4		—		—		.4
Banks	.2		.2		—		—		.4
Collateralized mortgage obligations	.2		—		—		.1		.3
Autos	—		—		.3		—		.3
United States Treasury securities and obligations of United States government corporations and agencies	.2		—		—		—		.2
Debt securities issued by foreign governments	.1		.1		—		—		.2
Food/beverage	—		—		—		.1		.1
Real estate/REITs	—		.1		—		—		.1
Capital goods	.1		—		—		—		.1
Consumer products	—		—		—		.1		.1
Utilities	.1		—		—		—		.1
Other	.6		.2		—		—		.8
Total fixed maturities, available for sale	$	13.0	$	14.9	$	8.6	$	6.0	$	42.5

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active strategic asset allocation and investment management. Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities.

Our fixed maturity securities consist predominantly of publicly traded securities. We classify securities issued in the Rule 144A market as publicly traded. Securities not publicly traded comprise approximately 8 percent of our total fixed maturity securities portfolio.

89

Fair Value of Investments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price.  We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives.  We carry our COLI, which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs.

The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information.  Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value.  Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value.

Valuation Hierarchy

There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable.

• Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities.  Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.

• Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data.  Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies.  These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include:  certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.

• Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions.  Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information.  Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities.  Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.

At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value.  This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions.  Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. Any transfers between levels are reported as having occurred at the beginning of the period. There were no transfers between Level 1 and Level 2 in both 2017 and 2016.

90

The vast majority of our fixed maturity and equity securities, including those held in trading portfolios and those held by consolidated VIEs, short-term and separate account assets use Level 2 inputs for the determination of fair value.  These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value.  Our Level 2 assets are valued as follows:

•Fixed maturities available for sale, equity securities and trading securities

Corporate securities are generally priced using market and income approaches. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads.

U.S. Treasuries and obligations of U.S. Government corporations and agencies are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets and maturity.

States and political subdivisions are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances and credit spreads.

Asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations are generally priced using market and income approaches. Inputs generally consist of quoted prices in inactive markets, spreads on actively traded securities, expected prepayments, expected default rates, expected recovery rates, and issue specific information including, but not limited to, collateral type, seniority and vintage.

Equity securities (primarily comprised of non-redeemable preferred stock) are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads.

• Investments held by VIEs

Corporate securities are generally priced using market and income approaches using pricing vendors. Inputs generally consist of issuer rating, benchmark yields, maturity, and credit spreads.

• Other invested assets - derivatives

The fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotes; time value and volatility factors underlying options; market interest rates; and non-performance risk.

Third party pricing services normally derive security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information.  If there are no recently reported trades, the third party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are discounted at an estimated risk-adjusted market rate.  The number of prices obtained for a given security is dependent on the Company's analysis of such prices as further described below.

As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value.  The Company's analysis includes:  (i) a review of the methodology used by third party pricing services; (ii) where available, a comparison of multiple pricing services' valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably dated; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties.  As a result of such procedures, the Company may conclude a particular price received from a third party is not reflective of current market conditions.  In those instances, we may request additional pricing quotes or apply internally developed valuations.  However, the number of such instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received.

91

The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company's judgment of the inputs or methodologies used by the independent pricing services to value different asset classes.  Such inputs typically include:  benchmark yields, reported trades, broker dealer quotes, issuer spreads, benchmark securities, bids, offers and other relevant data.  The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments.

For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes.  These broker quotes are non-binding andrepresent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs.  Approximately 29 percent of our Level 3 fixed maturity securities were valued using unadjusted broker quotes or broker-provided valuation inputs.  The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs.  For these securities, we use internally developed valuations.  Key assumptions used to determine fair value for these securities may include risk premiums, projected performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market.  For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are discounted at an estimated market rate.  The pricing matrix incorporates term interest rates as well as a spread level based on the issuer's credit rating, other factors relating to the issuer, and the security's maturity.  In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity.

For certain embedded derivatives, we use actuarial assumptions in the determination of fair value which we consider to be Level 3 inputs.

92

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2017 is as follows (dollars in millions):

	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	14,728.0	$	230.4	$	14,958.4
United States Treasury securities and obligations of United States government corporations and agencies	—		177.7		—		177.7
States and political subdivisions	—		2,056.3		—		2,056.3
Debt securities issued by foreign governments	—		79.2		3.9		83.1
Asset-backed securities	—		3,230.2		24.2		3,254.4
Collateralized debt obligations	—		259.4		—		259.4
Commercial mortgage-backed securities	—		1,377.5		—		1,377.5
Mortgage pass-through securities	—		2.0		—		2.0
Collateralized mortgage obligations	—		742.1		—		742.1
Total fixed maturities, available for sale	—		22,652.4		258.5		22,910.9
Equity securities - corporate securities	287.8		202.7		21.2		511.7
Trading securities:
Corporate securities	—		21.6		—		21.6
United States Treasury securities and obligations of United States government corporations and agencies	—		.5		—		.5
Asset-backed securities	—		95.8		—		95.8
Collateralized debt obligations	—		2.7		—		2.7
Commercial mortgage-backed securities	—		92.5		—		92.5
Collateralized mortgage obligations	—		68.7		—		68.7
Equity securities	2.8		—		—		2.8
Total trading securities	2.8		281.8		—		284.6
Investments held by variable interest entities - corporate securities	—		1,522.0		4.9		1,526.9
Other invested assets - derivatives	—		170.2		—		170.2
Assets held in separate accounts	—		5.0		—		5.0
Total assets carried at fair value by category	$	290.6	$	24,834.1	$	284.6	$	25,409.3
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	1,334.8	$	1,334.8

93

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2017 (dollars in millions):

	December 31, 2017
	Beginning balance as of December 31, 2016			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income		Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2017			Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	258.5		$	(70.4	)	$	5.8	$	5.3		$	31.2	$	—		$	230.4		$	(8.0	)
Debt securities issued by foreign governments	3.9			—			—		—			—		—			3.9			—
Asset-backed securities	60.4			(4.3		)	—		.7			—		(32.6		)	24.2			—
Collateralized debt obligations	5.4			(2.5		)	—		—			—		(2.9		)	—			—
Commercial mortgage-backed securities	32.0			(1.2		)	.1		(.1		)	—		(30.8		)	—			—
Total fixed maturities, available for sale	360.2			(78.4		)	5.9		5.9			31.2		(66.3		)	258.5			(8.0		)
Equity securities - corporate securities	25.2			(8.5		)	6.3		(1.8		)	—		—			21.2			—
Investments held by variable interest entities - corporate securities	—			4.9			—		—			—		—			4.9			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,092.3		)	(267.5		)	25.0		—			—		—			(1,334.8		)	25.0

94

_________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  The following summarizes such activity for the year ended December 31, 2017 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	76.6		$	(147.0	)	$	—		$	—	$	(70.4	)
Asset-backed securities	—			(4.3		)	—			—		(4.3		)
Collateralized debt obligations	—			(2.5		)	—			—		(2.5		)
Commercial mortgage-backed securities	—			(1.2		)	—			—		(1.2		)
Total fixed maturities, available for sale	76.6			(155.0		)	—			—		(78.4		)
Equity securities - corporate securities	—			(8.5		)	—			—		(8.5		)
Investments held by variable interest entities - corporate securities	8.9			(4.0		)	—			—		4.9
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(178.9		)	5.4			(159.3		)	65.3		(267.5		)

At December 31, 2017, 52 percent of our Level 3 fixed maturities, available for sale, were investment grade and 89 percent of our Level 3 fixed maturities, available for sale, consisted of corporate securities.

Realized and unrealized investment gains and losses presented in the preceding tables represent gains and losses during the time the applicable financial instruments were classified as Level 3.

Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and other special-purpose portfolios, net realized investment gains (losses) or insurance policy benefits within the consolidated statement of operations or accumulated other comprehensive income within shareholders' equity based on the appropriate accounting treatment for the instrument.

The amount presented for gains (losses) included in our net loss for assets and liabilities still held as of the reporting date primarily represents impairments for fixed maturities, available for sale, changes in fair value of trading securities and certain derivatives and changes in fair value of embedded derivative instruments included in liabilities for insurance products that exist as of the reporting date.

Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations (Moody's, S&P or Fitch), or if not rated by such firms, the rating assigned by the NAIC.  NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by

95

S&P and Fitch).  NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch).  References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above. The following table sets forth fixed maturity investments at December 31, 2017, classified by ratings (dollars in millions):

			Estimated fair value
Investment rating	Amortized cost		Amount		Percent of fixed maturities
AAA	$	1,521.2	$	1,552.6	7	%
AA	1,588.4		1,770.8		7
A	4,967.3		5,678.2		25
BBB+	2,910.5		3,354.0		15
BBB	3,870.5		4,291.6		19
BBB-	3,194.8		3,410.2		15
Investment grade	18,052.7		20,057.4		88
BB+	244.3		254.5		1
BB	266.7		272.4		1
BB-	290.0		293.6		1
B+ and below	1,848.4		2,033.0		9
Below-investment grade	2,649.4		2,853.5		12
Total fixed maturity securities	$	20,702.1	$	22,910.9	100	%

The following table summarizes investment yields earned over the past three years on the general account invested assets of our insurance subsidiaries. General account investments exclude the value of options (dollars in millions).

	2017			2016			2015
Weighted average general account invested assets at amortized cost	$	23,819.5		$	22,539.5		$	21,624.6
Net investment income on general account invested assets	1,290.3			1,219.3			1,217.7
Yield earned	5.42		%	5.41		%	5.63		%

Although investment income is a significant component of total revenues, the profitability of certain of our insurance products is evaluated primarily by the spreads between the interest rates we earn and the rates we credit or accrue to our insurance liabilities. At December 31, 2017, the average yield, computed on the cost basis of our fixed maturity portfolio, was 5.3 percent, and the average interest rate credited or accruing to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or fixed index products) was 4.6 percent.

Fixed Maturities, Available for Sale

Our fixed maturity portfolio at December 31, 2017, included primarily debt securities of the United States government, various corporations, and structured securities. Asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations are collectively referred to as "structured securities".

At December 31, 2017, our fixed maturity portfolio had $2,251.3 million of unrealized gains and $42.5 million of unrealized losses, for a net unrealized gain of $2,208.8 million. Estimated fair values of fixed maturity investments were determined based on estimates from: (i) nationally recognized pricing services (93 percent of the portfolio); (ii) broker-dealer market makers (1 percent of the portfolio); and (iii) internally developed methods (6 percent of the portfolio).

At December 31, 2017, approximately 10 percent of our invested assets (12 percent of fixed maturity investments) were fixed maturities rated below-investment grade. Our level of investments in below-investment grade fixed maturities could change based on market conditions or changes in our management policies. Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities. Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade securities and in many cases severity

96

of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer. Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are more sensitive to adverse economic conditions. The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry. At December 31, 2017, our below-investment grade fixed maturity investments had an amortized cost of $2,649.4 million and an estimated fair value of $2,853.5 million.

We continually evaluate the creditworthiness of each issuer whose securities we hold. We pay special attention to large investments, investments which have significant risk characteristics and to those securities whose fair values have declined materially for reasons other than changes in general market conditions. We evaluate the realizable value of the investment, the specific condition of the issuer and the issuer's ability to comply with the material terms of the security. We review the recent operational results and financial position of the issuer, information about its industry, information about factors affecting the issuer's performance and other information. 40|86 Advisors employs experienced securities analysts in a broad variety of specialty areas who compile and review such data. If evidence does not exist to support a realizable value equal to or greater than the amortized cost of the investment, and such decline in fair value is determined to be other than temporary, we reduce the amortized cost to its fair value, which becomes the new cost basis. We report the amount of the reduction as a realized loss. We recognize any recovery of such reductions as investment income over the remaining life of the investment (but only to the extent our current valuations indicate such amounts will ultimately be collected), or upon the repayment of the investment. During 2017, we recognized net realized investment gains of $50.3 million, which were comprised of: (i) $63.1 million of net gains from the sales of investments; (ii) $4.3 million of losses on the dissolution of VIEs; (iii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $11.5 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $2.8 million; and (v) $22.8 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

Our investment portfolio is subject to the risk of declines in realizable value. However, we attempt to mitigate this risk through the diversification and active management of our portfolio.

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active strategic asset allocation and investment management. Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities.

As of December 31, 2017, we had $13.4 million of investments in substantive default (i.e., in default due to nonpayment of interest or principal). There were no other fixed maturity investments about which we had serious doubts as to the recoverability of the carrying value of the investment.

When a security defaults or securities (other than structured securities) are other-than-temporarily impaired, our policy is to discontinue the accrual of interest and eliminate all previous interest accruals, if we determine that such amounts will not be ultimately realized in full.

At December 31, 2017, fixed maturity investments included structured securities with an estimated fair value of $5.6 billion (or 25 percent of all fixed maturity securities).  The yield characteristics of structured securities generally differ in some respects from those of traditional corporate fixed-income securities or government securities.  For example, interest and principal payments on structured securities may occur more frequently, often monthly.  In many instances, we are subject to variability in the amount and timing of principal and interest payments.  For example, in many cases, partial prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including:  the relative sensitivity of prepayments on the underlying assets backing the security to changes in interest rates and asset values; the availability of alternative financing; a variety of economic, geographic and other factors; the timing, pace and proceeds of liquidations of defaulted collateral; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure).  In addition, the total amount of payments for non-agency structured securities may be affected by changes to cumulative default rates or loss severities of the related collateral.

Historically, the rate of prepayments on structured securities has tended to increase when prevailing interest rates have declined significantly in absolute terms and also relative to the interest rates on the underlying collateral. The yields recognized on structured securities purchased at a discount to par will generally increase (relative to the stated rate) when the underlying collateral prepays faster than expected. The yields recognized on structured securities purchased at a premium will decrease

97

(relative to the stated rate) when the underlying collateral prepays faster than expected. When interest rates decline, the proceeds from prepayments may be reinvested at lower rates than we were earning on the prepaid securities. When interest rates increase, prepayments may decrease below expected levels. When this occurs, the average maturity and duration of structured securities increases, decreasing the yield on structured securities purchased at discounts and increasing the yield on those purchased at a premium because of a decrease in the annual amortization of premium.

For structured securities included in fixed maturities, available for sale, that were purchased at a discount or premium, we recognize investment income using an effective yield based on anticipated future prepayments and the estimated final maturity of the securities. Actual prepayment experience is periodically reviewed and effective yields are recalculated when differences arise between the prepayments originally anticipated and the actual prepayments received and currently anticipated. For credit sensitive mortgage-backed and asset-backed securities, and for securities that can be prepaid or settled in a way that we would not recover substantially all of our investment, the effective yield is recalculated on a prospective basis. Under this method, the amortized cost basis in the security is not immediately adjusted and a new yield is applied prospectively. For all other structured and asset-backed securities, the effective yield is recalculated when changes in assumptions are made, and reflected in our income on a retrospective basis. Under this method, the amortized cost basis of the investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments were not significant in 2017.

The following table sets forth the par value, amortized cost and estimated fair value of structured securities, summarized by interest rates on the underlying collateral, at December 31, 2017 (dollars in millions):

	Par value		Amortized cost		Estimated fair value
Below 4 percent	$	2,101.7	$	1,944.8	$	2,014.9
4 percent – 5 percent	1,656.3		1,516.0		1,596.5
5 percent – 6 percent	1,407.1		1,271.8		1,362.6
6 percent – 7 percent	286.6		260.6		276.8
7 percent – 8 percent	83.0		83.7		92.5
8 percent and above	291.3		291.1		292.1
Total structured securities	$	5,826.0	$	5,368.0	$	5,635.4

98

The amortized cost and estimated fair value of structured securities at December 31, 2017, summarized by type of security, were as follows (dollars in millions):

			Estimated fair value
Type	Amortized cost		Amount		Percent of fixed maturities
Pass-throughs, sequential and equivalent securities	$	557.7	$	617.2	2.7	%
Planned amortization classes, target amortization classes and accretion-directed bonds	95.3		108.5		.5
Commercial mortgage-backed securities	1,354.0		1,377.5		6.0
Asset-backed securities	3,085.9		3,254.4		14.2
Collateralized debt obligations	257.1		259.4		1.1
Other	18.0		18.4		.1
Total structured securities	$	5,368.0	$	5,635.4	24.6	%

Pass-throughs, sequentials and equivalent securities have unique prepayment variability characteristics.  Pass-through securities typically return principal to the holders based on cash payments from the underlying mortgage obligations. Sequential securities return principal to tranche holders in a detailed hierarchy.  Planned amortization classes, targeted amortization classes and accretion-directed bonds adhere to fixed schedules of principal payments as long as the underlying mortgage loans experience prepayments within certain estimated ranges.  In most circumstances, changes in prepayment rates are first absorbed by support or companion classes insulating the timing of receipt of cash flows from the consequences of both faster prepayments (average life shortening) and slower prepayments (average life extension).

Commercial mortgage-backed securities are secured by commercial real estate mortgages, generally income producing properties that are managed for profit.  Property types include multi-family dwellings including apartments, retail centers, hotels, restaurants, hospitals, nursing homes, warehouses, and office buildings.  While most commercial mortgage-backed securities have call protection features whereby underlying borrowers may not prepay their mortgages for stated periods of time without incurring prepayment penalties, recoveries on defaulted collateral may result in involuntary prepayments.

During 2017, we sold $427.6 million of fixed maturity investments which resulted in gross investment losses (before income taxes) of $24.2 million. Securities are generally sold at a loss following unforeseen issue-specific events or conditions or shifts in perceived relative values.  These reasons include but are not limited to:  (i) changes in the investment environment; (ii) expectation that the market value could deteriorate; (iii) our desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; or (v) changes in expected portfolio cash flows.

Other Investments

At December 31, 2017, we held commercial mortgage loan investments with a carrying value of $1,613.5 million (or 5.8 percent of total invested assets) and a fair value of $1,640.0 million. We had one mortgage loans that was in the process of foreclosure at December 31, 2017. During 2017, 2016 and 2015, we recognized $5.2 million, nil and nil, respectively, of impairments on commercial mortgage loans. Our commercial mortgage loan portfolio is comprised of large commercial mortgage loans. Our loans have risk characteristics that are individually unique. Accordingly, we measure potential losses on a loan-by-loan basis rather than establishing an allowance for losses on mortgage loans. Approximately 14 percent, 12 percent, 8 percent, 6 percent and 5 percent of the mortgage loan balance were on properties located in California, Texas, Maryland, Florida and Illinois, respectively. No other state comprised greater than five percent of the mortgage loan balance. At December 31, 2017, we held residential mortgage loan investments with a carrying value of $37.1 million and a fair value of $37.3 million.

99

The following table shows the distribution of our commercial mortgage loan portfolio by property type as of December 31, 2017 (dollars in millions):

	Number of loans	Carrying value
Retail	98	$	376.6
Multi-family	34	483.9
Industrial	33	278.6
Office building	29	290.5
Other	21	183.9
Total commercial mortgage loans	215	$	1,613.5

The following table shows our commercial mortgage loan portfolio by loan size as of December 31, 2017 (dollars in millions):

	Number of loans	Carrying value
Under $5 million	92	$	158.2
$5 million but less than $10 million	62	434.3
$10 million but less than $20 million	42	574.3
Over $20 million	19	446.7
Total commercial mortgage loans	215	$	1,613.5

The following table summarizes the distribution of maturities of our commercial mortgage loans as of December 31, 2017 (dollars in millions):

	Number of loans	Carrying value
2018	21	$	96.5
2019	19	32.6
2020	8	30.7
2021	10	59.5
2022	15	105.4
after 2022	142	1,288.8
Total commercial mortgage loans	215	$	1,613.5

The following table provides the carrying value and estimated fair value of our outstanding commercial mortgage loans and the underlying collateral as of December 31, 2017 (dollars in millions):

			Estimated fair value
Loan-to-value ratio (a)	Carrying value		Mortgage loans		Collateral
Less than 60%	$	944.7	$	960.8	$	2,330.6
60% to 70%	439.5		440.2		671.3
Greater than 70% to 80%	138.4		145.9		188.4
Greater than 80% to 90%	52.3		52.9		60.1
Greater than 90%	38.6		40.2		41.7
Total	$	1,613.5	$	1,640.0	$	3,292.1

________________

(a) Loan-to-value ratios are calculated as the ratio of:  (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.

100

At December 31, 2017, we held $284.6 million of trading securities. We carry trading securities at estimated fair value; changes in fair value are reflected in the statement of operations. Our trading securities include: (i) investments purchased with the intent of selling in the near term to generate income; (ii) investments supporting certain insurance liabilities (including investments backing the market strategies of our multibucket annuity products) and certain reinsurance agreements; and (iii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. Investment income from trading securities backing certain insurance liabilities and certain reinsurance agreements is substantially offset by the change in insurance policy benefits related to certain products and agreements.

Other invested assets also include options backing our fixed index products, COLI and certain nontraditional investments, including investments in limited partnerships, promissory notes and real estate investments held for sale.

At December 31, 2017, we held investments with an amortized cost of $1,524.9 million and an estimated fair value of $1,526.9 million related to VIEs that we are required to consolidate. The investment portfolio held by the VIEs is primarily comprised of commercial bank loans, the borrowers for which are almost entirely rated below-investment grade. Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information on these investments.

101

CONSOLIDATED FINANCIAL CONDITION

Changes in the Consolidated Balance Sheet

Changes in our consolidated balance sheet between December 31, 2017 and December 31, 2016, primarily reflect: (i) our net income for 2017; (ii) changes in the fair value of our fixed maturity securities, available for sale; and (iii) payments to repurchase common stock of $167.1 million.

In accordance with GAAP, we record our fixed maturity securities, available for sale, equity securities and certain other invested assets at estimated fair value with any unrealized gain or loss (excluding impairment losses, which are recognized through earnings), net of tax and related adjustments, recorded as a component of shareholders' equity. At December 31, 2017, the net unrealized gains on such investments were $2.2 billion.

Our capital structure as of December 31, 2017 and December 31, 2016 was as follows (dollars in millions):

	December 31, 2017		December 31, 2016
Total capital:
Corporate notes payable	$	914.6	$	912.9
Shareholders’ equity:
Common stock	1.7		1.7
Additional paid-in capital	3,073.3		3,212.1
Accumulated other comprehensive income	1,212.1		622.4
Retained earnings	560.4		650.7
Total shareholders’ equity	4,847.5		4,486.9
Total capital	$	5,762.1	$	5,399.8

The following table summarizes certain financial ratios as of and for the years ended December 31, 2017 and December 31, 2016:

	December 31, 2017			December 31, 2016
Book value per common share	$	29.05		$	25.82
Book value per common share, excluding accumulated other comprehensive income (a)	21.79			22.24
Ratio of earnings to fixed charges	2.94X			2.43X
Debt to total capital ratios:
Corporate debt to total capital	15.9		%	16.9		%
Corporate debt to total capital, excluding accumulated other comprehensive income (a)	20.1		%	19.1		%

_____________________

(a) This non-GAAP measure differs from the corresponding GAAP measure presented immediately above, because accumulated other comprehensive income has been excluded from the value of capital used to determine this measure.  Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income.  Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management.  However, this measure does not replace the corresponding GAAP measure.

Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off

In December 2013, two of our insurance subsidiaries with long-term care business (Washington National and BCLIC) entered into 100% coinsurance agreements ceding $495 million of long-term care reserves to BRe. BRe was a reinsurer that was not licensed or accredited by the states of domicile (Indiana and New York, respectively) of the insurance subsidiaries ceding the long-term care business and BRe was not rated by A.M. Best. As a result of its non-accredited status, BRe was

102

required to provide collateral which met the regulatory requirements of the states of domicile in order for our insurance subsidiaries to obtain full credit in their statutory financial statements for the reinsurance receivables due from BRe. Such collateral was required to be held in market value trusts subject to 7% over collateralization, investment guidelines and periodic true-up provisions. In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business.

Prior to the recapture, certain irregularities had come to our attention regarding BRe (including its relationship with Platinum Partners, LP ("Platinum") and the valuation and appropriateness of the collateral deposited in trusts by BRe for Washington National and BCLIC). As a result, CNO commenced an independent third-party audit by a forensic accounting firm in late June 2016 of certain investments deposited in the trusts by BRe. Such investments included assets valued at that time using unobservable inputs that contained assumptions determined by BRe. The initial scope of CNO’s audit was a subset of investments which had an estimated fair value of approximately $62 million as of September 30, 2016. In September 2016, Washington National and BCLIC expanded the scope of the independent audit to include additional investments for which we estimated the fair value to be approximately $63 million as of September 30, 2016.

The aforementioned independent audit of these investments was completed in the fourth quarter of 2016. The audit confirmed that the assets in the initial scope of the audit bore some connection to Platinum or to parties that have had past or present associations with Platinum. Based on information obtained through the audit, the investments included in the additional scope of the audit did not appear to have clear connections to Platinum or to parties that have had past or present associations with Platinum. However, CNO and the auditor retained by CNO also concluded that many of the values that had been assigned to these investments by BRe, and summarized in reports prepared by its valuation firm, were inaccurate due to the use of flawed methodologies.

In addition to the investments subject to the independent audits, Washington National and BCLIC received approximately $380 million in other investments and cash balances in the recapture. A substantial portion of these investments have been sold or redeemed since the recapture. The activity since the date of the recapture with respect to the assets received in the recapture is summarized below (dollars in millions):

							Investments not included in scope of audit
	Investments included in initial scope of audit			Investments included in additional scope of audit			Cash, fixed maturities and other invested assets			Total investments
September 30, 2016 values	$	62.2		$	62.6		$	379.8		$	504.6
Net cash flows (1)	(13.5		)	(11.6		)	(359.5		)	(384.6		)
Realized gains (losses) and impairments (2)	.4			(1.7		)	(4.0		)	(5.3		)
Other activity (7)	3.9			1.9			.6			6.4
December 31, 2016 values	53.0			51.2			16.9			121.1
Net cash flows (1)	(16.7		)	(5.5		)	(8.7		)	(30.9		)
Realized gains (losses) and impairments (3)	3.2			(4.5		)	1.0			(.3		)
Other activity (7)	(1.8		)	1.3			(1.4		)	(1.9		)
March 31, 2017 values	37.7			42.5			7.8			88.0
Net cash flows (1)	.5			(14.4		)	—			(13.9		)
Realized gains (losses) and impairments (4)	(3.1		)	4.5			—			1.4
Other activity (7)	(.6		)	(.4		)	.3			(.7		)
June 30, 2017 values	34.5			32.2			8.1			74.8
Net cash flows (1)	(33.5		)	(9.1		)	(1.3		)	(43.9		)
Realized gains (losses) and impairments (5)	7.0			(.6		)	.3			6.7
Other activity (7)	(.9		)	(.3		)	(3.0		)	(4.2		)
September 30, 2017 values	7.1			22.2			4.1			33.4
Net cash flows (1)	—			(8.4		)	(3.6		)	(12.0		)
Realized gains (losses) and impairments (6)	(1.0		)	(1.5		)	.1			(2.4		)
Other activity (7)	1.4			—			(.3		)	1.1
December 31, 2017 values	$	7.5		$	12.3		$	.3		$	20.1

103

A summary of the values for the remaining investments that were included in the aforementioned independent audits as of December 31, 2017, is summarized below (dollars in millions):

	Investments included in initial scope of audit		Investments included in additional scope of audit		Total investments included in the scope of audit
Lease related investments	$	—	$	1.7	$	1.7
Mortgage loans secured by real estate	—		10.6		10.6
Senior secured loans to companies in the energy sector (8)	2.4		—		2.4
Secured term loan issued by Platinum Partners Credit Opportunity Master Fund L.P.	5.1		—		5.1
Total investments	$	7.5	$	12.3	$	19.8

________________

(1) Net cash inflows from sales and redemptions of investments during the period.

(2) Includes $4.6 million of impairment charges and $.7 million of net realized losses recognized on the sale of transferred investments.

(3) Includes $8.4 million of impairment charges and $8.1 million of net realized gains recognized on the sale of transferred investments.

(4) Includes $3.7 million of impairment charges and $5.1 million of net realized gains recognized on the sale of transferred investments.

(5) Includes $4.7 million of impairment charges and $11.4 million of net realized gains recognized on the sale of transferred investments.

(6) Includes $1.5 million of impairment charges and $.9 million of net realized losses recognized on the sale of transferred investments.

(7) Includes amortization of discount and premium and changes in estimated fair values of investment during the period.

(8) Represents $2.4 million of loans issued by Golden Gate Oil, LLC with a par value of $11.7 million. The issuer of this debt has been referred to in articles regarding Platinum.

We recognized a pre-tax loss of $75.4 million in the third quarter of 2016 related to the termination of the reinsurance agreements and the recapture of the long-term care business as summarized below (dollars in millions):

Market value of investments	$	504.7
Insurance liabilities	(552.2		)
Write-off of reinsurance receivables	(17.9		)
Estimated transaction expenses	(10.0		)
Pre-tax loss	$	(75.4	)

As a result of the recapture, related charge and additional capital required to support the assets and liabilities of this business, CNO contributed $200 million to its insurance subsidiaries on September 30, 2016.

The impact of the recapture on our statutory earnings and surplus at September 30, 2016 is summarized below (dollars in millions):

Impact on surplus:
Market value of investments	$	504.7
Write-off of estimated receivable due from BRe	(17.9		)
Insurance liabilities	(587.2		)
Expenses incurred	(10.0		)
Statutory earnings impact	(110.4		)
Impact on admitted investments	(11.0		)
Impact on admitted deferred tax assets	(14.5		)
Statutory surplus impact	$	(135.9	)

104

Contractual Obligations

The Company's significant contractual obligations as of December 31, 2017, were as follows (dollars in millions):

			Payment due in
	Total		2018		2019-2020		2021-2022		Thereafter
Insurance liabilities (a)	$	59,106.0	$	3,619.7	$	7,517.6	$	7,156.9	$	40,811.8
Notes payable (b)	1,165.6		44.5		502.8		52.6		565.7
Investment borrowings (c)	1,799.1		41.6		789.7		926.8		41.0
Borrowings related to variable interest entities (d)	1,983.3		50.5		100.6		95.8		1,736.4
Postretirement plans (e)	267.6		7.4		15.5		16.3		228.4
Operating leases and certain other contractual commitments (f)	263.4		121.9		109.1		26.0		6.4
Total	$	64,585.0	$	3,885.6	$	9,035.3	$	8,274.4	$	43,389.7

________________

(a) These cash flows represent our estimates of the payments we expect to make to our policyholders, without consideration of future premiums or reinsurance recoveries. These estimates are based on numerous assumptions (depending on the product type) related to mortality, morbidity, lapses, withdrawals, future premiums, future deposits, interest rates on investments, credited rates, expenses and other factors which affect our future payments. The cash flows presented are undiscounted for interest. As a result, total outflows for all years exceed the corresponding liabilities of $23.5 billion included in our consolidated balance sheet as of December 31, 2017. As such payments are based on numerous assumptions, the actual payments may vary significantly from the amounts shown.

In estimating the payments we expect to make to our policyholders, we considered the following:

• For products such as immediate annuities and structured settlement annuities without life contingencies, the payment obligation is fixed and determinable based on the terms of the policy.

• For products such as universal life, ordinary life, long-term care, supplemental health and fixed rate annuities, the future payments are not due until the occurrence of an insurable event (such as death or disability) or a triggering event (such as a surrender or partial withdrawal). We estimated these payments using actuarial models based on historical experience and our expectation of the future payment patterns.

• For short-term insurance products such as Medicare supplement insurance, the future payments relate only to amounts necessary to settle all outstanding claims, including those that have been incurred but not reported as of the balance sheet date. We estimated these payments based on our historical experience and our expectation of future payment patterns.

• The average interest rate we assumed would be credited to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or fixed index products) over the term of the contracts was 4.6 percent.

(b) Includes projected interest payments based on interest rates, as applicable, as of December 31, 2017. Refer to the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for additional information on notes payable.

(c) These borrowings primarily represent collateralized borrowings from the FHLB.

(d) These borrowings represent the securities issued by VIEs and include projected interest payments based on interest rates, as applicable, as of December 31, 2017.

(e) Includes benefits expected to be paid pursuant to our deferred compensation plan and postretirement plans based on numerous actuarial assumptions and interest credited at 3.75 percent.

105

(f) Includes amounts related to noncancellable operating leases, sponsorship agreements and commitments to purchase investments. Also included are obligations with third parties for information technology services, software maintenance and license agreements and consulting services.

It is possible that the ultimate outcomes of various uncertainties could affect our liquidity in future periods. For example, the following events could have a material adverse effect on our cash flows:

• An adverse decision in pending or future litigation.

• An inability to obtain rate increases on certain of our insurance products.

• Worse than anticipated claims experience.

• Lower than expected dividends and/or surplus debenture interest payments from our insurance subsidiaries (resulting from inadequate earnings or capital or regulatory requirements).

• An inability to meet and/or maintain the covenants in our Revolving Credit Agreement.

• A significant increase in policy surrender levels.

• A significant increase in investment defaults.

• An inability of our reinsurers to meet their financial obligations.

• The amount we may need to pay to a reinsurer in connection with a long-term care reinsurance transaction.

While we actively manage the relationship between the duration and cash flows of our invested assets and the estimated duration and cash flows of benefit payments arising from contract liabilities, there could be significant variations in the timing of such cash flows. Although we believe our current estimates properly project future claim experience, if these estimates prove to be wrong, and our experience worsens (as it did in some prior periods), our future liquidity could be adversely affected.

Liquidity for Insurance Operations

Our insurance companies generally receive adequate cash flows from premium collections and investment income to meet their obligations.  Life insurance, long-term care insurance and annuity liabilities are generally long-term in nature.  Life and annuity policyholders may, however, withdraw funds or surrender their policies, subject to any applicable penalty provisions; there are generally no withdrawal or surrender benefits for long-term care insurance.  We actively manage the relationship between the duration of our invested assets and the estimated duration of benefit payments arising from contract liabilities.

Three of the Company's insurance subsidiaries (Washington National, Bankers Life and Colonial Penn) are members of the FHLB.  As members of the FHLB, our insurance subsidiaries have the ability to borrow on a collateralized basis from the FHLB.  We are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings.  At December 31, 2017, the carrying value of the FHLB common stock was $71.2 million.  As of December 31, 2017, collateralized borrowings from the FHLB totaled $1.6 billion and the proceeds were used to purchase fixed maturity securities.  The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.  The borrowings are collateralized by investments with an estimated fair value of $1.9 billion at December 31, 2017, which are maintained in custodial accounts for the benefit of the FHLB.  

106

The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions):

Amount		Maturity	Interest rate at
borrowed		date	December 31, 2017
$	50.0	January 2019	Variable rate – 1.779%
50.0		February 2019	Variable rate – 1.509%
100.0		March 2019	Variable rate – 1.971%
21.8		July 2019	Variable rate – 2.001%
15.0		October 2019	Variable rate – 1.887%
50.0		May 2020	Variable rate – 1.997%
21.8		June 2020	Fixed rate – 1.960%
25.0		September 2020	Variable rate – 2.300%
100.0		September 2020	Variable rate – 2.212%
50.0		September 2020	Variable rate – 2.224%
75.0		September 2020	Variable rate – 1.813%
100.0		October 2020	Variable rate – 1.453%
50.0		December 2020	Variable rate – 2.072%
100.0		July 2021	Variable rate – 1.909%
100.0		July 2021	Variable rate – 1.879%
57.7		August 2021	Variable rate – 1.921%
28.2		August 2021	Fixed rate – 2.550%
125.0		August 2021	Variable rate – 2.032%
50.0		September 2021	Variable rate – 2.002%
22.0		May 2022	Variable rate – 1.829%
100.0		May 2022	Variable rate – 1.780%
10.0		June 2022	Variable rate – 2.150%
50.0		July 2022	Variable rate – 1.726%
50.0		July 2022	Variable rate – 1.745%
50.0		July 2022	Variable rate – 1.758%
50.0		August 2022	Variable rate – 1.782%
50.0		December 2022	Variable rate – 1.795%
50.0		December 2022	Variable rate – 1.795%
24.7		March 2023	Fixed rate – 2.160%
20.5		June 2025	Fixed rate – 2.940%
$	1,646.7

State laws generally give state insurance regulatory agencies broad authority to protect policyholders in their jurisdictions. Regulators have used this authority in the past to restrict the ability of our insurance subsidiaries to pay any dividends or other amounts without prior approval. We cannot be assured that the regulators will not seek to assert greater supervision and control over our insurance subsidiaries' businesses and financial affairs.

Our estimated consolidated statutory RBC ratio of 446 percent at December 31, 2017, reflects: (i) estimated consolidated statutory operating earnings of $362 million; (ii) a $46 million reduction of statutory admitted deferred tax assets due to the Tax Reform Act; and (iii) dividends to the holding company of $357.7 million during 2017. Certain formulas used to calculate risk-based capital have embedded tax rate assumptions that will not change to be consistent with the Tax Reform Act until actions are taken by the NAIC. Although no action was taken by the NAIC for the 2017 calculation of the RBC ratio, it is possible that changes will be made for future periods. We estimate that the full impact of changing the embedded tax rate

107

assumptions to be consistent with the Tax Reform Act is an increase to required capital of approximately $80 million (equivalent to a 65 percentage point decrease to the RBC ratio).

During 2017, the financial statements of three of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities reflected asset adequacy or premium deficiency reserves. Total asset adequacy and premium deficiency reserves for Washington National, BCLIC and Bankers Life were $115.0 million, $34.5 million and $246.6 million, respectively, at December 31, 2017. Due to differences between statutory and GAAP insurance liabilities, we were not required to recognize a similar asset adequacy or premium deficiency reserve in our consolidated financial statements prepared in accordance with GAAP. The determination of the need for and amount of asset adequacy or premium deficiency reserves is subject to numerous actuarial assumptions, including the Company's ability to change NGEs related to certain products consistent with contract provisions.

Our insurance subsidiaries transfer exposure to certain risk to others through reinsurance arrangements. When we obtain reinsurance, we are still liable for those transferred risks in the event the reinsurer defaults on its obligations. The failure, insolvency, inability or unwillingness of one or more of the Company's reinsurers to perform in accordance with the terms of its reinsurance agreement could negatively impact our earnings or financial position and our consolidated statutory RBC ratio.

Financial Strength Ratings of our Insurance Subsidiaries

Financial strength ratings provided by A.M. Best, Fitch, S&P and Moody's are the rating agency's opinions of the ability of our insurance subsidiaries to pay policyholder claims and obligations when due.

On August 15, 2017, Fitch affirmed its "BBB+" financial strength ratings of our primary insurance subsidiaries. The outlook for these ratings is stable. A "BBB" rating, in Fitch's opinion, indicates that there is currently a low expectation of ceased or interrupted payments. The capacity to meet policyholder and contract obligations on a timely basis is considered adequate, but adverse changes in circumstances and economic conditions are more likely to impact this capacity. Fitch ratings for the industry range from "AAA Exceptionally Strong" to "C Distressed" and some companies are not rated. Pluses and minuses show the relative standing within a category. Fitch has nineteen possible ratings. There are seven ratings above the "BBB+" rating of our primary insurance subsidiaries and eleven ratings that are below that rating.

On June 23, 2017, S&P affirmed the financial strength ratings of "BBB+" of our primary insurance subsidiaries and revised the outlook for these ratings to stable from negative. S&P financial strength ratings range from "AAA" to "R" and some companies are not rated.  An insurer rated "BBB" or higher is regarded as having financial security characteristics that outweigh any vulnerabilities, and is highly likely to have the ability to meet financial commitments. An insurer rated "BBB", in S&P's opinion, has good financial security characteristics, but is more likely to be affected by adverse business conditions than are higher-rated insurers.  Pluses and minuses show the relative standing within a category.  S&P has twenty-one possible ratings.  There are seven ratings above the "BBB+" rating of our primary insurance subsidiaries and thirteen ratings that are below that rating.

On February 8, 2017, A.M. Best affirmed the financial strength ratings of "A-" of our primary insurance subsidiaries and the outlook for these ratings is stable. The "A-" rating is assigned to companies that have an excellent ability, in A.M. Best's opinion, to meet their ongoing obligations to policyholders.  A.M. Best ratings for the industry currently range from "A++ (Superior)" to "F (In Liquidation)" and some companies are not rated.  An "A++" rating indicates a superior ability to meet ongoing obligations to policyholders.  A.M. Best has sixteen possible ratings.  There are three ratings above the "A-" rating of our primary insurance subsidiaries and twelve ratings that are below that rating.

On May 9, 2016, Moody's affirmed the financial strength ratings of "Baa1" of our primary insurance subsidiaries and the outlook for these ratings is stable. Moody’s financial strength ratings range from "Aaa" to "C".  These ratings may be supplemented with numbers "1", "2", or "3" to show relative standing within a category.  In Moody's view, an insurer rated "Baa" offers adequate financial security, however, certain protective elements may be lacking or may be characteristically unreliable over any great length of time. Moody's has twenty-one possible ratings.  There are seven ratings above the "Baa1" rating of our primary insurance subsidiaries and thirteen ratings that are below that rating.

Rating agencies have increased the frequency and scope of their credit reviews and requested additional information from the companies that they rate, including us.  They may also adjust upward the capital and other requirements employed in the rating agency models for maintenance of certain ratings levels.  We cannot predict what actions rating agencies may take, or what actions we may take in response.  Accordingly, downgrades and outlook revisions related to us or the life insurance industry may occur in the future at any time and without notice by any rating agency.  These could increase policy surrenders

108

and withdrawals, adversely affect relationships with our distribution channels, reduce new sales, reduce our ability to borrow and increase our future borrowing costs.

Liquidity of the Holding Companies

Availability and Sources and Uses of Holding Company Liquidity; Limitations on Ability of Insurance Subsidiaries to Make Dividend and Surplus Debenture Interest Payments to the Holding Companies; Limitations on Holding Company Activities

At December 31, 2017, CNO, CDOC and our other non-insurance subsidiaries held: (i) unrestricted cash and cash equivalents of $153.0 million; (ii) fixed income investments of $116.8 million; and (iii) equity securities of $126.8 million.  CNO and CDOC are holding companies with no business operations of their own; they depend on their operating subsidiaries for cash to make principal and interest payments on debt, and to pay administrative expenses and income taxes.  CNO and CDOC receive cash from insurance subsidiaries, consisting of dividends and distributions, interest payments on surplus debentures and tax-sharing payments, as well as cash from non-insurance subsidiaries consisting of dividends, distributions, loans and advances.  The principal non-insurance subsidiaries that provide cash to CNO and CDOC are 40|86 Advisors, which receives fees from the insurance subsidiaries for investment services, and CNO Services which receives fees from the insurance subsidiaries for providing administrative services.  The agreements between our insurance subsidiaries and CNO Services and 40|86 Advisors, respectively, were previously approved by the domestic insurance regulator for each insurance company, and any payments thereunder do not require further regulatory approval.

The following table sets forth the aggregate amount of dividends (net of capital contributions) and other distributions that our insurance subsidiaries paid to our non-insurance subsidiaries in each of the last three fiscal years (dollars in millions):

	Years ended December 31,
	2017		2016		2015
Dividends from insurance subsidiaries, net of contributions	$	357.7	$	74.3	$	265.7
Surplus debenture interest	56.8		56.0		60.6
Fees for services provided pursuant to service agreements	108.1		78.6		70.1
Total dividends and other distributions paid by insurance subsidiaries	$	522.6	$	208.9	$	396.4

The following summarizes the current ownership structure of CNO’s primary subsidiaries:

The ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from GAAP.  These regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in some states, the lesser of):  (i) statutory net gain from operations or net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year.  However, as each of the immediate insurance subsidiaries of CDOC has significant negative earned surplus, any dividend payments from the insurance subsidiaries require the prior approval of the director or commissioner of the applicable state insurance department.  In 2017, our insurance

109

subsidiaries paid dividends to CDOC totaling $357.7 million.  We expect to receive regulatory approval for future dividends from our subsidiaries, but there can be no assurance that such payments will be approved or that the financial condition of our insurance subsidiaries will not change, making future approvals less likely. 

CDOC holds surplus debentures from CLTX with an aggregate principal amount of $749.6 million.  Interest payments on those surplus debentures do not require additional approval provided the RBC ratio of CLTX exceeds 100 percent (but do require prior written notice to the Texas state insurance department).  The estimated RBC ratio of CLTX was 383 percent at December 31, 2017.  CDOC also holds a surplus debenture from Colonial Penn with a principal balance of $160.0 million. Interest payments on that surplus debenture require prior approval by the Pennsylvania state insurance department. Dividends and other payments from our non-insurance subsidiaries, including 40|86 Advisors and CNO Services, to CNO or CDOC do not require approval by any regulatory authority or other third party.  However, insurance regulators may prohibit payments by our insurance subsidiaries to parent companies if they determine that such payments could be adverse to our policyholders or contractholders.

The insurance subsidiaries of CDOC receive funds to pay dividends primarily from:  (i) the earnings of their direct businesses; (ii) tax sharing payments received from subsidiaries (if applicable); and (iii) with respect to CLTX, dividends received from subsidiaries.  At December 31, 2017, the subsidiaries of CLTX had earned surplus (deficit) as summarized below (dollars in millions):

Subsidiary of CLTX	Earned surplus (deficit)			Additional information
Bankers Life	$	578.2		(a)
Colonial Penn	(304.5		)	(b)

____________________

(a) Bankers Life paid dividends of $159.0 million to CLTX in 2017.

(b) The deficit is primarily due to transactions which occurred several years ago, including a tax planning transaction and the fee paid to recapture a block of business previously ceded to an unaffiliated insurer.

A significant deterioration in the financial condition, earnings or cash flow of the material subsidiaries of CNO or CDOC for any reason could hinder such subsidiaries' ability to pay cash dividends or other disbursements to CNO and/or CDOC, which, in turn, could limit CNO's ability to meet debt service requirements and satisfy other financial obligations.  In addition, we may choose to retain capital in our insurance subsidiaries or to contribute additional capital to our insurance subsidiaries to maintain or strengthen their surplus or fund a long-term care reinsurance transaction, and these decisions could limit the amount available at our top tier insurance subsidiaries to pay dividends to the holding companies. As further described above under the caption "Termination of Long-Term Care Reinsurance Agreements and Recapture of Related Long-Term Care Business in Run-off", CNO made $200.0 million of capital contributions to its insurance subsidiaries on September 30, 2016.

The scheduled principal and interest payments on our direct corporate obligations are as follows (dollars in millions):

	Principal			Interest (a)
2018	$	—		$	44.5
2019	100.0		(b)	44.2
2020	325.0			33.6
2021	—			26.3
2022	—			26.3
2023 and thereafter	500.0			65.7
	$	925.0		$	240.6

_________________________

(a) Based on interest rates as of December 31, 2017.

(b) The maturity date of the Revolving Credit Agreement is the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s 4.50% senior notes due 2020, which is November 30, 2019.

110

On October 13, 2017, the Company entered into the Amendment Agreement with respect to its Revolving Credit Agreement. The Amendment Agreement, among other things, increased the total commitments available under the revolving credit facility from $150.0 million to $250.0 million, increased the aggregate amount of additional incremental loans the Company may incur from $50.0 million to $100.0 million and extended the maturity date of the revolving credit facility from May 19, 2019 to the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s 4.50% senior notes due 2020, which is November 30, 2019. The amount drawn under the Revolving Credit Agreement continues to be $100.0 million.

The interest rate applicable to loans under the Revolving Credit Agreement continues to be calculated as the eurodollar rate or the base rate, at the Company’s option, plus a margin based on the Company’s unsecured debt rating. The margins under the Revolving Credit Agreement range from 1.375% to 2.125% (1.75% to 2.25% prior to the Amendment Agreement), in the case of loans at the eurodollar rate, and 0.375% to 1.125% (.75% to 1.25% prior to the Amendment Agreement), in the case of loans at the base rate. The commitment fee under the Revolving Credit Agreement continues to be based on the Company’s unsecured debt rating.

Additionally, the Revolving Credit Agreement revised the debt to total capitalization ratio that the Company is required to maintain from not more than 30.0 percent to not more than 35.0 percent. The Revolving Credit Agreement continues to contain certain other restrictive covenants with which the Company must comply.

The Tax Reform Act makes broad and complex changes to the Code including reducing the federal corporate income tax rate to 21% from 35% effective January 1, 2018. As a result of the reduction in the federal corporate income tax rate, we reduced the value of our net deferred tax assets by $172.5 million which was recorded as additional income tax expense for the year ended December 31, 2017. The Tax Reform Act will be an ongoing benefit with our estimated effective tax rate in the 21 to 23 percent range. We estimate that tax expense recognized in the future will be reduced by approximately $60 million per year. However, we estimate that the amount of cash taxes paid to the IRS will only decrease by approximately $10 million annually due to the acceleration of taxable income as a result of certain provisions in the Tax Reform Act.

In May 2011, the Company adopted a common share repurchase program. In 2017, we repurchased 7.8 million shares of common stock for $167.1 million under our securities repurchase program. The Company had remaining repurchase authority of $385.6 million as of December 31, 2017. CNO continues to expect free cash flow generation of approximately $300 million per year. The Company is committed to deploying 100 percent of its free cash flow into investments to accelerate profitable growth, funding potential long-term care risk reduction transactions, common stock dividends and share repurchases. The amount and timing of the securities repurchases (if any) will be based on business and market conditions and other factors including, but not limited to, the current price of our common stock, opportunities to invest in our business, acquisition transactions or ceding commissions related to reinsurance transactions.

We have previously disclosed that our strategic priorities include a reduction of our relative long-term care exposure. To achieve this goal, it is likely that we will need to transfer the risks of a portion of this business through one or more reinsurance transactions. The comprehensive, nursing home and home health care long-term care business written before 2003 has negative margins. In order to meaningfully reduce the risk associated with our long-term care block, a substantial ceding commission would be paid by the Company to transfer long-term care risk through reinsurance. Such a reduction of our long-term care exposure would result in the recognition of a loss. Due to our current tax position, it is likely that a portion of the tax benefit recognized on the loss would not be realized and we may be required to increase our valuation allowance for deferred tax assets. Although we believe reducing our exposure to the risk of long-term care business would benefit the Company in the long term, such a transaction could initially adversely impact certain aspects of our financial position, results of operations and/or cash flow.

In 2017, 2016 and 2015, dividends declared and paid on common stock totaled $59.6 million ($0.35 per common share), $54.8 million ($0.31 per common share) and $52.0 million ($0.27 per common share), respectively. In May 2017, the Company increased its quarterly common stock dividend to $0.09 per share from $0.08 per share.

On August 15, 2017, Fitch affirmed its “BB+” rating on our issuer credit and senior unsecured debt. The outlook for these ratings is stable. In Fitch's view, an obligation rated "BB" indicates an elevated vulnerability to default risk, particularly in the event of adverse changes in business or economic conditions over time; however, business or financial flexibility exists which supports the servicing of financial commitments. Pluses and minuses show the relative standing within a category. Fitch has a total of 21 possible ratings ranging from "AAA" to "D". There are ten ratings above CNO's "BB+" rating and ten ratings that are below its rating.

111

On June 23, 2017, S&P affirmed our issuer credit and unsecured debt ratings of "BB+" and revised the outlook for these ratings to stable from negative. In S&P's view, an obligation rated "BB" is less vulnerable to nonpayment than other speculative issues; however, it faces major ongoing uncertainties or exposure to adverse business, financial or economic conditions which could lead to the obligor's inadequate capacity to meet its financial commitment on the obligation. Pluses and minuses show the relative standing within a category. S&P has a total of 22 possible ratings ranging from "AAA (Extremely Strong)" to "D (Payment Default)". There are ten ratings above CNO's "BB+" rating and eleven ratings that are below its rating.

On February 8, 2017, A.M. Best affirmed our issuer credit and senior unsecured debt ratings of "bbb-" and the outlook for these ratings is stable. In A.M. Best's view, a company rated "bbb-" has an adequate ability to meet the terms of its obligations; however, the issuer is more susceptible to changes in economic or other conditions. Pluses and minuses show the relative standing within a category. A.M. Best has a total of 22 possible ratings ranging from "aaa (Exceptional)" to "d (In default)". There are nine ratings above CNO's "bbb-" rating and twelve ratings that are below its rating.

On May 9, 2016, Moody's affirmed our issuer credit and senior unsecured debt ratings of "Ba1" and the outlook for these ratings is stable. In Moody's view, obligations rated "Ba" are judged to have speculative elements and are subject to substantial credit risk. A rating is supplemented with numerical modifiers "1", "2" or "3" to show the relative standing within a category. Moody's has a total of 21 possible ratings ranging from "Aaa" to "C". There are ten ratings above CNO's "Ba1" rating and ten ratings that are below its rating.

Outlook

We believe that the existing cash available to the holding company, the cash flows to be generated from operations and other transactions will be sufficient to allow us to meet our debt service obligations, pay corporate expenses and satisfy other financial obligations. However, our cash flow is affected by a variety of factors, many of which are outside of our control, including insurance regulatory issues, competition, financial markets and other general business conditions. We cannot provide assurance that we will possess sufficient income and liquidity to meet all of our debt service requirements and other holding company obligations. For additional discussion regarding the liquidity and other risks that we face, see "Risk Factors".

MARKET-SENSITIVE INSTRUMENTS AND RISK MANAGEMENT

Our spread-based insurance business is subject to several inherent risks arising from movements in interest rates, especially if we fail to anticipate or respond to such movements. First, interest rate changes can cause compression of our net spread between interest earned on investments and interest credited on customer deposits, thereby adversely affecting our results. Second, if interest rate changes produce an unanticipated increase in surrenders of our spread-based products, we may be forced to sell invested assets at a loss in order to fund such surrenders. Many of our products include surrender charges, market interest rate adjustments or other features to encourage persistency; however, at December 31, 2017, approximately 23 percent of our total insurance liabilities, or approximately $5.4 billion, could be surrendered by the policyholder without penalty. Finally, changes in interest rates can have significant effects on our investment portfolio. We use asset/liability strategies that are designed to mitigate the effect of interest rate changes on our profitability. However, there can be no assurance that management will be successful in implementing such strategies and sustaining adequate investment spreads.

We seek to invest our available funds in a manner that will fund future obligations to policyholders, subject to appropriate risk considerations. We seek to meet this objective through investments that: (i) have similar cash flow characteristics with the liabilities they support; (ii) are diversified (including by types of obligors); and (iii) are predominantly investment-grade in quality.

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active strategic asset allocation and investment management. Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities. From time to time, we invest in securities for trading purposes, although such investments are a relatively small portion of our total portfolio.

The profitability of many of our products depends on the spread between the interest earned on investments and the rates credited on our insurance liabilities. In addition, changes in competition and other factors, including the level of surrenders and withdrawals, may limit our ability to adjust or to maintain crediting rates at levels necessary to avoid narrowing of spreads under certain market conditions. As of December 31, 2017, approximately 21 percent of our insurance liabilities had interest

112

rates that may be reset annually; 50 percent had a fixed explicit interest rate for the duration of the contract; 26 percent had credited rates which approximate the income earned by the Company; and the remainder had no explicit interest rates. At December 31, 2017, the average yield, computed on the cost basis of our fixed maturity portfolio, was 5.3 percent, and the average interest rate credited or accruing to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or fixed index products) was 4.6 percent.

We simulate the cash flows expected from our existing insurance business under various interest rate scenarios. These simulations help us to measure the potential gain or loss in fair value of our interest rate-sensitive investments and to manage the relationship between the interest sensitivity of our assets and liabilities. When the estimated durations of assets and liabilities are similar, absent other factors, a change in the value of assets related to changes in interest rates should be largely offset by a change in the value of liabilities. At December 31, 2017, the estimated duration of our fixed income securities (as modified to reflect estimated prepayments and call premiums) and the estimated duration of our insurance liabilities were approximately 8.6 years and 8.4 years, respectively. We estimate that our fixed maturity securities and short-term investments (net of corresponding changes in insurance acquisition costs) would decline in fair value by approximately $445 million if interest rates were to increase by 10 percent from their levels at December 31, 2017. Our simulations incorporate numerous assumptions, require significant estimates and assume an immediate change in interest rates without any management of the investment portfolio in reaction to such change. Consequently, potential changes in value of our financial instruments indicated by the simulations will likely be different from the actual changes experienced under given interest rate scenarios, and the differences may be material. Because we actively manage our investments and liabilities, our net exposure to interest rates can vary over time.

We are subject to the risk that our investments will decline in value. This has occurred in the past and may occur again, particularly if interest rates rise from their current low levels. During 2017, we recognized net realized investment gains of $50.3 million, which were comprised of: (i) $63.1 million of net gains from the sales of investments; (ii) $4.3 million of losses on the dissolution of VIEs; (iii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $11.5 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $2.8 million; and (v) $22.8 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2016, we recognized net realized investment gains of $8.3 million, which were comprised of: (i) $47.5 million of net gains from the sales of investments; (ii) a $7.3 million loss on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $.4 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $.8 million; and (v) $32.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($35.9 million, prior to the $3.6 million of impairment losses recognized through accumulated other comprehensive income). During 2015, we recognized net realized investment losses of $36.6 million, which were comprised of: (i) $8.2 million of net gains from the sales of investments; (ii) an $11.3 million gain on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $9.2 million; (iv) the decrease in fair value of embedded derivatives related to a modified coinsurance agreement of $7.0 million; and (v) $39.9 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($42.9 million, prior to the $3.0 million of impairment losses recognized through accumulated other comprehensive income).

The Company is subject to risk resulting from fluctuations in market prices of our equity securities. In general, these investments have more year-to-year price variability than our fixed maturity investments. However, returns over longer time frames have been consistently higher. We manage this risk by limiting our equity securities to a relatively small portion of our total investments.

Our investment in options backing our equity-linked products is closely matched with our obligation to fixed index annuity holders. Fair value changes associated with that investment are substantially offset by an increase or decrease in the amounts added to policyholder account balances for fixed index products.

Inflation

Inflation rates may impact the financial statements and operating results in several areas. Inflation influences interest rates, which in turn impact the fair value of the investment portfolio and yields on new investments. Inflation also impacts a portion of our insurance policy benefits affected by increased medical coverage costs. Operating expenses, including payrolls, are impacted to a certain degree by the inflation rate.

113

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The information included under the caption "Market-Sensitive Instruments and Risk Management" in Item 7. "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations" is incorporated herein by reference.

ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS.

Index to Consolidated Financial Statements
	Page
Report of Independent Registered Public Accounting Firm	115
Consolidated Balance Sheet at December 31, 2017 and 2016	117
Consolidated Statement of Operations for the years ended December 31, 2017, 2016 and 2015	119
Consolidated Statement of Comprehensive Income for the years ended December 31, 2017, 2016 and 2015	120
Consolidated Statement of Shareholders' Equity for the years ended December 31, 2017, 2016 and 2015	121
Consolidated Statement of Cash Flows for the years ended December 31, 2017, 2016 and 2015	122
Notes to Consolidated Financial Statements	123

114

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

Report of Independent Registered Public Accounting Firm

To theShareholders and Board of Directors of CNO Financial Group, Inc.:

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheet of CNO Financial Group, Inc. and its subsidiaries as of December 31, 2017and 2016,and the related consolidated statements of operations, comprehensive income, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2017, including the related notes and financial statement schedules listed in the index appearing under item 15(a)2. (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2017 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework(2013)issued by the COSO.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, appearing under Item 9A: Management's Report on Internal Control over Financial Reporting. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the

115

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/PricewaterhouseCoopers LLP

Indianapolis, Indiana

February 23, 2018

We have served as the Company’s auditor since 1983.

116

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET

December 31, 2017 and 2016

(Dollars in millions)

ASSETS

	2017		2016
Investments:
Fixed maturities, available for sale, at fair value (amortized cost: 2017 - $20,702.1; 2016 - $19,803.1)	$	22,910.9	$	21,096.2
Equity securities at fair value (cost: 2017 - $491.1; 2016 - $580.7)	511.7		584.2
Mortgage loans	1,650.6		1,768.0
Policy loans	116.0		112.0
Trading securities	284.6		363.4
Investments held by variable interest entities	1,526.9		1,724.3
Other invested assets	853.4		589.5
Total investments	27,854.1		26,237.6
Cash and cash equivalents - unrestricted	578.4		478.9
Cash and cash equivalents held by variable interest entities	178.9		189.3
Accrued investment income	245.9		239.6
Present value of future profits	359.6		401.8
Deferred acquisition costs	1,026.8		1,044.7
Reinsurance receivables	2,175.2		2,260.4
Income tax assets, net	366.9		789.7
Assets held in separate accounts	5.0		4.7
Other assets	319.5		328.5
Total assets	$	33,110.3	$	31,975.2

(continued on next page)

The accompanying notes are an integral part

of the consolidated financial statements.

117

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET, continued

December 31, 2017 and 2016

(Dollars in millions)

LIABILITIES AND SHAREHOLDERS' EQUITY

	2017		2016
Liabilities:
Liabilities for insurance products:
Policyholder account balances	$	11,220.7	$	10,912.7
Future policy benefits	11,521.3		10,953.3
Liability for policy and contract claims	530.3		500.6
Unearned and advanced premiums	261.7		282.5
Liabilities related to separate accounts	5.0		4.7
Other liabilities	751.8		611.4
Investment borrowings	1,646.7		1,647.4
Borrowings related to variable interest entities	1,410.7		1,662.8
Notes payable – direct corporate obligations	914.6		912.9
Total liabilities	28,262.8		27,488.3
Commitments and Contingencies
Shareholders' equity:
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)	1.7		1.7
Additional paid-in capital	3,073.3		3,212.1
Accumulated other comprehensive income	1,212.1		622.4
Retained earnings	560.4		650.7
Total shareholders' equity	4,847.5		4,486.9
Total liabilities and shareholders' equity	$	33,110.3	$	31,975.2

The accompanying notes are an integral part

of the consolidated financial statements.

118

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF OPERATIONS

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions, except per share data)

	2017			2016			2015
Revenues:
Insurance policy income	$	2,647.3		$	2,601.1		$	2,556.0
Net investment income:
General account assets	1,285.4			1,204.1			1,203.6
Policyholder and other special-purpose portfolios	265.9			121.1			30.0
Realized investment gains (losses):
Net realized investment gains (losses), excluding impairment losses	77.4			47.9			(8.0		)
Other-than-temporary impairments:
Total other-than-temporary impairment losses	(21.9		)	(35.9		)	(42.9		)
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income	(.9		)	3.6			3.0
Net impairment losses recognized	(22.8		)	(32.3		)	(39.9		)
Gain (loss) on dissolution of variable interest entities	(4.3		)	(7.3		)	11.3
Total realized gains (losses)	50.3			8.3			(36.6		)
Fee revenue and other income	48.3			50.5			58.9
Total revenues	4,297.2			3,985.1			3,811.9
Benefits and expenses:
Insurance policy benefits	2,602.7			2,390.5			2,308.3
Loss on reinsurance transaction and transition expenses	—			75.4			9.0
Interest expense	123.7			116.4			94.9
Amortization	239.3			253.3			260.0
Loss on extinguishment of debt	—			—			32.8
Loss on extinguishment of borrowings related to variable interest entities	9.5			—			—
Other operating costs and expenses	841.5			796.3			739.2
Total benefits and expenses	3,816.7			3,631.9			3,444.2
Income before income taxes	480.5			353.2			367.7
Income tax expense (benefit):
Tax expense on period income	162.8			127.8			129.5
Valuation allowance for deferred tax assets and other tax items	142.1			(132.8		)	(32.5		)
Net income	$	175.6		$	358.2		$	270.7
Earnings per common share:
Basic:
Weighted average shares outstanding	170,025,000			176,638,000			193,054,000
Net income	$	1.03		$	2.03		$	1.40
Diluted:
Weighted average shares outstanding	172,144,000			178,323,000			195,166,000
Net income	$	1.02		$	2.01		$	1.39

The accompanying notes are an integral part

of the consolidated financial statements.

119

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions)

	2017			2016			2015
Net income	$	175.6		$	358.2		$	270.7
Other comprehensive income, before tax:
Unrealized gains (losses) for the period	959.3			424.4			(1,337.6		)
Amortization of present value of future profits and deferred acquisition costs	(29.7		)	(27.9		)	157.9
Amount related to premium deficiencies assuming the net unrealized gains (losses) had been realized	(310.5		)	(46.9		)	495.3
Reclassification adjustments:
For net realized investment (gains) losses included in net income	(40.2		)	(18.6		)	29.6
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains (losses) included in net income	1.0			.7			(.5		)
Unrealized gains (losses) on investments	579.9			331.7			(655.3		)
Change related to deferred compensation plan	—			8.6			(.1		)
Other comprehensive income (loss) before tax	579.9			340.3			(655.4		)
Income tax (expense) benefit related to items of accumulated other comprehensive income	(195.6		)	(120.7		)	232.9
Other comprehensive income (loss), net of tax	384.3			219.6			(422.5		)
Comprehensive income (loss)	$	559.9		$	577.8		$	(151.8	)

The accompanying notes are an integral part

of the consolidated financial statements.

120

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY

(Dollars in millions)

	Common stock and additional paid-in capital			Accumulated other  comprehensive income			Retained earnings			Total
Balance, December 31, 2014	$	3,734.4		$	825.3		$	128.5		$	4,688.2
Net income	—			—			270.7			270.7
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax benefit of $231.7)	—			(420.4		)	—			(420.4		)
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax benefit of $1.2)	—			(2.1		)	—			(2.1		)
Cost of common stock repurchased	(365.2		)	—			—			(365.2		)
Dividends on common stock	—			—			(52.1		)	(52.1		)
Stock options, restricted stock and performance units	19.4			—			—			19.4
Balance, December 31, 2015	3,388.6			402.8			347.1			4,138.5
Net income	—			—			358.2			358.2
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $121.5)	—			221.1			—			221.1
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax benefit of $.8)	—			(1.5		)	—			(1.5		)
Cost of common stock repurchased	(203.0		)	—			—			(203.0		)
Dividends on common stock	—			—			(54.6		)	(54.6		)
Stock options, restricted stock and performance units	28.2			—			—			28.2
Balance, December 31, 2016	3,213.8			622.4			650.7			4,486.9
Cumulative effect of accounting change	.9			—			(.6		)	.3
Net income	—			—			175.6			175.6
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense of $194.4)	—			382.1			—			382.1
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense of $1.2)	—			2.2			—			2.2
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	—			205.4			(205.4		)	—
Cost of common stock repurchased	(167.1		)	—			—			(167.1		)
Dividends on common stock	—			—			(59.9		)	(59.9		)
Stock options, restricted stock and performance units	27.4			—			—			27.4
Balance, December 31, 2017	$	3,075.0		$	1,212.1		$	560.4		$	4,847.5

The accompanying notes are an integral part

of the consolidated financial statements.

121

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions)

	2017			2016			2015
Cash flows from operating activities:
Insurance policy income	$	2,483.2		$	2,457.0		$	2,423.4
Net investment income	1,229.6			1,201.0			1,205.9
Fee revenue and other income	48.3			50.5			58.9
Cash and cash equivalents received upon recapture of reinsurance	—			73.6			—
Insurance policy benefits	(1,973.1		)	(1,916.0		)	(1,879.4		)
Interest expense	(120.5		)	(106.0		)	(90.0		)
Deferrable policy acquisition costs	(236.1		)	(242.7		)	(246.4		)
Other operating costs	(740.9		)	(747.9		)	(720.5		)
Income taxes	(77.4		)	(6.7		)	(4.1		)
Net cash from operating activities	613.1			762.8			747.8
Cash flows from investing activities:
Sales of investments	2,487.4			2,841.8			2,177.6
Maturities and redemptions of investments	3,324.6			2,507.2			1,853.4
Purchases of investments	(6,141.0		)	(6,159.8		)	(4,767.2		)
Net sales (purchases) of trading securities	108.9			(84.2		)	(12.3		)
Change in cash and cash equivalents held by variable interest entities	10.4			175.1			(296.1		)
Other	(29.9		)	(22.5		)	(25.0		)
Net cash provided (used) by investing activities	(239.6		)	(742.4		)	(1,069.6		)
Cash flows from financing activities:
Issuance of notes payable, net	—			—			910.0
Payments on notes payable	—			—			(797.1		)
Expenses related to extinguishment of debt	—			—			(17.8		)
Issuance of common stock	8.3			8.4			6.3
Payments to repurchase common stock	(168.3		)	(210.0		)	(365.4		)
Common stock dividends paid	(59.6		)	(54.8		)	(52.0		)
Amounts received for deposit products	1,445.9			1,386.7			1,241.9
Withdrawals from deposit products	(1,232.6		)	(1,181.6		)	(1,225.0		)
Issuance of investment borrowings:
Federal Home Loan Bank	432.0			432.7			475.0
Related to variable interest entities	981.6			493.2			544.7
Payments on investment borrowings:
Federal Home Loan Bank	(432.7		)	(333.5		)	(425.7		)
Related to variable interest entities and other	(1,248.6		)	(514.9		)	(132.0		)
Investment borrowings - repurchase agreements, net	—			—			(20.4		)
Net cash provided (used) by financing activities	(274.0		)	26.2			142.5
Net increase (decrease) in cash and cash equivalents	99.5			46.6			(179.3		)
Cash and cash equivalents, beginning of year	478.9			432.3			611.6
Cash and cash equivalents, end of year	$	578.4		$	478.9		$	432.3

The accompanying notes are an integral part

of the consolidated financial statements.

122

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

1. BUSINESS AND BASIS OF PRESENTATION

CNO Financial Group, Inc., a Delaware corporation ("CNO"), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products.  The terms "CNO Financial Group, Inc.", "CNO", the "Company", "we", "us", and "our" as used in these financial statements refer to CNO and its subsidiaries.  Such terms, when used to describe insurance business and products, refer to the insurance business and products of CNO's insurance subsidiaries.

We focus on serving middle-income pre-retiree and retired Americans, which we believe are attractive, underserved, high growth markets.  We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; long-term care in run off; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting as an additional business segment, the long-term care block recaptured from Beechwood Re Ltd. ("BRe"), as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance". The Company’s insurance segments are described below:

• Bankers Life,which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices.  The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life").  Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plan products in exchange for a fee.

• Washington National, which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite.  These products are marketed through Performance Matters Associates, Inc. and through independent marketing organizations and insurance agencies including worksite marketing.  The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.

• Colonial Penn, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing.  The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").

• Long-term care in run-off consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC").

We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"). We have reclassified certain amounts from the prior periods to conform to the 2017 presentation. These reclassifications have no effect on net income or shareholders' equity.

The accompanying financial statements include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude transactions between us and our consolidated affiliates, or among our consolidated affiliates.

When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods.  For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value

123

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

measurements of certain investments (including derivatives), other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals.  If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Investments

Fixed maturity securities include available for sale bonds and redeemable preferred stocks. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders’ equity.

Equity securities include available for sale investments in common stock, exchange-traded funds and non-redeemable preferred stock. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders' equity.

Mortgage loans held in our investment portfolio are carried at amortized unpaid balances, net of provisions for estimated losses. Interest income is accrued on the principal amount of the loan based on the loan's contractual interest rate. Payment terms specified for mortgage loans may include a prepayment penalty for unscheduled payoff of the investment. Prepayment penalties are recognized as investment income when received.

Policy loans are stated at current unpaid principal balances. Policy loans are collateralized by the cash surrender value of the life insurance policy. Interest income is recorded as earned using the contractual interest rate.

Trading securities include: (i) investments purchased with the intent of selling in the near team to generate income; (ii) investments supporting certain insurance liabilities (including investments backing the market strategies of our multibucket annuity products); and (iii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in fair value of the income generating investments and investments supporting insurance liabilities and reinsurance agreements is recognized in income from policyholder and other special-purpose portfolios (a component of net investment income). The change in fair value of securities with embedded derivatives is recognized in realized investment gains (losses). Investment income related to investments supporting certain insurance liabilities is substantially offset by the change in insurance policy benefits related to certain products.

Other invested assets include: (i) call options purchased in an effort to offset or hedge the effects of certain policyholder benefits related to our fixed index annuity and life insurance products; (ii) Company-owned life insurance ("COLI"); and (iii) certain non-traditional investments. We carry the call options at estimated fair value as further described in the section of this note entitled "Accounting for Derivatives". We carry COLI at its cash surrender value which approximates its net realizable value. Non-traditional investments include investments in certain limited partnerships and hedge funds which are accounted for using the equity method; and promissory notes, which are accounted for using the cost method. In accounting for limited partnerships and hedge funds, we consistently use the most recently available financial information provided by the general partner or manager of each of these investments, which is one to three months prior to the end of our reporting period.

Interest income on fixed maturity securities is recognized when earned using a constant effective yield method giving effect to amortization of premiums and accretion of discounts. Prepayment fees are recognized when earned. Dividends on equity securities are recognized when declared.

When we sell a security (other than trading securities), we report the difference between the sale proceeds and amortized cost (determined based on specific identification) as a realized investment gain or loss.

We regularly evaluate our investments for possible impairment as further described in the note to the consolidated financial statements entitled "Investments".

When a security defaults (including mortgage loans) or securities are other-than-temporarily impaired, our policy is to discontinue the accrual of interest and eliminate all previous interest accruals, if we determine that such amounts will not be ultimately realized in full.

124

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Cash and Cash Equivalents

Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value.

Deferred Acquisition Costs

Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For interest-sensitive life or annuity products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate.

When we realize a gain or loss on investments backing our interest-sensitive life or annuity products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust deferred acquisition costs for the change in amortization that would have been recorded if our fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We limit the total adjustment related to the impact of unrealized losses to the total of costs capitalized plus interest related to insurance policies issued in a particular year. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity.

We regularly evaluate the recoverability of the unamortized balance of the deferred acquisition costs. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the deferred acquisition costs may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the deferred acquisition costs over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years.

Present Value of Future Profits

The present value of future profits is the value assigned to the right to receive future cash flows from policyholder insurance contracts existing at September 10, 2003 (the "Effective Date", the effective date of the bankruptcy reorganization of Conseco, Inc., an Indiana corporation (our "Predecessor")). The discount rate we used to determine the present value of future profits was 12 percent. The balance of this account is amortized and evaluated for recovery in the same manner as described above for deferred acquisition costs.  We also adjust the present value of future profits for the change in amortization that would have been recorded if the fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields, similar to the manner described above for deferred acquisition costs.  We limit the total adjustment related to the impact of unrealized losses to the total present value of future profits plus interest.

125

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts

For interest-sensitive life and annuity contracts that do not involve significant mortality or morbidity risk, the amounts collected from policyholders are considered deposits and are not included in revenue. Revenues for these contracts consist of charges for policy administration, cost of insurance charges and surrender charges assessed against policyholders' account balances. Such revenues are recognized when the service or coverage is provided, or when the policy is surrendered.

We establish liabilities for annuity and interest-sensitive life products equal to the accumulated policy account values, which include an accumulation of deposit payments plus credited interest, less withdrawals and the amounts assessed against the policyholder through the end of the period. In addition, policyholder account values for certain interest-sensitive life products are impacted by our assumptions related to changes of certain non-guaranteed elements that we are allowed to make under the terms of the policy, such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. Sales inducements provided to the policyholders of these products are recognized as liabilities over the period that the contract must remain in force to qualify for the inducement. The options attributed to the policyholder related to our fixed index annuity products are accounted for as embedded derivatives as described in the section of this note entitled "Accounting for Derivatives".

Premiums from individual life products (other than interest-sensitive life contracts) and health products are recognized when due. When premiums are due over a significantly shorter period than the period over which benefits are provided, any gross premium in excess of the net premium (i.e., the portion of the gross premium required to provide for all expected future benefits and expenses) is deferred and recognized into revenue in a constant relationship to insurance in force. Benefits are recorded as an expense when they are incurred.

We establish liabilities for traditional life, accident and health insurance, and life contingent payment annuity products using mortality tables in general use in the United States, which are modified to reflect the Company's actual experience when appropriate. We establish liabilities for accident and health insurance products using morbidity tables based on the Company's actual or expected experience. These reserves are computed at amounts that, with additions from estimated future premiums received and with interest on such reserves at estimated future rates, are expected to be sufficient to meet our obligations under the terms of the policy. Liabilities for future policy benefits are computed on a net-level premium method based upon assumptions as to future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses determined when the policies were issued (or with respect to policies inforce at August 31, 2003, the Company's best estimate of such assumptions on the Effective Date). We make an additional provision to allow for potential adverse deviation for some of our assumptions. Once established, assumptions on these products are generally not changed unless a premium deficiency exists. In that case, a premium deficiency reserve is recognized and the future pattern of reserve changes is modified to reflect the relationship of premiums to benefits based on the current best estimate of future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses, determined without an additional provision for potential adverse deviation.

We establish claim reserves based on our estimate of the loss to be incurred on reported claims plus estimates of incurred but unreported claims based on our past experience.

Accounting for Long-term Care Premium Rate Increases

Many of our long-term care policies have been subject to premium rate increases. In some cases, these premium rate increases were materially consistent with the assumptions we used to value the particular block of business at the Effective Date. With respect to certain premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these policyholder options:

• Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.

126

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

• Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.

• Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.

Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit.

Accounting for Certain Marketing Agreements

Bankers Life has entered into various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute prescription drug and Medicare Advantage plans. These agreements allow Bankers Life to offer these products to current and potential future policyholders without investment in management and infrastructure. We receive fee income related to the plans sold through our distribution channels. We account for these distribution agreements as follows:

• We recognize distribution income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract.

• We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract.

Reinsurance

In the normal course of business, we seek to limit our loss exposure on any single insured or to certain groups of policies by ceding reinsurance to other insurance enterprises. We currently retain no more than $.8 million of mortality risk on any one policy. We diversify the risk of reinsurance loss by using a number of reinsurers that have strong claims-paying ratings. In each case, the ceding CNO subsidiary is directly liable for claims reinsured in the event the assuming company is unable to pay.

The cost of reinsurance ceded totaled $105.0 million, $123.9 million and $133.6 million in 2017, 2016 and 2015, respectively.  We deduct this cost from insurance policy income.  Reinsurance recoveries netted against insurance policy benefits totaled $88.6 million, $130.1 million and $167.7 million in 2017, 2016 and 2015, respectively.

From time to time, we assume insurance from other companies.  Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs.  Reinsurance premiums assumed totaled $30.4 million, $34.0 million and $38.5 million in 2017, 2016 and 2015, respectively. Insurance policy benefits related to reinsurance assumed totaled $44.7 million, $47.5 million and $48.0 million in 2017, 2016 and 2015, respectively.

In December 2013, two of our insurance subsidiaries entered into 100% coinsurance agreements ceding $495 million of long-term care reserves to BRe. Pursuant to the agreements, the insurance subsidiaries paid an additional premium of $96.9 million to BRe and an amount equal to the related net liabilities. The insurance subsidiaries' ceded reserve credits were secured by assets in market-value trusts subject to a 7% overcollateralization, investment guidelines and periodic true-up provisions. Future payments into the trusts to maintain collateral requirements were the responsibility of BRe.

127

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business. As a result of the recapture, we were required to value the assets and liabilities as of the date of recapture based on valuation methodologies that are consistent with the methodologies used by CNO to value its other investments and insurance liabilities. Accordingly, we recognized a loss on the recapture of the long-term care business as summarized below (dollars in millions):

Market value of investments	$	504.7
Insurance liabilities	(552.2		)
Write-off of reinsurance receivables	(17.9		)
Estimated transaction expenses	(10.0		)
Pre-tax loss	(75.4		)
Tax benefit	26.4
Increase in valuation allowance for deferred tax assets	(4.1		)
After-tax loss	$	(53.1	)

Income Taxes

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and net operating loss carryforwards ("NOLs"). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire.

At December 31, 2017, our valuation allowance for our net deferred tax assets was $89.1 million, as we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax assets and assessing the effects of limitations and/or interpretations on the value of such component to be fully recognized in the future.

128

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Investments in Variable Interest Entities

We have concluded that we are the primary beneficiary with respect to certain variable interest entities ("VIEs"), which are consolidated in our financial statements. All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments.  The assets held by the trusts are legally isolated and not available to the Company.  The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company.  The Company has no financial obligation to the VIEs beyond its investment in each VIE.

The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade.  Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information about VIEs.

In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager.  These structured securities include asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, residential mortgage-backed securities and collateralized mortgage obligations.  Our maximum exposure to loss on these securities is limited to our cost basis in the investment.  We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses.

At December 31, 2017, we held investments in various limited partnerships, in which we are not the primary beneficiary, totaling $371.1 million (classified as other invested assets).  At December 31, 2017, we had unfunded commitments to these partnerships of $276.5 million.  Our maximum exposure to loss on these investments is limited to the amount of our investment.

Investment borrowings

Three of the Company's insurance subsidiaries (Washington National, Bankers Life and Colonial Penn) are members of the Federal Home Loan Bank ("FHLB").  As members of the FHLB, our insurance subsidiaries have the ability to borrow on a collateralized basis from the FHLB.  We are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings.  At December 31, 2017, the carrying value of the FHLB common stock was $71.2 million.  As of December 31, 2017, collateralized borrowings from the FHLB totaled $1.6 billion and the proceeds were used to purchase fixed maturity securities.  The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.  The borrowings are collateralized by investments with an estimated fair value of $1.9 billion at December 31, 2017, which are maintained in a custodial account for the benefit of the FHLB.  Substantially all of such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet.

129

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions):

Amount		Maturity	Interest rate at
borrowed		date	December 31, 2017
$	50.0	January 2019	Variable rate – 1.779%
50.0		February 2019	Variable rate – 1.509%
100.0		March 2019	Variable rate – 1.971%
21.8		July 2019	Variable rate – 2.001%
15.0		October 2019	Variable rate – 1.887%
50.0		May 2020	Variable rate – 1.997%
21.8		June 2020	Fixed rate – 1.960%
25.0		September 2020	Variable rate – 2.300%
100.0		September 2020	Variable rate – 2.212%
50.0		September 2020	Variable rate – 2.224%
75.0		September 2020	Variable rate – 1.813%
100.0		October 2020	Variable rate – 1.453%
50.0		December 2020	Variable rate – 2.072%
100.0		July 2021	Variable rate – 1.909%
100.0		July 2021	Variable rate – 1.879%
57.7		August 2021	Variable rate – 1.921%
28.2		August 2021	Fixed rate – 2.550%
125.0		August 2021	Variable rate – 2.032%
50.0		September 2021	Variable rate – 2.002%
22.0		May 2022	Variable rate – 1.829%
100.0		May 2022	Variable rate – 1.780%
10.0		June 2022	Variable rate – 2.150%
50.0		July 2022	Variable rate – 1.726%
50.0		July 2022	Variable rate – 1.745%
50.0		July 2022	Variable rate – 1.758%
50.0		August 2022	Variable rate – 1.782%
50.0		December 2022	Variable rate – 1.795%
50.0		December 2022	Variable rate – 1.795%
24.7		March 2023	Fixed rate – 2.160%
20.5		June 2025	Fixed rate – 2.940%
$	1,646.7

The variable rate borrowings are pre-payable on each interest reset date without penalty.  The fixed rate borrowings are pre-payable subject to payment of a yield maintenance fee based on prevailing market interest rates.  At December 31, 2017, the aggregate yield maintenance fee to prepay all fixed rate borrowings was $2.1 million.

Interest expense of $27.0 million, $17.5 million and $10.9 million in 2017, 2016 and 2015, respectively, was recognized related to total borrowings from the FHLB.

130

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Accounting for Derivatives

Our fixed index annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period.  Typically, on each policy anniversary date, a new index period begins.  We are generally able to change the participation rate at the beginning of each index period during a policy year, subject to contractual minimums.  The Company accounts for the options attributed to the policyholder for the estimated life of the contract as embedded derivatives. These accounting requirements often create volatility in the earnings from these products. We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy's return is linked.

From time to time, we utilize United States Treasury interest rate futures primarily to hedge interest rate risk related to anticipated mortgage loan transactions.

We purchase certain fixed maturity securities that contain embedded derivatives that are required to be held at fair value on the consolidated balance sheet. We have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income.

Multibucket Annuity Products

The Company's multibucket annuity is an annuity product that credits interest based on the experience of a particular market strategy. Policyholders allocate their annuity premium payments to several different market strategies based on different asset classes within the Company's investment portfolio. Interest is credited to this product based on the market return of the given strategy, less management fees, and funds may be moved between different strategies. The Company guarantees a minimum return of premium plus approximately 3 percent per annum over the life of the contract. The investments backing the market strategies of these products are designated by the Company as trading securities. The change in the fair value of these securities is recognized as investment income (classified as income from policyholder and other special-purpose portfolios), which is substantially offset by the change in insurance policy benefits for these products. We hold insurance liabilities of $32.3 million and $32.8 million related to multibucket annuity products as of December 31, 2017 and 2016, respectively.

Sales Inducements

Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract.  Certain of our life insurance products offer persistency bonuses credited to the contract holder's balance after the policy has been outstanding for a specified period of time.  These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP.  Such amounts are deferred and amortized in the same manner as deferred acquisition costs.  Sales inducements deferred totaled $2.0 million, $3.4 million and $3.8 million during 2017, 2016 and 2015, respectively.  Amounts amortized totaled $8.9 million, $11.4 million and $13.8 million during 2017, 2016 and 2015, respectively.  The unamortized balance of deferred sales inducements was $42.5 million and $49.4 million at December 31, 2017 and 2016, respectively. The balance of insurance liabilities for persistency bonus benefits was $.3 million and $.5 million at December 31, 2017 and 2016, respectively.

131

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Out-of-Period Adjustments

In 2017, we recorded the net effect of out-of-period adjustments which decreased insurance policy benefits by $4.2 million, increased other operating costs and expenses by $2.0 million, increased tax expense by $.8 million and increased our net income by $1.4 million (or 1 cent per diluted share). We evaluated these adjustments taking into account both qualitative and quantitative factors and considered the impact of these adjustments in relation to each period, as well as the periods in which they originated. The impact of recognizing these adjustments in prior years was not significant to any individual period. Management believes these adjustments are immaterial to the consolidated financial statements and all previously issued financial statements.

Recently Issued Accounting Standards

Pending Accounting Standards

In May 2014, the Financial Accounting Standards Board (the "FASB") issued authoritative guidance for recognizing revenue from contracts with customers. Certain contracts with customers are specifically excluded from this guidance, including insurance contracts. The core principle of the new guidance is that an entity should recognize revenue when it transfers promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will be effective for the Company on January 1, 2018 and permits two methods of transition upon adoption; full retrospective and modified retrospective. Under the full retrospective method, prior periods would be restated under the new revenue standard, providing for comparability in all periods presented. Under the modified retrospective method, prior periods would not be restated. Instead, revenues and other disclosures for pre-2018 periods would be provided in the notes to the financial statements as previously reported under the current revenue standard. The new guidance will impact our accounting for various distribution and marketing agreements with other insurance companies pursuant to which Bankers Life's career agents distribute third party products including prescription drug and Medicare Advantage plans. The revenue associated with these distribution agreements has been less than 1 percent of our total revenue. Our annual fee income earned during a calendar year will not change, but the amount recognized during each quarterly period will vary based on the sales of such products in each period. Accordingly, the adoption of this guidance is not expected to have a material impact on our consolidated financial statements. The Company will adopt the new guidance using the modified retrospective method.

In January 2016, the FASB issued authoritative guidance related to the recognition and measurement of financial assets and financial liabilities which made targeted improvements to GAAP as follows:

(i) Require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

(ii) Simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value.

(iii) Eliminate the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet.

(iv) Require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes.

(v) Require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments.

(vi) Require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements.

132

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

(vii) Clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets.

An entity should apply this guidance by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of the guidance. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company currently holds equity securities classified as available for sale securities that are measured at fair value with changes in fair value recognized through accumulated other comprehensive income. Upon adoption of this guidance, changes in fair value of such equity securities will be recognized through net income. Based upon the equity securities held at December 31, 2017, the estimated impact of the new guidance, assuming it was adopted on January 1, 2018, would be a cumulative effect adjustment that would increase retained earnings by approximately $17 million with a corresponding decrease to accumulated other comprehensive income of approximately $17 million. The Company may experience an increase in volatility in the income statement due to the requirement to measure equity investments at fair value with changes in fair value recognized in income. In addition, the Company will be required to modify certain disclosures upon adoption.

In February 2016, the FASB issued authoritative guidance related to accounting for leases, requiring lessees to report most leases on their balance sheets, regardless of whether the lease is classified as a finance lease or an operating lease. For lessees, the initial lease liability is equal to the present value of future lease payments, and a corresponding asset, adjusted for certain items, is also recorded. Expense recognition for lessees will remain similar to current accounting requirements for capital and operating leases. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

In June 2016, the FASB issued authoritative guidance related to the measurement of credit losses on financial instruments. The new guidance replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The guidance will be effective for the Company for fiscal years beginning in 2020, including interim periods within the fiscal year. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

In August 2016, the FASB issued authoritative guidance related to how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, and others. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this guidance will result in reclassifications to certain cash receipts and payments within our consolidated statement of cash flows, but will have no impact on our consolidated financial position, results of operations or cash flows.

In November 2016, the FASB issued authoritative guidance to address the diversity in practice that currently exists regarding the classification and presentation of changes in restricted cash on the statement of cash flows. The new guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Entities will also be required to disclose information about the nature of their restricted cash and restricted cash equivalents. Additionally, if cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item in the statement of financial position, entities will be required to present a reconciliation, either on the face of the statement of cash flows or disclosed in the notes, of the totals in the statement of cash flows to the related line item captions in the statement of financial position. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early

133

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

adoption is permitted, including adoption in an interim period. The adoption of this guidance will impact the presentation of our consolidated statement of cash flows and related cash flow disclosures, but will have no impact on our consolidated financial position, results of operations or cash flows.

In January 2017, the FASB issued authoritative guidance that removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reported unit's fair value. Upon adoption, the guidance is to be applied prospectively. The guidance will be effective for the Company on January 1, 2020, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows.

In March 2017, the FASB issued authoritative guidance related to the premium amortization on purchased callable debt securities. The guidance shortens the amortization period for certain callable debt securities held at a premium. Specifically, the new guidance requires the premium to be amortized to the earliest call date. The guidance does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance will be effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the guidance in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company has not yet determined the expected impact of adoption of this guidance on our consolidated financial position, results of operations or cash flows.

In May 2017, the FASB issued authoritative guidance related to which changes to the terms or conditions of a share-based award require an entity to apply modification accounting. The guidance will be effective for the Company in 2018. The guidance is to be applied prospectively to an award modified on or after the adoption date. The adoption of this guidance is not expected to have a material impact to the Company's consolidated financial position, results of operations or cash flows.

In August 2017, the FASB issued authoritative guidance related to derivatives and hedging. The new guidance expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instruments and the hedged item in the financial statements. The new guidance also includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

Adopted Accounting Standards

In March 2016, the FASB issued authoritative guidance that clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under this guidance is required to assess the embedded call (put) options solely in accordance with a four-step decision sequence. The guidance is effective for the Company on January 1, 2017. The adoption of this guidance had no effect on our consolidated financial statements.

134

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

In March 2016, the FASB issued authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting policy for forfeiture rate assumptions, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new guidance requires all income tax effects of stock-based compensation awards to be recognized in the income statement when the awards vest or are settled. The new guidance also allows an employer to withhold shares upon settlement of an award to satisfy the employer's tax withholding requirements up to the highest marginal tax rate applicable to employees, without resulting in liability classification of the award. Current guidance strictly limits the withholding to the employer's minimum statutory tax withholding requirement. The guidance was effective for the Company on January 1, 2017. The impact of adoption was as follows (dollars in millions):

	January 1, 2017
				Effect of Adoption of Authoritative Guidance
	Amounts prior to effect of adoption of authoritative guidance			Election to account for forfeitures as they occur			Recognition of excess tax benefits			As adjusted
Income tax assets	$	1,029.9		$	.3		$	15.7		$	1,045.9
Valuation allowance for deferred income tax assets	(240.2		)	—			(15.7		)	(255.9		)
Income tax assets, net	789.7			.3			—			790.0
Total assets	31,975.2			.3			—			31,975.5
Additional paid-in capital	3,212.1			.9			—			3,213.0
Retained earnings	650.7			(.6		)	—			650.1
Total shareholders' equity	4,486.9			.3			—			4,487.2
Total liabilities and shareholders' equity	31,975.2			.3			—			31,975.5

	December 31, 2016
	Amounts prior to effect of adoption of authoritative guidance			Effect of adoption of authoritative guidance			As adjusted
Cash flows from operating activities:
Other operating costs	$	(751.2	)	$	3.3		$	(747.9	)
Net cash flow from operating activities	759.5			3.3			762.8
Cash flows from financing activities:
Payments to repurchase common stock	(206.7		)	(3.3		)	(210.0		)
Net cash provided by financing activities	29.5			(3.3		)	26.2
Net increase in cash and cash equivalents	46.6			—			46.6

135

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

	December 31, 2015
	Amounts prior to effect of adoption of authoritative guidance			Effect of adoption of authoritative guidance			As adjusted
Cash flows from operating activities:
Other operating costs	$	(724.4	)	$	3.9		$	(720.5	)
Net cash flow from operating activities	743.9			3.9			747.8
Cash flows from financing activities:
Payments to repurchase common stock	(361.5		)	(3.9		)	(365.4		)
Net cash provided by financing activities	146.4			(3.9		)	142.5
Net decrease in cash and cash equivalents	(179.3		)	—			(179.3		)

In October 2016, the FASB issued authoritative guidance to amend the consolidation guidance on how a reporting entity that is the single decision maker of a VIE should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The guidance is effective for the Company on January 1, 2017. The adoption of this guidance had no impact on our consolidated financial statements.

In February 2018, the FASB issued authoritative guidance that allows a reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects resulting from the Tax Cuts and Jobs Act (the "Tax Reform Act") enacted by the U.S. federal government on December 22, 2017. Such guidance only relates to the reclassification of the income tax effects of the Tax Reform Act. The Company early adopted this guidance and elected to reclassify the income tax effects of the Tax Reform Act from accumulated other comprehensive income as of December 31, 2017. As a result of such reclassification, retained earnings decreased by $205.4 million and accumulated other comprehensive income increased by $205.4 million. Such amount represents the decrease in the income tax rate from 35 percent to 21 percent on the net unrealized gains of our fixed maturity securities, available for sale, equity securities and certain other invested assets, net of related adjustments, included in accumulated other comprehensive income. Refer to the note to the consolidated financial statements entitled "Income Taxes" for additional information related to the Tax Reform Act.

136

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

3. INVESTMENTS

At December 31, 2017, the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than-temporary impairments included in accumulated other comprehensive income
Investment grade (a):
Corporate securities	$	12,419.3	$	1,670.7	$	(14.6	)	$	14,075.4	$	—
United States Treasury securities and obligations of United States government corporations and agencies	146.4		31.5		(.2		)	177.7		—
States and political subdivisions	1,819.9		234.8		(.4		)	2,054.3		—
Debt securities issued by foreign governments	79.5		3.8		(.2		)	83.1		—
Asset-backed securities	1,730.7		39.7		(3.2		)	1,767.2		—
Collateralized debt obligations	257.1		2.3		—			259.4		—
Commercial mortgage-backed securities	1,304.1		33.2		(9.1		)	1,328.2		—
Mortgage pass-through securities	1.8		.2		—			2.0		—
Collateralized mortgage obligations	293.9		16.4		(.2		)	310.1		(.2		)
Total investment grade fixed maturities, available for sale	18,052.7		2,032.6		(27.9		)	20,057.4		(.2		)
Below-investment grade (a) (b):
Corporate securities	867.0		28.4		(12.4		)	883.0		—
States and political subdivisions	2.0		—		—			2.0		—
Asset-backed securities	1,355.2		132.9		(.9		)	1,487.2		—
Commercial mortgage-backed securities	49.9		.6		(1.2		)	49.3		—
Collateralized mortgage obligations	375.3		56.8		(.1		)	432.0		(.8		)
Total below-investment grade fixed maturities, available for sale	2,649.4		218.7		(14.6		)	2,853.5		(.8		)
Total fixed maturities, available for sale	$	20,702.1	$	2,251.3	$	(42.5	)	$	22,910.9	$	(1.0	)
Equity securities	$	491.1	$	23.6	$	(3.0	)	$	511.7

_______________

(a) Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's Investor Services, Inc. ("Moody's"), S&P Global Ratings ("S&P") or Fitch Ratings ("Fitch")), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC").  NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch).  NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch).  References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.

(b) Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations.

137

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The NAIC evaluates the fixed maturity investments of insurers for regulatory and capital assessment purposes and assigns securities to one of six credit quality categories called NAIC designations, which are used by insurers when preparing their annual statements based on statutory accounting principles. The NAIC designations are generally similar to the credit quality designations of the NRSROs for marketable fixed maturity securities, except for certain structured securities. However, certain structured securities rated below investment grade by the NRSROs can be assigned NAIC 1 or NAIC 2 designations depending on the cost basis of the holding relative to estimated recoverable amounts as determined by the NAIC. The following summarizes the NAIC designations and NRSRO equivalent ratings:

NAIC Designation	NRSRO Equivalent Rating
1	AAA/AA/A
2	BBB
3	BB
4	B
5	CCC and lower
6	In or near default

A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of December 31, 2017 is as follows (dollars in millions):

NAIC designation	Amortized cost		Estimated fair value		Percentage of total estimated fair value
1	$	9,923.7	$	11,028.5	48.1	%
2	9,821.6		10,906.2		47.6
Total NAIC 1 and 2 (investment grade)	19,745.3		21,934.7		95.7
3	676.2		693.8		3.0
4	225.0		225.9		1.0
5	46.3		45.9		.2
6	9.3		10.6		.1
Total NAIC 3,4,5 and 6 (below-investment grade)	956.8		976.2		4.3
	$	20,702.1	$	22,910.9	100.0	%

138

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

At December 31, 2016, the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than-temporary impairments included in accumulated other comprehensive income
Investment grade:
Corporate securities	$	11,582.6	$	1,073.9	$	(99.8	)	$	12,556.7	$	—
United States Treasury securities and obligations of United States government corporations and agencies	143.8		20.5		—			164.3		—
States and political subdivisions	1,798.2		186.7		(7.9		)	1,977.0		—
Debt securities issued by foreign governments	37.1		.2		(.4		)	36.9		—
Asset-backed securities	1,169.6		29.2		(8.7		)	1,190.1		—
Collateralized debt obligations	227.5		1.0		(.3		)	228.2		—
Commercial mortgage-backed securities	1,467.2		32.9		(26.6		)	1,473.5		—
Mortgage pass-through securities	2.3		.2		—			2.5		—
Collateralized mortgage obligations	304.8		14.6		(.2		)	319.2		—
Total investment grade fixed maturities, available for sale	16,733.1		1,359.2		(143.9		)	17,948.4		—
Below-investment grade:
Corporate securities	967.3		26.1		(39.2		)	954.2		(3.6		)
States and political subdivisions	13.6		—		(1.7		)	11.9		(3.0		)
Asset-backed securities	1,471.9		55.1		(6.8		)	1,520.2		—
Collateralized debt obligations	2.5		—		—			2.5		—
Commercial mortgage-backed securities	63.8		.2		(1.3		)	62.7		—
Collateralized mortgage obligations	550.9		46.8		(1.4		)	596.3		(1.4		)
Total below-investment grade fixed maturities, available for sale	3,070.0		128.2		(50.4		)	3,147.8		(8.0		)
Total fixed maturities, available for sale	$	19,803.1	$	1,487.4	$	(194.3	)	$	21,096.2	$	(8.0	)
Equity securities	$	580.7	$	11.5	$	(8.0	)	$	584.2

139

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments.  These amounts, included in shareholders' equity as of December 31, 2017 and 2016, were as follows (dollars in millions):

	2017			2016
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	$	2.6		$	(1.1	)
Net unrealized gains on all other investments	2,227.3			1,311.9
Adjustment to present value of future profits (a)	(94.0		)	(106.2		)
Adjustment to deferred acquisition costs	(292.6		)	(223.5		)
Adjustment to insurance liabilities	(295.8		)	(13.5		)
Deferred income tax liabilities	(335.4		)	(345.2		)
Accumulated other comprehensive income	$	1,212.1		$	622.4

________

(a) The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003, the date our Predecessor emerged from bankruptcy.

At December 31, 2017, adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred tax assets included $(83.8) million, $(134.9) million, $(295.8) million and $111.1 million, respectively, for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields.

At December 31, 2016, adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred tax assets included $(94.1) million, $(96.4) million, $(13.5) million and $72.5 million, respectively, for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields.

Below-Investment Grade Securities

At December 31, 2017, the amortized cost of the Company's below-investment grade fixed maturity securities was $2,649.4 million, or 13 percent of the Company's fixed maturity portfolio. The estimated fair value of the below-investment grade portfolio was $2,853.5 million, or 108 percent of the amortized cost.

Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities.  Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade corporate debt securities and in many cases severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer.  Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are generally more sensitive to adverse economic conditions.  The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

140

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Contractual Maturity

The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.  Structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as "structured securities") frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	328.1	$	335.1
Due after one year through five years	1,947.3		2,052.3
Due after five years through ten years	1,508.7		1,601.3
Due after ten years	11,550.0		13,286.8
Subtotal	15,334.1		17,275.5
Structured securities	5,368.0		5,635.4
Total fixed maturities, available for sale	$	20,702.1	$	22,910.9

Net Investment Income

Net investment income consisted of the following (dollars in millions):

	2017		2016			2015
General account assets:
Fixed maturities	$	1,133.8	$	1,081.4		$	1,090.1
Equity securities	25.3		21.5			18.3
Mortgage loans	91.5		91.0			91.4
Policy loans	7.7		7.3			7.3
Other invested assets	44.4		24.3			17.4
Cash and cash equivalents	5.9		2.0			.8
Policyholder and other special-purpose portfolios:
Trading securities (a)	12.8		12.2			10.7
Options related to fixed index products:
Option income (loss)	110.3		(40.1		)	36.5
Change in value of options	52.2		69.3			(72.7		)
Other special-purpose portfolios	90.6		79.7			55.5
Gross investment income	1,574.5		1,348.6			1,255.3
Less investment expenses	23.2		23.4			21.7
Net investment income	$	1,551.3	$	1,325.2		$	1,233.6

_________________

(a) Changes in the estimated fair value for trading securities still held as of the end of the respective years and included in net investment income were $3.8 million, $(.2) million and $.4 million for the years ended December 31, 2017, 2016 and 2015, respectively.

At December 31, 2017, the carrying value of fixed maturities and mortgage loans that were non-income producing during 2017 totaled $2.8 million and $10.6 million, respectively.

141

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Net Realized Investment Gains (Losses)

The following table sets forth the net realized investment gains (losses) for the periods indicated (dollars in millions):

	2017			2016			2015
Fixed maturity securities, available for sale:
Gross realized gains on sale	$	68.0		$	137.7		$	95.7
Gross realized losses on sale	(24.2		)	(95.2		)	(88.4		)
Impairments:
Total other-than-temporary impairment losses	(12.5		)	(15.2		)	(17.9		)
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(.9		)	3.6			3.0
Net impairment losses recognized	(13.4		)	(11.6		)	(14.9		)
Net realized investment gains (losses) from fixed maturities	30.4			30.9			(7.6		)
Equity securities	11.6			20.9			3.7
Mortgage loans	1.1			—			(2.3		)
Impairments on preferred stock and other investments	(9.4		)	(20.7		)	(25.0		)
Gain (loss) on dissolution of variable interest entities	(4.3		)	(7.3		)	11.3
Other (a)	20.9			(15.5		)	(16.7		)
Net realized investment gains (losses)	$	50.3		$	8.3		$	(36.6	)

_________________

(a) Changes in the estimated fair value of trading securities that we have elected the fair value option (and are still held as of the end of the respective years) were $12.8 million, $(.5) million and $(9.2) million for the years ended December 31, 2017, 2016 and 2015, respectively.

During 2017, we recognized net realized investment gains of $50.3 million, which were comprised of: (i) $63.1 million of net gains from the sales of investments; (ii) $4.3 million of losses on the dissolution of VIEs; (iii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $11.5 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $2.8 million; and (v) $22.8 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

During 2017, 2016 and 2015, VIEs that were required to be consolidated were dissolved. We recognized losses of $4.3 million and $7.3 million during 2017 and 2016, respectively, and a gain of $11.3 million during 2015, representing the difference between the borrowings of such VIEs and the contractual distributions required following the liquidation of the underlying assets.

During 2016, we recognized net realized investment gains of $8.3 million, which were comprised of: (i) $47.5 million of net gains from the sales of investments; (ii) a $7.3 million loss on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $.4 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $.8 million; and (v) $32.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($35.9 million, prior to the $3.6 million of impairment losses recognized through accumulated other comprehensive income).

During 2015, we recognized net realized investment losses of $36.6 million, which were comprised of: (i) $8.2 million of net gains from the sales of investments; (ii) an $11.3 million gain on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $9.2 million; (iv) the decrease in fair value of embedded derivatives related to a modified coinsurance agreement of $7.0 million; and (v) $39.9 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($42.9 million, prior to the $3.0 million of impairment losses recognized through accumulated other comprehensive income).

142

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

At December 31, 2017, there was one fixed maturity investment in default with an amortized cost and carrying value of $.5 million and $.4 million, respectively.

During 2017, the $24.2 million of realized losses on sales of $427.6 million of fixed maturity securities, available for sale, included: (i) $16.8 million related to various corporate securities; (ii) $3.6 million related to commercial mortgage-backed securities; and (iii) $3.8 million related to various other investments. Securities are generally sold at a loss following unforeseen issuer-specific events or conditions or shifts in perceived relative values.  These reasons include but are not limited to:  (i) changes in the investment environment; (ii) expectation that the market value could deteriorate; (iii) our desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; or (v) changes in expected portfolio cash flows.

During 2017, we recognized $22.8 million of impairment losses recorded in earnings which included: (i) $6.7 million of writedowns on fixed maturities in the energy sector; (ii) $5.2 million of writedowns related to a mortgage loan; and (iii) $10.9 million of writedowns on other investments. Factors considered in determining the writedowns of investments in 2017 included changes in the estimated recoverable value of the assets related to each investment and the timing of and complexities related to the recovery process.

During 2016, the $95.2 million of realized losses on sales of $790.2 million of fixed maturity securities, available for sale included: (i) $79.2 million related to various corporate securities (including $63.5 million related to sales of investments in the energy sector); (ii) $5.8 million related to commercial mortgage-backed securities; (iii) $5.7 million related to asset-backed securities; and (iv) $4.5 million related to various other investments.

During 2016, we recognized $32.3 million of impairment losses recorded in earnings which included: (i) $9.3 million of writedowns on fixed maturities in the energy sector; (ii) $3.7 million of writedowns on a direct loan due to borrower specific events; (iii) $12.7 million of writedowns on a privately placed preferred stock of an entity formed to construct and operate a chemical plant; (iv) $1.2 million of writedowns of investments held by VIEs due to other-than-temporary declines in value; and (v) $5.4 million of writedowns on other investments. Factors considered in determining the writedowns of investments in 2016 included the subordination status of each investment, the impact of recent downgrades and issuer specific events, including the impact of low oil prices on issuers in the energy sector.

During 2015, the $88.4 million of realized losses on sales of $724.4 million of fixed maturity securities, available for sale, primarily related to various corporate securities (including $59.7 million related to sales of investments in the energy sector).  

During 2015, we recognized $39.9 million of impairment losses recorded in earnings which included: (i) $10.2 million of writedowns on fixed maturities in the energy sector; (ii) $16.4 million of writedowns on commercial bank loans held by VIEs; (iii) a $7.9 million writedown of a legacy investment in a private company that was liquidated; and (iv) $5.4 million of losses on other investments (primarily fixed maturities). We no longer have any exposure to legacy private companies related to investments acquired by our Predecessor.

Our fixed maturity investments are generally purchased in the context of various long-term strategies, including funding insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities.  In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities.

143

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following summarizes the investments sold at a loss during 2017 which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period indicated (dollars in millions):

		At date of sale
	Number of issuers	Amortized cost		Fair value
Less than 6 months prior to sale	4	$	17.8	$	13.0
Greater than or equal to 6 months and less than 12 months prior to sale	1	2.7		1.9
Greater than 12 months prior to sale	1	.7		.5
	6	$	21.2	$	15.4

We regularly evaluate all of our investments with unrealized losses for possible impairment.  Our assessment of whether unrealized losses are "other than temporary" requires significant judgment.  Factors considered include:  (i) the extent to which fair value is less than the cost basis; (ii) the length of time that the fair value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for specific events, developments or circumstances likely to affect the value of the investment; (v) the investment's rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) whether we intend to sell the investment or it is more likely than not that circumstances will require us to sell the investment before recovery occurs; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values; (ix) projections of, and unfavorable changes in, cash flows on structured securities including mortgage-backed and asset-backed securities; (x) our best estimate of the value of any collateral; and (xi) other objective and subjective factors.

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio.  Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

Impairment losses on equity securities are recognized in net income.  The manner in which impairment losses on fixed maturity securities, available for sale, are recognized in the financial statements is dependent on the facts and circumstances related to the specific security.  If we intend to sell a security or it is more likely than not that we would be required to sell a security before the recovery of its amortized cost, the security is other-than-temporarily impaired and the full amount of the impairment is recognized as a loss through earnings.  If we do not expect to recover the amortized cost basis, we do not plan to sell the security, and if it is not more likely than not that we would be required to sell a security before the recovery of its amortized cost, less any current period credit loss, the recognition of the other-than-temporary impairment is bifurcated.  We recognize the credit loss portion in net income and the noncredit loss portion in accumulated other comprehensive income.

We estimate the amount of the credit loss component of a fixed maturity security impairment as the difference between amortized cost and the present value of the expected cash flows of the security.  The present value is determined using the best estimate of future cash flows discounted at the effective interest rate implicit to the security at the date of purchase or the current yield to accrete an asset-backed or floating-rate security.  The methodology and assumptions for establishing the best estimate of future cash flows vary depending on the type of security.

For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including overcollateralization, excess spread, subordination and guarantees.  For corporate bonds, cash flow estimates are derived from scenario-based outcomes of expected corporate restructurings or the disposition of assets using bond-specific facts and circumstances. The previous amortized cost basis less the impairment recognized in net income becomes the security's new cost basis.  We accrete the new cost basis to the estimated future cash flows over the expected remaining life of the security, except when the security is in default or considered nonperforming.

144

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The remaining noncredit impairment, which is recorded in accumulated other comprehensive income, is the difference between the security's estimated fair value and our best estimate of future cash flows discounted at the effective interest rate prior to impairment.  The remaining noncredit impairment typically represents changes in the market interest rates, current market liquidity and risk premiums.  As of December 31, 2017, other-than-temporary impairments included in accumulated other comprehensive income totaled $1.0 million (before taxes and related amortization).

Mortgage loans are impaired when it is probable that we will not collect the contractual principal and interest on the loan. We measure impairment based upon the difference between the carrying value of the loan and the estimated fair value of the collateral securing the loan less cost to sell.

The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the years ended December 31, 2017, 2016 and 2015 (dollars in millions):

	Year ended
	December 31,
	2017			2016			2015
Credit losses on fixed maturity securities, available for sale, beginning of period	$	(5.5	)	$	(2.6	)	$	(1.0	)
Add:  credit losses on other-than-temporary impairments not previously recognized	—			(3.0		)	(2.0		)
Less:  credit losses on securities sold	4.7			.1			.4
Less:  credit losses on securities impaired due to intent to sell (a)	—			—			—
Add:  credit losses on previously impaired securities	(2.0		)	—			—
Less:  increases in cash flows expected on previously impaired securities	—			—			—
Credit losses on fixed maturity securities, available for sale, end of period	$	(2.8	)	$	(5.5	)	$	(2.6	)

__________

(a) Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.

145

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Investments with Unrealized Losses

The following table sets forth the amortized cost and estimated fair value of those fixed maturities, available for sale, with unrealized losses at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.  Structured securities frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	26.9	$	26.9
Due after one year through five years	195.4		193.3
Due after five years through ten years	108.9		105.2
Due after ten years	602.0		580.0
Subtotal	933.2		905.4
Structured securities	1,268.3		1,253.6
Total	$	2,201.5	$	2,159.0

The following summarizes the investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis for the period indicated as of December 31, 2017 (dollars in millions):

	Number of issuers	Cost basis		Unrealized loss			Estimated fair value
Less than 6 months	1	$	9.2	$	(1.9	)	$	7.3
		$	9.2	$	(1.9	)	$	7.3

146

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2017 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	28.2	$	(.2	)	$	.7	$	—		$	28.9	$	(.2	)
States and political subdivisions	18.3		(.1		)	14.9		(.3		)	33.2		(.4		)
Debt securities issued by foreign governments	7.7		(.1		)	5.4		(.1		)	13.1		(.2		)
Corporate securities	470.5		(6.8		)	359.7		(20.2		)	830.2		(27.0		)
Asset-backed securities	601.4		(2.0		)	122.2		(2.1		)	723.6		(4.1		)
Collateralized debt obligations	3.0		—			—		—			3.0		—
Commercial mortgage-backed securities	276.8		(1.7		)	218.2		(8.6		)	495.0		(10.3		)
Collateralized mortgage obligations	20.5		(.2		)	11.5		(.1		)	32.0		(.3		)
Total fixed maturities, available for sale	$	1,426.4	$	(11.1	)	$	732.6	$	(31.4	)	$	2,159.0	$	(42.5	)
Equity securities	$	58.7	$	(1.7	)	$	21.2	$	(1.3	)	$	79.9	$	(3.0	)

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2016 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	8.0	$	—		$	—	$	—		$	8.0	$	—
States and political subdivisions	176.3		(7.8		)	18.3		(1.8		)	194.6		(9.6		)
Debt securities issued by foreign governments	18.9		(.4		)	—		—			18.9		(.4		)
Corporate securities	1,907.6		(75.5		)	559.6		(63.5		)	2,467.2		(139.0		)
Asset-backed securities	692.9		(8.5		)	262.5		(7.0		)	955.4		(15.5		)
Collateralized debt obligations	38.3		(.1		)	30.8		(.2		)	69.1		(.3		)
Commercial mortgage-backed securities	525.2		(16.6		)	154.0		(11.3		)	679.2		(27.9		)
Collateralized mortgage obligations	73.6		(.6		)	34.6		(1.0		)	108.2		(1.6		)
Total fixed maturities, available for sale	$	3,440.8	$	(109.5	)	$	1,059.8	$	(84.8	)	$	4,500.6	$	(194.3	)
Equity securities	$	239.4	$	(8.0	)	$	—	$	—		$	239.4	$	(8.0	)

Based on management's current assessment of investments with unrealized losses at December 31, 2017, the Company believes the issuers of the securities will continue to meet their obligations (or with respect to equity-type securities, the

147

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

investment value will recover to its cost basis).  While we do not have the intent to sell securities with unrealized losses and it is not more likely than not that we will be required to sell securities with unrealized losses prior to their anticipated recovery, our intent on an individual security may change, based upon market or other unforeseen developments.  In such instances, if a loss is recognized from a sale subsequent to a balance sheet date due to these unexpected developments, the loss is recognized in the period in which we had the intent to sell the security before its anticipated recovery.

Structured Securities

At December 31, 2017 fixed maturity investments included structured securities with an estimated fair value of $5.6 billion (or 25 percent of all fixed maturity securities).  The yield characteristics of structured securities generally differ in some respects from those of traditional corporate fixed-income securities or government securities.  For example, interest and principal payments on structured securities may occur more frequently, often monthly.  In many instances, we are subject to variability in the amount and timing of principal and interest payments.  For example, in many cases, partial prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including:  the relative sensitivity of prepayments on the underlying assets backing the security to changes in interest rates and asset values; the availability of alternative financing; a variety of economic, geographic and other factors; the timing, pace and proceeds of liquidations of defaulted collateral; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure).  In addition, the total amount of payments for non-agency structured securities may be affected by changes to cumulative default rates or loss severities of the related collateral.

Historically, the rate of prepayments on structured securities has tended to increase when prevailing interest rates have declined significantly in absolute terms and also relative to the interest rates on the underlying collateral. The yields recognized on structured securities purchased at a discount to par will generally increase (relative to the stated rate) when the underlying collateral prepays faster than expected. The yields recognized on structured securities purchased at a premium will decrease (relative to the stated rate) when the underlying collateral prepays faster than expected. When interest rates decline, the proceeds from prepayments may be reinvested at lower rates than we were earning on the prepaid securities. When interest rates increase, prepayments may decrease below expected levels. When this occurs, the average maturity and duration of structured securities increases, decreasing the yield on structured securities purchased at discounts and increasing the yield on those purchased at a premium because of a decrease in the annual amortization of premium.

For structured securities included in fixed maturities, available for sale, that were purchased at a discount or premium, we recognize investment income using an effective yield based on anticipated future prepayments and the estimated final maturity of the securities. Actual prepayment experience is periodically reviewed and effective yields are recalculated when differences arise between the prepayments originally anticipated and the actual prepayments received and currently anticipated. For credit sensitive mortgage-backed and asset-backed securities, and for securities that can be prepaid or settled in a way that we would not recover substantially all of our investment, the effective yield is recalculated on a prospective basis. Under this method, the amortized cost basis in the security is not immediately adjusted and a new yield is applied prospectively. For all other structured and asset-backed securities, the effective yield is recalculated when changes in assumptions are made, and reflected in our income on a retrospective basis. Under this method, the amortized cost basis of the investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments were not significant in 2017.

For purchased credit impaired securities, at acquisition, the difference between the undiscounted expected future cash flows and the recorded investment in the securities represents the initial accretable yield, which is accreted into net investment income over the securities’ remaining lives on a level-yield basis. Subsequently, effective yields recognized on purchased credit impaired securities are recalculated and adjusted prospectively to reflect changes in the contractual benchmark interest rates on variable rate securities and any significant increases in undiscounted expected future cash flows arising due to reasons other than interest rate changes. Significant decreases in expected cash flows arising from credit events would result in impairment if such security's fair value is below amortized cost.

148

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table sets forth the par value, amortized cost and estimated fair value of structured securities, summarized by interest rates on the underlying collateral, at December 31, 2017 (dollars in millions):

	Par value		Amortized cost		Estimated fair value
Below 4 percent	$	2,101.7	$	1,944.8	$	2,014.9
4 percent – 5 percent	1,656.3		1,516.0		1,596.5
5 percent – 6 percent	1,407.1		1,271.8		1,362.6
6 percent – 7 percent	286.6		260.6		276.8
7 percent – 8 percent	83.0		83.7		92.5
8 percent and above	291.3		291.1		292.1
Total structured securities	$	5,826.0	$	5,368.0	$	5,635.4

The amortized cost and estimated fair value of structured securities at December 31, 2017, summarized by type of security, were as follows (dollars in millions):

			Estimated fair value
Type	Amortized cost		Amount		Percent of fixed maturities
Pass-throughs, sequential and equivalent securities	$	557.7	$	617.2	2.7	%
Planned amortization classes, target amortization classes and accretion-directed bonds	95.3		108.5		.5
Commercial mortgage-backed securities	1,354.0		1,377.5		6.0
Asset-backed securities	3,085.9		3,254.4		14.2
Collateralized debt obligations	257.1		259.4		1.1
Other	18.0		18.4		.1
Total structured securities	$	5,368.0	$	5,635.4	24.6	%

Pass-throughs, sequentials and equivalent securities have unique prepayment variability characteristics.  Pass-through securities typically return principal to the holders based on cash payments from the underlying mortgage obligations. Sequential securities return principal to tranche holders in a detailed hierarchy.  Planned amortization classes, targeted amortization classes and accretion-directed bonds adhere to fixed schedules of principal payments as long as the underlying mortgage loans experience prepayments within certain estimated ranges.  In most circumstances, changes in prepayment rates are first absorbed by support or companion classes insulating the timing of receipt of cash flows from the consequences of both faster prepayments (average life shortening) and slower prepayments (average life extension).

Commercial mortgage-backed securities are secured by commercial real estate mortgages, generally income producing properties that are managed for profit.  Property types include multi-family dwellings including apartments, retail centers, hotels, restaurants, hospitals, nursing homes, warehouses, and office buildings.  While most commercial mortgage-backed securities have call protection features whereby underlying borrowers may not prepay their mortgages for stated periods of time without incurring prepayment penalties, recoveries on defaulted collateral may result in involuntary prepayments.

149

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Mortgage Loans

At December 31, 2017, the mortgage loan balance was primarily comprised of commercial mortgage loans. Approximately 14 percent, 12 percent, 8 percent, 6 percent and 5 percent of the commercial mortgage loan balance were on properties located in California, Texas, Maryland, Florida and Illinois, respectively. No other state comprised greater than five percent of the commercial mortgage loan balance. At December 31, 2017, there was one mortgage loan in process of foreclosure with a carrying value of $10.6 million. There were no other mortgage loans that were noncurrent at December 31, 2017. Our commercial mortgage loan portfolio is comprised of large commercial mortgage loans. Our loans have risk characteristics that are individually unique. Accordingly, we measure potential losses on a loan-by-loan basis rather than establishing an allowance for losses on mortgage loans. At December 31, 2017, we held residential mortgage loan investments with a carrying value of $37.1 million and a fair value of $37.3 million.

The following table provides the carrying value and estimated fair value of our outstanding commercial mortgage loans and the underlying collateral as of December 31, 2017 (dollars in millions):

			Estimated fair value
Loan-to-value ratio (a)	Carrying value		Mortgage loans		Collateral
Less than 60%	$	944.7	$	960.8	$	2,330.6
60% to 70%	439.5		440.2		671.3
Greater than 70% to 80%	138.4		145.9		188.4
Greater than 80% to 90%	52.3		52.9		60.1
Greater than 90%	38.6		40.2		41.7
Total	$	1,613.5	$	1,640.0	$	3,292.1

________________

(a) Loan-to-value ratios are calculated as the ratio of:  (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.

Other Investment Disclosures

Life insurance companies are required to maintain certain investments on deposit with state regulatory authorities. Such assets had aggregate carrying values of $38.5 million and $36.7 million at December 31, 2017 and 2016, respectively.

The Company had no fixed maturity investments that were in excess of 10 percent of shareholders' equity at December 31, 2017 and 2016.

150

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

4. FAIR VALUE MEASUREMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price.  We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives.  We carry our COLI, which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs.

The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information.  Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value.  Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value.

Valuation Hierarchy

There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable.

• Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities.  Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.

• Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data.  Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies.  These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include:  certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.

• Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions.  Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information.  Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities.  Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.

At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value.  This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions.  Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. Any transfers between levels

151

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

are reported as having occurred at the beginning of the period. There were no transfers between Level 1 and Level 2 in both 2017 and 2016.

The vast majority of our fixed maturity and equity securities, including those held in trading portfolios and those held by consolidated VIEs, short-term and separate account assets use Level 2 inputs for the determination of fair value.  These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value.  Our Level 2 assets are valued as follows:

•Fixed maturities available for sale, equity securities and trading securities

Corporate securities are generally priced using market and income approaches. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads.

U.S. Treasuries and obligations of U.S. Government corporations and agencies are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets and maturity.

States and political subdivisions are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances and credit spreads.

Asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations are generally priced using market and income approaches. Inputs generally consist of quoted prices in inactive markets, spreads on actively traded securities, expected prepayments, expected default rates, expected recovery rates, and issue specific information including, but not limited to, collateral type, seniority and vintage.

Equity securities (primarily comprised of non-redeemable preferred stock) are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads.

• Investments held by VIEs

Corporate securities are generally priced using market and income approaches using pricing vendors. Inputs generally consist of issuer rating, benchmark yields, maturity, and credit spreads.

• Other invested assets - derivatives

The fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotes; time value and volatility factors underlying options; market interest rates; and non-performance risk.

Third party pricing services normally derive security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information.  If there are no recently reported trades, the third party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are discounted at an estimated risk-adjusted market rate.  The number of prices obtained for a given security is dependent on the Company's analysis of such prices as further described below.

As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value.  The Company's analysis includes:  (i) a review of the methodology used by third party pricing services;

152

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

(ii) where available, a comparison of multiple pricing services' valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably dated; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties.  As a result of such procedures, the Company may conclude a particular price received from a third party is not reflective of current market conditions.  In those instances, we may request additional pricing quotes or apply internally developed valuations.  However, the number of such instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received.

The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company's judgment of the inputs or methodologies used by the independent pricing services to value different asset classes.  Such inputs typically include:  benchmark yields, reported trades, broker dealer quotes, issuer spreads, benchmark securities, bids, offers and other relevant data.  The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments.

For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes.  These broker quotes are non-binding andrepresent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs.  Approximately 29 percent of our Level 3 fixed maturity securities were valued using unadjusted broker quotes or broker-provided valuation inputs.  The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs.  For these securities, we use internally developed valuations.  Key assumptions used to determine fair value for these securities may include risk premiums, projected performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market.  For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are discounted at an estimated market rate.  The pricing matrix incorporates term interest rates as well as a spread level based on the issuer's credit rating, other factors relating to the issuer, and the security's maturity.  In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity.

For certain embedded derivatives, we use actuarial assumptions in the determination of fair value which we consider to be Level 3 inputs.

153

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2017 is as follows (dollars in millions):

	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	14,728.0	$	230.4	$	14,958.4
United States Treasury securities and obligations of United States government corporations and agencies	—		177.7		—		177.7
States and political subdivisions	—		2,056.3		—		2,056.3
Debt securities issued by foreign governments	—		79.2		3.9		83.1
Asset-backed securities	—		3,230.2		24.2		3,254.4
Collateralized debt obligations	—		259.4		—		259.4
Commercial mortgage-backed securities	—		1,377.5		—		1,377.5
Mortgage pass-through securities	—		2.0		—		2.0
Collateralized mortgage obligations	—		742.1		—		742.1
Total fixed maturities, available for sale	—		22,652.4		258.5		22,910.9
Equity securities - corporate securities	287.8		202.7		21.2		511.7
Trading securities:
Corporate securities	—		21.6		—		21.6
United States Treasury securities and obligations of United States government corporations and agencies	—		.5		—		.5
Asset-backed securities	—		95.8		—		95.8
Collateralized debt obligations	—		2.7		—		2.7
Commercial mortgage-backed securities	—		92.5		—		92.5
Collateralized mortgage obligations	—		68.7		—		68.7
Equity securities	2.8		—		—		2.8
Total trading securities	2.8		281.8		—		284.6
Investments held by variable interest entities - corporate securities	—		1,522.0		4.9		1,526.9
Other invested assets - derivatives	—		170.2		—		170.2
Assets held in separate accounts	—		5.0		—		5.0
Total assets carried at fair value by category	$	290.6	$	24,834.1	$	284.6	$	25,409.3
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	1,334.8	$	1,334.8

154

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2016 is as follows (dollars in millions):

	Quoted prices in active markets  for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	13,252.4	$	258.5	$	13,510.9
United States Treasury securities and obligations of United States government corporations and agencies	—		164.3		—		164.3
States and political subdivisions	—		1,988.9		—		1,988.9
Debt securities issued by foreign governments	—		33.0		3.9		36.9
Asset-backed securities	—		2,649.9		60.4		2,710.3
Collateralized debt obligations	—		225.3		5.4		230.7
Commercial mortgage-backed securities	—		1,504.2		32.0		1,536.2
Mortgage pass-through securities	—		2.5		—		2.5
Collateralized mortgage obligations	—		915.5		—		915.5
Total fixed maturities, available for sale	—		20,736.0		360.2		21,096.2
Equity securities - corporate securities	359.9		199.1		25.2		584.2
Trading securities:
Corporate securities	—		19.0		—		19.0
United States Treasury securities and obligations of United States government corporations and agencies	—		.5		—		.5
Asset-backed securities	—		94.3		—		94.3
Collateralized debt obligations	—		2.4		—		2.4
Commercial mortgage-backed securities	—		163.9		—		163.9
Collateralized mortgage obligations	—		78.4		—		78.4
Equity securities	4.9		—		—		4.9
Total trading securities	4.9		358.5		—		363.4
Investments held by variable interest entities - corporate securities	—		1,724.3		—		1,724.3
Other invested assets - derivatives	—		111.9		—		111.9
Assets held in separate accounts	—		4.7		—		4.7
Total assets carried at fair value by category	$	364.8	$	23,134.5	$	385.4	$	23,884.7
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	1,092.3	$	1,092.3

155

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

For those financial instruments disclosed at fair value, we use the following methods and assumptions to determine the estimated fair values:

Mortgage loans and policy loans.  We discount future expected cash flows based on interest rates currently being offered for similar loans with similar risk characteristics.  We aggregate loans with similar characteristics in our calculations.  The fair value of policy loans approximates their carrying value.

Company-owned life insurance is backed by a series of mutual funds and is carried at cash surrender value which approximates estimated fair value.

Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value.

Liabilities for policyholder account balances.  The estimated fair value of insurance liabilities for policyholder account balances was approximately equal to its carrying value as interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.

Investment borrowings, notes payable and borrowings related to variable interest entities.  For publicly traded debt, we use current fair values.  For other notes, we use discounted cash flow analyses based on our current incremental borrowing rates for similar types of borrowing arrangements.

The fair value measurements for our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions):

	December 31, 2017
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,677.3	$	1,677.3	$	1,650.6
Policy loans	—		—		116.0		116.0		116.0
Other invested assets:
Company-owned life insurance	—		182.3		—		182.3		182.3
Cash and cash equivalents:
Unrestricted	578.4		—		—		578.4		578.4
Held by variable interest entities	178.9		—		—		178.9		178.9
Liabilities:
Policyholder account balances	—		—		11,220.7		11,220.7		11,220.7
Investment borrowings	—		1,648.8		—		1,648.8		1,646.7
Borrowings related to variable interest entities	—		1,432.9		—		1,432.9		1,410.7
Notes payable – direct corporate obligations	—		962.3		—		962.3		914.6

156

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

	December 31, 2016
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,800.1	$	1,800.1	$	1,768.0
Policy loans	—		—		112.0		112.0		112.0
Other invested assets:
Company-owned life insurance	—		165.0		—		165.0		165.0
Cash and cash equivalents:
Unrestricted	473.6		5.3		—		478.9		478.9
Held by variable interest entities	189.3		—		—		189.3		189.3
Liabilities:
Policyholder account balances	—		—		10,912.7		10,912.7		10,912.7
Investment borrowings	—		1,650.0		—		1,650.0		1,647.4
Borrowings related to variable interest entities	—		1,675.2		—		1,675.2		1,662.8
Notes payable – direct corporate obligations	—		931.9		—		931.9		912.9

157

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2017 (dollars in millions):

	December 31, 2017
	Beginning balance as of December 31, 2016			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income		Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2017			Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	258.5		$	(70.4	)	$	5.8	$	5.3		$	31.2	$	—		$	230.4		$	(8.0	)
Debt securities issued by foreign governments	3.9			—			—		—			—		—			3.9			—
Asset-backed securities	60.4			(4.3		)	—		.7			—		(32.6		)	24.2			—
Collateralized debt obligations	5.4			(2.5		)	—		—			—		(2.9		)	—			—
Commercial mortgage-backed securities	32.0			(1.2		)	.1		(.1		)	—		(30.8		)	—			—
Total fixed maturities, available for sale	360.2			(78.4		)	5.9		5.9			31.2		(66.3		)	258.5			(8.0		)
Equity securities - corporate securities	25.2			(8.5		)	6.3		(1.8		)	—		—			21.2			—
Investments held by variable interest entities - corporate securities	—			4.9			—		—			—		—			4.9			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,092.3		)	(267.5		)	25.0		—			—		—			(1,334.8		)	25.0

158

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

_________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended December 31, 2017 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	76.6		$	(147.0	)	$	—		$	—	$	(70.4	)
Asset-backed securities	—			(4.3		)	—			—		(4.3		)
Collateralized debt obligations	—			(2.5		)	—			—		(2.5		)
Commercial mortgage-backed securities	—			(1.2		)	—			—		(1.2		)
Total fixed maturities, available for sale	76.6			(155.0		)	—			—		(78.4		)
Equity securities - corporate securities	—			(8.5		)	—			—		(8.5		)
Investments held by variable interest entities - corporate securities	8.9			(4.0		)	—			—		4.9
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(178.9		)	5.4			(159.3		)	65.3		(267.5		)

159

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2016 (dollars in millions):

	December 31, 2016
	Beginning balance as of December 31, 2015			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2016			Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	170.4		$	76.5		$	(10.7	)	$	9.1		$	20.3	$	(7.1	)	$	258.5		$	(10.9	)
Debt securities issued by foreign governments	—			4.0			—			(.1		)	—		—			3.9			—
Asset-backed securities	35.9			9.7			—			2.2			26.3		(13.7		)	60.4			—
Collateralized debt obligations	—			5.4			—			—			—		—			5.4			—
Commercial mortgage-backed securities	1.1			16.9			—			.1			13.9		—			32.0			—
Mortgage pass-through securities	.1			(.1		)	—			—			—		—			—			—
Total fixed maturities, available for sale	207.5			112.4			(10.7		)	11.3			60.5		(20.8		)	360.2			(10.9		)
Equity securities - corporate securities	32.0			5.5			(12.7		)	.4			—		—			25.2			(12.7		)
Trading securities - commercial mortgage-backed securities	39.9			—			—			—			—		(39.9		)	—			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,057.1		)	(96.0		)	60.8			—			—		—			(1,092.3		)	60.8

160

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

____________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended December 31, 2016 (dollars in millions):

	Purchases			Received in reinsurance recapture		Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	18.5		$	89.2	$	(31.2	)	$	—		$	—	$	76.5
Debt securities issued by foreign governments	4.0			—		—			—			—		4.0
Asset-backed securities	16.9			—		(7.2		)	—			—		9.7
Collateralized debt obligations	5.4			—		—			—			—		5.4
Commercial mortgage-backed securities	17.0			—		(.1		)	—			—		16.9
Mortgage pass-through securities	—			—		(.1		)	—			—		(.1		)
Total fixed maturities, available for sale	61.8			89.2		(38.6		)	—			—		112.4
Equity securities - corporate securities	3.3			2.2		—			—			—		5.5
Trading securities - corporate securities	.2			—		(.2		)	—			—		—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(148.3		)	—		21.2			(28.9		)	60.0		(96.0		)

At December 31, 2017, 52 percent of our Level 3 fixed maturities, available for sale, were investment grade and 89 percent of our Level 3 fixed maturities, available for sale, consisted of corporate securities.

Realized and unrealized investment gains and losses presented in the preceding tables represent gains and losses during the time the applicable financial instruments were classified as Level 3.

Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and other special-purpose portfolios, net realized investment gains (losses) or insurance policy benefits within the consolidated statement of operations or accumulated other comprehensive income within shareholders' equity based on the appropriate accounting treatment for the instrument.

161

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The amount presented for gains (losses) included in our net loss for assets and liabilities still held as of the reporting date primarily represents impairments for fixed maturities, available for sale, changes in fair value of trading securities and certain derivatives and changes in fair value of embedded derivative instruments included in liabilities for insurance products that exist as of the reporting date.

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2017 (dollars in millions):

	Fair value at December 31, 2017		Valuation techniques	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	149.2	Discounted cash flow analysis	Discount margins	1.45% - 71.29% (6.96%)
Corporate securities (b)	2.8		Recovery method	Percent of recovery expected	0% - 21.73% (18.42%)
Asset-backed securities (c)	24.2		Discounted cash flow analysis	Discount margins	1.80% - 3.71% (2.67%)
Equity securities (d)	21.2		Market comparables	EBITDA multiples	1.1X - 8.9X (1.1X)
Other assets categorized as Level 3 (e)	87.2		Unadjusted third-party price source	Not applicable	Not applicable
Total	284.6
Liabilities:
Future policy benefits (f)	1,334.8		Discounted projected embedded derivatives	Projected portfolio yields	5.15% - 5.61% (5.60%)
				Discount rates	0.92 - 2.51% (2.00%)
				Surrender rates	1.20% - 46.40% (12.30%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected.  Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.

(c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before interest, taxes, depreciation and amortization ("EBITDA"). Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements.

(e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

162

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2016 (dollars in millions):

	Fair value at December 31, 2016		Valuation techniques	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	148.5	Discounted cash flow analysis	Discount margins	1.35% - 27.71% (13.52%)
Corporate securities (b)	14.8		Recovery method	Percent of recovery expected	5% - 69% (55%)
Asset-backed securities (c)	24.0		Discounted cash flow analysis	Discount margins	2.06% - 3.64% (2.76%)
Equity securities (d)	25.2		Market comparables	EBITDA multiples	0.4X - 6.2X (5.9X)
Other assets categorized as Level 3 (e)	172.9		Unadjusted third-party price source	Not applicable	Not applicable
Total	385.4
Liabilities:
Future policy benefits (f)	1,092.3		Discounted projected embedded derivatives	Projected portfolio yields	5.15% - 5.61% (5.59%)
				Discount rates	0.18 - 3.06% (2.07%)
				Surrender rates	0.94% - 46.48% (13.52%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.

(c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is EBITDA multiples. Generally, increases (decreases) in EBITDA multiples would result in higher (lower) fair value measurements.

(e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

163

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

5. LIABILITIES FOR INSURANCE PRODUCTS

Our future policy benefits are summarized as follows (dollars in millions):

	Withdrawal assumption	Morbidity assumption	Mortality assumption	Interest rate assumption	2017		2016
Long-term care	Company experience	Company experience	Company experience	6%	$	5,669.0	$	5,346.1
Traditional life insurance contracts	Company experience	Company experience	(a)	5%	2,401.2		2,322.1
Accident and health contracts	Company experience	Company experience	Company experience	5%	2,812.0		2,695.6
Interest-sensitive life insurance contracts	Company experience	Company experience	Company experience	5%	44.9		52.2
Annuities and supplemental contracts with life contingencies	Company experience	Company experience	(b)	4%	594.2		537.3
Total					$	11,521.3	$	10,953.3

____________________

(a) Principally, modifications of: (i) the 1965 ‑ 70 and 1975 - 80 Basic Tables; and (ii) the 1941, 1958 and 1980 Commissioners' Standard Ordinary Tables; as well as Company experience.

(b) Principally, modifications of: (i) the 1971 Individual Annuity Mortality Table; (ii) the 1983 Table "A"; and (iii) the Annuity 2000 Mortality Table; as well as Company experience.

Our policyholder account balances are summarized as follows (dollars in millions):

	2017		2016
Fixed index annuities	$	5,942.2	$	5,324.5
Other annuities	4,183.8		4,541.8
Interest-sensitive life insurance contracts	1,094.7		1,046.4
Total	$	11,220.7	$	10,912.7

The Company establishes reserves for insurance policy benefits based on assumptions as to investment yields, mortality, morbidity, withdrawals, lapses and maintenance expenses. These reserves include amounts for estimated future payment of claims based on actuarial assumptions. The balance includes provision for the Company's best estimate of the future policyholder benefits to be incurred on this business, given recent and expected future changes in experience.

164

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Changes in the unpaid claims reserve (included in claims payable) and disabled life reserves related to accident and health insurance (included in the liability for future policy benefits) were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	1,777.6		$	1,731.8		$	1,679.5
Less reinsurance (receivables) payables	14.0			(130.0		)	(125.0		)
Net balance, beginning of year	1,791.6			1,601.8			1,554.5
Incurred claims related to:
Current year	1,548.1			1,526.4			1,481.0
Prior years (a)	(26.7		)	96.6			(13.3		)
Total incurred	1,521.4			1,623.0			1,467.7
Interest on claim reserves	78.4			75.3			71.0
Paid claims related to:
Current year	845.5			837.2			841.8
Prior years	702.6			671.3			649.6
Total paid	1,548.1			1,508.5			1,491.4
Net balance, end of year	1,843.3			1,791.6			1,601.8
Add reinsurance receivables (payables)	(15.1		)	(14.0		)	130.0
Balance, end of year	$	1,828.2		$	1,777.6		$	1,731.8

___________

(a) The reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. Such amounts will fluctuate based upon the estimation procedures used to determine the amount of unpaid losses. It is possible that actual claims will exceed our reserves and have a material adverse effect on our results of operations and financial condition.

6. INCOME TAXES

The components of income tax expense (benefit) were as follows (dollars in millions):

	2017			2016			2015
Current tax expense (benefit)	$	90.8		$	(45.2	)	$	10.7
Deferred tax expense	72.0			173.0			118.6
Valuation allowance applicable to current year income	(15.3		)	(14.0		)	—
Income tax expense calculated based on annual effective tax rate	147.5			113.8			129.3
Income tax expense on discrete items:
Change in valuation allowance	(13.4		)	40.7			(32.5		)
Impact of federal tax reform	310.6			—			—
Change in valuation allowance related to federal tax reform	(138.1		)	—			—
IRS settlement	—			(170.4		)	—
Other items	(1.7		)	10.9			.2
Total income tax expense (benefit)	$	304.9		$	(5.0	)	$	97.0

The Tax Reform Act makes broad and complex changes to the Code including reducing the federal corporate income tax rate to 21% from 35% effective January 1, 2018. As a result of the reduction in the federal corporate income tax rate, we reduced the value of our net deferred tax assets by $172.5 million (net of the reduction in the valuation allowance for deferred tax assets) which was recorded as additional income tax expense for the year ended December 31, 2017.

165

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The $172.5 million adjustment to our net deferred tax assets is a provisional amount as defined in the SEC's Staff Accounting Bulletin No. 118 ("SAB 118"), issued in December 2017 to address complexities in completing the calculations resulting from the Tax Reform Act. Although we were able to make a reasonable estimate of the impact of the Tax Reform Act based on the information available, we have not analyzed the calculations in sufficient detail to complete the accounting process, including the analysis of the calculations of life insurance tax reserves and future taxable income used to estimate the deferred tax valuation allowance. SAB 118 provides guidance on accounting for the effects of the Tax Reform Act when our accounting process is incomplete but we are able to determine a reasonable estimate. A final determination is required to be made within a measurement period not to extend beyond one year from the enactment date of the Tax Reform Act. We will continue to analyze our estimate of the impact of the Tax Reform Act and expect the process to be completed in the fourth quarter of 2018.

A reconciliation of the U.S. statutory corporate tax rate to the effective rate reflected in the consolidated statement of operations is as follows:

	2017		2016		2015
U.S. statutory corporate rate	35.0	%	35.0	%	35.0	%
Valuation allowance	(6.0	)	7.6		(8.8	)
Non-taxable income and nondeductible benefits, net	(2.0	)	(1.1	)	(.2	)
State taxes	.6		2.2		2.1
Impact of federal tax reform	64.7		—		—
Change in valuation allowance related to federal tax reform	(28.8	)	—		—
Impact of IRS settlement	—		(48.2	)	—
Other items	—		3.1		(1.7	)
Effective tax rate	63.5	%	(1.4	)%	26.4	%

The components of the Company's income tax assets and liabilities are summarized below (dollars in millions):

	2017			2016
Deferred tax assets:
Net federal operating loss carryforwards	$	489.6		$	882.9
Net state operating loss carryforwards	9.3			12.3
Investments	4.3			17.8
Insurance liabilities	415.8			668.4
Other	48.9			66.3
Gross deferred tax assets	967.9			1,647.7
Deferred tax liabilities:
Present value of future profits and deferred acquisition costs	(165.4		)	(277.8		)
Accumulated other comprehensive income	(337.2		)	(344.1		)
Gross deferred tax liabilities	(502.6		)	(621.9		)
Net deferred tax assets before valuation allowance	465.3			1,025.8
Valuation allowance	(89.1		)	(240.2		)
Net deferred tax assets	376.2			785.6
Current income taxes prepaid (accrued)	(9.3		)	4.1
Income tax assets, net	$	366.9		$	789.7

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and NOLs. Deferred tax assets and liabilities are measured using enacted tax

166

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire.

Based on our assessment, it appears more likely than not that $376.2 million of our total deferred tax assets of $465.3 million will be realized through future taxable earnings. Accordingly, we have established a deferred tax valuation allowance of $89.1 million at December 31, 2017 ($77.4 million of which relates to our net federal operating loss carryforwards and $11.7 million relates to state deferred tax assets). We will continue to assess the need for a valuation allowance in the future. If future results are less than projected, an increase to the valuation allowance may be required to reduce the deferred tax asset, which could have a material impact on our results of operations in the period in which it is recorded.

We use a deferred tax valuation model to assess the need for a valuation allowance. Our model is adjusted to reflect changes in our projections of future taxable income including changes resulting from the Tax Reform Act, investment strategies, the impact of the sale or reinsurance of business and the recapture of business previously ceded. Our estimates of future taxable income are based on evidence we consider to be objective and verifiable.

At December 31, 2017, our projection of future taxable income for purposes of determining the valuation allowance is based on our adjusted average annual taxable income which is assumed to increase by 3 percent for the next five years, and level taxable income is assumed thereafter. In the projections used for our analysis, our adjusted average taxable income of approximately $345 million consisted of $85 million of non-life taxable income and $260 million of life taxable income.

Based on our assessment, we recognized a decrease to the allowance for deferred tax assets of $151.1 million in 2017, including the impacts of the Tax Reform Act. We have evaluated the recovery of our deferred tax assets and assessed the effect of limitations and/or interpretations on their value and have concluded that it is more likely than not that the value recognized will be fully realized in the future.

Changes in our valuation allowance are summarized as follows (dollars in millions):

Balance, December 31, 2014	$	246.0
Decrease in 2015	(32.5		)	(a)
Balance, December 31, 2015	213.5
Increase in 2016	26.7			(b)
Balance, December 31, 2016	240.2
Decrease in 2017	(166.8		)	(c)
Cumulative effect of accounting change	15.7			(d)
Balance, December 31, 2017	$	89.1

___________________

(a) The 2015 reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income.

(b) The 2016 increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the Internal Revenue Service (the "IRS").

(c) The 2017 decrease to the deferred tax valuation allowance includes: (i) $138.1 million related to a reduction in the federal corporate income tax rate and other changes from the Tax Reform Act; (ii) $13.4 million of reductions to the deferred tax valuation allowance primarily related to the recognition of capital gains; and (iii) $15.3 million of

167

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

reductions in the deferred tax valuation allowance reflecting higher current year taxable income than previously reflected in our deferred tax valuation model.

(d) Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences. Under the new guidance, any excess tax benefits are recognized as an income tax benefit in the income statement. The new guidance is applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings for all tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable. The Company had NOL carryforwards of $15.7 million related to deductions for stock options and restricted stock on the date of adoption. However, a corresponding valuation allowance of $15.7 million was recognized as a result of adopting this guidance. Therefore, there was no impact to our consolidated financial statements related to the initial adoption of this provision of the new guidance.

Recovery of our deferred tax asset is dependent on achieving the level of future taxable income projected in our deferred tax valuation model and failure to do so could result in an increase in the valuation allowance in a future period.  Any future increase in the valuation allowance may result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future.

The Internal Revenue Code (the "Code") limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of:  (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities).  There is no similar limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities). This limitation is the primary reason a valuation allowance for NOLs is required.

Section 382 of the Code imposes limitations on a corporation's ability to use its NOLs when the company undergoes a 50 percent ownership change over a three year period.  Future transactions and the timing of such transactions could cause an ownership change for Section 382 income tax purposes.  Such transactions may include, but are not limited to, additional repurchases under our securities repurchase program, issuances of common stock and acquisitions or sales of shares of CNO stock by certain holders of our shares, including persons who have held, currently hold or may accumulate in the future, five percent or more of our outstanding common stock for their own account.  Many of these transactions are beyond our control.  If an additional ownership change were to occur for purposes of Section 382, we would be required to calculate an annual restriction on the use of our NOLs to offset future taxable income.  The annual restriction would be calculated based upon the value of CNO's equity at the time of such ownership change, multiplied by a federal long-term tax exempt rate (1.96 percent at December 31, 2017), and the annual restriction could limit our ability to use a substantial portion of our NOLs to offset future taxable income.  We regularly monitor ownership change (as calculated for purposes of Section 382) and, as of December 31, 2017, we were below the 50 percent ownership change level that would trigger further impairment of our ability to utilize our NOLs.

In 2009, the Company's Board of Directors adopted a Section 382 Rights Agreement designed to protect shareholder value by preserving the value of our tax assets primarily associated with tax NOLs under Section 382. The Section 382 Rights Agreement was adopted to reduce the likelihood of an ownership change occurring by deterring the acquisition of stock that would create "5 percent shareholders" as defined in Section 382. The Section 382 Rights Agreement has been amended three times, most recently effective November 13, 2017 (the "Third Amended Section 382 Rights Agreement"). The Third Amended Section 382 Rights Agreement extended the expiration date of the Section 382 Rights Agreement to November 13, 2020, updated the purchase price of the rights described below and provided for a new series of preferred stock relating to the rights that is substantially identical to the prior series of preferred stock. The Company expects to submit the Third Amended Section 382 Rights Agreement to the Company’s stockholders for approval at the Company’s 2018 annual meeting.

Under the Section 382 Rights Agreement, one right was distributed for each share of our common stock outstanding as of the close of business on January 30, 2009 and for each share issued after that date. Pursuant to the Third Amended Section 382 Rights Agreement, if any person or group (subject to certain exemptions) becomes an owner of more than 4.99 percent of the Company's outstanding common stock (or any other interest in the Company that would be treated as "stock" under applicable Section 382 regulations) without the approval of the Board of Directors, there would be a triggering event causing significant dilution in the voting power and economic ownership of that person or group. Shareholders who held more than 4.99 percent of the Company's outstanding common stock as of December 6, 2011 will trigger a dilutive event only if they acquire additional shares exceeding one percent of our outstanding shares without prior approval from the Board of Directors.

168

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

In 2010, our shareholders approved an amendment to CNO's certificate of incorporation designed to prevent certain transfers of common stock which could otherwise adversely affect our ability to use our NOLs (the "Original Section 382 Charter Amendment"). Subject to the provisions set forth in the Original Section 382 Charter Amendment, transfers of our common stock would be void and of no effect if the effect of the purported transfer would be to: (i) increase the direct or indirect ownership of our common stock by any person or public group (as such term is defined in the regulations under Section 382) from less than 5% to 5% or more of our common stock; (ii) increase the percentage of our common stock owned directly or indirectly by a person or public group owning or deemed to own 5% or more of our common stock; or (iii) create a new public group. The Original Section 382 Charter Amendment was amended and extended in 2013 and in 2016 (the "2016 Section 382 Charter Amendment"). The expiration date for the 2016 Section 382 Charter Amendment is July 31, 2019.

As of December 31, 2017, we had $2.3 billion of federal NOLs (all of which were non-life NOLs). The following table summarizes the expiration dates of our loss carryforwards (dollars in millions):

	Net operating loss
Year of expiration	carryforwards
2023	$	1,744.8
2025	85.2
2026	149.9
2027	10.8
2028	80.3
2029	213.2
2030	.3
2031	.2
2032	44.4
2033	.6
2034	.9
2035	.8
Total federal NOLs	$	2,331.4

We also had deferred tax assets related to NOLs for state income taxes of $9.3 million and $12.3 million at December 31, 2017 and 2016, respectively.  The related state NOLs are available to offset future state taxable income in certain states through 2025.

There were no unrecognized tax benefits in 2017. A reconciliation of the beginning and ending amount of unrecognized tax benefits for the year ended December 31, 2016 is as follows (dollars in millions):

	2016
Balance at beginning of year	$	234.2
Increase based on tax positions taken in prior years	3.4
Decrease in unrecognized tax benefits related to settlements with taxing authorities	(237.6		)
Balance at end of year	$	—

In the fourth quarter of 2016, we reached a settlement with the IRS related to two uncertain tax positions: (i) $280.7 million of life NOLs and $130.0 million of non-life NOLs related to the classification of the loss on our investment in Conseco Senior Health Insurance Company when it was transferred to an independent trust in 2008; and (ii) $66.7 million of non-life NOLs related to a bad debt deduction with respect to a stock purchase loan made by our Predecessor to a member of its board

169

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

of directors. The settlement resulted in a reduction to tax expense of approximately $118.7 million in the fourth quarter of 2016 (the period in which these matters were settled and the fully executed documentation was received). The $118.7 million benefit includes: (i) a $98.2 million tax benefit related to additional life NOLs; (ii) a $17.1 million tax benefit related to additional non-life NOLs (net of an increase to the deferred tax valuation allowance of $51.7 million); and (iii) a $3.4 million reduction in interest recognized in prior periods on alternative minimum tax that will no longer be required to be paid.

The additional life NOLs related to the settlement offset our life taxable income in the third and fourth quarters of 2016 and the tax gain realized on the recapture of the ceded long-term care business from BRe. The settlement also reduced the amount of current income tax accrued at December 31, 2016, as presented in the components of income tax assets and liabilities schedule provided in this note to consolidated financial statements by approximately $50 million.

All of the life NOLs were utilized by December 31, 2016. Accordingly, we began making estimated federal tax payments equal to the prescribed federal tax rate applied to 65 percent of our life insurance company taxable income due to the limitations on the extent to which we can use non-life NOLs to offset life insurance company taxable income. Under current law, we will continue to pay tax on 65 percent of our life insurance company taxable income until all non-life NOLs are utilized or expire.

The IRS is also conducting an examination of 2013 through 2014. In connection with this exam, we have agreed to extend the statute of limitations for 2013 through September 30, 2018. The Company’s various state income tax returns are generally open for tax years beginning in 2014, based on individual state statutes of limitation. Generally, for tax years which generate NOLs, capital losses or tax credit carryforwards, the statute remains open until the expiration of the statute of limitations for the tax year in which such carryforwards are utilized. The outcome of tax audits cannot be predicted with certainty. If the Company’s tax audits are not resolved in a manner consistent with management’s expectations, the Company may be required to adjust its provision for income taxes.

7. NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

The following notes payable were direct corporate obligations of the Company as of December 31, 2017 and 2016 (dollars in millions):

	2017			2016
4.500% Senior Notes due May 2020	$	325.0		$	325.0
5.250% Senior Notes due May 2025	500.0			500.0
Revolving Credit Agreement (as defined below)	100.0			100.0
Unamortized debt issuance costs	(10.4		)	(12.1		)
Direct corporate obligations	$	914.6		$	912.9

Notes

On May 19, 2015, the Company executed the Indenture, dated as of May 19, 2015 (the "Base Indenture") and the First Supplemental Indenture, dated as of May 19, 2015 (the "Supplemental Indenture" and, together with the Base Indenture, the "Indenture"), between the Company and Wilmington Trust, National Association, as trustee (the "Trustee") pursuant to which the Company issued $325.0 million aggregate principal amount of 4.500% Senior Notes due 2020 (the "2020 Notes") and $500.0 million aggregate principal amount of 5.250% Senior Notes due 2025 (the "2025 Notes" and, together with the 2020 Notes, the "Notes").

The Company used the proceeds of the offering of the Notes, together with borrowings under the Revolving Credit Agreement (as defined below): (i) to repay all amounts outstanding under our previous senior secured credit agreement; (ii) to redeem and satisfy and discharge all of the outstanding 6.375% Senior Secured Notes due October 2020 (the "6.375% Notes"); and (iii) to pay fees and expenses related to the offering of the Notes and the foregoing transactions. The remaining proceeds of the Notes and the borrowings under the Revolving Credit Agreement were used for general corporate purposes, including share repurchases.

170

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The 2020 Notes mature on May 30, 2020, and the 2025 Notes mature on May 30, 2025. Interest on the 2020 Notes is payable at 4.500% per annum. Interest on the 2025 Notes is payable at 5.250% per annum. Interest on the Notes is payable semi-annually in cash in arrears on May 30 and November 30 of each year, commencing on November 30, 2015.

The Notes are the Company's senior unsecured obligations and rank equally with the Company's other senior unsecured and unsubordinated debt from time to time outstanding, including obligations under the Revolving Credit Agreement (as defined below). The Notes are effectively subordinated to all of the Company's existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness. The Notes are structurally subordinated to all existing and future indebtedness and other liabilities of the Company's subsidiaries.

The Company may redeem some or all of the 2020 Notes at any time or from time to time at a "make-whole" redemption price plus accrued and unpaid interest to, but not including, the redemption date.

Prior to February 28, 2025, the Company may redeem some or all of the 2025 Notes at any time or from time to time at a "make-whole" redemption price plus accrued and unpaid interest to, but not including, the redemption date. On and after February 28, 2025, the Company may redeem some or all of the 2025 Notes at any time or from time to time at a redemption price equal to 100% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date.

Upon the occurrence of a Change of Control Repurchase Event (as defined in the Indenture), the Company will be required to make an offer to repurchase the Notes at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including, the date of repurchase.

The Indenture contains covenants that restrict the Company’s ability, with certain exceptions, to:

• incur certain subsidiary indebtedness without also guaranteeing the Notes;

• create liens;

• enter into sale and leaseback transactions;

• issue, sell, transfer or otherwise dispose of any shares of capital stock of any Insurance Subsidiary (as defined in the Indenture); and

• consolidate or merge with or into other companies or transfer all or substantially all of the Company’s assets.

The Indenture provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, breach of covenants in the Indenture, failure to pay at maturity or acceleration of other indebtedness, a failure to pay certain judgments and certain events of bankruptcy and insolvency. Generally, if an event of default occurs, the Trustee or holders of at least 25% in principal amount of the then outstanding Notes may declare the principal of and accrued but unpaid interest, including any additional interest, on all of the Notes to be due and payable.

Revolving Credit Agreement

On May 19, 2015, the Company entered into a $150.0 millionfour-year unsecured revolving credit agreement with KeyBank National Association, as administrative agent (the "Agent"), and the lenders from time to time party thereto. On May 19, 2015, the Company made an initial drawing of $100.0 million under the Revolving Credit Agreement, resulting in $50.0 million available for additional borrowings. On October 13, 2017, the Company entered into an amendment and restatement agreement (the "Amendment Agreement") with respect to its revolving credit agreement (as amended by the Amendment Agreement, the "Revolving Credit Agreement"). The Amendment Agreement, among other things, increased the total commitments available under the revolving credit facility from $150.0 million to $250.0 million, increased the aggregate amount of additional incremental loans the Company may incur from $50.0 million to $100.0 million and extended the maturity date of the revolving credit facility from May 19, 2019 to the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the 2020 Notes, which is November 30, 2019.

The Revolving Credit Agreement includes an uncommitted subfacility for swingline loans of up to $5.0 million, and up to $5.0 million of the Revolving Credit Agreement is available for the issuance of letters of credit. The Company may incur additional incremental loans under the Revolving Credit Agreement in an aggregate principal amount of up to $100.0 million provided that there are no events of default and subject to certain other terms and conditions including the delivery of certain documentation.

171

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The interest rates with respect to loans under the Revolving Credit Agreement are based on, at the Company's option, a floating base rate (defined as a per annum rate equal to the highest of: (i) the federal funds rate plus 0.50%; (ii) the "prime rate" of the Agent; and (iii) the eurodollar rate for a one-month interest period plus an applicable margin based on the Company's unsecured debt rating), or a eurodollar rate plus an applicable margin based on the Company's unsecured debt rating. The margins under the Revolving Credit Agreement range from 1.375% to 2.125% (1.75% to 2.25% prior to the Amendment Agreement), in the case of loans at the eurodollar rate, and 0.375% to 1.125% (.75% to 1.25% prior to the Amendment Agreement), in the case of loans at the base rate. At December 31, 2017, the interest rate on the amounts outstanding under the Revolving Credit Agreement was 3.44 percent. In addition, the daily average undrawn portion of the Revolving Credit Agreement will accrue a commitment fee payable quarterly in arrears. The applicable margin for, and the commitment fee applicable to, the Revolving Credit Agreement, will be adjusted from time to time pursuant to a ratings based pricing grid. In addition, a fronting fee, in an amount equal to 0.125% per annum on the aggregate face amount of the outstanding letters of credit, will be payable to the issuers of such letters of credit.

The Revolving Credit Agreement contains certain financial, affirmative and negative covenants. The negative covenants in the Revolving Credit Agreement include restrictions that relate to, among other things and subject to customary baskets, exceptions and limitations for facilities of this type:

• subsidiary debt;

• liens;

• restrictive agreements;

• restricted payments during the continuance of an event of default;

• disposition of assets and sale and leaseback transactions;

• transactions with affiliates;

• change in business;

• fundamental changes;

• modification of certain agreements; and

• changes to fiscal year.

The Revolving Credit Agreement requires the Company to maintain (each as calculated in accordance with the Revolving Credit Agreement): (i) a debt to total capitalization ratio of not more than 35.0 percent (30.0 percent prior to the Amendment Agreement) (such ratio was 20.3 percent at December 31, 2017); (ii) an aggregate ratio of total adjusted capital to company action level risk-based capital for the Company's insurance subsidiaries of not less than 250 percent (such ratio was estimated to be 446 percent at December 31, 2017); and (iii) a minimum consolidated net worth of not less than the sum of (x) $2,674 million plus (y) 50.0% of the net equity proceeds received by the Company from the issuance and sale of equity interests in the Company (the Company's consolidated net worth was $3,635.4 million at December 31, 2017 compared to the minimum requirement of $2,684.9 million).

The Revolving Credit Agreement provides for customary events of default (subject in certain cases to customary grace and cure periods), which include, without limitation, the following:

• non-payment;

• breach of representations, warranties or covenants;

• cross-default and cross-acceleration;

• bankruptcy and insolvency events;

• judgment defaults;

• actual or asserted invalidity of documentation with respect to the Revolving Credit Agreement;

• change of control; and

• customary ERISA defaults.

If an event of default under the Revolving Credit Agreement occurs and is continuing, the Agent may accelerate the amounts and terminate all commitments outstanding under the Revolving Credit Agreement.

172

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Loss on Extinguishment of Debt

In 2015, we recognized a loss on extinguishment of debt totaling $32.8 million primarily related to: (i) the redemption premium related to the repayment of the 6.375% Notes; and (ii) the write-off of unamortized discount and issuance costs associated with the repayment of our previous senior secured credit agreement and the 6.375% Notes.

Scheduled Repayment of our Direct Corporate Obligations

The scheduled repayment of our direct corporate obligations was as follows at December 31, 2017 (dollars in millions):

Year ending December 31,
2018	$	—
2019	100.0		(a)
2020	325.0
2021	—
2022	—
Thereafter	500.0
	$	925.0

_________________________

(a) The maturity date of the Revolving Credit Agreement is the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s 4.50% senior notes due 2020, which is November 30, 2019.

8. LITIGATION AND OTHER LEGAL PROCEEDINGS

Legal Proceedings

The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts.  We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred.  The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict.  In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows.  In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies.  Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.

In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters.  The Company reviews these matters on an ongoing basis.  When assessing

173

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.

On September 29, 2016, Washington National and BCLIC commenced an arbitration proceeding seeking compensatory, consequential and punitive damages against BRe based upon BRe’s incurable material breaches of the long-term care reinsurance agreements, conversion, fraud, and breaches of fiduciary duties and the obligation to deal honestly and in good faith. BRe filed a counterclaim against Washington National and BCLIC in the arbitration alleging damages relating to the reinsurance agreements and their termination.  In addition, on September 29, 2016, a complaint was filed by BCLIC and Washington National in the United States District Court for the Southern District of New York, Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Moshe M. Feuer, Scott Taylor and David Levy, Case No. 16-cv-7646, alleging, among other claims, fraud/fraudulent concealment, and violation of the Racketeer Influenced and Corrupt Organizations Act. These allegations relate to the long-term care reinsurance agreements between BRe and Washington National and BCLIC, respectively, and emanate from the undisclosed relationships between and among the defendants (who were the principal owners and officers of BRe) and Platinum Partners, LP and its affiliates. On April 27, 2017, an amended complaint was filed adding Beechwood Capital Group, LLC as a defendant. Feuer, Taylor and Levy have moved to compel arbitration of Washington National's and BCLIC's claims. Washington National and BCLIC intend to vigorously pursue their claims for damages and other remedies in the arbitration and the litigation described above.

By public notice dated July 26, 2017, the Cayman Islands Monetary Authority advised that, effective July 25, 2017, two individuals (the "Controllers") had been appointed pursuant to Section 24(2)(h) of the Cayman Islands Insurance Law to assume control of the affairs of BRe.  According to the public notice, effective with their appointment, the Controllers assumed immediate control of the affairs of BRe and have all the powers necessary to administer the affairs of BRe including power to terminate its insurance business.  The Controllers are responsible for assessing the financial position of BRe and submitting a report to the Cayman Islands Monetary Authority by a date to be specified.  We are in the process of assessing the potential impact of this action on the proceedings described in the foregoing paragraph.

On July 20, 2007, a complaint was filed in the Hamilton County, Indiana Circuit Court, Signature Estates of Indiana, Inc. d/b/a Gordon Marketing, Stephens-Matthews Marketing, Inc., Shields Brokerage, Inc. and Edwin A. Hildebrand d/b/a Hildebrand Insurance Services v. Conseco Medical Insurance Company, Conseco Medical Insurance Company a/k/a Washington National Insurance Company and Washington National Insurance Company, Cause No. 29D02- 0707-PL-790.  The Plaintiffs are independent insurance marketing organizations which previously marketed Conseco Medical Insurance Company ("CMIC") individual major medical products and which are claiming damages for allegedly fraudulent conduct by CMIC in withdrawing from this business in 2002.  The Plaintiffs contend that they relied on CMIC’s alleged representations that its major medical business was profitable and that CMIC was committed to it.  The Plaintiffs further allege that when CMIC exited the market, it caused agents that were previously writing business through their organizations to cease doing business with them, thereby causing irreparable damage.  CMIC merged into Washington National, effective July 1, 2003.  On December 16, 2016, following a jury trial, verdicts were entered in favor of the plaintiffs, and compensatory damages aggregating $4.7 million and punitive damages aggregating $6.0 million were awarded to the plaintiffs.  Washington National filed post-trial motions requesting the court correct errors, grant a new trial, find that punitive damages were improper, and reduce both compensatory and punitive damages.  Plaintiffs filed motions requesting pre-judgment interest and attorney fees. On June 19, 2017, the court reduced punitive damages by $1.5 million and denied plaintiffs' motions for pre-judgment interest and attorney fees. Each side appealed the decision and the case was subsequently settled.

Regulatory Examinations and Fines

Insurance companies face significant risks related to regulatory investigations and actions.  Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers.  We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities.  The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty.  In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.

174

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

In August 2011, we were notified of an examination to be done on behalf of a number of states for the purpose of determining compliance with unclaimed property laws by the Company and its subsidiaries.  Such examination has included inquiries related to the use of data available on the U.S. Social Security Administration's Death Master File to identify instances where benefits under life insurance policies, annuities and retained asset accounts are payable. We are continuing to provide information to the examiners in response to their requests. A total of 38 states and the District of Columbia are currently participating in this examination.

Guaranty Fund Assessments

The balance sheet at December 31, 2017, included: (i) accruals of $14.1 million, representing our estimate of all known assessments that will be levied against the Company's insurance subsidiaries by various state guaranty associations based on premiums written through December 31, 2017; and (ii) receivables of $20.0 million that we estimate will be recovered through a reduction in future premium taxes as a result of such assessments. At December 31, 2016, such guaranty fund assessment accruals were $24.9 million and such receivables were $26.7 million. These estimates are subject to change when the associations determine more precisely the losses that have occurred and how such losses will be allocated among the insurance companies. We recognized expense for such assessments of $11.0 million, $2.8 million and $1.2 million in 2017, 2016 and 2015, respectively.

Guarantees

In accordance with the terms of the employment agreements of two of the Company's former chief executive officers, certain wholly-owned subsidiaries of the Company are the guarantors of the former executives' nonqualified supplemental retirement benefits. The liability for such benefits was $24.2 million and $25.0 million at December 31, 2017 and 2016, respectively, and is included in the caption "Other liabilities" in the consolidated balance sheet.

Leases and Certain Other Long-Term Commitments

The Company rents office space, equipment and computer software under noncancellable operating lease agreements. In addition, the Company has entered into certain sponsorship agreements which require future payments. Total expense pursuant to these lease and sponsorship agreements was $61.4 million, $56.8 million and $48.8 million in 2017, 2016 and 2015, respectively. Future required minimum payments as of December 31, 2017, were as follows (dollars in millions):

2018	$	33.5
2019	18.2
2020	11.8
2021	8.0
2022	5.6
Thereafter	3.6
Total	$	80.7

9. AGENT DEFERRED COMPENSATION PLAN

For our agent deferred compensation plan, it is our policy to immediately recognize changes in the actuarial benefit obligation resulting from either actual experience being different than expected or from changes in actuarial assumptions.

One of our insurance subsidiaries has a noncontributory, unfunded deferred compensation plan for qualifying members of its career agency force. Benefits are based on years of service and career earnings. In 2016, the agent deferred compensation plan was amended to: (i) freeze participation in the plan; (ii) freeze benefits accrued under the plan; and (iii) add a limited cashout feature. During the third quarter of 2016, we made lump sum settlement distributions to plan participants with account balances that were below a certain threshold consistent with the provision of the amended plan. We recognized a pre-tax gain of $6.1 million related to the settlement distributions in the third quarter of 2016.

175

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The actuarial measurement date of this deferred compensation plan is December 31. The liability recognized in the consolidated balance sheet for the agent deferred compensation plan was $168.2 million and $156.3 million at December 31, 2017 and 2016, respectively. Expenses incurred on this plan were $18.8 million, $8.1 million and $2.2 million during 2017, 2016 and 2015, respectively (including the recognition of gains (losses) of $(12.2) million, $3.1 million and $15.2 million in 2017, 2016 and 2015, respectively, primarily resulting from: (i) changes in the discount rate assumption used to determine the deferred compensation plan liability to reflect current investment yields; (ii) changes in mortality table assumptions; and (iii) the aforementioned settlement distributions in 2016). We purchased COLI as an investment vehicle to fund the agent deferred compensation plan. The COLI assets are not assets of the agent deferred compensation plan, and as a result, are accounted for outside the plan and are recorded in the consolidated balance sheet as other invested assets. The carrying value of the COLI assets was $182.3 million and $165.0 million at December 31, 2017 and 2016, respectively. Death benefits related to the COLI and changes in the cash surrender value (which approximates net realizable value) of the COLI assets are recorded as net investment income on special-purpose portfolios and totaled $24.6 million, $6.9 million and $.5 million in 2017, 2016 and 2015, respectively.

We used the following assumptions for the deferred compensation plan to calculate:

	2017		2016
Benefit obligations:
Discount rate	3.75	%	4.25	%
Net periodic cost:
Discount rate	4.25	%	4.50	%

The discount rate is based on the yield of a hypothetical portfolio of high quality debt instruments which could effectively settle plan benefits on a present value basis as of the measurement date.

The benefits expected to be paid pursuant to our agent deferred compensation plan as of December 31, 2017 were as follows (dollars in millions):

2018	$	7.4
2019	7.6
2020	7.9
2021	8.0
2022	8.3
2023 - 2027	45.2

One of our insurance subsidiaries has another unfunded nonqualified deferred compensation program for qualifying members of its career agency force. Such agents may defer a certain percentage of their net commissions into the program. In addition, annual Company contributions are made based on the agent's production and vest over a period of five to 10 years. The liability recognized in the consolidated balance sheet for this program was $22.9 million and $11.2 million at December 31, 2017 and 2016, respectively. Company contribution expense totaled $6.6 million and $4.4 million in 2017 and 2016, respectively. We purchased Trust-Owned Life Insurance ("TOLI") as an investment vehicle to fund the program. The TOLI assets are not assets of the program, and as a result, are accounted for outside the program and are recorded in the consolidated balance sheet as other invested assets. The carrying value of the TOLI assets was $18.0 million and $5.1 million at December 31, 2017 and 2016, respectively.

The Company has a qualified defined contribution plan for which substantially all employees are eligible. Company contributions, which match a portion of certain voluntary employee contributions to the plan, totaled $5.5 million, $5.3 million and $5.0 million in 2017, 2016 and 2015, respectively. Employer matching contributions are discretionary.

176

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

10. DERIVATIVES

Our freestanding and embedded derivatives, which are not designated as hedging instruments, are held at fair value and are summarized as follows (dollars in millions):

	Fair value
	2017			2016
Assets:
Other invested assets:
Fixed index call options	$	170.2		$	111.9
Reinsurance receivables	(1.4		)	(4.2		)
Total assets	$	168.8		$	107.7
Liabilities:
Future policy benefits:
Fixed index products	$	1,334.8		$	1,092.3
Total liabilities	$	1,334.8		$	1,092.3

The activity associated with freestanding derivative instruments is measured as either the notional or the number of contracts. The activity associated with the fixed index annuity embedded derivatives are shown by the number of policies. The following table represents activity associated with derivative instruments as of the dates indicated:

	Measurement	December 31, 2016		Additions		Maturities/terminations			December 31, 2017
Fixed index annuities - embedded derivative	Policies	100,812		11,437		(7,560		)	104,689
Fixed index call options	Notional (a)	$	2,455.1	$	3,021.8	$	(2,471.1	)	$	3,005.8

_________________

(a) Dollars in millions.

We are required to establish an embedded derivative related to a modified coinsurance agreement pursuant to which we assume the risks of a block of health insurance business. The embedded derivative represents the mark-to-market adjustment for approximately $126 million in underlying investments held by the ceding reinsurer.

177

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table provides the pre-tax gains (losses) recognized in net income for derivative instruments, which are not designated as hedges for the periods indicated (dollars in millions):

	2017		2016			2015
Net investment income from policyholder and other special-purpose portfolios:
Fixed index call options	$	162.5	$	29.2		$	(36.2	)
Net realized gains (losses):
Interest rate futures	—		(1.1		)	(2.7		)
Embedded derivative related to modified coinsurance agreement	2.8		.8			(7.0		)
Total	2.8		(.3		)	(9.7		)
Insurance policy benefits:
Embedded derivative related to fixed index annuities	25.0		60.8			36.3
Total	$	190.3	$	89.7		$	(9.6	)

Derivative Counterparty Risk

If the counterparties to the call options fail to meet their obligations, we may recognize a loss.  We limit our exposure to such a loss by diversifying among several counterparties believed to be strong and creditworthy.  At December 31, 2017, all of our counterparties were rated "A-" or higher by S&P.

From time to time, we enter into exchange-traded interest rate future contracts. The contracts are marked to market and margined on a daily basis. The Company has minimal exposure to credit-related losses in the event of nonperformance.

The Company and its subsidiaries are parties to master netting arrangements with its counterparties related to entering into various derivative contracts. Exchange-traded derivatives require margin accounts which we offset.

The following table summarizes information related to derivatives with master netting arrangements or collateral as of December 31, 2017 and 2016 (dollars in millions):

								Gross amounts not offset in the balance sheet
		Gross amounts recognized		Gross amounts offset in the balance sheet		Net amounts of assets presented in the balance sheet		Financial instruments		Cash collateral received		Net amount
December 31, 2017:
	Fixed index call options	$	170.2	$	—	$	170.2	$	—	$	—	$	170.2
December 31, 2016:
	Fixed index call options	111.9		—		111.9		—		—		111.9

178

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

11. SHAREHOLDERS' EQUITY

Changes in the number of shares of common stock outstanding were as follows (shares in thousands):

	2017		2016		2015
Balance, beginning of year	173,754		184,029		203,324
Treasury stock purchased and retired	(7,808	)	(11,688	)	(20,582	)
Stock options exercised	725		978		769
Restricted and performance stock vested (a)	187		435		518
Balance, end of year	166,858		173,754		184,029

____________________

(a) In 2017, 2016 and 2015, such amount was reduced by 103 thousand, 191 thousand and 237 thousand shares, respectively, which were tendered to the Company for the payment of required federal and state tax withholdings owed on the vesting of restricted and performance stock.

In May 2011, the Company announced a securities repurchase program of up to $100.0 million. In February 2012, June 2012, December 2012, December 2013, November 2014, November 2015 and May 2017, the Company's Board of Directors approved, in aggregate, an additional $1,900.0 million to repurchase the Company's outstanding securities. In 2017, 2016 and 2015, we repurchased 7.8 million, 11.7 million and 20.6 million shares, respectively, for $167.1 million, $203.0 million and $365.2 million, respectively, under the securities repurchase program. The Company had remaining repurchase authority of $385.6 million as of December 31, 2017.

In 2017, 2016 and 2015, dividends declared and paid on common stock totaled $59.6 million ($0.35 per common share), $54.8 million ($0.31 per common share) and $52.0 million ($0.27 per common share), respectively. In May 2017, the Company increased its quarterly common stock dividend to $0.09 per share from $0.08 per share. In May 2016, the Company increased its quarterly common stock dividend to $0.08 per share from $0.07 per share. In May 2015, the Company increased its quarterly common stock dividend to $0.07 per share from $0.06 per share.

The Company has a long-term incentive plan which permits the grant of CNO incentive or non-qualified stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance shares or units and certain other equity-based awards to certain directors, officers and employees of the Company and certain other individuals who perform services for the Company. As of December 31, 2017, 7.5 million shares remained available for issuance under the plan. Our stock option awards are generally granted with an exercise price equal to the market price of the Company's stock on the date of grant and a maximum term of ten years. Our stock option awards granted in 2007 through 2009 generally vested on a graded basis over a three year service term and expired five years from the date of grant. Our stock options granted in 2010 through 2014 generally vest on a graded basis over a three year service term and expire seven years from the date of grant. Our stock options granted in 2015, 2016 and 2017 generally vest on a graded basis over a three year service term and expire ten years from the date of grant. The vesting periods for our awards of restricted stock and restricted stock units (collectively "restricted stock") range from immediate vesting to a period of three years.

179

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

A summary of the Company's stock option activity and related information for 2017 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,354		$	14.73
Options granted	729		21.06
Exercised	(237	)	(17.81		)		$	5.2
Forfeited or terminated	(725	)	(11.43		)
Outstanding at the end of the year	5,121		15.95			5.4	$	37.2
Options exercisable at the end of the year	2,440					3.0	$	19.2
Available for future grant	7,488

A summary of the Company's stock option activity and related information for 2016 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,199		$	13.32
Options granted	1,706		17.45
Exercised	(978	)	(8.70		)		$	6.1
Forfeited or terminated	(573	)	(20.41		)
Outstanding at the end of the year	5,354		14.73			5.9	$	37.1
Options exercisable at the end of the year	2,187					2.7	$	15.1
Available for future grant	4,620

180

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

A summary of the Company's stock option activity and related information for 2015 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,011		$	12.04
Options granted	1,361		16.45
Exercised	(769	)	(8.20		)		$	4.8
Forfeited or terminated	(404	)	(17.70		)
Outstanding at the end of the year	5,199		13.32			4.8	$	38.4
Options exercisable at the end of the year	2,399					2.5	$	15.3
Available for future grant	6,882

We recognized compensation expense related to stock options totaling $6.3 million ($4.1 million after income taxes) in 2017, $12.2 million ($7.9 million after income taxes) in 2016 and $9.6 million ($6.2 million after income taxes) in 2015. Compensation expense related to stock options reduced both basic and diluted earnings per share by two cents in 2017, four cents in 2016 and three cents in 2015. At December 31, 2017, the unrecognized compensation expense for non-vested stock options totaled $4.2 million which is expected to be recognized over a weighted average period of 1.5 years. Cash received by the Company from the exercise of stock options was $8.3 million, $8.4 million and $6.3 million during 2017, 2016 and 2015, respectively.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions:

	2017			2016			2015
	Grants			Grants			Grants
Weighted average risk-free interest rates	2.2		%	1.4		%	1.7		%
Weighted average dividend yields	1.5		%	1.6		%	1.5		%
Volatility factors	32		%	36		%	85		%
Weighted average expected life (in years)	6.3			6.3			6.3
Weighted average fair value per share	$	6.20		$	5.48		$	10.83

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on the Company's history and expectation of dividend payouts. Volatility factors are based on the weekly historical volatility of the Company's common stock equal to the expected life of the option. The expected life is based on the average of the graded vesting period and the contractual terms of the option.

The exercise price was equal to the market price of our stock on the date of grant for all options granted in 2017, 2016 and 2015.

181

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table summarizes information about stock options outstanding at December 31, 2017 (shares in thousands):

		Options outstanding			Options exercisable
Range of exercise prices	Number outstanding	Remaining life (in years)	Average exercise price		Number exercisable	Average exercise price
$6.77 - $7.51	605	0.9	$	7.47	605	$	7.47
$10.88 - $16.22	683	2.3	11.12		670	11.02
$16.42 - $21.48	3,833	6.7	18.15		1,165	18.04
	5,121				2,440

During 2017, 2016 and 2015, the Company granted restricted stock of .3 million, .4 million and .1 million, respectively, to certain directors, officers and employees of the Company at a weighted average fair value of $20.87 per share, $18.17 per share and $17.59 per share, respectively. The fair value of such grants totaled $6.9 million, $7.3 million and $1.7 million in 2017, 2016 and 2015, respectively. Such amounts are recognized as compensation expense over the vesting period of the restricted stock. A summary of the Company's non-vested restricted stock activity for 2017 is presented below (shares in thousands):

	Shares		Weighted average grant date fair value
Non-vested shares, beginning of year	369		$	18.10
Granted	330		20.87
Vested	(147	)	(18.38		)
Forfeited	(17	)	(20.59		)
Non-vested shares, end of year	535		19.65

At December 31, 2017, the unrecognized compensation expense for non-vested restricted stock totaled $5.5 million which is expected to be recognized over a weighted average period of 1.8 years. At December 31, 2016, the unrecognized compensation expense for non-vested restricted stock totaled $5.0 million. We recognized compensation expense related to restricted stock awards totaling $6.1 million, $3.1 million and $2.2 million in 2017, 2016 and 2015, respectively. The fair value of restricted stock that vested during 2017, 2016 and 2015 was $2.7 million, $2.1 million and $2.7 million, respectively.

Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the accounting policy for forfeiture rate assumptions. Under the new guidance, we elected to account for forfeitures as they occur. The impact of adoption of this provision of the guidance increased additional paid-in capital by $.9 million, decreased retained earnings by $.6 million and increased income tax assets by $.3 million. Prior to 2017, authoritative guidance required us to estimate the amount of unvested stock-based awards that would be forfeited in future periods and reduce the amount of compensation expense recognized over the applicable service period to reflect such estimate.

In 2017, 2016 and 2015 the Company granted performance units totaling 452,900, 507,976 and 516,660, respectively, pursuant to its long-term incentive plan to certain officers of the Company. The criteria for payment for such awards are based on certain company-wide performance levels that must be achieved within a specified performance time (generally three years), each as defined in the award. The performance units granted in 2017, 2016 and 2015 provide for a payout of up to 200 percent of the award if certain performance thresholds are achieved, and the performance units granted prior to 2015 provide for a payout of up to 150 percent of the award if certain performance thresholds are achieved. Unless antidilutive, the diluted weighted average shares outstanding would reflect the number of performance units expected to be issued, using the treasury stock method.

182

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

A summary of the Company's performance units is presented below (shares in thousands):

	Total shareholder return awards		Operating return on equity awards		Pre-tax operating income awards
Awards outstanding at December 31, 2014	519		343		176
Granted in 2015	258		258		—
Additional shares issued pursuant to achieving certain performance criteria (a)	85		—		85
Shares vested in 2015	(260	)	—		(260	)
Forfeited	(53	)	(52	)	(1	)
Awards outstanding at December 31, 2015	549		549		—
Granted in 2016	254		254		—
Additional shares issued pursuant to achieving certain performance criteria (a)	87		65		—
Shares vested in 2016	(261	)	(239	)	—
Forfeited	(59	)	(59	)	—
Awards outstanding at December 31, 2016	570		570		—
Granted in 2017	226		226		—
Additional shares issued pursuant to achieving certain performance criteria (a)	—		30		—
Shares vested in 2017	—		(144	)	—
Forfeited	(167	)	(53	)	—
Awards outstanding at December 31, 2017	629		629		—

_________________________

(a) The performance units that vested in these years provided for a payout of up to 150 percent of the award if certain performance levels were achieved.

The grant date fair value of the performance units awarded was $11.2 million and $10.3 million in 2017 and 2016, respectively. We recognized compensation expense of $9.0 million, $7.7 million and $5.3 million in 2017, 2016 and 2015, respectively, related to the performance units.

As further discussed in the footnote to the consolidated financial statements entitled "Income Taxes", the Company's Board of Directors adopted the Section 382 Rights Agreement in 2009 and has amended and extended the Section 382 Rights Agreement on three occasions. The Section 382 Rights Agreement, as amended, is designed to protect shareholder value by preserving the value of our tax assets primarily associated with NOLs. At the time the Section 382 Rights Agreement was adopted, the Company declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of common stock. The dividend was payable on January 30, 2009, to the shareholders of record as of the close of business on that date and a Right is also attached to each share of CNO common stock issued after that date. Pursuant to the Section 382 Rights Agreement, as amended, each Right entitles the shareholder to purchase from the Company one one-thousandth of a share of Series D Junior Participating Preferred Stock, par value $.01 per share (the "Junior Preferred Stock") of the Company at a price of $90.00 per one one-thousandth of a share of Junior Preferred Stock. The description and terms of the Rights are set forth in the Section 382 Rights Agreement, as amended. The Rights would become exercisable in the event any person or group (subject to certain exemptions) becomes an owner of more than 4.99 percent of the outstanding stock of CNO (a "Threshold Holder") without the approval of the Board of Directors or an existing shareholder who is currently a Threshold Holder acquires additional shares exceeding one percent of our outstanding shares without prior approval from the Board of Directors.

183

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

A reconciliation of net income and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands):

	2017		2016		2015
Net income for diluted earnings per share	$	175.6	$	358.2	$	270.7
Shares:
Weighted average shares outstanding for basic earnings per share	170,025		176,638		193,054
Effect of dilutive securities on weighted average shares:
Stock options, restricted stock and performance units	2,119		1,685		2,112
Weighted average shares outstanding for diluted earnings per share	172,144		178,323		195,166

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding for the period.  Restricted shares (including our performance units) are not included in basic earnings per share until vested.  Diluted earnings per share reflect the potential dilution that could occur if outstanding stock options were exercised and restricted stock was vested.  The dilution from options and restricted shares is calculated using the treasury stock method.  Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the average market price during the period, reducing the dilutive effect of the exercise of the options (or the vesting of the restricted stock and performance units).

184

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

12. OTHER OPERATING STATEMENT DATA

Insurance policy income consisted of the following (dollars in millions):

	2017			2016			2015
Direct premiums collected	$	4,013.4		$	3,942.7		$	3,769.6
Reinsurance assumed	30.2			33.8			38.4
Reinsurance ceded	(114.4		)	(132.9		)	(142.8		)
Premiums collected, net of reinsurance	3,929.2			3,843.6			3,665.2
Change in unearned premiums	19.0			6.2			5.9
Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities	(1,445.9		)	(1,386.7		)	(1,241.9		)
Premiums on traditional products with mortality or morbidity risk	2,502.3			2,463.1			2,429.2
Fees and surrender charges on interest-sensitive products	145.0			138.0			126.8
Insurance policy income	$	2,647.3		$	2,601.1		$	2,556.0

The four states with the largest shares of 2017 collected premiums were Florida (10 percent), Pennsylvania (6 percent), Texas (6 percent) and California (5 percent). No other state accounted for more than five percent of total collected premiums.

Other operating costs and expenses were as follows (dollars in millions):

	2017		2016		2015
Commission expense	$	115.6	$	110.5	$	103.8
Salaries and wages	237.3		231.0		205.2
Other	488.6		454.8		430.2
Total other operating costs and expenses	$	841.5	$	796.3	$	739.2

Changes in the present value of future profits were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	401.8		$	449.0		$	489.4
Amortization	(54.4		)	(62.2		)	(69.1		)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	12.2			15.0			28.7
Balance, end of year	$	359.6		$	401.8		$	449.0

Based on current conditions and assumptions as to future events on all policies inforce, the Company expects to amortize approximately 11 percent of the December 31, 2017 balance of the present value of future profits in 2018, 10 percent in 2019, 9 percent in 2020, 7 percent in 2021 and 7 percent in 2022. The discount rate used to determine the amortization of the present value of future profits averaged approximately 5 percent in the years ended December 31, 2017, 2016 and 2015.

In accordance with authoritative guidance, we are required to amortize the present value of future profits in relation to estimated gross profits for interest-sensitive life products and annuity products. Such guidance also requires that estimates of expected gross profits used as a basis for amortization be evaluated regularly, and that the total amortization recorded to date be adjusted by a charge or credit to the statement of operations, if actual experience or other evidence suggests that earlier estimates should be revised.

185

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Changes in deferred acquisition costs were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	1,044.7		$	1,083.3		$	770.6
Additions	236.1			242.7			246.4
Amortization	(184.9		)	(191.1		)	(190.9		)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	(69.1		)	(90.2		)	257.2
Balance, end of year	$	1,026.8		$	1,044.7		$	1,083.3

13. CONSOLIDATED STATEMENT OF CASH FLOWS

The following disclosures supplement our consolidated statement of cash flows.

The following reconciles net income to net cash provided by operating activities (dollars in millions):

	2017			2016			2015
Cash flows from operating activities:
Net income	$	175.6		$	358.2		$	270.7
Adjustments to reconcile net income to net cash from operating activities:
Amortization and depreciation	265.4			275.0			283.4
Income taxes	227.5			(11.7		)	92.9
Insurance liabilities	464.7			332.8			297.4
Accrual and amortization of investment income	(321.6		)	(124.2		)	(27.6		)
Deferral of policy acquisition costs	(236.1		)	(242.7		)	(246.4		)
Net realized investment (gains) losses	(50.3		)	(8.3		)	36.6
Loss on reinsurance transactions and transition expenses	—			75.4			9.0
Cash and cash equivalents received upon recapture of reinsurance	—			73.6			—
Loss on extinguishment of borrowings related to variable interest entities	9.5			—			—
Loss on extinguishment of debt	—			—			32.8
Other	78.4			34.7			(1.0		)
Net cash from operating activities	$	613.1		$	762.8		$	747.8

Other non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions):

	2017		2016		2015
Stock options, restricted stock and performance units	$	21.4	$	23.0	$	17.1
Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe	—		431.1		—

186

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

14. STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES)

Statutory accounting practices prescribed or permitted by regulatory authorities for the Company's insurance subsidiaries differ from GAAP. The Company's insurance subsidiaries reported the following amounts to regulatory agencies, after appropriate elimination of intercompany accounts among such subsidiaries (dollars in millions):

	2017		2016
Statutory capital and surplus	$	1,904.4	$	1,956.8
Asset valuation reserve	246.8		253.3
Interest maintenance reserve	487.0		486.9
Total	$	2,638.2	$	2,697.0

Statutory capital and surplus included investments in upstream affiliates of $42.6 million at both December 31, 2017 and 2016, which were eliminated in the consolidated financial statements prepared in accordance with GAAP.

Statutory earnings build the capital required by ratings agencies and regulators. Statutory earnings, fees and interest paid by the insurance companies to the parent company create the "cash flow capacity" the parent company needs to meet its obligations, including debt service. The consolidated statutory net income (a non-GAAP measure) of our insurance subsidiaries was $352.3 million, $256.6 million (including approximately $110 million loss on the recapture of long-term care business) and $332.6 million in 2017, 2016 and 2015, respectively. Included in such net income were net realized capital losses, net of income taxes, of $9.9 million, $29.7 million and $18.0 million in 2017, 2016 and 2015, respectively. In addition, such net income included pre-tax amounts for fees and interest paid to CNO or its non-life subsidiaries totaling $158.3 million, $153.9 million and $154.2 million in 2017, 2016 and 2015, respectively.

Insurance regulators may prohibit the payment of dividends or other payments by our insurance subsidiaries to parent companies if they determine that such payment could be adverse to our policyholders or contract holders. Otherwise, the ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations. Insurance regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in some states, the lesser of): (i) statutory net gain from operations or statutory net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. However, as each of the immediate insurance subsidiaries of CDOC, Inc. ("CDOC", our wholly owned subsidiary and the immediate parent of Washington National and Conseco Life Insurance Company of Texas) has negative earned surplus, any dividend payments from the insurance subsidiaries to CNO requires the prior approval of the director or commissioner of the applicable state insurance department. During 2017, our insurance subsidiaries paid dividends of $357.7 million to CDOC.

The payment of interest on surplus debentures requires either prior written notice or approval of the director or commissioner of the applicable state insurance department. Dividends and other payments from our non-insurance subsidiaries to CNO or CDOC do not require approval by any regulatory authority or other third party.

In accordance with an order from the Florida Office of Insurance Regulation, Washington National may not distribute funds to any affiliate or shareholder, except pursuant to agreements that have been approved, without prior notice to the Florida Office of Insurance Regulation. In addition, the risk-based capital ("RBC") and other capital requirements described below can also limit, in certain circumstances, the ability of our insurance subsidiaries to pay dividends.

RBC requirements provide a tool for insurance regulators to determine the levels of statutory capital and surplus an insurer must maintain in relation to its insurance and investment risks and the need for possible regulatory attention. The RBC requirements provide four levels of regulatory attention, varying with the ratio of the insurance company's total adjusted capital (defined as the total of its statutory capital and surplus, asset valuation reserve and certain other adjustments) to its RBC (as measured on December 31 of each year) as follows: (i) if a company's total adjusted capital is less than 100 percent but greater than or equal to 75 percent of its RBC, the company must submit a comprehensive plan to the regulatory authority proposing corrective actions aimed at improving its capital position (the "Company Action Level"); (ii) if a company's total adjusted capital is less than 75 percent but greater than or equal to 50 percent of its RBC, the regulatory authority will perform a special examination of the company and issue an order specifying the corrective actions that must be taken; (iii) if a company's total adjusted capital is less than 50 percent but greater than or equal to 35 percent of its RBC, the regulatory authority may take any

187

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

action it deems necessary, including placing the company under regulatory control; and (iv) if a company's total adjusted capital is less than 35 percent of its RBC, the regulatory authority must place the company under its control. In addition, the RBC requirements provide for a trend test if a company's total adjusted capital is between 100 percent and 150 percent of its RBC at the end of the year. The trend test calculates the greater of the decrease in the margin of total adjusted capital over RBC: (i) between the current year and the prior year; and (ii) for the average of the last 3 years. It assumes that such decrease could occur again in the coming year. Any company whose trended total adjusted capital is less than 95 percent of its RBC would trigger a requirement to submit a comprehensive plan as described above for the Company Action Level. The 2017 statutory annual statements of each of our insurance subsidiaries reflect total adjusted capital in excess of the levels subjecting the subsidiaries to any regulatory action.

In addition, although we are under no obligation to do so, we may elect to contribute additional capital or retain greater amounts of capital to strengthen the surplus of certain insurance subsidiaries. Any election to contribute or retain additional capital could impact the amounts our insurance subsidiaries pay as dividends to the holding company. The ability of our insurance subsidiaries to pay dividends is also impacted by various criteria established by rating agencies to maintain or receive higher ratings and by the capital levels that we target for our insurance subsidiaries.

At December 31, 2017, the consolidated RBC ratio of our insurance subsidiaries exceeded the minimum RBC requirement included in our Revolving Credit Agreement. See the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for further discussion of various financial ratios and balances we are required to maintain. We calculate the consolidated RBC ratio by assuming all of the assets, liabilities, capital and surplus and other aspects of the business of our insurance subsidiaries are combined together in one insurance subsidiary, with appropriate intercompany eliminations.

15. BUSINESS SEGMENTS

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting the long-term care block recaptured from BRe effective September 30, 2016, as an additional business segment.

We measure segment performance by excluding the loss on reinsurance transaction and transition expenses, net realized investment gains (losses), fair value changes in embedded derivative liabilities (net of related amortization), fair value changes and amendment in the agent deferred compensation plan, loss on extinguishment of debt, income taxes and other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to VIEs ("pre-tax operating earnings") because we believe that this performance measure is a better indicator of the ongoing business and trends in our business.  Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of net realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business.

The loss on reinsurance transaction and transition expenses, net realized investment gains (losses), fair value changes in embedded derivative liabilities (net of related amortization), fair value changes and amendment in the agent deferred compensation plan, loss on extinguishment of debt and other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to VIEs depend on market conditions or represent unusual items that do not necessarily relate to the underlying business of our segments.  Net realized investment gains (losses) and fair value changes in embedded derivative liabilities (net of related amortization) may affect future earnings levels since our underlying business is long-term in nature and changes in our investment portfolio may impact our ability to earn the assumed interest rates needed to maintain the profitability of our business.

188

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Operating information by segment was as follows (dollars in millions):

	2017		2016		2015
Revenues:
Bankers Life:
Insurance policy income:
Annuities	$	20.3	$	22.0	$	22.4
Health	1,231.1		1,244.1		1,251.0
Life	415.2		393.0		375.3
Net investment income (a)	1,107.3		936.8		884.7
Fee revenue and other income (a)	44.1		34.4		27.7
Total Bankers Life revenues	2,818.0		2,630.3		2,561.1
Washington National:
Insurance policy income:
Annuities	2.1		2.9		3.0
Health	642.9		627.9		615.4
Life	26.4		25.0		25.4
Net investment income (a)	270.2		259.3		253.6
Fee revenue and other income (a)	1.0		1.3		1.3
Total Washington National revenues	942.6		916.4		898.7
Colonial Penn:
Insurance policy income:
Health	2.1		2.6		3.0
Life	289.7		278.8		260.5
Net investment income (a)	44.4		44.2		43.0
Fee revenue and other income (a)	1.3		1.1		1.0
Total Colonial Penn revenues	337.5		326.7		307.5
Long-term care in run-off:
Insurance policy income - health	17.5		4.8		—
Net investment income (a)	34.6		9.4		—
Total Long-term care in run-off revenues	52.1		14.2		—
Corporate operations:
Net investment income	35.5		16.6		11.3
Fee revenue and other income	8.5		10.0		8.6
Total corporate revenues	44.0		26.6		19.9
Total revenues	$	4,194.2	$	3,914.2	$	3,787.2

(continued on next page)

189

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

(continued from previous page)

	2017			2016			2015
Expenses:
Bankers Life:
Insurance policy benefits	$	1,771.8		$	1,620.6		$	1,588.4
Amortization	163.6			176.5			187.1
Interest expense on investment borrowings	19.8			13.2			8.8
Other operating costs and expenses	443.9			422.1			407.2
Total Bankers Life expenses	2,399.1			2,232.4			2,191.5
Washington National:
Insurance policy benefits	581.1			561.7			546.6
Amortization	58.8			59.1			55.2
Interest expense on investment borrowings	6.3			3.7			2.0
Other operating costs and expenses	198.1			189.0			183.4
Total Washington National expenses	844.3			813.5			787.2
Colonial Penn:
Insurance policy benefits	199.6			201.9			189.0
Amortization	16.3			15.3			14.4
Interest expense on investment borrowings	.9			.6			.1
Other operating costs and expenses	98.1			107.2			98.4
Total Colonial Penn expenses	314.9			325.0			301.9
Long-term care in run-off:
Insurance policy benefits	47.3			17.6			—
Other operating costs and expenses	3.1			.5			—
Total Long-term care in run-off expenses	50.4			18.1			—
Corporate operations:
Interest expense on corporate debt	46.5			45.8			45.0
Interest expense on investment borrowings	—			—			.2
Other operating costs and expenses	84.3			69.1			38.6
Total corporate expenses	130.8			114.9			83.8
Total expenses	3,739.5			3,503.9			3,364.4
Pre-tax operating earnings by segment:
Bankers Life	418.9			397.9			369.6
Washington National	98.3			102.9			111.5
Colonial Penn	22.6			1.7			5.6
Long-term care in run-off	1.7			(3.9		)	—
Corporate operations	(86.8		)	(88.3		)	(63.9		)
Pre-tax operating earnings	$	454.7		$	410.3		$	422.8

___________________

(a) It is not practicable to provide additional components of revenue by product or services.

190

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

A reconciliation of segment revenues and expenses to consolidated revenues and expenses and net income is as follows (dollars in millions):

	2017			2016			2015
Total segment revenues	$	4,194.2		$	3,914.2		$	3,787.2
Net realized investment gains (losses)	50.3			8.3			(36.6		)
Revenues related to certain non-strategic investments and earnings attributable to VIEs	52.7			52.6			36.3
Fee revenue related to transition and support services agreements	—			10.0			25.0
Consolidated revenues	4,297.2			3,985.1			3,811.9
Total segment expenses	3,739.5			3,503.9			3,364.4
Insurance policy benefits - fair value changes in embedded derivative liabilities	2.9			(11.3		)	(15.7		)
Amortization related to fair value changes in embedded derivative liabilities	(.4		)	1.7			3.8
Amortization related to net realized investment gains (losses)	1.0			.7			(.5		)
Expenses related to certain non-strategic investments and expenses attributable to VIEs	61.5			54.6			43.0
Fair value changes and amendment related to agent deferred compensation plan	12.2			(3.1		)	(15.1		)
Loss on extinguishment of debt	—			—			32.8
Loss on reinsurance transaction and transition expenses	—			75.4			9.0
Expenses related to transition and support services agreements	—			10.0			22.5
Consolidated expenses	3,816.7			3,631.9			3,444.2
Income before tax	480.5			353.2			367.7
Income tax expense:
Tax expense on period income	162.8			127.8			129.5
Valuation allowance for deferred tax assets and other tax items	142.1			(132.8		)	(32.5		)
Net income	$	175.6		$	358.2		$	270.7

191

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Segment balance sheet information was as follows (dollars in millions):

	2017		2016
Assets:
Bankers Life	$	21,134.9	$	19,876.4
Washington National	7,674.3		7,555.7
Colonial Penn	1,059.3		1,022.9
Long-term care in run-off	692.9		656.2
Corporate operations	2,548.9		2,864.0
Total assets	$	33,110.3	$	31,975.2
Liabilities:
Bankers Life	$	18,031.6	$	17,144.9
Washington National	6,101.5		6,096.9
Colonial Penn	921.0		898.5
Long-term care in run-off	580.4		562.2
Corporate operations	2,628.3		2,785.8
Total liabilities	$	28,262.8	$	27,488.3

The following table presents selected financial information of our segments (dollars in millions):

Segment	Present value of future profits		Deferred acquisition costs		Insurance liabilities
2017
Bankers Life	$	81.1	$	606.5	$	16,541.2
Washington National	243.7		310.8		5,590.7
Colonial Penn	34.8		109.5		834.4
Long-term care in run-off	—		—		572.7
Total	$	359.6	$	1,026.8	$	23,539.0
2016
Bankers Life	$	95.5	$	646.2	$	15,702.8
Washington National	266.8		299.9		5,586.7
Colonial Penn	39.5		98.6		809.6
Long-term care in run-off	—		—		554.7
Total	$	401.8	$	1,044.7	$	22,653.8

192

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

16. QUARTERLY FINANCIAL DATA (UNAUDITED)

We compute earnings per common share for each quarter independently of earnings per share for the year. The sum of the quarterly earnings per share may not equal the earnings per share for the year because of: (i) transactions affecting the weighted average number of shares outstanding in each quarter; and (ii) the uneven distribution of earnings during the year. Quarterly financial data (unaudited) were as follows (dollars in millions, except per share data):

2017	1st Qtr.			2nd Qtr.		3rd Qtr.		4th Qtr. (a)
Revenues	$	1,070.7		$	1,057.1	$	1,079.3	$	1,090.1
Income before income taxes	$	96.7		$	128.5	$	129.9	$	125.4
Income tax expense	34.4			45.1		29.1		196.3
Net income (loss)	$	62.3		$	83.4	$	100.8	$	(70.9	)
Earnings per common share:
Basic:
Net income (loss)	$	.36		$	.49	$	.60	$	(.42	)
Diluted:
Net income (loss)	$	.36		$	.48	$	.59	$	(.42	)
2016	1st Qtr.			2nd Qtr.		3rd Qtr.		4th Qtr.
Revenues	$	960.4		$	1,003.9	$	1,015.9	$	1,004.9
Income before income taxes	$	40.5		$	82.7	$	49.3	$	180.7
Income tax expense (benefit)	(5.0		)	22.8		30.7		(53.5		)
Net income	$	45.5		$	59.9	$	18.6	$	234.2
Earnings per common share:
Basic:
Net income	$	.25		$	.34	$	.11	$	1.35
Diluted:
Net income	$	.25		$	.33	$	.11	$	1.34

___________________

(a) In the fourth quarter of 2017, our net loss reflected the unfavorable impact of $172.5 million related to the Tax Reform Act which was enacted in December 2017.

17. INVESTMENTS IN VARIABLE INTEREST ENTITIES

We have concluded that we are the primary beneficiary with respect to certain VIEs, which are consolidated in our financial statements.  In consolidating the VIEs, we consistently use the financial information most recently distributed to investors in the VIE.

All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments.  The assets held by the trusts are legally isolated and not available to the Company.  The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company.  During the three years ended December 31, 2017, VIEs that were required to be consolidated were dissolved. We recognized losses of $4.3 million and $7.3 million during 2017 and 2016, respectively, and a gain of $11.3 million during 2015, representing the difference between the borrowings of such VIEs and the contractual distributions required following the liquidation of the underlying assets. The scheduled repayment of the remaining principal balance of the borrowings related to the VIEs are as follows: $3.0 million in 2018; $3.6 million in 2019; $2.1 million in 2020; $1.3 million in 2021; $539.9 million in 2028; and $878.0 million in 2030. The Company has no financial obligation to the VIEs beyond its investment in each VIE.

193

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

Certain of our insurance subsidiaries are noteholders of the VIEs.  Another subsidiary of the Company is the investment manager for the VIEs.  As such, it has the power to direct the most significant activities of the VIEs which materially impacts the economic performance of the VIEs.

The following table provides supplemental information about the assets and liabilities of the VIEs which have been consolidated (dollars in millions):

	December 31, 2017
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	1,526.9	$	—		$	1,526.9
Notes receivable of VIEs held by insurance subsidiaries	—		(155.5		)	(155.5		)
Cash and cash equivalents held by variable interest entities	178.9		—			178.9
Accrued investment income	2.6		(.1		)	2.5
Income tax assets, net	.7		—			.7
Other assets	10.0		(1.5		)	8.5
Total assets	$	1,719.1	$	(157.1	)	$	1,562.0
Liabilities:
Other liabilities	$	158.3	$	(4.4	)	$	153.9
Borrowings related to variable interest entities	1,410.7		—			1,410.7
Notes payable of VIEs held by insurance subsidiaries	167.6		(167.6		)	—
Total liabilities	$	1,736.6	$	(172.0	)	$	1,564.6

	December 31, 2016
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	1,724.3	$	—		$	1,724.3
Notes receivable of VIEs held by insurance subsidiaries	—		(204.2		)	(204.2		)
Cash and cash equivalents held by variable interest entities	189.3		—			189.3
Accrued investment income	3.0		(.1		)	2.9
Income tax assets, net	6.4		(1.3		)	5.1
Other assets	13.1		(1.8		)	11.3
Total assets	$	1,936.1	$	(207.4	)	$	1,728.7
Liabilities:
Other liabilities	$	81.8	$	(6.4	)	$	75.4
Borrowings related to variable interest entities	1,662.8		—			1,662.8
Notes payable of VIEs held by insurance subsidiaries	203.3		(203.3		)	—
Total liabilities	$	1,947.9	$	(209.7	)	$	1,738.2

194

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table provides supplemental information about the revenues and expenses of the VIEs which have been consolidated in accordance with authoritative guidance, after giving effect to the elimination of our investment in the VIEs and investment management fees earned by a subsidiary of the Company (dollars in millions):

	2017			2016			2015
Revenues:
Net investment income – policyholder and other special-purpose portfolios	$	69.8		$	78.9		$	62.1
Fee revenue and other income	5.9			6.4			1.6
Total revenues	75.7			85.3			63.7
Expenses:
Interest expense	50.2			53.1			38.8
Other operating expenses	1.8			1.5			2.0
Total expenses	52.0			54.6			40.8
Income before net realized investment losses and income taxes	23.7			30.7			22.9
Net realized investment losses	(5.6		)	(20.4		)	(6.4		)
Loss on extinguishment of borrowings	(9.5		)	—			—
Income before income taxes	$	8.6		$	10.3		$	16.5

The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade.  At December 31, 2017, such loans had an amortized cost of $1,524.9 million; gross unrealized gains of $8.6 million; gross unrealized losses of $6.6 million; and an estimated fair value of $1,526.9 million.

The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	11.2	$	11.2
Due after one year through five years	541.8		542.0
Due after five years through ten years	971.9		973.7
Total	$	1,524.9	$	1,526.9

195

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

___________________

The following table sets forth the amortized cost and estimated fair value of those investments held by the VIEs with unrealized losses at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	2.4	$	2.4
Due after one year through five years	178.2		174.3
Due after five years through ten years	299.8		297.1
Total	$	480.4	$	473.8

During 2017, the VIEs recognized net realized investment losses of $5.6 million, which were comprised of: (i) $1.2 million of net gains from the sales of fixed maturities; (ii) $4.3 million of losses on the dissolution of VIEs; and (iii) $2.5 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2016, the VIEs recognized net realized investment losses of $20.4 million which were comprised of: (i) $11.9 million of net losses from the sales of fixed maturities; (ii) a $7.3 million loss on the dissolution of a VIE; and (iii) $1.2 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2015, the VIEs recognized net realized investment losses of $6.4 million which were comprised of: (i) $1.3 million of net losses from the sales of fixed maturities; (ii) an $11.3 million gain on the dissolution of a VIE; and (iii) $16.4 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

At December 31, 2017, there were no investments held by the VIEs that were in default.

During 2017, $109.6 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $3.0 million. During 2016, $192.2 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $20.3 million. During 2015, $46.1 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $1.8 million.

At December 31, 2017, the VIEs held:  (i) investments with a fair value of $445.4 million and gross unrealized losses of $4.9 million that had been in an unrealized loss position for less than twelve months; and (ii) investments with a fair value of $28.4 million and gross unrealized losses of $1.7 million that had been in an unrealized loss position for greater than twelve months.

At December 31, 2016, the VIEs held: (i) investments with a fair value of $93.8 million and gross unrealized losses of $.9 million that had been in an unrealized loss position for less than twelve months; and (ii) investments with a fair value of $143.9 million and gross unrealized losses of $2.9 million that had been in an unrealized loss position for greater than twelve months.

The investments held by the VIEs are evaluated for other-than-temporary declines in fair value in a manner that is consistent with the Company's fixed maturities, available for sale.

196

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures.  CNO's management, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of CNO's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended).  Based on its evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2017, CNO's disclosure controls and procedures were effective to ensure that information required to be disclosed by CNO in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's (the "SEC") rules and forms.  Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Limitations on the Effectiveness of Controls. Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls over financial reporting will prevent all error and fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures. Based on our controls evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of the end of the period covered by this annual report, our disclosure controls and procedures were effective to provide reasonable assurance that: (i) the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms; and (ii) material information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management's Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control - Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective as of December 31, 2017.

The effectiveness of our internal control over financial reporting as of December 31, 2017 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.

Changes to Internal Control Over Financial Reporting.  There were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) during the quarter ended December 31, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION.

None.

197

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

We will provide information that is responsive to this Item 10 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 10. Additional information called for by this item is contained in Part I of this Annual Report under the caption "Executive Officers of the Registrant."

ITEM 11. EXECUTIVE COMPENSATION.

We will provide information that is responsive to this Item 11 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 11.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

We will provide information that is responsive to this Item 12 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 12.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

We will provide information that is responsive to this Item 13 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 13.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

We will provide information that is responsive to this Item 14 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 14.

198

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

___________________

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

			Page
(a)	1.	Financial Statements. See Index to Consolidated Financial Statements for a list of financial statements included in this Report.	114
	2.	Financial Statement Schedules:
		Schedule II ‑‑ Condensed Financial Information of Registrant (Parent Company)
		Balance Sheet at December 31, 2017 and 2016	202
		Statement of Operations for the years ended December 31, 2017, 2016 and 2015	203
		Statement of Cash Flows for the years ended December 31, 2017, 2016 and 2015	204
		Notes to Condensed Financial Information	205
		Schedule IV ‑‑ Reinsurance for the years ended December 31, 2017, 2016 and 2015	206

All other schedules are omitted, either because they are not applicable, not required, or because the information they contain is included elsewhere in the consolidated financial statements or notes.

3. Exhibits. See Exhibit Index immediately preceding the Exhibits filed with this report.

ITEM 16. FORM 10-K SUMMARY.

None.

199

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CNO FINANCIAL GROUP, INC.

Dated:  February 23, 2018

By:	/s/ Gary C. Bhojwani
	Gary C. Bhojwani
	Chief Executive Officer

200

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Signature	Title (Capacity)	Date
/s/ GARY C. BHOJWANI	Director and Chief Executive Officer	February 23, 2018
Gary C. Bhojwani	(Principal Executive Officer)
/s/ ERIK M. HELDING	Executive Vice President	February 23, 2018
Erik M. Helding	and Chief Financial Officer
	(Principal Financial Officer)
/s/ JOHN R. KLINE	Senior Vice President	February 23, 2018
John R. Kline	and Chief Accounting Officer
	(Principal Accounting Officer)
/s/ ELLYN L. BROWN	Director	February 23, 2018
Ellyn L. Brown
/s/ STEPHEN DAVID	Director	February 23, 2018
Stephen David
/s/ ROBERT C. GREVING	Director	February 23, 2018
Robert C. Greving
/s/ MARY R. HENDERSON	Director	February 23, 2018
Mary R. Henderson
/s/ CHARLES J. JACKLIN	Director	February 23, 2018
Charles J. Jacklin
/s/ DANIEL R. MAURER	Director	February 23, 2018
Daniel R. Maurer
/s/ NEAL C. SCHNEIDER	Director	February 23, 2018
Neal C. Schneider
/s/ FREDERICK J. SIEVERT	Director	February 23, 2018
Frederick J. Sievert

201

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

SCHEDULE II

Condensed Financial Information of Registrant (Parent Company)

Balance Sheet

as of December 31, 2017 and 2016

(Dollars in millions)

ASSETS
	2017		2016
Cash and cash equivalents - unrestricted	$	161.1	$	106.1
Equity securities at fair value (cost: 2017 - $225.7; 2016 - $166.5)	243.6		167.9
Investment in wholly-owned subsidiaries (eliminated in consolidation)	5,440.7		5,220.3
Income tax assets, net	129.6		99.5
Receivable from subsidiaries (eliminated in consolidation)	6.3		2.0
Other assets	12.7		1.8
Total assets	$	5,994.0	$	5,597.6
LIABILITIES AND SHAREHOLDERS' EQUITY
Liabilities:
Notes payable	$	914.6	$	912.9
Payable to subsidiaries (eliminated in consolidation)	143.0		128.4
Other liabilities	88.9		69.4
Total liabilities	1,146.5		1,110.7
Commitments and Contingencies
Shareholders' equity:
Common stock and additional paid-in capital ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)	3,075.0		3,213.8
Accumulated other comprehensive income	1,212.1		622.4
Retained earnings	560.4		650.7
Total shareholders' equity	4,847.5		4,486.9
Total liabilities and shareholders' equity	$	5,994.0	$	5,597.6

The accompanying notes are an integral part

of the condensed financial statements.

202

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

SCHEDULE II

Condensed Financial Information of Registrant (Parent Company)

Statement of Operations

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions)

	2017			2016			2015
Revenues:
Net investment income	$	14.2		$	15.6		$	16.9
Net realized investment gains	2.4			17.7			3.5
Intercompany losses (eliminated in consolidation)	—			—			(1.5		)
Total revenues	16.6			33.3			18.9
Expenses:
Interest expense	46.5			45.8			45.2
Intercompany expenses (eliminated in consolidation)	1.7			.9			.4
Operating costs and expenses	75.4			48.2			21.0
Loss on extinguishment of debt	—			—			32.8
Total expenses	123.6			94.9			99.4
Loss before income taxes and equity in undistributed earnings of subsidiaries	(107.0		)	(61.6		)	(80.5		)
Income tax expense (benefit)	27.4			(54.6		)	(37.9		)
Loss before equity in undistributed earnings of subsidiaries	(134.4		)	(7.0		)	(42.6		)
Equity in undistributed earnings of subsidiaries (eliminated in consolidation)	310.0			365.2			313.3
Net income	$	175.6		$	358.2		$	270.7

The accompanying notes are an integral part

of the condensed financial statements.

203

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

SCHEDULE II

Condensed Financial Information of Registrant (Parent Company)

Statement of Cash Flows

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions)

	2017			2016			2015
Cash flows from operating activities	$	(181.8	)	$	(110.7	)	$	(51.2	)
Cash flows from investing activities:
Sales of investments	54.9			305.0			66.5
Sales of investments - affiliated*	—			—			16.0
Maturities and redemptions of investments - affiliated*	—			—			8.3
Purchases of investments	(123.6		)	(198.4		)	(68.6		)
Purchases of investments - affiliated*	—			—			(3.4		)
Net sales of trading securities	9.1			12.0			11.8
Dividends received from consolidated subsidiary, net of capital contributions of nil in 2017, $200.0 in 2016 and nil in 2015*	363.5			92.5			269.7
Net cash provided by investing activities	303.9			211.1			300.3
Cash flows from financing activities:
Issuance of notes payable, net	—			—			910.0
Payments on notes payable	—			—			(797.1		)
Expenses related to extinguishment of debt	—			—			(17.8		)
Issuance of common stock	8.3			8.4			6.3
Payments to repurchase common stock	(168.3		)	(210.0		)	(365.4		)
Common stock dividends paid	(59.6		)	(54.8		)	(52.0		)
Investment borrowings - repurchase agreements, net	—			—			(20.4		)
Issuance of notes payable to affiliates*	310.8			217.1			234.4
Payments on notes payable to affiliates*	(158.3		)	(83.9		)	(104.8		)
Net cash used by financing activities	(67.1		)	(123.2		)	(206.8		)
Net increase (decrease) in cash and cash equivalents	55.0			(22.8		)	42.3
Cash and cash equivalents, beginning of the year	106.1			128.9			86.6
Cash and cash equivalents, end of the year	$	161.1		$	106.1		$	128.9

* Eliminated in consolidation

The accompanying notes are an integral part

of the condensed financial statements.

204

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

SCHEDULE II

Notes to Condensed Financial Information

1. Basis of Presentation

The condensed financial information should be read in conjunction with the consolidated financial statements of CNO Financial Group, Inc. The condensed financial information includes the accounts and activity of the parent company.

205

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

SCHEDULE IV

Reinsurance

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions)

	2017			2016			2015
Life insurance inforce:
Direct	$	27,154.3		$	27,048.1		$	25,807.0
Assumed	120.5			128.7			137.4
Ceded	(3,452.6		)	(3,604.0		)	(3,780.8		)
Net insurance inforce	$	23,822.2		$	23,572.8		$	22,163.6
Percentage of assumed to net	.5		%	.5		%	.6		%

	2017			2016			2015
Insurance policy income:
Direct	$	2,576.9		$	2,553.0		$	2,524.3
Assumed	30.4			34.0			38.5
Ceded	(105.0		)	(123.9		)	(133.6		)
Net premiums	$	2,502.3		$	2,463.1		$	2,429.2
Percentage of assumed to net	1.2		%	1.4		%	1.6		%

206

EXHIBIT INDEX

Exhibit

No.Description

3.1 Amended and Restated Certificate of Incorporation of CNO Financial Group, Inc., incorporated by reference to Exhibit 3.1 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.

3.2 Amended and Restated Bylaws of CNO Financial Group, Inc. dated as of February 28, 2013, incorporated by reference to Exhibit 3.2 of our Current Report on Form 8-K filed February 28, 2013.

3.3 Certificate of Designations of Series D Junior Participating Preferred Stock of CNO Financial Group, Inc., incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K filed October 4, 2017.

4.1 Third Amended and Restated Section 382 Rights Agreement, dated as of October 3, 2017, between the Corporation and American Stock Transfer & Trust Company, LLC, as Rights Agent, which includes the Certificate of Designations for the Series D Junior Participating Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C, incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed October 4, 2017.

4.2 Form of specimen stock certificate, incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed May 12, 2010.

4.3 Indenture, dated as of May 19, 2015, between CNO Financial Group, Inc. and Wilmington Trust, National Association, as trustee (the “Trustee”), incorporated by reference to Exhibit 4.1 of our Current Report on Form 8-K filed May 19, 2015.

4.4 First Supplemental Indenture, dated as of May 19, 2015, between the Corporation and the Trustee, relating to the 4.500% Senior Notes due 2020 and the 5.250% Senior Notes due 2025, incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K filed May 19, 2015.

4.5 Form of 4.500% Senior Notes due 2020 (included in Exhibit 4.4).

4.6 Form of 5.250% Senior Notes due 2025 (included in Exhibit 4.4).

10.1 First Amendment and Restatement Agreement, dated as of October 13, 2017, among CNO Financial Group, Inc., the lenders party thereto, and KeyBank National Association, as administrative agent for the lenders, in respect of the Credit Agreement, dated as of May 19, 2015, among CNO Financial Group, Inc., the lenders from time to time party thereto, and KeyBank National Association, as administrative agent for the lenders, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed October 16, 2017.

10.2* Letter of agreement dated as of August 3, 2007 between CNO Services, LLC (formerly Conseco Services, LLC) and John R. Kline, incorporated by reference to Exhibit 10.11 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.

10.3* CNO Financial Group, Inc. Amended and Restated Long-Term Incentive Plan (included as Annex A to the proxy statement filed on March 30, 2017).

10.4* Form of stock option agreement under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.

10.5* Form of stock option agreement for 2015 under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

10.6* Form of restricted stock agreement for 2015 under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

10.7* Form of performance unit award agreement (TSR) for 2015 under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.3 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

207

10.8* Form of performance unit award agreement (ROE) for 2015 under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.4 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

10.9* Form of amendment to outstanding stock option agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.5 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

10.10* Form of amendment to outstanding restricted stock agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.6 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

10.11* Form of amendment to outstanding performance unit award agreements under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.7 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.

10.12* Form of stock option agreement for 2017 under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017.

10.13* Form of restricted stock unit award agreement for 2017 under Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017.

10.14* Form of performance stock unit award agreement for 2017 under the Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.3 of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017.

10.15 Form of Indemnification Agreement among the Corporation, CDOC, Inc., CNO Services, LLC (formerly Conseco Services, LLC) and each director of the Corporation, incorporated by reference to Exhibit 10.16 of our Annual Report on Form 10-K for the year ended December 31, 2008.

10.16* 2015 Pay for Performance Incentive Plan, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed March 12, 2015.

10.17* Deferred Compensation Plan amended and restated effective January 1, 2017, incorporated by reference to Exhibit 10.20 of our Annual Report on Form 10-K for the year ended December 31, 2016.

10.18* Amended and Restated Employment Agreement dated as of December 18, 2014 between CNO Services, LLC and Christopher J. Nickele, incorporated by reference to Exhibit 10.17 of our Annual Report on Form 10-K for the year ended December 31, 2014, as amended by Amendment dated as of August 17, 2017, incorporated by reference to Exhibit 10.5 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, and as further amended by Amendment dated as of October 31, 2017, incorporated by reference to Exhibit 10.7 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.

10.19* Amended and Restated Employment Agreement dated as of December 18, 2014 between CNO Financial Group, Inc. and Edward J. Bonach, incorporated by reference to Exhibit 10.20 of our Annual Report on Form 10-K for the year ended December 31, 2014, as amended by Amendment dated as of May 16, 2017, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, and as further amended by Amendment dated as of August 14, 2017, incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.

10.20* Amended and Restated Employment Agreement dated as of September 30, 2016 between 40|86 Advisors, Inc. and Eric R. Johnson, incorporated by reference to Exhibit 10.25 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, as amended by Amendment dated as of August 10, 2017, incorporated by reference to Exhibit 10.4 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.

208

10.21* Amended and Restated Employment Agreement dated as of January 12, 2015 between CNO Services, LLC and Matthew J. Zimpfer, incorporated by reference to Exhibit 10.22 of our Annual Report on Form 10-K for the year ended December 31, 2014, as amended by Amendment dated as of August 21, 2017, incorporated by reference to Exhibit 10.6 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.

10.22* Amended and Restated Employment Agreement dated as of January 6, 2015 between CNO Services, LLC and Bruce Baude, incorporated by reference to Exhibit 10.23 of our Annual Report on Form 10-K for the year ended December 31, 2014, as amended by Amendment dated July 30, 2015, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, and as further amended by Amendment dated as of August 11, 2017, incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.

10.23 Coinsurance and Administration Agreement between Conseco Insurance Company and Reassure American Life Insurance Company, incorporated by reference to Exhibit 10.34 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.

10.24 Employment Agreement dated as of April 6, 2016 between CNO Financial Group, Inc. and Gary C. Bhojwani, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed April 12, 2016, as amended by Amendment dated as of August 9, 2017, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K/A filed on August 11, 2017.

10.25* Employment Agreement dated as of April 8, 2016 between CNO Financial Group, Inc. and Erik M. Helding, incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed April 12, 2016, as amended by Amendment dated as of August 17, 2017, incorporated by reference to Exhibit 10.3 of our Current Report on Form 10-Q for the quarter ended September 30, 2017.

10.26* CNO Board of Directors Deferred Compensation Plan, incorporated by reference to Exhibit 10.31 of our Annual Report on Form 10-K for the year ended December 31, 2016.

10.27* Employment Agreement dated as of November 15, 2017 between CNO Services, LLC and Yvonne K. Franzese.

12.1 Computation of Ratio of Earnings to Fixed Charges and Preferred Dividends.

21 Subsidiaries of the Registrant.

23.1 Consent of PricewaterhouseCoopers LLP.

31.1 Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

209

101.INS XBRL Instance Document.

101.SCH XBRL Taxonomy Extension Schema Document.

101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB XBRL Taxonomy Extension Label Linkbase Document.

101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.

*Compensatory plan or arrangement

210

EX-10.3

Exhibit 10.3

CNO FINANCIAL GROUP, INC.

AMENDED AND RESTATED LONG-TERM

INCENTIVE PLAN

A-1

CNO FINANCIAL GROUP, INC.

AMENDED AND RESTATED LONG-TERM INCENTIVE PLAN

	Page
1. Purpose	A-3
2. Definitions	A-3
3. Administration	A-5
4. Stock Subject to Plan	A-6
5. Eligibility; Per-Person Award Limitations	A-7
6. Specific Terms of Awards	A-7
7. Performance-Based Compensation	A-12
8. Certain Provisions Applicable to Awards	A-15
9. Change in Control	A-16
10. Additional Award Forfeiture Provisions	A-16
11. General Provisions	A-18

A-2

CNO FINANCIAL GROUP, INC.

AMENDED AND RESTATED LONG-TERM INCENTIVE PLAN

1. Purpose. The purpose of this Amended and Restated Long-Term Incentive Plan (the “Plan”) is to aid CNO Financial Group, Inc., a Delaware corporation (together with its successors and assigns, the “Company”), in attracting, retaining, motivating and rewarding certain employees and non-employee directors of the Company or its subsidiaries or affiliates, to provide for equitable and competitive compensation opportunities, to recognize individual contributions and reward achievement of Company goals, and promote the creation of long-term value for stockholders by closely aligning the interests of Participants with those of stockholders. The Plan authorizes stock based incentives for Participants. The Plan was initially established as the Conseco, Inc. 2003 Long-Term Incentive Plan, has been amended from time to time thereafter, and is hereby amended and restated effective upon approval by the stockholders of the Company.

2. Definitions. In addition to the terms defined in Section 1 above and elsewhere in the Plan, the following capitalized terms used in the Plan have the respective meanings set forth in this Section:

(a) “Annual Limit”shall have the meaning specified in Section 5(b).

(b) “Award” means any Option, SAR, Restricted Stock, Restricted Stock Unit, Stock granted as a bonus or in lieu of another award, Dividend Equivalent, Other Stock-Based Award or Performance Award, together with any related right or interest, granted to a Participant under the Plan.

(c) “Beneficiary” means the legal representatives of the Participant’s estate entitled by will or the laws of descent and distribution to receive the benefits under a Participant’s Award upon a Participant’s death, provided that, if and to the extent authorized by the Committee, a Participant may be permitted to designate a Beneficiary, in which case the “Beneficiary” instead will be the person, persons, trust or trusts (if any are then surviving) which have been designated by the Participant in his or her most recent written and duly filed beneficiary designation to receive the benefits specified under the Participant’s Award upon such Participant’s death.

(d) “Board” means the Company’s Board of Directors.

(e) “Code” means the Internal Revenue Code of 1986, as amended. References to any provision of the Code or regulation thereunder shall include any successor provisions and regulations, and reference to regulations includes any applicable guidance or pronouncement of the Department of the Treasury and Internal Revenue Service.

(f) “Committee” means the Human Resources and Compensation Committee of the Board, the composition and governance of which is established in the Committee’s Charter as approved from time to time by the Board and subject to Section 303A.05 of the Listed Company Manual of the New York Stock Exchange, and other corporate governance documents of the Company. No action of the Committee shall be void or deemed to be without authority due to the failure of any member, at the time the action was taken, to meet any qualification standard set forth in the Committee Charter or the Plan. The full Board may perform any function of the Committee hereunder except to the extent limited under Section 303A.05 of the Listed Company Manual, in which case the term “Committee” shall refer to the Board.

(g) “Covered Employee”means an Eligible Person who is a Covered Employee as specified in Section 11(j).

A-3

(h) “Dividend Equivalent”means a right, granted under this Plan, to receive cash, Stock, other Awards or other property equal in value to all or a specified portion of the dividends paid with respect to a specified number of shares of Stock.

(i) “Effective Date”means the effective date specified in Section 11(q).

(j) “Eligible Person”has the meaning specified in Section 5.

(k) “Exchange Act”means the Securities Exchange Act of 1934, as amended. References to any provision of the Exchange Act or rule (including a proposed rule) thereunder shall include any successor provisions and rules.

(l) “Fair Market Value”means the fair market value of Stock, Awards or other property as determined in good faith by the Committee or under procedures established by the Committee. Unless otherwise determined by the Committee, the Fair Market Value of Stock shall be the officially-quoted closing selling price of the Stock on the principal stock exchange or market on which Stock is traded on the day as of which such value is being determined or, if there is no sale on that day, then on the last previous day on which a sale was reported. Fair Market Value relating to the exercise price or base price of any Non-409A Option or SAR shall conform to requirements under Code Section 409A.

(m) “409A Awards”means Awards that constitute a deferral of compensation under Code Section 409A and regulations thereunder. “Non-409A Awards” means Awards other than 409A Awards. Although the Committee retains authority under the Plan to grant Options, SARs and Restricted Stock on terms that will qualify those Awards as 409A Awards, Options, SARs exercisable for Stock, and Restricted Stock will be Non-409A Awards unless otherwise expressly specified by the Committee.

(n) “Incentive Stock Option”or “ISO”means any Option designated as an incentive stock option within the meaning of Code Section 422 and qualifying thereunder.

(o) “Option”means a right, granted under the Plan, to purchase Stock.

(p) “Other Stock-Based Awards”means Awards granted to a Participant under Section 6(h).

(q) “Participant”means a person who has been granted an Award under the Plan which remains outstanding, including a person who is no longer an Eligible Person.

(r) “Performance Award”means a conditional right, granted to a Participant under Sections 6(i) and 7, to receive cash, Stock or other Awards or payments.

(s) “Restricted Stock”means Stock granted under the Plan which is subject to certain restrictions and to a risk of forfeiture.

(t) “Restricted Stock Unit”or “RSU”means a right, granted under the Plan, to receive Stock, cash or other Awards or a combination thereof at the end of a specified deferral period.

(u) “Retirement” means, unless otherwise stated in an applicable Award agreement, Participant’s voluntary termination of employment after achieving either (i) 62 years of age or (ii) 60 years of age with at least 10 years of employment with the Company.

(v) “Rule 16b-3”means Rule 16b-3, as from time to time in effect and applicable to Participants, promulgated by the Securities and Exchange Commission under Section 16 of the Exchange Act.

A-4

(w) “Stock”means the Company’s Common Stock, par value $0.01 per share, and any other equity securities of the Company that may be substituted or resubstituted for Stock pursuant to Section 11(c).

(x) “Stock Appreciation Rights”or “SAR”means a right granted to a Participant under Section 6(c).

3.    Administration.

(a) Authority of the Committee. The Plan shall be administered by the Committee, which shall have full and final authority, in each case subject to and consistent with the provisions of the Plan, to select Eligible Persons to become Participants; to grant Awards; to determine the type and number of Awards, the dates on which Awards may be exercised and on which the risk of forfeiture or deferral period relating to Awards shall lapse or terminate, the acceleration of any such dates, the expiration date of any Award, whether, to what extent, and under what circumstances an Award may be settled, or the exercise price of an Award may be paid, in cash, Stock, other Awards, or other property, and other terms and conditions of, and all other matters relating to, Awards; to prescribe documents evidencing or setting terms of Awards (such Award documents need not be identical for each Participant), amendments thereto, and rules and regulations for the administration of the Plan and amendments thereto (including outstanding Awards); to construe and interpret the Plan and Award documents and correct defects, supply omissions or reconcile inconsistencies therein; and to make all other decisions and determinations as the Committee may deem necessary or advisable for the administration of the Plan. Decisions of the Committee with respect to the administration and interpretation of the Plan shall be final, conclusive, and binding upon all persons interested in the Plan, including Participants, Beneficiaries, transferees under Section 11(b) and other persons claiming rights from or through a Participant, and stockholders.

(b) Manner of Exercise of Committee Authority.The express grant of any specific power to the Committee, and the taking of any action by the Committee, shall not be construed as limiting any power or authority of the Committee. The Committee may act through subcommittees, including for purposes of perfecting exemptions under Rule 16b-3 or qualifying Awards under Code Section 162(m) as performance-based compensation, in which case the subcommittee shall be subject to and have authority under the charter applicable to the Committee, and the acts of the subcommittee shall be deemed to be acts of the Committee hereunder. The Committee may delegate the administration of the Plan to one or more officers or employees of the Company, and such administrator(s) may have the authority to execute and distribute Award agreements or other documents evidencing or relating to Awards granted by the Committee under this Plan, to maintain records relating to Awards, to process or oversee the issuance of Stock under Awards, to interpret and administer the terms of Awards, to make grants of Awards to officers (other than any officer subject to Section 16 of the Exchange Act) and employees of the Company (including any prospective officer (other than any such officer who is expected to be subject to Section 16 of the Exchange Act) or employee) subject to an individual maximum annual Award limit as determined and approved at the Compensation Committee’s discretion, and all necessary and appropriate decisions and determinations with respect thereto and to take such other actions as may be necessary or appropriate for the administration of the Plan and of Awards under the Plan, provided that in no case shall any such administrator be authorized (i) to take any action that would result in the loss of an exemption under Rule 16b-3 for Awards granted to or held by Participants who at the time are subject to Section 16 of the Exchange Act in respect of the Company or that would cause Awards intended to qualify as “performance-based compensation” under Code Section 162(m) to fail to so qualify, (ii) to take any action inconsistent with Section 157 and other applicable provisions of the Delaware General Corporation Law, or (iii) to make any determination required to be made by the Committee under the New York Stock Exchange corporate governance standards applicable to listed

A-5

company compensation committees (currently, Rule 303A.05). Any action by any such administrator within the scope of its delegation shall be deemed for all purposes to have been taken by the Committee and, except as otherwise specifically provided, references in this Plan to the Committee shall include any such administrator. The Committee (and, to the extent it so provides, any subcommittee) shall have sole authority to determine whether to review any actions and/or interpretations of any such administrator, and if the Committee shall decide to conduct such a review, any such actions and/or interpretations of any such administrator shall be subject to approval, disapproval or modification by the Committee.

(c) Limitation of Liability.The Committee and each member thereof, and any person acting pursuant to authority delegated by the Committee, shall be entitled, in good faith, to rely or act upon any report or other information furnished by any executive officer, other officer or employee of the Company or a subsidiary or affiliate, the Company’s independent auditors, consultants or any other agents assisting in the administration of the Plan. Members of the Committee, any person acting pursuant to authority delegated by the Committee, and any officer or employee of the Company or a subsidiary or affiliate acting at the direction or on behalf of the Committee or a delegee shall not be personally liable for any action or determination taken or made in good faith with respect to the Plan, and shall, to the extent permitted by law, be fully indemnified and protected by the Company with respect to any such action or determination.

4.    Stock Subject to Plan.

(a) Overall Number of Shares Available for Delivery. The total number of shares of Stock reserved for delivery in connection with Awards under this Plan shall be 30,039,505 shares. The total number of shares available is subject to adjustment as provided in Section 11(c). Any shares of Stock delivered under the Plan shall consist of authorized and unissued shares or treasury shares. No more than 10,000,000 shares may be delivered hereunder as ISOs.

(b) Share Counting Rules. The Committee may adopt reasonable counting procedures to ensure appropriate counting, avoid double counting (as, for example, in the case of tandem or substitute awards) and make adjustments in accordance with this Section 4(b). Shares shall be counted against those reserved to the extent such shares have been delivered and are no longer subject to a risk of forfeiture; provided, however, that notwithstanding the above, the number of shares available for issuance under the Plan shall be reduced by 1.25 shares of Stock for every one share of Stock issued in respect of an Award other than an Award of an Option, SAR, or Award that must be settled in cash. To the extent that an Award under the Plan is canceled, expired, forfeited, settled in cash, or otherwise terminated without delivery of shares to the Participant, the shares retained by or returned to the Company will be available under the Plan. The preceding sentence shall not be applicable with respect to (i) the cancellation of an SAR granted in tandem with an Option upon the exercise of the Option or (ii) the cancellation of an Option granted in tandem with an SAR upon the exercise of the SAR. The following shares, however, may not be made available for issuance as Awards under this Plan: (a) shares not issued or delivered as a result of the net settlement of an outstanding Option or SAR, (b) shares used to pay the exercise price or withholding taxes related to an outstanding Award, or (c) shares repurchased on the open market with the proceeds from the exercise of an Option. In addition, in the case of any Award granted in assumption of or in substitution for an award of a company or business acquired by the Company or a subsidiary or affiliate or with which the Company or a subsidiary or affiliate combines, shares issued or issuable in connection with such substitute Award shall not be counted against the number of shares reserved under the Plan.

A-6

5.    Eligibility; Per-Person Award Limitations.

(a) Eligibility. Awards may be granted under the Plan only to Eligible Persons. For purposes of the Plan, an “Eligible Person” means (i) an employee of the Company or any subsidiary or affiliate, including any person who has been offered employment by the Company or a subsidiary or affiliate, provided that such prospective employee may not receive any payment or exercise any right relating to an Award until such person has commenced employment with the Company or a subsidiary or affiliate, (ii) any non-employee directors of the Company or (iii) other individuals who perform services for the Company or any subsidiary or affiliate. An employee on leave of absence may be considered as still in the employ of the Company or a subsidiary or affiliate for purposes of eligibility for participation in the Plan, if so determined by the Committee. For purposes of the Plan, a joint venture in which the Company or a subsidiary has a substantial direct or indirect equity investment shall be deemed an affiliate, if so determined by the Committee. Holders of awards who will become Eligible Persons granted by a company or business acquired by the Company or a subsidiary or affiliate, or with which the Company or a subsidiary or affiliate combines, are eligible for grants of substitute awards granted in assumption of or in substitution for such outstanding awards previously granted under the Plan in connection with such acquisition or combination transaction, if so determined by the Committee.

(b) Per-Person Award Limitations. In each calendar year during any part of which the Plan is in effect, an Eligible Person may be granted Awards under each of Section 6(b) through (i) relating to up to his or her Annual Limit (such Annual Limit to apply separately to the type of Award authorized under each specified subsection). A Participant’s Annual Limit, in any year during any part of which the Participant is then eligible under the Plan, shall equal 1,000,000 shares, subject to adjustment as provided in Section 11(c). In the case of an Award which is not valued in a way in which the limitation set forthin the preceding sentence would operate as an effective limitation satisfying applicable law (including Treasury Regulation 1.162-27(e)(4)), an Eligible Person may not be granted Awards authorizing the earning during any calendar year of an amount that exceeds the Eligible Person’s Annual Limit, which for this purpose shall equal $4 million (this limitation is separate and not affected by the number of Awards granted during such calendar year subject to the limitation in the preceding sentence). For this purpose, (i) “earning” means satisfying performance conditions so that an amount becomes payable, without regard to whether it is to be paid currently or on a deferred basis or continues to be subject to any service requirement or other non-performance condition, and (ii) a Participant’s Annual Limit is used to the extent an amount or number of shares may be potentially earned or paid under an Award, regardless of whether such amount or shares are in fact earned or paid. Additionally, the maximum number of shares of Stock subject to Awards granted during a single calendar year to any non-employee director, taken together with any cash or other fees earned by such non-employee director during such calendar year, shall not exceed (i) $500,000 in total value in the case of non-employee directors other than the Board Chair or Lead Director or (ii) $950,000 in total value in the case of the Board Chair or Lead Director (in each case, calculating the value of any such Awards based on the grant date fair value of such Awards for financial reporting purposes).

6.    Specific Terms of Awards.

(a) General. Awards may be granted on the terms and conditions set forth in this Section 6. In addition, the Committee may impose on any Award or the exercise thereof, at the date of grant or thereafter (subject to Sections 11(e) and 11(k)), such additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committee shall determine, including terms requiring forfeiture of Awards in the event of termination of employment or service by the Participant and terms permitting a Participant to make elections relating to his or her Award. The Committee shall retain full power and discretion with respect to any term or condition of an Award that is not mandatory under the Plan, subject to Section 11(k). The Committee shall require the payment of lawful consideration for an Award to the extent necessary to satisfy the

A-7

requirements of the Delaware General Corporation Law, and may otherwise require payment of consideration for an Award except as limited by the Plan.

(b) Options. The Committee is authorized to grant Options to Participants on the following terms and conditions:

(i) Exercise Price. The exercise price per share of Stock purchasable under an Option (including both ISOs and non-qualified Options) shall be determined by the Committee, provided that, notwithstanding anything contained herein to the contrary such exercise price shall be (A) fixed as of the grant date, and (B) not less than the Fair Market Value of a share of Stock on the grant date. Notwithstanding the foregoing, any substitute award granted in assumption of or in substitution for an outstanding award granted by a company or business acquired by the Company or a subsidiary or affiliate, or with which the Company or a subsidiary or affiliate combines, may be granted with an exercise price per share of Stock other than as required above.

(ii) No Repricing. Except for adjustments as permitted by Section 11(c), without the approval of stockholders, the Committee will not amend, replace, substitute, or exchange previously granted Options in a transaction that constitutes a “repricing,” which means any of the following: (i) changing the terms of an Option to lower its exercise price; (ii) any other action that is treated as a “repricing” under generally accepted accounting principles; (iii) repurchasing for cash or canceling an Option at a time when its exercise price is greater than the Fair Market Value of the underlying shares of Stock in exchange for another Award; or (iv) as such term is used in Section 303A.08 of the Listed Company Manual of the New York Stock Exchange.

(iii) Option Term; Time and Method of Exercise. The Committee shall determine the term of each Option, provided that in no event shall the term of any Option exceed a period of ten years from the date of grant. The Committee shall determine the time or times at which or the circumstances under which an Option may be exercised in whole or in part. In addition, the Committee shall determine the methods by which such exercise price may be paid or deemed to be paid and the form of such payment (subject to Sections 11(k) and 11(l)), including, without limitation, cash, Stock (including by withholding Stock deliverable upon exercise), other Awards or awards granted under other plans of the Company or any subsidiary or affiliate, or other property (including through broker-assisted “cashless exercise” arrangements, to the extent permitted by applicable law), and the methods by or forms in which Stock will be delivered or deemed to be delivered in satisfaction of Options to Participants.

(iv) ISOs. Notwithstanding anything to the contrary in this Section 6, in the case of the grant of an Option intending to qualify as an ISO: (i) if the Participant owns stock possessing more than 10 percent of the combined voting power of all classes of stock of the Company (a “10% Shareholder”), the purchase price of such Option must be at least 110 percent of the fair market value of the Common Stock on the date of grant and the Option must expire within a period of not more than five (5) years from the date of grant, and (ii) termination of employment will occur when the person to whom an Award was granted ceases to be an employee (as determined in accordance with Section 3401(c) of the Code and the regulations promulgated thereunder) of the Company and its subsidiaries. Notwithstanding anything in this Section 6 to the contrary, Options designated as ISOs shall not be eligible for treatment under the Code as ISOs to the extent that either (iii) the aggregate fair market value of shares of Common Stock (determined as of the time of grant) with respect to which such Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Subsidiary) exceeds $100,000, taking Options into account in the order in which they were granted, and (iv) such Options otherwise remain

A-8

exercisable but are not exercised within three (3) months of termination of employment (or such other period of time provided in Section 422 of the Code).

(v) Minimum Vesting. Options may not vest earlier than the first anniversary of the grant date (or the grantee’s commencement of service)(if such grant is made in connection with such commencement), The foregoing minimum vesting condition need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as Options without regard to such minimum vesting requirements.

(c) Stock Appreciation Rights. The Committee is authorized to grant SARs to Participants on the following terms and conditions:

(i) Right to Payment. An SAR shall confer on the Participant to whom it is granted a right to receive, upon exercise thereof, shares of Stock having a value equal to the excess of (A) the Fair Market Value of one share of Stock on the date of exercise (or, in the case of a “Limited SAR,” the Fair Market Value determined by reference to the change in control price, as defined under the applicable award agreement) over (B) the exercise or settlement price of the SAR as determined by the Committee. Stock Appreciation Rights may be granted to Participants from time to time either in tandem with or as a component of other Awards granted under the Plan (“tandem SARs”) or not in conjunction with other Awards (“freestanding SARs”) and may, but need not, relate to a specific Option granted under Section 6(b). The per share price for exercise or settlement of SARs (including both tandem SARs and freestanding SARs) shall be determined by the Committee, but in the case of SARs that are granted in tandem to an Option shall not be less than the exercise price of the Option and in the case of freestanding SARs shall be (A) fixed as of the grant date, and (B) not less than the Fair Market Value of a share of Stock on the grant date.

(ii) No Repricing. Except for adjustments as permitted by Section 11(c), without the approval of stockholders, the Committee will not amend, replace, substitute, or exchange previously granted SARs in a transaction that constitutes a “repricing,” which means any of the following (i) changing the terms of an SAR to lower its exercise or settlement price; (ii) any other action that is treated as a “repricing” under generally accepted accounting principles; (iii) repurchasing for cash or canceling an SAR at a time when its exercise or settlement price is greater than the Fair Market Value of the underlying shares of Stock in exchange for another Award; or (iv) as such term is used in Section 303A.08 of the Listed Company Manual of the New York Stock Exchange.

(iii) Other Terms. The Committee shall determine the term of each SAR, provided that in no event shall the term of an SAR exceed a period of ten years from the date of grant. The Committee shall determine at the date of grant or thereafter, the time or times at which and the circumstances under which a SAR may be exercised in whole or in part (including based on future service requirements), the method of exercise, method of settlement, method by or forms in which Stock will be delivered or deemed to be delivered to Participants, and whether or not a SAR shall be free-standing or in tandem or combination with any other Award. Limited SARs that may only be exercised in connection with a change in control or termination of service following a change in control as specified by the Committee may be granted on such terms, not inconsistent with this Section 6(c), as the Committee may determine. The Committee may require that an outstanding Option be exchanged for an SAR exercisable for Stock having vesting, expiration, and other terms substantially the same as the Option, so long as such exchange will not result in additional accounting expense to the Company.

A-9

(iv) Minimum Vesting. SARs may not vest earlier than the first anniversary of the grant date (or the grantee’s commencement of service)(if such grant is made in connection with such commencement), The foregoing minimum vesting condition need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control, and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as SARs without regard to such minimum vesting requirements.

(d) Restricted Stock. The Committee is authorized to grant Restricted Stock to Participants on the following terms and conditions:

(i) Award and Restrictions. Subject to Section 6(d)(ii), Restricted Stock shall be subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the Committee may impose, which restrictions may lapse separately or in combination at such times, under such circumstances, in such installments or otherwise and under such other circumstances as the Committee may determine at the date of grant or thereafter. Except to the extent restricted under the terms of the Plan and any Award document relating to the Restricted Stock, a Participant granted Restricted Stock shall have all of the rights of a stockholder, including the right to vote the Restricted Stock and the right to receive dividends thereon (subject to any mandatory reinvestment or other requirement imposed by the Committee).

(ii) Forfeiture. Except as otherwise determined by the Committee, upon termination of employment or service during the applicable restriction period, Restricted Stock that is at that time subject to restrictions shall be forfeited and reacquired by the Company; provided that the Committee may provide, by rule or regulation or in any Award document, or may determine in any individual case, that restrictions or forfeiture conditions relating to Restricted Stock will lapse in whole or in part, including in the event of terminations resulting from specified causes.

(iii) Limitation on Vesting. The grant, issuance, retention, vesting and/or settlement of Restricted Stock shall occur at such time and in such installments as determined by the Committee or under criteria established by the Committee. Subject to Section 10, the Committee shall have the right to make the timing of the grant and/or the issuance, ability to retain, vesting and/or settlement of Restricted Stock subject to continued employment, passage of time and/or such performance conditions as deemed appropriate by the Committee; provided that the grant, issuance, retention, vesting and/or settlement of a Restricted Stock Award that is based in whole or in part on performance conditions and/or the level of achievement versus such performance conditions shall be subject to a performance period of not less than one year, and any Award based solely upon continued employment or the passage of time shall vest over a period not less than three years, with no portion vesting in less than one year, from the date the Award is made, provided that such vesting may occur ratably over the three-year period. The foregoing minimum vesting conditions need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as Restricted Stock or RSUs without regard to such minimum vesting requirements.

(iv) Certificates for Stock. Restricted Stock granted under the Plan may be evidenced in such manner as the Committee shall determine. If certificates representing Restricted Stock are registered in the name of the Participant, the Committee may require that such certificates bear an appropriate legend referring to the terms, conditions and restrictions applicable to such Restricted Stock, that the Company retain physical possession of the certificates, and

A-10

that the Participant deliver a stock power to the Company, endorsed in blank, relating to the Restricted Stock.

(v) Dividends and Splits. As a condition to the grant of an Award of Restricted Stock on or after the Effective Date of the Plan, the Committee shall require that any dividends paid on a share of Restricted Stock shall be held in an account for the benefit of the Participant, to be paid out only upon vesting of such Restricted Stock, or automatically reinvested in additional Restricted Stock, which shall be subject to the same terms as applied to the original Restricted Stock to which it relates. Unless otherwise determined by the Committee, Stock distributed in connection with a Stock split or Stock dividend, and other property distributed as a dividend, shall be subject to restrictions and a risk of forfeiture to the same extent as the Restricted Stock with respect to which such Stock or other property has been distributed.

(e) Restricted Stock Units. The Committee is authorized to grant RSUs to Participants, subject to the following terms and conditions:

(i) Award and Restrictions. Subject to Section 6(e)(ii), RSUs shall be subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the Committee may impose, which restrictions may lapse separately or in combination at such times, under such circumstances (including based on achievement of performance conditions and/or future service requirements), in such installments or otherwise and under such other circumstances as the Committee may determine at the date of grant or thereafter. A Participant granted RSUs shall not have any of the rights of a stockholder, including the right to vote, until Stock shall have been issued in the Participant’s name pursuant to the RSUs, except that the Committee may provide for dividend equivalents pursuant to Section 6(e)(iii) below.

(ii) Limitation on Vesting. The grant, issuance, retention, vesting and/or settlement of RSUs shall occur at such time and in such installments as determined by the Committee or under criteria established by the Committee. Subject to Section 10, the Committee shall have the right to make the timing of the grant and/or the issuance, ability to retain, vesting and/or settlement of RSUs subject to continued employment, passage of time and/or such performance conditions as deemed appropriate by the Committee; provided that the grant, issuance, retention, vesting and/or settlement of an RSU that is based in whole or in part on performance conditions and/or the level of achievement versus such performance conditions shall be subject to a performance period of not less than one year, and any Award based solely upon continued employment or the passage of time shall vest over a period not less than three years from the date the Award is made, provided that such vesting may occur ratably over the three-year period. RSUs may not vest earlier than the first anniversary of the grant date (or the grantee’s commencement of service,if such grant is made in connection with such commencement). The foregoing minimum vesting conditions need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control, and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as Restricted Stock or RSUs without regard to such minimum vesting requirements.

(iii) Dividend Equivalents. As a condition to the grant of an Award of RSUs on or after the Effective Date of the Plan, Dividend Equivalents on the specified number of shares of Stock covered by an Award of RSUs shall be payable only upon vesting of such RSUs, or deferred with respect to such RSUs, either as a cash deferral or with the amount or value thereof automatically deemed reinvested in additional RSUs, other Awards or other investment vehicles having a Fair Market Value equal to the amount of such dividends, as the Committee shall determine or permit a Participant to elect.

A-11

(f) Bonus Stock and Awards in Lieu of Obligations. The Committee is authorized to grant Stock as a bonus, or to grant Stock or other Awards in lieu of obligations of the Company or a subsidiary or affiliate to pay cash or deliver other property under the Plan or under other plans or compensatory arrangements, subject to such terms as shall be determined by the Committee.

(g) Dividend Equivalents. The Committee is authorized to grant Dividend Equivalents to a Participant, which may be awarded on a free-standing basis or in connection with another Award other than an Option, ISO, or SAR. The Committee may provide that Dividend Equivalents shall be held in an account for the benefit of the Participant, to be paid out upon vesting of such Award or shall be deemed to have been reinvested in additional Stock, Awards, or other investment vehicles, and subject to restrictions on transferability, risks of forfeiture and such other terms as the Committee may specify. Notwithstanding the foregoing, the Committee may not payout any dividends or Dividend Equivalents with respect to any unvested Award under this Plan.

(h) Other Stock-Based Awards. The Committee is authorized, subject to limitations under applicable law, to grant to Participants such other Awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Stock or factors that may influence the value of Stock, including, without limitation, convertible or exchangeable debt securities, other rights convertible or exchangeable into Stock, purchase rights for Stock, Awards with value and payment contingent upon performance of the Company or business units thereof or any other factors designated by the Committee, and Awards valued by reference to the book value of Stock or the value of securities of or the performance of specified subsidiaries or affiliates or other business units. The Committee shall determine the terms and conditions of such Awards. Stock delivered pursuant to an Award in the nature of a purchase right granted under this Section 6(h) shall be purchased for such consideration, paid for at such times, by such methods, and in such forms, including, without limitation, cash, Stock, other Awards, notes, or other property, as the Committee shall determine. Any such other Stock-based Award that is based in whole or in part on performance conditions and/or the level of achievement versus such performance conditions shall be subject to a performance period of not less than one year, and any such other Stock-based Award based solely on continued employment or the passage of time shall vest over a period of not less than three years, with no portion vesting in less than one year, from the date the Award is made, provided that such vesting may occur ratably over the three-year period. The foregoing minimum vesting conditions need not apply (A) in the case of the death, disability or Retirement of the Participant or termination in connection with a Change in Control and (B) with respect to up to an aggregate of five percent of the shares of Stock authorized under the Plan, which may be granted (or regranted upon forfeiture) as other Awards without regard to such minimum vesting requirements. Cash awards, as an element of or supplement to any other Award under the Plan, may also be granted pursuant to this Section 6(h).

(i) Performance Awards. Performance Awards, denominated in cash or in Stock or other Awards, may be granted by the Committee in accordance with Section 7.

7.    Performance-Based Compensation.

(a) Performance Awards Generally. Performance Awards may be denominated as a cash amount, number of shares of Stock, or specified number of other Awards (or a combination) which may be earned upon achievement or satisfaction of performance conditions specified by the Committee. In addition, the Committee may specify that any other Award shall constitute a Performance Award by conditioning the right of a Participant to exercise the Award or have it settled, and the timing thereof, upon achievement or satisfaction of such performance conditions as may be specified by the Committee. The Committee may use such business criteria and other measures of performance as it may deem appropriate in establishing any performance

A-12

conditions, and may exercise its discretion to reduce or increase the amounts payable under any Award subject to performance conditions, except as limited under Sections 7(b) and 7(c) in the case of a Performance Award intended to qualify as “performance-based compensation” under Section 162(m).

(b) Performance Awards Granted to Covered Employees. If the Committee determines that a Performance Award to be granted to an Eligible Person who is designated by the Committee as likely to be a Covered Employee should qualify as “performance-based compensation” for purposes of Section 162(m), the grant, exercise and/or settlement of such Performance Award shall be contingent upon achievement of a pre-established performance goal and other terms set forth in this Section 7(b).

(i) Performance Goal Generally. The performance goal for such Performance Awards shall consist of one or more business criteria and a targeted level or levels of performance with respect to each of such criteria, as specified by the Committee consistent with this Section 7(b). The performance goal shall be objective and shall otherwise meet the requirements of Code Section 162(m) and regulations thereunder, including the requirement that the level or levels of performance targeted by the Committee result in the achievement of performance goals being “substantially uncertain.” The Committee may determine that such Performance Awards shall be granted, exercised and/or settled upon achievement of any one performance goal or that two or more of the performance goals must be achieved as a condition to grant, exercise and/or settlement of such Performance Awards. Performance goals may differ for Performance Awards granted to any one Participant or to different Participants.

(ii) Business Criteria. For purposes of this Plan, a “performance goal” shall mean any one or more of the following business criteria, in each case as specified by the Committee: (1) gross or net revenue, premiums collected, new annualized premiums, and investment income, (2) any earnings or net income measure, including earnings from operations, earnings before taxes, earnings before interest and/or taxes and/or depreciation, statutory earnings before realized gains (losses), or net income available to common shareholders, (3) operating earnings per common share (either basic or diluted); (4) return on assets, return on investment, return on capital, return on equity, or return on tangible equity; (5) economic value created including the value of new business; (6) operating margin or profit margin; (7) net interest margin; (8) asset quality; (9) stock price or total stockholder return; and (10) strategic business criteria, consisting of one or more objectives based on meeting specified market penetration, total market capitalization, business retention, new product generation, rate increase actions, geographic business expansion goals, cost targets (including cost of capital), investment portfolio yield, risk-based capital, statutory capital, Best Capital Adequacy Ratio, tax net operating loss utilization, customer satisfaction, employee satisfaction, agency ratings, management of employment practices and employee benefits, supervision of litigation and information technology, and goals relating to acquisitions or divestitures of subsidiaries, affiliates or joint ventures.The targeted level or levels of performance with respect to such business criteria may be established at such levels and in such terms as the Committee may determine, in its discretion, including in absolute terms, on a per share basis (either basic or diluted), as a goal relative to performance in prior periods, or as a goal compared to the performance of one or more comparable companies or an index covering multiple companies.

The Committee may provide in any Performance Award that any evaluation of performance shall include or exclude any of the following items: (1) asset write-downs; (2) litigation or claim judgments or settlements; (3) the effect of changes in tax laws, accounting principles, regulations, or other laws or regulations affecting reported results; (4) any reorganization and restructuring programs; (5) acquisitions or divestitures; (6) unusual nonrecurring or

A-13

extraordinary items identified in the Company’s audited financial statements, including footnotes; (7) annual incentive payments or other bonuses; or(8) capital charges.

(iii) Performance Period; Timing for Establishing Performance Goals. Achievement of performance goals in respect of such Performance Awards shall be measured over a performance period of up to one year or more than one year, as specified by the Committee. A performance goal shall be established not later than the earlier of (A) 90 days after the beginning of any performance period applicable to such Performance Award or (B) the time twenty-five percent of such performance period has elapsed.

(iv) Performance Award Pool. The Committee may establish a Performance Award pool, which shall be an unfunded pool, for purposes of measuring performance of the Company in connection with Performance Awards. The amount of such Performance Award pool shall be based upon the achievement of a performance goal or goals based on one or more of the business criteria set forth in Section 7(b)(ii) during the given performance period, as specified by the Committee in accordance with Section 7(b)(iv). The Committee may specify the amount of the Performance Award pool as a percentage of any of such business criteria, a percentage thereof in excess of a threshold amount, or as another amount which need not bear a strictly mathematical relationship to such business criteria.

(v) Settlement of Performance Awards; Other Terms. Settlement of Performance Awards shall be in cash, Stock, other Awards or other property, in the discretion of the Committee. The Committee may, in its discretion, increase or reduce the amount of a settlement otherwise to be made in connection with such Performance Awards, but may not exercise discretion to increase any such amount payable to a Covered Employee in respect of a Performance Award subject to this Section 7(b). Any settlement which changes the form of payment from that originally specified shall be implemented in a manner such that the Performance Award and other related Awards do not, solely for that reason, fail to qualify as “performance-based compensation” for purposes of Section 162(m). The Committee shall specify the circumstances in which such Performance Awards shall be paid or forfeited in the event of termination of employment by the Participant or other event (including a change in control) prior to the end of a performance period or settlement of such Performance Awards.

(vi) Recapture Rights. If at any time after the date on which a Participant has been granted or becomes vested in an Award pursuant to the achievement of a performance goal under Section 7, the Committee determines that the earlier determination as to the achievement of the performance goal was based on incorrect data and that in fact the performance goal had not been achieved or had been achieved to a lesser extent than originally determined and a portion of an Award would not have been granted, vested or paid, given the correct data, then (i) such portion of the Award that was granted shall be forfeited and any related shares (or if such shares were disposed of the cash equivalent) shall be returned to the Company as provided by the Committee, (ii) such portion of the Award that became vested shall be deemed to be not vested and any related shares (or if such shares were disposed of the cash equivalent) shall be returned to the Company as provided by the Committee, and (iii) such portion of the Award paid to the Participant shall be paid by the Participant to the Company upon notice from the Company as provided by the Committee.

(c) Written Determinations. Determinations by the Committee as to the establishment of performance goals, the amount potentially payable in respect of Performance Awards, the level of actual achievement of the specified performance goals shall be recorded in writing in the case of Performance Awards intended to qualify under Section 162(m). Specifically, the Committee shall certify in writing, in a manner conforming to applicable regulations under Section 162(m), prior to settlement of each such Award granted to a Covered Employee, that the performance

A-14

objective relating to the Performance Award and other material terms of the Award upon which settlement of the Award was conditioned have been satisfied.

8.    Certain Provisions Applicable To Awards.

(a) Stand-Alone, Additional, Tandem, and Substitute Awards. Subject to the provisions of Sections 6(b)(ii) and 6(c)(ii), awards granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, in tandem with, or in substitution or exchange for, any other Award or any award granted under another plan of the Company, any subsidiary or affiliate, or any business entity to be acquired by the Company or a subsidiary or affiliate, or any other right of a Participant to receive payment from the Company or any subsidiary or affiliate; provided, however, that a 409A Award may not be granted in tandem with a Non-409A Award. Awards granted in addition to or in tandem with other Awards or awards may be granted either as of the same time as or a different time from the grant of such other Awards or awards. Subject to Sections 11(k) and (l), the Committee may determine that, in granting a new Award, the in-the-money value or fair value of any surrendered Award or award or the value of any other right to payment surrendered by the Participant may be applied to reduce the exercise price of any Option, grant price of any SAR, or purchase price of any other Award.

(b) Term of Awards. The term of each Award shall be for such period as may be determined by the Committee, subject to the express limitations set forth in the Plan.

(c) Form and Timing of Payment under Awards; Deferrals. Subject to the terms of the Plan (including Sections 11(k) and (l)) and any applicable Award document, payments to be made by the Company or a subsidiary or affiliate upon the exercise of an Option or other Award or settlement of an Award may be made in such forms as the Committee shall determine, including, without limitation, cash, Stock, other Awards or other property, and may be made in a single payment or transfer, in installments, or on a deferred basis. The settlement of any Award may be accelerated, and cash paid in lieu of Stock in connection with such settlement, in the discretion of the Committee or upon occurrence of one or more specified events, subject to Sections 11(k) and (l). Subject to Section 11(k), installment or deferred payments may be required by the Committee (subject to Section 11(e)) or permitted at the election of the Participant on terms and conditions established by the Committee. Payments may include, without limitation, provisions for the payment or crediting of reasonable interest on installment or deferred payments or the grant or crediting of Dividend Equivalents or other amounts in respect of installment or deferred payments denominated in Stock. In the case of any 409A Award that is vested and no longer subject to a risk of forfeiture (within the meaning of Code Section 83), such Award will be distributed to the Participant, upon application of the Participant, if the Participant has had an unforeseeable emergency within the meaning of Code Sections 409A(a)(2)(A)(vi) and 409A(a)(2)(B)(ii), in accordance with Section 409A(a)(2)(B)(ii).

(d) Limitation on Vesting of Certain Awards. Subject to Section 8, Restricted Stock will vest over a minimum period of three years, with no portion vesting in less than one year, except in the event of a Participant’s death, disability, or retirement, or in the event of a change in control or other special circumstances. The foregoing notwithstanding, Restricted Stock as to which either the grant or vesting is based on, among other things, the achievement of one or more performance conditions generally will vest over a minimum period of one year except in the event of a Participant’s death, disability, or retirement, or in the event of a change in control or other special circumstances, and provided further up to five percent of the shares of Stock authorized under the Plan including non-employee director awards may be granted as Restricted Stock without any minimum vesting requirements. For purposes of this Section 8(d), a performance period that precedes the grant of the Restricted Stock will be treated as part of the

A-15

vesting period if the participant has been notified promptly after the commencement of the performance period that he or she has the opportunity to earn the Award based on performance and continued service, and vesting over a three-year period or one-year period will include periodic vesting over such period if the rate of such vesting is proportional (or less rapid) throughout such period.

(e) Cash Settlement of Awards. To the extent permitted by the Committee at the time of grant or thereafter, the Company may deliver cash in full or partial satisfaction, payment and/or settlement upon exercise, cancellation, forfeiture or surrender of any Award.

9. Change in Control. The Committee may set forth in any Award Agreement the effect, if any, that a change in control or other, similar transaction shall have on any awards granted under this Plan.

10. Additional Award Forfeiture Provisions.

(a) Forfeiture of Options and Other Awards and Gains Realized Upon Prior Option Exercises or Award Settlements. Unless otherwise determined by the Committee, each Award granted hereunder, other than Awards granted to non-employee directors, shall be subject to the following additional forfeiture conditions, to which the Participant, by accepting an Award hereunder, agrees. If any of the events specified in Section 10(b)(i), (ii), or (iii) occurs (a “Forfeiture Event”), all of the following forfeitures will result:

(i) The unexercised portion of each Option held by the Participant, whether or not vested, and any other Award not then settled will be immediately forfeited and canceled upon the occurrence of the Forfeiture Event; and

(ii) The Participant will be obligated to repay to the Company, in cash, within five business days after demand is made therefore by the Company, the total amount of Award Gain (as defined herein) realized by the Participant upon each exercise of an Option or settlement of an Award that occurred on or after (A) the date that is six months prior to the occurrence of the Forfeiture Event, if the Forfeiture Event occurred while the Participant was employed by the Company or a subsidiary or affiliate, or (B) the date that is six months prior to the date the Participant’s employment by the Company or a subsidiary or affiliate terminated, if the Forfeiture Event occurred after the Participant ceased to be so employed. For purposes of this Section, the term “Award Gain” shall mean (i), in respect of a given Option exercise, the product of (X) the Fair Market Value per share of Stock at the date of such exercise (without regard to any subsequent change in the market price of shares) minus the exercise price times (Y) the number of shares as to which the Option was exercised at that date, and (ii), in respect of any other settlement of an Award granted to the Participant, the Fair Market Value of the cash or Stock paid or payable to Participant (regardless of any elective deferral) less any cash or the Fair Market Value of any Stock or property (other than an Award or award which would have itself then been forfeitable hereunder and excluding any payment of tax withholding) paid by the Participant to the Company as a condition of or in connection such settlement.

(b) Events Triggering Forfeiture. The forfeitures specified in Section 10(a) will be triggered upon the occurrence of any one of the following Forfeiture Events at any time during Participant’s employment by the Company or a subsidiary or affiliate, or during the one-year period following termination of such employment:

(i) Participant, acting alone or with others, directly or indirectly, (A) engages, either as employee, employer, consultant, advisor, or director, or as an owner, investor, partner, or stockholder unless Participant’s interest is insubstantial, in any business in an area or region in which the Company conducts business at the date the event occurs, which is directly in

A-16

competition with a business then conducted by the Company or a subsidiary or affiliate; (B) induces any customer or supplier of the Company or a subsidiary or affiliate, with which the Company or a subsidiary or affiliate has a business relationship, to curtail, cancel, not renew, or not continue his or her or its business with the Company or any subsidiary or affiliate; or (C) induces, or attempts to influence, any employee of or service provider to the Company or a subsidiary or affiliate to terminate such employment or service. The Committee shall, in its discretion, determine which lines of business the Company conducts on any particular date and which third parties may reasonably be deemed to be in competition with the Company. For purposes of this Section 10(b)(i), a Participant’s interest as a stockholder is insubstantial if it represents beneficial ownership of less than five percent of the outstanding class of stock, and a Participant’s interest as an owner, investor, or partner is insubstantial if it represents ownership, as determined by the Committee in its discretion, of less than five percent of the outstanding equity of the entity;

(ii) Participant discloses, uses, sells, or otherwise transfers, except in the course of employment with or other service to the Company or any subsidiary or affiliate, any confidential or proprietary information of the Company or any subsidiary or affiliate, including but not limited to information regarding the Company’s current and potential customers, organization, employees, finances, and methods of operations and investments, so long as such information has not otherwise been disclosed to the public or is not otherwise in the public domain (other than by Participant’s breach of this provision), except as required by law or pursuant to legal process, or Participant makes statements or representations, or otherwise communicates, directly or indirectly, in writing, orally, or otherwise, or takes any other action which may, directly or indirectly, disparage or be damaging to the Company or any of its subsidiaries or affiliates or their respective officers, directors, employees, advisors, businesses or reputations, except as required by law or pursuant to legal process; or

(iii) Participant fails to cooperate with the Company or any subsidiary or affiliate in any way, including, without limitation, by making himself or herself available to testify on behalf of the Company or such subsidiary or affiliate in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, or otherwise fails to assist the Company or any subsidiary or affiliate in any way, including, without limitation, in connection with any such action, suit, or proceeding by providing information and meeting and consulting with members of management of, other representatives of, or counsel to, the Company or such subsidiary or affiliate, as reasonably requested.

(c) Agreement Does Not Prohibit Competition or Other Participant Activities. Although the conditions set forth in this Section 10 shall be deemed to be incorporated into an Award, a Participant is not thereby prohibited from engaging in any activity, including but not limited to competition with the Company and its subsidiaries and affiliates. Rather, the non-occurrence of the Forfeiture Events set forth in Section 10(b) is a condition to the Participant’s right to realize and retain value from his or her compensatory Options and Awards, and the consequence under the Plan if the Participant engages in an activity giving rise to any such Forfeiture Event are the forfeitures specified herein. The Company and Participant shall not be precluded by this provision or otherwise from entering into other agreements concerning the subject matter of Sections 10(a) and 10(b).

(d) Committee Discretion. The Committee may, in its discretion, waive in whole or in part the Company’s right to forfeiture under this Section, but no such waiver shall be effective unless evidenced by a writing signed by a duly authorized officer of the Company. In addition, the Committee may impose additional conditions on Awards, by inclusion of appropriate provisions in the document evidencing or governing any such Award.

A-17

11. General Provisions.

(a) Compliance with Legal and Other Requirements. The Company may, to the extent deemed necessary or advisable by the Committee and subject to Section 11(k), postpone the issuance or delivery of Stock or payment of other benefits under any Award until completion of such registration or qualification of such Stock or other required action under any federal or state law, rule or regulation, listing or other required action with respect to any stock exchange or automated quotation system upon which the Stock or other securities of the Company are listed or quoted, or compliance with any other obligation of the Company, as the Committee may consider appropriate, and may require any Participant to make such representations, furnish such information and comply with or be subject to such other conditions as it may consider appropriate in connection with the issuance or delivery of Stock or payment of other benefits in compliance with applicable laws, rules, and regulations, listing requirements, or other obligations.

(b) Limits on Transferability; Beneficiaries. No Award or other right or interest of a Participant under the Plan shall be pledged, hypothecated or otherwise encumbered or subject to any lien, obligation or liability of such Participant to any party (other than the Company or a subsidiary or affiliate thereof), or assigned or transferred by such Participant otherwise than by will or the laws of descent and distribution or to a Beneficiary upon the Participant’s death, and such Awards or rights that may be exercisable shall be exercised during the lifetime of the Participant only by the Participant or his or her guardian or legal representative. A Beneficiary, transferee, or other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award document applicable to such Participant, except as otherwise determined by the Committee, and to any additional terms and conditions deemed necessary or appropriate by the Committee.

(c) Adjustments. In the event of any large, special and non-recurring dividend or other distribution (whether in the form of cash or property other than Stock), recapitalization, forward or reverse split, Stock dividend, reorganization, merger, consolidation, spin-off, combination, repurchase, share exchange, liquidation, dissolution or other similar corporate transaction or event, the Committee, in order to prevent dilution or enlargement of a Participant’s rights under this Plan shall, in an equitable manner as determined by the Committee, adjust any or all of (i) the number and kind of shares of Stock or other securities of the Company or other issuer which are subject to the Plan, (ii) the number and kind of shares of Stock or other securities of the Company or other issuer by which annual per-person Award limitations are measured under Section 5, including the share limits applicable to non-employee director Awards under Section 5(c), (iii) the number and kind of shares of Stock or other securities of the Company or other issuer subject to or deliverable in respect of outstanding Awards and (iv) the exercise price, settlement price or purchase price relating to any Award or, if deemed appropriate, the Committee may make provision for a payment of cash or property to the holder of an outstanding Option (subject to Section 11(l)) or other Award. In addition, the Committee is authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards (including performance-based Awards and performance goals and any hypothetical funding pool relating thereto) in recognition of unusual or nonrecurring events (including, without limitation, events described in the preceding sentence, as well as acquisitions and dispositions of businesses and assets, or in response to changes in applicable laws, regulations, or accounting principles) affecting any performance conditions; provided that no such adjustment shall be authorized or made if and to the extent that the existence of such authority (i) would cause Options, SARs, or Performance Awards granted under the Plan to Participants designated by the Committee as Covered Employees and intended to qualify as “performance-based compensation” under Code Section 162(m) and regulations thereunder to otherwise fail to qualify as “performance-based compensation” under Code Section 162(m) and regulations thereunder, or (ii) would cause the Committee to be deemed to have authority to change the targets, within the meaning of Treasury Regulation 1.162-27(e)(4)(vi), under the performance

A-18

goals relating to Options or SARs granted to Covered Employees and intended to qualify as “performance-based compensation” under Code Section 162(m) and regulations thereunder.

(d) Tax Provisions.

(i) Withholding. The Company and any subsidiary or affiliate is authorized to withhold from any Award granted, any payment relating to an Award under the Plan, including from a distribution of Stock, or any payroll or other payment to a Participant, amounts of withholding and other taxes due or potentially payable in connection with any transaction or event involving an Award, or to require a Participant to remit to the Company an amount in cash or other property (including Stock) to satisfy such withholding before taking any action with respect to an Award, and to take such other action as the Committee may deem advisable to enable the Company and Participants to satisfy obligations for the payment of withholding taxes and other tax obligations relating to any Award, provided that the Committee may allow for additional withholding not to exceed any maximum statutorily permitted amount. This authority shall include authority to withhold or receive Stock or other property and to make cash payments in respect thereof in satisfaction of a Participant’s withholding obligations, either on a mandatory or elective basis in the discretion of the Committee, or in satisfaction of other tax obligations. The Company can delay the delivery to a Participant of Stock under any Award to the extent necessary to allow the Company to determine the amount of withholding to be collected and to collect and process such withholding.

(ii) Required Consent to and Notification of Code Section 83(b) Election. No election under Section 83(b) of the Code (to include in gross income in the year of transfer the amounts specified in Code Section 83(b)) or under a similar provision of the laws of a jurisdiction outside the United States may be made unless expressly permitted by the terms of the Award document or by action of the Committee in writing prior to the making of such election. In any case in which a Participant is permitted to make such an election in connection with an Award, the Participant shall notify the Company of such election within ten days of filing notice of the election with the Internal Revenue Service or other governmental authority, in addition to any filing and notification required pursuant to regulations issued under Code Section 83(b) or other applicable provision.

(iii) Requirement of Notification Upon Disqualifying Disposition Under Code Section 421(b). If any Participant shall make any disposition of shares of Stock delivered pursuant to the exercise of an ISO under the circumstances described in Code Section 421(b) (i.e., a disqualifying disposition), such Participant shall notify the Company of such disposition within ten days thereof.

(e) Changes to the Plan. The Board may amend, suspend or terminate the Plan or the Committee’s authority to grant Awards under the Plan without the consent of stockholders or Participants; provided, however, that any amendment to the Plan shall be submitted to the Company’s stockholders for approval not later than the earliest annual meeting for which the record date is at or after the date of such Board action:

(i) If such stockholder approval is required by any federal or state law or regulation or the rules of the New York Stock Exchange or any other stock exchange or automated quotation system on which the Stock may then be listed or quoted; or

(ii) If such amendment would materially increase the number of shares reserved for issuance and delivery under the Plan; or

A-19

(iii) If such amendment would alter the provisions of the Plan restricting the Company’s ability to grant Options or SARs with an exercise price that is not less than the Fair Market Value of Stock; or

(iv) In connection with any action to amend or replace previously granted Options or SARs in a transaction that constitutes a “repricing,” as such term defined herein under Sections 6(b)(ii) and 6(c)(ii).

The Board may otherwise, in its discretion, determine to submit other amendments to the Plan to stockholders for approval; and provided further, that, without the consent of an affected Participant, no such Board (or any Committee) action may materially and adversely affect the rights of such Participant under any outstanding Award (for this purpose, actions that alter the timing of federal income taxation of a Participant will not be deemed material unless such action results in an income tax penalty on the Participant). With regard to other terms of Awards, the Committee shall have no authority to waive or modify any such Award term after the Award has been granted to the extent the waived or modified term would be mandatory under the Plan for any Award newly granted at the date of the waiver or modification.

(f) Right of Setoff. The Company or any subsidiary or affiliate may, to the extent permitted by applicable law, deduct from and set off against any amounts the Company or a subsidiary or affiliate may owe to the Participant from time to time (including amounts payable in connection with any Award, owed as wages, fringe benefits, or other compensation owed to the Participant), such amounts as may be owed by the Participant to the Company, including but not limited to amounts owed under Section 10(a), although the Participant shall remain liable for any part of the Participant’s payment obligation not satisfied through such deduction and setoff. By accepting any Award granted hereunder, the Participant agrees to any deduction or setoff under this Section 11(f).

(g) Unfunded Status of Awards; Creation of Trusts. To the extent that any Award is deferred compensation, the Plan is intended to constitute an “unfunded” plan for deferred compensation with respect to such Award. With respect to any payments not yet made to a Participant or obligation to deliver Stock pursuant to an Award, nothing contained in the Plan or any Award shall give any such Participant any rights that are greater than those of a general creditor of the Company; provided that the Committee may authorize the creation of trusts and deposit therein cash, Stock, other Awards or other property, or make other arrangements to meet the Company’s obligations under the Plan. Such trusts or other arrangements shall be consistent with the “unfunded” status of the Plan unless the Committee otherwise determines with the consent of each affected Participant.

(h) Nonexclusivity of the Plan. Neither the adoption of the Plan by the Board nor its submission to the stockholders of the Company for approval shall be construed as creating any limitations on the power of the Board or a committee thereof to adopt such other incentive arrangements, apart from the Plan, as it may deem desirable, including incentive arrangements and awards which do not qualify under Code Section 162(m), and such other arrangements may be either applicable generally or only in specific cases.

(i) Payments in the Event of Forfeitures; Fractional Shares. No fractional shares of Stock shall be issued or delivered pursuant to the Plan or any Award. The Committee shall determine whether cash, other Awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.

(j) Compliance with Code Section 162(m). It is the intent of the Company that Options and SARs granted to Covered Employees and other Awards designated as Awards to Covered Employees subject to Section 7 shall constitute qualified “performance-based compensation” within the meaning of Code Section 162(m) and regulations thereunder, unless otherwise determined by the Committee at the time of allocation of an Award. Accordingly, the terms of Sections 7(b)

A-20

and (c), including the definitions of Covered Employee and other terms used therein, shall be interpreted in a manner consistent with Code Section 162(m) and regulations thereunder. The foregoing notwithstanding, because the Committee cannot determine with certainty whether a given Participant will be a Covered Employee with respect to a fiscal year that has not yet been completed, the term Covered Employee as used herein shall mean only a person designated by the Committee as likely to be a Covered Employee with respect to a specified fiscal year. If any provision of the Plan or any Award document relating to a Performance Award that is designated as intended to comply with Code Section 162(m) does not comply or is inconsistent with the requirements of Code Section 162(m) or regulations thereunder, such provision shall be construed or deemed amended to the extent necessary to conform to such requirements, and no provision shall be deemed to confer upon the Committee or any other person discretion to increase the amount of compensation otherwise payable in connection with any such Award upon attainment of the applicable performance objectives.

(k) Certain Limitations on Awards to Ensure Compliance with Code Section 409A. For purposes of this Plan, references to an award term or event (including any authority or right of the Company or a Participant) being “permitted” under Section 409A mean, for a 409A Award, that the term or event will not cause the Participant to be liable for payment of interest or a tax penalty under Section 409A and, for a Non-409A Award, that the term or event will not cause the Award to be treated as subject to Section 409A. Other provisions of the Plan notwithstanding, the terms of any 409A Award and any Non-409A Award, including any authority of the Company and rights of the Participant with respect to the Award, shall be limited to those terms permitted under Section 409A, and any terms not permitted under Section 409A shall be automatically modified and limited to the extent necessary to conform with Section 409A. For this purpose, other provisions of the Plan notwithstanding, the Company shall have no authority to accelerate distributions relating to 409A Awards in excess of the authority permitted under Section 409A, and any distribution subject to Section 409A(a)(2)(A)(i) (separation from service) to a “key employee” as defined under Section 409A(a)(2)(B)(i), shall not occur earlier than the earliest time permitted under Section 409A(a)(2)(B)(i).

(l) Certain Limitations Relating to Accounting Treatment of Awards. Other provisions of the Plan notwithstanding, the Committee’s authority under the Plan (including under Sections 8(c), 11(c) and 11(d)) is limited to the extent necessary to ensure that any Option or other Award of a type that the Committee has intended to be subject to fixed accounting shall not become subject to “variable” accounting solely due to the existence of such authority, unless the Committee specifically determines that the Award shall remain outstanding despite such “variable” accounting.

(m) Governing Law. The validity, construction, and effect of the Plan, any rules and regulations relating to the Plan and any Award document shall be determined in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of laws, and applicable provisions of federal law.

(n) Awards to Participants Outside the United States. The Committee may modify the terms of any Award under the Plan made to or held by a Participant who is then resident or primarily employed outside of the United States in any manner deemed by the Committee to be necessary or appropriate in order that such Award shall conform to laws, regulations, and customs of the country in which the Participant is then resident or primarily employed, or so that the value and other benefits of the Award to the Participant, as affected by foreign tax laws and other restrictions applicable as a result of the Participant’s residence or employment abroad shall be comparable to the value of such an Award to a Participant who is resident or primarily employed in the United States. An Award may be modified under this Section 11(n) in a manner that is inconsistent with the express terms of the Plan, so long as such modifications will not contravene any applicable law or regulation or result in actual liability under Section 16(b) for the Participant whose Award is modified.

A-21

(o) Limitation on Rights Conferred under Plan. Neither the Plan nor any action taken hereunder shall be construed as (i) giving any Eligible Person or Participant the right to continue as an Eligible Person or Participant or in the employ or service of the Company or a subsidiary or affiliate, (ii) interfering in any way with the right of the Company or a subsidiary or affiliate to terminate any Eligible Person’s or Participant’s employment or service at any time (subject to the terms and provisions of any separate written agreements), (iii) giving an Eligible Person or Participant any claim to be granted any Award under the Plan or to be treated uniformly with other Participants and employees, or (iv) conferring on a Participant any of the rights of a stockholder of the Company unless and until the Participant is duly issued or transferred shares of Stock in accordance with the terms of an Award or an Option is duly exercised. Except as expressly provided in the Plan and an Award document, neither the Plan nor any Award document shall confer on any person other than the Company and the Participant any rights or remedies thereunder.

(p) Severability; Entire Agreement. If any of the provisions of the Plan or any Award document is finally held to be invalid, illegal or unenforceable (whether in whole or in part), such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability, and the remaining provisions shall not be affected thereby; provided, that, if any of such provisions is finally held to be invalid, illegal, or unenforceable because it exceeds the maximum scope determined to be acceptable to permit such provision to be enforceable, such provision shall be deemed to be modified to the minimum extent necessary to modify such scope in order to make such provision enforceable hereunder. The Plan and any agreements or documents designated by the Committee as setting forth the terms of an Award contain the entire agreement of the parties with respect to the subject matter thereof and supersede all prior agreements, promises, covenants, arrangements, communications, representations and warranties between them, whether written or oral with respect to the subject matter thereof.

(q) Plan Effective Date and Termination. The Plan as hereby amended shall become effective if, and at such time as, the stockholders of the Company have approved it in accordance with applicable law and stock exchange requirements. Unless earlier terminated by action of the Board of Directors, the authority of the Committee to make grants under the Plan shall terminate on the date that is ten years after the latest date upon which stockholders of the Company have approved the Plan, and the Plan will remain in effect until such time as no Stock remains available for delivery under the Plan or as set forth above and the Company has no further rights or obligations under the Plan with respect to outstanding Awards under the Plan.

A-22

EX-10.27

Exhibit 10.27

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT, dated as of the 15^th day of November, 2017, is between CNO Services, LLC, an Indiana limited liability company (“Company”), and Yvonne K. Franzese (“Executive”).

WHEREAS, the Company desires to have the benefit and advantage of the services of Executive to assist the Company and CNO Financial Group, Inc. (“CNO”) upon the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.Employment. The Company hereby employs Executive and Executive hereby accepts employment upon the terms and conditions hereinafter set forth.

2.Term. The effective date of this agreement (the “Agreement”) shall be November 27, 2017 (the “Effective Date”). Subject to the provisions for termination as provided in Section 10 hereof, the term of Executive’s employment under this Agreement shall be the period beginning on the Effective Date and ending on November 27, 2020 (the “Term"). The Term shall not be automatically renewed and shall end upon any earlier termination of Executive’s employment with the Company.

3.Duties. During the Term, Executive shall be engaged by the Company in the capacity of Executive Vice President, Human Resources of the Company and CNO, or in such other senior executive capacity as the Chief Executive Officer of CNO shall specify. During the period from November 27, 2017 through December 31, 2017, Executive shall report to the President of CNO and for the remainder of the Term Executive shall report to the Chief Executive Officer of CNO regarding the performance of her duties.

4.Extent of Services. During the Term, subject to the direction and control of the Chief Executive Officer of CNO, Executive shall have the power and authority commensurate with her executive status and necessary to perform her duties hereunder. Executive shall devote her entire employable time, attention and best efforts to the business of the Company and, during the Term, shall not, without the consent of the Company, be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage; provided, however, that this shall not be construed as preventing Executive from serving on boards of professional, community, civic, education, charitable and corporate organizations on which she presently serves or may choose to serve or investing her assets in such form or manner as will not require any services on the part of Executive in the operation of the affairs of the companies in which such investments are made (to the extent not in violation of the non-solicitation provisions of Section 9 hereof); provided, however, that corporate organizations shall be limited to those mutually agreed upon by Executive and the Company.

5.Compensation. During the Term:

(a)As compensation for services hereunder rendered during the Term hereof, Executive shall receive a base salary (“Base Salary”) of Four Hundred Forty-Five Thousand Dollars ($445,000) per year payable in equal installments in accordance with the Company’s payroll procedure for its salaried executives. Salary payments and other payments under this Agreement shall be subject to withholding of taxes and other appropriate and customary amounts. Executive may receive increases in her Base Salary from time to time, based upon her performance, subject to approval of the Company.

(b)In addition to Base Salary, Executive will have an opportunity to earn a bonus each year, as determined by the Company, with a target annual bonus equal to 75% of Executive's Base Salary (the “Target Bonus”) and a maximum annual bonus of 150% of Executive's Base Salary with respect to any calendar year, with such bonus payable at such time that other similar payments are made to other Company executives but in no event later than March 15 of the year following the year with respect to which such bonus was payable, unless the bonus amounts to be paid cannot be confirmed and paid on or before March 15, in which event the bonuses will be paid within 15 days after the bonus amounts have been confirmed by the Company. For purposes of clarification, annual executive bonuses are payable on or before March 15 of the year following the year with respect to which such bonuses are payable, if Executive remains employed with the Company through such date or as otherwise payable under Section 11 of this Agreement. Notwithstanding the above, a pro-rata portion of the 2020 bonus will be paid at the same time that similar payments are made to other Company executives if Executive remains employed through the end of the Term. For 2017, Executive shall be entitled to a bonus of Three Hundred Thousand Dollars ($300,000), payable at the same time as bonuses are paid for 2017 to other executive officers. The performance requirements for Target Bonuses will be based on financial and other objective targets that the CNO Board of Directors (the “Board”) or the Human Resources and Compensation Committee of the Board (the “Compensation Committee”) believes are reasonably attainable at the time that they are set.

(c)On or about March 2018, Executive shall receive equity awards under the CNO Long-Term Incentive Plan with an aggregate value of approximately $600,000, one-half of which award shall be in the form of performance share units based on total shareholder return and operating return on equity, one-fourth of which shall be restricted stock units vesting ratably over three years, and one-fourth of which shall be options to purchase shares of CNO common stock, one-half of which options shall vest on the second anniversary of the date of grant and one-half of which shall vest on the third anniversary of the date of grant. The exercise price of the options will be equal to the closing sale price of CNO’s common stock on the date of grant and the options will expire on the tenth anniversary of the date of grant. The equity awards will be governed by the terms and conditions of the award agreements between CNO and Executive.

(d)Executive shall be eligible to participate in and receive future grants under any CNO stock or equity-based program offered to senior executives, subject to the discretion of the Board or the Compensation Committee.

2

6.Additional Benefits. During the Term:

(a)Executive shall be entitled to participate in such existing executive benefit plans and insurance programs offered by the Company, or which it may adopt from time to time, for its executive management or supervisory personnel generally, in accordance with the eligibility requirements for participation therein. Nothing herein shall be construed so as to prevent the Company from modifying or terminating any executive benefit plans or programs, or additional executive benefits, that it may adopt from time to time.

(b)Executive shall be entitled to five weeks of vacation with pay each year.

(c)Executive may incur reasonable expenses in connection with the Company’s business, including expenses for entertainment, travel, and similar items. The Company shall reimburse Executive for all such reasonable expenses upon Executive’s periodic presentation of an itemized account of such expenditures in accordance with the Company’s policies and procedures and Section 21 hereof; provided, however, that any such reimbursement will be made no later than March 15 of the year following the year in which the expense was incurred.

(d)Executive shall be entitled to reimbursement of reasonable and customary relocation expenses for moving her family to the Chicago, Illinois area (including, without limitation, realtor’s commission on the sale of Executive’s current home, amounts to be repaid to her current employer, one trip for Executive and her family for house hunting, as well as expenses for moving her family and household items, including two vehicles) in accordance with the Company’s current relocation policy, provided that these expenses shall be capped at $200,000. All expenses must be appropriately documented by Executive to the Company. In the event that Executive’s employment is terminated for Just Cause or if she terminates her employment other than With Reason prior to the first anniversary of the Effective Date, Executive agrees to repay such expenses to the Company.

(e) For the period from the Effective Date through June 30, 2018, the Company shall reimburse Executive for, or provide at its expense, temporary housing in the Chicago, Illinois area in an amount not to exceed $3,500 per month.

(f)The Company agrees to pay Executive an additional amount to cover the incremental additional income taxes incurred by Executive, if any, with respect to payment or reimbursement of any reasonable business expenses pursuant to subsections (c), (d) and (e) above; provided, however, that any such payment will be made no later than March 15 of the year following the year in which the income tax was incurred.

(g)Executive shall be permitted to make elective contributions to any Company-sponsored, non-qualified deferred compensation plan in accordance with the terms of such plan.

3

7.Disability.

(a) If Executive shall become physically or mentally disabled during the Term to the extent that her ability to perform her duties and services hereunder is materially and adversely impaired (any such incapacity, a “Disability”), her Base Salary, bonus and other compensation provided herein shall continue while she remains employed by the Company; provided, that if such Disability (as determined in the Company’s reasonable judgment, exercised in good faith) continues for at least three (3) consecutive months, the Company may terminate Executive’s employment hereunder, in which case the Company within 10 business days shall pay Executive a cash payment equal to (i) her annual Base Salary as provided in Section 5(a) hereof to the extent earned but unpaid as of the date of termination (“Unpaid Salary”), (ii) the bonus payable pursuant to Section 5(b) for the fiscal year of the Company ending prior to the date of termination (to the extent earned based on performance under the goals and objectives of the applicable plan but not previously paid) (“Unpaid Bonus”) and (iii) Executive’s then accrued but unused vacation (“Unpaid Vacation”) (the Unpaid Salary, Unpaid Bonus and Unpaid Vacation referred to sometimes together as the “Accrued Amounts”). Additionally, in the event of a termination of employment due to Disability, the Company shall pay to Executive a pro-rata portion of the Target Bonus for the year in which the termination for Disability occurred. All options, restricted stock and/or other awards held by Executive on the date of termination for Disability shall vest only through the date of termination according to the normal vesting schedule applicable to such options, restricted stock and/or other awards and shall be treated in accordance with the applicable award agreements.

(b) No payments or vesting under this Section 7 will be made if such Disability arose primarily from (a) chronic use of intoxicants, drugs or narcotics (other than drugs prescribed to Executive by a physician and used by Executive for their intended purpose for which they had been prescribed) or (b) intentionally self-inflicted injury or intentionally self-induced illness.

8.Disclosure of Information. Executive acknowledges that, in and as a result of her employment with the Company, she will be making use of, acquiring and/or adding to confidential information of the Company and its affiliates of a special and unique nature and value. As a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5, as well as any additional benefits stated herein, Executive covenants and agrees that she shall not, at any time while she is employed by the Company or at any time thereafter, directly or indirectly, divulge or disclose for any purpose whatsoever, any confidential information (whether or not specifically labeled or identified as “confidential information”), in any form or medium, that has been obtained by or disclosed to her as a result of her employment with the Company and which the Company or any of its affiliates has taken appropriate steps to safeguard, except to the extent that such confidential information (a) becomes a matter of public record or is otherwise available to the general public, other than as a result of any act or omission of Executive, (b) is required to be disclosed by any law, regulation or order of any court or regulatory commission, department or agency, in which event Executive shall give prompt notice of such requirement to the Company to enable the Company to seek an appropriate protective order or confidential treatment, (c) must be disclosed to enable Executive properly to perform her duties under this Agreement or (d) was developed by Executive prior to her employment by the Company. Upon the termination of Executive’s employment, Executive shall

4

return such information (in whatever form) obtained from or belonging to the Company or any of its affiliates which she may have in her possession or control.

9.Covenant Against Solicitation. Executive acknowledges that the services she is to render to the Company and its affiliates are of a special and unusual character, with a unique value to the Company and its affiliates, the loss of which cannot adequately be compensated by damages or an action at law. In view of the unique value to the Company and its affiliates of the services of Executive for which the Company has contracted hereunder, because of the confidential information to be obtained by, or disclosed to, Executive as set forth in Section 8 above, and as a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5 hereof, as well as any additional benefits stated herein, and other good and valuable consideration, Executive covenants and agrees that throughout the period Executive remains employed or compensated hereunder and for one year thereafter, Executive shall not, directly or indirectly, anywhere in the United States of America (i) solicit or attempt to convert to other insurance carriers or other corporations, persons or other entities providing these same or similar products or services provided by the Company and its affiliates, any customers or policyholders of the Company or any of its affiliates; or (ii) solicit for employment or employ any individual who was employed by the Company or any of its affiliates during the term of Executive’s employment with the Company. Should any particular covenant or provision of this Section 9 be held unreasonable or contrary to public policy for any reason, including, without limitation, the time period, geographical area, or scope of activity covered by any restrictive covenant or provision, the Company and Executive acknowledge and agree that such covenant or provision shall automatically be deemed modified such that the contested covenant or provision shall have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so modified to whatever extent would be reasonable and enforceable under applicable law.

10.Termination. During the Term:

(a)Either the Company or Executive may terminate her employment at any time for any reason upon written notice to the other. Without limiting the foregoing, the Company may terminate Executive’s employment for Just Cause pursuant to Section 10(b) below or in a Control Termination pursuant to Section 10(c) below. Without limiting the foregoing, Executive may terminate her employment pursuant to Section 10(d) below. Executive’s employment shall also terminate (i) upon the death of Executive or (ii) after Disability of Executive pursuant to Section 7 hereof. The date on which Executive’s employment with the Company terminates for any reason is called the “Termination Date”.

(b)The Company may terminate Executive’s employment at any time for Just Cause. For purposes of this Agreement, “Just Cause” shall mean:

(i) (A) material breach by Executive of this Agreement not cured within 15 days after written notice to Executive by the Company, (B) a material breach of Executive’s duty of loyalty to the Company or its affiliates not cured within 15 days after written notice to Executive by the Company, or (C) willful malfeasance or fraud or dishonesty of a substantial nature in performing Executive’s services on

5

behalf of the Company or its affiliates, which in each case is willful and deliberate on Executive’s part and committed in bad faith or without reasonable belief that such breach or action is in the best interests of the Company or its affiliates;

(ii) Executive’s use of alcohol or drugs (other than drugs prescribed to Executive by a physician and used by Executive for their intended purposes for which they had been prescribed) or other repeated conduct which materially and repeatedly interferes with the performance of her duties hereunder, which materially compromises the integrity or the reputation of the Company or its affiliates, or which results in other substantial economic harm to the Company or its affiliates;

(iii) Executive’s conviction by a court of law, admission that she is guilty, or entry of a plea of nolo contendere with regard to a felony or other crime involving moral turpitude;

(iv) Executive’s unscheduled absence from her employment duties other than as a result of illness or disability, for whatever cause, for a period of more than three (3) consecutive days, without consent from the Company prior to the expiration of the three (3) day period;

(v) Executive’s failure to take action or to abstain from taking action, as directed in writing by a member of the Board or a higher ranking executive of the Company or CNO, where such failure continues after Executive has been given written notice of such failure and at least five (5) business days thereafter to cure such failure; or

(vi) Any intentional wrongful act or omission by Executive that results in the restatement of CNO’s financial statements due to a violation of the Sarbanes-Oxley Act of 2002.

No termination shall be deemed to be a termination by the Company for Just Cause if the termination is as a result of Executive refusing to act in a manner that Executive believes in good faith would be a violation of applicable law or where Executive acts (or refrains from taking action) in good faith in accordance with directions of a member of the Board or higher-ranking executive but was unable to attain the desired results because such results were inherently unreasonable or unattainable.

(c)Executive’s employment may be terminated in a Control Termination. A "Control Termination" shall mean any termination by the Company (or its successor) of Executive’s employment for any reason, or by Executive With Reason as so defined, within six months in anticipation of or within two years following a Change in Control.

The term "Change in Control" shall mean the occurrence of any of the following:

6

(i) the acquisition (other than an acquisition in connection with a “Non-Control Transaction”) by any "person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the "1934 Act")) of "beneficial ownership" (as such term is defined in Rule 13d-3 promulgated under the 1934 Act), directly or indirectly, of securities of CNO or its Ultimate Parent representing 51% or more of the combined voting power of the then outstanding securities of CNO or its Ultimate Parent entitled to vote generally with respect to the election of the Board or the board of directors of CNO’s Ultimate Parent; or

(ii) as a result of or in connection with a tender or exchange offer or contest for election of directors, individual board members of CNO (identified as of the date of commencement of such tender or exchange offer, or the commencement of such election contest, as the case may be) cease to constitute at least a majority of the Board; or

(iii) the consummation of a merger, consolidation or reorganization with or into CNO unless (x) the stockholders of CNO immediately before such transaction beneficially own, directly or indirectly, immediately following such transaction securities representing 51% or more of the combined voting power of the then outstanding securities entitled to vote generally with respect to the election of the board of directors of CNO (or its successor) or, if applicable, the Ultimate Parent and (y) individual board members of CNO (identified as of the date that a binding agreement providing for such transaction is signed) constitute at least a majority of the board of directors of CNO (or its successor) or, if applicable, the Ultimate Parent (a transaction to which clauses (x) and (y) apply, a “Non-Control Transaction”).

For purposes of this Agreement, “Ultimate Parent” shall mean the parent corporation (or if there is more than one parent corporation, the ultimate parent corporation) that, following a transaction, directly or indirectly beneficially owns a majority of the voting power of the outstanding securities entitled to vote with respect to the election of the board of directors of CNO (or its successor).

(d)At Executive's option, she may terminate employment with the Company "With Reason" provided one or more of the following conditions are met: (i) any reduction in Executive's Base Salary or Target Bonus without her consent, or (ii) there is a "Change in Control" as defined in Section 10(c) and, following Executive's written request made prior to the Change in Control, the ultimate parent entity or entities directly or indirectly gaining control of a majority of the Board or outstanding securities entitled to vote with respect to the Board fails to affirm and guarantee the Company's current and future obligations under this Agreement; provided that the events described in clauses (i) and (ii) above shall constitute With Reason only if the Company fails to cure such event (if capable of being cured) within 30 days after receipt from Executive of written notice of the event which constitutes With Reason; provided, further, that With Reason shall cease to exist for an event on the 60^th day following the later of its occurrence or Executive’s knowledge thereof, unless Executive has given the Company written notice thereof prior to such date.

7

(e)Upon termination of Executive’s employment with the Company for any reason (whether voluntary or involuntary), Executive shall be deemed to have voluntarily resigned from all positions that Executive may then hold with the Company and any of its affiliates; provided that such deemed resignation shall not adversely affect Executive’s rights to compensation or benefits under this Agreement and shall not affect the determination of whether Executive's termination was for Just Cause or With Reason.

11. Payments Following Termination.

(a)In the event that Executive’s employment is terminated by the Company for Just Cause or if Executive voluntarily resigns (other than With Reason), then (i) the Company within 10 business days shall pay Executive a cash payment of her Base Salary as provided in Section 5(a) hereof that was earned but unpaid as of the date of termination and (ii) no bonus for the year of termination will be earned or paid to Executive. All stock options, restricted stock and/or other equity awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(b)In the event Executive’s employment is terminated by the death of Executive, then the Company shall pay Executive’s estate within 30 days (i) the Accrued Amounts and (ii) a pro-rata portion of the Target Bonus for the year in which her death occurs. All stock options, restricted stock and/or other equity awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(c) In the event that Executive is terminated (i) by the Company without Just Cause (and other than a termination due to expiration of the Term, death, Disability or a Control Termination) or (ii) by Executive With Reason, then the Company shall pay Executive within 30 days of the Termination Date the Accrued Amounts. Additionally, following such a termination, Executive shall be entitled to receive (i) a bonus pursuant to Section 5(b) based on CNO’s actual performance for the year in which Executive is terminated (prorated for the partial year period ending on the Termination Date), payable at the same time when such bonus amount normally would have been paid pursuant to Section 5(b), and (ii) a cash lump sum (payable within 75 days following the Termination Date) equal to the sum of her annual Base Salary and Target Bonus. All stock options, restricted stock and/or other equity awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(d) In the event that Executive is terminated by the Company (or its successor) in a Control Termination as so defined, or if Executive terminates her employment With Reason in a Control Termination, then the Company shall pay Executive within 30 days of the Termination Date the Accrued Amounts. Additionally, following such a termination, Executive shall be entitled to receive (i) a bonus pursuant to Section 5(b) based on CNO’s actual performance for the year during which Executive is terminated (prorated for the partial year period ending on the Termination Date), payable at the same time as such bonus payment would have been paid pursuant to Section 5(b), and (ii) a cash lump sum (payable within 75 days following the Termination Date) equal to two times the sum of (A) her Target Bonus and (B) her annual Base Salary. All stock options, restricted stock and/or

8

other equity awards held by Executive upon the occurrence of a Change in Control shall be treated in accordance with the applicable award agreements.

(e)Notwithstanding anything to the contrary, payment of any severance under this Agreement is conditioned upon the execution by Executive within 60 days following the Termination Date of a separation and release agreement in a form acceptable to the Company and the observation of such waiting or revocation periods, if any, before and after execution of the agreement by Executive as are required by law, such as, for example, the waiting or revocation periods required for a waiver and release to be effective with respect to claims under the Age Discrimination in Employment Act, provided that the Company delivers to Executive such agreement within seven days of the Termination Date. In the event that the 60-day period following the Termination Date straddles two calendar years, the severance payments described above shall not be paid prior to the second of such calendar years.

12.Character of Termination Payments. The amounts payable to Executive upon any termination of her employment shall be considered severance pay in consideration of past services rendered on behalf of the Company and her continued service from the date hereof to the date she becomes entitled to such payments and shall be the sole amount of severance pay to which Executive is entitled from the Company and its affiliates upon termination of her employment during the Term. Executive shall have no duty to mitigate her damages by seeking other employment and, should Executive actually receive compensation from any such other employment, the payments required hereunder shall not be reduced or offset by any such other compensation.

13.Representations of the Parties.

(a)The Company represents and warrants to Executive that (i) this Agreement has been duly authorized, executed and delivered by the Company and constitutes valid and binding obligations of the Company; and (ii) the employment of Executive on the terms and conditions contained in this Agreement will not conflict with, result in a breach or violation of, constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to: (A) the certificate of formation, (B) the terms of any indenture, contract, lease, mortgage, deed of trust, note, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party or bound or to which its property is subject, or (C) any statute, law, rule, regulation, judgment, order or decree applicable to the Company, or any regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company.

(b)Executive represents and warrants to the Company that: (i) this Agreement has been duly executed and delivered by Executive and constitutes a valid and binding obligation of Executive; and (ii) neither the execution of this Agreement by Executive nor her employment by the Company on the terms and conditions contained herein will conflict with, result in a breach or violation of, or constitute a default under any agreement, obligation, condition, covenant or instrument to which Executive is a party or bound or to

9

which her property is subject, or any statute, law, rule, regulation, judgment, order or decree applicable to Executive of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over Executive or any of her property.

14.Arbitration of Disputes; Injunctive Relief.

(a)Arbitration. Except as provided in subsection (b) below, any controversy or claim arising out of or relating to this Agreement or the breach thereof shall be settled by binding arbitration in the City of Indianapolis, Indiana, in accordance with the laws of the State of Indiana by three arbitrators, one of whom shall be appointed by the Company, one by Executive, and the third of whom shall be appointed by the first two arbitrators. If the first two arbitrators cannot agree on the appointment of a third arbitrator, then the third arbitrator shall be appointed by the Chief Judge of the United States District Court for the Southern District of Indiana. The arbitration shall be conducted in accordance with the rules of the American Arbitration Association, except with respect to the selection of arbitrators, which shall be as provided in this Section. Judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. All reasonable costs and expenses (including fees and disbursements of counsel) incurred by Executive pursuant to this Section 14 shall be paid on behalf of or reimbursed to Executive promptly by the Company; provided, however, that in the event the Company prevails in such proceedings, Executive shall immediately repay all such amounts to the Company.

(b)Executive acknowledges that a breach or threatened breach by Executive of Sections 8 or 9 of this Agreement will give rise to irreparable injury to the Company and that money damages will not be adequate relief for such injury. Notwithstanding paragraph (a) above, the Company and Executive agree that the Company may seek and obtain injunctive relief, including, without limitation, temporary restraining orders, preliminary injunctions and/or permanent injunctions, in a court of proper jurisdiction to restrain or prohibit a breach or threatened breach of Section 8 or 9 of this Agreement. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies available to the Company for such breach or threatened breach, including the recovery of damages from Executive.

15.Notices. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered mail to her residence, in the case of Executive, or to the business office of its General Counsel, in the case of the Company.

16.Waiver of Breach and Severability. The waiver by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by either party. In the event any provision of this Agreement is found to be invalid or unenforceable, it may be severed from the Agreement, and the remaining provisions of the Agreement shall continue to be binding and effective.

17.Entire Agreement. Other than any equity award agreements entered into pursuant to the CNO Financial Group, Inc. Amended and Restated Long-Term Incentive Plan or any subsequent incentive plan, this instrument contains the entire agreement of the parties and, as of the Effective Date, supersedes all other obligations of the Company and its affiliates under other

10

agreements or otherwise. The compensation and benefits to be paid under the terms of this Agreement are in lieu of all other compensation or benefits to which Executive is entitled from CNO, the Company, and its affiliates, and upon termination of Executive’s employment with the Company Executive will not be entitled to receive any severance or other payments beyond those specified in this Agreement. This Agreement may not be changed orally, but only by an instrument in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

18.Binding Agreement and Governing Law; Assignment Limited. This Agreement shall be binding upon and shall inure to the benefit of the parties and their lawful successors in interest (including, without limitation, Executive’s estate, heirs and personal representatives) and, except for issues or matters as to which federal law is applicable, shall be construed in accordance with and governed by the laws of the State of Indiana. This Agreement is personal to each of the parties hereto, and neither party may assign or delegate any of its rights or obligations hereunder without the prior written consent of the other.

19.Indemnification. If Executive was or is made a party or is threatened to be made a party to or is otherwise involved (including involvement as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that she is or was an officer or employee of the Company or any of its affiliates, Executive shall be indemnified and held harmless by the Company to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than permitted prior thereto), against all expense, liability and loss (including attorneys’ fees, judgments, fines, excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by Executive in connection therewith and such indemnification shall continue as to Executive if she ceases to be an officer or employee and shall inure to the benefit of Executive's heirs, executors and administrators; provided, however, that the Company shall indemnify Executive in connection with a Proceeding (or part thereof) initiated by Executive only if such Proceeding (or part thereof) was authorized by the managing member of the Company. The right to indemnification conferred in this paragraph shall include the obligation of the Company to pay the expenses incurred in defending any such Proceeding in advance of its final disposition (an “Advance of Expenses”); provided, however, that, if and to the extent that the Delaware General Corporation Law requires, an Advance of Expenses incurred by Executive in her capacity as an officer or employee shall be made only upon delivery to the Company of an undertaking, by or on behalf of Executive, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that Executive is not entitled to be indemnified for such expenses under this paragraph or otherwise.

20. No Third Party Beneficiaries. The terms and provisions of this Agreement are intended solely for the benefit of each party hereto and their respective successors or permitted assigns, and it is not intended to confer third-party beneficiary rights upon any other person.

21.Section 409A. This Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended from time to time (the “Code”), and will be interpreted accordingly. References under this Agreement to Executive’s termination of employment shall be deemed to refer to the date upon which Executive has experienced a “separation from service” within the meaning of Section 409A of the Code. Notwithstanding anything herein to the contrary,

11

(i) if at the time of Executive’s separation from service with the Company Executive is a “specified employee” as defined in Section 409A of the Code (and any related regulations or announcements thereunder) and the deferral of the commencement of any payments or benefits otherwise payable hereunder or payable under any other compensatory arrangement between Executive and the Company or any of its affiliates as a result of such separation from service is necessary in order to prevent any accelerated or additional tax under Section 409A of the Code, then the Company will defer the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive’s separation from service (or the earliest date as is permitted under Section 409A of the Code), at which point all payments deferred pursuant to this Section 21 shall be paid to Executive in a lump sum and (ii) if any payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional tax under Section 409A of the Code, such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a manner that does not cause such an accelerated or additional tax. To the extent any reimbursements or in-kind benefits due to Executive under this Agreement constitute “deferred compensation” under Section 409A of the Code, any such reimbursements or in-kind benefits shall be paid to Executive in a manner consistent with Treas. Reg. Section 1.409A-3(i)(l)(iv). Additionally, to the extent that Executive’s receipt of any in-kind benefits from the Company or its affiliates must be delayed pursuant to this Section 21 due to his status as a “specified employee,” Executive may elect to instead purchase and receive such benefits during the period in which the provision of benefits would otherwise be delayed by paying the Company (or its affiliates) for the fair market value of such benefits (as determined by the Company in good faith) during such period. Any amounts paid by Executive pursuant to the preceding sentence shall be reimbursed to Executive as described above on the date that is six months following her separation from service. Each payment made under this Agreement shall be designated as a “separate payment” within the meaning of Section 409A of the Code. The Company shall consult with Executive in good faith regarding the implementation of the provisions of this Section 21, provided that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect thereto.

22. Effect of Excise Tax and Limit on Golden Parachute Payments.

(a)Contingent Reduction of Parachute Payments. If there is a change in ownership or control of CNO that would cause any payment or distribution by the Company or any of its subsidiaries or any other person or entity to Executive or for Executive’s benefit (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise) (each, a “Payment”, and collectively, the “Payments”) to be subject to the excise tax imposed by Section 4999 of the Code (such excise tax, together with any interest or penalties incurred by Executive with respect to such excise tax, the “Excise Tax”), then Executive will receive the greatest of the following, whichever gives Executive the highest net after-tax amount (after taking into account federal, state, local and social security taxes): (1) the Payments or (2) one dollar less than the amount of the Payments that would subject Executive to the Excise Tax (the “Safe Harbor Amount”). If a reduction in the Payments is necessary so that the Payments equal the Safe Harbor Amount, then the reduction will be determined in a manner which has the least economic cost to Executive and, to the extent the economic cost is equivalent, will be reduced in the inverse order of when payment would have been made to Executive, until the reduction is

12

achieved. Any reductions pursuant to this Section shall be made in a manner intended to be consistent with the requirements of Section 409A of the Internal Revenue Code.

(b)Determination of the Payments. All determinations required to be made under this Section, including whether and when the Safe Harbor Amount is required and the amount of the reduction of the Payments and the assumptions to be utilized in arriving at such determination, shall be made by the Company which shall provide detailed supporting calculations to Executive. Executive shall cooperate with any reasonable requests by the Company in connection with any contests or disputes with the Internal Revenue Service in connection with the Excise Tax.

(c) Adjustments.As a result of the uncertainty in the application of Section 4999 of the Code at the time of a determination hereunder, it is possible that Payments will be made which should not have been made under clause (a) of this Section (“Overpayment”) or that additional Payments which are not made pursuant to clause (a) of this Section should have been made (“Underpayment”). In the event that there is a final determination by the Internal Revenue Service, or a final determination by a court of competent jurisdiction, that an Overpayment has been made, any such Overpayment shall be treated for all purposes as a loan to Executive which Executive shall repay to the Company together with interest at the applicable Federal rate provided for in Section 7872(f)(2) of the Code. In the event that there is a final determination by the Internal Revenue Service, a final determination by a court of competent jurisdiction or a change in the provisions of the Code or regulations pursuant to which an Underpayment arises under this Agreement, any such Underpayment shall be promptly paid by the Company to or for the benefit of Executive, together with interest at the applicable Federal rate provided for in Section 7872(f)(2) of the Code.

23. Counterparts: This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written, effective as of the Effective Date.

COMPANY:

CNO SERVICES, LLC

/s/ Gary C. Bhojwani

Gary C. Bhojwani

President

EXECUTIVE:

/s/ Yvonne K. Franzese

Yvonne K. Franzese

13

EX-12.1

Exhibit 12.1

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

Computation of Ratio of Earnings to Fixed Charges

(Dollars in millions)

	2017		2016			2015		2014		2013
Pretax income from operations:
Net income	$	175.6	$	358.2		$	270.7	$	51.4	$	478.0
Add income tax expense (benefit)	304.9		(5.0		)	97.0		123.7		(173.2		)
Pretax income from operations	480.5		353.2			367.7		175.1		304.8
Add fixed charges:
Interest expense on corporate debt	46.5		45.8			45.0		43.9		51.3
Interest expense on investment borrowings and borrowings related to variable interest entities	77.2		70.6			49.9		48.9		54.0
Interest added to policyholder account balances	105.2		112.9			122.7		173.0		232.5
Portion of rental (a)	18.7		17.2			14.1		15.1		13.3
Fixed charges	247.6		246.5			231.7		280.9		351.1
Adjusted earnings	$	728.1	$	599.7		$	599.4	$	456.0	$	655.9
Ratio of earnings to fixed charges	2.94X		2.43X			2.59X		1.62X		1.87X

____________________

(a) Interest portion of rental is estimated to be 33 percent.

EX-21

Exhibit 21

Subsidiaries of CNO Financial Group, Inc.

Name	State or Other Jurisdiction
40|86 Advisors, Inc.	DE
40|86 Mortgage Capital, Inc.	DE
American Life and Casualty Marketing Division Co.	IA
Bankers Conseco Life Insurance Company	NY
Bankers Life Advisory Services, Inc.	IN
Bankers Life and Casualty Company	IL
Bankers Life Securities General Agency, Inc.	IN
Bankers Life Securities, Inc.	IN
Business Credit Administration Corp.	IN
C.P. Real Estate Services Corp.	NJ
CDOC, Inc.	DE
CNO Financial Group, Inc.	DE
CNO Financial Investments Corp.	IL
CNO Management Services Company	TX
CNO Services, LLC	IN
Colonial Penn Life Insurance Company	PA
Conseco Life Insurance Company of Texas	TX
Conseco Marketing, L.L.C.	IN
Design Benefit Plans, Inc.	IL
Hawthorne Advertising Agency Incorporated	PA
Illinois General Investment Corp.	DE
Indiana General Investment Corp.	DE
K.F. Agency, Inc.	IL
K.F. Insurance Agency of Massachusetts, Inc.	MA
Performance Matters Associates, Inc.	IN
Resource Life Insurance Company	IL
Washington National Insurance Company	IN

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (No. 333-108835, 333-166788, and 333-217884) and Form S-3 (No. 333-204039) of CNO Financial Group, Inc. of our reportdated February 23, 2018 relating to the consolidated financial statements, financial statement schedules and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.

/s/ PricewaterhouseCoopers LLP

Indianapolis, Indiana

February 23, 2018

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Gary C. Bhojwani, certify that:

1. I have reviewed this annual report on Form 10-K of CNO Financial Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  February 23, 2018

/s/ Gary C. Bhojwani

Gary C. Bhojwani

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Erik M. Helding, certify that:

1. I have reviewed this annual report on Form 10-K of CNO Financial Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  February 23, 2018

/s/ Erik M. Helding

Erik M. Helding

Executive Vice President

and Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of CNO Financial Group, Inc. (the "Company") on Form 10-K for the year ending December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gary C. Bhojwani, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my actual knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Gary C. Bhojwani

Gary C. Bhojwani

Chief Executive Officer

February 23, 2018

A signed original of this written statement required by Section 906 has been provided to CNO Financial Group, Inc. and will be retained by CNO Financial Group, Inc. and furnished to the Securities and Exchange Commission upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of CNO Financial Group, Inc. (the "Company") on Form 10-K for the year ending December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Erik M. Helding, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my actual knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Erik M. Helding

Erik M. Helding

Executive Vice President and

Chief Financial Officer

February 23, 2018

A signed original of this written statement required by Section 906 has been provided to CNO Financial Group, Inc. and will be retained by CNO Financial Group, Inc. and furnished to the Securities and Exchange Commission upon request.

XML

DOCUMENT AND ENTITY INFORMATION - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2017	Feb. 08, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	CNO Financial Group, Inc.
Entity Central Index Key	0001224608
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Entity Filer Category	Large Accelerated Filer
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Amendment Flag	false
Entity Public Float			$ 3.5
Entity Common Stock, Shares Outstanding		166,876,131

XML

CONSOLIDATED BALANCE SHEET - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Investments:
Fixed maturities, available for sale, at fair value (amortized cost: 2017 - $20,702.1; 2016 - $19,803.1)	$ 22,910.9	$ 21,096.2
Equity securities at fair value (cost: 2017 - $491.1; 2016 - $580.7)	511.7	584.2
Mortgage loans	1,650.6	1,768.0
Policy loans	116.0	112.0
Trading securities	284.6	363.4
Investments held by variable interest entities	1,526.9	1,724.3
Other invested assets	853.4	589.5
Total investments	27,854.1	26,237.6
Cash and cash equivalents - unrestricted	578.4	478.9
Cash and cash equivalents held by variable interest entities	178.9	189.3
Accrued investment income	245.9	239.6
Present value of future profits	359.6	401.8
Deferred acquisition costs	1,026.8	1,044.7
Reinsurance receivables	2,175.2	2,260.4
Income tax assets, net	366.9	789.7
Assets held in separate accounts	5.0	4.7
Other assets	319.5	328.5
Total assets	33,110.3	31,975.2
Liabilities for insurance products:
Policyholder account balances	11,220.7	10,912.7
Future policy benefits	11,521.3	10,953.3
Liability for policy and contract claims	530.3	500.6
Unearned and advanced premiums	261.7	282.5
Liabilities related to separate accounts	5.0	4.7
Other liabilities	751.8	611.4
Investment borrowings	1,646.7	1,647.4
Borrowings related to variable interest entities	1,410.7	1,662.8
Notes payable – direct corporate obligations	914.6	912.9
Total liabilities	28,262.8	27,488.3
Commitments and Contingencies
Shareholders' equity:
Common stock ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)	1.7	1.7
Additional paid-in capital	3,073.3	3,212.1
Accumulated other comprehensive income	1,212.1	622.4
Retained earnings	560.4	650.7
Total shareholders' equity	4,847.5	4,486.9
Total liabilities and shareholders' equity	$ 33,110.3	$ 31,975.2

XML

CONSOLIDATED BALANCE SHEET (Parentheticals) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Investments:
Fixed maturities, available for sale, amortized cost	$ 20,702.1	$ 19,803.1
Equity securities cost	$ 491.1	$ 580.7
Shareholders' equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000,000	8,000,000,000
Common stock, shares issued (in shares)	166,857,931	173,753,614
Common stock, shares outstanding (in shares)	166,857,931	173,753,614

XML

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Insurance policy income	$ 2,647.3	$ 2,601.1	$ 2,556.0
Net investment income:
General account assets	1,285.4	1,204.1	1,203.6
Policyholder and other special-purpose portfolios	265.9	121.1	30.0
Realized investment gains (losses):
Net realized investment gains (losses), excluding impairment losses	77.4	47.9	(8.0)
Other-than-temporary impairments:
Total other-than-temporary impairment losses	(21.9)	(35.9)	(42.9)
Portion of other-than-temporary impairment losses recognized in accumulated other comprehensive income	(0.9)	3.6	3.0
Net impairment losses recognized	(22.8)	(32.3)	(39.9)
Gain (loss) on dissolution of variable interest entities	(4.3)	(7.3)	11.3
Total realized gains (losses)	50.3	8.3	(36.6)
Fee revenue and other income	48.3	50.5	58.9
Total revenues	4,297.2	3,985.1	3,811.9
Benefits and expenses:
Insurance policy benefits	2,602.7	2,390.5	2,308.3
Loss on reinsurance transaction and transition expenses	0.0	75.4	9.0
Interest expense	123.7	116.4	94.9
Amortization	239.3	253.3	260.0
Loss on extinguishment of debt	0.0	0.0	32.8
Loss on extinguishment of borrowings related to variable interest entities	9.5	0.0	0.0
Other operating costs and expenses	841.5	796.3	739.2
Total benefits and expenses	3,816.7	3,631.9	3,444.2
Income before income taxes	480.5	353.2	367.7
Income tax expense (benefit):
Tax expense on period income	162.8	127.8	129.5
Valuation allowance for deferred tax assets and other tax items	142.1	(132.8)	(32.5)
Net income	$ 175.6	$ 358.2	$ 270.7
Basic:
Weighted average shares outstanding (in shares)	170,025	176,638	193,054
Net income (in dollars per share)	$ 1.03	$ 2.03	$ 1.40
Diluted:
Weighted average shares outstanding (in shares)	172,144	178,323	195,166
Net income (in dollars per share)	$ 1.02	$ 2.01	$ 1.39

XML

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 175.6	$ 358.2	$ 270.7
Other comprehensive income, before tax:
Unrealized gains (losses) for the period	959.3	424.4	(1,337.6)
Amortization of present value of future profits and deferred acquisition costs	(29.7)	(27.9)	157.9
Amount related to premium deficiencies assuming the net unrealized gains (losses) had been realized	(310.5)	(46.9)	495.3
Reclassification adjustments:
For net realized investment (gains) losses included in net income	(40.2)	(18.6)	29.6
For amortization of the present value of future profits and deferred acquisition costs related to net realized investment gains (losses) included in net income	1.0	0.7	(0.5)
Unrealized gains (losses) on investments	579.9	331.7	(655.3)
Change related to deferred compensation plan	0.0	8.6	(0.1)
Other comprehensive income (loss) before tax	579.9	340.3	(655.4)
Income tax (expense) benefit related to items of accumulated other comprehensive income	(195.6)	(120.7)	232.9
Other comprehensive income (loss), net of tax	384.3	219.6	(422.5)
Comprehensive income (loss)	$ 559.9	$ 577.8	$ (151.8)

XML

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common stock and additional paid-in capital	Accumulated other comprehensive income	Retained earnings
Balance, beginning of period at Dec. 31, 2014	$ 4,688.2	$ 3,734.4	$ 825.3	$ 128.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	270.7			270.7
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit))	(420.4)		(420.4)
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit))	(2.1)		(2.1)
Cost of common stock repurchased	(365.2)	(365.2)
Dividends on common stock	(52.1)			(52.1)
Stock options, restricted stock and performance units	19.4	19.4
Balance, end of period at Dec. 31, 2015	4,138.5	3,388.6	402.8	347.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	358.2			358.2
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit))	221.1		221.1
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit))	(1.5)		(1.5)
Cost of common stock repurchased	(203.0)	(203.0)
Dividends on common stock	(54.6)			(54.6)
Stock options, restricted stock and performance units	28.2	28.2
Balance, end of period at Dec. 31, 2016	4,486.9	3,213.8	622.4	650.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of accounting change	0.3	0.9		(0.6)
Net income	175.6			175.6
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax expense (benefit))	382.1		382.1
Change in noncredit component of impairment losses on fixed maturities, available for sale (net of applicable income tax expense (benefit))	2.2		2.2
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	0.0		205.4	(205.4)
Cost of common stock repurchased	(167.1)	(167.1)
Dividends on common stock	(59.9)			(59.9)
Stock options, restricted stock and performance units	27.4	27.4
Balance, end of period at Dec. 31, 2017	$ 4,847.5	$ 3,075.0	$ 1,212.1	$ 560.4

XML

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Parentheticals) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Stockholders' Equity [Abstract]
Change in unrealized appreciation (depreciation) of investments, applicable income tax expense (benefit)	$ 194.4	$ 121.5	$ (231.7)
Change in noncredit component of impairment losses on fixed maturities, available for sale, applicable income tax expense (benefit)	$ 1.2	$ (0.8)	$ (1.2)

XML

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Insurance policy income	$ 2,483.2	$ 2,457.0	$ 2,423.4
Net investment income	1,229.6	1,201.0	1,205.9
Fee revenue and other income	48.3	50.5	58.9
Cash and cash equivalents received upon recapture of reinsurance	0.0	73.6	0.0
Insurance policy benefits	(1,973.1)	(1,916.0)	(1,879.4)
Interest expense	(120.5)	(106.0)	(90.0)
Deferrable policy acquisition costs	(236.1)	(242.7)	(246.4)
Other operating costs	(740.9)	(747.9)	(720.5)
Income taxes	(77.4)	(6.7)	(4.1)
Net cash from operating activities	613.1	762.8	747.8
Cash flows from investing activities:
Sales of investments	2,487.4	2,841.8	2,177.6
Maturities and redemptions of investments	3,324.6	2,507.2	1,853.4
Purchases of investments	(6,141.0)	(6,159.8)	(4,767.2)
Net sales (purchases) of trading securities	108.9	(84.2)	(12.3)
Change in cash and cash equivalents held by variable interest entities	10.4	175.1	(296.1)
Other	(29.9)	(22.5)	(25.0)
Net cash provided (used) by investing activities	(239.6)	(742.4)	(1,069.6)
Cash flows from financing activities:
Issuance of notes payable, net	0.0	0.0	910.0
Payments on notes payable	0.0	0.0	(797.1)
Expenses related to extinguishment of debt	0.0	0.0	(17.8)
Issuance of common stock	8.3	8.4	6.3
Payments to repurchase common stock	(168.3)	(210.0)	(365.4)
Common stock dividends paid	(59.6)	(54.8)	(52.0)
Amounts received for deposit products	1,445.9	1,386.7	1,241.9
Withdrawals from deposit products	(1,232.6)	(1,181.6)	(1,225.0)
Issuance of investment borrowings:
Federal Home Loan Bank	432.0	432.7	475.0
Related to variable interest entities	981.6	493.2	544.7
Payments on investment borrowings:
Federal Home Loan Bank	(432.7)	(333.5)	(425.7)
Related to variable interest entities and other	(1,248.6)	(514.9)	(132.0)
Investment borrowings - repurchase agreements, net	0.0	0.0	(20.4)
Net cash provided (used) by financing activities	(274.0)	26.2	142.5
Net increase (decrease) in cash and cash equivalents	99.5	46.6	(179.3)
Cash and cash equivalents, beginning of year	478.9	432.3	611.6
Cash and cash equivalents, end of year	$ 578.4	$ 478.9	$ 432.3

XML

BUSINESS AND BASIS OF PRESENTATION

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BUSINESS AND BASIS OF PRESENTATION

BUSINESS AND BASIS OF PRESENTATION

CNO Financial Group, Inc., a Delaware corporation ("CNO"), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer health insurance, annuity, individual life insurance and other insurance products.  The terms "CNO Financial Group, Inc.", "CNO", the "Company", "we", "us", and "our" as used in these financial statements refer to CNO and its subsidiaries.  Such terms, when used to describe insurance business and products, refer to the insurance business and products of CNO's insurance subsidiaries.

We focus on serving middle-income pre-retiree and retired Americans, which we believe are attractive, underserved, high growth markets.  We sell our products through three distribution channels: career agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; long-term care in run off; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting as an additional business segment, the long-term care block recaptured from Beechwood Re Ltd. ("BRe"), as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance". The Company’s insurance segments are described below:

• Bankers Life,which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices.  The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life").  Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plan products in exchange for a fee.

• Washington National, which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite.  These products are marketed through Performance Matters Associates, Inc. and through independent marketing organizations and insurance agencies including worksite marketing.  The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.

• Colonial Penn, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing.  The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").

• Long-term care in run-off consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC").

We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"). We have reclassified certain amounts from the prior periods to conform to the 2017 presentation. These reclassifications have no effect on net income or shareholders' equity.

The accompanying financial statements include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude transactions between us and our consolidated affiliates, or among our consolidated affiliates.

When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods.  For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals.  If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Investments

Fixed maturity securities include available for sale bonds and redeemable preferred stocks. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders’ equity.

Equity securities include available for sale investments in common stock, exchange-traded funds and non-redeemable preferred stock. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders' equity.

Mortgage loans held in our investment portfolio are carried at amortized unpaid balances, net of provisions for estimated losses. Interest income is accrued on the principal amount of the loan based on the loan's contractual interest rate. Payment terms specified for mortgage loans may include a prepayment penalty for unscheduled payoff of the investment. Prepayment penalties are recognized as investment income when received.

Policy loans are stated at current unpaid principal balances. Policy loans are collateralized by the cash surrender value of the life insurance policy. Interest income is recorded as earned using the contractual interest rate.

Trading securities include: (i) investments purchased with the intent of selling in the near team to generate income; (ii) investments supporting certain insurance liabilities (including investments backing the market strategies of our multibucket annuity products); and (iii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in fair value of the income generating investments and investments supporting insurance liabilities and reinsurance agreements is recognized in income from policyholder and other special-purpose portfolios (a component of net investment income). The change in fair value of securities with embedded derivatives is recognized in realized investment gains (losses). Investment income related to investments supporting certain insurance liabilities is substantially offset by the change in insurance policy benefits related to certain products.

Other invested assets include: (i) call options purchased in an effort to offset or hedge the effects of certain policyholder benefits related to our fixed index annuity and life insurance products; (ii) Company-owned life insurance ("COLI"); and (iii) certain non-traditional investments. We carry the call options at estimated fair value as further described in the section of this note entitled "Accounting for Derivatives". We carry COLI at its cash surrender value which approximates its net realizable value. Non-traditional investments include investments in certain limited partnerships and hedge funds which are accounted for using the equity method; and promissory notes, which are accounted for using the cost method. In accounting for limited partnerships and hedge funds, we consistently use the most recently available financial information provided by the general partner or manager of each of these investments, which is one to three months prior to the end of our reporting period.

Interest income on fixed maturity securities is recognized when earned using a constant effective yield method giving effect to amortization of premiums and accretion of discounts. Prepayment fees are recognized when earned. Dividends on equity securities are recognized when declared.

When we sell a security (other than trading securities), we report the difference between the sale proceeds and amortized cost (determined based on specific identification) as a realized investment gain or loss.

We regularly evaluate our investments for possible impairment as further described in the note to the consolidated financial statements entitled "Investments".

When a security defaults (including mortgage loans) or securities are other-than-temporarily impaired, our policy is to discontinue the accrual of interest and eliminate all previous interest accruals, if we determine that such amounts will not be ultimately realized in full.

Cash and Cash Equivalents

Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value.

Deferred Acquisition Costs

Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For interest-sensitive life or annuity products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate.

When we realize a gain or loss on investments backing our interest-sensitive life or annuity products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust deferred acquisition costs for the change in amortization that would have been recorded if our fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We limit the total adjustment related to the impact of unrealized losses to the total of costs capitalized plus interest related to insurance policies issued in a particular year. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity.

We regularly evaluate the recoverability of the unamortized balance of the deferred acquisition costs. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the deferred acquisition costs may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the deferred acquisition costs over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years.

Present Value of Future Profits

The present value of future profits is the value assigned to the right to receive future cash flows from policyholder insurance contracts existing at September 10, 2003 (the "Effective Date", the effective date of the bankruptcy reorganization of Conseco, Inc., an Indiana corporation (our "Predecessor")). The discount rate we used to determine the present value of future profits was 12 percent. The balance of this account is amortized and evaluated for recovery in the same manner as described above for deferred acquisition costs.  We also adjust the present value of future profits for the change in amortization that would have been recorded if the fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields, similar to the manner described above for deferred acquisition costs.  We limit the total adjustment related to the impact of unrealized losses to the total present value of future profits plus interest.

Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts

For interest-sensitive life and annuity contracts that do not involve significant mortality or morbidity risk, the amounts collected from policyholders are considered deposits and are not included in revenue. Revenues for these contracts consist of charges for policy administration, cost of insurance charges and surrender charges assessed against policyholders' account balances. Such revenues are recognized when the service or coverage is provided, or when the policy is surrendered.

We establish liabilities for annuity and interest-sensitive life products equal to the accumulated policy account values, which include an accumulation of deposit payments plus credited interest, less withdrawals and the amounts assessed against the policyholder through the end of the period. In addition, policyholder account values for certain interest-sensitive life products are impacted by our assumptions related to changes of certain non-guaranteed elements that we are allowed to make under the terms of the policy, such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. Sales inducements provided to the policyholders of these products are recognized as liabilities over the period that the contract must remain in force to qualify for the inducement. The options attributed to the policyholder related to our fixed index annuity products are accounted for as embedded derivatives as described in the section of this note entitled "Accounting for Derivatives".

Premiums from individual life products (other than interest-sensitive life contracts) and health products are recognized when due. When premiums are due over a significantly shorter period than the period over which benefits are provided, any gross premium in excess of the net premium (i.e., the portion of the gross premium required to provide for all expected future benefits and expenses) is deferred and recognized into revenue in a constant relationship to insurance in force. Benefits are recorded as an expense when they are incurred.

We establish liabilities for traditional life, accident and health insurance, and life contingent payment annuity products using mortality tables in general use in the United States, which are modified to reflect the Company's actual experience when appropriate. We establish liabilities for accident and health insurance products using morbidity tables based on the Company's actual or expected experience. These reserves are computed at amounts that, with additions from estimated future premiums received and with interest on such reserves at estimated future rates, are expected to be sufficient to meet our obligations under the terms of the policy. Liabilities for future policy benefits are computed on a net-level premium method based upon assumptions as to future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses determined when the policies were issued (or with respect to policies inforce at August 31, 2003, the Company's best estimate of such assumptions on the Effective Date). We make an additional provision to allow for potential adverse deviation for some of our assumptions. Once established, assumptions on these products are generally not changed unless a premium deficiency exists. In that case, a premium deficiency reserve is recognized and the future pattern of reserve changes is modified to reflect the relationship of premiums to benefits based on the current best estimate of future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses, determined without an additional provision for potential adverse deviation.

We establish claim reserves based on our estimate of the loss to be incurred on reported claims plus estimates of incurred but unreported claims based on our past experience.

Accounting for Long-term Care Premium Rate Increases

Many of our long-term care policies have been subject to premium rate increases. In some cases, these premium rate increases were materially consistent with the assumptions we used to value the particular block of business at the Effective Date. With respect to certain premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these policyholder options:

• Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.

• Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.

• Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.

Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit.

Accounting for Certain Marketing Agreements

Bankers Life has entered into various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute prescription drug and Medicare Advantage plans. These agreements allow Bankers Life to offer these products to current and potential future policyholders without investment in management and infrastructure. We receive fee income related to the plans sold through our distribution channels. We account for these distribution agreements as follows:

• We recognize distribution income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract.

• We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract.

Reinsurance

In the normal course of business, we seek to limit our loss exposure on any single insured or to certain groups of policies by ceding reinsurance to other insurance enterprises. We currently retain no more than $.8 million of mortality risk on any one policy. We diversify the risk of reinsurance loss by using a number of reinsurers that have strong claims-paying ratings. In each case, the ceding CNO subsidiary is directly liable for claims reinsured in the event the assuming company is unable to pay.

The cost of reinsurance ceded totaled $105.0 million, $123.9 million and $133.6 million in 2017, 2016 and 2015, respectively.  We deduct this cost from insurance policy income.  Reinsurance recoveries netted against insurance policy benefits totaled $88.6 million, $130.1 million and $167.7 million in 2017, 2016 and 2015, respectively.

From time to time, we assume insurance from other companies.  Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs.  Reinsurance premiums assumed totaled $30.4 million, $34.0 million and $38.5 million in 2017, 2016 and 2015, respectively. Insurance policy benefits related to reinsurance assumed totaled $44.7 million, $47.5 million and $48.0 million in 2017, 2016 and 2015, respectively.

In December 2013, two of our insurance subsidiaries entered into 100% coinsurance agreements ceding $495 million of long-term care reserves to BRe. Pursuant to the agreements, the insurance subsidiaries paid an additional premium of $96.9 million to BRe and an amount equal to the related net liabilities. The insurance subsidiaries' ceded reserve credits were secured by assets in market-value trusts subject to a 7% overcollateralization, investment guidelines and periodic true-up provisions. Future payments into the trusts to maintain collateral requirements were the responsibility of BRe.

In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business. As a result of the recapture, we were required to value the assets and liabilities as of the date of recapture based on valuation methodologies that are consistent with the methodologies used by CNO to value its other investments and insurance liabilities. Accordingly, we recognized a loss on the recapture of the long-term care business as summarized below (dollars in millions):

Market value of investments	$	504.7
Insurance liabilities	(552.2		)
Write-off of reinsurance receivables	(17.9		)
Estimated transaction expenses	(10.0		)
Pre-tax loss	(75.4		)
Tax benefit	26.4
Increase in valuation allowance for deferred tax assets	(4.1		)
After-tax loss	$	(53.1	)

Income Taxes

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and net operating loss carryforwards ("NOLs"). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire.

At December 31, 2017, our valuation allowance for our net deferred tax assets was $89.1 million, as we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax assets and assessing the effects of limitations and/or interpretations on the value of such component to be fully recognized in the future.

Investments in Variable Interest Entities

We have concluded that we are the primary beneficiary with respect to certain variable interest entities ("VIEs"), which are consolidated in our financial statements. All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments.  The assets held by the trusts are legally isolated and not available to the Company.  The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company.  The Company has no financial obligation to the VIEs beyond its investment in each VIE.

The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade.  Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information about VIEs.

In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager.  These structured securities include asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, residential mortgage-backed securities and collateralized mortgage obligations.  Our maximum exposure to loss on these securities is limited to our cost basis in the investment.  We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses.

At December 31, 2017, we held investments in various limited partnerships, in which we are not the primary beneficiary, totaling $371.1 million (classified as other invested assets).  At December 31, 2017, we had unfunded commitments to these partnerships of $276.5 million.  Our maximum exposure to loss on these investments is limited to the amount of our investment.

Investment borrowings

Three of the Company's insurance subsidiaries (Washington National, Bankers Life and Colonial Penn) are members of the Federal Home Loan Bank ("FHLB").  As members of the FHLB, our insurance subsidiaries have the ability to borrow on a collateralized basis from the FHLB.  We are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings.  At December 31, 2017, the carrying value of the FHLB common stock was $71.2 million.  As of December 31, 2017, collateralized borrowings from the FHLB totaled $1.6 billion and the proceeds were used to purchase fixed maturity securities.  The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.  The borrowings are collateralized by investments with an estimated fair value of $1.9 billion at December 31, 2017, which are maintained in a custodial account for the benefit of the FHLB.  Substantially all of such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet.

The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions):

Amount		Maturity	Interest rate at
borrowed		date	December 31, 2017
$	50.0	January 2019	Variable rate – 1.779%
50.0		February 2019	Variable rate – 1.509%
100.0		March 2019	Variable rate – 1.971%
21.8		July 2019	Variable rate – 2.001%
15.0		October 2019	Variable rate – 1.887%
50.0		May 2020	Variable rate – 1.997%
21.8		June 2020	Fixed rate – 1.960%
25.0		September 2020	Variable rate – 2.300%
100.0		September 2020	Variable rate – 2.212%
50.0		September 2020	Variable rate – 2.224%
75.0		September 2020	Variable rate – 1.813%
100.0		October 2020	Variable rate – 1.453%
50.0		December 2020	Variable rate – 2.072%
100.0		July 2021	Variable rate – 1.909%
100.0		July 2021	Variable rate – 1.879%
57.7		August 2021	Variable rate – 1.921%
28.2		August 2021	Fixed rate – 2.550%
125.0		August 2021	Variable rate – 2.032%
50.0		September 2021	Variable rate – 2.002%
22.0		May 2022	Variable rate – 1.829%
100.0		May 2022	Variable rate – 1.780%
10.0		June 2022	Variable rate – 2.150%
50.0		July 2022	Variable rate – 1.726%
50.0		July 2022	Variable rate – 1.745%
50.0		July 2022	Variable rate – 1.758%
50.0		August 2022	Variable rate – 1.782%
50.0		December 2022	Variable rate – 1.795%
50.0		December 2022	Variable rate – 1.795%
24.7		March 2023	Fixed rate – 2.160%
20.5		June 2025	Fixed rate – 2.940%
$	1,646.7

The variable rate borrowings are pre-payable on each interest reset date without penalty.  The fixed rate borrowings are pre-payable subject to payment of a yield maintenance fee based on prevailing market interest rates.  At December 31, 2017, the aggregate yield maintenance fee to prepay all fixed rate borrowings was $2.1 million.

Interest expense of $27.0 million, $17.5 million and $10.9 million in 2017, 2016 and 2015, respectively, was recognized related to total borrowings from the FHLB.

Accounting for Derivatives

Our fixed index annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period.  Typically, on each policy anniversary date, a new index period begins.  We are generally able to change the participation rate at the beginning of each index period during a policy year, subject to contractual minimums.  The Company accounts for the options attributed to the policyholder for the estimated life of the contract as embedded derivatives. These accounting requirements often create volatility in the earnings from these products. We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy's return is linked.

From time to time, we utilize United States Treasury interest rate futures primarily to hedge interest rate risk related to anticipated mortgage loan transactions.

We purchase certain fixed maturity securities that contain embedded derivatives that are required to be held at fair value on the consolidated balance sheet. We have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income.

Multibucket Annuity Products

The Company's multibucket annuity is an annuity product that credits interest based on the experience of a particular market strategy. Policyholders allocate their annuity premium payments to several different market strategies based on different asset classes within the Company's investment portfolio. Interest is credited to this product based on the market return of the given strategy, less management fees, and funds may be moved between different strategies. The Company guarantees a minimum return of premium plus approximately 3 percent per annum over the life of the contract. The investments backing the market strategies of these products are designated by the Company as trading securities. The change in the fair value of these securities is recognized as investment income (classified as income from policyholder and other special-purpose portfolios), which is substantially offset by the change in insurance policy benefits for these products. We hold insurance liabilities of $32.3 million and $32.8 million related to multibucket annuity products as of December 31, 2017 and 2016, respectively.

Sales Inducements

Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract.  Certain of our life insurance products offer persistency bonuses credited to the contract holder's balance after the policy has been outstanding for a specified period of time.  These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP.  Such amounts are deferred and amortized in the same manner as deferred acquisition costs.  Sales inducements deferred totaled $2.0 million, $3.4 million and $3.8 million during 2017, 2016 and 2015, respectively.  Amounts amortized totaled $8.9 million, $11.4 million and $13.8 million during 2017, 2016 and 2015, respectively.  The unamortized balance of deferred sales inducements was $42.5 million and $49.4 million at December 31, 2017 and 2016, respectively. The balance of insurance liabilities for persistency bonus benefits was $.3 million and $.5 million at December 31, 2017 and 2016, respectively.

Out-of-Period Adjustments

In 2017, we recorded the net effect of out-of-period adjustments which decreased insurance policy benefits by $4.2 million, increased other operating costs and expenses by $2.0 million, increased tax expense by $.8 million and increased our net income by $1.4 million (or 1 cent per diluted share). We evaluated these adjustments taking into account both qualitative and quantitative factors and considered the impact of these adjustments in relation to each period, as well as the periods in which they originated. The impact of recognizing these adjustments in prior years was not significant to any individual period. Management believes these adjustments are immaterial to the consolidated financial statements and all previously issued financial statements.

Recently Issued Accounting Standards

Pending Accounting Standards

In May 2014, the Financial Accounting Standards Board (the "FASB") issued authoritative guidance for recognizing revenue from contracts with customers. Certain contracts with customers are specifically excluded from this guidance, including insurance contracts. The core principle of the new guidance is that an entity should recognize revenue when it transfers promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will be effective for the Company on January 1, 2018 and permits two methods of transition upon adoption; full retrospective and modified retrospective. Under the full retrospective method, prior periods would be restated under the new revenue standard, providing for comparability in all periods presented. Under the modified retrospective method, prior periods would not be restated. Instead, revenues and other disclosures for pre-2018 periods would be provided in the notes to the financial statements as previously reported under the current revenue standard. The new guidance will impact our accounting for various distribution and marketing agreements with other insurance companies pursuant to which Bankers Life's career agents distribute third party products including prescription drug and Medicare Advantage plans. The revenue associated with these distribution agreements has been less than 1 percent of our total revenue. Our annual fee income earned during a calendar year will not change, but the amount recognized during each quarterly period will vary based on the sales of such products in each period. Accordingly, the adoption of this guidance is not expected to have a material impact on our consolidated financial statements. The Company will adopt the new guidance using the modified retrospective method.

In January 2016, the FASB issued authoritative guidance related to the recognition and measurement of financial assets and financial liabilities which made targeted improvements to GAAP as follows:

(i) Require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

(ii) Simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value.

(iii) Eliminate the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet.

(iv) Require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes.

(v) Require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments.

(vi) Require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements.

(vii) Clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets.

An entity should apply this guidance by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of the guidance. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company currently holds equity securities classified as available for sale securities that are measured at fair value with changes in fair value recognized through accumulated other comprehensive income. Upon adoption of this guidance, changes in fair value of such equity securities will be recognized through net income. Based upon the equity securities held at December 31, 2017, the estimated impact of the new guidance, assuming it was adopted on January 1, 2018, would be a cumulative effect adjustment that would increase retained earnings by approximately $17 million with a corresponding decrease to accumulated other comprehensive income of approximately $17 million. The Company may experience an increase in volatility in the income statement due to the requirement to measure equity investments at fair value with changes in fair value recognized in income. In addition, the Company will be required to modify certain disclosures upon adoption.

In February 2016, the FASB issued authoritative guidance related to accounting for leases, requiring lessees to report most leases on their balance sheets, regardless of whether the lease is classified as a finance lease or an operating lease. For lessees, the initial lease liability is equal to the present value of future lease payments, and a corresponding asset, adjusted for certain items, is also recorded. Expense recognition for lessees will remain similar to current accounting requirements for capital and operating leases. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

In June 2016, the FASB issued authoritative guidance related to the measurement of credit losses on financial instruments. The new guidance replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The guidance will be effective for the Company for fiscal years beginning in 2020, including interim periods within the fiscal year. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

In August 2016, the FASB issued authoritative guidance related to how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, and others. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this guidance will result in reclassifications to certain cash receipts and payments within our consolidated statement of cash flows, but will have no impact on our consolidated financial position, results of operations or cash flows.

In November 2016, the FASB issued authoritative guidance to address the diversity in practice that currently exists regarding the classification and presentation of changes in restricted cash on the statement of cash flows. The new guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Entities will also be required to disclose information about the nature of their restricted cash and restricted cash equivalents. Additionally, if cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item in the statement of financial position, entities will be required to present a reconciliation, either on the face of the statement of cash flows or disclosed in the notes, of the totals in the statement of cash flows to the related line item captions in the statement of financial position. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The adoption of this guidance will impact the presentation of our consolidated statement of cash flows and related cash flow disclosures, but will have no impact on our consolidated financial position, results of operations or cash flows.

In January 2017, the FASB issued authoritative guidance that removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reported unit's fair value. Upon adoption, the guidance is to be applied prospectively. The guidance will be effective for the Company on January 1, 2020, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows.

In March 2017, the FASB issued authoritative guidance related to the premium amortization on purchased callable debt securities. The guidance shortens the amortization period for certain callable debt securities held at a premium. Specifically, the new guidance requires the premium to be amortized to the earliest call date. The guidance does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance will be effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the guidance in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company has not yet determined the expected impact of adoption of this guidance on our consolidated financial position, results of operations or cash flows.

In May 2017, the FASB issued authoritative guidance related to which changes to the terms or conditions of a share-based award require an entity to apply modification accounting. The guidance will be effective for the Company in 2018. The guidance is to be applied prospectively to an award modified on or after the adoption date. The adoption of this guidance is not expected to have a material impact to the Company's consolidated financial position, results of operations or cash flows.

In August 2017, the FASB issued authoritative guidance related to derivatives and hedging. The new guidance expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instruments and the hedged item in the financial statements. The new guidance also includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

Adopted Accounting Standards

In March 2016, the FASB issued authoritative guidance that clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under this guidance is required to assess the embedded call (put) options solely in accordance with a four-step decision sequence. The guidance is effective for the Company on January 1, 2017. The adoption of this guidance had no effect on our consolidated financial statements.

In March 2016, the FASB issued authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting policy for forfeiture rate assumptions, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new guidance requires all income tax effects of stock-based compensation awards to be recognized in the income statement when the awards vest or are settled. The new guidance also allows an employer to withhold shares upon settlement of an award to satisfy the employer's tax withholding requirements up to the highest marginal tax rate applicable to employees, without resulting in liability classification of the award. Current guidance strictly limits the withholding to the employer's minimum statutory tax withholding requirement. The guidance was effective for the Company on January 1, 2017. The impact of adoption was as follows (dollars in millions):

	January 1, 2017
				Effect of Adoption of Authoritative Guidance
	Amounts prior to effect of adoption of authoritative guidance			Election to account for forfeitures as they occur			Recognition of excess tax benefits			As adjusted
Income tax assets	$	1,029.9		$	.3		$	15.7		$	1,045.9
Valuation allowance for deferred income tax assets	(240.2		)	—			(15.7		)	(255.9		)
Income tax assets, net	789.7			.3			—			790.0
Total assets	31,975.2			.3			—			31,975.5
Additional paid-in capital	3,212.1			.9			—			3,213.0
Retained earnings	650.7			(.6		)	—			650.1
Total shareholders' equity	4,486.9			.3			—			4,487.2
Total liabilities and shareholders' equity	31,975.2			.3			—			31,975.5

	December 31, 2016
	Amounts prior to effect of adoption of authoritative guidance			Effect of adoption of authoritative guidance			As adjusted
Cash flows from operating activities:
Other operating costs	$	(751.2	)	$	3.3		$	(747.9	)
Net cash flow from operating activities	759.5			3.3			762.8
Cash flows from financing activities:
Payments to repurchase common stock	(206.7		)	(3.3		)	(210.0		)
Net cash provided by financing activities	29.5			(3.3		)	26.2
Net increase in cash and cash equivalents	46.6			—			46.6

	December 31, 2015
	Amounts prior to effect of adoption of authoritative guidance			Effect of adoption of authoritative guidance			As adjusted
Cash flows from operating activities:
Other operating costs	$	(724.4	)	$	3.9		$	(720.5	)
Net cash flow from operating activities	743.9			3.9			747.8
Cash flows from financing activities:
Payments to repurchase common stock	(361.5		)	(3.9		)	(365.4		)
Net cash provided by financing activities	146.4			(3.9		)	142.5
Net decrease in cash and cash equivalents	(179.3		)	—			(179.3		)

In October 2016, the FASB issued authoritative guidance to amend the consolidation guidance on how a reporting entity that is the single decision maker of a VIE should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The guidance is effective for the Company on January 1, 2017. The adoption of this guidance had no impact on our consolidated financial statements.

In February 2018, the FASB issued authoritative guidance that allows a reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects resulting from the Tax Cuts and Jobs Act (the "Tax Reform Act") enacted by the U.S. federal government on December 22, 2017. Such guidance only relates to the reclassification of the income tax effects of the Tax Reform Act. The Company early adopted this guidance and elected to reclassify the income tax effects of the Tax Reform Act from accumulated other comprehensive income as of December 31, 2017. As a result of such reclassification, retained earnings decreased by $205.4 million and accumulated other comprehensive income increased by $205.4 million. Such amount represents the decrease in the income tax rate from 35 percent to 21 percent on the net unrealized gains of our fixed maturity securities, available for sale, equity securities and certain other invested assets, net of related adjustments, included in accumulated other comprehensive income. Refer to the note to the consolidated financial statements entitled "Income Taxes" for additional information related to the Tax Reform Act.

XML

INVESTMENTS

12 Months Ended

Dec. 31, 2017

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS

INVESTMENTS

At December 31, 2017, the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than-temporary impairments included in accumulated other comprehensive income
Investment grade (a):
Corporate securities	$	12,419.3	$	1,670.7	$	(14.6	)	$	14,075.4	$	—
United States Treasury securities and obligations of United States government corporations and agencies	146.4		31.5		(.2		)	177.7		—
States and political subdivisions	1,819.9		234.8		(.4		)	2,054.3		—
Debt securities issued by foreign governments	79.5		3.8		(.2		)	83.1		—
Asset-backed securities	1,730.7		39.7		(3.2		)	1,767.2		—
Collateralized debt obligations	257.1		2.3		—			259.4		—
Commercial mortgage-backed securities	1,304.1		33.2		(9.1		)	1,328.2		—
Mortgage pass-through securities	1.8		.2		—			2.0		—
Collateralized mortgage obligations	293.9		16.4		(.2		)	310.1		(.2		)
Total investment grade fixed maturities, available for sale	18,052.7		2,032.6		(27.9		)	20,057.4		(.2		)
Below-investment grade (a) (b):
Corporate securities	867.0		28.4		(12.4		)	883.0		—
States and political subdivisions	2.0		—		—			2.0		—
Asset-backed securities	1,355.2		132.9		(.9		)	1,487.2		—
Commercial mortgage-backed securities	49.9		.6		(1.2		)	49.3		—
Collateralized mortgage obligations	375.3		56.8		(.1		)	432.0		(.8		)
Total below-investment grade fixed maturities, available for sale	2,649.4		218.7		(14.6		)	2,853.5		(.8		)
Total fixed maturities, available for sale	$	20,702.1	$	2,251.3	$	(42.5	)	$	22,910.9	$	(1.0	)
Equity securities	$	491.1	$	23.6	$	(3.0	)	$	511.7

_______________

(a) Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's Investor Services, Inc. ("Moody's"), S&P Global Ratings ("S&P") or Fitch Ratings ("Fitch")), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC").  NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch).  NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch).  References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.

(b) Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations.

The NAIC evaluates the fixed maturity investments of insurers for regulatory and capital assessment purposes and assigns securities to one of six credit quality categories called NAIC designations, which are used by insurers when preparing their annual statements based on statutory accounting principles. The NAIC designations are generally similar to the credit quality designations of the NRSROs for marketable fixed maturity securities, except for certain structured securities. However, certain structured securities rated below investment grade by the NRSROs can be assigned NAIC 1 or NAIC 2 designations depending on the cost basis of the holding relative to estimated recoverable amounts as determined by the NAIC. The following summarizes the NAIC designations and NRSRO equivalent ratings:

NAIC Designation	NRSRO Equivalent Rating
1	AAA/AA/A
2	BBB
3	BB
4	B
5	CCC and lower
6	In or near default

A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of December 31, 2017 is as follows (dollars in millions):

NAIC designation	Amortized cost		Estimated fair value		Percentage of total estimated fair value
1	$	9,923.7	$	11,028.5	48.1	%
2	9,821.6		10,906.2		47.6
Total NAIC 1 and 2 (investment grade)	19,745.3		21,934.7		95.7
3	676.2		693.8		3.0
4	225.0		225.9		1.0
5	46.3		45.9		.2
6	9.3		10.6		.1
Total NAIC 3,4,5 and 6 (below-investment grade)	956.8		976.2		4.3
	$	20,702.1	$	22,910.9	100.0	%

At December 31, 2016, the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than-temporary impairments included in accumulated other comprehensive income
Investment grade:
Corporate securities	$	11,582.6	$	1,073.9	$	(99.8	)	$	12,556.7	$	—
United States Treasury securities and obligations of United States government corporations and agencies	143.8		20.5		—			164.3		—
States and political subdivisions	1,798.2		186.7		(7.9		)	1,977.0		—
Debt securities issued by foreign governments	37.1		.2		(.4		)	36.9		—
Asset-backed securities	1,169.6		29.2		(8.7		)	1,190.1		—
Collateralized debt obligations	227.5		1.0		(.3		)	228.2		—
Commercial mortgage-backed securities	1,467.2		32.9		(26.6		)	1,473.5		—
Mortgage pass-through securities	2.3		.2		—			2.5		—
Collateralized mortgage obligations	304.8		14.6		(.2		)	319.2		—
Total investment grade fixed maturities, available for sale	16,733.1		1,359.2		(143.9		)	17,948.4		—
Below-investment grade:
Corporate securities	967.3		26.1		(39.2		)	954.2		(3.6		)
States and political subdivisions	13.6		—		(1.7		)	11.9		(3.0		)
Asset-backed securities	1,471.9		55.1		(6.8		)	1,520.2		—
Collateralized debt obligations	2.5		—		—			2.5		—
Commercial mortgage-backed securities	63.8		.2		(1.3		)	62.7		—
Collateralized mortgage obligations	550.9		46.8		(1.4		)	596.3		(1.4		)
Total below-investment grade fixed maturities, available for sale	3,070.0		128.2		(50.4		)	3,147.8		(8.0		)
Total fixed maturities, available for sale	$	19,803.1	$	1,487.4	$	(194.3	)	$	21,096.2	$	(8.0	)
Equity securities	$	580.7	$	11.5	$	(8.0	)	$	584.2

Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments.  These amounts, included in shareholders' equity as of December 31, 2017 and 2016, were as follows (dollars in millions):

	2017			2016
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	$	2.6		$	(1.1	)
Net unrealized gains on all other investments	2,227.3			1,311.9
Adjustment to present value of future profits (a)	(94.0		)	(106.2		)
Adjustment to deferred acquisition costs	(292.6		)	(223.5		)
Adjustment to insurance liabilities	(295.8		)	(13.5		)
Deferred income tax liabilities	(335.4		)	(345.2		)
Accumulated other comprehensive income	$	1,212.1		$	622.4

________

(a) The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003, the date our Predecessor emerged from bankruptcy.

At December 31, 2017, adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred tax assets included $(83.8) million, $(134.9) million, $(295.8) million and $111.1 million, respectively, for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields.

At December 31, 2016, adjustments to the present value of future profits, deferred acquisition costs, insurance liabilities and deferred tax assets included $(94.1) million, $(96.4) million, $(13.5) million and $72.5 million, respectively, for premium deficiencies that would exist on certain blocks of business (primarily long-term care products) if unrealized gains on the assets backing such products had been realized and the proceeds from the sales of such assets were invested at then current yields.

Below-Investment Grade Securities

At December 31, 2017, the amortized cost of the Company's below-investment grade fixed maturity securities was $2,649.4 million, or 13 percent of the Company's fixed maturity portfolio. The estimated fair value of the below-investment grade portfolio was $2,853.5 million, or 108 percent of the amortized cost.

Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities.  Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade corporate debt securities and in many cases severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer.  Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are generally more sensitive to adverse economic conditions.  The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

Contractual Maturity

The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.  Structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as "structured securities") frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	328.1	$	335.1
Due after one year through five years	1,947.3		2,052.3
Due after five years through ten years	1,508.7		1,601.3
Due after ten years	11,550.0		13,286.8
Subtotal	15,334.1		17,275.5
Structured securities	5,368.0		5,635.4
Total fixed maturities, available for sale	$	20,702.1	$	22,910.9

Net Investment Income

Net investment income consisted of the following (dollars in millions):

	2017		2016			2015
General account assets:
Fixed maturities	$	1,133.8	$	1,081.4		$	1,090.1
Equity securities	25.3		21.5			18.3
Mortgage loans	91.5		91.0			91.4
Policy loans	7.7		7.3			7.3
Other invested assets	44.4		24.3			17.4
Cash and cash equivalents	5.9		2.0			.8
Policyholder and other special-purpose portfolios:
Trading securities (a)	12.8		12.2			10.7
Options related to fixed index products:
Option income (loss)	110.3		(40.1		)	36.5
Change in value of options	52.2		69.3			(72.7		)
Other special-purpose portfolios	90.6		79.7			55.5
Gross investment income	1,574.5		1,348.6			1,255.3
Less investment expenses	23.2		23.4			21.7
Net investment income	$	1,551.3	$	1,325.2		$	1,233.6

_________________

(a) Changes in the estimated fair value for trading securities still held as of the end of the respective years and included in net investment income were $3.8 million, $(.2) million and $.4 million for the years ended December 31, 2017, 2016 and 2015, respectively.

At December 31, 2017, the carrying value of fixed maturities and mortgage loans that were non-income producing during 2017 totaled $2.8 million and $10.6 million, respectively.

Net Realized Investment Gains (Losses)

The following table sets forth the net realized investment gains (losses) for the periods indicated (dollars in millions):

	2017			2016			2015
Fixed maturity securities, available for sale:
Gross realized gains on sale	$	68.0		$	137.7		$	95.7
Gross realized losses on sale	(24.2		)	(95.2		)	(88.4		)
Impairments:
Total other-than-temporary impairment losses	(12.5		)	(15.2		)	(17.9		)
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(.9		)	3.6			3.0
Net impairment losses recognized	(13.4		)	(11.6		)	(14.9		)
Net realized investment gains (losses) from fixed maturities	30.4			30.9			(7.6		)
Equity securities	11.6			20.9			3.7
Mortgage loans	1.1			—			(2.3		)
Impairments on preferred stock and other investments	(9.4		)	(20.7		)	(25.0		)
Gain (loss) on dissolution of variable interest entities	(4.3		)	(7.3		)	11.3
Other (a)	20.9			(15.5		)	(16.7		)
Net realized investment gains (losses)	$	50.3		$	8.3		$	(36.6	)

_________________

(a) Changes in the estimated fair value of trading securities that we have elected the fair value option (and are still held as of the end of the respective years) were $12.8 million, $(.5) million and $(9.2) million for the years ended December 31, 2017, 2016 and 2015, respectively.

During 2017, we recognized net realized investment gains of $50.3 million, which were comprised of: (i) $63.1 million of net gains from the sales of investments; (ii) $4.3 million of losses on the dissolution of VIEs; (iii) the increase in fair value of certain fixed maturity investments with embedded derivatives of $11.5 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $2.8 million; and (v) $22.8 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

During 2017, 2016 and 2015, VIEs that were required to be consolidated were dissolved. We recognized losses of $4.3 million and $7.3 million during 2017 and 2016, respectively, and a gain of $11.3 million during 2015, representing the difference between the borrowings of such VIEs and the contractual distributions required following the liquidation of the underlying assets.

During 2016, we recognized net realized investment gains of $8.3 million, which were comprised of: (i) $47.5 million of net gains from the sales of investments; (ii) a $7.3 million loss on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $.4 million; (iv) the increase in fair value of embedded derivatives related to a modified coinsurance agreement of $.8 million; and (v) $32.3 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($35.9 million, prior to the $3.6 million of impairment losses recognized through accumulated other comprehensive income).

During 2015, we recognized net realized investment losses of $36.6 million, which were comprised of: (i) $8.2 million of net gains from the sales of investments; (ii) an $11.3 million gain on the dissolution of a VIE; (iii) the decrease in fair value of certain fixed maturity investments with embedded derivatives of $9.2 million; (iv) the decrease in fair value of embedded derivatives related to a modified coinsurance agreement of $7.0 million; and (v) $39.9 million of writedowns of investments for other than temporary declines in fair value recognized through net income ($42.9 million, prior to the $3.0 million of impairment losses recognized through accumulated other comprehensive income).

At December 31, 2017, there was one fixed maturity investment in default with an amortized cost and carrying value of $.5 million and $.4 million, respectively.

During 2017, the $24.2 million of realized losses on sales of $427.6 million of fixed maturity securities, available for sale, included: (i) $16.8 million related to various corporate securities; (ii) $3.6 million related to commercial mortgage-backed securities; and (iii) $3.8 million related to various other investments. Securities are generally sold at a loss following unforeseen issuer-specific events or conditions or shifts in perceived relative values.  These reasons include but are not limited to:  (i) changes in the investment environment; (ii) expectation that the market value could deteriorate; (iii) our desire to reduce our exposure to an asset class, an issuer or an industry; (iv) prospective or actual changes in credit quality; or (v) changes in expected portfolio cash flows.

During 2017, we recognized $22.8 million of impairment losses recorded in earnings which included: (i) $6.7 million of writedowns on fixed maturities in the energy sector; (ii) $5.2 million of writedowns related to a mortgage loan; and (iii) $10.9 million of writedowns on other investments. Factors considered in determining the writedowns of investments in 2017 included changes in the estimated recoverable value of the assets related to each investment and the timing of and complexities related to the recovery process.

During 2016, the $95.2 million of realized losses on sales of $790.2 million of fixed maturity securities, available for sale included: (i) $79.2 million related to various corporate securities (including $63.5 million related to sales of investments in the energy sector); (ii) $5.8 million related to commercial mortgage-backed securities; (iii) $5.7 million related to asset-backed securities; and (iv) $4.5 million related to various other investments.

During 2016, we recognized $32.3 million of impairment losses recorded in earnings which included: (i) $9.3 million of writedowns on fixed maturities in the energy sector; (ii) $3.7 million of writedowns on a direct loan due to borrower specific events; (iii) $12.7 million of writedowns on a privately placed preferred stock of an entity formed to construct and operate a chemical plant; (iv) $1.2 million of writedowns of investments held by VIEs due to other-than-temporary declines in value; and (v) $5.4 million of writedowns on other investments. Factors considered in determining the writedowns of investments in 2016 included the subordination status of each investment, the impact of recent downgrades and issuer specific events, including the impact of low oil prices on issuers in the energy sector.

During 2015, the $88.4 million of realized losses on sales of $724.4 million of fixed maturity securities, available for sale, primarily related to various corporate securities (including $59.7 million related to sales of investments in the energy sector).  

During 2015, we recognized $39.9 million of impairment losses recorded in earnings which included: (i) $10.2 million of writedowns on fixed maturities in the energy sector; (ii) $16.4 million of writedowns on commercial bank loans held by VIEs; (iii) a $7.9 million writedown of a legacy investment in a private company that was liquidated; and (iv) $5.4 million of losses on other investments (primarily fixed maturities). We no longer have any exposure to legacy private companies related to investments acquired by our Predecessor.

Our fixed maturity investments are generally purchased in the context of various long-term strategies, including funding insurance liabilities, so we do not generally seek to generate short-term realized gains through the purchase and sale of such securities.  In certain circumstances, including those in which securities are selling at prices which exceed our view of their underlying economic value, or when it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities.

The following summarizes the investments sold at a loss during 2017 which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period indicated (dollars in millions):

		At date of sale
	Number of issuers	Amortized cost		Fair value
Less than 6 months prior to sale	4	$	17.8	$	13.0
Greater than or equal to 6 months and less than 12 months prior to sale	1	2.7		1.9
Greater than 12 months prior to sale	1	.7		.5
	6	$	21.2	$	15.4

We regularly evaluate all of our investments with unrealized losses for possible impairment.  Our assessment of whether unrealized losses are "other than temporary" requires significant judgment.  Factors considered include:  (i) the extent to which fair value is less than the cost basis; (ii) the length of time that the fair value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for specific events, developments or circumstances likely to affect the value of the investment; (v) the investment's rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) whether we intend to sell the investment or it is more likely than not that circumstances will require us to sell the investment before recovery occurs; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values; (ix) projections of, and unfavorable changes in, cash flows on structured securities including mortgage-backed and asset-backed securities; (x) our best estimate of the value of any collateral; and (xi) other objective and subjective factors.

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio.  Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

Impairment losses on equity securities are recognized in net income.  The manner in which impairment losses on fixed maturity securities, available for sale, are recognized in the financial statements is dependent on the facts and circumstances related to the specific security.  If we intend to sell a security or it is more likely than not that we would be required to sell a security before the recovery of its amortized cost, the security is other-than-temporarily impaired and the full amount of the impairment is recognized as a loss through earnings.  If we do not expect to recover the amortized cost basis, we do not plan to sell the security, and if it is not more likely than not that we would be required to sell a security before the recovery of its amortized cost, less any current period credit loss, the recognition of the other-than-temporary impairment is bifurcated.  We recognize the credit loss portion in net income and the noncredit loss portion in accumulated other comprehensive income.

We estimate the amount of the credit loss component of a fixed maturity security impairment as the difference between amortized cost and the present value of the expected cash flows of the security.  The present value is determined using the best estimate of future cash flows discounted at the effective interest rate implicit to the security at the date of purchase or the current yield to accrete an asset-backed or floating-rate security.  The methodology and assumptions for establishing the best estimate of future cash flows vary depending on the type of security.

For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including overcollateralization, excess spread, subordination and guarantees.  For corporate bonds, cash flow estimates are derived from scenario-based outcomes of expected corporate restructurings or the disposition of assets using bond-specific facts and circumstances. The previous amortized cost basis less the impairment recognized in net income becomes the security's new cost basis.  We accrete the new cost basis to the estimated future cash flows over the expected remaining life of the security, except when the security is in default or considered nonperforming.

The remaining noncredit impairment, which is recorded in accumulated other comprehensive income, is the difference between the security's estimated fair value and our best estimate of future cash flows discounted at the effective interest rate prior to impairment.  The remaining noncredit impairment typically represents changes in the market interest rates, current market liquidity and risk premiums.  As of December 31, 2017, other-than-temporary impairments included in accumulated other comprehensive income totaled $1.0 million (before taxes and related amortization).

Mortgage loans are impaired when it is probable that we will not collect the contractual principal and interest on the loan. We measure impairment based upon the difference between the carrying value of the loan and the estimated fair value of the collateral securing the loan less cost to sell.

The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the years ended December 31, 2017, 2016 and 2015 (dollars in millions):

	Year ended
	December 31,
	2017			2016			2015
Credit losses on fixed maturity securities, available for sale, beginning of period	$	(5.5	)	$	(2.6	)	$	(1.0	)
Add:  credit losses on other-than-temporary impairments not previously recognized	—			(3.0		)	(2.0		)
Less:  credit losses on securities sold	4.7			.1			.4
Less:  credit losses on securities impaired due to intent to sell (a)	—			—			—
Add:  credit losses on previously impaired securities	(2.0		)	—			—
Less:  increases in cash flows expected on previously impaired securities	—			—			—
Credit losses on fixed maturity securities, available for sale, end of period	$	(2.8	)	$	(5.5	)	$	(2.6	)

__________

(a) Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.

Investments with Unrealized Losses

The following table sets forth the amortized cost and estimated fair value of those fixed maturities, available for sale, with unrealized losses at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.  Structured securities frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	26.9	$	26.9
Due after one year through five years	195.4		193.3
Due after five years through ten years	108.9		105.2
Due after ten years	602.0		580.0
Subtotal	933.2		905.4
Structured securities	1,268.3		1,253.6
Total	$	2,201.5	$	2,159.0

The following summarizes the investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis for the period indicated as of December 31, 2017 (dollars in millions):

	Number of issuers	Cost basis		Unrealized loss			Estimated fair value
Less than 6 months	1	$	9.2	$	(1.9	)	$	7.3
		$	9.2	$	(1.9	)	$	7.3

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2017 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	28.2	$	(.2	)	$	.7	$	—		$	28.9	$	(.2	)
States and political subdivisions	18.3		(.1		)	14.9		(.3		)	33.2		(.4		)
Debt securities issued by foreign governments	7.7		(.1		)	5.4		(.1		)	13.1		(.2		)
Corporate securities	470.5		(6.8		)	359.7		(20.2		)	830.2		(27.0		)
Asset-backed securities	601.4		(2.0		)	122.2		(2.1		)	723.6		(4.1		)
Collateralized debt obligations	3.0		—			—		—			3.0		—
Commercial mortgage-backed securities	276.8		(1.7		)	218.2		(8.6		)	495.0		(10.3		)
Collateralized mortgage obligations	20.5		(.2		)	11.5		(.1		)	32.0		(.3		)
Total fixed maturities, available for sale	$	1,426.4	$	(11.1	)	$	732.6	$	(31.4	)	$	2,159.0	$	(42.5	)
Equity securities	$	58.7	$	(1.7	)	$	21.2	$	(1.3	)	$	79.9	$	(3.0	)

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2016 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	8.0	$	—		$	—	$	—		$	8.0	$	—
States and political subdivisions	176.3		(7.8		)	18.3		(1.8		)	194.6		(9.6		)
Debt securities issued by foreign governments	18.9		(.4		)	—		—			18.9		(.4		)
Corporate securities	1,907.6		(75.5		)	559.6		(63.5		)	2,467.2		(139.0		)
Asset-backed securities	692.9		(8.5		)	262.5		(7.0		)	955.4		(15.5		)
Collateralized debt obligations	38.3		(.1		)	30.8		(.2		)	69.1		(.3		)
Commercial mortgage-backed securities	525.2		(16.6		)	154.0		(11.3		)	679.2		(27.9		)
Collateralized mortgage obligations	73.6		(.6		)	34.6		(1.0		)	108.2		(1.6		)
Total fixed maturities, available for sale	$	3,440.8	$	(109.5	)	$	1,059.8	$	(84.8	)	$	4,500.6	$	(194.3	)
Equity securities	$	239.4	$	(8.0	)	$	—	$	—		$	239.4	$	(8.0	)

Based on management's current assessment of investments with unrealized losses at December 31, 2017, the Company believes the issuers of the securities will continue to meet their obligations (or with respect to equity-type securities, the investment value will recover to its cost basis).  While we do not have the intent to sell securities with unrealized losses and it is not more likely than not that we will be required to sell securities with unrealized losses prior to their anticipated recovery, our intent on an individual security may change, based upon market or other unforeseen developments.  In such instances, if a loss is recognized from a sale subsequent to a balance sheet date due to these unexpected developments, the loss is recognized in the period in which we had the intent to sell the security before its anticipated recovery.

Structured Securities

At December 31, 2017 fixed maturity investments included structured securities with an estimated fair value of $5.6 billion (or 25 percent of all fixed maturity securities).  The yield characteristics of structured securities generally differ in some respects from those of traditional corporate fixed-income securities or government securities.  For example, interest and principal payments on structured securities may occur more frequently, often monthly.  In many instances, we are subject to variability in the amount and timing of principal and interest payments.  For example, in many cases, partial prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including:  the relative sensitivity of prepayments on the underlying assets backing the security to changes in interest rates and asset values; the availability of alternative financing; a variety of economic, geographic and other factors; the timing, pace and proceeds of liquidations of defaulted collateral; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure).  In addition, the total amount of payments for non-agency structured securities may be affected by changes to cumulative default rates or loss severities of the related collateral.

Historically, the rate of prepayments on structured securities has tended to increase when prevailing interest rates have declined significantly in absolute terms and also relative to the interest rates on the underlying collateral. The yields recognized on structured securities purchased at a discount to par will generally increase (relative to the stated rate) when the underlying collateral prepays faster than expected. The yields recognized on structured securities purchased at a premium will decrease (relative to the stated rate) when the underlying collateral prepays faster than expected. When interest rates decline, the proceeds from prepayments may be reinvested at lower rates than we were earning on the prepaid securities. When interest rates increase, prepayments may decrease below expected levels. When this occurs, the average maturity and duration of structured securities increases, decreasing the yield on structured securities purchased at discounts and increasing the yield on those purchased at a premium because of a decrease in the annual amortization of premium.

For structured securities included in fixed maturities, available for sale, that were purchased at a discount or premium, we recognize investment income using an effective yield based on anticipated future prepayments and the estimated final maturity of the securities. Actual prepayment experience is periodically reviewed and effective yields are recalculated when differences arise between the prepayments originally anticipated and the actual prepayments received and currently anticipated. For credit sensitive mortgage-backed and asset-backed securities, and for securities that can be prepaid or settled in a way that we would not recover substantially all of our investment, the effective yield is recalculated on a prospective basis. Under this method, the amortized cost basis in the security is not immediately adjusted and a new yield is applied prospectively. For all other structured and asset-backed securities, the effective yield is recalculated when changes in assumptions are made, and reflected in our income on a retrospective basis. Under this method, the amortized cost basis of the investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments were not significant in 2017.

For purchased credit impaired securities, at acquisition, the difference between the undiscounted expected future cash flows and the recorded investment in the securities represents the initial accretable yield, which is accreted into net investment income over the securities’ remaining lives on a level-yield basis. Subsequently, effective yields recognized on purchased credit impaired securities are recalculated and adjusted prospectively to reflect changes in the contractual benchmark interest rates on variable rate securities and any significant increases in undiscounted expected future cash flows arising due to reasons other than interest rate changes. Significant decreases in expected cash flows arising from credit events would result in impairment if such security's fair value is below amortized cost.

The following table sets forth the par value, amortized cost and estimated fair value of structured securities, summarized by interest rates on the underlying collateral, at December 31, 2017 (dollars in millions):

	Par value		Amortized cost		Estimated fair value
Below 4 percent	$	2,101.7	$	1,944.8	$	2,014.9
4 percent – 5 percent	1,656.3		1,516.0		1,596.5
5 percent – 6 percent	1,407.1		1,271.8		1,362.6
6 percent – 7 percent	286.6		260.6		276.8
7 percent – 8 percent	83.0		83.7		92.5
8 percent and above	291.3		291.1		292.1
Total structured securities	$	5,826.0	$	5,368.0	$	5,635.4

The amortized cost and estimated fair value of structured securities at December 31, 2017, summarized by type of security, were as follows (dollars in millions):

			Estimated fair value
Type	Amortized cost		Amount		Percent of fixed maturities
Pass-throughs, sequential and equivalent securities	$	557.7	$	617.2	2.7	%
Planned amortization classes, target amortization classes and accretion-directed bonds	95.3		108.5		.5
Commercial mortgage-backed securities	1,354.0		1,377.5		6.0
Asset-backed securities	3,085.9		3,254.4		14.2
Collateralized debt obligations	257.1		259.4		1.1
Other	18.0		18.4		.1
Total structured securities	$	5,368.0	$	5,635.4	24.6	%

Pass-throughs, sequentials and equivalent securities have unique prepayment variability characteristics.  Pass-through securities typically return principal to the holders based on cash payments from the underlying mortgage obligations. Sequential securities return principal to tranche holders in a detailed hierarchy.  Planned amortization classes, targeted amortization classes and accretion-directed bonds adhere to fixed schedules of principal payments as long as the underlying mortgage loans experience prepayments within certain estimated ranges.  In most circumstances, changes in prepayment rates are first absorbed by support or companion classes insulating the timing of receipt of cash flows from the consequences of both faster prepayments (average life shortening) and slower prepayments (average life extension).

Commercial mortgage-backed securities are secured by commercial real estate mortgages, generally income producing properties that are managed for profit.  Property types include multi-family dwellings including apartments, retail centers, hotels, restaurants, hospitals, nursing homes, warehouses, and office buildings.  While most commercial mortgage-backed securities have call protection features whereby underlying borrowers may not prepay their mortgages for stated periods of time without incurring prepayment penalties, recoveries on defaulted collateral may result in involuntary prepayments.

Mortgage Loans

At December 31, 2017, the mortgage loan balance was primarily comprised of commercial mortgage loans. Approximately 14 percent, 12 percent, 8 percent, 6 percent and 5 percent of the commercial mortgage loan balance were on properties located in California, Texas, Maryland, Florida and Illinois, respectively. No other state comprised greater than five percent of the commercial mortgage loan balance. At December 31, 2017, there was one mortgage loan in process of foreclosure with a carrying value of $10.6 million. There were no other mortgage loans that were noncurrent at December 31, 2017. Our commercial mortgage loan portfolio is comprised of large commercial mortgage loans. Our loans have risk characteristics that are individually unique. Accordingly, we measure potential losses on a loan-by-loan basis rather than establishing an allowance for losses on mortgage loans. At December 31, 2017, we held residential mortgage loan investments with a carrying value of $37.1 million and a fair value of $37.3 million.

The following table provides the carrying value and estimated fair value of our outstanding commercial mortgage loans and the underlying collateral as of December 31, 2017 (dollars in millions):

			Estimated fair value
Loan-to-value ratio (a)	Carrying value		Mortgage loans		Collateral
Less than 60%	$	944.7	$	960.8	$	2,330.6
60% to 70%	439.5		440.2		671.3
Greater than 70% to 80%	138.4		145.9		188.4
Greater than 80% to 90%	52.3		52.9		60.1
Greater than 90%	38.6		40.2		41.7
Total	$	1,613.5	$	1,640.0	$	3,292.1

________________

(a) Loan-to-value ratios are calculated as the ratio of:  (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.

Other Investment Disclosures

Life insurance companies are required to maintain certain investments on deposit with state regulatory authorities. Such assets had aggregate carrying values of $38.5 million and $36.7 million at December 31, 2017 and 2016, respectively.

The Company had no fixed maturity investments that were in excess of 10 percent of shareholders' equity at December 31, 2017 and 2016.

XML

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price.  We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives.  We carry our COLI, which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs.

The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information.  Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value.  Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value.

Valuation Hierarchy

There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable.

• Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities.  Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.

• Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data.  Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies.  These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include:  certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.

• Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions.  Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information.  Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities.  Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.

At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value.  This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions.  Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. Any transfers between levels are reported as having occurred at the beginning of the period. There were no transfers between Level 1 and Level 2 in both 2017 and 2016.

The vast majority of our fixed maturity and equity securities, including those held in trading portfolios and those held by consolidated VIEs, short-term and separate account assets use Level 2 inputs for the determination of fair value.  These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value.  Our Level 2 assets are valued as follows:

•Fixed maturities available for sale, equity securities and trading securities

Corporate securities are generally priced using market and income approaches. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads.

U.S. Treasuries and obligations of U.S. Government corporations and agencies are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets and maturity.

States and political subdivisions are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances and credit spreads.

Asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations are generally priced using market and income approaches. Inputs generally consist of quoted prices in inactive markets, spreads on actively traded securities, expected prepayments, expected default rates, expected recovery rates, and issue specific information including, but not limited to, collateral type, seniority and vintage.

Equity securities (primarily comprised of non-redeemable preferred stock) are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads.

• Investments held by VIEs

Corporate securities are generally priced using market and income approaches using pricing vendors. Inputs generally consist of issuer rating, benchmark yields, maturity, and credit spreads.

• Other invested assets - derivatives

The fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotes; time value and volatility factors underlying options; market interest rates; and non-performance risk.

Third party pricing services normally derive security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information.  If there are no recently reported trades, the third party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are discounted at an estimated risk-adjusted market rate.  The number of prices obtained for a given security is dependent on the Company's analysis of such prices as further described below.

As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value.  The Company's analysis includes:  (i) a review of the methodology used by third party pricing services; (ii) where available, a comparison of multiple pricing services' valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably dated; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties.  As a result of such procedures, the Company may conclude a particular price received from a third party is not reflective of current market conditions.  In those instances, we may request additional pricing quotes or apply internally developed valuations.  However, the number of such instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received.

The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company's judgment of the inputs or methodologies used by the independent pricing services to value different asset classes.  Such inputs typically include:  benchmark yields, reported trades, broker dealer quotes, issuer spreads, benchmark securities, bids, offers and other relevant data.  The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments.

For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes.  These broker quotes are non-binding andrepresent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs.  Approximately 29 percent of our Level 3 fixed maturity securities were valued using unadjusted broker quotes or broker-provided valuation inputs.  The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs.  For these securities, we use internally developed valuations.  Key assumptions used to determine fair value for these securities may include risk premiums, projected performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market.  For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are discounted at an estimated market rate.  The pricing matrix incorporates term interest rates as well as a spread level based on the issuer's credit rating, other factors relating to the issuer, and the security's maturity.  In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity.

For certain embedded derivatives, we use actuarial assumptions in the determination of fair value which we consider to be Level 3 inputs.

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2017 is as follows (dollars in millions):

	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	14,728.0	$	230.4	$	14,958.4
United States Treasury securities and obligations of United States government corporations and agencies	—		177.7		—		177.7
States and political subdivisions	—		2,056.3		—		2,056.3
Debt securities issued by foreign governments	—		79.2		3.9		83.1
Asset-backed securities	—		3,230.2		24.2		3,254.4
Collateralized debt obligations	—		259.4		—		259.4
Commercial mortgage-backed securities	—		1,377.5		—		1,377.5
Mortgage pass-through securities	—		2.0		—		2.0
Collateralized mortgage obligations	—		742.1		—		742.1
Total fixed maturities, available for sale	—		22,652.4		258.5		22,910.9
Equity securities - corporate securities	287.8		202.7		21.2		511.7
Trading securities:
Corporate securities	—		21.6		—		21.6
United States Treasury securities and obligations of United States government corporations and agencies	—		.5		—		.5
Asset-backed securities	—		95.8		—		95.8
Collateralized debt obligations	—		2.7		—		2.7
Commercial mortgage-backed securities	—		92.5		—		92.5
Collateralized mortgage obligations	—		68.7		—		68.7
Equity securities	2.8		—		—		2.8
Total trading securities	2.8		281.8		—		284.6
Investments held by variable interest entities - corporate securities	—		1,522.0		4.9		1,526.9
Other invested assets - derivatives	—		170.2		—		170.2
Assets held in separate accounts	—		5.0		—		5.0
Total assets carried at fair value by category	$	290.6	$	24,834.1	$	284.6	$	25,409.3
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	1,334.8	$	1,334.8

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2016 is as follows (dollars in millions):

	Quoted prices in active markets  for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	13,252.4	$	258.5	$	13,510.9
United States Treasury securities and obligations of United States government corporations and agencies	—		164.3		—		164.3
States and political subdivisions	—		1,988.9		—		1,988.9
Debt securities issued by foreign governments	—		33.0		3.9		36.9
Asset-backed securities	—		2,649.9		60.4		2,710.3
Collateralized debt obligations	—		225.3		5.4		230.7
Commercial mortgage-backed securities	—		1,504.2		32.0		1,536.2
Mortgage pass-through securities	—		2.5		—		2.5
Collateralized mortgage obligations	—		915.5		—		915.5
Total fixed maturities, available for sale	—		20,736.0		360.2		21,096.2
Equity securities - corporate securities	359.9		199.1		25.2		584.2
Trading securities:
Corporate securities	—		19.0		—		19.0
United States Treasury securities and obligations of United States government corporations and agencies	—		.5		—		.5
Asset-backed securities	—		94.3		—		94.3
Collateralized debt obligations	—		2.4		—		2.4
Commercial mortgage-backed securities	—		163.9		—		163.9
Collateralized mortgage obligations	—		78.4		—		78.4
Equity securities	4.9		—		—		4.9
Total trading securities	4.9		358.5		—		363.4
Investments held by variable interest entities - corporate securities	—		1,724.3		—		1,724.3
Other invested assets - derivatives	—		111.9		—		111.9
Assets held in separate accounts	—		4.7		—		4.7
Total assets carried at fair value by category	$	364.8	$	23,134.5	$	385.4	$	23,884.7
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	1,092.3	$	1,092.3

For those financial instruments disclosed at fair value, we use the following methods and assumptions to determine the estimated fair values:

Mortgage loans and policy loans.  We discount future expected cash flows based on interest rates currently being offered for similar loans with similar risk characteristics.  We aggregate loans with similar characteristics in our calculations.  The fair value of policy loans approximates their carrying value.

Company-owned life insurance is backed by a series of mutual funds and is carried at cash surrender value which approximates estimated fair value.

Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value.

Liabilities for policyholder account balances.  The estimated fair value of insurance liabilities for policyholder account balances was approximately equal to its carrying value as interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.

Investment borrowings, notes payable and borrowings related to variable interest entities.  For publicly traded debt, we use current fair values.  For other notes, we use discounted cash flow analyses based on our current incremental borrowing rates for similar types of borrowing arrangements.

The fair value measurements for our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions):

	December 31, 2017
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,677.3	$	1,677.3	$	1,650.6
Policy loans	—		—		116.0		116.0		116.0
Other invested assets:
Company-owned life insurance	—		182.3		—		182.3		182.3
Cash and cash equivalents:
Unrestricted	578.4		—		—		578.4		578.4
Held by variable interest entities	178.9		—		—		178.9		178.9
Liabilities:
Policyholder account balances	—		—		11,220.7		11,220.7		11,220.7
Investment borrowings	—		1,648.8		—		1,648.8		1,646.7
Borrowings related to variable interest entities	—		1,432.9		—		1,432.9		1,410.7
Notes payable – direct corporate obligations	—		962.3		—		962.3		914.6

	December 31, 2016
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,800.1	$	1,800.1	$	1,768.0
Policy loans	—		—		112.0		112.0		112.0
Other invested assets:
Company-owned life insurance	—		165.0		—		165.0		165.0
Cash and cash equivalents:
Unrestricted	473.6		5.3		—		478.9		478.9
Held by variable interest entities	189.3		—		—		189.3		189.3
Liabilities:
Policyholder account balances	—		—		10,912.7		10,912.7		10,912.7
Investment borrowings	—		1,650.0		—		1,650.0		1,647.4
Borrowings related to variable interest entities	—		1,675.2		—		1,675.2		1,662.8
Notes payable – direct corporate obligations	—		931.9		—		931.9		912.9

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2017 (dollars in millions):

	December 31, 2017
	Beginning balance as of December 31, 2016			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income		Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2017			Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	258.5		$	(70.4	)	$	5.8	$	5.3		$	31.2	$	—		$	230.4		$	(8.0	)
Debt securities issued by foreign governments	3.9			—			—		—			—		—			3.9			—
Asset-backed securities	60.4			(4.3		)	—		.7			—		(32.6		)	24.2			—
Collateralized debt obligations	5.4			(2.5		)	—		—			—		(2.9		)	—			—
Commercial mortgage-backed securities	32.0			(1.2		)	.1		(.1		)	—		(30.8		)	—			—
Total fixed maturities, available for sale	360.2			(78.4		)	5.9		5.9			31.2		(66.3		)	258.5			(8.0		)
Equity securities - corporate securities	25.2			(8.5		)	6.3		(1.8		)	—		—			21.2			—
Investments held by variable interest entities - corporate securities	—			4.9			—		—			—		—			4.9			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,092.3		)	(267.5		)	25.0		—			—		—			(1,334.8		)	25.0

_________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended December 31, 2017 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	76.6		$	(147.0	)	$	—		$	—	$	(70.4	)
Asset-backed securities	—			(4.3		)	—			—		(4.3		)
Collateralized debt obligations	—			(2.5		)	—			—		(2.5		)
Commercial mortgage-backed securities	—			(1.2		)	—			—		(1.2		)
Total fixed maturities, available for sale	76.6			(155.0		)	—			—		(78.4		)
Equity securities - corporate securities	—			(8.5		)	—			—		(8.5		)
Investments held by variable interest entities - corporate securities	8.9			(4.0		)	—			—		4.9
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(178.9		)	5.4			(159.3		)	65.3		(267.5		)

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2016 (dollars in millions):

	December 31, 2016
	Beginning balance as of December 31, 2015			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2016			Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	170.4		$	76.5		$	(10.7	)	$	9.1		$	20.3	$	(7.1	)	$	258.5		$	(10.9	)
Debt securities issued by foreign governments	—			4.0			—			(.1		)	—		—			3.9			—
Asset-backed securities	35.9			9.7			—			2.2			26.3		(13.7		)	60.4			—
Collateralized debt obligations	—			5.4			—			—			—		—			5.4			—
Commercial mortgage-backed securities	1.1			16.9			—			.1			13.9		—			32.0			—
Mortgage pass-through securities	.1			(.1		)	—			—			—		—			—			—
Total fixed maturities, available for sale	207.5			112.4			(10.7		)	11.3			60.5		(20.8		)	360.2			(10.9		)
Equity securities - corporate securities	32.0			5.5			(12.7		)	.4			—		—			25.2			(12.7		)
Trading securities - commercial mortgage-backed securities	39.9			—			—			—			—		(39.9		)	—			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,057.1		)	(96.0		)	60.8			—			—		—			(1,092.3		)	60.8

____________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended December 31, 2016 (dollars in millions):

	Purchases			Received in reinsurance recapture		Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	18.5		$	89.2	$	(31.2	)	$	—		$	—	$	76.5
Debt securities issued by foreign governments	4.0			—		—			—			—		4.0
Asset-backed securities	16.9			—		(7.2		)	—			—		9.7
Collateralized debt obligations	5.4			—		—			—			—		5.4
Commercial mortgage-backed securities	17.0			—		(.1		)	—			—		16.9
Mortgage pass-through securities	—			—		(.1		)	—			—		(.1		)
Total fixed maturities, available for sale	61.8			89.2		(38.6		)	—			—		112.4
Equity securities - corporate securities	3.3			2.2		—			—			—		5.5
Trading securities - corporate securities	.2			—		(.2		)	—			—		—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(148.3		)	—		21.2			(28.9		)	60.0		(96.0		)

At December 31, 2017, 52 percent of our Level 3 fixed maturities, available for sale, were investment grade and 89 percent of our Level 3 fixed maturities, available for sale, consisted of corporate securities.

Realized and unrealized investment gains and losses presented in the preceding tables represent gains and losses during the time the applicable financial instruments were classified as Level 3.

Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and other special-purpose portfolios, net realized investment gains (losses) or insurance policy benefits within the consolidated statement of operations or accumulated other comprehensive income within shareholders' equity based on the appropriate accounting treatment for the instrument.

The amount presented for gains (losses) included in our net loss for assets and liabilities still held as of the reporting date primarily represents impairments for fixed maturities, available for sale, changes in fair value of trading securities and certain derivatives and changes in fair value of embedded derivative instruments included in liabilities for insurance products that exist as of the reporting date.

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2017 (dollars in millions):

	Fair value at December 31, 2017		Valuation techniques	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	149.2	Discounted cash flow analysis	Discount margins	1.45% - 71.29% (6.96%)
Corporate securities (b)	2.8		Recovery method	Percent of recovery expected	0% - 21.73% (18.42%)
Asset-backed securities (c)	24.2		Discounted cash flow analysis	Discount margins	1.80% - 3.71% (2.67%)
Equity securities (d)	21.2		Market comparables	EBITDA multiples	1.1X - 8.9X (1.1X)
Other assets categorized as Level 3 (e)	87.2		Unadjusted third-party price source	Not applicable	Not applicable
Total	284.6
Liabilities:
Future policy benefits (f)	1,334.8		Discounted projected embedded derivatives	Projected portfolio yields	5.15% - 5.61% (5.60%)
				Discount rates	0.92 - 2.51% (2.00%)
				Surrender rates	1.20% - 46.40% (12.30%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected.  Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.

(c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before interest, taxes, depreciation and amortization ("EBITDA"). Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements.

(e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2016 (dollars in millions):

	Fair value at December 31, 2016		Valuation techniques	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	148.5	Discounted cash flow analysis	Discount margins	1.35% - 27.71% (13.52%)
Corporate securities (b)	14.8		Recovery method	Percent of recovery expected	5% - 69% (55%)
Asset-backed securities (c)	24.0		Discounted cash flow analysis	Discount margins	2.06% - 3.64% (2.76%)
Equity securities (d)	25.2		Market comparables	EBITDA multiples	0.4X - 6.2X (5.9X)
Other assets categorized as Level 3 (e)	172.9		Unadjusted third-party price source	Not applicable	Not applicable
Total	385.4
Liabilities:
Future policy benefits (f)	1,092.3		Discounted projected embedded derivatives	Projected portfolio yields	5.15% - 5.61% (5.59%)
				Discount rates	0.18 - 3.06% (2.07%)
				Surrender rates	0.94% - 46.48% (13.52%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.

(c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is EBITDA multiples. Generally, increases (decreases) in EBITDA multiples would result in higher (lower) fair value measurements.

(e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

XML

LIABILITIES FOR INSURANCE PRODUCTS

12 Months Ended

Dec. 31, 2017

Insurance [Abstract]

LIABILITIES FOR INSURANCE PRODUCTS

LIABILITIES FOR INSURANCE PRODUCTS

Our future policy benefits are summarized as follows (dollars in millions):

	Withdrawal assumption	Morbidity assumption	Mortality assumption	Interest rate assumption	2017		2016
Long-term care	Company experience	Company experience	Company experience	6%	$	5,669.0	$	5,346.1
Traditional life insurance contracts	Company experience	Company experience	(a)	5%	2,401.2		2,322.1
Accident and health contracts	Company experience	Company experience	Company experience	5%	2,812.0		2,695.6
Interest-sensitive life insurance contracts	Company experience	Company experience	Company experience	5%	44.9		52.2
Annuities and supplemental contracts with life contingencies	Company experience	Company experience	(b)	4%	594.2		537.3
Total					$	11,521.3	$	10,953.3

____________________

(a) Principally, modifications of: (i) the 1965 ‑ 70 and 1975 - 80 Basic Tables; and (ii) the 1941, 1958 and 1980 Commissioners' Standard Ordinary Tables; as well as Company experience.

(b) Principally, modifications of: (i) the 1971 Individual Annuity Mortality Table; (ii) the 1983 Table "A"; and (iii) the Annuity 2000 Mortality Table; as well as Company experience.

Our policyholder account balances are summarized as follows (dollars in millions):

	2017		2016
Fixed index annuities	$	5,942.2	$	5,324.5
Other annuities	4,183.8		4,541.8
Interest-sensitive life insurance contracts	1,094.7		1,046.4
Total	$	11,220.7	$	10,912.7

The Company establishes reserves for insurance policy benefits based on assumptions as to investment yields, mortality, morbidity, withdrawals, lapses and maintenance expenses. These reserves include amounts for estimated future payment of claims based on actuarial assumptions. The balance includes provision for the Company's best estimate of the future policyholder benefits to be incurred on this business, given recent and expected future changes in experience.

Changes in the unpaid claims reserve (included in claims payable) and disabled life reserves related to accident and health insurance (included in the liability for future policy benefits) were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	1,777.6		$	1,731.8		$	1,679.5
Less reinsurance (receivables) payables	14.0			(130.0		)	(125.0		)
Net balance, beginning of year	1,791.6			1,601.8			1,554.5
Incurred claims related to:
Current year	1,548.1			1,526.4			1,481.0
Prior years (a)	(26.7		)	96.6			(13.3		)
Total incurred	1,521.4			1,623.0			1,467.7
Interest on claim reserves	78.4			75.3			71.0
Paid claims related to:
Current year	845.5			837.2			841.8
Prior years	702.6			671.3			649.6
Total paid	1,548.1			1,508.5			1,491.4
Net balance, end of year	1,843.3			1,791.6			1,601.8
Add reinsurance receivables (payables)	(15.1		)	(14.0		)	130.0
Balance, end of year	$	1,828.2		$	1,777.6		$	1,731.8

___________

(a) The reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. Such amounts will fluctuate based upon the estimation procedures used to determine the amount of unpaid losses. It is possible that actual claims will exceed our reserves and have a material adverse effect on our results of operations and financial condition.

XML

INCOME TAXES

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

INCOME TAXES

The components of income tax expense (benefit) were as follows (dollars in millions):

	2017			2016			2015
Current tax expense (benefit)	$	90.8		$	(45.2	)	$	10.7
Deferred tax expense	72.0			173.0			118.6
Valuation allowance applicable to current year income	(15.3		)	(14.0		)	—
Income tax expense calculated based on annual effective tax rate	147.5			113.8			129.3
Income tax expense on discrete items:
Change in valuation allowance	(13.4		)	40.7			(32.5		)
Impact of federal tax reform	310.6			—			—
Change in valuation allowance related to federal tax reform	(138.1		)	—			—
IRS settlement	—			(170.4		)	—
Other items	(1.7		)	10.9			.2
Total income tax expense (benefit)	$	304.9		$	(5.0	)	$	97.0

The Tax Reform Act makes broad and complex changes to the Code including reducing the federal corporate income tax rate to 21% from 35% effective January 1, 2018. As a result of the reduction in the federal corporate income tax rate, we reduced the value of our net deferred tax assets by $172.5 million (net of the reduction in the valuation allowance for deferred tax assets) which was recorded as additional income tax expense for the year ended December 31, 2017.

The $172.5 million adjustment to our net deferred tax assets is a provisional amount as defined in the SEC's Staff Accounting Bulletin No. 118 ("SAB 118"), issued in December 2017 to address complexities in completing the calculations resulting from the Tax Reform Act. Although we were able to make a reasonable estimate of the impact of the Tax Reform Act based on the information available, we have not analyzed the calculations in sufficient detail to complete the accounting process, including the analysis of the calculations of life insurance tax reserves and future taxable income used to estimate the deferred tax valuation allowance. SAB 118 provides guidance on accounting for the effects of the Tax Reform Act when our accounting process is incomplete but we are able to determine a reasonable estimate. A final determination is required to be made within a measurement period not to extend beyond one year from the enactment date of the Tax Reform Act. We will continue to analyze our estimate of the impact of the Tax Reform Act and expect the process to be completed in the fourth quarter of 2018.

A reconciliation of the U.S. statutory corporate tax rate to the effective rate reflected in the consolidated statement of operations is as follows:

	2017		2016		2015
U.S. statutory corporate rate	35.0	%	35.0	%	35.0	%
Valuation allowance	(6.0	)	7.6		(8.8	)
Non-taxable income and nondeductible benefits, net	(2.0	)	(1.1	)	(.2	)
State taxes	.6		2.2		2.1
Impact of federal tax reform	64.7		—		—
Change in valuation allowance related to federal tax reform	(28.8	)	—		—
Impact of IRS settlement	—		(48.2	)	—
Other items	—		3.1		(1.7	)
Effective tax rate	63.5	%	(1.4	)%	26.4	%

The components of the Company's income tax assets and liabilities are summarized below (dollars in millions):

	2017			2016
Deferred tax assets:
Net federal operating loss carryforwards	$	489.6		$	882.9
Net state operating loss carryforwards	9.3			12.3
Investments	4.3			17.8
Insurance liabilities	415.8			668.4
Other	48.9			66.3
Gross deferred tax assets	967.9			1,647.7
Deferred tax liabilities:
Present value of future profits and deferred acquisition costs	(165.4		)	(277.8		)
Accumulated other comprehensive income	(337.2		)	(344.1		)
Gross deferred tax liabilities	(502.6		)	(621.9		)
Net deferred tax assets before valuation allowance	465.3			1,025.8
Valuation allowance	(89.1		)	(240.2		)
Net deferred tax assets	376.2			785.6
Current income taxes prepaid (accrued)	(9.3		)	4.1
Income tax assets, net	$	366.9		$	789.7

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and NOLs. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire.

Based on our assessment, it appears more likely than not that $376.2 million of our total deferred tax assets of $465.3 million will be realized through future taxable earnings. Accordingly, we have established a deferred tax valuation allowance of $89.1 million at December 31, 2017 ($77.4 million of which relates to our net federal operating loss carryforwards and $11.7 million relates to state deferred tax assets). We will continue to assess the need for a valuation allowance in the future. If future results are less than projected, an increase to the valuation allowance may be required to reduce the deferred tax asset, which could have a material impact on our results of operations in the period in which it is recorded.

We use a deferred tax valuation model to assess the need for a valuation allowance. Our model is adjusted to reflect changes in our projections of future taxable income including changes resulting from the Tax Reform Act, investment strategies, the impact of the sale or reinsurance of business and the recapture of business previously ceded. Our estimates of future taxable income are based on evidence we consider to be objective and verifiable.

At December 31, 2017, our projection of future taxable income for purposes of determining the valuation allowance is based on our adjusted average annual taxable income which is assumed to increase by 3 percent for the next five years, and level taxable income is assumed thereafter. In the projections used for our analysis, our adjusted average taxable income of approximately $345 million consisted of $85 million of non-life taxable income and $260 million of life taxable income.

Based on our assessment, we recognized a decrease to the allowance for deferred tax assets of $151.1 million in 2017, including the impacts of the Tax Reform Act. We have evaluated the recovery of our deferred tax assets and assessed the effect of limitations and/or interpretations on their value and have concluded that it is more likely than not that the value recognized will be fully realized in the future.

Changes in our valuation allowance are summarized as follows (dollars in millions):

Balance, December 31, 2014	$	246.0
Decrease in 2015	(32.5		)	(a)
Balance, December 31, 2015	213.5
Increase in 2016	26.7			(b)
Balance, December 31, 2016	240.2
Decrease in 2017	(166.8		)	(c)
Cumulative effect of accounting change	15.7			(d)
Balance, December 31, 2017	$	89.1

___________________

(a) The 2015 reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income.

(b) The 2016 increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the Internal Revenue Service (the "IRS").

(c) The 2017 decrease to the deferred tax valuation allowance includes: (i) $138.1 million related to a reduction in the federal corporate income tax rate and other changes from the Tax Reform Act; (ii) $13.4 million of reductions to the deferred tax valuation allowance primarily related to the recognition of capital gains; and (iii) $15.3 million of reductions in the deferred tax valuation allowance reflecting higher current year taxable income than previously reflected in our deferred tax valuation model.

(d) Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences. Under the new guidance, any excess tax benefits are recognized as an income tax benefit in the income statement. The new guidance is applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings for all tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable. The Company had NOL carryforwards of $15.7 million related to deductions for stock options and restricted stock on the date of adoption. However, a corresponding valuation allowance of $15.7 million was recognized as a result of adopting this guidance. Therefore, there was no impact to our consolidated financial statements related to the initial adoption of this provision of the new guidance.

Recovery of our deferred tax asset is dependent on achieving the level of future taxable income projected in our deferred tax valuation model and failure to do so could result in an increase in the valuation allowance in a future period.  Any future increase in the valuation allowance may result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future.

The Internal Revenue Code (the "Code") limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of:  (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities).  There is no similar limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities). This limitation is the primary reason a valuation allowance for NOLs is required.

Section 382 of the Code imposes limitations on a corporation's ability to use its NOLs when the company undergoes a 50 percent ownership change over a three year period.  Future transactions and the timing of such transactions could cause an ownership change for Section 382 income tax purposes.  Such transactions may include, but are not limited to, additional repurchases under our securities repurchase program, issuances of common stock and acquisitions or sales of shares of CNO stock by certain holders of our shares, including persons who have held, currently hold or may accumulate in the future, five percent or more of our outstanding common stock for their own account.  Many of these transactions are beyond our control.  If an additional ownership change were to occur for purposes of Section 382, we would be required to calculate an annual restriction on the use of our NOLs to offset future taxable income.  The annual restriction would be calculated based upon the value of CNO's equity at the time of such ownership change, multiplied by a federal long-term tax exempt rate (1.96 percent at December 31, 2017), and the annual restriction could limit our ability to use a substantial portion of our NOLs to offset future taxable income.  We regularly monitor ownership change (as calculated for purposes of Section 382) and, as of December 31, 2017, we were below the 50 percent ownership change level that would trigger further impairment of our ability to utilize our NOLs.

In 2009, the Company's Board of Directors adopted a Section 382 Rights Agreement designed to protect shareholder value by preserving the value of our tax assets primarily associated with tax NOLs under Section 382. The Section 382 Rights Agreement was adopted to reduce the likelihood of an ownership change occurring by deterring the acquisition of stock that would create "5 percent shareholders" as defined in Section 382. The Section 382 Rights Agreement has been amended three times, most recently effective November 13, 2017 (the "Third Amended Section 382 Rights Agreement"). The Third Amended Section 382 Rights Agreement extended the expiration date of the Section 382 Rights Agreement to November 13, 2020, updated the purchase price of the rights described below and provided for a new series of preferred stock relating to the rights that is substantially identical to the prior series of preferred stock. The Company expects to submit the Third Amended Section 382 Rights Agreement to the Company’s stockholders for approval at the Company’s 2018 annual meeting.

Under the Section 382 Rights Agreement, one right was distributed for each share of our common stock outstanding as of the close of business on January 30, 2009 and for each share issued after that date. Pursuant to the Third Amended Section 382 Rights Agreement, if any person or group (subject to certain exemptions) becomes an owner of more than 4.99 percent of the Company's outstanding common stock (or any other interest in the Company that would be treated as "stock" under applicable Section 382 regulations) without the approval of the Board of Directors, there would be a triggering event causing significant dilution in the voting power and economic ownership of that person or group. Shareholders who held more than 4.99 percent of the Company's outstanding common stock as of December 6, 2011 will trigger a dilutive event only if they acquire additional shares exceeding one percent of our outstanding shares without prior approval from the Board of Directors.

In 2010, our shareholders approved an amendment to CNO's certificate of incorporation designed to prevent certain transfers of common stock which could otherwise adversely affect our ability to use our NOLs (the "Original Section 382 Charter Amendment"). Subject to the provisions set forth in the Original Section 382 Charter Amendment, transfers of our common stock would be void and of no effect if the effect of the purported transfer would be to: (i) increase the direct or indirect ownership of our common stock by any person or public group (as such term is defined in the regulations under Section 382) from less than 5% to 5% or more of our common stock; (ii) increase the percentage of our common stock owned directly or indirectly by a person or public group owning or deemed to own 5% or more of our common stock; or (iii) create a new public group. The Original Section 382 Charter Amendment was amended and extended in 2013 and in 2016 (the "2016 Section 382 Charter Amendment"). The expiration date for the 2016 Section 382 Charter Amendment is July 31, 2019.

As of December 31, 2017, we had $2.3 billion of federal NOLs (all of which were non-life NOLs). The following table summarizes the expiration dates of our loss carryforwards (dollars in millions):

	Net operating loss
Year of expiration	carryforwards
2023	$	1,744.8
2025	85.2
2026	149.9
2027	10.8
2028	80.3
2029	213.2
2030	.3
2031	.2
2032	44.4
2033	.6
2034	.9
2035	.8
Total federal NOLs	$	2,331.4

We also had deferred tax assets related to NOLs for state income taxes of $9.3 million and $12.3 million at December 31, 2017 and 2016, respectively.  The related state NOLs are available to offset future state taxable income in certain states through 2025.

There were no unrecognized tax benefits in 2017. A reconciliation of the beginning and ending amount of unrecognized tax benefits for the year ended December 31, 2016 is as follows (dollars in millions):

	2016
Balance at beginning of year	$	234.2
Increase based on tax positions taken in prior years	3.4
Decrease in unrecognized tax benefits related to settlements with taxing authorities	(237.6		)
Balance at end of year	$	—

In the fourth quarter of 2016, we reached a settlement with the IRS related to two uncertain tax positions: (i) $280.7 million of life NOLs and $130.0 million of non-life NOLs related to the classification of the loss on our investment in Conseco Senior Health Insurance Company when it was transferred to an independent trust in 2008; and (ii) $66.7 million of non-life NOLs related to a bad debt deduction with respect to a stock purchase loan made by our Predecessor to a member of its board of directors. The settlement resulted in a reduction to tax expense of approximately $118.7 million in the fourth quarter of 2016 (the period in which these matters were settled and the fully executed documentation was received). The $118.7 million benefit includes: (i) a $98.2 million tax benefit related to additional life NOLs; (ii) a $17.1 million tax benefit related to additional non-life NOLs (net of an increase to the deferred tax valuation allowance of $51.7 million); and (iii) a $3.4 million reduction in interest recognized in prior periods on alternative minimum tax that will no longer be required to be paid.

The additional life NOLs related to the settlement offset our life taxable income in the third and fourth quarters of 2016 and the tax gain realized on the recapture of the ceded long-term care business from BRe. The settlement also reduced the amount of current income tax accrued at December 31, 2016, as presented in the components of income tax assets and liabilities schedule provided in this note to consolidated financial statements by approximately $50 million.

All of the life NOLs were utilized by December 31, 2016. Accordingly, we began making estimated federal tax payments equal to the prescribed federal tax rate applied to 65 percent of our life insurance company taxable income due to the limitations on the extent to which we can use non-life NOLs to offset life insurance company taxable income. Under current law, we will continue to pay tax on 65 percent of our life insurance company taxable income until all non-life NOLs are utilized or expire.

The IRS is also conducting an examination of 2013 through 2014. In connection with this exam, we have agreed to extend the statute of limitations for 2013 through September 30, 2018. The Company’s various state income tax returns are generally open for tax years beginning in 2014, based on individual state statutes of limitation. Generally, for tax years which generate NOLs, capital losses or tax credit carryforwards, the statute remains open until the expiration of the statute of limitations for the tax year in which such carryforwards are utilized. The outcome of tax audits cannot be predicted with certainty. If the Company’s tax audits are not resolved in a manner consistent with management’s expectations, the Company may be required to adjust its provision for income taxes.

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

The following notes payable were direct corporate obligations of the Company as of December 31, 2017 and 2016 (dollars in millions):

	2017			2016
4.500% Senior Notes due May 2020	$	325.0		$	325.0
5.250% Senior Notes due May 2025	500.0			500.0
Revolving Credit Agreement (as defined below)	100.0			100.0
Unamortized debt issuance costs	(10.4		)	(12.1		)
Direct corporate obligations	$	914.6		$	912.9

Notes

On May 19, 2015, the Company executed the Indenture, dated as of May 19, 2015 (the "Base Indenture") and the First Supplemental Indenture, dated as of May 19, 2015 (the "Supplemental Indenture" and, together with the Base Indenture, the "Indenture"), between the Company and Wilmington Trust, National Association, as trustee (the "Trustee") pursuant to which the Company issued $325.0 million aggregate principal amount of 4.500% Senior Notes due 2020 (the "2020 Notes") and $500.0 million aggregate principal amount of 5.250% Senior Notes due 2025 (the "2025 Notes" and, together with the 2020 Notes, the "Notes").

The Company used the proceeds of the offering of the Notes, together with borrowings under the Revolving Credit Agreement (as defined below): (i) to repay all amounts outstanding under our previous senior secured credit agreement; (ii) to redeem and satisfy and discharge all of the outstanding 6.375% Senior Secured Notes due October 2020 (the "6.375% Notes"); and (iii) to pay fees and expenses related to the offering of the Notes and the foregoing transactions. The remaining proceeds of the Notes and the borrowings under the Revolving Credit Agreement were used for general corporate purposes, including share repurchases.

The 2020 Notes mature on May 30, 2020, and the 2025 Notes mature on May 30, 2025. Interest on the 2020 Notes is payable at 4.500% per annum. Interest on the 2025 Notes is payable at 5.250% per annum. Interest on the Notes is payable semi-annually in cash in arrears on May 30 and November 30 of each year, commencing on November 30, 2015.

The Notes are the Company's senior unsecured obligations and rank equally with the Company's other senior unsecured and unsubordinated debt from time to time outstanding, including obligations under the Revolving Credit Agreement (as defined below). The Notes are effectively subordinated to all of the Company's existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness. The Notes are structurally subordinated to all existing and future indebtedness and other liabilities of the Company's subsidiaries.

The Company may redeem some or all of the 2020 Notes at any time or from time to time at a "make-whole" redemption price plus accrued and unpaid interest to, but not including, the redemption date.

Prior to February 28, 2025, the Company may redeem some or all of the 2025 Notes at any time or from time to time at a "make-whole" redemption price plus accrued and unpaid interest to, but not including, the redemption date. On and after February 28, 2025, the Company may redeem some or all of the 2025 Notes at any time or from time to time at a redemption price equal to 100% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date.

Upon the occurrence of a Change of Control Repurchase Event (as defined in the Indenture), the Company will be required to make an offer to repurchase the Notes at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but not including, the date of repurchase.

The Indenture contains covenants that restrict the Company’s ability, with certain exceptions, to:

• incur certain subsidiary indebtedness without also guaranteeing the Notes;

• create liens;

• enter into sale and leaseback transactions;

• issue, sell, transfer or otherwise dispose of any shares of capital stock of any Insurance Subsidiary (as defined in the Indenture); and

• consolidate or merge with or into other companies or transfer all or substantially all of the Company’s assets.

The Indenture provides for customary events of default (subject in certain cases to customary grace and cure periods), which include nonpayment, breach of covenants in the Indenture, failure to pay at maturity or acceleration of other indebtedness, a failure to pay certain judgments and certain events of bankruptcy and insolvency. Generally, if an event of default occurs, the Trustee or holders of at least 25% in principal amount of the then outstanding Notes may declare the principal of and accrued but unpaid interest, including any additional interest, on all of the Notes to be due and payable.

Revolving Credit Agreement

On May 19, 2015, the Company entered into a $150.0 millionfour-year unsecured revolving credit agreement with KeyBank National Association, as administrative agent (the "Agent"), and the lenders from time to time party thereto. On May 19, 2015, the Company made an initial drawing of $100.0 million under the Revolving Credit Agreement, resulting in $50.0 million available for additional borrowings. On October 13, 2017, the Company entered into an amendment and restatement agreement (the "Amendment Agreement") with respect to its revolving credit agreement (as amended by the Amendment Agreement, the "Revolving Credit Agreement"). The Amendment Agreement, among other things, increased the total commitments available under the revolving credit facility from $150.0 million to $250.0 million, increased the aggregate amount of additional incremental loans the Company may incur from $50.0 million to $100.0 million and extended the maturity date of the revolving credit facility from May 19, 2019 to the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the 2020 Notes, which is November 30, 2019.

The Revolving Credit Agreement includes an uncommitted subfacility for swingline loans of up to $5.0 million, and up to $5.0 million of the Revolving Credit Agreement is available for the issuance of letters of credit. The Company may incur additional incremental loans under the Revolving Credit Agreement in an aggregate principal amount of up to $100.0 million provided that there are no events of default and subject to certain other terms and conditions including the delivery of certain documentation.

The interest rates with respect to loans under the Revolving Credit Agreement are based on, at the Company's option, a floating base rate (defined as a per annum rate equal to the highest of: (i) the federal funds rate plus 0.50%; (ii) the "prime rate" of the Agent; and (iii) the eurodollar rate for a one-month interest period plus an applicable margin based on the Company's unsecured debt rating), or a eurodollar rate plus an applicable margin based on the Company's unsecured debt rating. The margins under the Revolving Credit Agreement range from 1.375% to 2.125% (1.75% to 2.25% prior to the Amendment Agreement), in the case of loans at the eurodollar rate, and 0.375% to 1.125% (.75% to 1.25% prior to the Amendment Agreement), in the case of loans at the base rate. At December 31, 2017, the interest rate on the amounts outstanding under the Revolving Credit Agreement was 3.44 percent. In addition, the daily average undrawn portion of the Revolving Credit Agreement will accrue a commitment fee payable quarterly in arrears. The applicable margin for, and the commitment fee applicable to, the Revolving Credit Agreement, will be adjusted from time to time pursuant to a ratings based pricing grid. In addition, a fronting fee, in an amount equal to 0.125% per annum on the aggregate face amount of the outstanding letters of credit, will be payable to the issuers of such letters of credit.

The Revolving Credit Agreement contains certain financial, affirmative and negative covenants. The negative covenants in the Revolving Credit Agreement include restrictions that relate to, among other things and subject to customary baskets, exceptions and limitations for facilities of this type:

• subsidiary debt;

• liens;

• restrictive agreements;

• restricted payments during the continuance of an event of default;

• disposition of assets and sale and leaseback transactions;

• transactions with affiliates;

• change in business;

• fundamental changes;

• modification of certain agreements; and

• changes to fiscal year.

The Revolving Credit Agreement requires the Company to maintain (each as calculated in accordance with the Revolving Credit Agreement): (i) a debt to total capitalization ratio of not more than 35.0 percent (30.0 percent prior to the Amendment Agreement) (such ratio was 20.3 percent at December 31, 2017); (ii) an aggregate ratio of total adjusted capital to company action level risk-based capital for the Company's insurance subsidiaries of not less than 250 percent (such ratio was estimated to be 446 percent at December 31, 2017); and (iii) a minimum consolidated net worth of not less than the sum of (x) $2,674 million plus (y) 50.0% of the net equity proceeds received by the Company from the issuance and sale of equity interests in the Company (the Company's consolidated net worth was $3,635.4 million at December 31, 2017 compared to the minimum requirement of $2,684.9 million).

The Revolving Credit Agreement provides for customary events of default (subject in certain cases to customary grace and cure periods), which include, without limitation, the following:

• non-payment;

• breach of representations, warranties or covenants;

• cross-default and cross-acceleration;

• bankruptcy and insolvency events;

• judgment defaults;

• actual or asserted invalidity of documentation with respect to the Revolving Credit Agreement;

• change of control; and

• customary ERISA defaults.

If an event of default under the Revolving Credit Agreement occurs and is continuing, the Agent may accelerate the amounts and terminate all commitments outstanding under the Revolving Credit Agreement.

Loss on Extinguishment of Debt

In 2015, we recognized a loss on extinguishment of debt totaling $32.8 million primarily related to: (i) the redemption premium related to the repayment of the 6.375% Notes; and (ii) the write-off of unamortized discount and issuance costs associated with the repayment of our previous senior secured credit agreement and the 6.375% Notes.

Scheduled Repayment of our Direct Corporate Obligations

The scheduled repayment of our direct corporate obligations was as follows at December 31, 2017 (dollars in millions):

Year ending December 31,
2018	$	—
2019	100.0		(a)
2020	325.0
2021	—
2022	—
Thereafter	500.0
	$	925.0

_________________________

(a) The maturity date of the Revolving Credit Agreement is the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s 4.50% senior notes due 2020, which is November 30, 2019.

XML

LITIGATION AND OTHER LEGAL PROCEEDINGS

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

LITIGATION AND OTHER LEGAL PROCEEDINGS

LITIGATION AND OTHER LEGAL PROCEEDINGS

Legal Proceedings

The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts.  We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred.  The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict.  In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows.  In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies.  Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.

In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters.  The Company reviews these matters on an ongoing basis.  When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.

On September 29, 2016, Washington National and BCLIC commenced an arbitration proceeding seeking compensatory, consequential and punitive damages against BRe based upon BRe’s incurable material breaches of the long-term care reinsurance agreements, conversion, fraud, and breaches of fiduciary duties and the obligation to deal honestly and in good faith. BRe filed a counterclaim against Washington National and BCLIC in the arbitration alleging damages relating to the reinsurance agreements and their termination.  In addition, on September 29, 2016, a complaint was filed by BCLIC and Washington National in the United States District Court for the Southern District of New York, Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Moshe M. Feuer, Scott Taylor and David Levy, Case No. 16-cv-7646, alleging, among other claims, fraud/fraudulent concealment, and violation of the Racketeer Influenced and Corrupt Organizations Act. These allegations relate to the long-term care reinsurance agreements between BRe and Washington National and BCLIC, respectively, and emanate from the undisclosed relationships between and among the defendants (who were the principal owners and officers of BRe) and Platinum Partners, LP and its affiliates. On April 27, 2017, an amended complaint was filed adding Beechwood Capital Group, LLC as a defendant. Feuer, Taylor and Levy have moved to compel arbitration of Washington National's and BCLIC's claims. Washington National and BCLIC intend to vigorously pursue their claims for damages and other remedies in the arbitration and the litigation described above.

By public notice dated July 26, 2017, the Cayman Islands Monetary Authority advised that, effective July 25, 2017, two individuals (the "Controllers") had been appointed pursuant to Section 24(2)(h) of the Cayman Islands Insurance Law to assume control of the affairs of BRe.  According to the public notice, effective with their appointment, the Controllers assumed immediate control of the affairs of BRe and have all the powers necessary to administer the affairs of BRe including power to terminate its insurance business.  The Controllers are responsible for assessing the financial position of BRe and submitting a report to the Cayman Islands Monetary Authority by a date to be specified.  We are in the process of assessing the potential impact of this action on the proceedings described in the foregoing paragraph.

On July 20, 2007, a complaint was filed in the Hamilton County, Indiana Circuit Court, Signature Estates of Indiana, Inc. d/b/a Gordon Marketing, Stephens-Matthews Marketing, Inc., Shields Brokerage, Inc. and Edwin A. Hildebrand d/b/a Hildebrand Insurance Services v. Conseco Medical Insurance Company, Conseco Medical Insurance Company a/k/a Washington National Insurance Company and Washington National Insurance Company, Cause No. 29D02- 0707-PL-790.  The Plaintiffs are independent insurance marketing organizations which previously marketed Conseco Medical Insurance Company ("CMIC") individual major medical products and which are claiming damages for allegedly fraudulent conduct by CMIC in withdrawing from this business in 2002.  The Plaintiffs contend that they relied on CMIC’s alleged representations that its major medical business was profitable and that CMIC was committed to it.  The Plaintiffs further allege that when CMIC exited the market, it caused agents that were previously writing business through their organizations to cease doing business with them, thereby causing irreparable damage.  CMIC merged into Washington National, effective July 1, 2003.  On December 16, 2016, following a jury trial, verdicts were entered in favor of the plaintiffs, and compensatory damages aggregating $4.7 million and punitive damages aggregating $6.0 million were awarded to the plaintiffs.  Washington National filed post-trial motions requesting the court correct errors, grant a new trial, find that punitive damages were improper, and reduce both compensatory and punitive damages.  Plaintiffs filed motions requesting pre-judgment interest and attorney fees. On June 19, 2017, the court reduced punitive damages by $1.5 million and denied plaintiffs' motions for pre-judgment interest and attorney fees. Each side appealed the decision and the case was subsequently settled.

Regulatory Examinations and Fines

Insurance companies face significant risks related to regulatory investigations and actions.  Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers.  We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities.  The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty.  In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.

In August 2011, we were notified of an examination to be done on behalf of a number of states for the purpose of determining compliance with unclaimed property laws by the Company and its subsidiaries.  Such examination has included inquiries related to the use of data available on the U.S. Social Security Administration's Death Master File to identify instances where benefits under life insurance policies, annuities and retained asset accounts are payable. We are continuing to provide information to the examiners in response to their requests. A total of 38 states and the District of Columbia are currently participating in this examination.

Guaranty Fund Assessments

The balance sheet at December 31, 2017, included: (i) accruals of $14.1 million, representing our estimate of all known assessments that will be levied against the Company's insurance subsidiaries by various state guaranty associations based on premiums written through December 31, 2017; and (ii) receivables of $20.0 million that we estimate will be recovered through a reduction in future premium taxes as a result of such assessments. At December 31, 2016, such guaranty fund assessment accruals were $24.9 million and such receivables were $26.7 million. These estimates are subject to change when the associations determine more precisely the losses that have occurred and how such losses will be allocated among the insurance companies. We recognized expense for such assessments of $11.0 million, $2.8 million and $1.2 million in 2017, 2016 and 2015, respectively.

Guarantees

In accordance with the terms of the employment agreements of two of the Company's former chief executive officers, certain wholly-owned subsidiaries of the Company are the guarantors of the former executives' nonqualified supplemental retirement benefits. The liability for such benefits was $24.2 million and $25.0 million at December 31, 2017 and 2016, respectively, and is included in the caption "Other liabilities" in the consolidated balance sheet.

Leases and Certain Other Long-Term Commitments

The Company rents office space, equipment and computer software under noncancellable operating lease agreements. In addition, the Company has entered into certain sponsorship agreements which require future payments. Total expense pursuant to these lease and sponsorship agreements was $61.4 million, $56.8 million and $48.8 million in 2017, 2016 and 2015, respectively. Future required minimum payments as of December 31, 2017, were as follows (dollars in millions):

2018	$	33.5
2019	18.2
2020	11.8
2021	8.0
2022	5.6
Thereafter	3.6
Total	$	80.7

XML

AGENT DEFERRED COMPENSATION PLAN

12 Months Ended

Dec. 31, 2017

Retirement Benefits [Abstract]

AGENT DEFERRED COMPENSATION PLAN

AGENT DEFERRED COMPENSATION PLAN

For our agent deferred compensation plan, it is our policy to immediately recognize changes in the actuarial benefit obligation resulting from either actual experience being different than expected or from changes in actuarial assumptions.

One of our insurance subsidiaries has a noncontributory, unfunded deferred compensation plan for qualifying members of its career agency force. Benefits are based on years of service and career earnings. In 2016, the agent deferred compensation plan was amended to: (i) freeze participation in the plan; (ii) freeze benefits accrued under the plan; and (iii) add a limited cashout feature. During the third quarter of 2016, we made lump sum settlement distributions to plan participants with account balances that were below a certain threshold consistent with the provision of the amended plan. We recognized a pre-tax gain of $6.1 million related to the settlement distributions in the third quarter of 2016.

The actuarial measurement date of this deferred compensation plan is December 31. The liability recognized in the consolidated balance sheet for the agent deferred compensation plan was $168.2 million and $156.3 million at December 31, 2017 and 2016, respectively. Expenses incurred on this plan were $18.8 million, $8.1 million and $2.2 million during 2017, 2016 and 2015, respectively (including the recognition of gains (losses) of $(12.2) million, $3.1 million and $15.2 million in 2017, 2016 and 2015, respectively, primarily resulting from: (i) changes in the discount rate assumption used to determine the deferred compensation plan liability to reflect current investment yields; (ii) changes in mortality table assumptions; and (iii) the aforementioned settlement distributions in 2016). We purchased COLI as an investment vehicle to fund the agent deferred compensation plan. The COLI assets are not assets of the agent deferred compensation plan, and as a result, are accounted for outside the plan and are recorded in the consolidated balance sheet as other invested assets. The carrying value of the COLI assets was $182.3 million and $165.0 million at December 31, 2017 and 2016, respectively. Death benefits related to the COLI and changes in the cash surrender value (which approximates net realizable value) of the COLI assets are recorded as net investment income on special-purpose portfolios and totaled $24.6 million, $6.9 million and $.5 million in 2017, 2016 and 2015, respectively.

We used the following assumptions for the deferred compensation plan to calculate:

	2017		2016
Benefit obligations:
Discount rate	3.75	%	4.25	%
Net periodic cost:
Discount rate	4.25	%	4.50	%

The discount rate is based on the yield of a hypothetical portfolio of high quality debt instruments which could effectively settle plan benefits on a present value basis as of the measurement date.

The benefits expected to be paid pursuant to our agent deferred compensation plan as of December 31, 2017 were as follows (dollars in millions):

2018	$	7.4
2019	7.6
2020	7.9
2021	8.0
2022	8.3
2023 - 2027	45.2

One of our insurance subsidiaries has another unfunded nonqualified deferred compensation program for qualifying members of its career agency force. Such agents may defer a certain percentage of their net commissions into the program. In addition, annual Company contributions are made based on the agent's production and vest over a period of five to 10 years. The liability recognized in the consolidated balance sheet for this program was $22.9 million and $11.2 million at December 31, 2017 and 2016, respectively. Company contribution expense totaled $6.6 million and $4.4 million in 2017 and 2016, respectively. We purchased Trust-Owned Life Insurance ("TOLI") as an investment vehicle to fund the program. The TOLI assets are not assets of the program, and as a result, are accounted for outside the program and are recorded in the consolidated balance sheet as other invested assets. The carrying value of the TOLI assets was $18.0 million and $5.1 million at December 31, 2017 and 2016, respectively.

The Company has a qualified defined contribution plan for which substantially all employees are eligible. Company contributions, which match a portion of certain voluntary employee contributions to the plan, totaled $5.5 million, $5.3 million and $5.0 million in 2017, 2016 and 2015, respectively. Employer matching contributions are discretionary.

XML

DERIVATIVES

12 Months Ended

Dec. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVES

DERIVATIVES

Our freestanding and embedded derivatives, which are not designated as hedging instruments, are held at fair value and are summarized as follows (dollars in millions):

	Fair value
	2017			2016
Assets:
Other invested assets:
Fixed index call options	$	170.2		$	111.9
Reinsurance receivables	(1.4		)	(4.2		)
Total assets	$	168.8		$	107.7
Liabilities:
Future policy benefits:
Fixed index products	$	1,334.8		$	1,092.3
Total liabilities	$	1,334.8		$	1,092.3

The activity associated with freestanding derivative instruments is measured as either the notional or the number of contracts. The activity associated with the fixed index annuity embedded derivatives are shown by the number of policies. The following table represents activity associated with derivative instruments as of the dates indicated:

	Measurement	December 31, 2016		Additions		Maturities/terminations			December 31, 2017
Fixed index annuities - embedded derivative	Policies	100,812		11,437		(7,560		)	104,689
Fixed index call options	Notional (a)	$	2,455.1	$	3,021.8	$	(2,471.1	)	$	3,005.8

_________________

(a) Dollars in millions.

We are required to establish an embedded derivative related to a modified coinsurance agreement pursuant to which we assume the risks of a block of health insurance business. The embedded derivative represents the mark-to-market adjustment for approximately $126 million in underlying investments held by the ceding reinsurer.

The following table provides the pre-tax gains (losses) recognized in net income for derivative instruments, which are not designated as hedges for the periods indicated (dollars in millions):

	2017		2016			2015
Net investment income from policyholder and other special-purpose portfolios:
Fixed index call options	$	162.5	$	29.2		$	(36.2	)
Net realized gains (losses):
Interest rate futures	—		(1.1		)	(2.7		)
Embedded derivative related to modified coinsurance agreement	2.8		.8			(7.0		)
Total	2.8		(.3		)	(9.7		)
Insurance policy benefits:
Embedded derivative related to fixed index annuities	25.0		60.8			36.3
Total	$	190.3	$	89.7		$	(9.6	)

Derivative Counterparty Risk

If the counterparties to the call options fail to meet their obligations, we may recognize a loss.  We limit our exposure to such a loss by diversifying among several counterparties believed to be strong and creditworthy.  At December 31, 2017, all of our counterparties were rated "A-" or higher by S&P.

From time to time, we enter into exchange-traded interest rate future contracts. The contracts are marked to market and margined on a daily basis. The Company has minimal exposure to credit-related losses in the event of nonperformance.

The Company and its subsidiaries are parties to master netting arrangements with its counterparties related to entering into various derivative contracts. Exchange-traded derivatives require margin accounts which we offset.

The following table summarizes information related to derivatives with master netting arrangements or collateral as of December 31, 2017 and 2016 (dollars in millions):

								Gross amounts not offset in the balance sheet
		Gross amounts recognized		Gross amounts offset in the balance sheet		Net amounts of assets presented in the balance sheet		Financial instruments		Cash collateral received		Net amount
December 31, 2017:
	Fixed index call options	$	170.2	$	—	$	170.2	$	—	$	—	$	170.2
December 31, 2016:
	Fixed index call options	111.9		—		111.9		—		—		111.9

XML

SHAREHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY

Changes in the number of shares of common stock outstanding were as follows (shares in thousands):

	2017		2016		2015
Balance, beginning of year	173,754		184,029		203,324
Treasury stock purchased and retired	(7,808	)	(11,688	)	(20,582	)
Stock options exercised	725		978		769
Restricted and performance stock vested (a)	187		435		518
Balance, end of year	166,858		173,754		184,029

____________________

(a) In 2017, 2016 and 2015, such amount was reduced by 103 thousand, 191 thousand and 237 thousand shares, respectively, which were tendered to the Company for the payment of required federal and state tax withholdings owed on the vesting of restricted and performance stock.

In May 2011, the Company announced a securities repurchase program of up to $100.0 million. In February 2012, June 2012, December 2012, December 2013, November 2014, November 2015 and May 2017, the Company's Board of Directors approved, in aggregate, an additional $1,900.0 million to repurchase the Company's outstanding securities. In 2017, 2016 and 2015, we repurchased 7.8 million, 11.7 million and 20.6 million shares, respectively, for $167.1 million, $203.0 million and $365.2 million, respectively, under the securities repurchase program. The Company had remaining repurchase authority of $385.6 million as of December 31, 2017.

In 2017, 2016 and 2015, dividends declared and paid on common stock totaled $59.6 million ($0.35 per common share), $54.8 million ($0.31 per common share) and $52.0 million ($0.27 per common share), respectively. In May 2017, the Company increased its quarterly common stock dividend to $0.09 per share from $0.08 per share. In May 2016, the Company increased its quarterly common stock dividend to $0.08 per share from $0.07 per share. In May 2015, the Company increased its quarterly common stock dividend to $0.07 per share from $0.06 per share.

The Company has a long-term incentive plan which permits the grant of CNO incentive or non-qualified stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance shares or units and certain other equity-based awards to certain directors, officers and employees of the Company and certain other individuals who perform services for the Company. As of December 31, 2017, 7.5 million shares remained available for issuance under the plan. Our stock option awards are generally granted with an exercise price equal to the market price of the Company's stock on the date of grant and a maximum term of ten years. Our stock option awards granted in 2007 through 2009 generally vested on a graded basis over a three year service term and expired five years from the date of grant. Our stock options granted in 2010 through 2014 generally vest on a graded basis over a three year service term and expire seven years from the date of grant. Our stock options granted in 2015, 2016 and 2017 generally vest on a graded basis over a three year service term and expire ten years from the date of grant. The vesting periods for our awards of restricted stock and restricted stock units (collectively "restricted stock") range from immediate vesting to a period of three years.

A summary of the Company's stock option activity and related information for 2017 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,354		$	14.73
Options granted	729		21.06
Exercised	(237	)	(17.81		)		$	5.2
Forfeited or terminated	(725	)	(11.43		)
Outstanding at the end of the year	5,121		15.95			5.4	$	37.2
Options exercisable at the end of the year	2,440					3.0	$	19.2
Available for future grant	7,488

A summary of the Company's stock option activity and related information for 2016 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,199		$	13.32
Options granted	1,706		17.45
Exercised	(978	)	(8.70		)		$	6.1
Forfeited or terminated	(573	)	(20.41		)
Outstanding at the end of the year	5,354		14.73			5.9	$	37.1
Options exercisable at the end of the year	2,187					2.7	$	15.1
Available for future grant	4,620

A summary of the Company's stock option activity and related information for 2015 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,011		$	12.04
Options granted	1,361		16.45
Exercised	(769	)	(8.20		)		$	4.8
Forfeited or terminated	(404	)	(17.70		)
Outstanding at the end of the year	5,199		13.32			4.8	$	38.4
Options exercisable at the end of the year	2,399					2.5	$	15.3
Available for future grant	6,882

We recognized compensation expense related to stock options totaling $6.3 million ($4.1 million after income taxes) in 2017, $12.2 million ($7.9 million after income taxes) in 2016 and $9.6 million ($6.2 million after income taxes) in 2015. Compensation expense related to stock options reduced both basic and diluted earnings per share by two cents in 2017, four cents in 2016 and three cents in 2015. At December 31, 2017, the unrecognized compensation expense for non-vested stock options totaled $4.2 million which is expected to be recognized over a weighted average period of 1.5 years. Cash received by the Company from the exercise of stock options was $8.3 million, $8.4 million and $6.3 million during 2017, 2016 and 2015, respectively.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions:

	2017			2016			2015
	Grants			Grants			Grants
Weighted average risk-free interest rates	2.2		%	1.4		%	1.7		%
Weighted average dividend yields	1.5		%	1.6		%	1.5		%
Volatility factors	32		%	36		%	85		%
Weighted average expected life (in years)	6.3			6.3			6.3
Weighted average fair value per share	$	6.20		$	5.48		$	10.83

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on the Company's history and expectation of dividend payouts. Volatility factors are based on the weekly historical volatility of the Company's common stock equal to the expected life of the option. The expected life is based on the average of the graded vesting period and the contractual terms of the option.

The exercise price was equal to the market price of our stock on the date of grant for all options granted in 2017, 2016 and 2015.

The following table summarizes information about stock options outstanding at December 31, 2017 (shares in thousands):

		Options outstanding			Options exercisable
Range of exercise prices	Number outstanding	Remaining life (in years)	Average exercise price		Number exercisable	Average exercise price
$6.77 - $7.51	605	0.9	$	7.47	605	$	7.47
$10.88 - $16.22	683	2.3	11.12		670	11.02
$16.42 - $21.48	3,833	6.7	18.15		1,165	18.04
	5,121				2,440

During 2017, 2016 and 2015, the Company granted restricted stock of .3 million, .4 million and .1 million, respectively, to certain directors, officers and employees of the Company at a weighted average fair value of $20.87 per share, $18.17 per share and $17.59 per share, respectively. The fair value of such grants totaled $6.9 million, $7.3 million and $1.7 million in 2017, 2016 and 2015, respectively. Such amounts are recognized as compensation expense over the vesting period of the restricted stock. A summary of the Company's non-vested restricted stock activity for 2017 is presented below (shares in thousands):

	Shares		Weighted average grant date fair value
Non-vested shares, beginning of year	369		$	18.10
Granted	330		20.87
Vested	(147	)	(18.38		)
Forfeited	(17	)	(20.59		)
Non-vested shares, end of year	535		19.65

At December 31, 2017, the unrecognized compensation expense for non-vested restricted stock totaled $5.5 million which is expected to be recognized over a weighted average period of 1.8 years. At December 31, 2016, the unrecognized compensation expense for non-vested restricted stock totaled $5.0 million. We recognized compensation expense related to restricted stock awards totaling $6.1 million, $3.1 million and $2.2 million in 2017, 2016 and 2015, respectively. The fair value of restricted stock that vested during 2017, 2016 and 2015 was $2.7 million, $2.1 million and $2.7 million, respectively.

Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the accounting policy for forfeiture rate assumptions. Under the new guidance, we elected to account for forfeitures as they occur. The impact of adoption of this provision of the guidance increased additional paid-in capital by $.9 million, decreased retained earnings by $.6 million and increased income tax assets by $.3 million. Prior to 2017, authoritative guidance required us to estimate the amount of unvested stock-based awards that would be forfeited in future periods and reduce the amount of compensation expense recognized over the applicable service period to reflect such estimate.

In 2017, 2016 and 2015 the Company granted performance units totaling 452,900, 507,976 and 516,660, respectively, pursuant to its long-term incentive plan to certain officers of the Company. The criteria for payment for such awards are based on certain company-wide performance levels that must be achieved within a specified performance time (generally three years), each as defined in the award. The performance units granted in 2017, 2016 and 2015 provide for a payout of up to 200 percent of the award if certain performance thresholds are achieved, and the performance units granted prior to 2015 provide for a payout of up to 150 percent of the award if certain performance thresholds are achieved. Unless antidilutive, the diluted weighted average shares outstanding would reflect the number of performance units expected to be issued, using the treasury stock method.

A summary of the Company's performance units is presented below (shares in thousands):

	Total shareholder return awards		Operating return on equity awards		Pre-tax operating income awards
Awards outstanding at December 31, 2014	519		343		176
Granted in 2015	258		258		—
Additional shares issued pursuant to achieving certain performance criteria (a)	85		—		85
Shares vested in 2015	(260	)	—		(260	)
Forfeited	(53	)	(52	)	(1	)
Awards outstanding at December 31, 2015	549		549		—
Granted in 2016	254		254		—
Additional shares issued pursuant to achieving certain performance criteria (a)	87		65		—
Shares vested in 2016	(261	)	(239	)	—
Forfeited	(59	)	(59	)	—
Awards outstanding at December 31, 2016	570		570		—
Granted in 2017	226		226		—
Additional shares issued pursuant to achieving certain performance criteria (a)	—		30		—
Shares vested in 2017	—		(144	)	—
Forfeited	(167	)	(53	)	—
Awards outstanding at December 31, 2017	629		629		—

_________________________

(a) The performance units that vested in these years provided for a payout of up to 150 percent of the award if certain performance levels were achieved.

The grant date fair value of the performance units awarded was $11.2 million and $10.3 million in 2017 and 2016, respectively. We recognized compensation expense of $9.0 million, $7.7 million and $5.3 million in 2017, 2016 and 2015, respectively, related to the performance units.

As further discussed in the footnote to the consolidated financial statements entitled "Income Taxes", the Company's Board of Directors adopted the Section 382 Rights Agreement in 2009 and has amended and extended the Section 382 Rights Agreement on three occasions. The Section 382 Rights Agreement, as amended, is designed to protect shareholder value by preserving the value of our tax assets primarily associated with NOLs. At the time the Section 382 Rights Agreement was adopted, the Company declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of common stock. The dividend was payable on January 30, 2009, to the shareholders of record as of the close of business on that date and a Right is also attached to each share of CNO common stock issued after that date. Pursuant to the Section 382 Rights Agreement, as amended, each Right entitles the shareholder to purchase from the Company one one-thousandth of a share of Series D Junior Participating Preferred Stock, par value $.01 per share (the "Junior Preferred Stock") of the Company at a price of $90.00 per one one-thousandth of a share of Junior Preferred Stock. The description and terms of the Rights are set forth in the Section 382 Rights Agreement, as amended. The Rights would become exercisable in the event any person or group (subject to certain exemptions) becomes an owner of more than 4.99 percent of the outstanding stock of CNO (a "Threshold Holder") without the approval of the Board of Directors or an existing shareholder who is currently a Threshold Holder acquires additional shares exceeding one percent of our outstanding shares without prior approval from the Board of Directors.

A reconciliation of net income and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands):

	2017		2016		2015
Net income for diluted earnings per share	$	175.6	$	358.2	$	270.7
Shares:
Weighted average shares outstanding for basic earnings per share	170,025		176,638		193,054
Effect of dilutive securities on weighted average shares:
Stock options, restricted stock and performance units	2,119		1,685		2,112
Weighted average shares outstanding for diluted earnings per share	172,144		178,323		195,166

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding for the period.  Restricted shares (including our performance units) are not included in basic earnings per share until vested.  Diluted earnings per share reflect the potential dilution that could occur if outstanding stock options were exercised and restricted stock was vested.  The dilution from options and restricted shares is calculated using the treasury stock method.  Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the average market price during the period, reducing the dilutive effect of the exercise of the options (or the vesting of the restricted stock and performance units).

XML

OTHER OPERATING STATEMENT DATA

12 Months Ended

Dec. 31, 2017

Insurance [Abstract]

OTHER OPERATING STATEMENT DATA

OTHER OPERATING STATEMENT DATA

Insurance policy income consisted of the following (dollars in millions):

	2017			2016			2015
Direct premiums collected	$	4,013.4		$	3,942.7		$	3,769.6
Reinsurance assumed	30.2			33.8			38.4
Reinsurance ceded	(114.4		)	(132.9		)	(142.8		)
Premiums collected, net of reinsurance	3,929.2			3,843.6			3,665.2
Change in unearned premiums	19.0			6.2			5.9
Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities	(1,445.9		)	(1,386.7		)	(1,241.9		)
Premiums on traditional products with mortality or morbidity risk	2,502.3			2,463.1			2,429.2
Fees and surrender charges on interest-sensitive products	145.0			138.0			126.8
Insurance policy income	$	2,647.3		$	2,601.1		$	2,556.0

The four states with the largest shares of 2017 collected premiums were Florida (10 percent), Pennsylvania (6 percent), Texas (6 percent) and California (5 percent). No other state accounted for more than five percent of total collected premiums.

Other operating costs and expenses were as follows (dollars in millions):

	2017		2016		2015
Commission expense	$	115.6	$	110.5	$	103.8
Salaries and wages	237.3		231.0		205.2
Other	488.6		454.8		430.2
Total other operating costs and expenses	$	841.5	$	796.3	$	739.2

Changes in the present value of future profits were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	401.8		$	449.0		$	489.4
Amortization	(54.4		)	(62.2		)	(69.1		)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	12.2			15.0			28.7
Balance, end of year	$	359.6		$	401.8		$	449.0

Based on current conditions and assumptions as to future events on all policies inforce, the Company expects to amortize approximately 11 percent of the December 31, 2017 balance of the present value of future profits in 2018, 10 percent in 2019, 9 percent in 2020, 7 percent in 2021 and 7 percent in 2022. The discount rate used to determine the amortization of the present value of future profits averaged approximately 5 percent in the years ended December 31, 2017, 2016 and 2015.

In accordance with authoritative guidance, we are required to amortize the present value of future profits in relation to estimated gross profits for interest-sensitive life products and annuity products. Such guidance also requires that estimates of expected gross profits used as a basis for amortization be evaluated regularly, and that the total amortization recorded to date be adjusted by a charge or credit to the statement of operations, if actual experience or other evidence suggests that earlier estimates should be revised.

Changes in deferred acquisition costs were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	1,044.7		$	1,083.3		$	770.6
Additions	236.1			242.7			246.4
Amortization	(184.9		)	(191.1		)	(190.9		)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	(69.1		)	(90.2		)	257.2
Balance, end of year	$	1,026.8		$	1,044.7		$	1,083.3

XML

CONSOLIDATED STATEMENT CASH FLOWS

12 Months Ended

Dec. 31, 2017

Supplemental Cash Flow Elements [Abstract]

CONSOLIDATED STATEMENT OF CASH FLOWS

CONSOLIDATED STATEMENT OF CASH FLOWS

The following disclosures supplement our consolidated statement of cash flows.

The following reconciles net income to net cash provided by operating activities (dollars in millions):

	2017			2016			2015
Cash flows from operating activities:
Net income	$	175.6		$	358.2		$	270.7
Adjustments to reconcile net income to net cash from operating activities:
Amortization and depreciation	265.4			275.0			283.4
Income taxes	227.5			(11.7		)	92.9
Insurance liabilities	464.7			332.8			297.4
Accrual and amortization of investment income	(321.6		)	(124.2		)	(27.6		)
Deferral of policy acquisition costs	(236.1		)	(242.7		)	(246.4		)
Net realized investment (gains) losses	(50.3		)	(8.3		)	36.6
Loss on reinsurance transactions and transition expenses	—			75.4			9.0
Cash and cash equivalents received upon recapture of reinsurance	—			73.6			—
Loss on extinguishment of borrowings related to variable interest entities	9.5			—			—
Loss on extinguishment of debt	—			—			32.8
Other	78.4			34.7			(1.0		)
Net cash from operating activities	$	613.1		$	762.8		$	747.8

Other non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions):

	2017		2016		2015
Stock options, restricted stock and performance units	$	21.4	$	23.0	$	17.1
Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe	—		431.1		—

XML

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES)

12 Months Ended

Dec. 31, 2017

Insurance [Abstract]

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES)

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES)

Statutory accounting practices prescribed or permitted by regulatory authorities for the Company's insurance subsidiaries differ from GAAP. The Company's insurance subsidiaries reported the following amounts to regulatory agencies, after appropriate elimination of intercompany accounts among such subsidiaries (dollars in millions):

	2017		2016
Statutory capital and surplus	$	1,904.4	$	1,956.8
Asset valuation reserve	246.8		253.3
Interest maintenance reserve	487.0		486.9
Total	$	2,638.2	$	2,697.0

Statutory capital and surplus included investments in upstream affiliates of $42.6 million at both December 31, 2017 and 2016, which were eliminated in the consolidated financial statements prepared in accordance with GAAP.

Statutory earnings build the capital required by ratings agencies and regulators. Statutory earnings, fees and interest paid by the insurance companies to the parent company create the "cash flow capacity" the parent company needs to meet its obligations, including debt service. The consolidated statutory net income (a non-GAAP measure) of our insurance subsidiaries was $352.3 million, $256.6 million (including approximately $110 million loss on the recapture of long-term care business) and $332.6 million in 2017, 2016 and 2015, respectively. Included in such net income were net realized capital losses, net of income taxes, of $9.9 million, $29.7 million and $18.0 million in 2017, 2016 and 2015, respectively. In addition, such net income included pre-tax amounts for fees and interest paid to CNO or its non-life subsidiaries totaling $158.3 million, $153.9 million and $154.2 million in 2017, 2016 and 2015, respectively.

Insurance regulators may prohibit the payment of dividends or other payments by our insurance subsidiaries to parent companies if they determine that such payment could be adverse to our policyholders or contract holders. Otherwise, the ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations. Insurance regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in some states, the lesser of): (i) statutory net gain from operations or statutory net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. However, as each of the immediate insurance subsidiaries of CDOC, Inc. ("CDOC", our wholly owned subsidiary and the immediate parent of Washington National and Conseco Life Insurance Company of Texas) has negative earned surplus, any dividend payments from the insurance subsidiaries to CNO requires the prior approval of the director or commissioner of the applicable state insurance department. During 2017, our insurance subsidiaries paid dividends of $357.7 million to CDOC.

The payment of interest on surplus debentures requires either prior written notice or approval of the director or commissioner of the applicable state insurance department. Dividends and other payments from our non-insurance subsidiaries to CNO or CDOC do not require approval by any regulatory authority or other third party.

In accordance with an order from the Florida Office of Insurance Regulation, Washington National may not distribute funds to any affiliate or shareholder, except pursuant to agreements that have been approved, without prior notice to the Florida Office of Insurance Regulation. In addition, the risk-based capital ("RBC") and other capital requirements described below can also limit, in certain circumstances, the ability of our insurance subsidiaries to pay dividends.

RBC requirements provide a tool for insurance regulators to determine the levels of statutory capital and surplus an insurer must maintain in relation to its insurance and investment risks and the need for possible regulatory attention. The RBC requirements provide four levels of regulatory attention, varying with the ratio of the insurance company's total adjusted capital (defined as the total of its statutory capital and surplus, asset valuation reserve and certain other adjustments) to its RBC (as measured on December 31 of each year) as follows: (i) if a company's total adjusted capital is less than 100 percent but greater than or equal to 75 percent of its RBC, the company must submit a comprehensive plan to the regulatory authority proposing corrective actions aimed at improving its capital position (the "Company Action Level"); (ii) if a company's total adjusted capital is less than 75 percent but greater than or equal to 50 percent of its RBC, the regulatory authority will perform a special examination of the company and issue an order specifying the corrective actions that must be taken; (iii) if a company's total adjusted capital is less than 50 percent but greater than or equal to 35 percent of its RBC, the regulatory authority may take any action it deems necessary, including placing the company under regulatory control; and (iv) if a company's total adjusted capital is less than 35 percent of its RBC, the regulatory authority must place the company under its control. In addition, the RBC requirements provide for a trend test if a company's total adjusted capital is between 100 percent and 150 percent of its RBC at the end of the year. The trend test calculates the greater of the decrease in the margin of total adjusted capital over RBC: (i) between the current year and the prior year; and (ii) for the average of the last 3 years. It assumes that such decrease could occur again in the coming year. Any company whose trended total adjusted capital is less than 95 percent of its RBC would trigger a requirement to submit a comprehensive plan as described above for the Company Action Level. The 2017 statutory annual statements of each of our insurance subsidiaries reflect total adjusted capital in excess of the levels subjecting the subsidiaries to any regulatory action.

In addition, although we are under no obligation to do so, we may elect to contribute additional capital or retain greater amounts of capital to strengthen the surplus of certain insurance subsidiaries. Any election to contribute or retain additional capital could impact the amounts our insurance subsidiaries pay as dividends to the holding company. The ability of our insurance subsidiaries to pay dividends is also impacted by various criteria established by rating agencies to maintain or receive higher ratings and by the capital levels that we target for our insurance subsidiaries.

At December 31, 2017, the consolidated RBC ratio of our insurance subsidiaries exceeded the minimum RBC requirement included in our Revolving Credit Agreement. See the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for further discussion of various financial ratios and balances we are required to maintain. We calculate the consolidated RBC ratio by assuming all of the assets, liabilities, capital and surplus and other aspects of the business of our insurance subsidiaries are combined together in one insurance subsidiary, with appropriate intercompany eliminations.

XML

BUSINESS SEGMENTS

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

BUSINESS SEGMENTS

BUSINESS SEGMENTS

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting the long-term care block recaptured from BRe effective September 30, 2016, as an additional business segment.

We measure segment performance by excluding the loss on reinsurance transaction and transition expenses, net realized investment gains (losses), fair value changes in embedded derivative liabilities (net of related amortization), fair value changes and amendment in the agent deferred compensation plan, loss on extinguishment of debt, income taxes and other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to VIEs ("pre-tax operating earnings") because we believe that this performance measure is a better indicator of the ongoing business and trends in our business.  Our primary investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of net realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business.

The loss on reinsurance transaction and transition expenses, net realized investment gains (losses), fair value changes in embedded derivative liabilities (net of related amortization), fair value changes and amendment in the agent deferred compensation plan, loss on extinguishment of debt and other non-operating items consisting primarily of equity in earnings of certain non-strategic investments and earnings attributable to VIEs depend on market conditions or represent unusual items that do not necessarily relate to the underlying business of our segments.  Net realized investment gains (losses) and fair value changes in embedded derivative liabilities (net of related amortization) may affect future earnings levels since our underlying business is long-term in nature and changes in our investment portfolio may impact our ability to earn the assumed interest rates needed to maintain the profitability of our business.

Operating information by segment was as follows (dollars in millions):

	2017		2016		2015
Revenues:
Bankers Life:
Insurance policy income:
Annuities	$	20.3	$	22.0	$	22.4
Health	1,231.1		1,244.1		1,251.0
Life	415.2		393.0		375.3
Net investment income (a)	1,107.3		936.8		884.7
Fee revenue and other income (a)	44.1		34.4		27.7
Total Bankers Life revenues	2,818.0		2,630.3		2,561.1
Washington National:
Insurance policy income:
Annuities	2.1		2.9		3.0
Health	642.9		627.9		615.4
Life	26.4		25.0		25.4
Net investment income (a)	270.2		259.3		253.6
Fee revenue and other income (a)	1.0		1.3		1.3
Total Washington National revenues	942.6		916.4		898.7
Colonial Penn:
Insurance policy income:
Health	2.1		2.6		3.0
Life	289.7		278.8		260.5
Net investment income (a)	44.4		44.2		43.0
Fee revenue and other income (a)	1.3		1.1		1.0
Total Colonial Penn revenues	337.5		326.7		307.5
Long-term care in run-off:
Insurance policy income - health	17.5		4.8		—
Net investment income (a)	34.6		9.4		—
Total Long-term care in run-off revenues	52.1		14.2		—
Corporate operations:
Net investment income	35.5		16.6		11.3
Fee revenue and other income	8.5		10.0		8.6
Total corporate revenues	44.0		26.6		19.9
Total revenues	$	4,194.2	$	3,914.2	$	3,787.2

(continued on next page)

(continued from previous page)

	2017			2016			2015
Expenses:
Bankers Life:
Insurance policy benefits	$	1,771.8		$	1,620.6		$	1,588.4
Amortization	163.6			176.5			187.1
Interest expense on investment borrowings	19.8			13.2			8.8
Other operating costs and expenses	443.9			422.1			407.2
Total Bankers Life expenses	2,399.1			2,232.4			2,191.5
Washington National:
Insurance policy benefits	581.1			561.7			546.6
Amortization	58.8			59.1			55.2
Interest expense on investment borrowings	6.3			3.7			2.0
Other operating costs and expenses	198.1			189.0			183.4
Total Washington National expenses	844.3			813.5			787.2
Colonial Penn:
Insurance policy benefits	199.6			201.9			189.0
Amortization	16.3			15.3			14.4
Interest expense on investment borrowings	.9			.6			.1
Other operating costs and expenses	98.1			107.2			98.4
Total Colonial Penn expenses	314.9			325.0			301.9
Long-term care in run-off:
Insurance policy benefits	47.3			17.6			—
Other operating costs and expenses	3.1			.5			—
Total Long-term care in run-off expenses	50.4			18.1			—
Corporate operations:
Interest expense on corporate debt	46.5			45.8			45.0
Interest expense on investment borrowings	—			—			.2
Other operating costs and expenses	84.3			69.1			38.6
Total corporate expenses	130.8			114.9			83.8
Total expenses	3,739.5			3,503.9			3,364.4
Pre-tax operating earnings by segment:
Bankers Life	418.9			397.9			369.6
Washington National	98.3			102.9			111.5
Colonial Penn	22.6			1.7			5.6
Long-term care in run-off	1.7			(3.9		)	—
Corporate operations	(86.8		)	(88.3		)	(63.9		)
Pre-tax operating earnings	$	454.7		$	410.3		$	422.8

___________________

(a) It is not practicable to provide additional components of revenue by product or services.

A reconciliation of segment revenues and expenses to consolidated revenues and expenses and net income is as follows (dollars in millions):

	2017			2016			2015
Total segment revenues	$	4,194.2		$	3,914.2		$	3,787.2
Net realized investment gains (losses)	50.3			8.3			(36.6		)
Revenues related to certain non-strategic investments and earnings attributable to VIEs	52.7			52.6			36.3
Fee revenue related to transition and support services agreements	—			10.0			25.0
Consolidated revenues	4,297.2			3,985.1			3,811.9
Total segment expenses	3,739.5			3,503.9			3,364.4
Insurance policy benefits - fair value changes in embedded derivative liabilities	2.9			(11.3		)	(15.7		)
Amortization related to fair value changes in embedded derivative liabilities	(.4		)	1.7			3.8
Amortization related to net realized investment gains (losses)	1.0			.7			(.5		)
Expenses related to certain non-strategic investments and expenses attributable to VIEs	61.5			54.6			43.0
Fair value changes and amendment related to agent deferred compensation plan	12.2			(3.1		)	(15.1		)
Loss on extinguishment of debt	—			—			32.8
Loss on reinsurance transaction and transition expenses	—			75.4			9.0
Expenses related to transition and support services agreements	—			10.0			22.5
Consolidated expenses	3,816.7			3,631.9			3,444.2
Income before tax	480.5			353.2			367.7
Income tax expense:
Tax expense on period income	162.8			127.8			129.5
Valuation allowance for deferred tax assets and other tax items	142.1			(132.8		)	(32.5		)
Net income	$	175.6		$	358.2		$	270.7

Segment balance sheet information was as follows (dollars in millions):

	2017		2016
Assets:
Bankers Life	$	21,134.9	$	19,876.4
Washington National	7,674.3		7,555.7
Colonial Penn	1,059.3		1,022.9
Long-term care in run-off	692.9		656.2
Corporate operations	2,548.9		2,864.0
Total assets	$	33,110.3	$	31,975.2
Liabilities:
Bankers Life	$	18,031.6	$	17,144.9
Washington National	6,101.5		6,096.9
Colonial Penn	921.0		898.5
Long-term care in run-off	580.4		562.2
Corporate operations	2,628.3		2,785.8
Total liabilities	$	28,262.8	$	27,488.3

The following table presents selected financial information of our segments (dollars in millions):

Segment	Present value of future profits		Deferred acquisition costs		Insurance liabilities
2017
Bankers Life	$	81.1	$	606.5	$	16,541.2
Washington National	243.7		310.8		5,590.7
Colonial Penn	34.8		109.5		834.4
Long-term care in run-off	—		—		572.7
Total	$	359.6	$	1,026.8	$	23,539.0
2016
Bankers Life	$	95.5	$	646.2	$	15,702.8
Washington National	266.8		299.9		5,586.7
Colonial Penn	39.5		98.6		809.6
Long-term care in run-off	—		—		554.7
Total	$	401.8	$	1,044.7	$	22,653.8

XML

QUARTERLY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Data [Abstract]

QUARTERLY FINANCIAL DATA (UNAUDITED)

QUARTERLY FINANCIAL DATA (UNAUDITED)

We compute earnings per common share for each quarter independently of earnings per share for the year. The sum of the quarterly earnings per share may not equal the earnings per share for the year because of: (i) transactions affecting the weighted average number of shares outstanding in each quarter; and (ii) the uneven distribution of earnings during the year. Quarterly financial data (unaudited) were as follows (dollars in millions, except per share data):

2017	1st Qtr.			2nd Qtr.		3rd Qtr.		4th Qtr. (a)
Revenues	$	1,070.7		$	1,057.1	$	1,079.3	$	1,090.1
Income before income taxes	$	96.7		$	128.5	$	129.9	$	125.4
Income tax expense	34.4			45.1		29.1		196.3
Net income (loss)	$	62.3		$	83.4	$	100.8	$	(70.9	)
Earnings per common share:
Basic:
Net income (loss)	$	.36		$	.49	$	.60	$	(.42	)
Diluted:
Net income (loss)	$	.36		$	.48	$	.59	$	(.42	)
2016	1st Qtr.			2nd Qtr.		3rd Qtr.		4th Qtr.
Revenues	$	960.4		$	1,003.9	$	1,015.9	$	1,004.9
Income before income taxes	$	40.5		$	82.7	$	49.3	$	180.7
Income tax expense (benefit)	(5.0		)	22.8		30.7		(53.5		)
Net income	$	45.5		$	59.9	$	18.6	$	234.2
Earnings per common share:
Basic:
Net income	$	.25		$	.34	$	.11	$	1.35
Diluted:
Net income	$	.25		$	.33	$	.11	$	1.34

___________________

(a) In the fourth quarter of 2017, our net loss reflected the unfavorable impact of $172.5 million related to the Tax Reform Act which was enacted in December 2017.

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

INVESTMENTS IN VARIABLE INTEREST ENTITIES

INVESTMENTS IN VARIABLE INTEREST ENTITIES

We have concluded that we are the primary beneficiary with respect to certain VIEs, which are consolidated in our financial statements.  In consolidating the VIEs, we consistently use the financial information most recently distributed to investors in the VIE.

All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments.  The assets held by the trusts are legally isolated and not available to the Company.  The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company.  During the three years ended December 31, 2017, VIEs that were required to be consolidated were dissolved. We recognized losses of $4.3 million and $7.3 million during 2017 and 2016, respectively, and a gain of $11.3 million during 2015, representing the difference between the borrowings of such VIEs and the contractual distributions required following the liquidation of the underlying assets. The scheduled repayment of the remaining principal balance of the borrowings related to the VIEs are as follows: $3.0 million in 2018; $3.6 million in 2019; $2.1 million in 2020; $1.3 million in 2021; $539.9 million in 2028; and $878.0 million in 2030. The Company has no financial obligation to the VIEs beyond its investment in each VIE.

Certain of our insurance subsidiaries are noteholders of the VIEs.  Another subsidiary of the Company is the investment manager for the VIEs.  As such, it has the power to direct the most significant activities of the VIEs which materially impacts the economic performance of the VIEs.

The following table provides supplemental information about the assets and liabilities of the VIEs which have been consolidated (dollars in millions):

	December 31, 2017
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	1,526.9	$	—		$	1,526.9
Notes receivable of VIEs held by insurance subsidiaries	—		(155.5		)	(155.5		)
Cash and cash equivalents held by variable interest entities	178.9		—			178.9
Accrued investment income	2.6		(.1		)	2.5
Income tax assets, net	.7		—			.7
Other assets	10.0		(1.5		)	8.5
Total assets	$	1,719.1	$	(157.1	)	$	1,562.0
Liabilities:
Other liabilities	$	158.3	$	(4.4	)	$	153.9
Borrowings related to variable interest entities	1,410.7		—			1,410.7
Notes payable of VIEs held by insurance subsidiaries	167.6		(167.6		)	—
Total liabilities	$	1,736.6	$	(172.0	)	$	1,564.6

	December 31, 2016
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	1,724.3	$	—		$	1,724.3
Notes receivable of VIEs held by insurance subsidiaries	—		(204.2		)	(204.2		)
Cash and cash equivalents held by variable interest entities	189.3		—			189.3
Accrued investment income	3.0		(.1		)	2.9
Income tax assets, net	6.4		(1.3		)	5.1
Other assets	13.1		(1.8		)	11.3
Total assets	$	1,936.1	$	(207.4	)	$	1,728.7
Liabilities:
Other liabilities	$	81.8	$	(6.4	)	$	75.4
Borrowings related to variable interest entities	1,662.8		—			1,662.8
Notes payable of VIEs held by insurance subsidiaries	203.3		(203.3		)	—
Total liabilities	$	1,947.9	$	(209.7	)	$	1,738.2

The following table provides supplemental information about the revenues and expenses of the VIEs which have been consolidated in accordance with authoritative guidance, after giving effect to the elimination of our investment in the VIEs and investment management fees earned by a subsidiary of the Company (dollars in millions):

	2017			2016			2015
Revenues:
Net investment income – policyholder and other special-purpose portfolios	$	69.8		$	78.9		$	62.1
Fee revenue and other income	5.9			6.4			1.6
Total revenues	75.7			85.3			63.7
Expenses:
Interest expense	50.2			53.1			38.8
Other operating expenses	1.8			1.5			2.0
Total expenses	52.0			54.6			40.8
Income before net realized investment losses and income taxes	23.7			30.7			22.9
Net realized investment losses	(5.6		)	(20.4		)	(6.4		)
Loss on extinguishment of borrowings	(9.5		)	—			—
Income before income taxes	$	8.6		$	10.3		$	16.5

The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade.  At December 31, 2017, such loans had an amortized cost of $1,524.9 million; gross unrealized gains of $8.6 million; gross unrealized losses of $6.6 million; and an estimated fair value of $1,526.9 million.

The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	11.2	$	11.2
Due after one year through five years	541.8		542.0
Due after five years through ten years	971.9		973.7
Total	$	1,524.9	$	1,526.9

The following table sets forth the amortized cost and estimated fair value of those investments held by the VIEs with unrealized losses at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	2.4	$	2.4
Due after one year through five years	178.2		174.3
Due after five years through ten years	299.8		297.1
Total	$	480.4	$	473.8

During 2017, the VIEs recognized net realized investment losses of $5.6 million, which were comprised of: (i) $1.2 million of net gains from the sales of fixed maturities; (ii) $4.3 million of losses on the dissolution of VIEs; and (iii) $2.5 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2016, the VIEs recognized net realized investment losses of $20.4 million which were comprised of: (i) $11.9 million of net losses from the sales of fixed maturities; (ii) a $7.3 million loss on the dissolution of a VIE; and (iii) $1.2 million of writedowns of investments for other than temporary declines in fair value recognized through net income. During 2015, the VIEs recognized net realized investment losses of $6.4 million which were comprised of: (i) $1.3 million of net losses from the sales of fixed maturities; (ii) an $11.3 million gain on the dissolution of a VIE; and (iii) $16.4 million of writedowns of investments for other than temporary declines in fair value recognized through net income.

At December 31, 2017, there were no investments held by the VIEs that were in default.

During 2017, $109.6 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $3.0 million. During 2016, $192.2 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $20.3 million. During 2015, $46.1 million of investments held by the VIEs were sold which resulted in gross investment losses (before income taxes) of $1.8 million.

At December 31, 2017, the VIEs held:  (i) investments with a fair value of $445.4 million and gross unrealized losses of $4.9 million that had been in an unrealized loss position for less than twelve months; and (ii) investments with a fair value of $28.4 million and gross unrealized losses of $1.7 million that had been in an unrealized loss position for greater than twelve months.

At December 31, 2016, the VIEs held: (i) investments with a fair value of $93.8 million and gross unrealized losses of $.9 million that had been in an unrealized loss position for less than twelve months; and (ii) investments with a fair value of $143.9 million and gross unrealized losses of $2.9 million that had been in an unrealized loss position for greater than twelve months.

The investments held by the VIEs are evaluated for other-than-temporary declines in fair value in a manner that is consistent with the Company's fixed maturities, available for sale.

XML

SCHEDULE II

12 Months Ended

Dec. 31, 2017

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Condensed Financial Information of Registrant (Parent Company)

SCHEDULE II

Condensed Financial Information of Registrant (Parent Company)

Balance Sheet

as of December 31, 2017 and 2016

(Dollars in millions)

ASSETS
	2017		2016
Cash and cash equivalents - unrestricted	$	161.1	$	106.1
Equity securities at fair value (cost: 2017 - $225.7; 2016 - $166.5)	243.6		167.9
Investment in wholly-owned subsidiaries (eliminated in consolidation)	5,440.7		5,220.3
Income tax assets, net	129.6		99.5
Receivable from subsidiaries (eliminated in consolidation)	6.3		2.0
Other assets	12.7		1.8
Total assets	$	5,994.0	$	5,597.6
LIABILITIES AND SHAREHOLDERS' EQUITY
Liabilities:
Notes payable	$	914.6	$	912.9
Payable to subsidiaries (eliminated in consolidation)	143.0		128.4
Other liabilities	88.9		69.4
Total liabilities	1,146.5		1,110.7
Commitments and Contingencies
Shareholders' equity:
Common stock and additional paid-in capital ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)	3,075.0		3,213.8
Accumulated other comprehensive income	1,212.1		622.4
Retained earnings	560.4		650.7
Total shareholders' equity	4,847.5		4,486.9
Total liabilities and shareholders' equity	$	5,994.0	$	5,597.6

The accompanying notes are an integral part

of the condensed financial statements.

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

SCHEDULE II

Condensed Financial Information of Registrant (Parent Company)

Statement of Operations

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions)

	2017			2016			2015
Revenues:
Net investment income	$	14.2		$	15.6		$	16.9
Net realized investment gains	2.4			17.7			3.5
Intercompany losses (eliminated in consolidation)	—			—			(1.5		)
Total revenues	16.6			33.3			18.9
Expenses:
Interest expense	46.5			45.8			45.2
Intercompany expenses (eliminated in consolidation)	1.7			.9			.4
Operating costs and expenses	75.4			48.2			21.0
Loss on extinguishment of debt	—			—			32.8
Total expenses	123.6			94.9			99.4
Loss before income taxes and equity in undistributed earnings of subsidiaries	(107.0		)	(61.6		)	(80.5		)
Income tax expense (benefit)	27.4			(54.6		)	(37.9		)
Loss before equity in undistributed earnings of subsidiaries	(134.4		)	(7.0		)	(42.6		)
Equity in undistributed earnings of subsidiaries (eliminated in consolidation)	310.0			365.2			313.3
Net income	$	175.6		$	358.2		$	270.7

The accompanying notes are an integral part

of the condensed financial statements.

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

SCHEDULE II

Condensed Financial Information of Registrant (Parent Company)

Statement of Cash Flows

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions)

	2017			2016			2015
Cash flows from operating activities	$	(181.8	)	$	(110.7	)	$	(51.2	)
Cash flows from investing activities:
Sales of investments	54.9			305.0			66.5
Sales of investments - affiliated*	—			—			16.0
Maturities and redemptions of investments - affiliated*	—			—			8.3
Purchases of investments	(123.6		)	(198.4		)	(68.6		)
Purchases of investments - affiliated*	—			—			(3.4		)
Net sales of trading securities	9.1			12.0			11.8
Dividends received from consolidated subsidiary, net of capital contributions of nil in 2017, $200.0 in 2016 and nil in 2015*	363.5			92.5			269.7
Net cash provided by investing activities	303.9			211.1			300.3
Cash flows from financing activities:
Issuance of notes payable, net	—			—			910.0
Payments on notes payable	—			—			(797.1		)
Expenses related to extinguishment of debt	—			—			(17.8		)
Issuance of common stock	8.3			8.4			6.3
Payments to repurchase common stock	(168.3		)	(210.0		)	(365.4		)
Common stock dividends paid	(59.6		)	(54.8		)	(52.0		)
Investment borrowings - repurchase agreements, net	—			—			(20.4		)
Issuance of notes payable to affiliates*	310.8			217.1			234.4
Payments on notes payable to affiliates*	(158.3		)	(83.9		)	(104.8		)
Net cash used by financing activities	(67.1		)	(123.2		)	(206.8		)
Net increase (decrease) in cash and cash equivalents	55.0			(22.8		)	42.3
Cash and cash equivalents, beginning of the year	106.1			128.9			86.6
Cash and cash equivalents, end of the year	$	161.1		$	106.1		$	128.9

* Eliminated in consolidation

The accompanying notes are an integral part

of the condensed financial statements.

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

SCHEDULE II

Notes to Condensed Financial Information

1. Basis of Presentation

The condensed financial information should be read in conjunction with the consolidated financial statements of CNO Financial Group, Inc. The condensed financial information includes the accounts and activity of the parent company.

XML

SCHEDULE IV

12 Months Ended

Dec. 31, 2017

Supplemental Schedule of Reinsurance Premiums for Insurance Companies [Abstract]

Reinsurance

SCHEDULE IV

Reinsurance

for the years ended December 31, 2017, 2016 and 2015

(Dollars in millions)

	2017			2016			2015
Life insurance inforce:
Direct	$	27,154.3		$	27,048.1		$	25,807.0
Assumed	120.5			128.7			137.4
Ceded	(3,452.6		)	(3,604.0		)	(3,780.8		)
Net insurance inforce	$	23,822.2		$	23,572.8		$	22,163.6
Percentage of assumed to net	.5		%	.5		%	.6		%

	2017			2016			2015
Insurance policy income:
Direct	$	2,576.9		$	2,553.0		$	2,524.3
Assumed	30.4			34.0			38.5
Ceded	(105.0		)	(123.9		)	(133.6		)
Net premiums	$	2,502.3		$	2,463.1		$	2,429.2
Percentage of assumed to net	1.2		%	1.4		%	1.6		%

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Segments

The Company manages its business through the following operating segments: Bankers Life, Washington National and Colonial Penn, which are defined on the basis of product distribution; long-term care in run off; and corporate operations, comprised of holding company activities and certain noninsurance company businesses. In the fourth quarter of 2016, we began reporting as an additional business segment, the long-term care block recaptured from Beechwood Re Ltd. ("BRe"), as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance". The Company’s insurance segments are described below:

• Bankers Life,which markets and distributes Medicare supplement insurance, interest-sensitive life insurance, traditional life insurance, fixed annuities and long-term care insurance products to the middle-income senior market through a dedicated field force of career agents, financial and investment advisors, and sales managers supported by a network of community-based sales offices.  The Bankers Life segment includes primarily the business of Bankers Life and Casualty Company ("Bankers Life").  Bankers Life also has various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute Medicare Advantage and prescription drug plan products in exchange for a fee.

• Washington National, which markets and distributes supplemental health (including specified disease, accident and hospital indemnity insurance products) and life insurance to middle-income consumers at home and at the worksite.  These products are marketed through Performance Matters Associates, Inc. and through independent marketing organizations and insurance agencies including worksite marketing.  The products being marketed are underwritten by Washington National Insurance Company ("Washington National"). This segment's business also includes certain closed blocks of annuities and Medicare supplement policies which are no longer being actively marketed by this segment and were primarily issued or acquired by Washington National.

• Colonial Penn, which markets primarily graded benefit and simplified issue life insurance directly to customers in the senior middle-income market through television advertising, direct mail, the internet and telemarketing.  The Colonial Penn segment includes primarily the business of Colonial Penn Life Insurance Company ("Colonial Penn").

• Long-term care in run-off consists of the long-term care business that was recaptured due to the termination of certain reinsurance agreements effective September 30, 2016. This business is not actively marketed and was issued or acquired by Washington National and Bankers Conseco Life Insurance Company ("BCLIC")

Basis of Accounting

We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"). We have reclassified certain amounts from the prior periods to conform to the 2017 presentation. These reclassifications have no effect on net income or shareholders' equity.

Consolidation

The accompanying financial statements include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude transactions between us and our consolidated affiliates, or among our consolidated affiliates.

Use of Estimates

When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods.  For example, we use significant estimates and assumptions to calculate values for deferred acquisition costs, the present value of future profits, fair value measurements of certain investments (including derivatives), other-than-temporary impairments of investments, assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation and guaranty fund assessment accruals.  If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.

Investments

Investments

Fixed maturity securities include available for sale bonds and redeemable preferred stocks. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders’ equity.

Equity securities include available for sale investments in common stock, exchange-traded funds and non-redeemable preferred stock. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders' equity.

Mortgage loans held in our investment portfolio are carried at amortized unpaid balances, net of provisions for estimated losses. Interest income is accrued on the principal amount of the loan based on the loan's contractual interest rate. Payment terms specified for mortgage loans may include a prepayment penalty for unscheduled payoff of the investment. Prepayment penalties are recognized as investment income when received.

Policy loans are stated at current unpaid principal balances. Policy loans are collateralized by the cash surrender value of the life insurance policy. Interest income is recorded as earned using the contractual interest rate.

Trading securities include: (i) investments purchased with the intent of selling in the near team to generate income; (ii) investments supporting certain insurance liabilities (including investments backing the market strategies of our multibucket annuity products); and (iii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option. The change in fair value of the income generating investments and investments supporting insurance liabilities and reinsurance agreements is recognized in income from policyholder and other special-purpose portfolios (a component of net investment income). The change in fair value of securities with embedded derivatives is recognized in realized investment gains (losses). Investment income related to investments supporting certain insurance liabilities is substantially offset by the change in insurance policy benefits related to certain products.

Other invested assets include: (i) call options purchased in an effort to offset or hedge the effects of certain policyholder benefits related to our fixed index annuity and life insurance products; (ii) Company-owned life insurance ("COLI"); and (iii) certain non-traditional investments. We carry the call options at estimated fair value as further described in the section of this note entitled "Accounting for Derivatives". We carry COLI at its cash surrender value which approximates its net realizable value. Non-traditional investments include investments in certain limited partnerships and hedge funds which are accounted for using the equity method; and promissory notes, which are accounted for using the cost method. In accounting for limited partnerships and hedge funds, we consistently use the most recently available financial information provided by the general partner or manager of each of these investments, which is one to three months prior to the end of our reporting period.

Interest income on fixed maturity securities is recognized when earned using a constant effective yield method giving effect to amortization of premiums and accretion of discounts. Prepayment fees are recognized when earned. Dividends on equity securities are recognized when declared.

When we sell a security (other than trading securities), we report the difference between the sale proceeds and amortized cost (determined based on specific identification) as a realized investment gain or loss.

We regularly evaluate our investments for possible impairment as further described in the note to the consolidated financial statements entitled "Investments".

When a security defaults (including mortgage loans) or securities are other-than-temporarily impaired, our policy is to discontinue the accrual of interest and eliminate all previous interest accruals, if we determine that such amounts will not be ultimately realized in full.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value.

Deferred Acquisition Costs

Deferred Acquisition Costs

Deferred acquisition costs represent incremental direct costs related to the successful acquisition of new or renewal insurance contracts. For interest-sensitive life or annuity products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate.

When we realize a gain or loss on investments backing our interest-sensitive life or annuity products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust deferred acquisition costs for the change in amortization that would have been recorded if our fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We limit the total adjustment related to the impact of unrealized losses to the total of costs capitalized plus interest related to insurance policies issued in a particular year. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity.

We regularly evaluate the recoverability of the unamortized balance of the deferred acquisition costs. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the deferred acquisition costs may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the deferred acquisition costs over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years.

Present Value of Future Profits

Present Value of Future Profits

The present value of future profits is the value assigned to the right to receive future cash flows from policyholder insurance contracts existing at September 10, 2003 (the "Effective Date", the effective date of the bankruptcy reorganization of Conseco, Inc., an Indiana corporation (our "Predecessor")). The discount rate we used to determine the present value of future profits was 12 percent. The balance of this account is amortized and evaluated for recovery in the same manner as described above for deferred acquisition costs.  We also adjust the present value of future profits for the change in amortization that would have been recorded if the fixed maturity securities, available for sale, had been sold at their stated aggregate fair value and the proceeds reinvested at current yields, similar to the manner described above for deferred acquisition costs.  We limit the total adjustment related to the impact of unrealized losses to the total present value of future profits plus interest.

Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts

Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts

For interest-sensitive life and annuity contracts that do not involve significant mortality or morbidity risk, the amounts collected from policyholders are considered deposits and are not included in revenue. Revenues for these contracts consist of charges for policy administration, cost of insurance charges and surrender charges assessed against policyholders' account balances. Such revenues are recognized when the service or coverage is provided, or when the policy is surrendered.

We establish liabilities for annuity and interest-sensitive life products equal to the accumulated policy account values, which include an accumulation of deposit payments plus credited interest, less withdrawals and the amounts assessed against the policyholder through the end of the period. In addition, policyholder account values for certain interest-sensitive life products are impacted by our assumptions related to changes of certain non-guaranteed elements that we are allowed to make under the terms of the policy, such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. Sales inducements provided to the policyholders of these products are recognized as liabilities over the period that the contract must remain in force to qualify for the inducement. The options attributed to the policyholder related to our fixed index annuity products are accounted for as embedded derivatives as described in the section of this note entitled "Accounting for Derivatives".

Premiums from individual life products (other than interest-sensitive life contracts) and health products are recognized when due. When premiums are due over a significantly shorter period than the period over which benefits are provided, any gross premium in excess of the net premium (i.e., the portion of the gross premium required to provide for all expected future benefits and expenses) is deferred and recognized into revenue in a constant relationship to insurance in force. Benefits are recorded as an expense when they are incurred.

We establish liabilities for traditional life, accident and health insurance, and life contingent payment annuity products using mortality tables in general use in the United States, which are modified to reflect the Company's actual experience when appropriate. We establish liabilities for accident and health insurance products using morbidity tables based on the Company's actual or expected experience. These reserves are computed at amounts that, with additions from estimated future premiums received and with interest on such reserves at estimated future rates, are expected to be sufficient to meet our obligations under the terms of the policy. Liabilities for future policy benefits are computed on a net-level premium method based upon assumptions as to future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses determined when the policies were issued (or with respect to policies inforce at August 31, 2003, the Company's best estimate of such assumptions on the Effective Date). We make an additional provision to allow for potential adverse deviation for some of our assumptions. Once established, assumptions on these products are generally not changed unless a premium deficiency exists. In that case, a premium deficiency reserve is recognized and the future pattern of reserve changes is modified to reflect the relationship of premiums to benefits based on the current best estimate of future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses, determined without an additional provision for potential adverse deviation.

We establish claim reserves based on our estimate of the loss to be incurred on reported claims plus estimates of incurred but unreported claims based on our past experience.

Accounting for Long-term Care Premium Rate Increases

Accounting for Long-term Care Premium Rate Increases

Many of our long-term care policies have been subject to premium rate increases. In some cases, these premium rate increases were materially consistent with the assumptions we used to value the particular block of business at the Effective Date. With respect to certain premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these policyholder options:

• Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.

• Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.

• Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.

Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit.

Accounting for Certain Marketing and Reinsurance Agreements

Accounting for Certain Marketing Agreements

Bankers Life has entered into various distribution and marketing agreements with other insurance companies to use Bankers Life's career agents to distribute prescription drug and Medicare Advantage plans. These agreements allow Bankers Life to offer these products to current and potential future policyholders without investment in management and infrastructure. We receive fee income related to the plans sold through our distribution channels. We account for these distribution agreements as follows:

• We recognize distribution income based on either: (i) a fixed fee per contract sold; or (ii) a percentage of premiums collected. This fee income is recognized over the calendar year term of the contract.

• We also pay commissions to our agents who sell the plans. These payments are deferred and amortized over the term of the contract.

Reinsurance

In the normal course of business, we seek to limit our loss exposure on any single insured or to certain groups of policies by ceding reinsurance to other insurance enterprises. We currently retain no more than $.8 million of mortality risk on any one policy. We diversify the risk of reinsurance loss by using a number of reinsurers that have strong claims-paying ratings. In each case, the ceding CNO subsidiary is directly liable for claims reinsured in the event the assuming company is unable to pay.

The cost of reinsurance ceded totaled $105.0 million, $123.9 million and $133.6 million in 2017, 2016 and 2015, respectively.  We deduct this cost from insurance policy income.  Reinsurance recoveries netted against insurance policy benefits totaled $88.6 million, $130.1 million and $167.7 million in 2017, 2016 and 2015, respectively.

From time to time, we assume insurance from other companies.  Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize deferred acquisition costs.  Reinsurance premiums assumed totaled $30.4 million, $34.0 million and $38.5 million in 2017, 2016 and 2015, respectively. Insurance policy benefits related to reinsurance assumed totaled $44.7 million, $47.5 million and $48.0 million in 2017, 2016 and 2015, respectively.

In December 2013, two of our insurance subsidiaries entered into 100% coinsurance agreements ceding $495 million of long-term care reserves to BRe. Pursuant to the agreements, the insurance subsidiaries paid an additional premium of $96.9 million to BRe and an amount equal to the related net liabilities. The insurance subsidiaries' ceded reserve credits were secured by assets in market-value trusts subject to a 7% overcollateralization, investment guidelines and periodic true-up provisions. Future payments into the trusts to maintain collateral requirements were the responsibility of BRe.

In September 2016, we terminated the reinsurance agreements with BRe and recaptured the ceded business. As a result of the recapture, we were required to value the assets and liabilities as of the date of recapture based on valuation methodologies that are consistent with the methodologies used by CNO to value its other investments and insurance liabilities. Accordingly, we recognized a loss on the recapture of the long-term care business as summarized below (dollars in millions):

Market value of investments	$	504.7
Insurance liabilities	(552.2		)
Write-off of reinsurance receivables	(17.9		)
Estimated transaction expenses	(10.0		)
Pre-tax loss	(75.4		)
Tax benefit	26.4
Increase in valuation allowance for deferred tax assets	(4.1		)
After-tax loss	$	(53.1	)

Income Taxes

Income Taxes

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities and net operating loss carryforwards ("NOLs"). Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which temporary differences are expected to be recovered or paid.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in earnings in the period when the changes are enacted.

A reduction of the net carrying amount of deferred tax assets by establishing a valuation allowance is required if, based on the available evidence, it is more likely than not that such assets will not be realized. In assessing the need for a valuation allowance, all available evidence, both positive and negative, shall be considered to determine whether, based on the weight of that evidence, a valuation allowance for deferred tax assets is needed. This assessment requires significant judgment and considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of carryforward periods, our experience with operating loss and tax credit carryforwards expiring unused, and tax planning strategies. We evaluate the need to establish a valuation allowance for our deferred income tax assets on an ongoing basis. The realization of our deferred tax assets depends upon generating sufficient future taxable income of the appropriate type during the periods in which our temporary differences become deductible and before our NOLs expire.

At December 31, 2017, our valuation allowance for our net deferred tax assets was $89.1 million, as we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax assets and assessing the effects of limitations and/or interpretations on the value of such component to be fully recognized in the future.

Investments in Variable Interest Entities

Investments in Variable Interest Entities

We have concluded that we are the primary beneficiary with respect to certain variable interest entities ("VIEs"), which are consolidated in our financial statements. All of the VIEs are collateralized loan trusts that were established to issue securities to finance the purchase of corporate loans and other permitted investments.  The assets held by the trusts are legally isolated and not available to the Company.  The liabilities of the VIEs are expected to be satisfied from the cash flows generated by the underlying loans held by the trusts, not from the assets of the Company.  The Company has no financial obligation to the VIEs beyond its investment in each VIE.

The investment portfolios held by the VIEs are primarily comprised of commercial bank loans to corporate obligors which are almost entirely rated below-investment grade.  Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information about VIEs.

In addition, the Company, in the normal course of business, makes passive investments in structured securities issued by VIEs for which the Company is not the investment manager.  These structured securities include asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, residential mortgage-backed securities and collateralized mortgage obligations.  Our maximum exposure to loss on these securities is limited to our cost basis in the investment.  We have determined that we are not the primary beneficiary of these structured securities due to the relative size of our investment in comparison to the total principal amount of the individual structured securities and the level of credit subordination which reduces our obligation to absorb gains or losses.

Investment borrowings

Substantially all of such investments are classified as fixed maturities, available for sale, in our consolidated balance sheet.

Accounting for Derivatives

Accounting for Derivatives

Our fixed index annuity products provide a guaranteed minimum rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period.  Typically, on each policy anniversary date, a new index period begins.  We are generally able to change the participation rate at the beginning of each index period during a policy year, subject to contractual minimums.  The Company accounts for the options attributed to the policyholder for the estimated life of the contract as embedded derivatives. These accounting requirements often create volatility in the earnings from these products. We typically buy call options (including call spreads) referenced to the applicable indices in an effort to offset or hedge potential increases to policyholder benefits resulting from increases in the particular index to which the policy's return is linked.

From time to time, we utilize United States Treasury interest rate futures primarily to hedge interest rate risk related to anticipated mortgage loan transactions.

We purchase certain fixed maturity securities that contain embedded derivatives that are required to be held at fair value on the consolidated balance sheet. We have elected the fair value option to carry the entire security at fair value with changes in fair value reported in net income.

Multibucket Annuity Products

Multibucket Annuity Products

The Company's multibucket annuity is an annuity product that credits interest based on the experience of a particular market strategy. Policyholders allocate their annuity premium payments to several different market strategies based on different asset classes within the Company's investment portfolio. Interest is credited to this product based on the market return of the given strategy, less management fees, and funds may be moved between different strategies. The Company guarantees a minimum return of premium plus approximately 3 percent per annum over the life of the contract. The investments backing the market strategies of these products are designated by the Company as trading securities. The change in the fair value of these securities is recognized as investment income (classified as income from policyholder and other special-purpose portfolios), which is substantially offset by the change in insurance policy benefits for these products.

Sales Inducements

Sales Inducements

Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract.  Certain of our life insurance products offer persistency bonuses credited to the contract holder's balance after the policy has been outstanding for a specified period of time.  These enhanced rates and persistency bonuses are considered sales inducements in accordance with GAAP.  Such amounts are deferred and amortized in the same manner as deferred acquisition costs.

Out-of-Period Adjustments

Out-of-Period Adjustments

In 2017, we recorded the net effect of out-of-period adjustments which decreased insurance policy benefits by $4.2 million, increased other operating costs and expenses by $2.0 million, increased tax expense by $.8 million and increased our net income by $1.4 million (or 1 cent per diluted share). We evaluated these adjustments taking into account both qualitative and quantitative factors and considered the impact of these adjustments in relation to each period, as well as the periods in which they originated. The impact of recognizing these adjustments in prior years was not significant to any individual period. Management believes these adjustments are immaterial to the consolidated financial statements and all previously issued financial statements.

Recently Issued Accounting Standards

Recently Issued Accounting Standards

Pending Accounting Standards

In May 2014, the Financial Accounting Standards Board (the "FASB") issued authoritative guidance for recognizing revenue from contracts with customers. Certain contracts with customers are specifically excluded from this guidance, including insurance contracts. The core principle of the new guidance is that an entity should recognize revenue when it transfers promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance will be effective for the Company on January 1, 2018 and permits two methods of transition upon adoption; full retrospective and modified retrospective. Under the full retrospective method, prior periods would be restated under the new revenue standard, providing for comparability in all periods presented. Under the modified retrospective method, prior periods would not be restated. Instead, revenues and other disclosures for pre-2018 periods would be provided in the notes to the financial statements as previously reported under the current revenue standard. The new guidance will impact our accounting for various distribution and marketing agreements with other insurance companies pursuant to which Bankers Life's career agents distribute third party products including prescription drug and Medicare Advantage plans. The revenue associated with these distribution agreements has been less than 1 percent of our total revenue. Our annual fee income earned during a calendar year will not change, but the amount recognized during each quarterly period will vary based on the sales of such products in each period. Accordingly, the adoption of this guidance is not expected to have a material impact on our consolidated financial statements. The Company will adopt the new guidance using the modified retrospective method.

In January 2016, the FASB issued authoritative guidance related to the recognition and measurement of financial assets and financial liabilities which made targeted improvements to GAAP as follows:

(i) Require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

(ii) Simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, an entity is required to measure the investment at fair value.

(iii) Eliminate the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet.

(iv) Require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes.

(v) Require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments.

(vi) Require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements.

(vii) Clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets.

An entity should apply this guidance by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The amendments related to equity securities without readily determinable fair values (including disclosure requirements) should be applied prospectively to equity investments that exist as of the date of adoption of the guidance. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company currently holds equity securities classified as available for sale securities that are measured at fair value with changes in fair value recognized through accumulated other comprehensive income. Upon adoption of this guidance, changes in fair value of such equity securities will be recognized through net income. Based upon the equity securities held at December 31, 2017, the estimated impact of the new guidance, assuming it was adopted on January 1, 2018, would be a cumulative effect adjustment that would increase retained earnings by approximately $17 million with a corresponding decrease to accumulated other comprehensive income of approximately $17 million. The Company may experience an increase in volatility in the income statement due to the requirement to measure equity investments at fair value with changes in fair value recognized in income. In addition, the Company will be required to modify certain disclosures upon adoption.

In February 2016, the FASB issued authoritative guidance related to accounting for leases, requiring lessees to report most leases on their balance sheets, regardless of whether the lease is classified as a finance lease or an operating lease. For lessees, the initial lease liability is equal to the present value of future lease payments, and a corresponding asset, adjusted for certain items, is also recorded. Expense recognition for lessees will remain similar to current accounting requirements for capital and operating leases. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

In June 2016, the FASB issued authoritative guidance related to the measurement of credit losses on financial instruments. The new guidance replaces the incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to form credit loss estimates. The guidance will be effective for the Company for fiscal years beginning in 2020, including interim periods within the fiscal year. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

In August 2016, the FASB issued authoritative guidance related to how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, and others. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this guidance will result in reclassifications to certain cash receipts and payments within our consolidated statement of cash flows, but will have no impact on our consolidated financial position, results of operations or cash flows.

In November 2016, the FASB issued authoritative guidance to address the diversity in practice that currently exists regarding the classification and presentation of changes in restricted cash on the statement of cash flows. The new guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. Entities will also be required to disclose information about the nature of their restricted cash and restricted cash equivalents. Additionally, if cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item in the statement of financial position, entities will be required to present a reconciliation, either on the face of the statement of cash flows or disclosed in the notes, of the totals in the statement of cash flows to the related line item captions in the statement of financial position. The guidance will be effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The adoption of this guidance will impact the presentation of our consolidated statement of cash flows and related cash flow disclosures, but will have no impact on our consolidated financial position, results of operations or cash flows.

In January 2017, the FASB issued authoritative guidance that removes Step 2 of the goodwill impairment test under current guidance, which requires a hypothetical purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reported unit's fair value. Upon adoption, the guidance is to be applied prospectively. The guidance will be effective for the Company on January 1, 2020, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows.

In March 2017, the FASB issued authoritative guidance related to the premium amortization on purchased callable debt securities. The guidance shortens the amortization period for certain callable debt securities held at a premium. Specifically, the new guidance requires the premium to be amortized to the earliest call date. The guidance does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance will be effective for the Company for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the guidance in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The guidance should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company has not yet determined the expected impact of adoption of this guidance on our consolidated financial position, results of operations or cash flows.

In May 2017, the FASB issued authoritative guidance related to which changes to the terms or conditions of a share-based award require an entity to apply modification accounting. The guidance will be effective for the Company in 2018. The guidance is to be applied prospectively to an award modified on or after the adoption date. The adoption of this guidance is not expected to have a material impact to the Company's consolidated financial position, results of operations or cash flows.

In August 2017, the FASB issued authoritative guidance related to derivatives and hedging. The new guidance expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instruments and the hedged item in the financial statements. The new guidance also includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company has not yet determined the expected impact of adoption of this guidance on its consolidated financial position, results of operations or cash flows.

Adopted Accounting Standards

In March 2016, the FASB issued authoritative guidance that clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts. An entity performing the assessment under this guidance is required to assess the embedded call (put) options solely in accordance with a four-step decision sequence. The guidance is effective for the Company on January 1, 2017. The adoption of this guidance had no effect on our consolidated financial statements.

In March 2016, the FASB issued authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting policy for forfeiture rate assumptions, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new guidance requires all income tax effects of stock-based compensation awards to be recognized in the income statement when the awards vest or are settled. The new guidance also allows an employer to withhold shares upon settlement of an award to satisfy the employer's tax withholding requirements up to the highest marginal tax rate applicable to employees, without resulting in liability classification of the award. Current guidance strictly limits the withholding to the employer's minimum statutory tax withholding requirement. The guidance was effective for the Company on January 1, 2017. The impact of adoption was as follows (dollars in millions):

	January 1, 2017
				Effect of Adoption of Authoritative Guidance
	Amounts prior to effect of adoption of authoritative guidance			Election to account for forfeitures as they occur			Recognition of excess tax benefits			As adjusted
Income tax assets	$	1,029.9		$	.3		$	15.7		$	1,045.9
Valuation allowance for deferred income tax assets	(240.2		)	—			(15.7		)	(255.9		)
Income tax assets, net	789.7			.3			—			790.0
Total assets	31,975.2			.3			—			31,975.5
Additional paid-in capital	3,212.1			.9			—			3,213.0
Retained earnings	650.7			(.6		)	—			650.1
Total shareholders' equity	4,486.9			.3			—			4,487.2
Total liabilities and shareholders' equity	31,975.2			.3			—			31,975.5

	December 31, 2016
	Amounts prior to effect of adoption of authoritative guidance			Effect of adoption of authoritative guidance			As adjusted
Cash flows from operating activities:
Other operating costs	$	(751.2	)	$	3.3		$	(747.9	)
Net cash flow from operating activities	759.5			3.3			762.8
Cash flows from financing activities:
Payments to repurchase common stock	(206.7		)	(3.3		)	(210.0		)
Net cash provided by financing activities	29.5			(3.3		)	26.2
Net increase in cash and cash equivalents	46.6			—			46.6

	December 31, 2015
	Amounts prior to effect of adoption of authoritative guidance			Effect of adoption of authoritative guidance			As adjusted
Cash flows from operating activities:
Other operating costs	$	(724.4	)	$	3.9		$	(720.5	)
Net cash flow from operating activities	743.9			3.9			747.8
Cash flows from financing activities:
Payments to repurchase common stock	(361.5		)	(3.9		)	(365.4		)
Net cash provided by financing activities	146.4			(3.9		)	142.5
Net decrease in cash and cash equivalents	(179.3		)	—			(179.3		)

In October 2016, the FASB issued authoritative guidance to amend the consolidation guidance on how a reporting entity that is the single decision maker of a VIE should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The guidance is effective for the Company on January 1, 2017. The adoption of this guidance had no impact on our consolidated financial statements.

In February 2018, the FASB issued authoritative guidance that allows a reclassification from accumulated other comprehensive income to retained earnings for the stranded tax effects resulting from the Tax Cuts and Jobs Act (the "Tax Reform Act") enacted by the U.S. federal government on December 22, 2017. Such guidance only relates to the reclassification of the income tax effects of the Tax Reform Act. The Company early adopted this guidance and elected to reclassify the income tax effects of the Tax Reform Act from accumulated other comprehensive income as of December 31, 2017. As a result of such reclassification, retained earnings decreased by $205.4 million and accumulated other comprehensive income increased by $205.4 million. Such amount represents the decrease in the income tax rate from 35 percent to 21 percent on the net unrealized gains of our fixed maturity securities, available for sale, equity securities and certain other invested assets, net of related adjustments, included in accumulated other comprehensive income. Refer to the note to the consolidated financial statements entitled "Income Taxes" for additional information related to the Tax Reform Act.

Fair Value Measurements

For those financial instruments disclosed at fair value, we use the following methods and assumptions to determine the estimated fair values:

Mortgage loans and policy loans.  We discount future expected cash flows based on interest rates currently being offered for similar loans with similar risk characteristics.  We aggregate loans with similar characteristics in our calculations.  The fair value of policy loans approximates their carrying value.

Company-owned life insurance is backed by a series of mutual funds and is carried at cash surrender value which approximates estimated fair value.

Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value.

Liabilities for policyholder account balances.  The estimated fair value of insurance liabilities for policyholder account balances was approximately equal to its carrying value as interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.

Investment borrowings, notes payable and borrowings related to variable interest entities.  For publicly traded debt, we use current fair values.  For other notes, we use discounted cash flow analyses based on our current incremental borrowing rates for similar types of borrowing arrangements.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and, therefore, represents an exit price, not an entry price.  We carry certain assets and liabilities at fair value on a recurring basis, including fixed maturities, equity securities, trading securities, investments held by VIEs, derivatives, separate account assets and embedded derivatives.  We carry our COLI, which is invested in a series of mutual funds, at its cash surrender value which approximates fair value. In addition, we disclose fair value for certain financial instruments, including mortgage loans, policy loans, cash and cash equivalents, insurance liabilities for interest-sensitive products, investment borrowings, notes payable and borrowings related to VIEs.

The degree of judgment utilized in measuring the fair value of financial instruments is largely dependent on the level to which pricing is based on observable inputs.  Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information.  Financial instruments with readily available active quoted prices would be considered to have fair values based on the highest level of observable inputs, and little judgment would be utilized in measuring fair value.  Financial instruments that rarely trade would often have fair value based on a lower level of observable inputs, and more judgment would be utilized in measuring fair value.

Valuation Hierarchy

There is a three-level hierarchy for valuing assets or liabilities at fair value based on whether inputs are observable or unobservable.

• Level 1 – includes assets and liabilities valued using inputs that are unadjusted quoted prices in active markets for identical assets or liabilities.  Our Level 1 assets primarily include cash and cash equivalents and exchange traded securities.

• Level 2 – includes assets and liabilities valued using inputs that are quoted prices for similar assets in an active market, quoted prices for identical or similar assets in a market that is not active, observable inputs, or observable inputs that can be corroborated by market data.  Level 2 assets and liabilities include those financial instruments that are valued by independent pricing services using models or other valuation methodologies.  These models consider various inputs such as credit rating, maturity, corporate credit spreads, reported trades and other inputs that are observable or derived from observable information in the marketplace or are supported by transactions executed in the marketplace. Financial assets in this category primarily include:  certain publicly registered and privately placed corporate fixed maturity securities; certain government or agency securities; certain mortgage and asset-backed securities; certain equity securities; most investments held by our consolidated VIEs; certain mutual fund investments; most short-term investments; and non-exchange-traded derivatives such as call options. Financial liabilities in this category include investment borrowings, notes payable and borrowings related to VIEs.

• Level 3 – includes assets and liabilities valued using unobservable inputs that are used in model-based valuations that contain management assumptions.  Level 3 assets and liabilities include those financial instruments whose fair value is estimated based on broker/dealer quotes, pricing services or internally developed models or methodologies utilizing significant inputs not based on, or corroborated by, readily available market information.  Financial assets in this category include certain corporate securities (primarily certain below-investment grade privately placed securities), certain structured securities, mortgage loans, and other less liquid securities.  Financial liabilities in this category include our insurance liabilities for interest-sensitive products, which includes embedded derivatives (including embedded derivatives related to our fixed index annuity products and to a modified coinsurance arrangement) since their values include significant unobservable inputs including actuarial assumptions.

At each reporting date, we classify assets and liabilities into the three input levels based on the lowest level of input that is significant to the measurement of fair value for each asset and liability reported at fair value.  This classification is impacted by a number of factors, including the type of financial instrument, whether the financial instrument is new to the market and not yet established, the characteristics specific to the transaction and overall market conditions.  Our assessment of the significance of a particular input to the fair value measurement and the ultimate classification of each asset and liability requires judgment and is subject to change from period to period based on the observability of the valuation inputs. Any transfers between levels are reported as having occurred at the beginning of the period. There were no transfers between Level 1 and Level 2 in both 2017 and 2016.

The vast majority of our fixed maturity and equity securities, including those held in trading portfolios and those held by consolidated VIEs, short-term and separate account assets use Level 2 inputs for the determination of fair value.  These fair values are obtained primarily from independent pricing services, which use Level 2 inputs for the determination of fair value.  Our Level 2 assets are valued as follows:

•Fixed maturities available for sale, equity securities and trading securities

Corporate securities are generally priced using market and income approaches. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads.

U.S. Treasuries and obligations of U.S. Government corporations and agencies are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets and maturity.

States and political subdivisions are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, new issuances and credit spreads.

Asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations are generally priced using market and income approaches. Inputs generally consist of quoted prices in inactive markets, spreads on actively traded securities, expected prepayments, expected default rates, expected recovery rates, and issue specific information including, but not limited to, collateral type, seniority and vintage.

Equity securities (primarily comprised of non-redeemable preferred stock) are generally priced using the market approach. Inputs generally consist of trades of identical or similar securities, quoted prices in inactive markets, issuer rating, benchmark yields, maturity, and credit spreads.

• Investments held by VIEs

Corporate securities are generally priced using market and income approaches using pricing vendors. Inputs generally consist of issuer rating, benchmark yields, maturity, and credit spreads.

• Other invested assets - derivatives

The fair value measurements for derivative instruments, including embedded derivatives requiring bifurcation, are determined based on the consideration of several inputs including closing exchange or over-the-counter market price quotes; time value and volatility factors underlying options; market interest rates; and non-performance risk.

Third party pricing services normally derive security prices through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information.  If there are no recently reported trades, the third party pricing services may use matrix or model processes to develop a security price where future cash flow expectations are discounted at an estimated risk-adjusted market rate.  The number of prices obtained for a given security is dependent on the Company's analysis of such prices as further described below.

As the Company is responsible for the determination of fair value, we have control processes designed to ensure that the fair values received from third-party pricing sources are reasonable and the valuation techniques and assumptions used appear reasonable and consistent with prevailing market conditions. Additionally, when inputs are provided by third-party pricing sources, we have controls in place to review those inputs for reasonableness. As part of these controls, we perform monthly quantitative and qualitative analysis on the prices received from third parties to determine whether the prices are reasonable estimates of fair value.  The Company's analysis includes:  (i) a review of the methodology used by third party pricing services; (ii) where available, a comparison of multiple pricing services' valuations for the same security; (iii) a review of month to month price fluctuations; (iv) a review to ensure valuations are not unreasonably dated; and (v) back testing to compare actual purchase and sale transactions with valuations received from third parties.  As a result of such procedures, the Company may conclude a particular price received from a third party is not reflective of current market conditions.  In those instances, we may request additional pricing quotes or apply internally developed valuations.  However, the number of such instances is insignificant and the aggregate change in value of such investments is not materially different from the original prices received.

The categorization of the fair value measurements of our investments priced by independent pricing services was based upon the Company's judgment of the inputs or methodologies used by the independent pricing services to value different asset classes.  Such inputs typically include:  benchmark yields, reported trades, broker dealer quotes, issuer spreads, benchmark securities, bids, offers and other relevant data.  The Company categorizes such fair value measurements based upon asset classes and the underlying observable or unobservable inputs used to value such investments.

For securities that are not priced by pricing services and may not be reliably priced using pricing models, we obtain broker quotes.  These broker quotes are non-binding andrepresent an exit price, but assumptions used to establish the fair value may not be observable and therefore represent Level 3 inputs.  Approximately 29 percent of our Level 3 fixed maturity securities were valued using unadjusted broker quotes or broker-provided valuation inputs.  The remaining Level 3 fixed maturity investments do not have readily determinable market prices and/or observable inputs.  For these securities, we use internally developed valuations.  Key assumptions used to determine fair value for these securities may include risk premiums, projected performance of underlying collateral and other factors involving significant assumptions which may not be reflective of an active market.  For certain investments, we use a matrix or model process to develop a security price where future cash flow expectations are discounted at an estimated market rate.  The pricing matrix incorporates term interest rates as well as a spread level based on the issuer's credit rating, other factors relating to the issuer, and the security's maturity.  In some instances issuer-specific spread adjustments, which can be positive or negative, are made based upon internal analysis of security specifics such as liquidity, deal size, and time to maturity.

For certain embedded derivatives, we use actuarial assumptions in the determination of fair value which we consider to be Level 3 inputs.

Realized and unrealized gains (losses) on Level 3 assets are primarily reported in either net investment income for policyholder and other special-purpose portfolios, net realized investment gains (losses) or insurance policy benefits within the consolidated statement of operations or accumulated other comprehensive income within shareholders' equity based on the appropriate accounting treatment for the instrument.

The amount presented for gains (losses) included in our net loss for assets and liabilities still held as of the reporting date primarily represents impairments for fixed maturities, available for sale, changes in fair value of trading securities and certain derivatives and changes in fair value of embedded derivative instruments included in liabilities for insurance products that exist as of the reporting date.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of loss recapture of long-term care business

Accordingly, we recognized a loss on the recapture of the long-term care business as summarized below (dollars in millions):

Market value of investments	$	504.7
Insurance liabilities	(552.2		)
Write-off of reinsurance receivables	(17.9		)
Estimated transaction expenses	(10.0		)
Pre-tax loss	(75.4		)
Tax benefit	26.4
Increase in valuation allowance for deferred tax assets	(4.1		)
After-tax loss	$	(53.1	)

Schedule of terms of federal home loan bank borrowing

The following summarizes the terms of the borrowings from the FHLB by our insurance subsidiaries (dollars in millions):

Amount		Maturity	Interest rate at
borrowed		date	December 31, 2017
$	50.0	January 2019	Variable rate – 1.779%
50.0		February 2019	Variable rate – 1.509%
100.0		March 2019	Variable rate – 1.971%
21.8		July 2019	Variable rate – 2.001%
15.0		October 2019	Variable rate – 1.887%
50.0		May 2020	Variable rate – 1.997%
21.8		June 2020	Fixed rate – 1.960%
25.0		September 2020	Variable rate – 2.300%
100.0		September 2020	Variable rate – 2.212%
50.0		September 2020	Variable rate – 2.224%
75.0		September 2020	Variable rate – 1.813%
100.0		October 2020	Variable rate – 1.453%
50.0		December 2020	Variable rate – 2.072%
100.0		July 2021	Variable rate – 1.909%
100.0		July 2021	Variable rate – 1.879%
57.7		August 2021	Variable rate – 1.921%
28.2		August 2021	Fixed rate – 2.550%
125.0		August 2021	Variable rate – 2.032%
50.0		September 2021	Variable rate – 2.002%
22.0		May 2022	Variable rate – 1.829%
100.0		May 2022	Variable rate – 1.780%
10.0		June 2022	Variable rate – 2.150%
50.0		July 2022	Variable rate – 1.726%
50.0		July 2022	Variable rate – 1.745%
50.0		July 2022	Variable rate – 1.758%
50.0		August 2022	Variable rate – 1.782%
50.0		December 2022	Variable rate – 1.795%
50.0		December 2022	Variable rate – 1.795%
24.7		March 2023	Fixed rate – 2.160%
20.5		June 2025	Fixed rate – 2.940%
$	1,646.7

Summary of Impacts of Adoption of Recent Accounting Pronouncements

The impact of adoption was as follows (dollars in millions):

	January 1, 2017
				Effect of Adoption of Authoritative Guidance
	Amounts prior to effect of adoption of authoritative guidance			Election to account for forfeitures as they occur			Recognition of excess tax benefits			As adjusted
Income tax assets	$	1,029.9		$	.3		$	15.7		$	1,045.9
Valuation allowance for deferred income tax assets	(240.2		)	—			(15.7		)	(255.9		)
Income tax assets, net	789.7			.3			—			790.0
Total assets	31,975.2			.3			—			31,975.5
Additional paid-in capital	3,212.1			.9			—			3,213.0
Retained earnings	650.7			(.6		)	—			650.1
Total shareholders' equity	4,486.9			.3			—			4,487.2
Total liabilities and shareholders' equity	31,975.2			.3			—			31,975.5

	December 31, 2016
	Amounts prior to effect of adoption of authoritative guidance			Effect of adoption of authoritative guidance			As adjusted
Cash flows from operating activities:
Other operating costs	$	(751.2	)	$	3.3		$	(747.9	)
Net cash flow from operating activities	759.5			3.3			762.8
Cash flows from financing activities:
Payments to repurchase common stock	(206.7		)	(3.3		)	(210.0		)
Net cash provided by financing activities	29.5			(3.3		)	26.2
Net increase in cash and cash equivalents	46.6			—			46.6

	December 31, 2015
	Amounts prior to effect of adoption of authoritative guidance			Effect of adoption of authoritative guidance			As adjusted
Cash flows from operating activities:
Other operating costs	$	(724.4	)	$	3.9		$	(720.5	)
Net cash flow from operating activities	743.9			3.9			747.8
Cash flows from financing activities:
Payments to repurchase common stock	(361.5		)	(3.9		)	(365.4		)
Net cash provided by financing activities	146.4			(3.9		)	142.5
Net decrease in cash and cash equivalents	(179.3		)	—			(179.3		)

XML

INVESTMENTS (Tables)

12 Months Ended

Dec. 31, 2017

Investments, Debt and Equity Securities [Abstract]

Schedule of fixed maturities for available for sale and equity securities

At December 31, 2017, the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than-temporary impairments included in accumulated other comprehensive income
Investment grade (a):
Corporate securities	$	12,419.3	$	1,670.7	$	(14.6	)	$	14,075.4	$	—
United States Treasury securities and obligations of United States government corporations and agencies	146.4		31.5		(.2		)	177.7		—
States and political subdivisions	1,819.9		234.8		(.4		)	2,054.3		—
Debt securities issued by foreign governments	79.5		3.8		(.2		)	83.1		—
Asset-backed securities	1,730.7		39.7		(3.2		)	1,767.2		—
Collateralized debt obligations	257.1		2.3		—			259.4		—
Commercial mortgage-backed securities	1,304.1		33.2		(9.1		)	1,328.2		—
Mortgage pass-through securities	1.8		.2		—			2.0		—
Collateralized mortgage obligations	293.9		16.4		(.2		)	310.1		(.2		)
Total investment grade fixed maturities, available for sale	18,052.7		2,032.6		(27.9		)	20,057.4		(.2		)
Below-investment grade (a) (b):
Corporate securities	867.0		28.4		(12.4		)	883.0		—
States and political subdivisions	2.0		—		—			2.0		—
Asset-backed securities	1,355.2		132.9		(.9		)	1,487.2		—
Commercial mortgage-backed securities	49.9		.6		(1.2		)	49.3		—
Collateralized mortgage obligations	375.3		56.8		(.1		)	432.0		(.8		)
Total below-investment grade fixed maturities, available for sale	2,649.4		218.7		(14.6		)	2,853.5		(.8		)
Total fixed maturities, available for sale	$	20,702.1	$	2,251.3	$	(42.5	)	$	22,910.9	$	(1.0	)
Equity securities	$	491.1	$	23.6	$	(3.0	)	$	511.7

_______________

(a) Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's Investor Services, Inc. ("Moody's"), S&P Global Ratings ("S&P") or Fitch Ratings ("Fitch")), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC").  NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch).  NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch).  References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.

(b) Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations.

Schedule of NAIC designations and NRSRO equivalent ratings

The following summarizes the NAIC designations and NRSRO equivalent ratings:

NAIC Designation	NRSRO Equivalent Rating
1	AAA/AA/A
2	BBB
3	BB
4	B
5	CCC and lower
6	In or near default

Summary of fixed maturity securities available for sale

A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of December 31, 2017 is as follows (dollars in millions):

NAIC designation	Amortized cost		Estimated fair value		Percentage of total estimated fair value
1	$	9,923.7	$	11,028.5	48.1	%
2	9,821.6		10,906.2		47.6
Total NAIC 1 and 2 (investment grade)	19,745.3		21,934.7		95.7
3	676.2		693.8		3.0
4	225.0		225.9		1.0
5	46.3		45.9		.2
6	9.3		10.6		.1
Total NAIC 3,4,5 and 6 (below-investment grade)	956.8		976.2		4.3
	$	20,702.1	$	22,910.9	100.0	%

Schedule of fixed maturities for available for sale and equity securities

At December 31, 2016, the amortized cost, gross unrealized gains and losses, estimated fair value and other-than-temporary impairments in accumulated other comprehensive income of fixed maturities, available for sale, and equity securities were as follows (dollars in millions):

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value		Other-than-temporary impairments included in accumulated other comprehensive income
Investment grade:
Corporate securities	$	11,582.6	$	1,073.9	$	(99.8	)	$	12,556.7	$	—
United States Treasury securities and obligations of United States government corporations and agencies	143.8		20.5		—			164.3		—
States and political subdivisions	1,798.2		186.7		(7.9		)	1,977.0		—
Debt securities issued by foreign governments	37.1		.2		(.4		)	36.9		—
Asset-backed securities	1,169.6		29.2		(8.7		)	1,190.1		—
Collateralized debt obligations	227.5		1.0		(.3		)	228.2		—
Commercial mortgage-backed securities	1,467.2		32.9		(26.6		)	1,473.5		—
Mortgage pass-through securities	2.3		.2		—			2.5		—
Collateralized mortgage obligations	304.8		14.6		(.2		)	319.2		—
Total investment grade fixed maturities, available for sale	16,733.1		1,359.2		(143.9		)	17,948.4		—
Below-investment grade:
Corporate securities	967.3		26.1		(39.2		)	954.2		(3.6		)
States and political subdivisions	13.6		—		(1.7		)	11.9		(3.0		)
Asset-backed securities	1,471.9		55.1		(6.8		)	1,520.2		—
Collateralized debt obligations	2.5		—		—			2.5		—
Commercial mortgage-backed securities	63.8		.2		(1.3		)	62.7		—
Collateralized mortgage obligations	550.9		46.8		(1.4		)	596.3		(1.4		)
Total below-investment grade fixed maturities, available for sale	3,070.0		128.2		(50.4		)	3,147.8		(8.0		)
Total fixed maturities, available for sale	$	19,803.1	$	1,487.4	$	(194.3	)	$	21,096.2	$	(8.0	)
Equity securities	$	580.7	$	11.5	$	(8.0	)	$	584.2

Schedule of accumulated other comprehensive income (loss)

Accumulated other comprehensive income is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments.  These amounts, included in shareholders' equity as of December 31, 2017 and 2016, were as follows (dollars in millions):

	2017			2016
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	$	2.6		$	(1.1	)
Net unrealized gains on all other investments	2,227.3			1,311.9
Adjustment to present value of future profits (a)	(94.0		)	(106.2		)
Adjustment to deferred acquisition costs	(292.6		)	(223.5		)
Adjustment to insurance liabilities	(295.8		)	(13.5		)
Deferred income tax liabilities	(335.4		)	(345.2		)
Accumulated other comprehensive income	$	1,212.1		$	622.4

________

(a) The present value of future profits is the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003, the date our Predecessor emerged from bankruptcy.

Schedule of investments classified by contractual maturity date

The following table sets forth the amortized cost and estimated fair value of fixed maturities, available for sale, at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.  Structured securities (such as asset-backed securities, collateralized debt obligations, commercial mortgage-backed securities, mortgage pass-through securities and collateralized mortgage obligations, collectively referred to as "structured securities") frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	328.1	$	335.1
Due after one year through five years	1,947.3		2,052.3
Due after five years through ten years	1,508.7		1,601.3
Due after ten years	11,550.0		13,286.8
Subtotal	15,334.1		17,275.5
Structured securities	5,368.0		5,635.4
Total fixed maturities, available for sale	$	20,702.1	$	22,910.9

Schedule of investment income

Net investment income consisted of the following (dollars in millions):

	2017		2016			2015
General account assets:
Fixed maturities	$	1,133.8	$	1,081.4		$	1,090.1
Equity securities	25.3		21.5			18.3
Mortgage loans	91.5		91.0			91.4
Policy loans	7.7		7.3			7.3
Other invested assets	44.4		24.3			17.4
Cash and cash equivalents	5.9		2.0			.8
Policyholder and other special-purpose portfolios:
Trading securities (a)	12.8		12.2			10.7
Options related to fixed index products:
Option income (loss)	110.3		(40.1		)	36.5
Change in value of options	52.2		69.3			(72.7		)
Other special-purpose portfolios	90.6		79.7			55.5
Gross investment income	1,574.5		1,348.6			1,255.3
Less investment expenses	23.2		23.4			21.7
Net investment income	$	1,551.3	$	1,325.2		$	1,233.6

_________________

(a) Changes in the estimated fair value for trading securities still held as of the end of the respective years and included in net investment income were $3.8 million, $(.2) million and $.4 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Schedule of realized gain (loss) on investments

The following table sets forth the net realized investment gains (losses) for the periods indicated (dollars in millions):

	2017			2016			2015
Fixed maturity securities, available for sale:
Gross realized gains on sale	$	68.0		$	137.7		$	95.7
Gross realized losses on sale	(24.2		)	(95.2		)	(88.4		)
Impairments:
Total other-than-temporary impairment losses	(12.5		)	(15.2		)	(17.9		)
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(.9		)	3.6			3.0
Net impairment losses recognized	(13.4		)	(11.6		)	(14.9		)
Net realized investment gains (losses) from fixed maturities	30.4			30.9			(7.6		)
Equity securities	11.6			20.9			3.7
Mortgage loans	1.1			—			(2.3		)
Impairments on preferred stock and other investments	(9.4		)	(20.7		)	(25.0		)
Gain (loss) on dissolution of variable interest entities	(4.3		)	(7.3		)	11.3
Other (a)	20.9			(15.5		)	(16.7		)
Net realized investment gains (losses)	$	50.3		$	8.3		$	(36.6	)

_________________

(a) Changes in the estimated fair value of trading securities that we have elected the fair value option (and are still held as of the end of the respective years) were $12.8 million, $(.5) million and $(9.2) million for the years ended December 31, 2017, 2016 and 2015, respectively.

Schedule of credit losses recognized in earnings

The following table summarizes the amount of credit losses recognized in earnings on fixed maturity securities, available for sale, held at the beginning of the period, for which a portion of the other-than-temporary impairment was also recognized in accumulated other comprehensive income for the years ended December 31, 2017, 2016 and 2015 (dollars in millions):

	Year ended
	December 31,
	2017			2016			2015
Credit losses on fixed maturity securities, available for sale, beginning of period	$	(5.5	)	$	(2.6	)	$	(1.0	)
Add:  credit losses on other-than-temporary impairments not previously recognized	—			(3.0		)	(2.0		)
Less:  credit losses on securities sold	4.7			.1			.4
Less:  credit losses on securities impaired due to intent to sell (a)	—			—			—
Add:  credit losses on previously impaired securities	(2.0		)	—			—
Less:  increases in cash flows expected on previously impaired securities	—			—			—
Credit losses on fixed maturity securities, available for sale, end of period	$	(2.8	)	$	(5.5	)	$	(2.6	)

__________

(a) Represents securities for which the amount previously recognized in accumulated other comprehensive income was recognized in earnings because we intend to sell the security or we more likely than not will be required to sell the security before recovery of its amortized cost basis.

Schedule of investments with unrealized losses classified by contractual maturity date

The following table sets forth the amortized cost and estimated fair value of those fixed maturities, available for sale, with unrealized losses at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.  Structured securities frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	26.9	$	26.9
Due after one year through five years	195.4		193.3
Due after five years through ten years	108.9		105.2
Due after ten years	602.0		580.0
Subtotal	933.2		905.4
Structured securities	1,268.3		1,253.6
Total	$	2,201.5	$	2,159.0

Schedule of investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position

The following summarizes the investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis for the period indicated as of December 31, 2017 (dollars in millions):

	Number of issuers	Cost basis		Unrealized loss			Estimated fair value
Less than 6 months	1	$	9.2	$	(1.9	)	$	7.3
		$	9.2	$	(1.9	)	$	7.3

The following summarizes the investments sold at a loss during 2017 which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period indicated (dollars in millions):

		At date of sale
	Number of issuers	Amortized cost		Fair value
Less than 6 months prior to sale	4	$	17.8	$	13.0
Greater than or equal to 6 months and less than 12 months prior to sale	1	2.7		1.9
Greater than 12 months prior to sale	1	.7		.5
	6	$	21.2	$	15.4

Schedule of unrealized loss on investments

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2017 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	28.2	$	(.2	)	$	.7	$	—		$	28.9	$	(.2	)
States and political subdivisions	18.3		(.1		)	14.9		(.3		)	33.2		(.4		)
Debt securities issued by foreign governments	7.7		(.1		)	5.4		(.1		)	13.1		(.2		)
Corporate securities	470.5		(6.8		)	359.7		(20.2		)	830.2		(27.0		)
Asset-backed securities	601.4		(2.0		)	122.2		(2.1		)	723.6		(4.1		)
Collateralized debt obligations	3.0		—			—		—			3.0		—
Commercial mortgage-backed securities	276.8		(1.7		)	218.2		(8.6		)	495.0		(10.3		)
Collateralized mortgage obligations	20.5		(.2		)	11.5		(.1		)	32.0		(.3		)
Total fixed maturities, available for sale	$	1,426.4	$	(11.1	)	$	732.6	$	(31.4	)	$	2,159.0	$	(42.5	)
Equity securities	$	58.7	$	(1.7	)	$	21.2	$	(1.3	)	$	79.9	$	(3.0	)

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2016 (dollars in millions):

	Less than 12 months					12 months or greater					Total
Description of securities	Fair value		Unrealized losses			Fair value		Unrealized losses			Fair value		Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies	$	8.0	$	—		$	—	$	—		$	8.0	$	—
States and political subdivisions	176.3		(7.8		)	18.3		(1.8		)	194.6		(9.6		)
Debt securities issued by foreign governments	18.9		(.4		)	—		—			18.9		(.4		)
Corporate securities	1,907.6		(75.5		)	559.6		(63.5		)	2,467.2		(139.0		)
Asset-backed securities	692.9		(8.5		)	262.5		(7.0		)	955.4		(15.5		)
Collateralized debt obligations	38.3		(.1		)	30.8		(.2		)	69.1		(.3		)
Commercial mortgage-backed securities	525.2		(16.6		)	154.0		(11.3		)	679.2		(27.9		)
Collateralized mortgage obligations	73.6		(.6		)	34.6		(1.0		)	108.2		(1.6		)
Total fixed maturities, available for sale	$	3,440.8	$	(109.5	)	$	1,059.8	$	(84.8	)	$	4,500.6	$	(194.3	)
Equity securities	$	239.4	$	(8.0	)	$	—	$	—		$	239.4	$	(8.0	)

Schedule of structured securities

The following table sets forth the par value, amortized cost and estimated fair value of structured securities, summarized by interest rates on the underlying collateral, at December 31, 2017 (dollars in millions):

	Par value		Amortized cost		Estimated fair value
Below 4 percent	$	2,101.7	$	1,944.8	$	2,014.9
4 percent – 5 percent	1,656.3		1,516.0		1,596.5
5 percent – 6 percent	1,407.1		1,271.8		1,362.6
6 percent – 7 percent	286.6		260.6		276.8
7 percent – 8 percent	83.0		83.7		92.5
8 percent and above	291.3		291.1		292.1
Total structured securities	$	5,826.0	$	5,368.0	$	5,635.4

The amortized cost and estimated fair value of structured securities at December 31, 2017, summarized by type of security, were as follows (dollars in millions):

			Estimated fair value
Type	Amortized cost		Amount		Percent of fixed maturities
Pass-throughs, sequential and equivalent securities	$	557.7	$	617.2	2.7	%
Planned amortization classes, target amortization classes and accretion-directed bonds	95.3		108.5		.5
Commercial mortgage-backed securities	1,354.0		1,377.5		6.0
Asset-backed securities	3,085.9		3,254.4		14.2
Collateralized debt obligations	257.1		259.4		1.1
Other	18.0		18.4		.1
Total structured securities	$	5,368.0	$	5,635.4	24.6	%

Summary of weighted average loan-to-value ratio for outstanding mortgage loans

The following table provides the carrying value and estimated fair value of our outstanding commercial mortgage loans and the underlying collateral as of December 31, 2017 (dollars in millions):

			Estimated fair value
Loan-to-value ratio (a)	Carrying value		Mortgage loans		Collateral
Less than 60%	$	944.7	$	960.8	$	2,330.6
60% to 70%	439.5		440.2		671.3
Greater than 70% to 80%	138.4		145.9		188.4
Greater than 80% to 90%	52.3		52.9		60.1
Greater than 90%	38.6		40.2		41.7
Total	$	1,613.5	$	1,640.0	$	3,292.1

________________

(a) Loan-to-value ratios are calculated as the ratio of:  (i) the carrying value of the commercial mortgage loans; to (ii) the estimated fair value of the underlying collateral.

XML

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair value measurements of financial instruments measured on a recurring basis

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2017 is as follows (dollars in millions):

	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	14,728.0	$	230.4	$	14,958.4
United States Treasury securities and obligations of United States government corporations and agencies	—		177.7		—		177.7
States and political subdivisions	—		2,056.3		—		2,056.3
Debt securities issued by foreign governments	—		79.2		3.9		83.1
Asset-backed securities	—		3,230.2		24.2		3,254.4
Collateralized debt obligations	—		259.4		—		259.4
Commercial mortgage-backed securities	—		1,377.5		—		1,377.5
Mortgage pass-through securities	—		2.0		—		2.0
Collateralized mortgage obligations	—		742.1		—		742.1
Total fixed maturities, available for sale	—		22,652.4		258.5		22,910.9
Equity securities - corporate securities	287.8		202.7		21.2		511.7
Trading securities:
Corporate securities	—		21.6		—		21.6
United States Treasury securities and obligations of United States government corporations and agencies	—		.5		—		.5
Asset-backed securities	—		95.8		—		95.8
Collateralized debt obligations	—		2.7		—		2.7
Commercial mortgage-backed securities	—		92.5		—		92.5
Collateralized mortgage obligations	—		68.7		—		68.7
Equity securities	2.8		—		—		2.8
Total trading securities	2.8		281.8		—		284.6
Investments held by variable interest entities - corporate securities	—		1,522.0		4.9		1,526.9
Other invested assets - derivatives	—		170.2		—		170.2
Assets held in separate accounts	—		5.0		—		5.0
Total assets carried at fair value by category	$	290.6	$	24,834.1	$	284.6	$	25,409.3
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	1,334.8	$	1,334.8

The categorization of fair value measurements, by input level, for our financial instruments carried at fair value on a recurring basis at December 31, 2016 is as follows (dollars in millions):

	Quoted prices in active markets  for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total
Assets:
Fixed maturities, available for sale:
Corporate securities	$	—	$	13,252.4	$	258.5	$	13,510.9
United States Treasury securities and obligations of United States government corporations and agencies	—		164.3		—		164.3
States and political subdivisions	—		1,988.9		—		1,988.9
Debt securities issued by foreign governments	—		33.0		3.9		36.9
Asset-backed securities	—		2,649.9		60.4		2,710.3
Collateralized debt obligations	—		225.3		5.4		230.7
Commercial mortgage-backed securities	—		1,504.2		32.0		1,536.2
Mortgage pass-through securities	—		2.5		—		2.5
Collateralized mortgage obligations	—		915.5		—		915.5
Total fixed maturities, available for sale	—		20,736.0		360.2		21,096.2
Equity securities - corporate securities	359.9		199.1		25.2		584.2
Trading securities:
Corporate securities	—		19.0		—		19.0
United States Treasury securities and obligations of United States government corporations and agencies	—		.5		—		.5
Asset-backed securities	—		94.3		—		94.3
Collateralized debt obligations	—		2.4		—		2.4
Commercial mortgage-backed securities	—		163.9		—		163.9
Collateralized mortgage obligations	—		78.4		—		78.4
Equity securities	4.9		—		—		4.9
Total trading securities	4.9		358.5		—		363.4
Investments held by variable interest entities - corporate securities	—		1,724.3		—		1,724.3
Other invested assets - derivatives	—		111.9		—		111.9
Assets held in separate accounts	—		4.7		—		4.7
Total assets carried at fair value by category	$	364.8	$	23,134.5	$	385.4	$	23,884.7
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	$	—	$	—	$	1,092.3	$	1,092.3

The fair value measurements for our financial instruments disclosed at fair value on a recurring basis are as follows (dollars in millions):

	December 31, 2017
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,677.3	$	1,677.3	$	1,650.6
Policy loans	—		—		116.0		116.0		116.0
Other invested assets:
Company-owned life insurance	—		182.3		—		182.3		182.3
Cash and cash equivalents:
Unrestricted	578.4		—		—		578.4		578.4
Held by variable interest entities	178.9		—		—		178.9		178.9
Liabilities:
Policyholder account balances	—		—		11,220.7		11,220.7		11,220.7
Investment borrowings	—		1,648.8		—		1,648.8		1,646.7
Borrowings related to variable interest entities	—		1,432.9		—		1,432.9		1,410.7
Notes payable – direct corporate obligations	—		962.3		—		962.3		914.6

	December 31, 2016
	Quoted prices in active markets for identical assets or liabilities (Level 1)		Significant other observable inputs  (Level 2)		Significant unobservable inputs  (Level 3)		Total estimated fair value		Total carrying amount
Assets:
Mortgage loans	$	—	$	—	$	1,800.1	$	1,800.1	$	1,768.0
Policy loans	—		—		112.0		112.0		112.0
Other invested assets:
Company-owned life insurance	—		165.0		—		165.0		165.0
Cash and cash equivalents:
Unrestricted	473.6		5.3		—		478.9		478.9
Held by variable interest entities	189.3		—		—		189.3		189.3
Liabilities:
Policyholder account balances	—		—		10,912.7		10,912.7		10,912.7
Investment borrowings	—		1,650.0		—		1,650.0		1,647.4
Borrowings related to variable interest entities	—		1,675.2		—		1,675.2		1,662.8
Notes payable – direct corporate obligations	—		931.9		—		931.9		912.9

Fair value, assets measured on recurring basis, unobservable input reconciliation

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2017 (dollars in millions):

	December 31, 2017
	Beginning balance as of December 31, 2016			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income		Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2017			Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	258.5		$	(70.4	)	$	5.8	$	5.3		$	31.2	$	—		$	230.4		$	(8.0	)
Debt securities issued by foreign governments	3.9			—			—		—			—		—			3.9			—
Asset-backed securities	60.4			(4.3		)	—		.7			—		(32.6		)	24.2			—
Collateralized debt obligations	5.4			(2.5		)	—		—			—		(2.9		)	—			—
Commercial mortgage-backed securities	32.0			(1.2		)	.1		(.1		)	—		(30.8		)	—			—
Total fixed maturities, available for sale	360.2			(78.4		)	5.9		5.9			31.2		(66.3		)	258.5			(8.0		)
Equity securities - corporate securities	25.2			(8.5		)	6.3		(1.8		)	—		—			21.2			—
Investments held by variable interest entities - corporate securities	—			4.9			—		—			—		—			4.9			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,092.3		)	(267.5		)	25.0		—			—		—			(1,334.8		)	25.0

_________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended December 31, 2017 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	76.6		$	(147.0	)	$	—		$	—	$	(70.4	)
Asset-backed securities	—			(4.3		)	—			—		(4.3		)
Collateralized debt obligations	—			(2.5		)	—			—		(2.5		)
Commercial mortgage-backed securities	—			(1.2		)	—			—		(1.2		)
Total fixed maturities, available for sale	76.6			(155.0		)	—			—		(78.4		)
Equity securities - corporate securities	—			(8.5		)	—			—		(8.5		)
Investments held by variable interest entities - corporate securities	8.9			(4.0		)	—			—		4.9
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(178.9		)	5.4			(159.3		)	65.3		(267.5		)

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2016 (dollars in millions):

	December 31, 2016
	Beginning balance as of December 31, 2015			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2016			Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	170.4		$	76.5		$	(10.7	)	$	9.1		$	20.3	$	(7.1	)	$	258.5		$	(10.9	)
Debt securities issued by foreign governments	—			4.0			—			(.1		)	—		—			3.9			—
Asset-backed securities	35.9			9.7			—			2.2			26.3		(13.7		)	60.4			—
Collateralized debt obligations	—			5.4			—			—			—		—			5.4			—
Commercial mortgage-backed securities	1.1			16.9			—			.1			13.9		—			32.0			—
Mortgage pass-through securities	.1			(.1		)	—			—			—		—			—			—
Total fixed maturities, available for sale	207.5			112.4			(10.7		)	11.3			60.5		(20.8		)	360.2			(10.9		)
Equity securities - corporate securities	32.0			5.5			(12.7		)	.4			—		—			25.2			(12.7		)
Trading securities - commercial mortgage-backed securities	39.9			—			—			—			—		(39.9		)	—			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,057.1		)	(96.0		)	60.8			—			—		—			(1,092.3		)	60.8

____________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended December 31, 2016 (dollars in millions):

	Purchases			Received in reinsurance recapture		Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	18.5		$	89.2	$	(31.2	)	$	—		$	—	$	76.5
Debt securities issued by foreign governments	4.0			—		—			—			—		4.0
Asset-backed securities	16.9			—		(7.2		)	—			—		9.7
Collateralized debt obligations	5.4			—		—			—			—		5.4
Commercial mortgage-backed securities	17.0			—		(.1		)	—			—		16.9
Mortgage pass-through securities	—			—		(.1		)	—			—		(.1		)
Total fixed maturities, available for sale	61.8			89.2		(38.6		)	—			—		112.4
Equity securities - corporate securities	3.3			2.2		—			—			—		5.5
Trading securities - corporate securities	.2			—		(.2		)	—			—		—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(148.3		)	—		21.2			(28.9		)	60.0		(96.0		)

Fair value, liabilities measured on recurring basis, unobservable input reconciliation

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2017 (dollars in millions):

	December 31, 2017
	Beginning balance as of December 31, 2016			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income		Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2017			Amount of total gains (losses) for the year ended December 31, 2017 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	258.5		$	(70.4	)	$	5.8	$	5.3		$	31.2	$	—		$	230.4		$	(8.0	)
Debt securities issued by foreign governments	3.9			—			—		—			—		—			3.9			—
Asset-backed securities	60.4			(4.3		)	—		.7			—		(32.6		)	24.2			—
Collateralized debt obligations	5.4			(2.5		)	—		—			—		(2.9		)	—			—
Commercial mortgage-backed securities	32.0			(1.2		)	.1		(.1		)	—		(30.8		)	—			—
Total fixed maturities, available for sale	360.2			(78.4		)	5.9		5.9			31.2		(66.3		)	258.5			(8.0		)
Equity securities - corporate securities	25.2			(8.5		)	6.3		(1.8		)	—		—			21.2			—
Investments held by variable interest entities - corporate securities	—			4.9			—		—			—		—			4.9			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,092.3		)	(267.5		)	25.0		—			—		—			(1,334.8		)	25.0

_________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts. The following summarizes such activity for the year ended December 31, 2017 (dollars in millions):

	Purchases			Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	76.6		$	(147.0	)	$	—		$	—	$	(70.4	)
Asset-backed securities	—			(4.3		)	—			—		(4.3		)
Collateralized debt obligations	—			(2.5		)	—			—		(2.5		)
Commercial mortgage-backed securities	—			(1.2		)	—			—		(1.2		)
Total fixed maturities, available for sale	76.6			(155.0		)	—			—		(78.4		)
Equity securities - corporate securities	—			(8.5		)	—			—		(8.5		)
Investments held by variable interest entities - corporate securities	8.9			(4.0		)	—			—		4.9
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(178.9		)	5.4			(159.3		)	65.3		(267.5		)

The following table presents additional information about assets and liabilities measured at fair value on a recurring basis and for which we have utilized significant unobservable (Level 3) inputs to determine fair value for the year ended December 31, 2016 (dollars in millions):

	December 31, 2016
	Beginning balance as of December 31, 2015			Purchases, sales, issuances and settlements, net (b)			Total realized and unrealized gains (losses) included in net income			Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)			Transfers into Level 3 (a)		Transfers out of Level 3 (a)			Ending balance as of December 31, 2016			Amount of total gains (losses) for the year ended December 31, 2016 included in our net income relating to assets and liabilities still held as of the reporting date
Assets:
Fixed maturities, available for sale:
Corporate securities	$	170.4		$	76.5		$	(10.7	)	$	9.1		$	20.3	$	(7.1	)	$	258.5		$	(10.9	)
Debt securities issued by foreign governments	—			4.0			—			(.1		)	—		—			3.9			—
Asset-backed securities	35.9			9.7			—			2.2			26.3		(13.7		)	60.4			—
Collateralized debt obligations	—			5.4			—			—			—		—			5.4			—
Commercial mortgage-backed securities	1.1			16.9			—			.1			13.9		—			32.0			—
Mortgage pass-through securities	.1			(.1		)	—			—			—		—			—			—
Total fixed maturities, available for sale	207.5			112.4			(10.7		)	11.3			60.5		(20.8		)	360.2			(10.9		)
Equity securities - corporate securities	32.0			5.5			(12.7		)	.4			—		—			25.2			(12.7		)
Trading securities - commercial mortgage-backed securities	39.9			—			—			—			—		(39.9		)	—			—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(1,057.1		)	(96.0		)	60.8			—			—		—			(1,092.3		)	60.8

____________

(a) Transfers into Level 3 are the result of unobservable inputs utilized within valuation methodologies for assets that were previously valued using observable inputs. Transfers out of Level 3 are due to the use of observable inputs in valuation methodologies as well as the utilization of pricing service information for certain assets that the Company is able to validate.

(b) Purchases, sales, issuances and settlements, net, represent the activity that occurred during the period that results in a change of the asset or liability but does not represent changes in fair value for the instruments held at the beginning of the period.  Such activity primarily consists of purchases and sales of fixed maturity and equity securities and changes to embedded derivative instruments related to insurance products resulting from the issuance of new contracts, or changes to existing contracts.  In addition, such activity includes the investments received upon the recapture of reinsurance agreements with BRe on September 29, 2016. The following summarizes such activity for the year ended December 31, 2016 (dollars in millions):

	Purchases			Received in reinsurance recapture		Sales			Issuances			Settlements		Purchases, sales, issuances and settlements, net
Assets:
Fixed maturities, available for sale:
Corporate securities	$	18.5		$	89.2	$	(31.2	)	$	—		$	—	$	76.5
Debt securities issued by foreign governments	4.0			—		—			—			—		4.0
Asset-backed securities	16.9			—		(7.2		)	—			—		9.7
Collateralized debt obligations	5.4			—		—			—			—		5.4
Commercial mortgage-backed securities	17.0			—		(.1		)	—			—		16.9
Mortgage pass-through securities	—			—		(.1		)	—			—		(.1		)
Total fixed maturities, available for sale	61.8			89.2		(38.6		)	—			—		112.4
Equity securities - corporate securities	3.3			2.2		—			—			—		5.5
Trading securities - corporate securities	.2			—		(.2		)	—			—		—
Liabilities:
Future policy benefits - embedded derivatives associated with fixed index annuity products	(148.3		)	—		21.2			(28.9		)	60.0		(96.0		)

Fair value inputs

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2017 (dollars in millions):

	Fair value at December 31, 2017		Valuation techniques	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	149.2	Discounted cash flow analysis	Discount margins	1.45% - 71.29% (6.96%)
Corporate securities (b)	2.8		Recovery method	Percent of recovery expected	0% - 21.73% (18.42%)
Asset-backed securities (c)	24.2		Discounted cash flow analysis	Discount margins	1.80% - 3.71% (2.67%)
Equity securities (d)	21.2		Market comparables	EBITDA multiples	1.1X - 8.9X (1.1X)
Other assets categorized as Level 3 (e)	87.2		Unadjusted third-party price source	Not applicable	Not applicable
Total	284.6
Liabilities:
Future policy benefits (f)	1,334.8		Discounted projected embedded derivatives	Projected portfolio yields	5.15% - 5.61% (5.60%)
				Discount rates	0.92 - 2.51% (2.00%)
				Surrender rates	1.20% - 46.40% (12.30%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected.  Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.

(c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is multiples of earnings before interest, taxes, depreciation and amortization ("EBITDA"). Generally, increases (decreases) in the EBITDA multiples would result in higher (lower) fair value measurements.

(e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

The following table provides additional information about the significant unobservable (Level 3) inputs developed internally by the Company to determine fair value for certain assets and liabilities carried at fair value at December 31, 2016 (dollars in millions):

	Fair value at December 31, 2016		Valuation techniques	Unobservable inputs	Range (weighted average)
Assets:
Corporate securities (a)	$	148.5	Discounted cash flow analysis	Discount margins	1.35% - 27.71% (13.52%)
Corporate securities (b)	14.8		Recovery method	Percent of recovery expected	5% - 69% (55%)
Asset-backed securities (c)	24.0		Discounted cash flow analysis	Discount margins	2.06% - 3.64% (2.76%)
Equity securities (d)	25.2		Market comparables	EBITDA multiples	0.4X - 6.2X (5.9X)
Other assets categorized as Level 3 (e)	172.9		Unadjusted third-party price source	Not applicable	Not applicable
Total	385.4
Liabilities:
Future policy benefits (f)	1,092.3		Discounted projected embedded derivatives	Projected portfolio yields	5.15% - 5.61% (5.59%)
				Discount rates	0.18 - 3.06% (2.07%)
				Surrender rates	0.94% - 46.48% (13.52%)

________________________________

(a) Corporate securities - The significant unobservable input used in the fair value measurement of our corporate securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(b) Corporate securities - The significant unobservable input used in the fair value measurement of these corporate securities is percentage of recovery expected. Significant increases (decreases) in percentage of recovery expected in isolation would result in a significantly higher (lower) fair value measurement.

(c) Asset-backed securities - The significant unobservable input used in the fair value measurement of these asset-backed securities is discount margin added to a riskless market yield. Significant increases (decreases) in discount margin in isolation would result in a significantly lower (higher) fair value measurement.

(d) Equity securities - The significant unobservable input used in the fair value measurement of these equity securities is EBITDA multiples. Generally, increases (decreases) in EBITDA multiples would result in higher (lower) fair value measurements.

(e) Other assets categorized as Level 3 - For these assets, there were no adjustments to quoted market prices obtained from third-party pricing sources.

(f) Future policy benefits - The significant unobservable inputs used in the fair value measurement of our embedded derivatives associated with fixed index annuity products are projected portfolio yields, discount rates and surrender rates. Increases (decreases) in projected portfolio yields in isolation would lead to a higher (lower) fair value measurement. The discount rate is based on the Treasury rate adjusted by a margin. Increases (decreases) in the discount rates would lead to a lower (higher) fair value measurement. Assumed surrender rates are used to project how long the contracts remain in force. Generally, the longer the contracts are assumed to be in force the higher the fair value of the embedded derivative.

XML

LIABILITIES FOR INSURANCE PRODUCTS (Tables)

12 Months Ended

Dec. 31, 2017

Insurance [Abstract]

Schedule of insurance liabilities by product segment

Our future policy benefits are summarized as follows (dollars in millions):

	Withdrawal assumption	Morbidity assumption	Mortality assumption	Interest rate assumption	2017		2016
Long-term care	Company experience	Company experience	Company experience	6%	$	5,669.0	$	5,346.1
Traditional life insurance contracts	Company experience	Company experience	(a)	5%	2,401.2		2,322.1
Accident and health contracts	Company experience	Company experience	Company experience	5%	2,812.0		2,695.6
Interest-sensitive life insurance contracts	Company experience	Company experience	Company experience	5%	44.9		52.2
Annuities and supplemental contracts with life contingencies	Company experience	Company experience	(b)	4%	594.2		537.3
Total					$	11,521.3	$	10,953.3

____________________

(a) Principally, modifications of: (i) the 1965 ‑ 70 and 1975 - 80 Basic Tables; and (ii) the 1941, 1958 and 1980 Commissioners' Standard Ordinary Tables; as well as Company experience.

(b) Principally, modifications of: (i) the 1971 Individual Annuity Mortality Table; (ii) the 1983 Table "A"; and (iii) the Annuity 2000 Mortality Table; as well as Company experience.

Our policyholder account balances are summarized as follows (dollars in millions):

	2017		2016
Fixed index annuities	$	5,942.2	$	5,324.5
Other annuities	4,183.8		4,541.8
Interest-sensitive life insurance contracts	1,094.7		1,046.4
Total	$	11,220.7	$	10,912.7

Summary of liabilities for unpaid claims adjustment expense

Changes in the unpaid claims reserve (included in claims payable) and disabled life reserves related to accident and health insurance (included in the liability for future policy benefits) were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	1,777.6		$	1,731.8		$	1,679.5
Less reinsurance (receivables) payables	14.0			(130.0		)	(125.0		)
Net balance, beginning of year	1,791.6			1,601.8			1,554.5
Incurred claims related to:
Current year	1,548.1			1,526.4			1,481.0
Prior years (a)	(26.7		)	96.6			(13.3		)
Total incurred	1,521.4			1,623.0			1,467.7
Interest on claim reserves	78.4			75.3			71.0
Paid claims related to:
Current year	845.5			837.2			841.8
Prior years	702.6			671.3			649.6
Total paid	1,548.1			1,508.5			1,491.4
Net balance, end of year	1,843.3			1,791.6			1,601.8
Add reinsurance receivables (payables)	(15.1		)	(14.0		)	130.0
Balance, end of year	$	1,828.2		$	1,777.6		$	1,731.8

___________

(a) The reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. Such amounts will fluctuate based upon the estimation procedures used to determine the amount of unpaid losses. It is possible that actual claims will exceed our reserves and have a material adverse effect on our results of operations and financial condition.

XML

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of components of income tax expense

The components of income tax expense (benefit) were as follows (dollars in millions):

	2017			2016			2015
Current tax expense (benefit)	$	90.8		$	(45.2	)	$	10.7
Deferred tax expense	72.0			173.0			118.6
Valuation allowance applicable to current year income	(15.3		)	(14.0		)	—
Income tax expense calculated based on annual effective tax rate	147.5			113.8			129.3
Income tax expense on discrete items:
Change in valuation allowance	(13.4		)	40.7			(32.5		)
Impact of federal tax reform	310.6			—			—
Change in valuation allowance related to federal tax reform	(138.1		)	—			—
IRS settlement	—			(170.4		)	—
Other items	(1.7		)	10.9			.2
Total income tax expense (benefit)	$	304.9		$	(5.0	)	$	97.0

Schedule of effective income tax rate reconciliation

A reconciliation of the U.S. statutory corporate tax rate to the effective rate reflected in the consolidated statement of operations is as follows:

	2017		2016		2015
U.S. statutory corporate rate	35.0	%	35.0	%	35.0	%
Valuation allowance	(6.0	)	7.6		(8.8	)
Non-taxable income and nondeductible benefits, net	(2.0	)	(1.1	)	(.2	)
State taxes	.6		2.2		2.1
Impact of federal tax reform	64.7		—		—
Change in valuation allowance related to federal tax reform	(28.8	)	—		—
Impact of IRS settlement	—		(48.2	)	—
Other items	—		3.1		(1.7	)
Effective tax rate	63.5	%	(1.4	)%	26.4	%

Schedule of deferred tax assets and liabilities

The components of the Company's income tax assets and liabilities are summarized below (dollars in millions):

	2017			2016
Deferred tax assets:
Net federal operating loss carryforwards	$	489.6		$	882.9
Net state operating loss carryforwards	9.3			12.3
Investments	4.3			17.8
Insurance liabilities	415.8			668.4
Other	48.9			66.3
Gross deferred tax assets	967.9			1,647.7
Deferred tax liabilities:
Present value of future profits and deferred acquisition costs	(165.4		)	(277.8		)
Accumulated other comprehensive income	(337.2		)	(344.1		)
Gross deferred tax liabilities	(502.6		)	(621.9		)
Net deferred tax assets before valuation allowance	465.3			1,025.8
Valuation allowance	(89.1		)	(240.2		)
Net deferred tax assets	376.2			785.6
Current income taxes prepaid (accrued)	(9.3		)	4.1
Income tax assets, net	$	366.9		$	789.7

Summary of valuation allowance

Changes in our valuation allowance are summarized as follows (dollars in millions):

Balance, December 31, 2014	$	246.0
Decrease in 2015	(32.5		)	(a)
Balance, December 31, 2015	213.5
Increase in 2016	26.7			(b)
Balance, December 31, 2016	240.2
Decrease in 2017	(166.8		)	(c)
Cumulative effect of accounting change	15.7			(d)
Balance, December 31, 2017	$	89.1

___________________

(a) The 2015 reduction to the deferred tax valuation allowance primarily resulted from higher actual and projected non-life income.

(b) The 2016 increase to the deferred tax valuation allowance primarily resulted from additional non-life NOLs due to the settlement with the Internal Revenue Service (the "IRS").

(c) The 2017 decrease to the deferred tax valuation allowance includes: (i) $138.1 million related to a reduction in the federal corporate income tax rate and other changes from the Tax Reform Act; (ii) $13.4 million of reductions to the deferred tax valuation allowance primarily related to the recognition of capital gains; and (iii) $15.3 million of reductions in the deferred tax valuation allowance reflecting higher current year taxable income than previously reflected in our deferred tax valuation model.

(d) Effective January 1, 2017, the Company adopted new authoritative guidance related to several aspects of the accounting for share-based payment transactions, including the income tax consequences. Under the new guidance, any excess tax benefits are recognized as an income tax benefit in the income statement. The new guidance is applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings for all tax benefits that were not previously recognized because the related tax deduction had not reduced taxes payable. The Company had NOL carryforwards of $15.7 million related to deductions for stock options and restricted stock on the date of adoption. However, a corresponding valuation allowance of $15.7 million was recognized as a result of adopting this guidance. Therefore, there was no impact to our consolidated financial statements related to the initial adoption of this provision of the new guidance.

Summary of operating loss carryforwards

As of December 31, 2017, we had $2.3 billion of federal NOLs (all of which were non-life NOLs). The following table summarizes the expiration dates of our loss carryforwards (dollars in millions):

	Net operating loss
Year of expiration	carryforwards
2023	$	1,744.8
2025	85.2
2026	149.9
2027	10.8
2028	80.3
2029	213.2
2030	.3
2031	.2
2032	44.4
2033	.6
2034	.9
2035	.8
Total federal NOLs	$	2,331.4

Reconciliation of unrecognized tax benefits

A reconciliation of the beginning and ending amount of unrecognized tax benefits for the year ended December 31, 2016 is as follows (dollars in millions):

	2016
Balance at beginning of year	$	234.2
Increase based on tax positions taken in prior years	3.4
Decrease in unrecognized tax benefits related to settlements with taxing authorities	(237.6		)
Balance at end of year	$	—

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of long-term debt instruments

The following notes payable were direct corporate obligations of the Company as of December 31, 2017 and 2016 (dollars in millions):

	2017			2016
4.500% Senior Notes due May 2020	$	325.0		$	325.0
5.250% Senior Notes due May 2025	500.0			500.0
Revolving Credit Agreement (as defined below)	100.0			100.0
Unamortized debt issuance costs	(10.4		)	(12.1		)
Direct corporate obligations	$	914.6		$	912.9

Schedule of maturities of long-term debt

The scheduled repayment of our direct corporate obligations was as follows at December 31, 2017 (dollars in millions):

Year ending December 31,
2018	$	—
2019	100.0		(a)
2020	325.0
2021	—
2022	—
Thereafter	500.0
	$	925.0

_________________________

(a) The maturity date of the Revolving Credit Agreement is the earlier of October 13, 2022 and the date that is six months prior to the maturity date of the Company’s 4.50% senior notes due 2020, which is November 30, 2019.

XML

LITIGATION AND OTHER LEGAL PROCEEDINGS (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum rental payments for operating leases

Future required minimum payments as of December 31, 2017, were as follows (dollars in millions):

2018	$	33.5
2019	18.2
2020	11.8
2021	8.0
2022	5.6
Thereafter	3.6
Total	$	80.7

XML

AGENT DEFERRED COMPENSATION PLAN (Tables)

12 Months Ended

Dec. 31, 2017

Retirement Benefits [Abstract]

Schedule of assumptions used

We used the following assumptions for the deferred compensation plan to calculate:

	2017		2016
Benefit obligations:
Discount rate	3.75	%	4.25	%
Net periodic cost:
Discount rate	4.25	%	4.50	%

Schedule of expected benefit payments

The benefits expected to be paid pursuant to our agent deferred compensation plan as of December 31, 2017 were as follows (dollars in millions):

2018	$	7.4
2019	7.6
2020	7.9
2021	8.0
2022	8.3
2023 - 2027	45.2

XML

DERIVATIVES (Tables)

12 Months Ended

Dec. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Fair value by balance sheet location

Our freestanding and embedded derivatives, which are not designated as hedging instruments, are held at fair value and are summarized as follows (dollars in millions):

	Fair value
	2017			2016
Assets:
Other invested assets:
Fixed index call options	$	170.2		$	111.9
Reinsurance receivables	(1.4		)	(4.2		)
Total assets	$	168.8		$	107.7
Liabilities:
Future policy benefits:
Fixed index products	$	1,334.8		$	1,092.3
Total liabilities	$	1,334.8		$	1,092.3

Schedule of derivative instruments

The following table represents activity associated with derivative instruments as of the dates indicated:

	Measurement	December 31, 2016		Additions		Maturities/terminations			December 31, 2017
Fixed index annuities - embedded derivative	Policies	100,812		11,437		(7,560		)	104,689
Fixed index call options	Notional (a)	$	2,455.1	$	3,021.8	$	(2,471.1	)	$	3,005.8

_________________

(a) Dollars in millions.

Schedule pre-tax gains (losses) recognized in net income for derivative instruments

The following table provides the pre-tax gains (losses) recognized in net income for derivative instruments, which are not designated as hedges for the periods indicated (dollars in millions):

	2017		2016			2015
Net investment income from policyholder and other special-purpose portfolios:
Fixed index call options	$	162.5	$	29.2		$	(36.2	)
Net realized gains (losses):
Interest rate futures	—		(1.1		)	(2.7		)
Embedded derivative related to modified coinsurance agreement	2.8		.8			(7.0		)
Total	2.8		(.3		)	(9.7		)
Insurance policy benefits:
Embedded derivative related to fixed index annuities	25.0		60.8			36.3
Total	$	190.3	$	89.7		$	(9.6	)

Derivatives with master netting arrangements

The following table summarizes information related to derivatives with master netting arrangements or collateral as of December 31, 2017 and 2016 (dollars in millions):

								Gross amounts not offset in the balance sheet
		Gross amounts recognized		Gross amounts offset in the balance sheet		Net amounts of assets presented in the balance sheet		Financial instruments		Cash collateral received		Net amount
December 31, 2017:
	Fixed index call options	$	170.2	$	—	$	170.2	$	—	$	—	$	170.2
December 31, 2016:
	Fixed index call options	111.9		—		111.9		—		—		111.9

XML

SHAREHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of common stock outstanding

Changes in the number of shares of common stock outstanding were as follows (shares in thousands):

	2017		2016		2015
Balance, beginning of year	173,754		184,029		203,324
Treasury stock purchased and retired	(7,808	)	(11,688	)	(20,582	)
Stock options exercised	725		978		769
Restricted and performance stock vested (a)	187		435		518
Balance, end of year	166,858		173,754		184,029

____________________

(a) In 2017, 2016 and 2015, such amount was reduced by 103 thousand, 191 thousand and 237 thousand shares, respectively, which were tendered to the Company for the payment of required federal and state tax withholdings owed on the vesting of restricted and performance stock.

Schedule of share-based compensation

A summary of the Company's stock option activity and related information for 2017 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,354		$	14.73
Options granted	729		21.06
Exercised	(237	)	(17.81		)		$	5.2
Forfeited or terminated	(725	)	(11.43		)
Outstanding at the end of the year	5,121		15.95			5.4	$	37.2
Options exercisable at the end of the year	2,440					3.0	$	19.2
Available for future grant	7,488

A summary of the Company's stock option activity and related information for 2016 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,199		$	13.32
Options granted	1,706		17.45
Exercised	(978	)	(8.70		)		$	6.1
Forfeited or terminated	(573	)	(20.41		)
Outstanding at the end of the year	5,354		14.73			5.9	$	37.1
Options exercisable at the end of the year	2,187					2.7	$	15.1
Available for future grant	4,620

A summary of the Company's stock option activity and related information for 2015 is presented below (shares in thousands; dollars in millions, except per share amounts):

	Shares		Weighted average exercise price			Weighted average remaining life (in years)	Aggregate intrinsic value
Outstanding at the beginning of the year	5,011		$	12.04
Options granted	1,361		16.45
Exercised	(769	)	(8.20		)		$	4.8
Forfeited or terminated	(404	)	(17.70		)
Outstanding at the end of the year	5,199		13.32			4.8	$	38.4
Options exercisable at the end of the year	2,399					2.5	$	15.3
Available for future grant	6,882

Schedule of valuation assumptions on payment awards

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions:

	2017			2016			2015
	Grants			Grants			Grants
Weighted average risk-free interest rates	2.2		%	1.4		%	1.7		%
Weighted average dividend yields	1.5		%	1.6		%	1.5		%
Volatility factors	32		%	36		%	85		%
Weighted average expected life (in years)	6.3			6.3			6.3
Weighted average fair value per share	$	6.20		$	5.48		$	10.83

Schedule of share-based compensation by exercise price range

The following table summarizes information about stock options outstanding at December 31, 2017 (shares in thousands):

		Options outstanding			Options exercisable
Range of exercise prices	Number outstanding	Remaining life (in years)	Average exercise price		Number exercisable	Average exercise price
$6.77 - $7.51	605	0.9	$	7.47	605	$	7.47
$10.88 - $16.22	683	2.3	11.12		670	11.02
$16.42 - $21.48	3,833	6.7	18.15		1,165	18.04
	5,121				2,440

Schedule of nonvested share activity

A summary of the Company's non-vested restricted stock activity for 2017 is presented below (shares in thousands):

	Shares		Weighted average grant date fair value
Non-vested shares, beginning of year	369		$	18.10
Granted	330		20.87
Vested	(147	)	(18.38		)
Forfeited	(17	)	(20.59		)
Non-vested shares, end of year	535		19.65

Schedule of performance share-based compensation

A summary of the Company's performance units is presented below (shares in thousands):

	Total shareholder return awards		Operating return on equity awards		Pre-tax operating income awards
Awards outstanding at December 31, 2014	519		343		176
Granted in 2015	258		258		—
Additional shares issued pursuant to achieving certain performance criteria (a)	85		—		85
Shares vested in 2015	(260	)	—		(260	)
Forfeited	(53	)	(52	)	(1	)
Awards outstanding at December 31, 2015	549		549		—
Granted in 2016	254		254		—
Additional shares issued pursuant to achieving certain performance criteria (a)	87		65		—
Shares vested in 2016	(261	)	(239	)	—
Forfeited	(59	)	(59	)	—
Awards outstanding at December 31, 2016	570		570		—
Granted in 2017	226		226		—
Additional shares issued pursuant to achieving certain performance criteria (a)	—		30		—
Shares vested in 2017	—		(144	)	—
Forfeited	(167	)	(53	)	—
Awards outstanding at December 31, 2017	629		629		—

_________________________

(a) The performance units that vested in these years provided for a payout of up to 150 percent of the award if certain performance levels were achieved.

Schedule of earnings per share reconciliation

A reconciliation of net income and shares used to calculate basic and diluted earnings per share is as follows (dollars in millions and shares in thousands):

	2017		2016		2015
Net income for diluted earnings per share	$	175.6	$	358.2	$	270.7
Shares:
Weighted average shares outstanding for basic earnings per share	170,025		176,638		193,054
Effect of dilutive securities on weighted average shares:
Stock options, restricted stock and performance units	2,119		1,685		2,112
Weighted average shares outstanding for diluted earnings per share	172,144		178,323		195,166

XML

OTHER OPERATING STATEMENT DATA (Tables)

12 Months Ended

Dec. 31, 2017

Insurance [Abstract]

Schedule of insurance policy income

Insurance policy income consisted of the following (dollars in millions):

	2017			2016			2015
Direct premiums collected	$	4,013.4		$	3,942.7		$	3,769.6
Reinsurance assumed	30.2			33.8			38.4
Reinsurance ceded	(114.4		)	(132.9		)	(142.8		)
Premiums collected, net of reinsurance	3,929.2			3,843.6			3,665.2
Change in unearned premiums	19.0			6.2			5.9
Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities	(1,445.9		)	(1,386.7		)	(1,241.9		)
Premiums on traditional products with mortality or morbidity risk	2,502.3			2,463.1			2,429.2
Fees and surrender charges on interest-sensitive products	145.0			138.0			126.8
Insurance policy income	$	2,647.3		$	2,601.1		$	2,556.0

Schedule of other operating cost and expense

Other operating costs and expenses were as follows (dollars in millions):

	2017		2016		2015
Commission expense	$	115.6	$	110.5	$	103.8
Salaries and wages	237.3		231.0		205.2
Other	488.6		454.8		430.2
Total other operating costs and expenses	$	841.5	$	796.3	$	739.2

Schedule of changes in present value of future insurance profits

Changes in the present value of future profits were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	401.8		$	449.0		$	489.4
Amortization	(54.4		)	(62.2		)	(69.1		)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	12.2			15.0			28.7
Balance, end of year	$	359.6		$	401.8		$	449.0

Schedule of changes in deferred acquisition costs

Changes in deferred acquisition costs were as follows (dollars in millions):

	2017			2016			2015
Balance, beginning of year	$	1,044.7		$	1,083.3		$	770.6
Additions	236.1			242.7			246.4
Amortization	(184.9		)	(191.1		)	(190.9		)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	(69.1		)	(90.2		)	257.2
Balance, end of year	$	1,026.8		$	1,044.7		$	1,083.3

XML

CONSOLIDATED STATEMENT CASH FLOWS (Tables)

12 Months Ended

Dec. 31, 2017

Supplemental Cash Flow Elements [Abstract]

Schedule of the reconciliation for net income provided by operating activities

The following reconciles net income to net cash provided by operating activities (dollars in millions):

	2017			2016			2015
Cash flows from operating activities:
Net income	$	175.6		$	358.2		$	270.7
Adjustments to reconcile net income to net cash from operating activities:
Amortization and depreciation	265.4			275.0			283.4
Income taxes	227.5			(11.7		)	92.9
Insurance liabilities	464.7			332.8			297.4
Accrual and amortization of investment income	(321.6		)	(124.2		)	(27.6		)
Deferral of policy acquisition costs	(236.1		)	(242.7		)	(246.4		)
Net realized investment (gains) losses	(50.3		)	(8.3		)	36.6
Loss on reinsurance transactions and transition expenses	—			75.4			9.0
Cash and cash equivalents received upon recapture of reinsurance	—			73.6			—
Loss on extinguishment of borrowings related to variable interest entities	9.5			—			—
Loss on extinguishment of debt	—			—			32.8
Other	78.4			34.7			(1.0		)
Net cash from operating activities	$	613.1		$	762.8		$	747.8

Schedule of other significant noncash transactions

Other non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows (dollars in millions):

	2017		2016		2015
Stock options, restricted stock and performance units	$	21.4	$	23.0	$	17.1
Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe	—		431.1		—

XML

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES) (Tables)

12 Months Ended

Dec. 31, 2017

Insurance [Abstract]

Schedule of statutory accounting practices

The Company's insurance subsidiaries reported the following amounts to regulatory agencies, after appropriate elimination of intercompany accounts among such subsidiaries (dollars in millions):

	2017		2016
Statutory capital and surplus	$	1,904.4	$	1,956.8
Asset valuation reserve	246.8		253.3
Interest maintenance reserve	487.0		486.9
Total	$	2,638.2	$	2,697.0

XML

BUSINESS SEGMENTS (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Schedule of segment reporting information by segment

Operating information by segment was as follows (dollars in millions):

	2017		2016		2015
Revenues:
Bankers Life:
Insurance policy income:
Annuities	$	20.3	$	22.0	$	22.4
Health	1,231.1		1,244.1		1,251.0
Life	415.2		393.0		375.3
Net investment income (a)	1,107.3		936.8		884.7
Fee revenue and other income (a)	44.1		34.4		27.7
Total Bankers Life revenues	2,818.0		2,630.3		2,561.1
Washington National:
Insurance policy income:
Annuities	2.1		2.9		3.0
Health	642.9		627.9		615.4
Life	26.4		25.0		25.4
Net investment income (a)	270.2		259.3		253.6
Fee revenue and other income (a)	1.0		1.3		1.3
Total Washington National revenues	942.6		916.4		898.7
Colonial Penn:
Insurance policy income:
Health	2.1		2.6		3.0
Life	289.7		278.8		260.5
Net investment income (a)	44.4		44.2		43.0
Fee revenue and other income (a)	1.3		1.1		1.0
Total Colonial Penn revenues	337.5		326.7		307.5
Long-term care in run-off:
Insurance policy income - health	17.5		4.8		—
Net investment income (a)	34.6		9.4		—
Total Long-term care in run-off revenues	52.1		14.2		—
Corporate operations:
Net investment income	35.5		16.6		11.3
Fee revenue and other income	8.5		10.0		8.6
Total corporate revenues	44.0		26.6		19.9
Total revenues	$	4,194.2	$	3,914.2	$	3,787.2

(continued on next page)

(continued from previous page)

	2017			2016			2015
Expenses:
Bankers Life:
Insurance policy benefits	$	1,771.8		$	1,620.6		$	1,588.4
Amortization	163.6			176.5			187.1
Interest expense on investment borrowings	19.8			13.2			8.8
Other operating costs and expenses	443.9			422.1			407.2
Total Bankers Life expenses	2,399.1			2,232.4			2,191.5
Washington National:
Insurance policy benefits	581.1			561.7			546.6
Amortization	58.8			59.1			55.2
Interest expense on investment borrowings	6.3			3.7			2.0
Other operating costs and expenses	198.1			189.0			183.4
Total Washington National expenses	844.3			813.5			787.2
Colonial Penn:
Insurance policy benefits	199.6			201.9			189.0
Amortization	16.3			15.3			14.4
Interest expense on investment borrowings	.9			.6			.1
Other operating costs and expenses	98.1			107.2			98.4
Total Colonial Penn expenses	314.9			325.0			301.9
Long-term care in run-off:
Insurance policy benefits	47.3			17.6			—
Other operating costs and expenses	3.1			.5			—
Total Long-term care in run-off expenses	50.4			18.1			—
Corporate operations:
Interest expense on corporate debt	46.5			45.8			45.0
Interest expense on investment borrowings	—			—			.2
Other operating costs and expenses	84.3			69.1			38.6
Total corporate expenses	130.8			114.9			83.8
Total expenses	3,739.5			3,503.9			3,364.4
Pre-tax operating earnings by segment:
Bankers Life	418.9			397.9			369.6
Washington National	98.3			102.9			111.5
Colonial Penn	22.6			1.7			5.6
Long-term care in run-off	1.7			(3.9		)	—
Corporate operations	(86.8		)	(88.3		)	(63.9		)
Pre-tax operating earnings	$	454.7		$	410.3		$	422.8

___________________

(a) It is not practicable to provide additional components of revenue by product or services.

Reconciliation of operating profit (loss) from segments to consolidated

A reconciliation of segment revenues and expenses to consolidated revenues and expenses and net income is as follows (dollars in millions):

	2017			2016			2015
Total segment revenues	$	4,194.2		$	3,914.2		$	3,787.2
Net realized investment gains (losses)	50.3			8.3			(36.6		)
Revenues related to certain non-strategic investments and earnings attributable to VIEs	52.7			52.6			36.3
Fee revenue related to transition and support services agreements	—			10.0			25.0
Consolidated revenues	4,297.2			3,985.1			3,811.9
Total segment expenses	3,739.5			3,503.9			3,364.4
Insurance policy benefits - fair value changes in embedded derivative liabilities	2.9			(11.3		)	(15.7		)
Amortization related to fair value changes in embedded derivative liabilities	(.4		)	1.7			3.8
Amortization related to net realized investment gains (losses)	1.0			.7			(.5		)
Expenses related to certain non-strategic investments and expenses attributable to VIEs	61.5			54.6			43.0
Fair value changes and amendment related to agent deferred compensation plan	12.2			(3.1		)	(15.1		)
Loss on extinguishment of debt	—			—			32.8
Loss on reinsurance transaction and transition expenses	—			75.4			9.0
Expenses related to transition and support services agreements	—			10.0			22.5
Consolidated expenses	3,816.7			3,631.9			3,444.2
Income before tax	480.5			353.2			367.7
Income tax expense:
Tax expense on period income	162.8			127.8			129.5
Valuation allowance for deferred tax assets and other tax items	142.1			(132.8		)	(32.5		)
Net income	$	175.6		$	358.2		$	270.7

Schedule of balance sheet information, by segment

Segment balance sheet information was as follows (dollars in millions):

	2017		2016
Assets:
Bankers Life	$	21,134.9	$	19,876.4
Washington National	7,674.3		7,555.7
Colonial Penn	1,059.3		1,022.9
Long-term care in run-off	692.9		656.2
Corporate operations	2,548.9		2,864.0
Total assets	$	33,110.3	$	31,975.2
Liabilities:
Bankers Life	$	18,031.6	$	17,144.9
Washington National	6,101.5		6,096.9
Colonial Penn	921.0		898.5
Long-term care in run-off	580.4		562.2
Corporate operations	2,628.3		2,785.8
Total liabilities	$	28,262.8	$	27,488.3

Schedule of selected financial information, by segment

The following table presents selected financial information of our segments (dollars in millions):

Segment	Present value of future profits		Deferred acquisition costs		Insurance liabilities
2017
Bankers Life	$	81.1	$	606.5	$	16,541.2
Washington National	243.7		310.8		5,590.7
Colonial Penn	34.8		109.5		834.4
Long-term care in run-off	—		—		572.7
Total	$	359.6	$	1,026.8	$	23,539.0
2016
Bankers Life	$	95.5	$	646.2	$	15,702.8
Washington National	266.8		299.9		5,586.7
Colonial Penn	39.5		98.6		809.6
Long-term care in run-off	—		—		554.7
Total	$	401.8	$	1,044.7	$	22,653.8

XML

QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Data [Abstract]

Schedule of quarterly financial information

Quarterly financial data (unaudited) were as follows (dollars in millions, except per share data):

2017	1st Qtr.			2nd Qtr.		3rd Qtr.		4th Qtr. (a)
Revenues	$	1,070.7		$	1,057.1	$	1,079.3	$	1,090.1
Income before income taxes	$	96.7		$	128.5	$	129.9	$	125.4
Income tax expense	34.4			45.1		29.1		196.3
Net income (loss)	$	62.3		$	83.4	$	100.8	$	(70.9	)
Earnings per common share:
Basic:
Net income (loss)	$	.36		$	.49	$	.60	$	(.42	)
Diluted:
Net income (loss)	$	.36		$	.48	$	.59	$	(.42	)
2016	1st Qtr.			2nd Qtr.		3rd Qtr.		4th Qtr.
Revenues	$	960.4		$	1,003.9	$	1,015.9	$	1,004.9
Income before income taxes	$	40.5		$	82.7	$	49.3	$	180.7
Income tax expense (benefit)	(5.0		)	22.8		30.7		(53.5		)
Net income	$	45.5		$	59.9	$	18.6	$	234.2
Earnings per common share:
Basic:
Net income	$	.25		$	.34	$	.11	$	1.35
Diluted:
Net income	$	.25		$	.33	$	.11	$	1.34

___________________

(a) In the fourth quarter of 2017, our net loss reflected the unfavorable impact of $172.5 million related to the Tax Reform Act which was enacted in December 2017.

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES (Tables)

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of impact on balance sheet of consolidating variable interest entities

The following table provides supplemental information about the assets and liabilities of the VIEs which have been consolidated (dollars in millions):

	December 31, 2017
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	1,526.9	$	—		$	1,526.9
Notes receivable of VIEs held by insurance subsidiaries	—		(155.5		)	(155.5		)
Cash and cash equivalents held by variable interest entities	178.9		—			178.9
Accrued investment income	2.6		(.1		)	2.5
Income tax assets, net	.7		—			.7
Other assets	10.0		(1.5		)	8.5
Total assets	$	1,719.1	$	(157.1	)	$	1,562.0
Liabilities:
Other liabilities	$	158.3	$	(4.4	)	$	153.9
Borrowings related to variable interest entities	1,410.7		—			1,410.7
Notes payable of VIEs held by insurance subsidiaries	167.6		(167.6		)	—
Total liabilities	$	1,736.6	$	(172.0	)	$	1,564.6

	December 31, 2016
	VIEs		Eliminations			Net effect on consolidated balance sheet
Assets:
Investments held by variable interest entities	$	1,724.3	$	—		$	1,724.3
Notes receivable of VIEs held by insurance subsidiaries	—		(204.2		)	(204.2		)
Cash and cash equivalents held by variable interest entities	189.3		—			189.3
Accrued investment income	3.0		(.1		)	2.9
Income tax assets, net	6.4		(1.3		)	5.1
Other assets	13.1		(1.8		)	11.3
Total assets	$	1,936.1	$	(207.4	)	$	1,728.7
Liabilities:
Other liabilities	$	81.8	$	(6.4	)	$	75.4
Borrowings related to variable interest entities	1,662.8		—			1,662.8
Notes payable of VIEs held by insurance subsidiaries	203.3		(203.3		)	—
Total liabilities	$	1,947.9	$	(209.7	)	$	1,738.2

Supplemental information, revenues and expenses of variable interest entities

The following table provides supplemental information about the revenues and expenses of the VIEs which have been consolidated in accordance with authoritative guidance, after giving effect to the elimination of our investment in the VIEs and investment management fees earned by a subsidiary of the Company (dollars in millions):

	2017			2016			2015
Revenues:
Net investment income – policyholder and other special-purpose portfolios	$	69.8		$	78.9		$	62.1
Fee revenue and other income	5.9			6.4			1.6
Total revenues	75.7			85.3			63.7
Expenses:
Interest expense	50.2			53.1			38.8
Other operating expenses	1.8			1.5			2.0
Total expenses	52.0			54.6			40.8
Income before net realized investment losses and income taxes	23.7			30.7			22.9
Net realized investment losses	(5.6		)	(20.4		)	(6.4		)
Loss on extinguishment of borrowings	(9.5		)	—			—
Income before income taxes	$	8.6		$	10.3		$	16.5

Summary of variable interest entities by contractual maturity

The following table sets forth the amortized cost and estimated fair value of the investments held by the VIEs at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	11.2	$	11.2
Due after one year through five years	541.8		542.0
Due after five years through ten years	971.9		973.7
Total	$	1,524.9	$	1,526.9

The following table sets forth the amortized cost and estimated fair value of those investments held by the VIEs with unrealized losses at December 31, 2017, by contractual maturity.  Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

	Amortized cost		Estimated fair value
	(Dollars in millions)
Due in one year or less	$	2.4	$	2.4
Due after one year through five years	178.2		174.3
Due after five years through ten years	299.8		297.1
Total	$	480.4	$	473.8

XML

BUSINESS AND BASIS OF PRESENTATION (NARRATIVE) (Details)	12 Months Ended
	Dec. 31, 2017 distribution_channel
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of product distribution channels	3

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (PRESENT VALUE OF FUTURE PROFITS) (Details)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Discount rate used to determine present value of future profits	12.00%

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (REINSURANCE) (Details) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2013 USD ($) subsidiary	Dec. 31, 2017 USD ($) subsidiary	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2016 USD ($)
Accounting Policies [Abstract]
Company retains no more than this amount of mortality risk		$ 0.8
Ceded premiums written		105.0	$ 123.9	$ 133.6
Reinsurance benefits netted against insurance policy benefits		88.6	130.1	167.7
Assumed premiums written		30.4	34.0	38.5
Insurance policy benefits related to reinsurance assumed		$ 44.7	$ 47.5	$ 48.0
Number of insurance subsidiaries | subsidiary	2	3
Percent of coinsurance agreements	100.00%
Ceded long-term reserves	$ 495.0
Additional premiums paid by subsidiaries to enter into coinsurance agreement	$ 96.9
Over-collateralization rate of market-value trusts	7.00%
Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures [Abstract]
Market value of investments					$ 504.7
Insurance liabilities					(552.2)
Write-off of reinsurance receivables					(17.9)
Estimated transaction expenses					(10.0)
Pre-tax loss					(75.4)
Tax benefit					26.4
Increase in valuation allowance for deferred tax assets					(4.1)
After-tax loss					$ (53.1)

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (INCOME TAXES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Valuation allowance for deferred income tax assets	$ 89.1	$ 255.9	$ 240.2	$ 213.5	$ 246.0

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (INVESTMENTS IN VARIABLE INTEREST ENTITIES) (Details) $ in Millions	Dec. 31, 2017 USD ($)
Accounting Policies [Abstract]
Investments held in limited partnerships	$ 371.1
Unfunded commitments to limited partnerships	$ 276.5

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (INVESTMENT BORROWINGS) (Details) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2013 subsidiary	Dec. 31, 2017 USD ($) subsidiary	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Number of insurance subsidiaries | subsidiary	2	3
Investment borrowings		$ 1,646.7	$ 1,647.4
Interest expense on FHLB borrowings		27.0	$ 17.5	$ 10.9
Federal Home Loan Bank Advances
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Federal home loan bank stock		71.2
Investment borrowings		1,646.7
Fair value of collateral for borrowings		1,900.0
Aggregate fee to prepay all fixed rate FHLB borrowings		2.1
Federal Home Loan Bank Advances | Borrowings due January 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Jan. 31, 2019
Interest rate		1.779%
Federal Home Loan Bank Advances | Borrowings due February 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Feb. 28, 2019
Interest rate		1.509%
Federal Home Loan Bank Advances | Borrowings due March 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100.0
Maturity date		Mar. 31, 2019
Interest rate		1.971%
Federal Home Loan Bank Advances | Borrowings due July 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 21.8
Maturity date		Jul. 31, 2019
Interest rate		2.001%
Federal Home Loan Bank Advances | Borrowings due October 2019
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 15.0
Maturity date		Oct. 31, 2019
Interest rate		1.887%
Federal Home Loan Bank Advances | Borrowing due May 2020
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		May 31, 2020
Interest rate		1.997%
Federal Home Loan Bank Advances | Borrowings due June 2020
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 21.8
Maturity date		Jun. 30, 2020
Interest rate		1.96%
Federal Home Loan Bank Advances | Borrowing due September 2020, Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 25.0
Maturity date		Sep. 30, 2020
Interest rate		2.30%
Federal Home Loan Bank Advances | Borrowings due September 2020, Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100.0
Maturity date		Sep. 30, 2020
Interest rate		2.212%
Federal Home Loan Bank Advances | Borrowings due September 2020, Rate Three
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Sep. 30, 2020
Interest rate		2.224%
Federal Home Loan Bank Advances | Borrowings due September 2020, Rate Four
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 75.0
Maturity date		Sep. 30, 2020
Interest rate		1.813%
Federal Home Loan Bank Advances | Borrowings due October 2020
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100.0
Maturity date		Oct. 31, 2020
Interest rate		1.453%
Federal Home Loan Bank Advances | Borrowings due December 2020
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Dec. 31, 2020
Interest rate		2.072%
Federal Home Loan Bank Advances | Borrowings Due July 2021
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100.0
Maturity date		Jul. 31, 2021
Interest rate		1.909%
Federal Home Loan Bank Advances | Borrowings due July 2021 Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100.0
Maturity date		Jul. 31, 2021
Interest rate		1.879%
Federal Home Loan Bank Advances | Borrowings Due August 2021, Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 57.7
Maturity date		Aug. 31, 2021
Interest rate		1.921%
Federal Home Loan Bank Advances | Borrowings Due August 2021, Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 28.2
Maturity date		Aug. 31, 2021
Interest rate		2.55%
Federal Home Loan Bank Advances | Borrowings Due August 2021, Rate Three
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 125.0
Maturity date		Aug. 31, 2021
Interest rate		2.032%
Federal Home Loan Bank Advances | Borrowings Due September 2021
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Sep. 30, 2021
Interest rate		2.002%
Federal Home Loan Bank Advances | Borrowings Due May 2022, Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 22.0
Maturity date		May 31, 2022
Interest rate		1.829%
Federal Home Loan Bank Advances | Borrowings Due May 2022, Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 100.0
Maturity date		May 31, 2022
Interest rate		1.78%
Federal Home Loan Bank Advances | Borrowings Due June 2022
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 10.0
Maturity date		Jun. 30, 2022
Interest rate		2.15%
Federal Home Loan Bank Advances | Borrowings Due July 2022 Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Jul. 31, 2022
Interest rate		1.726%
Federal Home Loan Bank Advances | Borrowings Due July 2022 Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Jul. 31, 2022
Interest rate		1.745%
Federal Home Loan Bank Advances | Borrowings Due July 2022 Rate 3
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Jul. 31, 2022
Interest rate		1.758%
Federal Home Loan Bank Advances | Borrowings Due August 2022
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Aug. 31, 2022
Interest rate		1.782%
Federal Home Loan Bank Advances | Borrowings Due December 2022, Rate One
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Dec. 31, 2022
Interest rate		1.795%
Federal Home Loan Bank Advances | Borrowings Due December 2022, Rate Two
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 50.0
Maturity date		Dec. 31, 2022
Interest rate		1.795%
Federal Home Loan Bank Advances | Borrowings due March 2023
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 24.7
Maturity date		Mar. 31, 2023
Interest rate		2.16%
Federal Home Loan Bank Advances | Borrowings due June 2025
Federal Home Loan Bank, Advances, Branch of FHLB Bank [Line Items]
Investment borrowings		$ 20.5
Maturity date		Jun. 30, 2025
Interest rate		2.94%

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (MULTIBUCKET ANNUITY PRODUCTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Return of premium annual percentage, multibucket annuity	3.00%
Insurance liabilities held, related to multibucket annuity products	$ 32.3	$ 32.8

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (SALE OF INDUCEMENTS) (NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Deferred sales inducements	$ 2.0	$ 3.4	$ 3.8
Deferred sales inducements, amortization expense	8.9	11.4	$ 13.8
Unamortized deferred sales inducements	42.5	49.4
Insurance liabilities for persistency bonus benefits	$ 0.3	$ 0.5

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (OUT-OF-PERIOD ADJUSTMENTS) (NARRATIVE) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease to Insurance policy benefits									$ (2,602.7)	$ (2,390.5)	$ (2,308.3)
Other operating costs and expenses									(841.5)	(796.3)	(739.2)
Increase in income tax expense	$ (196.3)	$ (29.1)	$ (45.1)	$ (34.4)	$ 53.5	$ (30.7)	$ (22.8)	$ 5.0	(304.9)	5.0	(97.0)
Out of period adjustment, effect on net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	$ 175.6	$ 358.2	$ 270.7
Adjustment to earnings per diluted share (in dollars per share)	$ (0.42)	$ 0.59	$ 0.48	$ 0.36	$ 1.34	$ 0.11	$ 0.33	$ 0.25	$ 1.02	$ 2.01	$ 1.39
Restatement Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease to Insurance policy benefits									$ (4.2)
Other operating costs and expenses									2.0
Increase in income tax expense									0.8
Out of period adjustment, effect on net income									$ 1.4
Adjustment to earnings per diluted share (in dollars per share)									$ 0.01

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	$ 0.0
Cumulative effect of accounting change		$ 0.3
Revenue | Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk, percentage	1.00%
Retained earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	$ (205.4)
Cumulative effect of accounting change		$ (0.6)
Retained earnings | Pro Forma | Accounting Standards Update 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of accounting change	17.0
Accumulated other comprehensive income
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of stranded income tax effects from the Tax Cuts and Jobs Act	205.4
Accumulated other comprehensive income | Pro Forma | Accounting Standards Update 2016-01
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of accounting change	$ (17.0)

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENT BALANCE SHEET iNFO) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax assets	$ 967.9	$ 1,045.9	$ 1,647.7
Valuation allowance for deferred income tax assets	(89.1)	(255.9)	(240.2)	$ (213.5)	$ (246.0)
Net deferred tax assets	376.2	790.0	785.6
Total assets	33,110.3	31,975.5	31,975.2
Additional paid-in capital	3,073.3	3,213.0	3,212.1
Retained earnings	560.4	650.1	650.7
Total shareholders' equity	4,847.5	4,487.2	4,486.9	$ 4,138.5	$ 4,688.2
Total liabilities and shareholders' equity	$ 33,110.3	31,975.5	$ 31,975.2
Amounts prior to effect of adoption of authoritative guidance
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax assets		1,029.9
Valuation allowance for deferred income tax assets		(240.2)
Net deferred tax assets		789.7
Total assets		31,975.2
Additional paid-in capital		3,212.1
Retained earnings		650.7
Total shareholders' equity		4,486.9
Total liabilities and shareholders' equity		31,975.2
Election to account for forfeitures as they occur
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax assets		0.3
Valuation allowance for deferred income tax assets		0.0
Net deferred tax assets		0.3
Total assets		0.3
Additional paid-in capital		0.9
Retained earnings		(0.6)
Total shareholders' equity		0.3
Total liabilities and shareholders' equity		0.3
Recognition of excess tax benefits
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Income tax assets		15.7
Valuation allowance for deferred income tax assets		15.7
Net deferred tax assets		0.0
Total assets		0.0
Additional paid-in capital		0.0
Retained earnings		0.0
Total shareholders' equity		0.0
Total liabilities and shareholders' equity		$ 0.0

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENT CASH FLOW INFO) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Other operating costs	$ (740.9)	$ (747.9)	$ (720.5)
Cash flows from operating activities	613.1	762.8	747.8
Cash flows from financing activities:
Payments to repurchase common stock	(168.3)	(210.0)	(365.4)
Net cash provided by financing activities	(274.0)	26.2	142.5
Net increase in cash and cash equivalents	$ 99.5	46.6	(179.3)
Amounts prior to effect of adoption of authoritative guidance
Cash flows from operating activities:
Other operating costs		(751.2)	(724.4)
Cash flows from operating activities		759.5	743.9
Cash flows from financing activities:
Payments to repurchase common stock		(206.7)	(361.5)
Net cash provided by financing activities		29.5	146.4
Net increase in cash and cash equivalents		46.6	(179.3)
Effect of adoption of authoritative guidance
Cash flows from operating activities:
Other operating costs		3.3	3.9
Cash flows from operating activities		3.3	3.9
Cash flows from financing activities:
Payments to repurchase common stock		(3.3)	(3.9)
Net cash provided by financing activities		(3.3)	(3.9)
Net increase in cash and cash equivalents		$ 0.0	$ 0.0

XML

INVESTMENTS (SCHEDULE OF FIXED MATURITIES FOR AVAILABLE FOR SALE AND EQUITY SECURITIES) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 20,702.1	$ 19,803.1
Gross unrealized gains	2,251.3	1,487.4
Gross unrealized losses	(42.5)	(194.3)
Estimated fair value	22,910.9	21,096.2
Other-than-temporary impairments included in accumulated other comprehensive income	(1.0)	(8.0)
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	491.1	580.7
Gross unrealized gains	23.6	11.5
Gross unrealized losses	(3.0)	(8.0)
Estimated fair value	511.7	584.2
Investment Grade
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	18,052.7	16,733.1
Gross unrealized gains	2,032.6	1,359.2
Gross unrealized losses	(27.9)	(143.9)
Estimated fair value	20,057.4	17,948.4
Other-than-temporary impairments included in accumulated other comprehensive income	(0.2)	0.0
Investment Grade | Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	12,419.3	11,582.6
Gross unrealized gains	1,670.7	1,073.9
Gross unrealized losses	(14.6)	(99.8)
Estimated fair value	14,075.4	12,556.7
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Investment Grade | US treasury and government
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	146.4	143.8
Gross unrealized gains	31.5	20.5
Gross unrealized losses	(0.2)	0.0
Estimated fair value	177.7	164.3
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Investment Grade | States and political subdivisions
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,819.9	1,798.2
Gross unrealized gains	234.8	186.7
Gross unrealized losses	(0.4)	(7.9)
Estimated fair value	2,054.3	1,977.0
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Investment Grade | Debt securities issued by foreign governments
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	79.5	37.1
Gross unrealized gains	3.8	0.2
Gross unrealized losses	(0.2)	(0.4)
Estimated fair value	83.1	36.9
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Investment Grade | Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,730.7	1,169.6
Gross unrealized gains	39.7	29.2
Gross unrealized losses	(3.2)	(8.7)
Estimated fair value	1,767.2	1,190.1
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Investment Grade | Collateralized debt obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	257.1	227.5
Gross unrealized gains	2.3	1.0
Gross unrealized losses	0.0	(0.3)
Estimated fair value	259.4	228.2
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Investment Grade | Commercial mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,304.1	1,467.2
Gross unrealized gains	33.2	32.9
Gross unrealized losses	(9.1)	(26.6)
Estimated fair value	1,328.2	1,473.5
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Investment Grade | Mortgage pass-through securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1.8	2.3
Gross unrealized gains	0.2	0.2
Gross unrealized losses	0.0	0.0
Estimated fair value	2.0	2.5
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Investment Grade | Collateralized mortgage obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	293.9	304.8
Gross unrealized gains	16.4	14.6
Gross unrealized losses	(0.2)	(0.2)
Estimated fair value	310.1	319.2
Other-than-temporary impairments included in accumulated other comprehensive income	(0.2)	0.0
Below-investment grade
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	2,649.4	3,070.0
Gross unrealized gains	218.7	128.2
Gross unrealized losses	(14.6)	(50.4)
Estimated fair value	2,853.5	3,147.8
Other-than-temporary impairments included in accumulated other comprehensive income	(0.8)	(8.0)
Below-investment grade | Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	867.0	967.3
Gross unrealized gains	28.4	26.1
Gross unrealized losses	(12.4)	(39.2)
Estimated fair value	883.0	954.2
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	(3.6)
Below-investment grade | States and political subdivisions
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	2.0	13.6
Gross unrealized gains	0.0	0.0
Gross unrealized losses	0.0	(1.7)
Estimated fair value	2.0	11.9
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	(3.0)
Below-investment grade | Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,355.2	1,471.9
Gross unrealized gains	132.9	55.1
Gross unrealized losses	(0.9)	(6.8)
Estimated fair value	1,487.2	1,520.2
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Below-investment grade | Collateralized debt obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost		2.5
Gross unrealized gains		0.0
Gross unrealized losses		0.0
Estimated fair value		2.5
Other-than-temporary impairments included in accumulated other comprehensive income		0.0
Below-investment grade | Commercial mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	49.9	63.8
Gross unrealized gains	0.6	0.2
Gross unrealized losses	(1.2)	(1.3)
Estimated fair value	49.3	62.7
Other-than-temporary impairments included in accumulated other comprehensive income	0.0	0.0
Below-investment grade | Collateralized mortgage obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	375.3	550.9
Gross unrealized gains	56.8	46.8
Gross unrealized losses	(0.1)	(1.4)
Estimated fair value	432.0	596.3
Other-than-temporary impairments included in accumulated other comprehensive income	$ (0.8)	$ (1.4)

XML

INVESTMENTS (SUMMARY OF FIXED MATURITY SECURITIES AVAILABLE FOR SALE) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 20,702.1	$ 19,803.1
Estimated fair value	$ 22,910.9	$ 21,096.2
Percentage of total estimated fair value	100.00%
NAIC designation 1
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 9,923.7
Estimated fair value	$ 11,028.5
Percentage of total estimated fair value	48.10%
NAIC designation 2
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 9,821.6
Estimated fair value	$ 10,906.2
Percentage of total estimated fair value	47.60%
Total NAIC Designation 1 and 2
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 19,745.3
Estimated fair value	$ 21,934.7
Percentage of total estimated fair value	95.70%
NAIC designation 3
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 676.2
Estimated fair value	$ 693.8
Percentage of total estimated fair value	3.00%
NAIC designation 4
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 225.0
Estimated fair value	$ 225.9
Percentage of total estimated fair value	1.00%
NAIC designation 5
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 46.3
Estimated fair value	$ 45.9
Percentage of total estimated fair value	0.20%
NAIC designation 6
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 9.3
Estimated fair value	$ 10.6
Percentage of total estimated fair value	0.10%
Total NAIC Designation 3, 4, 5 and 6
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 956.8
Estimated fair value	$ 976.2
Percentage of total estimated fair value	4.30%

XML

INVESTMENTS (SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Net unrealized appreciation (depreciation) on fixed maturity securities, available for sale, on which an other-than-temporary impairment loss has been recognized	$ 2.6	$ (1.1)
Net unrealized gains on all other investments	2,227.3	1,311.9
Adjustment to present value of future profits	(94.0)	(106.2)
Adjustment to deferred acquisition costs	(292.6)	(223.5)
Adjustment to insurance liabilities	(295.8)	(13.5)
Deferred income tax liabilities	(335.4)	(345.2)
Accumulated other comprehensive income	$ 1,212.1	$ 622.4

XML

INVESTMENTS (NARRATIVE) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) investment state	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Premium deficiencies adjustments to present value of future profits	$ (83.8)	$ (94.1)
Reduction to deferred acquisition costs due to unrealized gains that would result in premium deficiency if unrealized gains were realized	(134.9)	(96.4)
Adjustment to insurance liabilities	(295.8)	(13.5)
Increase to deferred tax assets due to unrealized gains that would result in premium deficiency if unrealized gains were realized	111.1	72.5
Fixed maturities, available for sale, amortized cost	20,702.1	19,803.1
Estimated fair value	22,910.9	21,096.2
Carrying value of fixed maturity investments not accruing investment income	2.8
Carrying value mortgage loans not accruing investment income	10.6
Net realized investment gains (losses)	50.3	8.3	$ (36.6)
Net realized investment gains (losses), excluding impairment losses	77.4	47.9	(8.0)
Gain (loss) on dissolution of variable interest entities	(4.3)	(7.3)	11.3
Net impairment losses recognized	(22.8)	(32.3)	(39.9)
Total other-than-temporary impairment losses	21.9	35.9	42.9
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	$ (0.9)	3.6	3.0
Number of investments in default or considered nonperforming | investment	1
Fixed maturities in default, aggregate amortized cost	$ 0.5
Fixed maturities in default, carrying value	0.4
Value of available for sale securities sold	427.6	790.2	724.4
Other than temporary impairment losses, losses on other investments following unforeseen events	10.9	5.4	5.4
Other-than-temporary impairments included in accumulated other comprehensive income	1.0	8.0
Estimated fair value	$ 5,635.4
Percent of fixed maturities	24.60%
Number of additional states greater than specified percentage of mortgage loan balance | state	0
Mortgage loans in process of foreclosure	$ 10.6
Mortgage loans	1,650.6	1,768.0
Assets held by insurance regulators	$ 38.5	36.7
Minimum
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	5.00%
California
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	14.00%
Texas
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	12.00%
Maryland
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	8.00%
Florida
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	6.00%
ILLINOIS
Schedule of Available-for-sale Securities [Line Items]
Percentage of mortgage loan balance	5.00%
Total fixed maturities, available for sale
Schedule of Available-for-sale Securities [Line Items]
Net realized investment gains (losses)	$ 30.4	30.9	(7.6)
Net impairment losses recognized	(12.5)	(15.2)	(17.9)
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(0.9)	3.6	3.0
Gross realized losses on sale	24.2	95.2	88.4
Embedded Derivative Financial Instruments
Schedule of Available-for-sale Securities [Line Items]
Loss on embedded derivatives		(0.4)	(9.2)
Gain on embedded derivatives	11.5
Coinsurance | Embedded Derivative Financial Instruments
Schedule of Available-for-sale Securities [Line Items]
Loss on embedded derivatives			(7.0)
Gain on embedded derivatives	2.8	0.8
Marketable Securities
Schedule of Available-for-sale Securities [Line Items]
Net realized investment gains (losses), excluding impairment losses	63.1	47.5	8.2
Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Gross realized losses on sale	16.8	79.2
Commercial mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Gross realized losses on sale	3.6	5.8
Other Investments
Schedule of Available-for-sale Securities [Line Items]
Gross realized losses on sale	3.8	4.5
Fixed income investments | Energy Sector
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses	6.7	9.3	10.2
Gross realized losses on sale		63.5	59.7
Direct Loan
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses		3.7
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Gross realized losses on sale		5.7
Preferred Stock
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses		12.7
Commercial bank loans held by VIEs
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses		1.2	16.4
Legacy private company investments
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses			$ 7.9
Mortgage loans
Schedule of Available-for-sale Securities [Line Items]
Total other-than-temporary impairment losses	5.2
Non Investment Grade
Schedule of Available-for-sale Securities [Line Items]
Fixed maturities, available for sale, amortized cost	$ 2,649.4	3,070.0
Percentage of available-for-sale debt securities	13.00%
Estimated fair value	$ 2,853.5	3,147.8
Available-for-sale securities, percentage of amortized cost	108.00%
Other-than-temporary impairments included in accumulated other comprehensive income	$ 0.8	$ 8.0
Continuous unrealized loss position	20.00%
Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Mortgage loans	$ 1,613.5
Total carrying amount | Residential Mortgage
Schedule of Available-for-sale Securities [Line Items]
Mortgage loans	37.1
Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Mortgage loans	1,640.0
Estimate of fair value | Residential Mortgage
Schedule of Available-for-sale Securities [Line Items]
Mortgage loans	$ 37.3

XML

INVESTMENTS (SCHEDULE OF INVESTMENTS CLASSIFIED BY CONTRACTUAL MATURITY DATE) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Available-for-sale Securities, Debt Maturities, Single Maturity Date, Amortized Cost Basis [Abstract]
Due in one year or less	$ 328.1
Due after one year through five years	1,947.3
Due after five years through ten years	1,508.7
Due after ten years	11,550.0
Subtotal	15,334.1
Structured securities	5,368.0
Amortized cost	20,702.1	$ 19,803.1
Available-for-sale Securities, Debt Maturities, Single Maturity Date [Abstract]
Due in one year or less	335.1
Due after one year through five years	2,052.3
Due after five years through ten years	1,601.3
Due after ten years	13,286.8
Subtotal	17,275.5
Structured securities	5,635.4
Estimated fair value	$ 22,910.9	$ 21,096.2

XML

INVESTMENTS (SCHEDULE OF INVESTMENT INCOME) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Trading Securities and Other Trading Assets [Line Items]
Fixed maturities	$ 1,133.8	$ 1,081.4	$ 1,090.1
Equity securities	25.3	21.5	18.3
Mortgage loans	91.5	91.0	91.4
Policy loans	7.7	7.3	7.3
Other invested assets	44.4	24.3	17.4
Cash and cash equivalents	5.9	2.0	0.8
Trading securities	12.8	12.2	10.7
Option income (loss)	110.3	(40.1)	36.5
Change in value of options	52.2	69.3	(72.7)
Other special-purpose portfolios	90.6	79.7	55.5
Gross investment income	1,574.5	1,348.6	1,255.3
Less investment expenses	23.2	23.4	21.7
Net investment income	1,551.3	1,325.2	1,233.6
Investment Income
Schedule of Trading Securities and Other Trading Assets [Line Items]
Increase (decrease) in trading securities	$ 3.8	$ (0.2)	$ 0.4

XML

INVESTMENTS (SCHEDULE OF REALIZED GAIN (LOSS) ON INVESTMENTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Investment [Line Items]
Total other than temporary impairment losses	$ 22.8	$ 32.3	$ 39.9
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(0.9)	3.6	3.0
Net realized investment gains (losses)	50.3	8.3	(36.6)
Gain (loss) on dissolution of variable interest entities	(4.3)	(7.3)	11.3
Total fixed maturities, available for sale
Investment [Line Items]
Gross realized gains on sale	68.0	137.7	95.7
Gross realized losses on sale	(24.2)	(95.2)	(88.4)
Total other than temporary impairment losses	12.5	15.2	17.9
Other-than-temporary impairment losses recognized in accumulated other comprehensive income	(0.9)	3.6	3.0
Net impairment losses recognized	(13.4)	(11.6)	(14.9)
Net realized investment gains (losses)	30.4	30.9	(7.6)
Equity securities
Investment [Line Items]
Net realized investment gains (losses)	11.6	20.9	3.7
Mortgage loans
Investment [Line Items]
Net realized investment gains (losses)	1.1	0.0	(2.3)
Impairments of preferred stock and other investments [Member]
Investment [Line Items]
Net realized investment gains (losses)	(9.4)	(20.7)	(25.0)
Other [Member]
Investment [Line Items]
Net realized investment gains (losses)	20.9	(15.5)	(16.7)
Investments
Investment [Line Items]
Change in estimated fair value of trading securities	$ 12.8	$ (0.5)	$ (9.2)

XML

INVESTMENTS (SCHEDULE OF INVESTMENTS IN OUR PORTFOLIO WHICH HAVE BEEN CONTINUOUSLY IN AN UNREALIZED LOSS POSITION EXCEEDING 20% OF AMORTIZED COST PRIOR TO SALE (Details) - Fixed Maturities $ in Millions	Dec. 31, 2017 USD ($) issuer
Schedule of Available-for-sale Securities [Line Items]
Less than 6 months prior to sale, Number of issuers | issuer	4
Greater than or equal to 6 months and less than 12 months prior to sale, Number of issuers | issuer	1
Greater than or equal to 12 months prior to sale, Number of issuers | issuer	1
Number of issuers, Total | issuer	6
Less than 6 months prior to sale, Amortized cost	$ 17.8
Greater than or equal to 6 months and less than 12 months prior to sale, Amortized cost	2.7
Greater than or equal to 12 months prior to sale, Amortized cost	0.7
Amortized cost, Total	21.2
Less than 6 months prior to sale, Fair value	13.0
Greater than or equal to 6 months and less than 12 months prior to sale, Fair value	1.9
Greater than or equal to 12 months prior to sale, Fair Value	0.5
Fair value, Total	$ 15.4

XML

INVESTMENTS (SCHEDULE OF CREDIT LOSSES RECOGNIZED IN EARNINGS) (Details) - Available-for-sale securities - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other than Temporary Impairment, Credit Losses Recognized in Earnings [Roll Forward]
Credit losses on fixed maturity securities, available for sale, beginning of period	$ (5.5)	$ (2.6)	$ (1.0)
Add: credit losses on other-than-temporary impairments not previously recognized	0.0	(3.0)	(2.0)
Less: credit losses on securities sold	4.7	0.1	0.4
Less: credit losses on securities impaired due to intent to sell	0.0	0.0	0.0
Add: credit losses on previously impaired securities	(2.0)	0.0	0.0
Less: increases in cash flows expected on previously impaired securities	0.0	0.0	0.0
Credit losses on fixed maturity securities, available for sale, end of period	$ (2.8)	$ (5.5)	$ (2.6)

XML

INVESTMENTS (SCHEDULE OF INVESTMENTS WITH UNREALIZED LOSSES CLASSIFIED BY CONTRACTUAL MATURITY DATE) (Details) $ in Millions	Dec. 31, 2017 USD ($)
Amortized cost
Due in one year or less	$ 26.9
Due after one year through five years	195.4
Due after five years through ten years	108.9
Due after ten years	602.0
Subtotal	933.2
Structured securities	1,268.3
Total	2,201.5
Estimated fair value
Due in one year or less	26.9
Due after one year through five years	193.3
Due after five years through ten years	105.2
Due after ten years	580.0
Subtotal	905.4
Structured securities	1,253.6
Total	$ 2,159.0

XML

INVESTMENTS (SCHEDULE OF INVESTMENTS IN OUR PORTFOLIO RATED BELOW-INVESTMENT GRADE WHICH HAVE BEEN CONTINUOUSLY IN AN UNREALIZED LOSS POSITION EXCEEDING 20% OF THE COST BASIS (Details) $ in Millions	Dec. 31, 2017 USD ($) issuer	Dec. 31, 2016 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Unrealized losses, total	$ (42.5)	$ (194.3)
Fair value, total	$ 2,159.0	$ 4,500.6
Non Investment Grade
Schedule of Available-for-sale Securities [Line Items]
Less than 6 months, Number of issuers | issuer	1
Less than 6 months, Cost basis	$ 9.2
Cost basis, Total	9.2
Less than 6 months, Unrealized loss	(1.9)
Unrealized losses, total	(1.9)
Less than 6 months, Estimated fair value	7.3
Fair value, total	$ 7.3

XML

INVESTMENTS (SCHEDULE OF UNREALIZED LOSS ON INVESTMENTS) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	$ 1,426.4	$ 3,440.8
Unrealized losses, less than 12 months	(11.1)	(109.5)
Fair value, twelve months or greater, Fair value	732.6	1,059.8
Unrealized losses, 12 months or greater	(31.4)	(84.8)
Fair value, total	2,159.0	4,500.6
Unrealized losses, total	(42.5)	(194.3)
US treasury and government
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	28.2	8.0
Unrealized losses, less than 12 months	(0.2)	0.0
Fair value, twelve months or greater, Fair value	0.7	0.0
Unrealized losses, 12 months or greater	0.0	0.0
Fair value, total	28.9	8.0
Unrealized losses, total	(0.2)	0.0
States and political subdivisions
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	18.3	176.3
Unrealized losses, less than 12 months	(0.1)	(7.8)
Fair value, twelve months or greater, Fair value	14.9	18.3
Unrealized losses, 12 months or greater	(0.3)	(1.8)
Fair value, total	33.2	194.6
Unrealized losses, total	(0.4)	(9.6)
Debt securities issued by foreign governments
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	7.7	18.9
Unrealized losses, less than 12 months	(0.1)	(0.4)
Fair value, twelve months or greater, Fair value	5.4	0.0
Unrealized losses, 12 months or greater	(0.1)	0.0
Fair value, total	13.1	18.9
Unrealized losses, total	(0.2)	(0.4)
Corporate securities
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	470.5	1,907.6
Unrealized losses, less than 12 months	(6.8)	(75.5)
Fair value, twelve months or greater, Fair value	359.7	559.6
Unrealized losses, 12 months or greater	(20.2)	(63.5)
Fair value, total	830.2	2,467.2
Unrealized losses, total	(27.0)	(139.0)
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	601.4	692.9
Unrealized losses, less than 12 months	(2.0)	(8.5)
Fair value, twelve months or greater, Fair value	122.2	262.5
Unrealized losses, 12 months or greater	(2.1)	(7.0)
Fair value, total	723.6	955.4
Unrealized losses, total	(4.1)	(15.5)
Collateralized debt obligations
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	3.0	38.3
Unrealized losses, less than 12 months	0.0	(0.1)
Fair value, twelve months or greater, Fair value	0.0	30.8
Unrealized losses, 12 months or greater	0.0	(0.2)
Fair value, total	3.0	69.1
Unrealized losses, total	0.0	(0.3)
Commercial mortgage-backed securities
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	276.8	525.2
Unrealized losses, less than 12 months	(1.7)	(16.6)
Fair value, twelve months or greater, Fair value	218.2	154.0
Unrealized losses, 12 months or greater	(8.6)	(11.3)
Fair value, total	495.0	679.2
Unrealized losses, total	(10.3)	(27.9)
Collateralized mortgage obligations
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	20.5	73.6
Unrealized losses, less than 12 months	(0.2)	(0.6)
Fair value, twelve months or greater, Fair value	11.5	34.6
Unrealized losses, 12 months or greater	(0.1)	(1.0)
Fair value, total	32.0	108.2
Unrealized losses, total	(0.3)	(1.6)
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Fair value, less than twelve months	58.7	239.4
Unrealized losses, less than 12 months	(1.7)	(8.0)
Fair value, twelve months or greater, Fair value	21.2	0.0
Unrealized losses, 12 months or greater	(1.3)	0.0
Fair value, total	79.9	239.4
Unrealized losses, total	$ (3.0)	$ (8.0)

XML

INVESTMENTS (SCHEDULE OF STRUCTURED SECURITIES) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	$ 5,826.0
Amortized cost	5,368.0
Estimated fair value	$ 5,635.4
Percent of fixed maturities	24.60%
Pass-throughs, sequential and equivalent securities[Member]
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 557.7
Estimated fair value	$ 617.2
Percent of fixed maturities	2.70%
Planned amortization classes, target amortization classes and accretion-directed bonds [Member]
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 95.3
Estimated fair value	$ 108.5
Percent of fixed maturities	0.50%
Commercial mortgage-backed securities
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 1,354.0
Estimated fair value	$ 1,377.5
Percent of fixed maturities	6.00%
Asset-backed securities
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 3,085.9
Estimated fair value	$ 3,254.4
Percent of fixed maturities	14.20%
Collateralized debt obligations
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 257.1
Estimated fair value	$ 259.4
Percent of fixed maturities	1.10%
Other
Financial Instruments Owned and Pledged as Collateral [Line Items]
Amortized cost	$ 18.0
Estimated fair value	$ 18.4
Percent of fixed maturities	0.10%
Below 4 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	$ 2,101.7
Amortized cost	1,944.8
Estimated fair value	2,014.9
4 Percent - 5 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	1,656.3
Amortized cost	1,516.0
Estimated fair value	1,596.5
5 Percent - 6 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	1,407.1
Amortized cost	1,271.8
Estimated fair value	1,362.6
6 Percent - 7 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	286.6
Amortized cost	260.6
Estimated fair value	276.8
7 Percent - 8 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	83.0
Amortized cost	83.7
Estimated fair value	92.5
8 Percent and Above
Financial Instruments Owned and Pledged as Collateral [Line Items]
Par value	291.3
Amortized cost	291.1
Estimated fair value	$ 292.1
Minimum | 4 Percent - 5 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	4.00%
Minimum | 5 Percent - 6 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	5.00%
Minimum | 6 Percent - 7 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	6.00%
Minimum | 7 Percent - 8 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	7.00%
Minimum | 8 Percent and Above
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	8.00%
Maximum | Below 4 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	4.00%
Maximum | 4 Percent - 5 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	5.00%
Maximum | 5 Percent - 6 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	6.00%
Maximum | 6 Percent - 7 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	7.00%
Maximum | 7 Percent - 8 Percent
Financial Instruments Owned and Pledged as Collateral [Line Items]
Structured settlement, interest rate	8.00%

XML

INVESTMENTS (SUMMARY OF WEIGHTED AVERAGE LOAN-TO-VALUE RATIO FOR OUTSTANDING MORTGAGE LOANS) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 1,650.6	$ 1,768.0
Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	1,613.5
Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	1,640.0
Collateral	3,292.1
Less than 60% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	944.7
Less than 60% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	960.8
Collateral	$ 2,330.6
Less than 60% | Maximum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	60.00%
60% to 70% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 439.5
60% to 70% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	440.2
Collateral	$ 671.3
60% to 70% | Minimum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	60.00%
60% to 70% | Maximum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	70.00%
Greater than 70% to 80% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 138.4
Greater than 70% to 80% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	145.9
Collateral	$ 188.4
Greater than 70% to 80% | Minimum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	70.00%
Greater than 70% to 80% | Maximum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	80.00%
Greater than 80% to 90% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 52.3
Greater than 80% to 90% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	52.9
Collateral	$ 60.1
Greater than 80% to 90% | Minimum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	80.00%
Greater than 80% to 90% | Maximum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	90.00%
Greater than 90% | Total carrying amount
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	$ 38.6
Greater than 90% | Estimate of fair value
Schedule of Available-for-sale Securities [Line Items]
Commercial mortgage loans	40.2
Collateral	$ 41.7
Greater than 90% | Minimum
Schedule of Available-for-sale Securities [Line Items]
Loan to value ratio	90.00%

XML

FAIR VALUE MEASUREMENTS (NARRATIVE) (Details)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair value of level 3 fixed maturity securities valued using broker quotes, percentage	29.00%
Available for sale fixed maturities classified as level 3, investment grade, percent	52.00%
Available for sale fixed maturities classified as level 3, corporate securities, percent	89.00%

XML

FAIR VALUE MEASUREMENTS (FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS MEASURED ON A RECURRING BASIS - SECURITIES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	$ 22,910.9	$ 21,096.2
Trading securities	284.6	363.4
Investments held by variable interest entities - corporate securities	1,526.9	1,724.3
Assets held in separate accounts	5.0	4.7
Fair value, measurements, recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	284.6	363.4
Investments held by variable interest entities - corporate securities	1,526.9	1,724.3
Assets held in separate accounts	5.0	4.7
Total assets carried at fair value by category	25,409.3	23,884.7
Fair value, measurements, recurring | Other invested assets - derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other invested assets - derivatives	170.2	111.9
Fair value, measurements, recurring | Embedded derivatives associated with fixed index annuity products [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities for insurance products	1,334.8	1,092.3
Fair value, measurements, recurring | Corporate securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	14,958.4	13,510.9
Equity securities - corporate securities	511.7	584.2
Trading securities	21.6	19.0
Fair value, measurements, recurring | US treasury and government
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	177.7	164.3
Trading securities	0.5	0.5
Fair value, measurements, recurring | States and political subdivisions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	2,056.3	1,988.9
Fair value, measurements, recurring | Debt securities issued by foreign governments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	83.1	36.9
Fair value, measurements, recurring | Asset-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	3,254.4	2,710.3
Trading securities	95.8	94.3
Fair value, measurements, recurring | Collateralized debt obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	259.4	230.7
Trading securities	2.7	2.4
Fair value, measurements, recurring | Commercial mortgage-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	1,377.5	1,536.2
Trading securities	92.5	163.9
Fair value, measurements, recurring | Mortgage pass-through securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	2.0	2.5
Fair value, measurements, recurring | Collateralized mortgage obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	742.1	915.5
Trading securities	68.7	78.4
Fair value, measurements, recurring | Total fixed maturities, available for sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	22,910.9	21,096.2
Fair value, measurements, recurring | Equity securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	2.8	4.9
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	2.8	4.9
Investments held by variable interest entities - corporate securities	0.0	0.0
Assets held in separate accounts	0.0	0.0
Total assets carried at fair value by category	290.6	364.8
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Other invested assets - derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other invested assets - derivatives	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Embedded derivatives associated with fixed index annuity products [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities for insurance products	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Corporate securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Equity securities - corporate securities	287.8	359.9
Trading securities	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | US treasury and government
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Trading securities	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | States and political subdivisions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Debt securities issued by foreign governments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Asset-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Trading securities	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Collateralized debt obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Trading securities	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Commercial mortgage-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Trading securities	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Mortgage pass-through securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Collateralized mortgage obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Trading securities	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Total fixed maturities, available for sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1) | Equity securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	2.8	4.9
Fair value, measurements, recurring | Significant other observable inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	281.8	358.5
Investments held by variable interest entities - corporate securities	1,522.0	1,724.3
Assets held in separate accounts	5.0	4.7
Total assets carried at fair value by category	24,834.1	23,134.5
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Other invested assets - derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other invested assets - derivatives	170.2	111.9
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Embedded derivatives associated with fixed index annuity products [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities for insurance products	0.0	0.0
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Corporate securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	14,728.0	13,252.4
Equity securities - corporate securities	202.7	199.1
Trading securities	21.6	19.0
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | US treasury and government
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	177.7	164.3
Trading securities	0.5	0.5
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | States and political subdivisions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	2,056.3	1,988.9
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Debt securities issued by foreign governments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	79.2	33.0
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Asset-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	3,230.2	2,649.9
Trading securities	95.8	94.3
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Collateralized debt obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	259.4	225.3
Trading securities	2.7	2.4
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Commercial mortgage-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	1,377.5	1,504.2
Trading securities	92.5	163.9
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Mortgage pass-through securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	2.0	2.5
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Collateralized mortgage obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	742.1	915.5
Trading securities	68.7	78.4
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Total fixed maturities, available for sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	22,652.4	20,736.0
Fair value, measurements, recurring | Significant other observable inputs (Level 2) | Equity securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	0.0	0.0
Investments held by variable interest entities - corporate securities	4.9	0.0
Assets held in separate accounts	0.0	0.0
Total assets carried at fair value by category	284.6	385.4
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Other invested assets - derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other invested assets - derivatives	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Embedded derivatives associated with fixed index annuity products [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities for insurance products	1,334.8	1,092.3
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Corporate securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	230.4	258.5
Equity securities - corporate securities	21.2	25.2
Trading securities	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | US treasury and government
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Trading securities	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | States and political subdivisions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Debt securities issued by foreign governments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	3.9	3.9
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Asset-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	24.2	60.4
Trading securities	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Collateralized debt obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	5.4
Trading securities	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Commercial mortgage-backed securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	32.0
Trading securities	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Mortgage pass-through securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Collateralized mortgage obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	0.0	0.0
Trading securities	0.0	0.0
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Total fixed maturities, available for sale
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total fixed maturities, available for sale	258.5	360.2
Fair value, measurements, recurring | Significant unobservable inputs (Level 3) | Equity securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Trading securities	$ 0.0	$ 0.0

XML

FAIR VALUE MEASUREMENTS (FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS MEASURED ON A RECURRING BASIS - FINANCIAL INSTRUMENTS) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents - unrestricted	$ 578.4	$ 478.9	$ 432.3	$ 611.6
Cash and cash equivalents held by variable interest entities	178.9	189.3
Fair value, measurements, recurring | Total estimated fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	1,677.3	1,800.1
Policy loans	116.0	112.0
Company-owned life insurance	182.3	165.0
Cash and cash equivalents - unrestricted	578.4	478.9
Cash and cash equivalents held by variable interest entities	178.9	189.3
Policyholder account balances	11,220.7	10,912.7
Investment borrowings	1,648.8	1,650.0
Borrowings related to variable interest entities	1,432.9	1,675.2
Notes payable – direct corporate obligations	962.3	931.9
Fair value, measurements, recurring | Total carrying amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	1,650.6	1,768.0
Policy loans	116.0	112.0
Company-owned life insurance	182.3	165.0
Cash and cash equivalents - unrestricted	578.4	478.9
Cash and cash equivalents held by variable interest entities	178.9	189.3
Policyholder account balances	11,220.7	10,912.7
Investment borrowings	1,646.7	1,647.4
Borrowings related to variable interest entities	1,410.7	1,662.8
Notes payable – direct corporate obligations	914.6	912.9
Fair value, measurements, recurring | Quoted prices in active markets for identical assets or liabilities (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	0.0	0.0
Policy loans	0.0	0.0
Company-owned life insurance	0.0	0.0
Cash and cash equivalents - unrestricted	578.4	473.6
Cash and cash equivalents held by variable interest entities	178.9	189.3
Policyholder account balances	0.0	0.0
Investment borrowings	0.0	0.0
Borrowings related to variable interest entities	0.0	0.0
Notes payable – direct corporate obligations	0.0	0.0
Fair value, measurements, recurring | Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	0.0	0.0
Policy loans	0.0	0.0
Company-owned life insurance	182.3	165.0
Cash and cash equivalents - unrestricted	0.0	5.3
Cash and cash equivalents held by variable interest entities	0.0	0.0
Policyholder account balances	0.0	0.0
Investment borrowings	1,648.8	1,650.0
Borrowings related to variable interest entities	1,432.9	1,675.2
Notes payable – direct corporate obligations	962.3	931.9
Fair value, measurements, recurring | Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mortgage loans	1,677.3	1,800.1
Policy loans	116.0	112.0
Company-owned life insurance	0.0	0.0
Cash and cash equivalents - unrestricted	0.0	0.0
Cash and cash equivalents held by variable interest entities	0.0	0.0
Policyholder account balances	11,220.7	10,912.7
Investment borrowings	0.0	0.0
Borrowings related to variable interest entities	0.0	0.0
Notes payable – direct corporate obligations	$ 0.0	$ 0.0

XML

FAIR VALUE MEASUREMENTS (FAIR VALUE ASSETS AND LIABILITIES MEASURED ON A RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Liabilities:
Cash and cash equivalents - unrestricted	$ 578.4	$ 478.9	$ 432.3	$ 611.6
Cash and cash equivalents held by variable interest entities	178.9	189.3
Future policy benefits - embedded derivatives associated with fixed index annuity products
Liabilities:
Purchases, sales, issuances and settlements, net	(267.5)	(96.0)
Corporate securities
Assets:
Purchases, sales, issuances and settlements, net	(70.4)	76.5
Debt securities issued by foreign governments
Assets:
Purchases, sales, issuances and settlements, net		4.0
Asset-backed securities
Assets:
Purchases, sales, issuances and settlements, net	(4.3)	9.7
Collateralized debt obligations
Assets:
Purchases, sales, issuances and settlements, net	(2.5)	5.4
Commercial mortgage-backed securities
Assets:
Purchases, sales, issuances and settlements, net	(1.2)	16.9
Mortgage pass-through securities
Assets:
Purchases, sales, issuances and settlements, net		(0.1)
Total fixed maturities, available for sale
Assets:
Purchases, sales, issuances and settlements, net	(78.4)	112.4
Equity securities - corporate securities
Assets:
Purchases, sales, issuances and settlements, net	(8.5)	5.5
Fair Value, Inputs, Level 1 | Fair value, measurements, recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Mortgage Loans on Real Estate, Fair Value	0.0	0.0
Liabilities:
Loans Receivable, Fair Value Disclosure	0.0	0.0
Company-owned life insurance	0.0	0.0
Cash and cash equivalents - unrestricted	578.4	473.6
Cash and cash equivalents held by variable interest entities	178.9	189.3
Liabilities For Interest Sensitive Products, Excluding Embedded Derivatives	0.0	0.0
Investment Borrowings, Fair Value Disclosure	0.0	0.0
Borrowings Related To Variable Interest Entities, Fair Value Disclosure	0.0	0.0
Notes Payable, Fair Value Disclosure	0.0	0.0
Fair Value, Inputs, Level 2 | Fair value, measurements, recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Mortgage Loans on Real Estate, Fair Value	0.0	0.0
Liabilities:
Loans Receivable, Fair Value Disclosure	0.0	0.0
Company-owned life insurance	182.3	165.0
Cash and cash equivalents - unrestricted	0.0	5.3
Cash and cash equivalents held by variable interest entities	0.0	0.0
Liabilities For Interest Sensitive Products, Excluding Embedded Derivatives	0.0	0.0
Investment Borrowings, Fair Value Disclosure	1,648.8	1,650.0
Borrowings Related To Variable Interest Entities, Fair Value Disclosure	1,432.9	1,675.2
Notes Payable, Fair Value Disclosure	962.3	931.9
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Mortgage Loans on Real Estate, Fair Value	1,677.3	1,800.1
Liabilities:
Loans Receivable, Fair Value Disclosure	116.0	112.0
Company-owned life insurance	0.0	0.0
Cash and cash equivalents - unrestricted	0.0	0.0
Cash and cash equivalents held by variable interest entities	0.0	0.0
Liabilities For Interest Sensitive Products, Excluding Embedded Derivatives	11,220.7	10,912.7
Investment Borrowings, Fair Value Disclosure	0.0	0.0
Borrowings Related To Variable Interest Entities, Fair Value Disclosure	0.0	0.0
Notes Payable, Fair Value Disclosure	0.0	0.0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Future policy benefits - embedded derivatives associated with fixed index annuity products
Liabilities:
Beginning balance	(1,092.3)	(1,057.1)
Purchases, sales, issuances and settlements, net	(267.5)	(96.0)
Total realized and unrealized gains (losses) included in net income	25.0	60.8
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.0	0.0
Transfers into level 3	0.0	0.0
Transfers out of level 3	0.0	0.0
Ending balance	(1,334.8)	(1,092.3)
Amount of total gains (losses) for the year included in our net income related to liabilities still held as of the reporting date	25.0	60.8
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Corporate securities
Assets:
Beginning balance	258.5	170.4
Purchases, sales, issuances and settlements, net	(70.4)	76.5
Total realized and unrealized gains (losses) included in net income	5.8	(10.7)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	5.3	9.1
Transfers into level 3	31.2	20.3
Transfers out of level 3	0.0	(7.1)
Ending balance	230.4	258.5
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	(8.0)	(10.9)
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Debt securities issued by foreign governments
Assets:
Beginning balance	3.9	0.0
Purchases, sales, issuances and settlements, net	0.0	4.0
Total realized and unrealized gains (losses) included in net income	0.0	0.0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.0	(0.1)
Transfers into level 3	0.0	0.0
Transfers out of level 3	0.0	0.0
Ending balance	3.9	3.9
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0.0	0.0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Asset-backed securities
Assets:
Beginning balance	60.4	35.9
Purchases, sales, issuances and settlements, net	(4.3)	9.7
Total realized and unrealized gains (losses) included in net income	0.0	0.0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.7	2.2
Transfers into level 3	0.0	26.3
Transfers out of level 3	(32.6)	(13.7)
Ending balance	24.2	60.4
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0.0	0.0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Collateralized debt obligations
Assets:
Beginning balance	5.4	0.0
Purchases, sales, issuances and settlements, net	(2.5)	5.4
Total realized and unrealized gains (losses) included in net income	0.0	0.0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.0	0.0
Transfers into level 3	0.0	0.0
Transfers out of level 3	(2.9)	0.0
Ending balance	0.0	5.4
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0.0	0.0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Commercial mortgage-backed securities
Assets:
Beginning balance	32.0	1.1
Purchases, sales, issuances and settlements, net	(1.2)	16.9
Total realized and unrealized gains (losses) included in net income	0.1	0.0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	(0.1)	0.1
Transfers into level 3	0.0	13.9
Transfers out of level 3	(30.8)	0.0
Ending balance	0.0	32.0
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0.0	0.0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Mortgage pass-through securities
Assets:
Beginning balance	0.0	0.1
Purchases, sales, issuances and settlements, net		(0.1)
Total realized and unrealized gains (losses) included in net income		0.0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		0.0
Transfers into level 3		0.0
Transfers out of level 3		0.0
Ending balance		0.0
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date		0.0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Total fixed maturities, available for sale
Assets:
Beginning balance	360.2	207.5
Purchases, sales, issuances and settlements, net	(78.4)	112.4
Total realized and unrealized gains (losses) included in net income	5.9	(10.7)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	5.9	11.3
Transfers into level 3	31.2	60.5
Transfers out of level 3	(66.3)	(20.8)
Ending balance	258.5	360.2
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	(8.0)	(10.9)
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Equity securities - corporate securities
Assets:
Beginning balance	25.2	32.0
Purchases, sales, issuances and settlements, net	(8.5)	5.5
Total realized and unrealized gains (losses) included in net income	6.3	(12.7)
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	(1.8)	0.4
Transfers into level 3	0.0	0.0
Transfers out of level 3	0.0	0.0
Ending balance	21.2	25.2
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	0.0	(12.7)
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Trading Securities [Member]
Assets:
Beginning balance	0.0	39.9
Purchases, sales, issuances and settlements, net		0.0
Total realized and unrealized gains (losses) included in net income		0.0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)		0.0
Transfers into level 3		0.0
Transfers out of level 3		(39.9)
Ending balance		0.0
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date		0.0
Fair Value, Inputs, Level 3 | Fair value, measurements, recurring | Investments Held By Variable Interest Entities
Assets:
Beginning balance	0.0
Purchases, sales, issuances and settlements, net	4.9
Total realized and unrealized gains (losses) included in net income	0.0
Total realized and unrealized gains (losses) included in accumulated other comprehensive income (loss)	0.0
Transfers into level 3	0.0
Transfers out of level 3	0.0
Ending balance	4.9	$ 0.0
Amount of total gains (losses) for the year included in our net income relating to assets still held as of the reporting date	$ 0.0

XML

FAIR VALUE MEASUREMENTS (FAIR VALUE ASSETS AND LIABILITIES MEASURED ON A RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION - ACTIVITY) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Corporate securities
Assets:
Purchases	$ 76.6	$ 18.5
Received in reinsurance recapture		89.2
Sales	(147.0)	(31.2)
Issuances	0.0	0.0
Settlements	0.0	0.0
Purchases, sales, issuances and settlements, net	(70.4)	76.5
Debt securities issued by foreign governments
Assets:
Purchases		4.0
Received in reinsurance recapture		0.0
Sales		0.0
Issuances		0.0
Settlements		0.0
Purchases, sales, issuances and settlements, net		4.0
Asset-backed securities
Assets:
Purchases	0.0	16.9
Received in reinsurance recapture		0.0
Sales	(4.3)	(7.2)
Issuances	0.0	0.0
Settlements	0.0	0.0
Purchases, sales, issuances and settlements, net	(4.3)	9.7
Collateralized debt obligations
Assets:
Purchases	0.0	5.4
Received in reinsurance recapture		0.0
Sales	(2.5)	0.0
Issuances	0.0	0.0
Settlements	0.0	0.0
Purchases, sales, issuances and settlements, net	(2.5)	5.4
Commercial mortgage-backed securities
Assets:
Purchases	0.0	17.0
Received in reinsurance recapture		0.0
Sales	(1.2)	(0.1)
Issuances	0.0	0.0
Settlements	0.0	0.0
Purchases, sales, issuances and settlements, net	(1.2)	16.9
Mortgage pass-through securities
Assets:
Purchases		0.0
Received in reinsurance recapture		0.0
Sales		(0.1)
Issuances		0.0
Settlements		0.0
Purchases, sales, issuances and settlements, net		(0.1)
Total fixed maturities, available for sale
Assets:
Purchases	76.6	61.8
Received in reinsurance recapture		89.2
Sales	(155.0)	(38.6)
Issuances	0.0	0.0
Settlements	0.0	0.0
Purchases, sales, issuances and settlements, net	(78.4)	112.4
Equity securities - corporate securities
Assets:
Purchases	0.0	3.3
Received in reinsurance recapture		2.2
Sales	(8.5)	0.0
Issuances	0.0	0.0
Settlements	0.0	0.0
Purchases, sales, issuances and settlements, net	(8.5)	5.5
Trading securities - corporate securities
Assets:
Purchases		0.2
Received in reinsurance recapture		0.0
Sales		(0.2)
Issuances		0.0
Settlements		0.0
Purchases, sales, issuances and settlements, net		0.0
Future policy benefits - embedded derivatives associated with fixed index annuity products
Liabilities:
Purchases	(178.9)	(148.3)
Received in reinsurance recapture		0.0
Sales	5.4	21.2
Issuances	(159.3)	(28.9)
Settlements	65.3	60.0
Purchases, sales, issuances and settlements, net	(267.5)	$ (96.0)
Investments Held By Variable Interest Entities | Investments held by variable interest entities - corporate securities
Assets:
Purchases	8.9
Sales	(4.0)
Issuances	0.0
Settlements	0.0
Purchases, sales, issuances and settlements, net	$ 4.9

XML

FAIR VALUE MEASUREMENTS (FAIR VALUE INPUTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 27,854.1	$ 26,237.6
Other invested assets	853.4	589.5
Policyholder account balances	11,220.7	10,912.7
Significant unobservable inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	284.6	385.4
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 149.2	$ 148.5
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	1.45%	1.35%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	71.29%	27.71%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	6.96%	13.52%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Asset-backed securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 24.2	$ 24.0
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Asset-backed securities | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	1.80%	2.06%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Asset-backed securities | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	3.71%	3.64%
Income Approach Valuation Technique | Significant unobservable inputs (Level 3) | Asset-backed securities | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	2.67%	2.76%
Cost Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 2.8	$ 14.8
Cost Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	0.00%	5.00%
Cost Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	21.73%	69.00%
Cost Approach Valuation Technique | Significant unobservable inputs (Level 3) | Corporate securities | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate	18.42%	55.00%
Market Approach Valuation Technique | Significant unobservable inputs (Level 3) | Equity securities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Investments	$ 21.2	$ 25.2
Market Approach Valuation Technique | Significant unobservable inputs (Level 3) | Equity securities | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected cash flows	110.00%	40.00%
Market Approach Valuation Technique | Significant unobservable inputs (Level 3) | Equity securities | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected cash flows	890.00%	620.00%
Market Approach Valuation Technique | Significant unobservable inputs (Level 3) | Equity securities | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected cash flows	110.00%	590.00%
Unadjusted Third-Party Price Source | Significant unobservable inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Other invested assets	$ 87.2	$ 172.9
Discounted Projected Embedded Derivatives | Significant unobservable inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Policyholder account balances	$ 1,334.8	$ 1,092.3
Future policy benefits - embedded derivatives associated with fixed index annuity products | Discounted Projected Embedded Derivatives | Significant unobservable inputs (Level 3) | Minimum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected portfolio yields	5.15%	5.15%
Discount rates	0.92%	0.18%
Surrender rates	1.20%	0.94%
Future policy benefits - embedded derivatives associated with fixed index annuity products | Discounted Projected Embedded Derivatives | Significant unobservable inputs (Level 3) | Maximum
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected portfolio yields	5.61%	5.61%
Discount rates	2.51%	3.06%
Surrender rates	46.40%	46.48%
Future policy benefits - embedded derivatives associated with fixed index annuity products | Discounted Projected Embedded Derivatives | Significant unobservable inputs (Level 3) | Weighted Average
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Projected portfolio yields	5.60%	5.59%
Discount rates	2.00%	2.07%
Surrender rates	12.30%	13.52%

XML

LIABILITIES FOR INSURANCE PRODUCTS (SCHEDULE OF INSURANCE LIABILITIES BY PRODUCT SEGMENT) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Liability for Future Policy Benefit, by Product Segment [Line Items]
Future policy benefits	$ 11,521.3	$ 10,953.3
Policyholder account balance	$ 11,220.7	10,912.7
Long-term care
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	6.00%
Future policy benefits	$ 5,669.0	5,346.1
Traditional life insurance contracts
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	5.00%
Future policy benefits	$ 2,401.2	2,322.1
Accident and health contracts
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	5.00%
Future policy benefits	$ 2,812.0	2,695.6
Interest-sensitive life insurance contracts
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	5.00%
Future policy benefits	$ 44.9	52.2
Policyholder account balance	$ 1,094.7	1,046.4
Annuities and supplemental contracts with life contingencies
Liability for Future Policy Benefit, by Product Segment [Line Items]
Interest rate assumption	4.00%
Future policy benefits	$ 594.2	537.3
Fixed index annuities
Liability for Future Policy Benefit, by Product Segment [Line Items]
Policyholder account balance	5,942.2	5,324.5
Other annuities
Liability for Future Policy Benefit, by Product Segment [Line Items]
Policyholder account balance	$ 4,183.8	$ 4,541.8

XML

LIABILITIES FOR INSURANCE PRODUCTS (SUMMARY OF LIABILITIES FOR UNPAID CLAIMS ADJUSTMENT EXPENSE) (Details) - Accident and Health Insurance Product Line - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of year	$ 1,777.6	$ 1,731.8	$ 1,679.5
Less reinsurance (receivables) payables	14.0	(130.0)	(125.0)
Net balance, beginning of year	1,791.6	1,601.8	1,554.5
Incurred claims related to:
Current year	1,548.1	1,526.4	1,481.0
Prior years	(26.7)	96.6	(13.3)
Total incurred	1,521.4	1,623.0	1,467.7
Interest on claim reserves	78.4	75.3	71.0
Paid claims related to:
Current year	845.5	837.2	841.8
Prior years	702.6	671.3	649.6
Total paid	1,548.1	1,508.5	1,491.4
Net balance, end of year	1,843.3	1,791.6	1,601.8
Add reinsurance receivables (payables)	(15.1)	(14.0)	130.0
Balance, end of year	$ 1,828.2	$ 1,777.6	$ 1,731.8

XML

INCOME TAXES (SCHEDULE OF COMPONENTS OF INCOME TAX EXPENSE) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Current tax expense (benefit)									$ 90.8	$ (45.2)	$ 10.7
Deferred tax expense									72.0	173.0	118.6
Valuation allowance applicable to current year income									(15.3)	(14.0)	0.0
Income tax expense calculated based on annual effective tax rate									147.5	113.8	129.3
Income tax expense on discrete items:
Change in valuation allowance									(13.4)	40.7	(32.5)
Impact of federal tax reform									310.6	0.0	0.0
Impact of federal tax reform									(138.1)	0.0	0.0
IRS settlement					$ (118.7)				0.0	(170.4)	0.0
Other items									(1.7)	10.9	0.2
Total income tax expense (benefit)	$ 196.3	$ 29.1	$ 45.1	$ 34.4	$ (53.5)	$ 30.7	$ 22.8	$ (5.0)	$ 304.9	$ (5.0)	$ 97.0

XML

INCOME TAXES (NARRATIVE) (Details) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) position	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jan. 01, 2017 USD ($)	Dec. 31, 2014 USD ($)	May 11, 2010	Jan. 20, 2009 right
Operating Loss Carryforwards [Line Items]
Tax reform provisional income tax expense (benefit)	$ 172.5		$ 172.5
Deferred tax assets more likely than not to be realized through future taxable earnings	376.2	$ 785.6	376.2	$ 785.6		$ 790.0
Deferred tax assets	465.3	1,025.8	465.3	1,025.8
Valuation allowance for deferred income tax assets	$ 89.1	240.2	$ 89.1	240.2	$ 213.5	$ 255.9	$ 246.0
Aggregate growth rate for the next five years	3.00%		3.00%
Forecast period of model			5 years
Adjusted average taxable income			$ 345.0
Adjusted average nonlife taxable income			85.0
Adjusted average life taxable income			260.0
Increase (decrease) in valuation allowance			$ 151.1	(26.7)	32.5
Loss limitation based on income of life insurance company, percent	35.00%		35.00%
Loss limitation based on loss of non-life entities, percent	35.00%		35.00%
Federal long-term tax exempt rate	1.96%		1.96%
Ownership change threshold restricting NOL usage	50.00%		50.00%
Ownership percentage threshold relating to company 382 provision, ownership percentage at which transfers of common stock become void (less than)								5.00%
Number of rights for each share | right									1
Ownership percentage threshold relating to company 382 securities									4.99%
Net operating loss carryforwards	$ 2,331.4		$ 2,331.4
Net state operating loss carryforwards	9.3	$ 12.3	9.3	12.3
Number of tax positions settled | position		2
IRS settlement		$ 118.7	0.0	170.4	0.0
Reduction in interest recognized from prior periods on alternative minimum tax		3.4
Decrease to income tax accrued			227.5	$ (11.7)	$ 92.9
Future cash tax payments as a percent of life insurance, taxable income due				65.00%
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Valuation allowance for deferred income tax assets	77.4		77.4
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Valuation allowance for deferred income tax assets	11.7		11.7
Life Insurance Related NOLs
Operating Loss Carryforwards [Line Items]
Tax Benefits Recognized On IRS Settlement		280.7
Additional life net operating loss carryforwards		98.2		$ 98.2
Decrease to income tax accrued			(50.0)
Non-Life Insurance Related NOLs, Classification Of Loss On Investment [Member]
Operating Loss Carryforwards [Line Items]
Tax Benefits Recognized On IRS Settlement		130.0
Non-Life Insurance Related NOLs, Bad Debt Deduction On Stock Purchase Loan [Member]
Operating Loss Carryforwards [Line Items]
Tax Benefits Recognized On IRS Settlement		66.7
Non-Life Insurance Related NOLs
Operating Loss Carryforwards [Line Items]
Increase (decrease) in valuation allowance		51.7
Additional life net operating loss carryforwards		$ 17.1		$ 17.1
Internal Revenue Service (IRS)
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 2,300.0		$ 2,300.0

XML

INCOME TAXES (SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILLIATION) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. statutory corporate rate	35.00%	35.00%	35.00%
Valuation allowance	(6.00%)	7.60%	(8.80%)
Non-taxable income and nondeductible benefits, net	(2.00%)	(1.10%)	(0.20%)
State taxes	0.60%	2.20%	2.10%
Impact of federal tax reform	64.70%	0.00%	0.00%
Change in valuation allowance related to federal tax reform	(28.80%)	0.00%	0.00%
Impact of IRS settlement	0.00%	(48.20%)	0.00%
Other items	0.00%	3.10%	(1.70%)
Effective tax rate	63.50%	(1.40%)	26.40%

XML

INCOME TAXES (SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net federal operating loss carryforwards	$ 489.6		$ 882.9
Net state operating loss carryforwards	9.3		12.3
Investments	4.3		17.8
Insurance liabilities	415.8		668.4
Other	48.9		66.3
Gross deferred tax assets	967.9	$ 1,045.9	1,647.7
Deferred tax liabilities:
Present value of future profits and deferred acquisition costs	(165.4)		(277.8)
Accumulated other comprehensive income	(337.2)		(344.1)
Gross deferred tax liabilities	(502.6)		(621.9)
Net deferred tax assets before valuation allowance	465.3		1,025.8
Valuation allowance	(89.1)	(255.9)	(240.2)	$ (213.5)	$ (246.0)
Net deferred tax assets	376.2	$ 790.0	785.6
Current income taxes prepaid (accrued)	(9.3)		4.1
Income tax assets, net	$ 366.9		$ 789.7

XML

INCOME TAXES (SUMMARY OF VALUATION ALLOWANCE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jan. 01, 2017
Increase (Decrease) in Valuation Allowance [Roll Forward]
Beginning valuation allowance	$ 240.2	$ 213.5	$ 246.0
Change in valuation allowance	(151.1)	26.7	(32.5)
Decrease in 2017	166.8
Cumulative effect of accounting change	967.9	1,647.7		$ 1,045.9
Ending valuation allowance	89.1	240.2	213.5
Impact of federal tax reform	138.1	$ 0.0	$ 0.0
Income Tax Expense (Benefit), change in valuation allowance in taxable income	15.3
Recognition of excess tax benefits
Increase (Decrease) in Valuation Allowance [Roll Forward]
Cumulative effect of accounting change				$ 15.7
Capital Gains
Increase (Decrease) in Valuation Allowance [Roll Forward]
Decrease in 2017	$ 13.4

XML

INCOME TAXES (SUMMARY OF OPERATING LOSS CARRYFORWARDS) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 2,331.4
2023
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2023
Net operating loss carryforwards	$ 1,744.8
2025
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2025
Net operating loss carryforwards	$ 85.2
2026
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2026
Net operating loss carryforwards	$ 149.9
2027
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2027
Net operating loss carryforwards	$ 10.8
2028
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2028
Net operating loss carryforwards	$ 80.3
2029
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2029
Net operating loss carryforwards	$ 213.2
2030
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2030
Net operating loss carryforwards	$ 0.3
2031
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2031
Net operating loss carryforwards	$ 0.2
2032
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2032
Net operating loss carryforwards	$ 44.4
2033
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2033
Net operating loss carryforwards	$ 0.6
2034
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2034
Net operating loss carryforwards	$ 0.9
2035
Operating Loss Carryforwards [Line Items]
Year of expiration	Dec. 31, 2035
Net operating loss carryforwards	$ 0.8

XML

INCOME TAXES (RECONCILIATION OF UNRECOGNIZED TAX BENEFITS) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 234.2
Increase based on tax positions taken in prior years	3.4
Decrease in unrecognized tax benefits related to settlements with taxing authorities	(237.6)
Balance at end of year	$ 0.0

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (SCHEDULE OF LONG-TERM DEBT INSTRUMENTS) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-term debt, gross	$ 925.0
Unamortized debt issuance costs	(10.4)	$ (12.1)
Direct corporate obligations	914.6	912.9
Senior Notes | 4.500% Senior Notes due May 2020
Debt Instrument [Line Items]
Long-term debt, gross	$ 325.0	325.0
Interest rate	4.50%
Senior Notes | 5.250% Senior Notes due May 2025
Debt Instrument [Line Items]
Long-term debt, gross	$ 500.0	500.0
Interest rate	5.25%
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 100.0	$ 100.0

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (NOTES) (Details) - Senior Notes - USD ($)	May 19, 2015	Dec. 31, 2017	Sep. 28, 2012
Debt Instrument [Line Items]
Event of default ownership percentage threshold to declare payment		25.00%
4.500% Senior Notes due May 2020
Debt Instrument [Line Items]
Aggregate principal amount	$ 325,000,000
Interest rate		4.50%
5.250% Senior Notes due May 2025
Debt Instrument [Line Items]
Aggregate principal amount	$ 500,000,000
Interest rate		5.25%
5.250% Senior Notes due May 2025 | On and After February 28, 2025
Debt Instrument [Line Items]
Redemption price, percent	100.00%
5.250% Senior Notes due May 2025 | Change of Control Repurchase Event
Debt Instrument [Line Items]
Redemption price, percent	101.00%
Senior Secured Note 6.375 Percent
Debt Instrument [Line Items]
Interest rate			6.375%

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (REVOLVING CREDIT AGREEMENT) (Details) - USD ($) $ in Millions	Oct. 13, 2017	May 19, 2015	Dec. 31, 2017
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 250.0	$ 150.0
Debt Instrument, term		4 years
Initial drawing amount		$ 100.0
Remaining borrowing capacity		50.0
Potential additional borrowing capacity		$ 100.0
Interest rate on amounts outstanding at period end			3.44%
Fronting fee as a percent of aggregate face amount of letters of credit outstanding		0.125%
Debt covenant, required minimum debt to total capitalization ratio	35.00%	30.00%
Debt covenant, actual debt to total capitalization ratio at period end			20.30%
Debt covenant, minimum required aggregate total adjusted capital to company action level risk-based capital ratio		250.00%
Debt covenant, actual aggregate total adjusted capital to company action level risk-based capital ratio at period end			446.00%
Debt covenant, minimum required consolidated net worth, component one, amount		$ 2,674.0
Debt covenant, minimum required consolidated net worth, component two, as a percent of net equity proceeds received from issuance and sale of equity interests		50.00%
Debt covenant, actual consolidated net worth at period end			$ 3,635.4
Debt covenant, required minimum consolidated net worth, amount			$ 2,684.9
Line of Credit | Revolving Credit Facility | Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Line of Credit | Bridge Loan
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 5.0
Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 5.0
Minimum | Eurodollar
Debt Instrument [Line Items]
Basis spread on variable rate	1.375%	1.75%
Minimum | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	0.375%	0.75%
Minimum | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Remaining borrowing capacity		$ 50.0
Maximum | Eurodollar
Debt Instrument [Line Items]
Basis spread on variable rate	2.125%	2.25%
Maximum | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.125%	1.25%
Maximum | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Remaining borrowing capacity	$ 100.0

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (LOSS ON EXTINGUISHMENT OF DEBT) (NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 28, 2012
Debt Instrument [Line Items]
Loss on extinguishment of debt	$ 0.0	$ 0.0	$ 32.8
Senior Notes | Senior Secured Note 6.375 Percent
Debt Instrument [Line Items]
Interest rate				6.375%

XML

NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS (SCHEDULE OF MATURITIES OF LONG-TERM DEBT) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
2018	$ 0.0
2019	100.0
2020	325.0
2021	0.0
2022	0.0
Thereafter	500.0
Direct corporate obligations	925.0
Senior Notes | 4.500% Senior Notes due May 2020
Debt Instrument [Line Items]
Direct corporate obligations	$ 325.0	$ 325.0
Interest rate	4.50%

XML

LITIGATION AND OTHER LEGAL PROCEEDINGS (NARRATIVE) (Details) $ in Millions			12 Months Ended
	Jun. 19, 2017 USD ($)	Dec. 16, 2016 USD ($)	Dec. 31, 2017 USD ($) state individual	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jul. 26, 2017 individual
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of individuals appointed to assume immediate control and power over affairs | individual						2
Number of states participating in examination of compliance with unclaimed property laws | state			38
Amount of insurance-related assessment liability			$ 14.1	$ 24.9
Premium tax offset for loss contingency accruals			20.0	26.7
Insurance-related assessment, expense recognized			11.0	2.8	$ 1.2
Operating leases and sponsorship agreements, expense			$ 61.4	56.8	$ 48.8
Former Chief Executive Officers
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of Company's former chief executive officers' retirement benefits guaranteed by subsidiaries | individual			2
Deferred compensation arrangement with individual, recorded liability			$ 24.2	$ 25.0
Compensatory Damages
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Damages awarded to plaintiffs		$ 4.7
Punitive Damages
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Damages awarded to plaintiffs		$ 6.0
Loss contingency, awarded damages reduced, value	$ 1.5

XML

LITIGATION AND OTHER LEGAL PROCEEDINGS (SCHEDULE OF FUTURE MINIMUM RENTAL PAYMENTS FOR OPERATING LEASES) (Details) $ in Millions	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 33.5
2019	18.2
2020	11.8
2021	8.0
2022	5.6
Thereafter	3.6
Total	$ 80.7

XML

AGENT DEFERRED COMPENSATION PLAN (NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Cost recognized for defined contribution plan	$ 5.5	$ 5.3	$ 5.0
Nonqualified Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Company-owned life insurance	18.0	5.1
Deferred compensation arrangement with individual, recorded liability	22.9	11.2
Deferred compensation arrangement contributions by employer	6.6	4.4
Unfunded Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Recognized pre-tax gain related to settlement distributions				$ 6.1
Net periodic benefit cost	18.8	8.1	2.2
Deferred Compensation Arrangement With Individual, Gain (Loss) Recognized	(12.2)	3.1	15.2
Company-owned life insurance	182.3	165.0
Change in value of corporate or bank owned life insurance	24.6	6.9	$ 0.5
Deferred compensation arrangement with individual, recorded liability	$ 168.2	$ 156.3
Minimum | Nonqualified Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred compensation arrangement vesting period	5 years
Maximum | Nonqualified Plan
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred compensation arrangement vesting period	10 years

XML

AGENT DEFERRED COMPENSATION PLAN (SCHEDULE OF ASSUMPTIONS USED) (Details) - Unfunded Plan	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Discount rate - Benefit Obligations	3.75%	4.25%
Discount rate - Net Period Costs	4.25%	4.50%

XML

AGENT DEFERRED COMPENSATION PLAN (SCHEDULE OF EXPECTED BENEFIT PAYMENTS) (Details) - Unfunded Plan $ in Millions	Dec. 31, 2017 USD ($)
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
2018	$ 7.4
2019	7.6
2020	7.9
2021	8.0
2022	8.3
2023 - 2027	$ 45.2

XML

DERIVATIVES (FAIR VALUE BY BALANCE SHEET LOCATION) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Fixed index call options
Derivatives, Fair Value [Line Items]
Gross amounts recognized	$ 170.2	$ 111.9
Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Gross amounts recognized	168.8	107.7
Gross derivative liability	1,334.8	1,092.3
Not Designated as Hedging Instrument | Fixed index call options | Other invested assets:
Derivatives, Fair Value [Line Items]
Gross amounts recognized	170.2	111.9
Not Designated as Hedging Instrument | Reinsurance receivables | Other invested assets:
Derivatives, Fair Value [Line Items]
Gross amounts recognized	(1.4)	(4.2)
Not Designated as Hedging Instrument | Fixed index products | Fixed index products
Derivatives, Fair Value [Line Items]
Gross derivative liability	$ 1,334.8	$ 1,092.3

XML

DERIVATIVES (SCHEDULE OF DERIVATIVE INSTRUMENTS) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) policy
Embedded Derivative Financial Instruments
Derivative Instrument [Roll Forward]
December 31, 2016 | policy	100,812
Additions | policy	11,437
Maturities/terminations | policy	(7,560)
December 31, 2017 | policy	104,689
Fixed index call options
Derivative, Notional Amount [Roll Forward]
December 31, 2016	$ 2,455.1
Additions	3,021.8
Maturities/terminations	(2,471.1)
December 31, 2017	3,005.8
Embedded Derivative Associated With Modified Coinsurance Agreement [Member]
Derivative, Notional Amount [Roll Forward]
Mark to market adjustment on embedded derivatives	$ 126.0

XML

DERIVATIVES (SCHEDULE PRE-TAX GAINS (LOSSES) RECOGNIZED IN NET INCOME FOR DERIVATIVE INSTRUMENTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	$ 190.3	$ 89.7	$ (9.6)
Investment Income | Equity Swap
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	162.5	29.2	(36.2)
Gain (Loss) on Investments
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	2.8	(0.3)	(9.7)
Gain (Loss) on Investments | Interest Rate Contract
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	0.0	(1.1)	(2.7)
Gain (Loss) on Investments | Embedded Derivative Financial Instruments | Coinsurance
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	2.8	0.8	(7.0)
Insurance Policy Benefits | Embedded Derivative Financial Instruments
Derivative [Line Items]
Gains (losses) on derivative instruments not designated as hedging instruments	$ 25.0	$ 60.8	$ 36.3

XML

DERIVATIVES (DERIVATIVES WITH MASTER NETTING ARRANGEMENTS) (Details) - Fixed index call options - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Derivative [Line Items]
Gross amounts recognized	$ 170.2	$ 111.9
Gross amounts offset in the balance sheet	0.0	0.0
Net amounts of assets presented in the balance sheet	170.2	111.9
Financial instruments	0.0	0.0
Cash collateral received	0.0	0.0
Net amount	$ 170.2	$ 111.9

XML

SHAREHOLDERS' EQUITY (SCHEDULE OF COMMON STOCK OUTSTANDING) (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Common Stock Outstanding [Roll Forward]
Balance, beginning of year (in shares)	173,753,614
Balance, end of year (in shares)	166,857,931	173,753,614
Number of stock tendered for payment of federal and state taxes owed	103,000	191,000	237,000
Common stock
Common Stock Outstanding [Roll Forward]
Balance, beginning of year (in shares)	173,754,000	184,029,000	203,324,000
Treasury stock purchased and retired (in shares)	(7,808,000)	(11,688,000)	(20,582,000)
Balance, end of year (in shares)	166,858,000	173,754,000	184,029,000
Common stock | Employee Stock Option
Common Stock Outstanding [Roll Forward]
Shares issued under employee benefit compensation plans (in shares)	725,000	978,000	769,000
Common stock | Restricted and Performance Stock
Common Stock Outstanding [Roll Forward]
Shares issued under employee benefit compensation plans (in shares)	187,000	435,000	518,000

XML

SHAREHOLDERS' EQUITY (NARRATIVE) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	4 Months Ended		8 Months Ended			12 Months Ended			36 Months Ended		60 Months Ended
	May 31, 2017	Apr. 30, 2017	Apr. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2009	Dec. 31, 2014	Jan. 01, 2017	May 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, increase in authorized amount	$ 1,900.0
Payments to repurchase common stock							$ 168.3	$ 210.0	$ 365.4
Stock repurchase program, remaining repurchase authorized amount				$ 385.6			385.6			$ 385.6
Common stock dividends paid							$ 59.6	$ 54.8	$ 52.0
Dividends (in dollars per share)		$ 0.08	$ 0.06	$ 0.09	$ 0.08	$ 0.07	$ 0.35	$ 0.31	$ 0.27
Available for future grant (in shares)				7,488,000	4,620,000	6,882,000	7,488,000	4,620,000	6,882,000	7,488,000
Proceeds from stock options exercised							$ 8.3	$ 8.4	$ 6.3
Additional paid-in capital				$ 3,073.3	$ 3,212.1		3,073.3	3,212.1		$ 3,073.3			$ 3,213.0
Retained earnings				560.4	650.7		560.4	650.7		560.4			650.1
Income tax assets				$ 967.9	1,647.7		$ 967.9	1,647.7		$ 967.9			1,045.9
Price of junior preferred stock (per 1/1000 of a share)				$ 90.00			$ 90.00			$ 90.00
Junior preferred stock right becomes exercisable when a person or group becomes owner of stated percentage (more than)							4.99%
Series B Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Series B junior participating preferred stock par value (in dollars per share)				$ 0.01			$ 0.01			$ 0.01
Junior preferred stock, purchase right to purchase fractional share (in shares)							0.001
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period							10 years
Allocated share-based compensation expense							$ 6.3	12.2	9.6
Allocated share-based compensation expense, net of tax							$ 4.1	$ 7.9	$ 6.2
Compensation expense related to stock options reduced both basic and diluted earnings per share (in dollars per share)							$ (0.02)	$ (0.04)	$ (0.03)
Unrecognized compensation expense				$ 4.2			$ 4.2			$ 4.2
Weighted average recognition period							1 year 5 months 24 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period										3 years
Allocated share-based compensation expense							$ 6.1	$ 3.1	$ 2.2
Unrecognized compensation expense				5.5	5.0		$ 5.5	$ 5.0		$ 5.5
Weighted average recognition period							1 year 9 months 24 days
Granted (in shares)							330,000
Granted (in dollars per share)							$ 20.87	$ 18.17	$ 17.59
Grant date fair value of performance shares awarded				6.9	7.3	$ 1.7	$ 6.9	$ 7.3	$ 1.7	6.9
Fair value of vested shares							$ 2.7	$ 2.1	$ 2.7
Restricted Stock | Directors, Officers, and Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)							300,000	400,000	100,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense							$ 9.0	$ 7.7	$ 5.3
Granted (in shares)							452,900	507,976	516,660
Grant date fair value of performance shares awarded				$ 11.2	$ 10.3		$ 11.2	$ 10.3		$ 11.2
Performance period							3 years
Performance unit payout							200.00%	150.00%
Years 2007 Through 2009 | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period											5 years
Vesting period											3 years
Years 2010 and Thereafter | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period												7 years
Vesting period												3 years
2015 | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period										10 years
Vesting period										3 years
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Treasury stock purchased and retired (in shares)							7,808,000	11,688,000	20,582,000
Common Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount														$ 100.0
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments to repurchase common stock							$ 167.1	$ 203.0	$ 365.2
Election to account for forfeitures as they occur
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional paid-in capital													0.9
Retained earnings													(0.6)
Income tax assets													$ 0.3

XML

SHAREHOLDERS' EQUITY (SCHEDULE OF SHARE-BASED COMPENSATION) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at the beginning of the year (in shares)	5,354	5,199	5,011
Options granted (in shares)	729	1,706	1,361
Exercised (in shares)	(237)	(978)	(769)
Forfeited or terminated (in shares)	(725)	(573)	(404)
Outstanding at the end of the year (in shares)	5,121	5,354	5,199
Options exercisable at the end of the year (in shares)	2,440	2,187	2,399
Available for future grant (in shares)	7,488	4,620	6,882
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at the beginning of the year (in dollars per share)	$ 14.73	$ 13.32	$ 12.04
Options granted (in dollars per share)	21.06	17.45	16.45
Exercised (in dollars per share)	(17.81)	(8.70)	(8.20)
Forfeited or terminated (in dollars per share)	(11.43)	(20.41)	(17.70)
Outstanding at the end of the year (in dollars per share)	$ 15.95	$ 14.73	$ 13.32
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Options outstanding, weighted average remaining life	5 years 4 months 24 days	5 years 10 months 24 days	4 years 9 months 24 days
Options exercisable at the end of the year, weighted average remaining life	3 years	2 years 8 months 24 days	2 years 5 months 24 days
Options exercised, aggregate intrinsic value	$ 5.2	$ 6.1	$ 4.8
Options outstanding, aggregate intrinsic value	37.2	37.1	38.4
Options exercisable at the end of the year, aggregate intrinsic value	$ 19.2	$ 15.1	$ 15.3

XML

SHAREHOLDERS' EQUITY (SCHEDULE OF VALUATION ASSUMPTIONS ON PAYMENT AWARDS) (Details) - Employee Stock Option - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rates	2.20%	1.40%	1.70%
Weighted average dividend yields	1.50%	1.60%	1.50%
Volatility factors	32.00%	36.00%	85.00%
Weighted average expected life (in years)	6 years 3 months 24 days	6 years 3 months 24 days	6 years 3 months 24 days
Weighted average fair value per share (in dollars per share)	$ 6.20	$ 5.48	$ 10.83

XML

SHAREHOLDERS' EQUITY (SCHEDULE OF SHARE-BASED COMPENSATION BY EXERCISE PRICE RANGE) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number outstanding (in shares) | shares	5,121
Number exercisable (in shares) | shares	2,440
Range of exercise prices: $6.77 - $7.51
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower range limit (in dollars per share)	$ 6.77
Exercise price range, upper range limit (in dollars per share)	$ 7.51
Number outstanding (in shares) | shares	605
Remaining life (in years)	10 months 24 days
Average exercise price (in dollars per share)	$ 7.47
Number exercisable (in shares) | shares	605
Average exercise price (in dollars per share)	$ 7.47
Range of exercise prices: $10.88 - $16.22
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower range limit (in dollars per share)	10.88
Exercise price range, upper range limit (in dollars per share)	$ 16.22
Number outstanding (in shares) | shares	683
Remaining life (in years)	2 years 3 months 24 days
Average exercise price (in dollars per share)	$ 11.12
Number exercisable (in shares) | shares	670
Average exercise price (in dollars per share)	$ 11.02
Range of exercise prices: $16.42 - $21.48
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower range limit (in dollars per share)	16.42
Exercise price range, upper range limit (in dollars per share)	$ 21.48
Number outstanding (in shares) | shares	3,833
Remaining life (in years)	6 years 8 months 24 days
Average exercise price (in dollars per share)	$ 18.15
Number exercisable (in shares) | shares	1,165
Average exercise price (in dollars per share)	$ 18.04

XML

SHAREHOLDERS' EQUITY (SCHEDULE OF NONVESTED SHARE ACTIVITY) (Details) - Restricted Stock - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested shares, beginning of year (in shares)	369
Granted (in shares)	330
Vested (in shares)	(147)
Forfeited (in shares)	(17)
Non-vested shares, end of year (in shares)	535	369
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested shares, beginning of year (in dollars per share)	$ 18.10
Granted (in dollars per share)	20.87	$ 18.17	$ 17.59
Vested (in dollars per share)	(18.38)
Forfeited (in dollars per share)	(20.59)
Non-vested shares, end of year (in dollars per share)	$ 19.65	$ 18.10

XML

SHAREHOLDERS' EQUITY (SCHEDULE OF PERFORMANCE SHARE-BASED COMPENSATION) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Total shareholder return awards
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Awards outstanding, beginning of period (in units)	570	549	519
Granted (in units)	226	254	258
Additional shares issued pursuant to achieving certain performance criteria (in units)	0	87	85
Vested (in units)	0	(261)	(260)
Forfeited (in units)	(167)	(59)	(53)
Awards outstanding, end of period (in units)	629	570	549
Performance unit payout	150.00%
Operating return on equity awards
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Awards outstanding, beginning of period (in units)	570	549	343
Granted (in units)	226	254	258
Additional shares issued pursuant to achieving certain performance criteria (in units)	30	65	0
Vested (in units)	(144)	(239)	0
Forfeited (in units)	(53)	(59)	(52)
Awards outstanding, end of period (in units)	629	570	549
Pre-tax operating income awards
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Awards outstanding, beginning of period (in units)	0	0	176
Granted (in units)	0	0	0
Additional shares issued pursuant to achieving certain performance criteria (in units)	0	0	85
Vested (in units)	0	0	(260)
Forfeited (in units)	0	0	(1)
Awards outstanding, end of period (in units)	0	0	0

XML

SHAREHOLDERS' EQUITY (SCHEDULE OF EARNINGS PER SHARE RECONCILIATION) (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Net income (loss) for diluted earnings per share	$ 175.6	$ 358.2	$ 270.7
Shares:
Weighted average shares outstanding for basic earnings per share (in dollars per share)	170,025	176,638	193,054
Effect of dilutive securities on weighted average shares:
Stock options, restricted stock and performance units (in shares)	2,119	1,685	2,112
Weighted average shares outstanding for diluted earnings per share (in shares)	172,144	178,323	195,166

XML

OTHER OPERATING STATEMENT DATA (SCHEDULE OF INSURANCE POLICY INCOME) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Insurance [Abstract]
Direct premiums collected	$ 4,013.4	$ 3,942.7	$ 3,769.6
Reinsurance assumed	30.2	33.8	38.4
Reinsurance ceded	(114.4)	(132.9)	(142.8)
Premiums collected, net of reinsurance	3,929.2	3,843.6	3,665.2
Change in unearned premiums	19.0	6.2	5.9
Less premiums on interest-sensitive life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities	(1,445.9)	(1,386.7)	(1,241.9)
Premiums on traditional products with mortality or morbidity risk	2,502.3	2,463.1	2,429.2
Fees and surrender charges on interest-sensitive products	145.0	138.0	126.8
Insurance policy income	$ 2,647.3	$ 2,601.1	$ 2,556.0

XML

OTHER OPERATING STATEMENT DATA (NARRATIVE) (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Present Value of Future Insurance Profits, Percentage of Amortization Expense, Next Five Years [Abstract]
2018	11.00%
2019	10.00%
2020	9.00%
2021	7.00%
2022	7.00%
Average interest accrual rate associated with amortization method of present value of future insurance profits	5.00%	5.00%	5.00%
Florida
Supplementary Insurance Information, by Segment [Line Items]
Percentage of total collected premiums (more than for 5%)	10.00%
Pennsylvania
Supplementary Insurance Information, by Segment [Line Items]
Percentage of total collected premiums (more than for 5%)	6.00%
Texas
Supplementary Insurance Information, by Segment [Line Items]
Percentage of total collected premiums (more than for 5%)	6.00%
California
Supplementary Insurance Information, by Segment [Line Items]
Percentage of total collected premiums (more than for 5%)	5.00%

XML

OTHER OPERATING STATEMENT DATA (SCHEDULE OF OTHER OPERATING COST AND EXPENSE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Expenses:
Commission expense	$ 115.6	$ 110.5	$ 103.8
Salaries and wages	237.3	231.0	205.2
Other	488.6	454.8	430.2
Total other operating costs and expenses	$ 841.5	$ 796.3	$ 739.2

XML

OTHER OPERATING STATEMENT DATA (SCHEDULE OF CHANGES IN PRESENT VALUE OF FUTURE INSURANCE PROFITS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement in Present Value of Future Insurance Profits [Roll Forward]
Balance, beginning of year	$ 401.8	$ 449.0	$ 489.4
Amortization	(54.4)	(62.2)	(69.1)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	12.2	15.0	28.7
Balance, end of year	$ 359.6	$ 401.8	$ 449.0

XML

OTHER OPERATING STATEMENT DATA (SCHEDULE OF CHANGES IN DEFERRED ACQUISITION COSTS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement Analysis of Deferred Policy Acquisition Costs [Roll Forward]
Balance, beginning of year	$ 1,044.7	$ 1,083.3	$ 770.6
Additions	236.1	242.7	246.4
Amortization	(184.9)	(191.1)	(190.9)
Amounts related to changes in unrealized investment gains (losses) on fixed maturities, available for sale	(69.1)	(90.2)	257.2
Balance, end of year	$ 1,026.8	$ 1,044.7	$ 1,083.3

XML

CONSOLIDATED STATEMENT CASH FLOWS (SCHEDULE OF THE RECONCILIATION FOR NET INCOME PROVIDED BY OPERATING ACTIVITIES) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	$ 175.6	$ 358.2	$ 270.7
Adjustments to reconcile net income to net cash from operating activities:
Amortization and depreciation									265.4	275.0	283.4
Income taxes									227.5	(11.7)	92.9
Insurance liabilities									464.7	332.8	297.4
Accrual and amortization of investment income									(321.6)	(124.2)	(27.6)
Deferral of policy acquisition costs									(236.1)	(242.7)	(246.4)
Net realized investment (gains) losses									(50.3)	(8.3)	36.6
Loss on reinsurance transaction and transition expenses									0.0	75.4	9.0
Cash and cash equivalents received upon recapture of reinsurance									0.0	73.6	0.0
Loss on extinguishment of borrowings related to variable interest entities									9.5	0.0	0.0
Loss on extinguishment of debt									0.0	0.0	32.8
Other									78.4	34.7	(1.0)
Net cash from operating activities									$ 613.1	$ 762.8	$ 747.8

XML

CONSOLIDATED STATEMENT CASH FLOWS (SCHEDULE OF OTHER SIGNIFICANT NONCASH TRANSACTIONS) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Stock options, restricted stock and performance units	$ 21.4	$ 23.0	$ 17.1
Market value of investments recaptured in connection with the termination of reinsurance agreements with BRe	$ 0.0	$ 431.1	$ 0.0

XML

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES) (SCHEDULE OF STATUTORY ACCOUNTING PRACTICES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Insurance [Abstract]
Statutory capital and surplus	$ 1,904.4	$ 1,956.8
Asset valuation reserve	246.8	253.3
Interest maintenance reserve	487.0	486.9
Total	$ 2,638.2	$ 2,697.0

XML

STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES) (NARRATIVE) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statutory Accounting Practices [Line Items]
Statutory capital and surplus included investments in upstream affiliates	$ 42.6	$ 42.6
Statutory accounting practices, statutory net income, amount	352.3	256.6	$ 332.6
Statutory accounting practices loss on recapture of long-term care business		110.0
Statutory accounting practices, net realized capital gain (loss), net of income taxes	(9.9)	(29.7)	(18.0)
Statutory accounting practices, pre-tax amounts for fees and interest paid	$ 158.3	$ 153.9	$ 154.2
Percentage of statutory capital and surplus, available for dividend distribution without prior approval from regulatory agency	10.00%
Amount of dividends paid by insurance subsidiaries	$ 357.7
Adjusted capital to risk-based capital ratio	95.00%
Maximum | Company Plan for Improving Capital Position
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	100.00%
Maximum | Regulatory Authority Special Examination
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	75.00%
Maximum | Regulatory Authority, Any Action Deemed Necessary
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	50.00%
Maximum | Regulatory Authority Control
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	35.00%
Maximum | Trend Test
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	150.00%
Minimum | Company Plan for Improving Capital Position
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	75.00%
Minimum | Regulatory Authority Special Examination
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	50.00%
Minimum | Regulatory Authority, Any Action Deemed Necessary
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	35.00%
Minimum | Trend Test
Statutory Accounting Practices [Line Items]
Adjusted capital to risk-based capital ratio	100.00%

XML

BUSINESS SEGMENTS (SCHEDULE OF SEGMENT REPORTING INFORMATION BY SEGMENT) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Net investment income	$ 1,551.3	$ 1,325.2	$ 1,233.6
Fee revenue and other income	48.3	50.5	58.9
Total revenues	4,194.2	3,914.2	3,787.2
Benefits and expenses:
Insurance policy benefits	2,602.7	2,390.5	2,308.3
Other operating costs and expenses	841.5	796.3	739.2
Total expenses	3,739.5	3,503.9	3,364.4
Pre-tax operating earnings by segment	454.7	410.3	422.8
Bankers Life:
Revenues:
Insurance policy income, Annuities	20.3	22.0	22.4
Insurance policy income, Health	1,231.1	1,244.1	1,251.0
Insurance policy income, Life	415.2	393.0	375.3
Net investment income	1,107.3	936.8	884.7
Fee revenue and other income	44.1	34.4	27.7
Total revenues	2,818.0	2,630.3	2,561.1
Benefits and expenses:
Insurance policy benefits	1,771.8	1,620.6	1,588.4
Amortization	163.6	176.5	187.1
Interest expense on investment borrowings	19.8	13.2	8.8
Other operating costs and expenses	443.9	422.1	407.2
Total expenses	2,399.1	2,232.4	2,191.5
Pre-tax operating earnings by segment	418.9	397.9	369.6
Washington National:
Revenues:
Insurance policy income, Annuities	2.1	2.9	3.0
Insurance policy income, Health	642.9	627.9	615.4
Insurance policy income, Life	26.4	25.0	25.4
Net investment income	270.2	259.3	253.6
Fee revenue and other income	1.0	1.3	1.3
Total revenues	942.6	916.4	898.7
Benefits and expenses:
Insurance policy benefits	581.1	561.7	546.6
Amortization	58.8	59.1	55.2
Interest expense on investment borrowings	6.3	3.7	2.0
Other operating costs and expenses	198.1	189.0	183.4
Total expenses	844.3	813.5	787.2
Pre-tax operating earnings by segment	98.3	102.9	111.5
Colonial Penn:
Revenues:
Insurance policy income, Health	2.1	2.6	3.0
Insurance policy income, Life	289.7	278.8	260.5
Net investment income	44.4	44.2	43.0
Fee revenue and other income	1.3	1.1	1.0
Total revenues	337.5	326.7	307.5
Benefits and expenses:
Insurance policy benefits	199.6	201.9	189.0
Amortization	16.3	15.3	14.4
Interest expense on investment borrowings	0.9	0.6	0.1
Other operating costs and expenses	98.1	107.2	98.4
Total expenses	314.9	325.0	301.9
Pre-tax operating earnings by segment	22.6	1.7	5.6
Long-term care in run-off:
Revenues:
Insurance policy income, Health	17.5	4.8	0.0
Net investment income	34.6	9.4	0.0
Total revenues	52.1	14.2	0.0
Benefits and expenses:
Insurance policy benefits	47.3	17.6	0.0
Other operating costs and expenses	3.1	0.5	0.0
Total expenses	50.4	18.1	0.0
Pre-tax operating earnings by segment	1.7	(3.9)	0.0
Corporate operations:
Revenues:
Net investment income	35.5	16.6	11.3
Fee revenue and other income	8.5	10.0	8.6
Total revenues	44.0	26.6	19.9
Benefits and expenses:
Interest expense on investment borrowings	0.0	0.0	0.2
Other operating costs and expenses	84.3	69.1	38.6
Interest expense on corporate debt	46.5	45.8	45.0
Total expenses	130.8	114.9	83.8
Pre-tax operating earnings by segment	$ (86.8)	$ (88.3)	$ (63.9)

XML

BUSINESS SEGMENTS (RECONCILIATION OF OPERATING PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting [Abstract]
Total segment revenues									$ 4,194.2	$ 3,914.2	$ 3,787.2
Net realized investment gains (losses)									50.3	8.3	(36.6)
Revenues related to certain non-strategic investments and earnings attributable to VIEs									52.7	52.6	36.3
Fee revenue related to transition and support services agreements									0.0	10.0	25.0
Total revenues	$ 1,090.1	$ 1,079.3	$ 1,057.1	$ 1,070.7	$ 1,004.9	$ 1,015.9	$ 1,003.9	$ 960.4	4,297.2	3,985.1	3,811.9
Total segment expenses									3,739.5	3,503.9	3,364.4
Insurance policy benefits - fair value changes in embedded derivative liabilities									2.9	(11.3)	(15.7)
Amortization related to fair value changes in embedded derivative liabilities									(0.4)	1.7	3.8
Amortization related to net realized investment gains (losses)									1.0	0.7	(0.5)
Expenses related to certain non-strategic investments and expenses attributable to VIEs									61.5	54.6	43.0
Fair value changes and amendment related to agent deferred compensation plan									12.2	(3.1)	(15.1)
Loss on extinguishment of debt									0.0	0.0	32.8
Loss on reinsurance transaction and transition expenses									0.0	75.4	9.0
Expenses related to transition and support services agreements									0.0	10.0	22.5
Total benefits and expenses									3,816.7	3,631.9	3,444.2
Income before income taxes	125.4	129.9	128.5	96.7	180.7	49.3	82.7	40.5	480.5	353.2	367.7
Tax expense on period income									162.8	127.8	129.5
Valuation allowance for deferred tax assets and other tax items									142.1	(132.8)	(32.5)
Net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	$ 175.6	$ 358.2	$ 270.7

XML

BUSINESS SEGMENTS (SCHEDULE OF BALANCE SHEET INFORMATION, BY SEGMENT) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Total assets	$ 33,110.3	$ 31,975.5	$ 31,975.2
Total liabilities	28,262.8		27,488.3
Bankers Life:
Segment Reporting Information [Line Items]
Total assets	21,134.9		19,876.4
Total liabilities	18,031.6		17,144.9
Washington National:
Segment Reporting Information [Line Items]
Total assets	7,674.3		7,555.7
Total liabilities	6,101.5		6,096.9
Colonial Penn:
Segment Reporting Information [Line Items]
Total assets	1,059.3		1,022.9
Total liabilities	921.0		898.5
Long-term care
Segment Reporting Information [Line Items]
Total assets	692.9		656.2
Total liabilities	580.4		562.2
Corporate operations:
Segment Reporting Information [Line Items]
Total assets	2,548.9		2,864.0
Total liabilities	$ 2,628.3		$ 2,785.8

XML

BUSINESS SEGMENTS (SCHEDULE OF SELECTED FINANCIAL INFORMATION, BY SEGMENT) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Present value of future profits	$ 359.6	$ 401.8	$ 449.0	$ 489.4
Deferred acquisition costs	1,026.8	1,044.7
Insurance liabilities	23,539.0	22,653.8
Bankers Life:
Segment Reporting Information [Line Items]
Present value of future profits	81.1	95.5
Deferred acquisition costs	606.5	646.2
Insurance liabilities	16,541.2	15,702.8
Washington National:
Segment Reporting Information [Line Items]
Present value of future profits	243.7	266.8
Deferred acquisition costs	310.8	299.9
Insurance liabilities	5,590.7	5,586.7
Colonial Penn:
Segment Reporting Information [Line Items]
Present value of future profits	34.8	39.5
Deferred acquisition costs	109.5	98.6
Insurance liabilities	834.4	809.6
Long-term care
Segment Reporting Information [Line Items]
Present value of future profits	0.0	0.0
Deferred acquisition costs	0.0	0.0
Insurance liabilities	$ 572.7	$ 554.7

XML

QUARTERLY FINANCIAL DATA (UNAUDITED) (SCHEDULE OF QUARTERLY FINANCIAL INFORMATION) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Data [Abstract]
Revenues	$ 1,090.1	$ 1,079.3	$ 1,057.1	$ 1,070.7	$ 1,004.9	$ 1,015.9	$ 1,003.9	$ 960.4	$ 4,297.2	$ 3,985.1	$ 3,811.9
Income before income taxes	125.4	129.9	128.5	96.7	180.7	49.3	82.7	40.5	480.5	353.2	367.7
Income tax expense (benefit)	196.3	29.1	45.1	34.4	(53.5)	30.7	22.8	(5.0)	304.9	(5.0)	97.0
Net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	$ 175.6	$ 358.2	$ 270.7
Basic:
Net income (loss) (in dollars per share)	$ (0.42)	$ 0.60	$ 0.49	$ 0.36	$ 1.35	$ 0.11	$ 0.34	$ 0.25	$ 1.03	$ 2.03	$ 1.40
Diluted:
Net income (in dollars per share)	$ (0.42)	$ 0.59	$ 0.48	$ 0.36	$ 1.34	$ 0.11	$ 0.33	$ 0.25	$ 1.02	$ 2.01	$ 1.39
Tax reform provisional income tax expense (benefit)	$ 172.5								$ 172.5

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES (NARRATIVE) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) entity	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Variable Interest Entity [Line Items]
Gain (loss) on dissolution of variable interest entities	$ (4.3)	$ (7.3)	$ 11.3
Repayments of Investment Borrowings Related to Variable Interest Entities, Amounts Due in 2018	3.0
Repayments of Investment Borrowings Related to Variable Interest Entities, Amounts Due in 2019	3.6
Repayments of Investment Borrowings Related to Variable Interest Entities, Amounts Due in 2020	2.1
Repayments of Investment Borrowings Related to Variable Interest Entities, Amounts Due in 2021	1.3
Repayments of investment borrowings related to variable interest entities, amounts due in 2028	539.9
Repayments of investment borrowings related to variable interest entities, amounts due in 2030	878.0
Variable interest entity amortized cost securities held	1,524.9
Variable interest entity, gross unrealized gains fixed maturity securities	8.6
Variable interest entity gross unrealized losses fixed maturity securities	(6.6)
Variable interest entity, estimated fair value of securities held	1,526.9
Variable interest entities net realized gain (loss) on investments	(5.6)	(20.4)	(6.4)
Variable interest entities, net losses from the sales of fixed maturities	1.2	(11.9)	(1.3)
Writedowns of investments for other than temporary declines in fair value recognized through net income	$ (2.5)	(1.2)	(16.4)
Number of VIEs in default | entity	0
Investments held by VIEs and sold	$ 109.6	192.2	46.1
Variable interest entity, gross investment losses from sale	3.0	20.3	$ 1.8
Less than twelve months
Variable Interest Entity [Line Items]
Fair value investments held by variable interest entity that had been in an unrealized loss position	445.4	93.8
Gross unrealized gain (loss) on investments held by VIEs	(4.9)	(0.9)
Greater than twelve months
Variable Interest Entity [Line Items]
Fair value investments held by variable interest entity that had been in an unrealized loss position	28.4	143.9
Gross unrealized gain (loss) on investments held by VIEs	$ (1.7)	$ (2.9)

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES (SCHEDULE OF IMPACT ON BALANCE SHEET OF CONSOLIDATING VARIABLE INTEREST ENTITIES) (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Assets [Abstract]
Investments held by variable interest entities	$ 1,526.9	$ 1,724.3
Cash and cash equivalents held by variable interest entities	178.9	189.3
Liabilities:
Borrowings related to variable interest entities	1,410.7	1,662.8
VIEs
Assets [Abstract]
Investments held by variable interest entities	1,526.9	1,724.3
Notes receivable of VIEs held by insurance subsidiaries	0.0	0.0
Cash and cash equivalents held by variable interest entities	178.9	189.3
Accrued investment income	2.6	3.0
Income tax assets, net	0.7	6.4
Other assets	10.0	13.1
Total assets	1,719.1	1,936.1
Liabilities:
Other liabilities	158.3	81.8
Borrowings related to variable interest entities	1,410.7	1,662.8
Notes payable of VIEs held by insurance subsidiaries	167.6	203.3
Total liabilities	1,736.6	1,947.9
Eliminations
Assets [Abstract]
Investments held by variable interest entities	0.0	0.0
Notes receivable of VIEs held by insurance subsidiaries	(155.5)	(204.2)
Cash and cash equivalents held by variable interest entities	0.0	0.0
Accrued investment income	(0.1)	(0.1)
Income tax assets, net	0.0	(1.3)
Other assets	(1.5)	(1.8)
Total assets	(157.1)	(207.4)
Liabilities:
Other liabilities	(4.4)	(6.4)
Borrowings related to variable interest entities	0.0	0.0
Notes payable of VIEs held by insurance subsidiaries	(167.6)	(203.3)
Total liabilities	(172.0)	(209.7)
Net effect on consolidated balance sheet
Assets [Abstract]
Investments held by variable interest entities	1,526.9	1,724.3
Notes receivable of VIEs held by insurance subsidiaries	(155.5)	(204.2)
Cash and cash equivalents held by variable interest entities	178.9	189.3
Accrued investment income	2.5	2.9
Income tax assets, net	0.7	5.1
Other assets	8.5	11.3
Total assets	1,562.0	1,728.7
Liabilities:
Other liabilities	153.9	75.4
Borrowings related to variable interest entities	1,410.7	1,662.8
Notes payable of VIEs held by insurance subsidiaries	0.0	0.0
Total liabilities	$ 1,564.6	$ 1,738.2

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES (SUPPLEMENTAL INFORMATION, REVENUES AND EXPENSES OF VARIABLE INTEREST ENTITIES) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Policyholder and other special-purpose portfolios									$ 265.9	$ 121.1	$ 30.0
Fee revenue and other income									48.3	50.5	58.9
Total revenues	$ 1,090.1	$ 1,079.3	$ 1,057.1	$ 1,070.7	$ 1,004.9	$ 1,015.9	$ 1,003.9	$ 960.4	4,297.2	3,985.1	3,811.9
Expenses:
Interest expense									123.7	116.4	94.9
Other operating costs and expenses									841.5	796.3	739.2
Total benefits and expenses									3,816.7	3,631.9	3,444.2
Net realized investment losses									50.3	8.3	(36.6)
Loss on extinguishment of borrowings									(9.5)	0.0	0.0
Income before income taxes	$ 125.4	$ 129.9	$ 128.5	$ 96.7	$ 180.7	$ 49.3	$ 82.7	$ 40.5	480.5	353.2	367.7
Variable Interest Entity, Primary Beneficiary
Revenues:
Policyholder and other special-purpose portfolios									69.8	78.9	62.1
Fee revenue and other income									5.9	6.4	1.6
Total revenues									75.7	85.3	63.7
Expenses:
Interest expense									50.2	53.1	38.8
Other operating costs and expenses									1.8	1.5	2.0
Total benefits and expenses									52.0	54.6	40.8
Income before net realized investment losses and income taxes									23.7	30.7	22.9
Net realized investment losses									(5.6)	(20.4)	(6.4)
Loss on extinguishment of borrowings									(9.5)	0.0	0.0
Income before income taxes									$ 8.6	$ 10.3	$ 16.5

XML

INVESTMENTS IN VARIABLE INTEREST ENTITIES (SUMMARY OF VARIABLE INTEREST ENTITIES BY CONTRACTUAL MATURITY) (Details) $ in Millions	Dec. 31, 2017 USD ($)
Variable Interest Entity [Line Items]
Total, Amortized Cost	$ 1,524.9
Total, Estimated Fair Value	1,526.9
Amortized cost
Variable Interest Entity [Line Items]
Due in one year or less	11.2
Due after one year through five years	541.8
Due after five years through ten years	971.9
Total, Amortized Cost	1,524.9
Due in one year or less	2.4
Due after one year through five years	178.2
Due after five years through ten years	299.8
Total, Amortized Cost	480.4
Estimated fair value
Variable Interest Entity [Line Items]
Due in one year or less	11.2
Due after one year through five years	542.0
Due after five years through ten years	973.7
Total, Estimated Fair Value	1,526.9
Due in one year or less	2.4
Due after one year through five years	174.3
Due after five years through ten years	297.1
Total, Estimated Fair Value	$ 473.8

XML

SCHEDULE II - BALANCE SHEET (Details) - USD ($) $ in Millions	Dec. 31, 2017	Jan. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Assets [Abstract]
Cash and cash equivalents - unrestricted	$ 578.4		$ 478.9	$ 432.3	$ 611.6
Equity securities at fair value (cost: 2017 - $225.7; 2016 - $166.5)	511.7		584.2
Income tax assets, net	366.9		789.7
Other assets	319.5		328.5
Total assets	33,110.3	$ 31,975.5	31,975.2
Liabilities:
Notes payable	914.6		912.9
Other liabilities	751.8		611.4
Total liabilities	28,262.8		27,488.3
Commitments and Contingencies
Shareholders' equity:
Accumulated other comprehensive income	1,212.1		622.4
Retained earnings	560.4	650.1	650.7
Total shareholders' equity	4,847.5	4,487.2	4,486.9	4,138.5	4,688.2
Total liabilities and shareholders' equity	33,110.3	$ 31,975.5	31,975.2
Parent Company
Assets [Abstract]
Cash and cash equivalents - unrestricted	161.1		106.1	$ 128.9	$ 86.6
Equity securities at fair value (cost: 2017 - $225.7; 2016 - $166.5)	243.6		167.9
Investment in wholly-owned subsidiaries (eliminated in consolidation)	5,440.7		5,220.3
Income tax assets, net	129.6		99.5
Receivable from subsidiaries (eliminated in consolidation)	6.3		2.0
Other assets	12.7		1.8
Total assets	5,994.0		5,597.6
Liabilities:
Notes payable	914.6		912.9
Payable to subsidiaries (eliminated in consolidation)	143.0		128.4
Other liabilities	88.9		69.4
Total liabilities	1,146.5		1,110.7
Commitments and Contingencies
Shareholders' equity:
Common stock and additional paid-in capital ($0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2017 - 166,857,931; 2016 - 173,753,614)	3,075.0		3,213.8
Accumulated other comprehensive income	1,212.1		622.4
Retained earnings	560.4		650.7
Total shareholders' equity	4,847.5		4,486.9
Total liabilities and shareholders' equity	$ 5,994.0		$ 5,597.6

XML

SCHEDULE II - BALANCE SHEET ADDITIONAL INFORMATION (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Condensed Financial Statements, Captions [Line Items]
Equity securities cost	$ 491.1	$ 580.7
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000,000	8,000,000,000
Common stock, shares issued (in shares)	166,857,931	173,753,614
Common stock, shares outstanding (in shares)	166,857,931	173,753,614
Parent Company
Condensed Financial Statements, Captions [Line Items]
Equity securities cost	$ 225.7	$ 166.5
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	8,000,000,000	8,000,000,000
Common stock, shares issued (in shares)	166,857,931	173,753,614
Common stock, shares outstanding (in shares)	166,857,931	173,753,614

XML

SCHEDULE II - STATEMENT OF OPERATIONS (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Net investment income									$ 1,551.3	$ 1,325.2	$ 1,233.6
Net realized investment gains (losses)									50.3	8.3	(36.6)
Total revenues	$ 1,090.1	$ 1,079.3	$ 1,057.1	$ 1,070.7	$ 1,004.9	$ 1,015.9	$ 1,003.9	$ 960.4	4,297.2	3,985.1	3,811.9
Expenses:
Interest expense									123.7	116.4	94.9
Loss on extinguishment of debt									0.0	0.0	32.8
Income before income taxes	125.4	129.9	128.5	96.7	180.7	49.3	82.7	40.5	480.5	353.2	367.7
Income tax expense (benefit)	196.3	29.1	45.1	34.4	(53.5)	30.7	22.8	(5.0)	304.9	(5.0)	97.0
Net income	$ (70.9)	$ 100.8	$ 83.4	$ 62.3	$ 234.2	$ 18.6	$ 59.9	$ 45.5	175.6	358.2	270.7
Parent Company
Revenues:
Net investment income									14.2	15.6	16.9
Net realized investment gains (losses)									2.4	17.7	3.5
Intercompany losses (eliminated in consolidation)									0.0	0.0	(1.5)
Total revenues									16.6	33.3	18.9
Expenses:
Interest expense									46.5	45.8	45.2
Intercompany expenses (eliminated in consolidation)									1.7	0.9	0.4
Operating costs and expenses									75.4	48.2	21.0
Loss on extinguishment of debt									0.0	0.0	32.8
Total expenses									123.6	94.9	99.4
Income before income taxes									(107.0)	(61.6)	(80.5)
Income tax expense (benefit)									27.4	(54.6)	(37.9)
Loss before equity in undistributed earnings of subsidiaries									(134.4)	(7.0)	(42.6)
Equity in undistributed earnings of subsidiaries (eliminated in consolidation)									310.0	365.2	313.3
Net income									$ 175.6	$ 358.2	$ 270.7

XML

SCHEDULE II - STATEMENT OF CASH FLOWS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Condensed Financial Statements, Captions [Line Items]
Cash flows from operating activities	$ 613.1	$ 762.8	$ 747.8
Cash flows from investing activities:
Sales of investments	2,487.4	2,841.8	2,177.6
Purchases of investments	(6,141.0)	(6,159.8)	(4,767.2)
Net sales of trading securities	108.9	(84.2)	(12.3)
Net cash provided (used) by investing activities	(239.6)	(742.4)	(1,069.6)
Cash flows from financing activities:
Issuance of notes payable, net	0.0	0.0	910.0
Payments on notes payable	0.0	0.0	(797.1)
Expenses related to extinguishment of debt	0.0	0.0	(17.8)
Issuance of common stock	8.3	8.4	6.3
Payments to repurchase common stock	(168.3)	(210.0)	(365.4)
Net cash provided (used) by financing activities	(274.0)	26.2	142.5
Net increase (decrease) in cash and cash equivalents	99.5	46.6	(179.3)
Cash and cash equivalents, beginning of year	478.9	432.3	611.6
Cash and cash equivalents, end of year	578.4	478.9	432.3
Parent Company
Condensed Financial Statements, Captions [Line Items]
Cash flows from operating activities	(181.8)	(110.7)	(51.2)
Cash flows from investing activities:
Sales of investments	54.9	305.0	66.5
Sales of investments - affiliated	0.0	0.0	16.0
Maturities and redemptions of investments - affiliated	0.0	0.0	8.3
Purchases of investments	(123.6)	(198.4)	(68.6)
Purchases of investments - affiliated	0.0	0.0	(3.4)
Net sales of trading securities	9.1	12.0	11.8
Dividends received from consolidated subsidiary, net of capital contributions of nil in 2017, $200.0 in 2016 and nil in 2015	363.5	92.5	269.7
Net cash provided (used) by investing activities	303.9	211.1	300.3
Cash flows from financing activities:
Issuance of notes payable, net	0.0	0.0	910.0
Payments on notes payable	0.0	0.0	(797.1)
Expenses related to extinguishment of debt	0.0	0.0	(17.8)
Issuance of common stock	8.3	8.4	6.3
Payments to repurchase common stock	(168.3)	(210.0)	(365.4)
Common stock dividends paid	(59.6)	(54.8)	(52.0)
Investment borrowings - repurchase agreements, net	0.0	0.0	(20.4)
Issuance of notes payable to affiliates	310.8	217.1	234.4
Payments on notes payable to affiliates	(158.3)	(83.9)	(104.8)
Net cash provided (used) by financing activities	(67.1)	(123.2)	(206.8)
Net increase (decrease) in cash and cash equivalents	55.0	(22.8)	42.3
Cash and cash equivalents, beginning of year	106.1	128.9	86.6
Cash and cash equivalents, end of year	$ 161.1	$ 106.1	$ 128.9

XML

SCHEDULE II - STATEMENT OF CASH FLOWS ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Parent Company
Condensed Financial Statements, Captions [Line Items]
Capital contributions	$ 0.0	$ 200.0	$ 0.0

XML

SCHEDULE IV (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Assumed premiums earned	$ 30.2	$ 33.8	$ 38.4
Reinsurance ceded	(114.4)	(132.9)	(142.8)
Insurance policy income	2,647.3	2,601.1	2,556.0
Life insurance inforce:
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Direct	27,154.3	27,048.1	25,807.0
Assumed	120.5	128.7	137.4
Ceded	(3,452.6)	(3,604.0)	(3,780.8)
Net insurance inforce	$ 23,822.2	$ 23,572.8	$ 22,163.6
Percentage of assumed to net	0.50%	0.50%	0.60%
Insurance policy income:
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Direct premiums earned	$ 2,576.9	$ 2,553.0	$ 2,524.3
Assumed premiums earned	30.4	34.0	38.5
Reinsurance ceded	(105.0)	(123.9)	(133.6)
Insurance policy income	$ 2,502.3	$ 2,463.1	$ 2,429.2
Premiums, percentage of assumed to net	1.20%	1.40%	1.60%